Aids: Nursing Perspectives

Jerry D. Durham, Ph.D, R.N., F.A.A.N., is professor and dean of the Barnes College of Nursing at the University of Missouri at St. Louis. Dr. Durham has earned six university degrees, including three in nursing and a doctorate in higher education administration. In addition to his role as an educator, he has held positions as a staff nurse, clinical manager, private practitioner in mental health nursing, and consultant in education and research. He was among the first researchers to investigate the nature of private practice in psychiatric nursing. He has received two fellowships in ethics from the National Endowment for the Humanities. In addition to The Person with HIV/AIDS: Nursing Perspectives, Dr. Durham has coedited Women, Children and HIV/AIDS (1993), as well as The Nurse Psychotherapist in Private Practice (1987). Together, these three books received five American Journal of Nursing Book-of-the-Year Awards. Dr. Durham also served as coeditor of Tuberculosis: A Sourcebook for Nursing Practice, which was selected as a "Best Book of 1995" by Nurse Practitioner. He serves as a reviewer for several nursing journals and is a member of the editorial board of the Journal of Psychosocial Nursing. Dr. Durham chaired the Education Committee of the Association of Nurses in AIDS Care. Felissa R. Lashley, Ph.D, R.N., A.C.R.N., F.A.A.N. (formerly Felissa L. Cohen), is professor and dean of the School of Nursing, Southern Illinois University, Edwardsville. She is also clinical professor of pediatrics at the School of Medicine, Southern Illinois University, Springfield. Dr. Lashley previously served as professor and head of the Department of Medical-Surgical Nursing at the University of Illinois at Chicago (UIC) College of Nursing, clinical chief for Medical-Surgical Nursing at the University of Illinois at Chicago Medical Center, and associate professor, Department of Genetics, School of Medicine, UIC. Dr. Lashley received her doctorate in human genetics with a minor in biochemistry from Illinois State University. She is

certified as a Ph.D. medical geneticist by the American Board of Medical Genetics (the first nurse to be so certified) and is a founding fellow of the American College of Medical Genetics. Dr. Lashley began her practice of genetic evaluation and counseling in 1973. She has authored more than 200 publications including Clinical Genetics in Nursing Practice, which received a Book-of-the-Year Award from the American Journal of Nursing in its first edition, as have two of her other books. She was a coeditor of the Association of Nurses in AIDS Care's Core Curriculum for HIV/AIDS Nursing. Dr. Lashley is a distinguished lecturer for Sigma Theta Tau International and an associate editor of the journal IMAGE: The Journal of Nursing Scholarship, as well as a fellow of the American Academy of Nursing. She was the first nurse to serve on the AIDS Research Review Committee, National Institute of Allergy and Infectious Diseases (NIH), and was a member of the Priority Expert Panel B HIV Infection: Prevention and Care, National Center of Nursing Research. She was a member of the HIV Nursing Clinical Advisory Committee of the National AIDS Education and Training Centers, HRSA Bureau of Health Professions, and was a co-project director and co-investigator of the award for the Midwest AIDS Training and Education Center. She is an active member of the Association of Nurses in AIDS Care and has served as chair of the Nominating Committee. She is presidentelect and a member of the board of directors of the HIV/AIDS Nursing Certifying Board.

The Person with

HIV/AIDS Third Edition

Nursing Perspectives Jerry D. Durham PhD, RN, FAAN

Felissa R. Lashley PhD, RN, ACRN, FAAN Editors

Springer Publishing Company

Copyright © 2000 by Springer Publishing Company, Inc. All rights reserved No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of Springer Publishing Company, Inc. Springer Publishing Company, Inc. 536 Broadway New York, NY 10012-3955 Acquisitions Editor: Ruth Chasek Production Editor: Helen Song Cover design by James Scotto-Lavino

Library of Congress Cataloging-in-Publication Data

The person with HIV/AIDS : nursing perspectives /Jerry D. Durham and Felissa R. Lashley, editors.—3rd ed. p. cm. Rev. ed. of: The person with AIDS. 2nd ed. c1991. Includes bibliographical references and index. ISBN 0-8261-1293-5 (hardcover) 1. AIDS (Disease)—Nursing. I. Durham, Jerry D. II. Lashley, Felissa R., 1941- . III. Person with AIDS. [DNLM: 1. Acquired Immunodeficiency Syndrome— nursing. 2. HIV Infections—nursing. WY 153.5 P467 1999] RC607.A26P47 2000 610.73'699—dc21 DNLM/DLC for Library of Congress 99-16258 CIP Printed in the United States of America

To Kathy, whose kindness, love, and understanding have sustained our lives together. Jerry D. Durham To my wonderful and growing family—Pete, Julie, and Benjamin; Neal and Anne; Heather; my mother, Ruth Lashley; and my friend Tony Oliver. Benjamin, may you grow up in a world where HIV disease no longer exists. Felissa R. Lashley

This page intentionally left blank

Contents

List of Tables List of Figures Con tribu tors Preface 1.

ix xii xiii xv

The Etiology, Epidemiology, Transmission, and Natural History of HIV Infection and AIDS Felissa R. Lashley, R.N., Ph.D., A.C.R.N, F.A.A.N.

1

2.

The Pathogenesis of HIV Infection Janice M. Zeller, R.N., Ph.D., F.A.A.N. Barbara Swanson, R.N., D.N.Sc., A.C.R.N.

75

3.

Preventing HIV Infection Barbara Burger, R.N., Ph.D., A.C.R.N. Vida M. Vizgirda, R.N., M.S.

97

4.

Promoting Wellness in Persons with HIV Infection Susan L. Keller, R.N., M.S.

5.

The Clinical Spectrum of HIV Infection and Its Treatment Felissa R. Lashley, R.N., Ph.,D., A.C.R.N., F.A.A.N.

139

167

6.

Symptom Management in HIV/AIDS AnthonyJ. Admolfi, R.N., M.S.N., A.N.P., A.C.R.N.

271

7.

The Medical Treatment of HIV Disease Susan L. Wightman, R.N., B.S.N., A.C.R.N. Michael K. Klebert, R.N., M.S.N., AMP.

311

8.

Principles of Infection Control Barbara Russell, R.N., M.P.H., C.I.C., A.C.R.N.

351

vii

viii

CONTENTS

9. Testing and Counseling Richard S. Ferri, R.N., Ph.D., A.N.P., A.C.R.N., F.A.A.N.

369

10. Principles of HIV/AIDS Case Management Demetrius Porche, R.N., D.N.S., C.S., C.C.R.N.

387

11. HIV Infection in Women Mary Jo Hoyt, R.N., M.S.N., F.N.P. Susan Holman, R.N., M.S., A.N.P.

401

12.

429

HIV Disease in Children Wendy M. Nehring, R.N., Ph.D.

13. Minorities Living with HIV Infection/AIDS: Stories and Practical Strategies Barbara Aranda-Naranjo, R.N., Ph.D. 14. Ethical and Legal Dimensions Jerry D. Durham, R.N., Ph.D., F.A.A.N.

511 523

Appendix I: Considerations in Caring for Persons after Potential Nonoccupational Exposure to HIV When Data Are Inadequate

551

Appendix II: Prophylaxis for First Episode of Opportunistic Disease in HIV-Infected Adults and Adolescents

55 7

Appendix III: Prophylaxis for Recurrence of Opportunistic Disease (After Chemotherapy for Acute Disease) in HIV-Infected Adults and Adolescents

563

Appendix TV: Advising Patients Concerning Prevention of Exposure to Opportunistic Pathogens 567 Appendix V: Selected Sources of Information on the World Wide Web

577

Index

585

List of Tables

1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 3.1 4.1 5.1 5.2 5.3 5.4 5.5 5.6 5.7

1992 Revised classification system for HIV infection and expanded AIDS surveillance case definition for adolescents and adults Clinical categories Conditions included in the 1993 AIDS surveillance case definition Selected common epidemiological definitions U.S. AIDS cases by age at diagnosis reported to CDC through December, 1998 Reported AIDS cases worldwide as of June 20, 1998 Adults and children living with HIV/AIDS worldwide, December, 1998 United States adult/adolescent AIDS cases by exposure category as reported to CDC through December, 1998 Pediatric AIDS cases in the United States as reported to CDC through December, 1998 Proper use of condoms to prevent sexual transmission of HIV Living with HIV disease: A summary of research on health promotion Selected opportunistic infections and conditions frequently associated with CD4+ cell count categories Selected HlV-related central nervous system disorders Early symptoms of AIDS dementia complex/HIVassociated dementia Clinical staging of the AIDS dementia complex Selected HIV-related gastrointestinal disorders Major oral disorders manifested in HIV infection Selected cutaneous manifestations seen in HIV infection ix

4 5 6 7 33 39 39 45 46 105

150 170 229 229 231 239 242 245

x

LIST OF TABLES

7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 7.10 8.1 8.2 8.3 8.4 9.1 10.1 10.2 10.3 10.4 11.1 11.2

12.1 12.2 12.3

Licensed anti-HIV drugs Potential risks and benefits of early initiation of antiretroviral therapy in the asymptomatic HIVinfected patient Guidelines for treatment initiation Strategies for improving adherence to ART At a glance—nucleoside reverse transcriptase inhibitors (NRTIs) At a glance—nonnucleoside reverse transcriptase inhibitors (NNRTIs) At a glance—protease inhibitors (Pis) At a glance—protease inhibitor drug interactions requiring dose modifications At a glance—drug interactions between protease inhibitors and nonnucleoside reverse transcriptase inhibitors Initial antiretroviral 1997 triple-therapy options Health care workers with documented occupationally acquired AIDS/HIV infection, by occupation through December 1998 Components of an effective infection control program Handling of medical devices/equipment for reuse Examples of transmission-based precautions Getting tested Case management process Potential HIV disease case management problems Essential components of prevention case management Basic needs that interfere with prevention interventions Treatment for vaginitis and related conditions Clinical scenarios and recommendations for the use of antiretroviral drugs to reduce perinatal HIV transmission 1994 Revised HIV pediatric classification system: clinical categories 1994 Revised HIV pediatric classification system Prophylaxis for first episode of opportunistic disease in HIV-infected infants and children

312 316 317 322 323 325 335 339 340 343

354 361 362 363 375 390 391 395 395 408

416 434 441 445

LIST OF TABLES

12.4

12.5

12.6 12.7

12.8

12.9 14.1

Recommended antiretroviral regimens for initial therapy for human immunodeficiency virus (HIV) infection in children Indications for initiation of an antiretroviral therapy in children with human immunodeficiency virus (HIV) infection Available pediatric antiretroviral drugs Considerations for changing antiretroviral therapy for human immunodeficiency virus (HIV)-infected children Prophylaxis for recurrence of opportunistic disease (after chemotherapy for acute disease) in HFVinfected infants and children Immunization schedule for HIV-infected children List of Selected Resources on the World Wide Web: Ethics, Law, Research, and Public Policy

xi

455

457 458

466

469 480 539

List of Figures

1.1 Determining the need for HIV postexposure prophylaxis (PEP) after an occupational exposure: step 1 1.2 Determining the need for HIV postexposure prophylaxis (PEP) after an occupational exposure: steps 2 and 3 2.1 HIVVirion 13.1 STAC Care Coordination/Case Management Model

xii

27 28 77 514

Contributors

Anthony J. Adinolfi, R.N., M.S.N., A.N.P, A.C.R.N., is assistant clinical professor of nursing and an adult nurse practitioner at the AIDS Research and Treatment Center at Duke University, Durham, North Carolina. Barbara Aranda-Naranjo, R.N., Ph.D., holds the Brigadier General Dunlap Professorial Chair at the University of the Incarnate Word, San Antonio, Texas. Barbara Berger, R.N., Ph.D., A.C.R.N., is clinical assistant professor of medical-surgical nursing at the University of Illinois Chicago, Illinois. Richard S. Ferri, R.N., Ph.D., A.N.P., A.C.R.N., F.A.A.N., is an adult nurse practitioner in private practice in Provincetown, Massachusetts. Susan Holman, R.N., M.S., A.N.P., is director of the Women's Interagency Study Project at the State University of New York at Brooklyn and a consultant to the AIDS Institute, New York State Department of Health. Mary Jo Hoyt, R.N., M.S.N., F.N.P., is manager of the HIV Clinical Trials Unit at the University of Medicine and Dentistry of New Jersey, Newark, New Jersey. Susan L. Keller, R.N., M.S., is Lifecare Program Coordinator at Clarian Health in Indianapolis and an adjunct faculty member at Indiana University School of Nursing, Indianapolis, Indiana. Michael K. Klebert, R.N., M.S.N., A.N.P., is study coordinator of the AIDS Clinical Trials Unit at Washington University, St. Louis, Missouri. xiii

xiv

CONTRIBUTORS

Wendy Nehring, R.N., Ph.D., is associate professor of nursing at Southern Illinois University, Edwardsville, Illinois. Demetrius Porche, R.N., D.N.S., C.S., C.C.R.N., is associate professor of adult nursing at Louisiana State University Medical Center, New Orleans, Louisiana. Barbara Russell, R.N., M.P.H., C.I.C, A.C.R.N., is an infection control practitioner at Baptist Hospital of Miami, Florida. Barbara Swanson, R.N., D.N.Sc., A.C.R.N., is assistant professor of adult health nursing at Rush University, Chicago, Illinois. Vida M. Vizgirda, R.N., M.S., is a doctoral candidate in nursing at the University of Illinois, Chicago, Illinois. Susan Wightman, R.N., B.S.N., A.C.R.N., is co-director of the Midwest AIDS Training and Education Center at Washington University, St. Louis, Missouri. Janice M. Zeller, R.N., Ph.D., F.A.A.N., is professor of adult health nursing and associate professor of immunology-microbiology at Rush University, Chicago, Illinois.

Preface

Since the second edition of this book was published in 1991, people throughout the world have witnessed dramatic changes in the HIV/ AIDS pandemic. In the United States, about a dozen drugs approved for treating HIV infection have extended and improved the lives of many thousands of HlV-infected persons. These drugs, and new ones under development, may eventually not only reduce HIV to undetectable levels but also clear the body of the virus. Other drugs have proven effective in treating or preventing the emergence of opportunistic infections. Although these drugs provide a source of hope for HlV-infected persons, many struggle with the burdensome costs of treatment. Indeed, some Americans, and most other infected persons throughout the world, will never receive the benefits of these expensive drugs. While no vaccine has yet proven effective in preventing HIV infection, several are in the clinical trial phase of development. Many persons living with HIV/AIDS are experiencing better and longer lives, forcing them to reconstruct their lives after expecting an early death (the so-called Lazarus Syndrome), even though their futures remain uncertain. This uncertainty, accompanied by survivor guilt in some persons with HIV/AIDS, has caused significant emotional stress and the need to find new ways of coping. An ever-widening gap between the rich and the poor of the world poses almost insurmountable challenges in controlling the HIV pandemic. Speaking at the 12th World AIDS Conference in the summer of 1998, Brian Boyle summarized the significance of this gap: While developed countries continue to bask in the glow of highly active antiretroviral therapy and other quantum leaps in HIV/AIDS treatment, HIV continues to ravage most of the developing world. Currently, approximately 30.6 million individuals are infected with HFV worldwide, and over two-thirds live in Sub-Saharan Africa, where few, and in most cases no, resources are xv

xvi

PREFACE

available for HIV care or prevention. All told, 89% of HIV-infected people live in countries that, taken as a group, account for less than 10% of the global gross national product.

It is a cruel irony that poor people of developing nations have served as subjects in the testing of drugs used to treat HIV infection, since they often find approved drug treatments beyond their reach. Another HlV-related challenge to the people of developing nations is that of balancing the risk of HIV transmission via breastfeeding (which accounts for a high percentage of mother-to-infant transmission in areas where HIV is endemic) with the need to provide nutrition to their infants. In the United States, the number of persons dying from AIDS declined in 1996 and 1997, even though the United States has one of the highest HIV/AIDS-related mortality rates among industrialized nations. The reduction in the number of Americans dying from AIDS can be largely attributed to early treatment with increasingly effective drug therapies, especially highly active antiretroviral therapy (HAART). While HIV infection and AIDS are increasingly treatable conditions, a cure continues to elude scientists. An emerging view of HIV infection as a chronic condition carries the risk that individuals and communities will lessen activities aimed at preventing infection, thereby leading to increasing numbers of new infections. Viewing HIV infection as a chronic condition remains dangerous because thousands of Americans continue to die of AIDS as a result of late, inadequate, or ineffective treatment. In spite of advances in the treatment of HIV infection, many thousands of Americans continue to be infected each year, even though ample evidence exists that most know those behaviors that place them at risk of infection. In the United States, the epidemiological features of the epidemic have changed, with African-Americans and Hispanics disproportionately affected, a shift that poses significant prevention and treatment challenges to these ethnic communities. Rural America has recently been termed a "new frontier for AIDS," aggravated by social taboos, remoteness and isolation, poverty, and lack of education. Although women now comprise a larger percentage of those with HIV infection and AIDS, better medical treatment during pregnancy has led to fewer infants being infected perinatally; however, detecting and treating HIV infection in pregnant women have spawned significant ethical controversies.

PREFACE

xvii

While injection drug use (IDU) is the second most frequently reported risk for AIDS in the United States, IDU has evolved as the main pathway of infection in women, infants, ethnic minority populations, and others. Unfortunately, public health experts and political leaders disagree on how to address the dual epidemics of HIV/AIDS and drug use in this country. (There are an estimated 1.5 million injection drug users in the United States.) This lack of consensus reflects not only the complexity of preventing and treating drug use but also the concerns of political leaders, many of whom view drug use largely as a legal, rather than a public health, issue. Even though sound evidence exists, for example, that carefully managed needle exchange programs can reduce HIV infection among IDUs, most political leaders have failed to endorse such programs, fearing a backlash from their constituents. Influenced by voters' fears of AIDS, legislators have increasingly passed laws aimed at protecting the public from AIDS. Many of these laws have chipped away at individual civil liberty protections and raise constitutional concerns in such areas as the right to privacy. Ethicist Lawrence Gostin interprets the recent legal shift as a move from a period when the civil rights and civil liberties of HFV-infected persons were protected to a "compulsory and punitive approach." This shift has also been seen as a departure from what has been termed "exceptionalism" for HIV/AIDS, that is, a move away from a time when HIV/AIDS was perceived to affect only gay men who, earlier in the epidemic, voiced well-founded concerns of discrimination. Because the epidemic now affects a broader spectrum of society, laws that protect the public, mandate testing for specific populations, and require reporting of names of HIV-positive persons may supersede laws protecting individual civil liberties. Nurses have played key roles in responding to the HIV/AIDS epidemic. They have conducted important survey and clinical research in efforts to better understand the epidemic and provide excellent care. They have crafted position statements aimed at protecting the rights of infected persons. They have formed a national organization, the Association of Nurses in AIDS Care, that has advanced the knowledge that nurses need to provide expert, compassionate care to HIV-infected persons. They have incorporated HIV/ AIDS content into their curricula and established graduate programs in HIV/AIDS nursing. And, finally, they have provided care for all

xviii

PREFACE

HIV-infected persons wherever they live and whenever possible. While the epidemic has significantly changed, nurses remain a constant source of hope for people struggling throughout the world with HIV/AIDS. JERRY D. DURHAM FELISSA R. LASHLEY

1

The Etiology, Epidemiology, Transmission, and

Natural History of HIV Infection and AIDS Felissa R. Lashley

Imost two decades ago the first observations of a strange immunodeficiency, rare opportunistic infections, and JCaposi's sarcoma (KS) were first made in previously healthy young homosexual men. These observations heralded the beginning of one of the most medically, emotionally, and politically troubling epidemics of this century (Centers for Disease Control, 1981a, 1981b). Yet we have learned more about human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) in a short time than perhaps any organism and disease in history, and some of what we have learned has been applied to other diseases such as cancer. Over the years, emphasis has shifted to the identification of behaviors that place an individual at risk of acquiring HIV infection rather than merely belonging to a certain population

A

l

2

THE PERSON WITH HIV/AIDS

group. Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), emphasized this shift when he stated that "the risk for becoming infected with the AIDS virus is really a behavior. The risk for AIDS is having sex with someone who is infected or being exposed to blood that is infected. The risk is not being a homosexual man or being a member of any group" (Barnes, 1986, p. 1589). Emphasis has also shifted to new approaches to the treatment of HIV, including possible prevention by postexposure prophylaxis, and vaccination based on information from virologic and immunologic studies of HIV and its pathogenesis in the body. DEFINITIONS AIDS is defined generally as a specific group of diseases or conditions that are indicative of severe immunosuppression related to infection with HIV (Centers for Disease Control and Prevention, 1998b). This immunosuppression is reflected in a decrease in CD4+ T lymphocytes (T-helper lymphocytes) below 500/mm3 as well as other abnormalities. In 1982, for surveillance and reporting purposes, the Centers for Disease Control (CDC) first developed case definitions for AIDS in children (see chapter 12) and adults (Centers for Disease Control, 1982d). Also in 1982 CDC defined, for national surveillance purposes, a case of AIDS as a disease at least moderately predictive of a defect in cell-mediated immunity occurring in a person with no known cause for diminished resistance to that disease (Selik, Haverkos, & Curran, 1984). Such diseases included Kaposi's sarcoma (in patients under 60 years of age), lymphoma limited to the brain, Pneumocystis carinii pneumonia, and serious opportunistic infections. At the time of the original surveillance definitions, the etiologic agent of AIDS was unknown. It was necessary, however, to have standardization for national reporting and the interpretation of disease trends. Minor revisions were made between 1982 and 1985. On June 28, 1985, the CDC published a major revision of the original case definition for immediate adoption, largely prompted by the discovery of HIV as the etiologic agent of AIDS (Centers for Disease Control, 1985c). As knowledge further expanded, major revisions of the surveillance definition occurred in 1987 (Centers for Disease

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

3

Control, 1987b) and 1993. The 1993 revision, which is the one in current use, had an impact on case reporting, resulting in an artificially high peak for a period after its implementation. A major change in that definition was that a CD4+ cell count below 200 mm3 in a person who was HIV-infected, even without the presence of other symptoms, was defined as AIDS. Three conditions were also added to the AIDS case definition—pulmonary tuberculosis (TB), invasive cervical cancer, and two occurrences within a year of bacterial pneumonia (Centers for Disease Control and Prevention, 1992). HIVinfected persons are now classified on the basis of CD4+ T-cell count or percent in three ranges and three clinical categories resulting in a matrix of nine mutually exclusive categories. These are shown in Table 1.1. The CD4+ T-cell categories are: Category 1 > 500 cells/|lL or mm 3 Category 2 200-499 cells/(lL or mm 3 Category 3 < 200 cells/uL or mm 3 The clinical categories for adults or adolescents are A, B, and C. Clinical categories are divided into A, B, and C (see Table 1.2). Category A consists of one or more of the following Asymptomatic HIV infection Persistent generalized lymphadenopathy (PGL) Acute or primary HIV infection with accompanying illness or history of acute HIV infection (Centers for Disease Control and Prevention, 1992. Category B consists of "symptomatic conditions" not included in Category C (Centers for Disease Control and Prevention, 1992). Examples of conditions in clinical Category B are listed in Table 1.2. Category C includes the clinical conditions listed in the AIDS surveillance case definition as shown in Table 1.3. Once a person has had a category C condition, the person remains in Category C. Because the CDC definition did not adequately address differences seen in Africa, the World Health Organization (WHO) developed a definition for AIDS in Africa. The WHO definition did not include CD4+ cell counts as an essential component partly because

4

THE PERSON WITH HIV/AIDS

TABLE 1.1 1992 Revised Classification System for HIV Infection and Expanded AIDS Surveillance Case Definition for Adolescents and Adults* Clinical categories

CD4+ Cell categories

(A) Asymptomatic, or persistent generalized lymphadenopathy, acute infection

(B) Symptomatic, not (A) or (C) conditions

(C) AIDS-indicator*

< 500/u.L

A1

B1

C1

200-499/u.L

A2

B2

C2

< 200/jiL AIDS-indicator cell count

A3

B3

C3

*The shaded cells illustrate the expansion of the AIDS surveillance case definition. People with AIDS-indicator conditions (category C) are currently reportable to health departments in every state and U.S. territory. In addition to people with clinical category C conditions (categories C1, C2, and C3), person with lymphocyte counts of less than 2007uL (categories A3 or B3) also will be reportable as AIDS cases. **See Table 1.3. Source: Centers for Disease Control and Prevention. (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report, 41, (No. RR-17), 7.

of less availability of technology to determine and follow such counts in individuals over time. A definition of AIDS has also been issued by the Pan American Health Organization. Definitions for epidemiological terms may be useful in reading the literature. Common ones are shown in Table 1.4. ETIOLOGY The etiologic agent of AIDS is the human immunodeficiency virus (HIV) of which there are two types designated as type 1 and type 2 or (HIV-1 and HIV-2). HIV-1 is further subdivided into three groups.

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

5

TABLE 1.2 Clinical Categories Category A Category A consists of one or more of the conditions listed below in an adolescent or adult (> 13 years) with documented HIV infection. Conditions listed in categories B and C must not have occurred. Asymptomatic HIV infection Persistent generalized lymphadenopathy Acute (primary) HIV infection with accompanying illness or history of acute HIV infection Category B Category B consists of symptomatic conditions in an HIV-infected adolescent or adult that are not included among conditions listed in clinical category C and that meet at least one of the following criteria: (1) the conditions are attributed to HIV infection or are indicative or a defect in cell-mediated immunity or (2) the conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection. Examples of conditions in clinical category B include but are not limited to: Bacillary angiomatosis Candidiasis, oropharyngeal (thrush) Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to therapy Cervical dysplasia (moderate or severe)/cervical carcinoma in situ Constitutional symptoms, such as fever (38.5° C) or diarrhea lasting > 1 month Hairy leukoplakia, oral Herpes zoster (shingles), involving at least two distinct episodes or more than one dermatome Idiopathic thrombocytopenic purpura Listeriosis Pelvic inflammatory disease, particularly if complicated by tubo-ovarian abscess Peripheral neuropathy For classification purposes, category B conditions take precedence over those in category A. For example, someone previously treated for oral or persistent vaginal candidiasis (and who has not developed a category C disease) but who is now asymptomatic should be classified in clinical category B. Category C Category C includes the clinical conditions listed in the AIDS surveillance case definition (see Table 1.3). For classification purposes, once a category C condition has occurred, the person will remain in category C. Source: Centers for Disease Control and Prevention. (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report, 41(No. RR-17), 3-4.

6

THE PERSON WITH HIV/AIDS

TABLE 1.3 Conditions Included in the 1993 AIDS Surveillance Case Definition Candidiasis of bronchi, trachea, or lungs Candidiasis, esophageal Cervical cancer, invasive* Coccidioidomycosis, disseminated or extrapulmonary Cryptococcosis, extrapulmonary Cryptosporidiosis, chronic intestinal (> 1 month's duration) Cytomegalovirus disease (other than liver, spleen, or nodes) Cytomegalovirus retinitis (with loss of vision) Encephalopathy, HIV-related Herpes simplex: chronic ulcer(s) (> 1 month's duration); or bronchitis, pneumonitis, or esophagitis Histoplasmosis, disseminated or extra pulmonary Isosporiasis, chronic intestinal (> 1 month's duration) Kaposi's sarcoma Lymphoma, Burkitt's (or equivalent term) Lymphoma, immunoblastic (or equivalent term) Lymphoma, primary, of brain Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary Mycobacterium tuberculosis, any site (pulmonary* or extrapulmonary) Mycobacterium, other species or unidentified species, disseminated or extrapulmonary Pneumocystis carinii pneumonia Pneumonia, recurrent* Progressive multifocal leukoencephalopathy Salmonella septicemia, recurrent Toxoplasmosis of brain Wasting syndrome due to HIV *Added in the 1993 expansion of the AIDS surveillance case definition. Source: Centers for Disease Control and Prevention. (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report, 47(No. RR-17), 15.

The first is called the major group and is known as M. The second is known as group O (outliers), and the proposed designation for the third group, which was recently reported in 1998 from a Cameroonian patient, is N for either "non M-non O" or "new" (Simon et al., 1998; Wain-Hobson, 1998). Group M consists of at least 10 major subtypes designated as A through J, some of which are very rare

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

TABLE 1.4

7

Selected Common Epidemiological Definitions

Case Control Studies—investigation of a group of persons with the disease or condition of interest (cases) compared retrospectively with another group that does not have the condition or disease (control). Cohort—a group of persons who have had a common experience who are followed over a time to determine whether or not the condition or disease of interest develops. Incidence rate—measure of frequency with which a new case of disease or condition occurs in a populous over a period of time. Measures pace of new illness in persons originally without the disease of interest. This is usually presented in a base multiple of 10 as either a percent or a rate per 1,000 or 100,000. Incidence rate = number of new cases of disease over a period x base of 10 total population at risk

Morbidity—departure from a state of health or a specified disease Mortality rate—frequency of occurrence among a specified population in a given time period Prevalence—measure of the number or proportion of persons in a given time period with a specific condition or disease. Prevalence rate =

number of persons with disease in a 9'ven time penod x base of

total population at risk Rate—measure of the occurrence or existence of a condition, disease, or time period. Risk—the probability of the occurrence of a condition, event, or disease Relative risk—refers to the degree of risk for a particular group with a factor of interest compared with the risk of a group without that factor to develop a certain condition or disease. Example: the relative risk for smokers to develop lung cancer is higher than non-smokers incidence rate among exposed Relative risk = incidence rate among non-exposed

(Kanki et al., 1999). They differ from one another in 21% to 31% of their gene sequences (Charneau, Borman, & Quillent, 1994; Jaffe & Schochetman, 1998). These are useful in tracing epidemiological origins and spread. Subtype B is most common in the United States and Europe, whereas subtype E has been most frequently seen in Central Africa (Janssens, Buve, & Nkengasong, 1997). Group O has been mainly seen in Central West Africa. The few persons in the United States possessing group O HIV-1 infection were natives of Africa (Jaffe & Schochetman, 1998). HIV-2 has at least five subtypes,

8

THE PERSON WITH HIV/AIDS

and possibly six (Jaffe & Schochetman, 1998). HFV-1 is responsible for most of the AIDS cases in the world at this time, except in West Africa, where HIV-2 is prevalent. When HIV is referred to in this chapter, HIV-1 is meant unless otherwise specified. HIV-2 is discussed in more detail later in this chapter. Duesberg (1989) has consistently argued that HIV is not the etiologic agent of AIDS. However, his arguments have not found wide support in the scientific community. Other suggested classifications of HIV are as follows: (1) as macrophage-tropic or T-cell line tropic; (2) as syncytium-inducing or nonsyncytium inducing (see chapter 2); and (3) as slow/low or rapid/ high in relation to growth in culture or based on coreceptor affinity such as to either CCR5 (R5 virus), CXCR4 (X4 virus), or both (R5X4 virus) (Berger et al., 1998). Historical Background Clues from epidemiological surveillance first suggested that AIDS was caused by a transmissible agent. These included the following: (1) the AIDS epidemic was new; (2) it appeared first in limited geographic areas and then spread; (3) the initial groups of people affected (homosexual men and intravenous drug users) and later identified groups (hemophiliacs and blood transfusion recipients) were prone to communicable diseases but were socially, economically, and geographically disparate; and (4) clustering of cases suggested common links and contacts. Early patterns of the distribution of affected persons were reminiscent of hepatitis B (Curran et al., 1985; Gallo, Shaw, & Markham, 1985; Scale, 1984). By 1982 the most probable virus candidates appeared to be cytomegalovirus, EpsteinBarr virus, certain adenoviruses, a human parvovirus, and the retroviruses (Fauci et al., 1984). Several lines of thinking began to implicate a retrovirus, particularly one similar to human T cell lymphotropic viruses (HTLV), which are also known as human T cell leukemia viruses. (HTLV-I causes adult T cell leukemia in humans.) These included the knowledge that (1) T-4 lymphocytes were selectively depleted in AIDS, and HTLV had already been shown to have this tropism; (2) HTLV could be transmitted by intimate contact or blood products; (3) HTLV could cause immunosuppression; (4) the retrovirus known

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

9

as the feline leukemia virus could cause a type of cancer (leukemia) as well as immunosuppression leading to opportunistic infections in cats; and (5) there was a high incidence of AIDS among Haitians and Africans. (Both Haiti and Africa are endemic areas for HTLVI.) Later assays of AIDS patients showed that they had evidence of exposure to an HTLV-I related virus (Broder & Gallo, 1985; Essex, Allan, et al., 1985; Fauci et al., 1984; Lane & Fauci, 1985). By 1983 and 1984, respectively, three groups of researchers had isolated, identified, and characterized the virus that was established as the cause of AIDS. Gallo and his group at the National Cancer Institute named it HTLV-III; Montagnier and his associates at the Pasteur Institute in Paris, in cooperation with the CDC, named it lymphadenopathy-associated virus (LAV); and Levy and his group in California named it AIDS-associated retrovirus (ARV) (Barre-Sinoussi et al., 1983; Gelman et al., 1983; Levy et al., 1984). A task force sponsored by the International Committee on the Taxonomy of Viruses was assembled to reach a decision on a name (Norman, 1985c). The name recommended by this committee in May 1986 was human immunodeficiency virus (HIV) (Coffin et al., 1986). This is still the accepted terminology. These named viruses were found to be variants of the same one. However, although these viruses are members of the retrovirus family, they are more closely related to the lentivirus subfamily rather than to the oncovims subfamily, which includes HTLV, and HIV is considered to be a member of the lentivirus subfamily of human retroviruses (Walker, 1998). The importance of determining the cause of AIDS included the ability to identify persons infected with HIV, characterize the viral characteristics, epidemiologically characterize viral transmission and patterns, describe the natural history of infection, and develop the potential for screening, prevention, treatment, and vaccination development. HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 (HIV-2) In October, 1985, Clavel, Montagnier, and their colleagues identified a new human immunodeficiency virus in blood samples from persons with AIDS in Portugal who had lived in western Africa. This virus was also described in asymptomatic West African prostitutes (Centers

10

THE PERSON WITH HIV/AIDS

for Disease Control, 1989; Gallo & Montagnier, 1988) and was eventually designated human immunodeficiency virus type 2 (HIV-2). HFV2 is more closely related to the simian immunodeficiency virus than to HIV-1 (Whittle, Ariyoshi, & Rowland-Jones, 1998). This relationship is so close that cross-species transmission is the logical explanation, probably from the sooty mangabey monkey (Wain-Hobson, 1998). When comparing HIV-1 and HFV-2, the most similarity is in the core structure, with most differences occurring in the envelope region. To date HIV-2 has been mainly detected, and is thought to have originated, in western Africa. Countries in Africa where HIV-2 infection has a prevalence of more than 1 % and is considered endemic include Guinea-Bissau, Ivory Coast, Mozambique, Angola, Gambia, Mali, Mauritania, and the Cape Verde islands (Centers for Disease Control and Prevention, 1998b). Its prevalence is 8% to 10% in parts of Guinea-Bissau (Whittle et al., 1998). The first reported AIDS case in the United States due to HIV-2 was diagnosed in December 1987 in New Jersey in a patient who was originally from western Africa (Centers for Disease Control, 1988a). Through December 1997, 77 United States cases of HIV-2 infection had been reported to the Centers for Disease Control and Prevention, 52 of these patients were born in western Africa (Centers for Disease Control and Prevention, 1998b). Based on screening for antibody in frozen sera, it is concluded that HIV-2 may have been present in western Africa since at least 1966 (Kawamura et al., 1989). HIV-2 is transmitted in the same ways as HIV-1, but it appears less transmissible sexually and perinatally. Persons with HIV-2 develop similar opportunistic infections and conditions but progression is slower in HIV-2 infection than in HIV-1 (Whittle et al., 1998). HIV2 testing is indicated for persons who have an illness suggestive of HIV infection but whose HIV-1 test results are not positive and for persons for whom the HIV-1 Western blot exhibits the unusual indeterminate test band pattern of Gag plus Pol in the absence of Env, which are HIV proteins (Centers for Disease Control and Prevention, 1998b). No FDA-licensed HIV-2 viral load assay is available at present, and those assays used for HIV-1 are not reliable for use in patients infected with HIV-2. The best approach to treatment for HIV-2 is still not elucidated. Zidovudine therapy to interrupt perinatal transmission should be considered for HIV-2-infected preg-

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

11

nant women, and therapy for their newborns should be initiated as described later in this chapter and in chapter 11 (Centers for Disease Control and Prevention, 1998b). ORIGIN OF HIV AND AIDS Scientists have remained interested in the origin of the human immunodeficiency virus for various reasons since identifying the origin and how the virus causes disease in other hosts might give clues to control HIV (Essex & Kanki, 1988). Attention has focused on Africa as a possible site of origin for AIDS. It has been postulated that HIV crossed the host-species barrier and spread as a "virgin soil" epidemic. Such an organism may be harmless to its natural host but highly lethal to its new host. Various lines of evidence suggest that the natural host for HIV-1 may be chimpanzees, whereas for HIV-2 the animal host may be the monkey known as the sooty mangabey (Gao et al., 1999; Wain-Hobson, 1998). Researchers have been interested in determining whether or not HIV and/or AIDS had made an appearance before the outbreak of the epidemic. Various data and case reports have now appeared that indicate that HIV infection was at least sporadically present decades earlier. The question has been asked, Where was HIV hiding all these years? (Gallo & Montagnier, 1988). The logical question that follows is, Why did HIV infection and AIDS become rampant at the time that it did? Recently HIV viral sequences from early stored blood samples reveal that HIV-1 and HIV-2 probably diverged from a common ancestor, which they shared in the 1940s or early 1950s. HIV-1 probably was introduced into humans shortly before that time (Zhu et al., 1998). Various case reports and retrospective analysis of stored serum samples suggest the presence of AIDS in 1968 in the United States, and perhaps even earlier, although it has also been suggested that some positive serological results may have been artifacts due to prolonged storage (Garry et al., 1989). At this time, the earliest reported case known was in a Norwegian merchant seaman who was infected in 1961 or 1962 with HIV-1 group O in Cameroon and transmitted it to his wife and daughter. Another early reported case in Africa was that of a female Danish surgeon who contracted the disease while working in Zaire in 1976 and who died in 1977 (Bygbjerg,

12

THE PERSON WITH HIV/AIDS

1983). Other early cases appear to have occurred in Kinshasha in 1959 (Hooper, 1997; Nahmias et al., 1986). The subject of the origin of HIV and AIDS became a political one. Currently, it is believed that earlier cases of AIDS were sporadic in the United States and elsewhere, although HIV infection may have existed as an endemic disease in Africa (Garry et al., 1989). The World Health Assembly stated in 1987 that HIV is a "naturally occurring retrovirus of undetermined geographic origin" (Mann, Chin, Piot, & Quinn, 1988, p. 82). HIV PREVALENCE In the United States an estimated 750,000 persons have been infected with HIV and about 6 million new infections occur each year (Baiter, 1999; Cohen, Sande, & Volberding, 1998). Worldwide, 33.4 million persons are thought to be infected (UNAIDS/WHO, 1998). Although AIDS is reportable in all states and the District of Columbia in the United States, HIV infection is not. As of December 1998, HIV infection reporting to CDC was in place for 33 states and territories; of these, 3 have it only for pediatric cases—Connecticut and Texas for all pediatric cases and Oregon only for children under 6 years of age. Alaska, Texas, and New York began in 1999 (Centers for Disease Control and Prevention, 1998b). The prevalence of AIDS cases has increased because mortality rates have decreased and thus persons with HIV infection are living longer (Buve & Rogers, 1998). This trend is attributed to advances in treatment, especially the use of protease inhibitors. The incidence of pediatric AIDS has decreased due to zidovidine effectiveness in preventing perinatal HIV transmission. Whether these epidemiologic trends will continue is unknown at present. Over the years, the CDC and others have conducted various surveys of HIV infection prevalence based on the presence of antibodies to HIV among various population segments. These have included surveys of prevalence among groups at recognized risk such as intravenous/injecting drug users; homosexual/bisexual males; hemophiliacs; heterosexual partners of persons with HIV infection or at recognized risk; selected segments of the general population such as blood donors, military recruits, newborns, pregnant women, and

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

13

sentinel hospital patients; and persons in special settings, including prisoners, prostitutes, and persons with tuberculosis. HIV prevalence has been analyzed by geographic area, race, ethnicity, age, sex, and other variables. Detailed information about HIV incidence and prevalence is beyond the scope of this chapter. A detailed analysis for the United States can be found in the reference by Holmberg (1996). Results vary widely with geographic area and population studied. About 47,000 new HIV cases can be predicted yearly in the United States, with about half occurring in injection drug users (IDU), the majority of whom are located in the Northeast, Miami, and San Juan, Puerto Rico. Overall, HIV infection is declining in men who have sex with men; however, HIV infection rates among younger minority homosexual and bisexual men are two to three times those of older or white homosexual and bisexual men. The profile of the person in the United States who is at high risk for HIV infection is the young, minority, indigent woman who uses crack, has multiple sexual partners, has genital ulcer disease such as herpes simplex virus type 2 or syphilis, who trades sex for drugs, money, or both, and who lives in the inner city of the Northeast or the rural South (Holmberg, 1996). HIV prevalence is discussed further under "Worldwide Patterns." TRANSMISSION To date, HIV has been isolated from a variety of body fluids, cells, and tissues including peripheral blood, lymph nodes, brain tissue, cerebrospinal fluid, tears, bone marrow, cell-free plasma, saliva, retina, cornea, ear secretions, bronchial fluid, semen, breast milk, cervical cells, Langerhans cells of the skin and mucous membranes, synovial fluid, and cervical and vaginal secretions. HIV has not been recovered from sweat (Centers for Disease Control, 1988b; Centers for Disease Control and Prevention, 1997c; Pomerantz et al., 1987; Thiryetal., 1985; Withrington etal., 1987). However, the importance of these fluids, cells, and tissues in transmission varies, as does the concentration of HIV within them. The CDC has recommended standard precautions be applied to the following fluids in addition to blood: semen, vaginal secretions, cerebrospinal fluid, synovial fluid, pleural fluid, pericardial fluid, and amniotic fluid. Standard

14

THE PERSON WITH HIV/AIDS

precautions should apply to the following only if visible blood is present: feces, nasal secretions, sputum, sweat, tears, urine, vomitus, and breast milk (Centers for Disease Control, 1988b). Periods of higher infectiousness and transmissibility coincide with higher viral load on the part of the HIV-infected person and increasing immunosuppression. Characteristics of HIV itself such as the viral phenotype and its cellular tropism (macrophage or other) are also important in degree of transmissibility (Vermund, 1997). HIV can survive for a week or more in fluids such as water or blood. Recently, it has been demonstrated that viable HIV can be recovered from inside used syringes when maintained at room temperature (Abdala et al., 1999). The major documented ways that HIV can be transmitted are by intimate sexual contact, both homosexual and heterosexual, with an HIV-infected person; exposure to contaminated blood or blood products either by direct inoculation, sharing of drug apparatus, transfusion, or other methods; and through passage of the virus from infected mothers to their fetus or newborn in utero, during labor and delivery, or in the early newborn period. It has been postulated that HIV could be spread by insects such as mosquitoes, particularly in tropical climates (Blaser, 1986), but no evidence has been found to support this supposition. Presently, it is considered that other transmission modes (e.g., insect vectors or others) for HIV, if they exist, are extremely rare (Centers for Disease Control and Prevention, 1997c; Vermund, 1997). In 1998 the CDC published recommendations for the management of persons who had nonoccupational exposures to HIV. They define a nonsexual, nonoccupational exposure (excluding perinatal exposures) that can place a person at risk for HIV infection as a percutaneous penetration (e.g., a needlestick, injection, piercing, or cut with a sharp object); contact with mucous membranes; or contact with skin (especially when the involved skin is chapped, abraded, or affected by dermatitis; when the contact is prolonged; or when the involved area is extensive) and substances that have been implicated in the transmission of HIV infection (i.e., blood, tissues, or other body fluids when contaminated with visible blood). The Centers for Disease Control and Prevention (1998b) describes a sexual exposure that can place a person at risk for HIV infection as "a discrete penetrative sex act (e.g., acts involving the insertion

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

15

of the penis into the vagina, anus, or mouth) involving vaginal, anal, penile, or oral contact with the sex partner's potentially infectious body fluids, including substances that have been implicated in the transmission of HIV infection (i.e., blood, semen, vaginal secretions, or other body fluids when contaminated with visible blood)" (p. 1). The report stresses that these guidelines should not replace prevention of HIV infection. Prevention should not be considered as a "morning-after pill." Before therapy is begun after nonoccupational HIV exposure, the CDC recommends that "health-care providers may want to provide their patients with a system for promptly initiating evaluation, counseling, and follow-up services" after such high-risk exposure (p. 2). Evaluation should include counseling in relation to risk reduction behaviors and prevention of secondary transmission. Besides potential benefits in using antiretroviral agents for postexposure prophylaxis, there are also risks that include side effects, drug toxicity, acquisition of resistant HIV strains, and cost of therapy. The cost may range from $600 to $1,000 for a 28-day course of antiretroviral therapy. Antiretroviral therapy is not recommended for those with low-risk exposures such as potentially infected body fluid on intact skin, or for persons who seek care more than 72 hours after exposure (Centers for Disease Control and Prevention, 1998b). Considerations in caring for persons and considering initiating antiretroviral therapy after nonoccupational exposure are outlined in Appendix 1. Sexual Transmission In the United States early in the HIV epidemic the most common mode of spread was male-to-male sexual transmission. Men who have sex with men is still cumulatively the major exposure category for men into which nearly half (48%) of the reported United States AIDS cases fall. When the combined category of "men who have sex with men and inject drugs" is added, about 54% of all adult cases of AIDS in the United States fall into this exposure category (Centers for Disease Control and Prevention, 1998h). Heterosexual transmission of HIV can occur both from males to females and from females to males. Male-to-female transmission appears more efficient than female-to-male transmission. Heterosexual transmission is believed

16

THE PERSON WITH HIV/AIDS

to occur during both penile-vaginal and penile-anal intercourse, and more rarely through oral-genital contact (Vernazza, Eron, Fiscus, & Cohen, 1999; Vermund, 1997). Because HIV may be transmitted during heterosexual or homosexual rape, some experts have proposed mandatory testing (with counseling) of both victim and presumed assailant. HIV transmission due to artificial insemination from an infected donor has been reported, although efforts to remove HIV from semen for safe artificial insemination have been reported. There have also been reports of female-to-female sexual transmission (Greenhouse, 1987; Marmor et al., 1986; Monzon & Capellan, 1987), but this mode is very rare, and women who have sex with women may also have sex with men, have artificial insemination with sperm, or use injecting drugs (Carroll, 1999). Transmission by oral sex has also been described, but the risk is believed to be very low and result from blood contact (Centers for Disease Control and Prevention, 1997c, 1997d; Rozenbaum, Gharakhanian, Cardon, Duval, & Coulaud, 1988; Spitzer & Weiner, 1989). There have been reports of HIV infection among children who had no risk factors other than sexual abuse (Gellert & Durfee, 1989; Gellert, Durfee, Berkowitz, Higgins, & Tubiolo, 1993). The HIV infection epidemic has exposed an ignorance of the type and frequency of various sexual practices in the United States. Sex researchers have estimated that about 25% of American women occasionally engage in anal receptive intercourse and that about 10% do so on a regular basis for either pleasure or contraception (Boiling & Voeller, 1987). This is considered risky because of the possibility of the tearing of tissue leading to bleeding. Any blood contact during sex increases the risk of HIV transmission (Cohen et al., 1998). Acquisition of HIV may be made easier by genital ulcers, sexually transmitted diseases, or trauma, and the presence of inflammation or exudates that can facilitate virus entry into the cell. Menstruation may facilitate transmission, whereas menopause, resulting in vaginal dryness, may lead to trauma, thereby facilitating HIV transmission. First sexual experiences may be associated with bleeding, and immature vaginal tissue in young girls may be less resistant to trauma and bleeding. Infectious cells such as lymphocytes and macrophages that enter the genital tract because of the presence of one of the above are believed to increase transmissibility. Lack of circumcision in men is believed to result in higher intraurethral

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

17

and subprepucal loads of infectious cells that increase transmissibility. Thus having sex with an uncircumcised man may pose a greater risk of HIV transmission than engaging in sex with a man who is circumcised (Vermund, 1997; Vernazza et al., 1999). Social and cultural changes have contributed to sexual experimentation and freedom. These include oral contraceptive availability, decreasing fear of pregnancy, weakening of traditional values, openness about homosexuality, and advances in air transportation, allowing greater intermingling (Haverkos & Edelman, 1988). The consequences of these changes have been an increase in many sexually transmitted diseases and increased infertility. In addition to factors mentioned above and biological factors, sexual transmission of HIV is influenced by the number of different sexual partners likelihood that the sexual partner is infected (e.g., behaviors such as drug use) prevalence of HIV infection in the geographic area number of sexual exposures with an HIV-infected person status of rectal and vaginal mucosa (e.g., whether it is dry or if ulcers are present) presence of sexually transmitted diseases infectiousness of the partner (including viral load and use of

antiviral drugs) immune status of partners use of barriers during sex (e.g., proper use of latex condoms) degree of risky sexual behaviors that are practiced (Vermund, 1997; Vernazza et al., 1999). Transmission between regular sexual partners, only one of whom is HIV-infected (i.e., "discordant"), has been of particular interest for many reasons, including the potential for prevention of spread. This transmission rate has varied among different exposure categories and studies but has been reported as ranging as high as 85% in one study (Pinching, Weiss, & Miller, 1988). (Most studies show lower frequencies.) A review of 26 reported studies of heterosexual partners of persons at risk who do not have identified risk factors themselves showed a range of 0% to 58%, with a median of 24% (Centers for Disease Control, 1989). One study estimated that the risk of

18

THE PERSON WITH HIV/AIDS

contracting gonorrhea from an infected female in a single sexual encounter is about 25% (Holmberg, Horsburgh, Ward, & Jaffe, 1989). The risk of acquiring HIV per sexual act with an HIV-infected person has been estimated as follows: receptive anal intercourse (0.008 to 0.032), risk to women of vaginal intercourse (0.0003 to 0.002), and the risk to men of vaginal intercourse (0.0003 to 0.0014) (Cohen et al., 1998). In some cases, infectivity of receptive anal intercourse may be as high as 10% (De Gruttola et al., 1989). In fact, it has been somewhat puzzling that the figures for HIV transmission should be as relatively low as they are. Some persons have multiple continuing exposures to HIV-infected partners without acquiring it. Sexual transmission is further discussed under exposure categories for men who have sex with men and heterosexual contact elsewhere in this chapter. Bloodborne Transmission Transmission of HIV by exposure to contaminated blood or blood products occurs mainly through piercing of the skin with a contaminated needle or sharp object, transfusion from an infected donor to someone requiring blood because of temporary illness or surgery, or chronic illness such as hemophilia or dialysis, or through sharing of needles or other drug-related apparatus, especially among injecting drug users. Injuries from needles and sharp objects to health care workers also falls in this category of transmission, as do using contaminated needles and equipment employed for therapeutic purposes. Tattooing has also been implicated in the spread of HIV (Doll, 1988), as has ear and body piercing. Reports of confirmed HIV transmission during bloody flstfights are rare but possible (Ippolitto, Poggio, & Arice, 1994). Concerns about blood-related spread have resulted in various precautions during contact sports. For example, Nevada requires a mandatory HIV test for boxers, who, if positive, are disqualified. Other states with similar rules include New York, New Jersey, Washington, Oregon, and Arizona, as well as Puerto Rico (Feller & Flanigan, 1997). In some states boxing officials require persons assisting the fighter to wear plastic gloves (Gunby, 1988). Other athletic events are not similarly regulated, and more than HIV would need to be considered in any wide-ranging legislation.

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

19

HIV infection after acupuncture has been described (Vittecoq, Mettetal, Rouzioux, Bach, & Bouchon, 1989), as it has from receiving transplanted organs from an HIV-infected person (Centers for Disease Control, 1987a). While HIV infection from receiving a contaminated unit of blood is now relatively uncommon in the United States, efficiency of transmission is high. Nearly all those receiving an HIVcontaminated unit of blood IV develop infection (Vernazza et al., 1999). HIV transmission through blood is discussed further below. Perinatal Transmission The third major transmission mode is vertical transmission of HIV from an infected mother to her fetus or child in the perinatal period including pregnancy, delivery, and postpartum. Prenatal transmission has been supported due to several lines of evidence. HIV has been isolated from fetal tissue and amniotic fluid and cells, and p24 antigen has been detected in fetal blood obtained by fetal blood sampling (Jovaisas, Koch, Schafer, Stauber, & Lowenthal, 1985; Mundy, Schinazi, Gerber, Nahmias, & Randall, 1987; Viscarello, Cullen, DeGennaro, 8c Hobbins, 1992). In utero infection could occur from transplacental transmission of HIV or of HIV-infected maternal lymphocytes (Maury, Potts, & Rabson, 1989). Around the time of delivery, transmission is thought to take place due to contact with infected maternal blood and tissue, and most perinatal transmission is believed to occur close to the time of childbirth. Postdelivery, breastfeeding has been implicated in transmission of HIV and HIV has been isolated from breast milk (Centers for Disease Control and Prevention, 1998c). Major advances have occurred in preventing HIV transmission from a mother to her child, and transmission rates have decreased to reported lows of 13% in some developed countries (Bryson, 1996). In 1994 results of the AIDS Clinical Trials Group Study 076 were reported. This study demonstrated that perinatal transmission of HIV infection could be markedly (nearly 70%) reduced by the administration of zidovudine to HIV-infected women during pregnancy and delivery and to their infants after birth (Connor et al., 1994). More recently, the CDC has reaffirmed these guidelines and recommended zidovudine in a regimen that might include additional man-

20

THE PERSON WITH HIV/AIDS

agement aspects depending upon the woman's illness status, whether or not she had prior therapy, and other factors (Centers for Disease Control and Prevention, 1998c). In addition, it is noteworthy that recent research indicates that even short-term courses of treatment with either zidovudine or nevirapine has been shown to significantly reduce the vertical transmission of HIV (Dobis, Msellati, Meda, Welffens-Ekra, You, Manigart, et al., 1999; National Institute of Allergy and Infectious Diseases, 1999). (See also chapter 11.) These findings are important in efforts to reduce vertical transmission of HIV in developing countries where infected women are often unable to afford lengthy treatment with multiple retroviral agents. In addition to pharmacologic therapy, other measures to decrease perinatal transmission have been suggested based on observed risk factors. For example, an increased risk of perinatal HIV transmission has been reported for first-born twins (possible greater exposure to blood and fluids), duration of ruptured membranes of 4 hours or more, advanced maternal HIV disease, the shedding of cervical virus, low maternal CD4+ T-cell count, maternal viral load, maternal lack of ability to produce autologous neutralizing antibodies, and fetal exposure to blood or trauma during delivery. The premature infant has appeared more vulnerable to infection (Newell, Gray, & Bryson, 1997). Decreased risk has been suggested for caesarean section delivery for which the average risk reduction is said by some to be 20% while others have not found a difference between vaginal and caesarean delivery (Bryson, 1996; Landesman et al., 1996). However, more recent studies suggest that elective caesarean section reduces the risk of mother to child transmission of HIV (European Mode of Delivery Collaboration, 1999; Hudson, 1999; International Perinatal HIV Group, 1999). Therapeutic approaches have included adjustments in obstetric management, such as avoiding scalp electrodes and invasive prenatal diagnosis and using chlorohexidine for vaginal washing before delivery (Bryson, 1996). Vitamin A supplementation has been suggested as a way of reducing perinatal transmission of HIV because HIV depletes vitamin A in some way. Women who had vitamin A deficiency had increased transmission of HIV to infants, and an increase in HIV-DNA has been noted in breast milk (Nduati et al., 1995; Semba, Miotti, & Chiphangwi, 1995). However, this approach needs further evaluation because vitamin A in large doses is teratogenic.

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

21

The strongest data implicating breastfeeding in transmission originally resulted from case reports of women who acquired HIV from postparturn blood transfusions and whose infants were subsequently infected (LePage et al., 1987; Zeigler, Cooper, Johnson, & Gold, 1985). However, other studies have indicated that HIV-infected mothers did not transmit HIV to their infants while breastfeeding (Lifson, 1988). This argument has been resolved with the recovery of HIV-1 DNA from breast milk (Nduati et al., 1995). In developed countries such as the United States, the standard recommendations have been for women to refrain from breastfeeding if they are HIVinfected (Centers for Disease Control, 1985b; Centers for Disease Control and Prevention, 1998f). In developing countries, where perinatal transmission is more prevalent, the restriction on breastfeeding is more complex and can also be a political issue. Breastfeeding had traditionally been advocated by the World Health Organization (WHO) because of concern about infant morbidity and mortality that included an increased risk of infectious diseases, including diarrheal diseases, and poor growth and development (Global Program on AIDS, 1992). Cultural issues in regard to breastfeeding were also at issue, and in addition to an increased disease risk, the purchase of infant formulas represented a financial burden. WHO, United Nations Children's Fund (UNICEF), and UNAIDS support that if safe and affordable alternatives are available, HIV-infected women should not breastfeed. Praetors to consider in the breastfeeding decision in developing countries include the availability of safe water, access to what is needed to prepare sterile feedings, the social implications of not breastfeeding in the culture, affordability, and the understanding of what must be done to prepare safe feedings (Newell et al., 1997). Further complicating the picture is that at present, antiretroviral therapy during and after pregnancy has been recommended for HIV-infected women. Some of these drugs, such as zidovudine, nevirapine, and lamivudine, are detectable in human breast milk when administered to nursing women, and the effects of these on the nursing infant are not yet known (Centers for Disease Control and Prevention, 1998c). Studies suggest that not all HIVinfected mothers transmit HIV to their infants via breastfeeding. A meta-analysis of the literature in this area suggested the average risk has been reported at 30% (Newell et al., 1997). However, one recent study found that the overall postnatal HIV transmission rate for one

22

THE PERSON WITH HIV/AIDS

group of infants born to HIV-infected mothers by breastfeeding was about 5% (Leroy et al., 1998). Others have estimated a risk of about 14% to 15% (Dunn, Newall, Ades, & Peckham, 1992; Gray, Maclntyre, & Lyons, 1996). Kuhn and Stein (1997) have pointed out that short-term breastfeeding of under 3 months may allow the advantages of breastfeeding with less of a transmission risk of HIV than longer term breastfeeding would engender. Some children become infected postnatally after maternal antibodies are lost. Thus, early cessation"may prevent these cases (Leroy et al., 1998). In the Ivory Coast (Cote d'lvoire), a recommendation for stopping breastfeeding at 6 months for HIV-infected women has been made. It has also been suggested that HIV transmission in the postnatal period might occur through Langerhans cells of the skin. Cocchi and Cocchi (1988) suggested that infants, because of their thin skin and mucous membranes, might be vulnerable to HIV entry through either intact or denuded skin. Therefore, washing the neonate after birth has been suggested for prevention (Newell et al., 1997). New ways of thinking about infant feeding in developing countries are needed. More information is also needed about vertical transmission and its prevention, especially in developing countries. Other Modes The presence of HIV in body fluids such as saliva and tears has caused concern among the public about the possibility of other modes of transmission, such as kissing, shaking hands, and other casual contacts. For nonsexual contacts of persons with AIDS or persons infected with HIV, the risk for acquiring infection appears very low or nonexistent. Except for those having sexual contact with an infected person, or children born to infected mothers, there is scant evidence of casual or household transmission (Centers for Disease Control and Prevention, 1997c). In one case in which a mother acquired HIV from her infected infant son, she was exposed to numerous secretions and apparently did not always follow recommended precautions (Centers for Disease Control, 1986). Another reported 1986 case suggests that transmission may have occurred between two young siblings via a bite that did not break the skin of the noninfected child (Allen & Curran, 1988). Other cases of apparent

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

23

transmission of HIV during biting incidents with blood presence have been reported (Centers for Disease Control and Prevention, 1997c). In a rare incident, HIV transmission occurred from an HFVinfected dentist to six of his patients (Centers for Disease Control, 1990), and an HlV-infected orthopedic surgeon in France may have infected one of his patients (Lot et al., 1999), but such cases are uncommon. The exchange of saliva during intimate kissing has not been completely exonerated as a route of HIV transmission, although if it exists, its actual occurrence is very rare. Microlesions of the oral mucosa have been demonstrated to occur during passionate kissing (Piazza et al., 1989). A case report of possible transmission in this manner involved the wife of a man who was infected with HIV by blood transfusion and who was impotent but was found to be viremic on one occasion (Haverkos & Edelman, 1988; Salahuddin et al., 1984). It is believed that contact with blood during kissing is needed for transmission of HIV in this manner (Centers for Disease Control and Prevention, 1997d). There may be inhibitory mechanisms in saliva that prevent HIV transmission (Baron, Poast, & Cloyd, 1999). Oro-genital contact has been implicated in the transmission of various viral sexually transmitted diseases including human papillomavirus infection (Cohen et al., 1998). TRANSMISSION AND HEALTH CARE WORKERS Health care workers are exposed to many health and safety hazards in the hospital setting. Many of these involve infectious agents such as HIV, hepatitis A, and hepatitis B. Thus, nurses and other health care workers need to follow recommended safeguards in order to protect themselves and be assertive in being sure that such safeguards are available to them. HIV seroconversion after an accident in the work setting has been a source of concern for health care workers. Early information on this risk came from the CDC Cooperative Needlestick Surveillance group, which consisted of 335 institutions throughout the United States. In the period from August 15, 1983, through April 20, 1989, 1,449 injured health care workers were identified as meeting the study criteria, and 1,172 of these were enrolled in the CDC prospective study (Marcus and the Cooperative

24

THE PERSON WITH HIV/AIDS

Needlestick Surveillance Group, 1989). Eighty percent of the injuries resulted from needlestick, 8% from cuts with sharp objects, 7% from contamination of open wounds and 5% from mucous membrane contamination. The overwhelming majority of accidents occurred in the patients' rooms (64%), followed by the intensive care unit (13%). The majority of the health care workers enrolled in this longitudinal study were nurses (63%), followed by physicians (14%). As many as 37% of the exposures were believed to be preventable. The greatest number of the preventable exposures occurred when caregivers either recapped needles or improperly disposed of needles and/or sharp objects. The greatest number of injuries (36%) occurred while manipulating an intravenous, phlebotomy, or arterial needle. Of those health care workers tested at 180 days after exposure, 4 were HIV seropositive, and all of these had received either a needlestick or cut with a sharp object. None of those in this study who had mucous membrane contamination or nonintact skin seroconverted (Marcus and the Cooperative Needlestick Surveillance Group, 1989). Since that time more data have been obtained regarding the risk for health care workers. However, the same basic pattern of the types of objects causing injury remain, and this information should be used in applying prevention and education. It is currently estimated by CDC that the average risk for HIV transmission is approximately 0.3% and 0.09% for percutaneous and mucous membrane exposure to HIV-infected blood respectively (Centers for Disease Control and Prevention, 1998d). Ippolito et al. (1999) estimate risk at below 0.5% for percutaneous or mucous membrane and higher for higher risk exposures. As of June 1997, 52 United States health care workers had documented HIV seroconversion after an occupational exposure to HIV, and an additional 114 were considered as "possible." Of the 52 documented cases, 47 were exposed to HIV-infected blood, 1 to bloody body fluid, 1 to an unspecified fluid, and 3 to concentrated virus in the laboratory. Most exposures (45) were percutaneous, and needles were involved in 41 cases (Centers for Disease Control and Prevention, 1998d). HIV seroconversion was examined, and among those who did seroconvert, 81% had a syndrome like that of primary HIV infection a median of 25 days after exposure; in one analysis the estimated median interval from exposure to seroconversion was 46 days, and the mean was 65 days. These intervals are similar to

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

25

those of persons who acquire HIV infection nonoccupationally (Centers for Disease Control and Prevention, 1998d). It is considered that occupational exposures are underreported (Henderson, 1999). Various factors increase the risk for HIV acquisition after occupational exposure, including exposure to a larger quantity of blood from the source patient, source patients with terminal illness reflecting factors such as the presence of syncytia-inducing strains, and a high viral load, as well as whether the device causing injury was used to enter the patient's blood vessel or had visible blood (Gerberding, 1997). Low viral loads in source patients do not rule out the possibility of transmission. Host factors also influence acquisition of HIV, including immune responses and HIV-specific cytotoxic T lymphocyte (CTL) response when peripheral mononuclear cells in the blood were stimulated in the laboratory with HIV mitogens (Centers for Disease Control and Prevention, 1998d). Current thinking is to try to interrupt or ameliorate HIV infection as soon as possible after exposure. This is presently accomplished through the use of postexposure prophylaxis (PEP) (Buchbinder, 1998). As discussed in chapter 5, it now appears that there is a brief "window of opportunity" that occurs after exposure and before systemic infection. In primate studies, migration of dendriticlike cells containing virus did not occur until 24 to 48 hours after infection. Thus, early counseling and antiretroviral therapy, if chosen, should be accomplished within 24 hours. In one retrospective case control study, the risk for HIV infection among those health care workers who used zidovudine for postexposure prophylaxis was reduced 81% (Cardo et al., 1997). However, failures have also been reported (Jochimsen, 1997). In choosing the regimen that should be followed for PEP, efficacy is one consideration, as is the need for adherence to the regimen; thus, side effects and toxicity are major considerations in maximizing adherence. Employers are required to have exposure control plans, and it is important that health care workers report any exposure immediately. When occupational exposure occurs, the report should include the date and time of exposure, details about what was being performed, details of exposure including duration of contact, amount of fluid or material injected, details about the exposure source or person, and details about counseling, management, and follow-up. After exposure the site should be washed with soap and water immediately (flushed with water for

26

THE PERSON WITH HIV/AIDS

mucous membranes). The CDC has a variety of algorithms to follow based on the type of exposure resulting in recommendations for a basic or expanded regimen that also includes consideration of whether the health care worker is pregnant or has any relevant conditions or is taking other medications (Centers for Disease Control and Prevention, 1998d). These are shown in Figures 1.1 and 1.2. Baseline evaluation and HIV testing should be done to establish serostatus at the time of exposure, and subsequent testing at 6 weeks, 3 months, and 6 months is recommended. The basic regimen usually consists of both zidovudine and lamivudine for 4 weeks, while the expanded regimen adds a protease inhibitor, usually either indinavir or nelfinavir, to it (Buchbinder, 1998; Centers for Disease Control and Prevention, 1998d; Gerberding, 1997). NATURAL HISTORY OF HIV INFECTION Much new information about the course of HIV infection has been acquired. Formerly it was believed that after infection with HIV there was a period of latency during which HIV was thought to be quiescent. New knowledge has disproven a period of quiescence, as discussed in chapters 2 and 5. Still, questions remain: Will HIV infection progress to clinical disease and/or AIDS in all cases? What factors influence this progression? Will all who develop AIDS die? After acquisition of HIV, many (but not all) individuals develop an acute illness similar to flu, with symptoms commonly appearing in about 2 to 6 weeks. This initial acute illness represents primary infection and is usually self-limited. After this acute illness, clinically speaking, most persons enter an asymptomatic phase, although in some cases lymphadenopathy may persist or other clinical symptom begin. It is now believed that this postacute period represents a unique opportunity for early treatment. (Primary HIV infection is discussed in chapter 5.) After infection, antibodies to HIV may appear by 3 to 6 weeks and are nearly always present by 3 months postHIV infection, although in some cases seroconversion may take 6 months or longer. This early period, during which the person is infected with HIV but does not demonstrate antibodies, has often been termed the "window period." Rarely, some individuals may not remain HIV seropositive but are still latently infected with HIV

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

27

FIGURE 1.1 Determining the need for HIV postexposure prophylaxis (PEP) after an occupational exposure: step 1.* Source: Centers for Disease Control and Prevention. (1998). Public health service guidelines for the management of health care worker exposures to HIV and recommendations for postexposure prophylaxis. Morbidity and Mortality Weekly Report, 47(No. RR-7), 14.

28

THE PERSON WITH HIV/AIDS

FIGURE 1.2 Determining the need for HIV postexposure prophylaxis (PEP) after an occupational exposure: steps 2 and 3.* Source: Centers for Disease Control and Prevention. (1998). Public health service guidelines for the management of health care worker exposures to HIV and recommendations for postexposure prophylaxis. Morbidity and Mortality Weekly Report, 47(No. RR-7), 15.

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

29

(Farzadegan etal., 1988). Phases of HIV infection can be conceptualized as the early or acute phase, which lasts for weeks; the middle or chronic phase, which can last for years and during which changes begin to occur; and the final, or crisis, stage, which can last months to years. Another critical question is, What is the time between becoming infected with HIV, developing steadily declining CD4+ cell counts, and manifesting symptoms and conditions, leading eventually to a diagnosis of AIDS? Various observations and projections have been made regarding progression to clinical illness with variations in estimated outcomes. These differences may be due to several factors, including the route by which HIV was acquired; patient factors (e.g., age, immune status, and the presence of other infections), cofactors, viral factors (e.g., the viral dose received and virulence), and assumptions (e.g., estimated rates of disease progression) made in those studies using mathematical models. In examining percentages of HIV-infected persons who progress to AIDS, data also result from observation, mathematical projections, and/or a combination of both. On average, before protease inhibitor therapy, the time between initial infection and the development of AIDS was about 10 to 12 years (Mellors et al., 1996). Persons who acquire HIV infection may be categorized as follows: rapid progressors typical progressors slow or non-progressors Rapid progressors are those whose time between infection and progression to AIDS is within 5 years. Slow progressors are those who will not develop AIDS within 20 years after infection (Mellors et al., 1996). At this time, most researchers believe that the ultimate outcome of AIDS is death. However, the longer that HIV-infected persons can survive without progressing to AIDS, and the longer persons can survive once they develop AIDS, the more hope there is to postpone a fatal outcome. The development, approval, and application of newer drug protocols should contribute to less morbidity and a longer life span. Ongoing vaccine development also holds the potential to prevent HIV infection.

30

THE PERSON WITH HIV/AIDS

COFACTORS AND RISK FACTORS IN ACQUISITION AND PROGRESSION While HIV is the etiologic agent of AIDS, other factors may also play a role. Cofactors are elements that may influence acquisition of HIV, efficiency of its transmission, development of specific clinical manifestations of AIDS, disease progression, and/or ultimate survival. Cofactors may act with HIV to modulate clinical expression. Proposed cofactors include those relating to the host, the organism, the environment, and the interaction effect of individual factors. Several factors might act together in producing a common effect, such as subclinical preexisting immune dysfunction occurring because of repeated exposure to antigens; repeated exposure to absorbed semen; exposure to infectious diseases, such as hepatitis B or tuberculosis, as well as chronic infections or parasitic diseases such as malaria; use of immunosuppressant drugs; pregnancy; malnutrition; and genetic susceptibility or even stress. The extent of the importance of such susceptibility factors and determinants remains speculative in many instances. Some factors associated with sexual transmission, such as genital ulcer disease due to both syphilis and herpes simplex virus, have been discussed. The consistent recovery of HIV from genital herpes simplex lesions suggests these lesions increase efficiency of sexual transmission of HIV (Schacker et al., 1998). As discussed in the section on natural history, increased age appears to be a major determinant in rapidity of disease progression. Behavioral factors such as types of sexual practices and the use of drugs and alcohol may play a role. These might act through the induction of immunosuppression or by reducing inhibition resulting in risky behavior. Amyl and butyl nitrites used during anal intercourse may cause vasodilation or may result in more vigorous intercourse and tearing, leading to a higher risk of HIV transmission (Cohen etal., 1998). Various host genes have been noted to play roles both in susceptibility to HIV and in progression to AIDS. The major ones of interest currently are the major histocompatibility genes such as HLA and genes determining receptors for chemokines as well as those for mannose-binding protein. The HLA complex is the major histocompatibility locus in humans and is located on chromosome 6. Meaning ful HLA associations are known for a variety of other diseases, such

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

31

as narcolepsy and ankylosing spondylitis. The exact nature of disease associations and HLA has remained unclear, although various theories exist that are related to the immune system. Persons can possess various combinations of the HLA genes which are present as a haplotype. For a review of HLA, see Lashley (1998). The haplotypes most associated with faster progression to AIDS are HLA Al-Cw7-B8-DR3DQ2 and HLA All-Cw4-B35-DRl-DQl. Association with faster progression to AIDS has also been demonstrated for A23, A24, A26, B21, and B38, whereas delayed progression has been shown for B17, B27, B51, B57, DR4, and DR7. Interactions between tumor antigen protein (TAP) alleles and HLA combinations may take place as well. Genes coding for complement are also in the HLA region. Complement C4A and C4B null alleles result in impaired antibody responses and have been demonstrated to be associated with rapid progression to AIDS (Roger, 1998). SDF1 chemokine gene variants may also influence progression (Maglerowska et al., 1999). In the process of HIV infection, HIV enters the cell by interaction with its viral envelope glycoprotein (gp!20) and cell surface molecules CD4+ and various coreceptors. The most important coreceptors are the (3 (or CC) chemokine receptor, CCR5, expressed mainly in peripheral blood mononuclear cells (PBMC) and macrophages, and the a (or CXC) chemokine receptor, CXCR4 found in PBMC, macrophages and also other tissues and cells (Sol et al., 1997). Some HFV1 strains can use both or additional chemokine receptors such as CCR3 and CCR2b. Some persons have a specific mutation in CCR5 that involves a deletion of 32 nucleotides (532-CCR5) that results in a loss of activity. This mutation occurs in about 1 % of the Caucasian population and is rare in others. Those who are homozygous (have two copies) of this mutant allele appear to be resistant to HFV-1 infection, although there are exceptions to this (Bid et al., 1997; Malo et al., 1998; Roger, 1998; Theodorou et al., 1997). In some studies those who were heterozygous (had one mutant allele and one normal allele) demonstrated slower progression to AIDS and had a slower rate of decline of CD4+ T cells and/or lower viral loads (Phair, 1999). This understanding does not fully explain long-term survival, since the majority of long-term survivors do not have this mu tation. Other mutations of CCR5 may also result in protection (Quillent et al., 1998). A specific polymorphism (CCR2b-64I) apparently does

32

THE PERSON WITH HIV/AIDS

not influence susceptibility to HIV infection but may result in slower progression to AIDS in both the heterozygous and homozygous state in both Caucasians and African Americans (Phair, 1999). There may be both independent and interactive effects. Mannose-binding protein activates complement and phagocytosis and is an opsonic factor. Certain variant alleles in the homozygous state appear to confer greater susceptibility to HIV infection (Roger, 1998). Characteristics of HIV itself appear to influence disease progression. HIV is replicating throughout the course of infection, even when the person is clinically asymptomatic; thus, while virus levels in the blood may appear stable, HIV is actually rapidly turning over (Fauci, 1996). The steady state of virus in the blood that is established early in HIV infection predicts rapidity of progression, as discussed in chapter 5. Some other viral factors influencing progression include viral replication, cellular tropisms, cytopathicity, and the propensity to mutate. However, these viral factors interplay with host factors and the environment. Viral replication occurs most efficiently in activated cells; thus, when the immune system is activated with a concurrent infection such as TB or chronic parasitic infections, HIV replication is increased. HIV-inducing cytokine expression also occurs. There are macrophage tropic HIV strains and those that are T cell tropic that do not usually infect macrophages and are usually syncitium inducing. Various strains may influence cell infections, and long-term nonprogressors often show a dominance of M strains (Fauci, 1996). HIV-1 subtypes may also differ in the rate of progression to AIDS (Kanki et al., 1999), but this has not been a consistent finding (Hu et al., 1999). Various studies have examined progression to AIDS in HlV-infected individuals. Some earlier studies had suggested progression differences among exposure categories, whereas others did not (Carre, Deveau, Balange, et al., 1994; Chaisson, Keruly, & Moore, 1995). Recent studies suggest that if age is considered as a covariate, there are no significant differences among various exposure categories in progression to AIDS. Age at seroconversion, however, does appear to be a major factor and more rapid progression has been noted in older individuals regardless of exposure categories or sex (Darby, Ewart, Giangrande, Spooner, & Rizza, 1996; Pezzotti et al., 1996; Rezza, 1998). Other associations with progression is that those who have symptomatic acute primary infections progress faster than

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

33

others and that early antiretroviral treatment retards progression (Rezza, 1998). Kaposi's sarcoma is said to accelerate the clinical course of HIV infection (Brodt, Kamps, Helm, Schofer, & Mitrou, 1998). Among male and female IDUs, progression to clinical AIDS was associated with crack-cocaine use (Webber et al., 1999). STATISTICAL PATTERNS IN THE UNITED STATES By December 31, 1998, 688,200 cases of AIDS had been reported to the Centers for Disease Control and Prevention (CDC). Of these, 679,739 cases occurred in adults or adolescents (13 years of age or over). The number of pediatric (under 13 years of age) cases reported was 8,461. The case fatality rate from before 1981 to December 1998 was about 60%. Among adults, 83.9% of cases occurred i males; among children under 13 years of age, approximately 51.5% were male (Centers for Disease Control and Prevention, 1997b, 1998h). Table 1.5 shows the distribution of cases by age group. A decrease of about 25% in deaths among persons with AIDS in the United States was noted in 1995 and 1996 (Centers for Disease Control and Prevention, 1997b); in 1997 the death rate from AIDS TABLE 1.5 U.S. AIDS Cases by Age at Diagnosis Reported to CDC through December, 1998 Age at diagnosis (years)

Number

Percentage*

Under 5 5-12 13-19 20-29 30-39 40-49 50-59 60+

6,574 1,887 3,423 117,717 310,196 176,239 52,437 19,724

1.0 0.27 0.5 17.1 45.1 25.6 7.6 2.9

Total

688,200

*May not add up to 100.0% due to rounding error. Source; Centers for Disease Control and Prevention. (1998). HIV/AIDS Surveillance Report, Vol. 10, No. 2, 1-43.

34

THE PERSON WITH HIV/AIDS

in the United States decreased almost 50%. In 1997 AIDS was the 14th cause of death in the United States (Perlman, 1998). Distribution by exposure category is discussed later in this chapter. The total number of persons living with AIDS has increased and the number of deaths decreased in 1997. These findings have been attributed to the use of combinations of antiretroviral therapy, including protease inhibitors and prophylaxis for opportunistic infections (Centers for Disease Control and Prevention, 1998h). There has not been a concomitant decline in the number of newly diagnosed HIV cases among young people. In 1999 AIDS was the second leading cause of death for Americans between 25 and 44 years of age and is the leading cause of death for African-Americans in this age group (Centers for Disease Control and Prevention, 1998g; Perlman, 1998). Geographic Distribution AIDS has been reported in all 50 states plus the District of Columbia (Centers for Disease Control and Prevention, 1998h). Since the onset of the epidemic, shifts in the geographic distribution of AIDS have occurred. Before 1983, New York, New Jersey, and Pennsylvania reported 63% of all AIDS cases in the United States, whereas as of the end of 1997, they accounted for only about 27% (Centers for Disease Control, 1989; Centers for Disease Control and Prevention, 1998h). As of December 31,1998, the highest cumulative percentage of AIDS cases (both adult and pediatric) was from New York state, which had about 19% of the total number. California reported the second highest, about 16%, followed by Florida (10.2%), Texas (7.0%), and New Jersey (5.6%). Those states having the lowest numbers of AIDS cases were North Dakota, South Dakota, Wyoming, Montana, Vermont, and Idaho. An examination of AIDS annual incidence rates per 100,000 population for states in 1998 reveals that Washington, D.C., had the highest rate, followed by New York, Florida, Maryland, New Jersey, Delaware, Louisiana, Connecticut, South Carolina, and Texas (Centers for Disease Control and Prevention, 1998h). Standard Metropolitan Statistical Area (SMSA) data regarding cases of AIDS by residence showed the greatest cumulative totals in

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

35

1998 reported in New York, Los Angeles, San Francisco, Miami, Washington, D.C., Chicago, Houston, Philadelphia, and Newark. The highest AIDS incidence rates per 100,000 population for 1998 in SMSAs with populations of 500,000 or more were New York (85.9), Miami (73.3), San Francisco (57.6), Fort Lauderdale (55.6), San Juan, Puerto Rico (53.1), and Jersey City (58.9) (Centers for Disease Control and Prevention, 1998h). In some rural areas, HIV and AIDS are increasing, especially in the South (Voelker, 1998). Sex Distribution As of December 31, 1998, the cumulative number of female cases of AIDS reported to the CDC was 109,311, accounting for 15.9% of all reported adult cases. Females also accounted for nearly half of reported pediatric cases. For new cases of AIDS in 1998 in the U.S., women accounted for 23% (Centers for Disease Control and Prevention, 1998h). The rates of AIDS in U.S. women have been rising. Between 1991 and 1995, the number of women reported with AIDS increased by 63%, more than any other group (Wortley & Fleming, 1997). For women, the major exposure category is IDU, accounting for about 43% of reported cases, followed by heterosexual contact (about 39%). When the category of IDU and the subcategory of "sex with IDU" is added, then about 60% of all AIDS cases in women are known to be related to IDU in some way (Centers for Disease Control and Prevention, 1998h). AIDS continues to have a disproportionate impact on minority women. In terms of prevalence, AIDS in women is as follows: Black, non-Hispanic 56.6%; White, non-Hispanic 22.4%; and Hispanic 20.1%; with the remainder in other groups. However, the 1998 AIDS incidence rates for U.S. women show the following: Black, non-Hispanic, 61.6%; Hispanic, 18.7%; and White, non-Hispanic, 18.5%, with the rest distributed as "other" (Centers for Disease Control and Prevention, 1998h). The majority of women with AIDS live in urban areas of the Northeast, but there has been a rapid increase in cases in women who live in the South (Wortley & Fleming, 1997). As discussed below, the proportion of new cases of AIDS in younger women is increasing. These trends indicate directions for future prevention, as discussed in chapter 3. There is no separate category for women who have

36

THE PERSON WITH HIV/AIDS

sex with women. Through 1996, of women with AIDS who reported that they had sex only with other women, 97% had another risk factor such as injecting drug use. This supports the proposition that woman-to-woman transmission of HIV is not common. However, education that includes the premise that sexual identity does not always predict behavior must be included in prevention (Centers for Disease Control and Prevention, 1997a).

Age Distribution In regard to age, the peak age range for reported AIDS cases at diagnosis cumulatively for males is 30 to 39 years of age, with abou 86% falling between the ages of 25 and 49 years. For females, the cumulative peak age range is also 30 to 39 years, with about 80% falling between the ages of 25 and 49 years. However, in looking at the year 1997, the proportion of women with AIDS is highest for the age group of 13 to 19, a finding similar to that for men (Centers for Disease Control and Prevention, 1998g). Persons 60 years of age and older account for about 3% of both male and female cases (Centers for Disease Control and Prevention, 1998h). Although this number is small, too often sexual practices in older persons are not discussed. A recent study showed that nearly half of those over 60 years of age engaged in sex at least once a month (Leary, 1998). Older people may also engage in IDU or have greater medical needs involving transfusion or transplant (Cohen, 1995). HIV was reported in a woman of 89 years of age (Rosenzweig & Fillit, 1992). Nonmonogamous sexual relationships are becoming increasingly common in the elderly, and they may not be engaging in safer sex such as condom use (Chiao, Ries, & Sande, 1999). Health care professionals often do not discuss safer sex or assess injecting drug use in elderly patients (Cohen, 1995). As discussed earlier, adolescents may be at particular risk for HIV acquisition. Adolescence is a time of risky behavior and exploring, with a high use of alcohol and experiments with drugs and sex. Data pertaining to adolescents from the Youth Behavior Survey are discussed later in this chapter. Gay adolescents who are first recognizing their homosexuality may engage in more risky behavior, and

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

37

adolescents who are alienated may engage in risky sex in exchange for money for living or for drugs. Racial/Ethnic Distribution The approximate racial composition of the United States is about 72% White non-Hispanic, 12% Black non-Hispanic, 11% Hispanic, and 5% other (U.S. Census Bureau, 6/23/99). However, AIDS cases in adults at the end of 1998 was distributed ethnically as follows: White, non-Hispanic persons, 44.5%; Black, non-Hispanic persons, 36.3%, and Hispanic persons, 18.1%. For pediatric cases of AIDS the distribution was Black, non-Hispanic persons, 58.3%; Hispanic persons, 23.1%; and White, non-Hispanic persons, 17.6% (Centers for Disease Control and Prevention, 1998h). (Pediatric AIDS is further discussed in chapter 12.) For all exposure categories, reported persons with AIDS in the United States are disproportionately Black and Hispanic. These differences have been attributed to such factors as nutritional status and social and economic conditions (e.g., access to quality health care) rather than race per se. When examined by exposure categories, there is particular disproportion in the category of injecting drug use for both men and women, with Black nonHispanic persons accounting for 53.3%, Hispanic persons for 26.0%, and White, non-Hispanic persons for 20.0% of individuals with AIDS in this category at the end of 1997 (Centers for Disease Control and Prevention, 1998h). It has been suggested that this reflects higher prevalence of injecting drug use in these same ethnic groups. For men who have sex with men (MSM), the racial/ethnic distribution at the end of 1997 was as follows: White, non-Hispanic persons, 63.0%; Black, non-Hispanic persons, 22.2%; and Hispanic persons, 13.4%, with others comprising the rest. In the category of heterosexual transmission at the end of 1997, the racial/ethnic distribution was also disproportional and was as follows: Black, non-Hispanic, 55.7%; Hispanic, 22.5%; and White, non-Hispanic, 20.7%, with the remainder comprised of others (Centers for Disease Control and Prevention, 1998h). New cases of HIV infection in the categories of MSM, IDU, and heterosexual contact appear to be occurring at disproportionately higher rates in minorities. The annual adult AIDS incidence rates per 100,000 by racial/ethnic group overall for 1998

38

THE PERSON WITH HIV/AIDS

were Black, non-Hispanic, 84.7; Hispanic, 37.8; White, non-Hispanic, 9.9; Asian, Pacific Islander, 4.8; and American Indian/Alaska Native, 9.7 (Centers for Disease Control and Prevention, 1998h). These data are useful in planning prevention programs. WORLDWIDE STATISTICS AND PATTERNS As of the end of 1998, about 33.4 million people worldwide were living with HIV/AIDS (UNAIDS/WHO, 1999). For many countries in the world, the reporting of AIDS may be less than reliable, and the definitions used to define AIDS may vary; however, accuracy has increased over the years. Of the 33.4 million people currently estimated to be living with HIV/AIDS, the distribution is as follows: Adults: 32.2 million Women: 13.8 million Children under 15 years of age: 1.2 million Worldwide, about 13.9 million persons, including 3.2 million children, have died of AIDS since the beginning of the epidemic. The number of AIDS orphans (children who lost their mother or both parents to AIDS when they were under the age of 15 years) since the beginning of the epidemic is about 8.2 million. When the worldwide AIDS epidemic was first examined, various geographic patterns were described on the basis of predominate exposure categories seen. These are not currently used, because the spread of the epidemic is complicated even within continents. Nearly 90% of people with HIV live in sub-Saharan Africa or Asia (UNAIDS/WHO, 1999). The toll has been tremendous, particularly in the developing countries of Africa, Asia, and Latin America. The worldwide AIDS statistics are shown in Table 1.6. The number of people living with HIV/ AIDS is shown in Table 1.7. Asia did not experience a major HIV epidemic until the late 1980s. As of June 1998, the greatest number of Asian AIDS cases has been reported by Thailand, followed by India, Myanmar (formerly Burma), Japan, Malaysia, and Vietnam (World Health Organization, 1998). The total number of AIDS cases for Asia reported to the World Health Organization as of June 1998 was 101,429. The distribution of

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

39

TABLE 1.6 Reported AIDS Cases Worldwide as of June 20, 1998 Area Africa Americas Asia Europe Oceania Total

Number 686,256 889,465 101,429 107,890 8,744 1,893,784

Source: World Health Organization. (1998). Global AIDS surveillance. Weekly Epidemiological Record, 73, 193-200.

TABLE 1.7 Adults and Children Living with HIV/AIDS Worldwide, December, 1998 Region

Number

Sub-Saharan Africa North Africa & Middle East South & South-East Asia East Asia & Pacific Latin America Caribbean East Europe & Central Asia Western Europe North America Australia & New Zealand

22.5 million 210,000 6.7 million 560,000 1.4 million 330,000 270,000 500,000 890,000 12,000

Total

33.4 million

Source: UNAIDS/WHO. AIDS epidemic update: December, 1998. UNAIDS Joint United Nations Programme on HIV/AIDS, 1-17.

these cases by transmission category varies by country. For example, in Thailand, about 75% of cases fall into the heterosexual transmission category, as do about 85% of cases in Laos, 78% of cases in India, and 77% in the Republic of South Korea. In China, about 53% are reported as due to IDU, as are about 71% in Myanmar, all in Vietnam, and 44% in Malaysia. The classification of "homosexual" is applied to about 52% of cases from Hong Kong, 51 % in Indonesia, 56% in Singapore, 37.1% in the Philippines, and 23.5% in Malaysia

40

THE PERSON WITH HIV/AIDS

(Li & Yeoh, 1996). India is said to have about four million people living with HIV, the largest number of HFV-infected persons of any country in the world. HIV prevalence varies across India. In Pondicherry, the rate of HIV infection in pregnant women was about 4%. A study of HIV prevalence in truck drivers in Madras showed an increase from 1.5% in 1995 to 6.2% in 1996. In Thailand, in 1996, about 2.3% of adults were estimated to be HlV-infected. The incidence of HlV-infection among sex workers appears to be falling in part due to educational measures, but among IDUs the prevalence has stabilized at about 40%. In studies of HIV prevalence in Cambodia, the following were found: 1 in 30 pregnant women, 1 in 16 soldiers and police, and almost 1 in 2 sex workers tested HIV positive. In Myanmar, HIV infection among sex workers in 1996 was about 20%, and about two thirds of that country's IDUs are HlV-infected (UNAIDS/WHO, 1998). In the Americas, about 890,000 cases were reported as of June 20, 1998. Without including the United States, this total is 248,417 (World Health Organization, 1998). The country reporting the highest number of cases was Brazil, followed by Mexico, Argentina, Colombia, Canada, Honduras, and Haiti. The incidence rate per 100,000 for 1996 was highest in the Bahamas (1,335.7), French Guiana (478.1), Jamaica (213.8), Grenada (190.9), Guyana (170.6), Antigua and Barbuda (168.8), Dominica (168.7), Honduras (137.0), Barbados (494.3), Belize (171.9), and Brazil (101.3). Looking by region, the highest incidence is for the Caribbean (246.2), followed by Central America (75.6). There are variations seen in transmission categories by subregions. Homosexual transmission is highest in the Andean area (58.7%), followed by Mexico (55.8%). IDU is highest in the southern cone (29.3%). Heterosexual transmission is highest in the Caribbean region (77%), followed by Central America (64%) and the Andean area (34.8%) (Cohen et al., 1998). In Brazil, about 20% of the HlV-infected adults are women, and about half of IDUs are HlV-infected, as is also seen in Argentina. In Haiti and the Dominican Republic about 8% of all pregnant women are HIVinfected (UNAIDS/WHO, 1998). Western European countries, Canada, Australia, and New Zealand share many commonalities in the patterns of HIV infection. As a group, the largest proportion of cases was among homosexuals, while the second greatest percentage was among IDUs. Within most

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

41

countries in western Europe, among the earliest diagnosed cases, a high proportion originally lived in central Africa or Haiti (Centers for Disease Control, 1985b; Mann et al., 1988). Overall in western Europe, new HIV infections appear to be decreasing, as evidenced by a 38% drop in 1997 (Harriers, Downs, Infuso, & Brunet, 1998). Many new infections are concentrated among IDUs in southern Europe in countries such as Greece and Portugal. In 1997 fewer than 500 children were newly infected with HIV (UNAIDS/WHO, 1998). In Europe, the highest number of cases of AIDS is reported in Spain, closely followed by France and Italy (World Health Organization, 1998). The incidence rate is highest in Spain, followed by Italy, Portugal, France, and Switzerland. In Australia, most (nearly 90%) of AIDS cases remain reported among homosexual/bisexual men; this is true for Canada as well (71%). Within western Europe there are regional differences. In northwestern European countries, AIDS has remained mostly in the homosexual/bisexual male population, whereas France and Switzerland report nearly equal proportions between MSM and IDU categories. IDUs and heterosexual contact are more important modes in Spain, Italy, and France. Within countries there may also be variation. For example, in Italy the prevalence of HIV infection among IDUs at one time was higher than 70% in Milan but never exceeded 10% in Naples (Hamers et al., 1998). In eastern Europe, low rates of HIV infection existed until 1994. But this has drastically changed. For example, in the Ukraine in 1994, 44 people were reported to test positive for HIV. By 1997, 15,000 new HIV infections were identified. In eastern Europe, most HIV infections are currently concentrated among IDUs. However, various signs point to the potential heterosexual spread of HIV. For example, a dramatic rise has been noted in sexually transmitted diseases (STDs), and in Kaliningrad, one third of the sex workers were IDUs. Four out of five women testing positive for HIV disease at the registered AIDS center were sex workers (UNAIDS/WHO, 1998). Spread among IDUs has also been high in Poland. There have been several exceptions to the current patterns. For example, Romania experienced nosocomial spread through the use of improperly sterilized needles and syringes, and about 10,000 children were infected (Hamers et al., 1998). Both HIV-l and HIV-2 infection are seen in Africa. HIV-2 is largely confined to western Africa. HIV is presently considered endemic in

42

THE PERSON WITH HIV/AIDS

central Africa, and about 70% of the worldwide cases of AIDS occur in sub-Saharan Africa. In Francistown, Botswana, 43% of pregnant women tested HIV positive in 1997. In the Cote d'lvoire, Djibouti, Central African Republic, and Kenya, 1 in 10 adults live with HIV. In Botswana, Namibia, Swaziland, and Zimbabwe, between 20% and 26% or persons aged 15-49 years are living with HIV/AIDS. Nigeria has an estimated adult prevalence of 4.1%, or 2.2 million HFVinfected persons. Uganda, which has been extremely active in education and counseling programs, has shown a decrease in HIV prevalence rates over time (UNAIDS/WHO, 1998, 1999). The impact of AIDS has been severe, and many medical units in hospitals are largely filled with persons with AIDS. AIDS in Africa and in other developing countries such as the Caribbean has the following characteristics: 1. Heterosexual contact seems to be the major mode of transmission. 2. Males and females are affected in nearly equal ratios. 3. Perinatal transmission is common, leading to larger numbers of HIV-infected children than are seen elsewhere. Cultural, social, and political events may have had an impact on AIDS in Africa. Factors, such as the weakening of traditional family structures, the emigration of young persons from rural to urban areas, and prostitution as a way to earn a living, all have had an impact (Pela & Platt, 1989). In some areas, HIV infection patterns follow the path of the major trucking routes. However, some researchers claim that cultural and social changes that differed from traditional village practices actually occurred decades ago and are not relevant to the spread of HIV (Vail, 1988). Cultural practices that might contribute to the type of HIV infection pattern seen in Africa have been discussed by anthropologists. For example, some anthropologists have explained the heterosexual spread by postulating a culturally normal period of homosexuality among young central African males before marriage (Weber, 1984). It is also possible that the practice of female genital mutilation practiced in some cultures may result in tearing and bleeding during vaginal intercourse and recourse to anal intercourse, thus allowing contact with blood during intercourse among heterosexuals in Africa. Other practices that have been proposed to contribute to HIV

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

43

infection in Africa have been "blood brotherhood" rituals, medicinal blood letting and use of unsterile needles, shared instruments, ritual scarification, genital tattooing, and group circumcision. To date, heterosexual transmission with a higher frequency of sexually transmitted diseases and a greater number of partners seems to be the most important factor in transmission (UNAIDS/WHO, 1998). Yet little is known about sexual behavioral patterns in many of the ethnic groups in Africa (Larson, 1989). In examining Africa in a cultural perspective, one must take into consideration the fact that Africa consists of many different countries with different cultures and subcultures. African women have been heavily affected by HIV. Four of five HFV-infected women live in Africa, as do about 87% of HFV-infected children. There are several reasons noted for the high proportion of HlV-infected children in Africa: 1. The large number of HlV-infected women of childbearing age. 2. African women have more children on the average than women in other countries, so an infected woman may pass HIV to more children. 3. Most African children are breastfed, and breastfeeding accounts for a substantial proportion of vertical transmission of HIV. 4. Drugs that can reduce perinatal HIV transmission are less accessible in Africa and in other developing countries than in industrialized ones (UNAIDS/WHO, 1998). It has been difficult to collect accurate data in many countries, and therefore accurate information is still somewhat limited, especially from developing countries. Cooperation has increased, however, and in 1998, 197 countries contributed data (World Health Organization, 1998). There remain many disparities in the HIV epidemic across the world in regard to the availability of HIV education, counseling, testing, and state-of-the-art treatment. EXPOSURE CATEGORIES FOR AIDS Terminology to describe epidemiological groupings of AIDS cases has undergone various transitions over the years. Since the switch

44

THE PERSON WITH HIV/AIDS

in March 1989 by the CDC to a monthly, instead of a weekly, update on AIDS cases, epidemiologic data reporting formerly entitled "transmission categories" became known as "exposure categories." This change superseded a previous revision that occurred in August 1986, when the hierarchy of risk factors for AIDS was revised and entitled "transmission categories" instead of "patient groups." The single exposure categories are still ordered in a hierarchical, mutually exclusive manner; thus, cases with multiple characteristics who belong in more than one exposure category are assigned to the group that is listed first. In hierarchical order in adults/adolescents, these currently are men who have sex with men; injecting drug use; men who have sex with men and inject drugs; hemophilia/coagulation disorder; heterosexual contact; receipt of blood transfusion, blood components, or tissue; and other risk not reported or identified. AIDS cases are also now reported by risk factor combinations as well as by single risk factors (Centers for Disease Control and Prevention, 1998h). By slightly changing the terminology used, behaviors were more emphasized rather than membership within a certain group. The distribution of all adult and adolescent (age 13 years and over) cases of AIDS according to these categories is shown in Table 1.8. Exposure categories for pediatric cases, in hierarchical mutually exclusive order, currently are as follows: hemophilia/coagulation disorder; mother with/at risk of HIV infection; receipt of blood transfusion, blood components, or tissue; and risk not reported or identified (see Table 1.9; Centers for Disease Control and Prevention, 1998h). Among the major changes that have occurred over time in exposure categories were the removal of Haitians as a separate group in 1985; the change in terminology for male homosexual/ bisexual contact to men who have sex with men; the addition of the group known as heterosexual contacts (also called "cases" at various times); the change from IV drug use to injecting drug use; the inclusion of other coagulation disorders to the group originally designated as hemophilia A, and the renaming of the "none of the above" group to "other/undetermined," and eventually to "risk not reported or identified." The separate category of male homosexual/bisexual contact who were also intravenous drug abusers was added in August 1986, and later the title was changed to men who have sex with men and inject drugs. For a period of time Haitians were considered to be a distinct high-risk group for the development of AIDS, but

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

45

TABLE 1.8 United States Adult/Adolescent AIDS Cases by Exposure Category as Reported to CDC through December, 1998 Adult/adolescent exposure categories

Number

Percentage*

Men who have sex with men Injecting drug use Men who have sex with men and inject drugs Hemophilia/coagulation disorder Heterosexual Sex with injecting drug user Sex with bisexual male Sex with person with hemophilia Sex with transfusion recipient with HIV infection Sex with HIV infected person, risk not specified Recipient of blood transfusion, blood components, or tissue Risk not reported or identified

326,051 173,693 43,640 4,911 66,490 26,246 3,132 429 935

48.0 25.6 6.4 0.73 9.8 3.9 0.46 0.06 0.14

35,748

5.3

8,382

1.2

56,572

8.3

Total

679,739

Source: Centers for Disease Control and Prevention. (1998). HIV/AIDS Surveillance Report, Year-end edition, Vol. 10, No. 2, 1-43. *May not add to 100.0% due to rounding error.

Haitians have been moved in regard to epidemiologic group placement. In 1985, when they were removed as a separate risk group, they were placed into the "other/none of the above" group. In August 1986 they were placed into the heterosexual cases category, now called "heterosexual contact"; eventually they were categorized in the same manner as other persons. In 1985 it was stated that it does not appear that "being of Haitian extraction by itself, in isolation from other risk factors, increases the relative risk of being exposed to HTLV-III" (Landesman, Ginzburg, & Weiss, 1985). Information about each exposure category is discussed below. MEN WHO HAVE SEX WITH MEN (MSM) There are about 1.7 million homosexual and bisexual men in the United States (Holmberg, 1996). AIDS was first identified among

46

THE PERSON WITH HIV/AIDS

TABLE 1.9 Pediatric AIDS Cases in the United States as Reported to CDC through December, 1998 Pediatric (< 13 years) exposure categories

Number

Percentage*

Hemophilia/coagulation disorders Mother with/at risk for AIDS/HIV infection: Injecting drug use Sex with an injecting drug user Sex with bisexual male Sex with person with hemophilia Sex with transfusion recipient with HIV infection Sex with HIV-infected person, risk not specified Receipt of blood transfusion, blood components, or tissue Has HIV infection, risk not specified Receipt of blood transfusion, blood components, or tissue Risk not reported or identified

234 7,687 3,032 1,400 165

2.8 90.8 35.8 16.5 2.0 0.34 0.30

Total

8,461

29 25 1,137

13.4

154

1.8

1,745 378

20.6 4.5

162

1.9

Source: Centers for Disease Control and Prevention. (1998). HIV/AIDS Surveillance Report, Year-end edition, Vol 10, No. 2, 1-43. *May not add to 100.0% due to rounding error.

homosexual men presenting with Kaposi's sarcoma and Pneumocystis carinii; pneumonia (Centers for Disease Control, 1981a, 1981b). In 1982 the CDC reported the occurrence of unexplained persistent generalized lymphadenopathy among homosexual males. It was recommended that such individuals be followed periodically (Centers for Disease Control, 1982a). Other clinicians noted the occurrence of such a syndrome as early as 1977 in some regions and 1979 in others (Abrams, Lewis, Backstead, Casavant, & Drew, 1984; Miller et al., 1984). A cluster of cases of autoimmune thrombocytopenic purpura in homosexual men was diagnosed in New York after November 1980. These reports suggested that sexually active homosexual men might be developing disorders of immune regulation (Morris, Distenfeld, Amorosi, & Karpatkin, 1982). Why AIDS first surfaced in large numbers among the homosexual population is not known. The first appearance of AIDS in recogniz-

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

47

able proportions among this group, however, provoked varying public reactions from lack of interest to condemnation to accusations to feelings that it was deserved. Persons in this exposure category, men who have sex with men (MSM), still comprise the largest percentage of cases of adult AIDS in the United States. As of December 31, 1998, MSM accounted for about 48% of the total adult cases of AIDS in the United States, and the category of "MSM and inject drugs" accounted for about another 6%, totaling about 54% (Centers for Disease Control and Prevention, 1998h). Studies to identify risk factors for HIV infection identified large numbers of different male sexual partners as the most important risk factor for HIV acquisition. In regard to the sexual practices studied, the ones most frequently associated with increased risk for infection were frequent receptive anal intercourse and "fisting" (a practice involving the insertion of a hand or fist into the rectum) (Vermund, 1997). These studies have provided important information for the development of educational programs and counseling geared at prevention, as described in chapter 3. Many homosexual males, especially in California and New York, became leading activists in the field of AIDS. Their extensive efforts in education and prevention of HIV infection have apparently had notable success. These have involved changes in behavior, including less promiscuity and increased condom use (Martin, 1987). Others are less optimistic about the success of behavioral interventions. Initially, MSM were demonstrating safer sexual behaviors. But by the 1990s younger homosexual men were noted to have higher levels of sexual risk taking (De Wit, 1996). In a report from San Francisco of homosexual men between 18 and 29 years of age, an HIV prevalence of about 18% was found and 27% of the group said they had unprotected anal sex in the year before participating in the study (Cohen et al., 1998; Osmond et al., 1994). A study reporting on about 2,100 homosexual men ages 15 to 22 years across the United States found a median HIV prevalence of 7%; in a Boston study, 26% of White male homosexuals reported unprotected anal sex (De Wit, 1996). In the Young Gay Men's Cohort study in the Netherlands, there was a 4.3% HIV prevalence; 38% reported that they engaged in unprotected anal sex in the six months before the study began (De Wit, 1996). While homosexual men are well educated about HIV, their behavior does not always reflect the understanding of risk

48

THE PERSON WITH HIV/AIDS

factors. Reasons have been attributed to the person's social norms, perceived attitude toward the behavior, and their assessment of whether they can carry out the particular behavior (de Wit, 1996). Thus, many preventive efforts are focusing on young homosexual men, as discussed in chapter 3. Clinically, Kaposi's sarcoma has a far greater prevalence among homosexuals with AIDS than in other groups, although it has been reported in all exposure categories. This is at least partly due to the fact that KS is caused by a herpes virus that is transmitted sexually (see chapter 5). Injecting Drug Use (IDU) In 1991, the CDC changed the terminology from "intravenous drug use" to "injecting drug use" to describe the use of needles for selfinjection of drugs not prescribed by a physician. These include those who share needles and apparatus, skin pop, and take unprescribed anabolic steroids, vitamins, or other medications by injection. It is estimated that about 36% of all cases of AIDS reported in 1997 were directly or indirectly associated with IDU (Centers for Disease Control and Prevention, 1998f). Furthermore, heterosexual partners of IDUs accounted for about 40% of the cumulative total cases in the exposure category of heterosexual contact at the end of 1998. Injecting drug use in females and heterosexual males accounts for about 26% of adult AIDS cases, whereas use in the category of MSM/IDU is approximately 6%, as shown in Table 1.8 (Centers for Disease Control and Prevention, 1998h). The highest rates of IDU-associated AIDS cases were in the Northeast, Puerto Rico, and Miami (Holmberg, 1996). AIDS in IDUs appears to have disproportionately affected Blacks and Hispanics. Of the AIDS cases in IDUs reported to CDC as of December 31, 1998, about 53% occurred in Black, non-Hispanic persons and about 26% were Hispanic (Centers for Disease Control and Prevention, 1998h). In the Youth Risk Behavior Study, 2.1% of adolescents surveyed said they had injected illegal drugs in their lifetime, and 8.2% used some form of cocaine (Centers for Disease Control and Prevention, 1998f). This distribution adds to the social challenge of HIV-infection in IDUs. IDUs represent, however, a heterogenous group of people whose behaviors vary, a

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

49

fact that influences both seroprevalence rates and the success of intervention strategies. IDU accounts for 44% of reported AIDS cases in Europe. Countries reporting rapid increases in HIV infection among IDUs include Ukraine, Vietnam, northern Thailand, and Vancouver. Higher numbers of IDUs are found in countries where drug traffic is heavy, such as southeast Asia, western Africa, parts of South America, and Myanmar (Burma), and in some Middle Eastern countries, such as Iran. Areas of high IDU are at risk for outbreaks of HIV and other viral diseases such as hepatitis B and hepatitis C. However, it has been noted that HIV may spread rapidly among IDUs for a time, such as was seen in Edinburgh, Scotland, in the early 1980s, then decrease and become more stable (Strathdee et al., 1998). In addition to comprising the second-largest exposure category for AIDS, IDUs are considered a bridge to heterosexuals and to HlV-infected children. Of the AIDS cases associated with perinatal transmission reported through 1997, mothers who injected drugs or their sexual partners accounted for nearly 58% of the cases reported (Centers for Disease Control and Prevention, 1998h). The CDC (1998d, 1998f) estimated that the risk for HIV transmission per episode of IV needle or syringe exposure is 0.67%. Many drug abusers share drug paraphernalia with others and often use unsterilized, contaminated needles and syringes. It is currently believed that AIDS is transmitted among drug users through the transfer of small amounts of blood during the sharing of needles, syringes, or other drug-related apparatus such as cookers, water used to prepare injections, and cotton (Strathdee et al., 1998). The latter three may initially become contaminated through the use of contaminated syringes (Jones & Vlahov, 1998). In addition, some of the substances that drug users use have been shown to have intrinsic immunosuppressive properties, which may enhance the effects of HIV. IDUs often inject themselves with drugs, some more than 1,000 times per year (Centers for Disease Control and Prevention, 1998F). This behavior is not compatible with using clean needles. In one report, those IDUs who were HIV seropositive were more likely to have injected drugs daily and shared needles with 4 or more persons. Many of the HIV seropositive group (41.5%) reported having no sexual partners in recent months, possibly due to diminished libido;

50

THE PERSON WITH HIV/AIDS

34.2% reported 11 or more partners, possibly because they were exchanging sex for drugs (Raymond, 1988). A study reported by researchers in New York showed that IDUs infrequently sterilized their works, although recognizing the risk of HIV infection. There were several reasons for this. These included strong and immediate desires to use drugs, believing their friends "would be insulted" if they sterilized equipment, inadequate sterilization techniques when they were used, choosing a partner whom they believed was "safe," economic pressures, not owning or wanting to carry drug-injecting equipment with them, and desires to please their partner (particularly in women) (Magura et al., 1989). Those who had been incarcerated were more likely to share syringes. In one study involving 12,323 IDUs in 19 sites in the United States, McCoy, Metsch, Chitwood, Shapshak, and Comerford (1998) found that 42.0% did not use needles, syringes, cookers, cotton, or water used by another IDU, but only 12.6% used new needles or syringes. In another study, Diaz et al. (1998) found that those who knew they had been infected with HIV for more than a year were less likely to share drug apparatus than those who knew about it one year or less. In one study in New York City, HIV prevalence was 11% among those who had been injecting 1 to 3 years and 18% for those injecting 4 to 6 years. Those who were more likely to be HIV-infected were African Americans, Hispanics, females, and men who engaged in male to male sex (Des Jarlais et al., 1999). Preventive activities with injecting drug users have been difficult. Drug users tend to be a less conspicuous group than the other groups at high risk for the development of AIDS. They tend not to have advocates in the general population, nor do they generally form advocacy and support groups among themselves. New York state researchers from the Division of Substance Abuse Services found some impediments to prevention that included limitations on the perception of risk by such individuals due to the long latency period in the development of severe AIDS, the difficulty in distinguishing AIDS from other narcotic-related deaths, and the ambiguity of some of the symptoms of AIDS. In addition, needle sharing may have associations with communal feeling and socialization in the drug subculture (Black et al., 1986). There are also economic motivations for sharing injection equipment. Syringe exchange programs have proliferated in the United States and Europe. There are 113 pro-

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

51

grams in the North American Syringe Exchange Programs. Many of these programs not only offer needle and syringe exchange but also offer other services such as HIV counseling and testing, TB testing, STD screening, and primary health care. IDUs participating in these programs increase the proportion of sterile syringes used for singleuse injections, thus decreasing potential contamination. IDUs participating in these programs have lower rates of HIV incidence compared to other IDUs (Centers for Disease Control and Prevention, 1998f). Another approach is to allow the purchase of sterile syringes over the counter in pharmacies, as is done in Connecticut. One concern has been injury, especially to children, from improperly disposed of needles and syringes. A variety of community-based programs have been developed to address this (Jones & Vlahov, 1998). Others have proposed the use of single-use or difficult-to-reuse syringes to decrease multiple use (Desjarlais, 1998). Multiple drug and alcohol use is common to persons who are IDUs, and some unique clinical characteristics have been noted. Clinically, a broader range of opportunistic infections are seen in IDUs with AIDS than in other groups. Particularly frequent infections noticed are STDs, bacterial pneumonias, bacterial endocarditis, and tuberculosis (Contoreggi, Rexroad, & Lange, 1999) (see chapter 5). Furthermore, lower socioeconomic status and malnutrition may contribute to poor general health, affecting clinical presentation. IDUs may also be less likely to seek health care. IDUs can be difficult for health care professionals to care for because of their negative feelings toward them. In a study of registered nurses across the United States, Cohen, Durham, and Smith (1988) found that negative and neutral feelings reported by respondents were 69.3% and 22.9%, respectively, with only 7.8% reporting positive feelings. Hemophilia/Coagulation Disorder In July 1982 the CDC first published reports of three cases of Pneumo cystis carinii pneumonia (PCP) among three hemophiliacs who had no other underlying disease. The first case was identified in January 1982, and the others were found through surveillance of the use of drugs to treat PCP. All were heterosexual without a history of intravenous drug abuse, and all had received factor VIII concentrates

52

THE PERSON WITH HIV/AIDS

(Centers for Disease Control, 1982b). As of December 31, 1998, the CDC had received reports of 4,911 adult and 234 pediatric cases of AIDS in persons with hemophilia or another coagulation disorder, representing about 1% of the adults with AIDS and about 3% of children with AIDS (Centers for Disease Control and Prevention, 1998h). Of these, the majority had hemophilia A, whereas the rest had hemophilia B, von Willebrand disease, or other blood coagulation defects. Hemophilia A or factor VIII deficiency is a genetic disorder of blood coagulation that is inherited in an X-linked recessive manner and is the classical type of hemophilia. Hemophilia B (Christmas disease) is a genetic disorder due to deficiency of clotting factor IX. It is also inherited in an X-linked recessive manner. It is only about one fifth as frequent as hemophilia A (Lashley, 1998). They are nondistinguishable clinically. Hemophilia B tends to be somewhat less severe than hemophilia A. Von Willebrand disease is a genetic disorder of coagulation that is usually inherited in an autosomal dominant manner but may also be inherited in other ways. Part of the management of these disorders includes the administration of clotting factors. Pooled plasma was traditionally used in making these clotting factor concentrates, and each vial could contain material from between 2,500 and 25,000 blood or plasma donors (Levine, 1985). The majority of persons with hemophilia in the United States became HIV seropositive between 1979 and 1982 and before 1985, when the screening of donated blood was implemented and the prevalence of HIV infection in adults with hemophilia A and hemophilia B was about 80% and 50%, respectively, of those who had been treated with factor concentrates (Rosenberg & Goedert, 1998). Older hemophiliacs have been more likely to be HIV-infected. Most of this group became infected with hepatitis C as well. Although the total case number of AIDS is small in persons with coagulation disorders, it does represent an important cause of mortality for this group. AIDS now exceeds hemorrhage as the leading cause of death among hemophiliacs (Pierce et al., 1989). Not using coagulation factor concentrates, however, would mean a return to the preclotting factor concentrate days, when death due to hemorrhage caused hemophiliacs to have a life expectancy that was less than half that of unaffected persons (Levine, 1985) and bleeding into joints

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

53

caused considerable morbidity (Cahill & Colvin, 1997). Viral inactivation techniques using heat and other methods have been developed. The cloning of the factor VIII gene allowed recombinant factor concentrates and monoclonally purified concentrates to be developed. Recombinant factor IX concentrates have become available more recently (Cahill & Colvin, 1997). Sexual partners of hemophiliacs are at increased risk for HIV infection through sexual activity. Various education programs have been introduced in hemophilia treatment centers to prevent spread by this method. Reported cases of AIDS resulting from sex with a person with hemophilia or a coagulation disorder accounted for only 0.65% of cases within the heterosexual contact category and 0.0063% of the total adult cases of AIDS in the United States (Centers for Disease Control and Prevention, 1998h). In one study of male hemophiliacs between the ages of 12 and 24 years, self-reported sexual behavior in the past 6 months revealed that 13% had intimate touch only, 21% had intercourse always with condoms, and 13% had unsafe intercourse. The rest did not report sexual activity in that time period. Thus, 87% of this group abstained or had safer sex. The "unsafe sex" group was older and more angry and anxiou than the others (Remafedi, Parsons, Schultz, & Schulz, 1997). In other studies, only about 20% of female sex partners of hemophilic men with HIV infection became infected. Those who did had partners with higher viral loads than those who did not (Ragni, Faruki, & Kingsley, 1998). Clinically, there are some aspects particular to the hemophilia group. KS and lymphomas are rare in persons with hemophilia. Most (about two thirds) present with Pneumocystis carinii pneumonia, followed by esophageal candidiasis and extrapulmonary cryptococcosis (Cohen, Sande, & Volberding, 1998). HIV-infected persons with hemophilia A with antibodies against factor VIII and persons with hemophilia B showed faster progression to AIDS than did HIV-infected persons with hemophilia B (Roosendaal et al., 1999). Heterosexual Contact This group includes all individuals who do not fit into one of the exposure categories listed first in the hierarchy (men who have sex

54

THE PERSON WITH HIV/AIDS

with men, injecting drug use, men who have sex with men and inject drugs, hemophilia/coagulation disorder). The following subcategories have been identified: (1) sex with injecting drug user; (2) sex with bisexual male; (3) sex with person with hemophilia; (4) sex with transfusion recipient with HIV infection; (5) sex with HIVinfected person, risk not specified. As of December 31, 1998, there were 66,490 reported adult AIDS cases in the heterosexual contact category, representing about 10% of the total adult cases. Of these, the largest subcategories were sex with "HIV-infected person, risk not specified" (35,748, or 53.8% of the cases in this category) and injecting drug user (26,246 cases, or 39.5% of the cases in this category) (Centers for Disease Control and Prevention, 1998h). (See Table 1.8.) There is racial/ethnic disproportion in this category, as described earlier. Geographically, the majority of cases in the heterosexual exposure category are concentrated in four states— New York, Florida, New Jersey, and California. In January 1983 the CDC published two cases of women with immunodeficiency who were the sexual partners of men with AIDS. One of these men was an intravenous drug abuser and one was a bisexual. The women themselves had no recognized risk factors (Centers for Disease Control, 1983a). Other cases began appearing in the literature (Harris et al., 1983), including the report of a previously healthy 71-year-old wife of a 74-year-old hemophiliac who developed Pneumocystis carinii pneumonia, developed AIDS, and died. Her only apparent risk factor was infrequent sexual contact with her husband when he was asymptomatic (Pitchenik, Shafron, Glasser, & Spira, 1984). Varying percentages of regular sexual partners of HIV-infected persons show evidence of HIV infection depending upon the study and factors related to the host (e.g., viral load) and the virus as well as whether there has been proper and consistent use of barrier protection. As with homosexual men, receptive anal intercourse may place women at increased risk, as discussed earlier, but HIV may be transmitted by both vaginal and anal intercourse (Cohen et al., 1998; Vermund, 1997). Although most of the initial reports emphasized the transmission of disease from males to females, it is bidirectional. In addition, cervical and vaginal tissues and secretions have been shown to contain HIV.

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

55

Heterosexual contact is an important exposure category for women. Females account for about 65% of all AIDS cases in this classification, and heterosexual contact is the second highest exposure category for women (IDU is first) (Centers for Disease Control and Prevention, 1998h). The category of heterosexual contact is complex. Women may be exposed to HIV through trading sex for drugs, money, or protection or may be unaware of, or choose to ignore, their partners' risky sexual practices such as promiscuity, IDU, or bisexuality for many reasons (Cohen & Durham, 1995b). Men may also be unaware of their partners' risky sexual activities. Men who seek sexual gratification with a commercial sex worker have a greater risk of acquiring HIV infection. Preventive efforts as discussed in chapter 3 focus on education, the proper and consistent use of condoms, access to appropriate health care, and womancontrolled prevention. RECEIPT OF BLOOD TRANSFUSION, BLOOD COMPONENTS, OR TISSUE Perhaps no other mechanism for the transmission of AIDS has been as frightening as that of receipt of blood transfusion, blood-components (e.g., plasma, platelets), or tissue. As of December 31, 1998, 8,382 adult and 378 pediatric cases were linked to receipt of blood transfusion and reported to the CDC, representing about 1.2% and 4.5% of the total cases, respectively (Centers for Disease Control and Prevention, 1998h). These figures do not include hemophiliacs who were in a separate category. The cases in this category ranged in age from newborns to more than 80 years of age (Centers for Disease Control, 1986). Most of the cases of AIDS now being diagnosed as a result of transfusion are in those who received blood or components before widespread screening was implemented in 1985; however, some have resulted from receiving HFV-infected blood that tested as negative for HIV antibody at the time of transfusion. Transfusion appears to be an effective transmission method for HPV7, as it is estimated that 95% of recipients of a single transfusion of HFVinfected blood became infected (Centers for Disease Control and Prevention, 1998c). Progression does not appear to be different than in persons in other exposure categories.

56

THE PERSON WITH HIV/AIDS

The first case of AIDS associated with a blood transfusion was reported by the CDC in December 1982. The White male infant, who was delivered by cesarean section in March 1981, had erythroblastosis fetalis resulting in hyperbilirubinemia. He received exchange transfusions, whole blood, platelets, and packed red cells during his month of hospitalization following birth. These blood and blood products were from 19 different donors and had been irradiated. After 1 month the infant appeared well and was discharged from the hospital. At 4 months of age he showed splenomegaly. By 7 months he developed opportunistic infections and showed evidence of unexplained cellular immunodeficiency. The infant ultimately died of Pneumocystis carinii pneumonia at 20 months of age. His parents were heterosexual, not intravenous drug users, and were not Haitian. Subsequent investigation of the blood products received by this infant revealed that one of the 19 donors of blood and blood products had been reported to the CDC later as having developed AIDS. This donor died in August 1982. At the time of this initial report the cause of AIDS was unknown, and thus it gave further support to the idea that AIDS was caused by an infectious agent. It also suggested that the agent could be present in the blood before causing symptomatic illness and that the incubation period could be a long one (Centers for Disease Control, 1982c), speculation that has since been verified. A major concern was that of protecting the nation's blood supply. In 1983 the United States Public Health Service (USPHS) recommended that blood and/or plasma not be donated by persons with signs and symptoms of AIDS, by sexual partners of AIDS patients or of persons at increased risk for AIDS, or by any other members of groups at increased risk for AIDS, as an interim measure to protect transfusion recipients until specific tests were available. The USPHS also recommended that physicians "adhere strictly to the medical indications for transfusion" (p. 103), and they encouraged autologous blood transfusions (Centers for Disease Control, 1983b). In 1985 testing of potential donors by enzyme-linked immunosorbent assay (ELISA) became possible. ELISA is sensitive, but it is estimated that of 8 million blood donors per year, 40,000 will be falsely positive using ELISA alone. Confirmatory tests, however, increase expense. The possibility of false negatives due to testing error and to latency between exposure to the virus and subsequent develop-

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

57

ment of antibody is also of concern. The combination of testing with voluntary deferral has proved effective but not entirely so. The HIV-infected blood of persons who are HIV-infected but who have not yet developed antibody and seroconverted would not be identified as HIV-infected when using ELISA (or a similar test) for screening. Thus, in 1996, the FDA recommended the use of the p24 antigen assay to screen all donated blood in the United States. Both HIV-1 and HIV-2 are tested for in U.S. blood donations. The risk for receiving an HIV-infected blood transfusion has been reduced markedly in the United States but not completely eliminated, because some persons at risk for HIV infection still donate blood; moreover, not all persons who are HIV-infected may be presently detected with tests in current use, although most will be. It has been estimated that, in the United States, 1 in 450,000 to 1 in 660,000 transfusions transmit HIV-1 per year (Cohen et al., 1998). This figure may be higher in urban areas such as San Francisco and New York, and lower in certain rural areas in low HIV prevalence states. In developing countries, the risk of HIV infection probability is markedly higher and is estimated overall at 1 in 50 to 1 in 100 blood transfusions (Lackritz et al., 1998). The possibility of transfusionassociated HIV transmission has affected clinical practice, including the revision of many criteria for administering blood transfusions and increased caution in making the decision to administer transfusions. Methods have been introduced to reduce blood loss during surgery. More consumers are requesting autologous blood donation provisions or designated donor programs or are requesting female donors. New screening techniques are expected to further reduce risk (Moor etal., 1999). ' Risk Not Reported or Identified Until November 1986 this category was known as "none of the above." Persons classified in this group are those with no reported history of HIV exposure through any of the routes listed in the hierarchy of exposure categories. "Risk not identified" cases include persons who are currently under investigation, those lost to follow-up through death, those who refused to be interviewed or other reasons, those for whom investigation is complete but no exposure mode was identi-

58

THE PERSON WITH HIV/AIDS

fied, and health care workers without identified risks (two as of April 30, 1990). As of December 31, 1998, about 8.3% of adult and about 2% of pediatric AIDS cases reported to CDC fell into this exposure category. Upon identification of an exposure mode, persons in this category are reclassified into the appropriate one (Centers for Disease Control and Prevention, 1998h). CDC investigations through 1999 have not identified the existence of any additional transmission modes. Some cases are included in this category because of delays in investigation. Failure to reclassify persons into other exposure categories is probably due to nonrecognition of contributing factors, especially heterosexual contacts. For example, an infected person might not know that his or her sexual partner is a bisexual or an IDU or that he or she has had contact with a prostitute or a sexual partner who has not been monogamous. A study following up on a group of unclassified cases in this category found that risk may not have been documented because of denial of risk, lack of awareness of risk, fear of discrimination or losing insurance, lack of assessment by health care provider because of lack of training, desire not to offend the patient, or assumptions that their patients are not at high risk (Elevens et al., 1999). Exposure Categories for Pediatric AIDS The pediatric exposure categories in hierarchical order, as shown in Table 1.9, are hemophilia/coagulation disorder; mother with/at risk for HIV infection; receipt of blood transfusion, blood components, or tissue; and risk not reported or identified. All have been discussed above, except for mother with/at risk for HIV infection. This category is the one into which the majority of the pediatric AIDS cases fall. As of December 31, 1998, 7,687 cases, or about 91% of all reported U.S. pediatric cases of AIDS, fell into this exposure category. The subcategories in descending order of frequency were IDU (39.4%); has HIV infection, risk not specified (22.7%); sex with IDU (18.2%); sex with HlV-infected person, risk not specified (14.8%); sex with bisexual male (2.2%); receipt of blood transfusion, blood components, or tissue (2.0%); sex with a hemophiliac (0.38%); and sex with transfusion recipient with HIV infection (0.33%). Thus, nearly 60% of the perinatally acquired cases of AIDS are attributable

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

59

in some way to injecting drug use (Centers for Disease Control and Prevention, 1998h). In the United States between 1992 and 1996, perinatally acquired AIDS declined 43%; in 1997 there was a 30% decline (Centers for Disease Control and Prevention, 1998f). A full discussion of perinatal transmission of HIV was presented earlier and is in chapter 11. CONCLUSION Studies of epidemiological aspects of the AIDS outbreak have contributed enormously to the identification of the involved etiological agent and its transmission. Yet many questions remain. Additional research is needed to further define and clarify the role of cofactors and their influence on both the development of AIDS and its progression. Further data are also needed on the natural history and consequences of HIV infection, seroconversion, immunosuppression, what the determinants for rapid and slow progression are and how they can be modified, and the spectrum of disease. In developed countries, the death rate has slowed and more people are living with HIV. However, infection is increasing explosively in Africa and parts of Asia and is still on the increase in developed countries. Further information is still needed on effective methods of education and behavior change. REFERENCES Abdala, N., Stephens, P. C., Griffith, B. P., & Heimer, R. (1999). Survival of HFV1 in syringes. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 20, 73-80. Abrams, D. I., Lewis, B. J., Beckstead, J. H., Casavant, C. A., & Drew, W. L. (1984). Persistent diffuse lymphadenopathy in homosexual men: Endpoint or prodrome? Annals of Internal Medicine, 100, 801-808. Adib, S. M., Joseph, J. G., & Ostrow, D. G. (1991). Relapse in sexual behavior among homosexual men: A 2-year follow up from the Chicago MACS/CCS. AIDS, 5, 757-760. Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Human Decision Processes, 50, 179-211. .Allen, J. R., & Curran, J. W. (1988). Prevention of AIDS and HlV-infection: Needs and priorities for epidemiologic research. American Journal of Public Health, 78, 381-386.

60

THE PERSON WITH HIV/AIDS

Auerbach, D. M., Darrow, W. W., Jaffe, H. W., & Curran, J. W. (1984). Cluster of cases of the acquired immune deficiency syndrome. American Journal of Medicine, 76, 487-492. Baiter, M. (1999). AIDS now world's fourth biggest killer. Science, 284, 1101. Barnes, D. M. (1986). Grim projections for AIDS epidemic. Science, 232, 1589-1590. Baron, S., Poast, J., & Cloyd, M. W. (1999). Why is HIV rarely transmitted by oral transmissions? Saliva can disrupt orally shed, infected leukocytes. Archives of Internal Medicine, 159, 303-310. Barre-Sinoussi, F., Chermann, J. G., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauget, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W., & Montagnier, L. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 220, 868-871. Berger, E. A., Doms, R. W., Fenyo, E. M., Korber, B. T. M., Littman, D. R., Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sofroski, J., & Weiss, R. A. (1998). A new classification for HIV-1. Nature, 391, 240. Bid, R., Ffrench, R., Young, J., Bennetts, B., Stewart G., & Liang, T. (1997). HIV1 infection in an individual homozygous for the CCR5 deletion allele. Nature Medicine, 3(3), 252-253. Black, J. L., Dolan, M. P., Deford, H. A., Rubenstein, J. A., Penk, W. E., Robinowitz, R., & Skinner, R. R. (1986). Sharing of needles among users of intravenous drugs. New England Journal of Medicine, 314, 445-447. Blaser, M. J. (1986). Insect-borne transmission of AIDS. Journal of the American Medical Association, 255, 463-464. Boiling, D. R., & Voeller, B. (1987). AIDS and heterosexual anal intercourse. Journal of the American Medical Association, 258, 474. Broder, S., & Gallo, R. C. (1985). Human T-cell leukemia viruses (HTLV): A unique family of pathogenic retroviruses. Annual Review of Immunology, 3, 321-336. Brodt, H. R., Kamps, B. S., Helm, E. B., Schofer, H., & Mitrou, P. (1998). Kaposi's sarcoma in HIV infection: impact on opportunistic infections and survival. AIDS, 12, 1475-1481. Bryson, Y. J. (1996). Perinatal HIV-1 transmission: Recent advances and therapeutic interventions. AIDS, 10(Suppl. 3), S33-S42. Buchbinder, S. (1998). Avoiding infection after HIV exposure. Scientific American, 2-79(1), 104-105. Buve, A., & Rogers, M. F. (1998). Epidemiology. AIDS, 72(Suppl. A), S53-S54. Bygbjerg, L. (1983). AIDS in a Danish surgeon. Lancet, 1, 925. Cahill, M. R., & Colvin, B. T. (1997). Haemophilia. Postgraduate Medical Journal, 73, 201-206. Caldwell, J. C., & Caldwell, P. (1996). The African AIDS epidemic. Scientific American, 274, 62-63, 66-68. Cardo, D. M., Culver, D. H., Ciesielski, C. A., Srivastava, P. U., Marcus, R., Abiteboul, D., Heptonstall, J., Ippolito, G., Lot, F., McKibben, P. S., & Bell, D. M. (1997). A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. New England Journal of Medicine, 337, 1485-1490.

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

61

Carre, N., Deveau, C., Belanger, F., Boufassa, F., Persoz, A.,Jadand, C., etal. (1994). Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. SEROCO Study Group. AIDS, 8, 797-802. Carroll, N. M. (1999). Optimal gynecologic and obstetric care for lesbians. Obstetrics and Gynecology, 93, 611-613. Centers for Disease Control. (1981a). Kaposi's sarcoma and pneumocystis pneumonia among homosexual men—New York and California. Morbidity and Mortality Weekly Report, 31, 507-515. (1981 b ) . Pneumocystis pneumonia—Los Angeles. Morbidity and Mortality Weekly Report, 30, 250-252. (1982a). Persistent, generalized lymphadenopathy among homosexual males. Morbidity and Mortality Weekly Report, 31, 249-251. (1982b). Pneumocystis carinii pneumonia among persons with hemophilia. Morbidity and Mortality Weekly Report, 31, 365-367. (1982ci. Possible transfusion-associated acquired immune deficiency syndrome (AIDS)—California. Morbidity and Mortality Weekly Report, 31, 652—655. (1982d). Update on acquired immunodeficiency syndrome (AIDS)— United States. Morbidity and Mortality Weekly Report, 31, 507-514. (1983a). Immunodeficiency among female sex partners of males with acquired immune deficiency syndrome (AIDS)—New York. Morbidity and Mortality Weekly Report, 31, 697-698. (1983b), Prevention of acquired immune deficiency syndrome (AIDS): Report of inter-agency recommendations. Morbidity and Mortality Weekly Report, 32, 101-103. (1985a). Heterosexual transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. Morbidity and Mortality Weekly Report, 34, 561-563. (1985b). Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathyassociated virus and acquired immunodeficiency syndrome. Morbidity and Mortality Weekly Report, 34, 721-732. (1985c). Revision of the case definition of acquired immodeficiency syndrome for national reporting—United States. Morbidity and Mortality Weekly Report, 34, 373-375. (1985d). Update: Acquired immunodeficiency syndrome—United States. Morbidity and Mortality Weekly Report, 34, 245-248. 1986). Apparent transmission of human T-lymphotropic virus type III/ lymphadenopathy associated virus from a child to a mother providing health care. Morbidity and Mortality Weekly Report, 35, 76-79. -. (1987a). Human immodeficiency virus infection transmitted from an organ donor screened for HIV antibody—North Carolina. Morbidity and Mortality Weekly Report, 36, 306-308. , (1987b). Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morbidity and Mortality Weekly Report, 36(1S), 1S15S.

62

THE PERSON WITH HIV/AIDS

(1988a). AIDS due to HIV-2 infection—New Jersey. Morbidity and Mortality Weekly Report, 37, 33-35. (1988b). Perspectives in disease prevention and health promotion update: Universal precautions for prevention of transmission of human immunodeficiency virus, Hepatitis B virus, and other bloodborne pathogens in health-care settings. Morbidity and Mortality Weekly Report, 37, 377-388. (1989). AIDS and human immunodeficiency virus infection in the United States: 1988 update. Morbidity and Mortality Weekly Report, 38, 1-38. (1990). Possible transmission of human immunodeficiency virus to a patient during an invasive dental procedure. Morbidity and Mortality Weekly Report, 39, 489493. Centers for Disease Control and Prevention. (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report, 47(No. RR17), 1-19. (1997a, July). HPvVAIDS and women who have sex with women (WSW) in the United States. Facts, 1-2. (1997b). HIV/AIDS Surveillance Report. Year End Edition, 9(2), 1-43.

(1997c, July). The human immunodeficiency virus and its transmission. HIV/AIDS Prevention, 1-4. (1997d). Transmission of HIV possibly associated with exposure of mucous membrane to contaminated blood. Morbidity and Mortality Weekly Report, 46(27), 620-623. (1998a, April). Human immunodeficiency virus type 2. CDC Facts, 1-5. (1998b). Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV including considerations related to antiretroviral therapy. Public Health Service Statement. Morbidity and Mortality Weekly Report, 47(No. RR-17), 1-14. (1998c). Public health service task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Morbidity and Mortality Weekly Report, 47(No. RR-2), 1-31. (1998d). Service guidelines for the management of health-care worker exposure to HFV and recommendations for postexposme prophylaxis. Morbidity and Mortality Weekly Report, 47(No. RR-7), 1-39. (1998e,June). Status of perinatal HIV prevention—U.S. declines continue: Hope for extending success to developing world. CDC Update, 1-3. (1998F). Update: Syringe exchange programs—United States. Morbidity and Mortality Weekly Report, 47(31), 652-655. (1998g, September). Young people at risk—epidemic shifts further toward young women and minorities, [http://www.cdc.gov/nchstp/hiv_aids/pubs/ facts/youth.htm] CDC Update, 1-3. (1998h). HIV/AIDS Surveillance Report, Year-end edition, Vol. 10, No. 2, 1-43. (1999). Characteristics of persons living with AIDS at the end of 1997. HIV/ AIDS Surveillance Supplemental Report, 5, 2-13.

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

63

Chaisson, R. F,., Keruly, J. C., & Moore, R. I). (1995). Race, sex, drug use, and progression of human immunodeficiency virus disease. New England Journal of Medicine, 333, 751-756. Charneau, P., Borman, A. M., & Quillent, C. (1994). Isolation and envelope sequence of a highly divergent HFV-1 isolate: Definition of a new HIV-1 group. Virology, 205, 247. Chiao, E. Y., Ries, K. M., & Sande, M. A. (1999). AIDS and the elderly. Clinical Infectious Diseases, 28, 740-745. Cocchi, P., & Cocchi, C. (1988). Postnatal transmission of HIV infection. Lancet, 2, 482. Coffin, J., Haase, A., Levy, J. A., Montagnier, L., Oroszlan, S., Teich, N., Temin, H., Toyoshima, K., Varmus, H., Vogt, P., & Weiss, R. (1986). Human immunodeficiency viruses. Science, 232, 697. Cohen, F. L. (1995). AIDS/HIV in older adults. In G. Maddox et al. (Eds.), The Encyclopedia of Aging (2nd ed., 48-50). New York: Springer. Cohen, F. L., Durham,]. D., & Smith, K. R. (1988). Opinions about public policy issues and AIDS fact knowledge among US nurses. Poster presented at Fifth International Conference on AIDS, Stockholm, Sweden. Cohen, F. L., & Durham, }. D. (Eds.). (1995a). Tuberculosis: A source book for nursing practice. New York: Springer. (1995b). Women, children, and HIV'/AIDS. New York: Springer. Cohen, P. T., Sande, M. A., &: Volberding, P. A. (Eds.). (1998). The AIDS knowledge base (3rd ed.) San Francisco: University of California, San Francisco and the San Francisco General Hospital, [http://hivinsite.ucsf.edu/akb/1997/] Connor, E. M. Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., et al. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Neiv England Journal of Medicine, 331 (IS), 11731180. Contoreggi, C., Rexroad, V. E., & Lange, W. R. (1998). Current management of infectious complications in the injecting drug user. Journal of Substance Abuse Treatment, 15, 95-106. Curran, J. W.. Morgan, W. M., Hardy, A. M.Jaffe, H. W., Darrow, W. W., & Dowdle, W. R. (19851. The epidemiology of AIDS: Current status and future prospects. Science, 229, 1352-1357. Darby, S. C., Ewart, D. W., Giangrande, P. L. F., Spooner, R. J. D., & Rizza, C. R., for the UK Haemophilia Centre Directors' Organisation. (1996). Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet, 347, 1573-1579. De Gruttola, \ ., Seage, G. R., Mayer, K. H., Horsburgh, C. R., Jr., et al. (1989). Infectioness of HIV between male homosexual partners. Journal of Clinical Epidemiology, 42, 849-856. Des Jarlais, D. C. (1998). "Single-use" needles and syringes for the prevention of HIV infection among injection drug users. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 7#(Suppl. 1), S52-S56.

64

THE PERSON WITH HIV/AIDS

Desjarlais, D. C., Friedman, S. R., Perlis, T., Chapman, T. F., Sotheran, J. L., Paone, D., et al. (1999). Risk behaviors and HIV infection among new drug injectors in the era of AIDS in New York City: Journal oj'Acquired Immune Deficiency Syndromes and Human Retrovirology, 20, 67-72.

De Wit, J. (1996). The epidemic of HIV among young homosexual men. AIDS J0(Suppl. 3),S21-S25. De Wit,J., van den Hoek,J., &Sandfort, T. (1993). Increase in unprotected anogenital intercourse among homosexual men. American Journal of Public Health, 83 1451-1453. Diaz, T., Chu, S. Y., Weinstein, B., Mokotoff, E.Jones, T. S., & the Supplement t HIV/AIDS surveillance Group. (1998). Injection and syringe sharing among HFV-infected injection drug users: Implications for prevention of HIV transmission. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, M(Suppl. 1), S76-S81. Dobis, F., Msellati, P., Meda, N., Welffens-Ekra, You, B., Manigart, O., et al. (1999). Six month efficacy, tolerance, and acceptability of a short term regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'lvoire and Burkina Faso: A double-blind placebo-controlled multicentre trial. Lancet, 353, 786-792. Doll, D. C. (1988). Tattooing in prison and HIV infection. Lancet, 7(8575-6), 66-67. Duesberg, P. H. (1989). Human immodeficiency virus and acquired immunodeficiency syndrome: Correlation but not causation. Proceedings of the National Academy of Science USA, 86, 755-764. Dunn, D. T., Newell, M. L., Ades, A. E., & Peckham, C. S. (1992). Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet, 340, 585-588. Durfee, M. J., Berkowitz, C. D., Higgins, K. V., & Tubiolo, V. C. (1993). Situational and sociodemographic characteristics of children infected with human immunodeficiency virus from pediatric sexual abuse. Pediatrics, 91, 39-44. Edwards, S., & Carrie, C. (1998). Oral sex and the transmission of viral STIs. Sexually Transmitted Infections, 74, 6-10. Ekpini, E. R., Wiktor, S. Z., Satten, G. A., Adjorlolo-Johnson, G. T., Sibailly, T. S., Ou, C. Y, et al. (1997). Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Cote d'lvoire. Lancet, 349, 1054-1059. Essex, M., Allan, J., Kanki, P., McLane, M. F., Malone, G., Kitchen, L., & Lee, T. H. (1985). Antigens of human T-lymphotropic virus type III/lymphadenopathyassociated virus. Annals of Internal Medicine, 103, 700-703. Essex, M., & Kanki, P. J. (1988). The origins of the AIDS virus. Scientific American, 259, 64-71. Essex, M., Kanki, P. J., & Alroy, J. (1985). Isolation of T-lymphotropic retrovirus related to HTLV-III/LAV from wild-caught African green monkeys. Science, 230, 951-954. The European Mode of Delivery Collaboration. (1999). Elective caesarean-section versus vaginal delivery in prevention of vertical HFV-1 transmission: A randomised clinical trial. Lancet, 353, 1035-1039.

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

65

Farzadegan, H., Polis, M. A., Wolinsky, S. M., Rinaldo, C. R., Sninsky, J. J., Kwok, S., Griffith, R. 1,, Kaslow, R. A., Phair, J. P., Polk, B. F., & Saah, A. J. (1988). Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men. Annals of Internal Medicine, 108, 785-790. Fauci, A. S. (1996). Host factors and the pathogenesis of HIV-induced disease. Nature, 384, 529-534. Fauci, A. S., Macher, A. M., Longo, D. L., Lane, H. C., Rook, A. H., Masur, H., & Gelman, E. P. (1984). Acquired immunodeficiency syndrome: Epidemiologic, clinical, irnmunologic, and therapeutic considerations. Annals of Internal Medicine, 100, 92-106. Feller, A., & Flanigan, T. P. (1997). HIV-infected competitive athletes. Journal of General Internal Medicine, 12, 243-246. Gallo, R. C., & Montagnier, L. (1988). AIDS in 1988. Scientific American, 259(4), 4048. Gallo, R. C., Shaw, G. M., & Markham, P. D. (1985). The etiology of AIDS. In V. T. DeVita, Jr., S. Hellman, & S. A. Rosenberg (Eds.), AIDS: Etiology, diagnosis, treatment, and prevention (pp. 31-54). Philadelphia: Lippincott. Gao, F., Bailes, E., Robertson, D. L., Chen, Y., Rodenburg, G. M., Michael, S. F., et al. (1999). Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature, 3^7, 436-441. Garry, R. F., Witte, M. H., Gottlieb, A. A., Elvin-Lewis, M., Gottlieb, M. S., Witte, C. L., Alexander, S. S., Gole, W. R., & Drake, W. L. (1989). HIV infection in 1968. Journal oj the A merican Medical Association, 261, 2199. Gellert, G. A.. & Durfee, M. J. (1989). HIV infection and child abuse. New England [ounial of Medicine, 32], 685. Gelman, E. D.. Popvic, M., Blayney, D., Masur, H., Siclhu, G., Stahl, R. E., & Gallo, R. G. (1983). Proviral DNA of a retrovirus, human T-cell leukemia virus, in two patients with AIDS. Science, 220, 862-865. Gerberding, J. L. (1997). Occupational HFVinfection. AIDS, 77(Suppl. A), S57-S60. Gourevitch, M N. (1996). The epidemiology of HIV and AIDS. Medical Clinics of North America, 80(6), 1223-1238. Gray, G., Mac Intyre, J., & Lyons, S. (1996). The effect of breastfeeding on vertical transmission of HIV in Soweto, South Africa. Xlth International Conference on AIDS, Vancouver, Canada (Abstract TUC415), 7-12. Graziosi, C., Soudyns, H., Rizzardi, G. P., Bart, P. A., Chapuis, A., & Pantaleo, G. (1998), Irmnunopathogenesis of HIV infection. AIDS Research and Human Retrmnmsfs, /4(Suppl. 2), S135-S142. Greenhouse, P. (1987). Female-to-female transmission of HIV. Lancet, 2, 401-402. Gunby, P. (1988). Boxing: AIDS? /ournalof the American Medical Association, 259,1613. Hamers, F. F., Downs, A. M., Infuso, A., & Brunei, J. (1998). AIDS, 72(Suppl. A). S63-S70. Harris, G., Small, C. B., Klein, R. S., Friedland, G. H., Moll, B., Emeson, E. E., Spigland, I., 8c Steigbigeel, N. H. (1983). Immunodeficiency syndrome. New England foit mal of Medicine, 308, 1181-1184.

66

THE PERSON WITH HIV/AIDS

Haverkos, H. W., £ Edelman, R. (1988). The epidemiology of acquired immodeficiency syndrome among heterosexuals. Journal of the American Medical Association, 260, 1922-1929. Henderson, D. K. (1999). Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. Journal of the American Medical Association, 281, 931-936. Hessol, N. A., & Palacio, H. (1996). Gender, ethnicity and transmission category variation in HIV disease progression. AIDS, 10(Suppl. A), S69-S74. Holmberg, S. D. (1996). The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. American Journal of Public Health, 86, 642-654. Holmberg, S. D., Horsburgh, C. R., Ward, J. W., & Jaffe, H. W. (1989). Biologic factors in the sexual transmission of human immunodeficiency virus. Journal of Infectious Diseases, 160, 116-125. Hooper, E. (1997). Sailors and starbursts, and the arrival of HIV. British Medical Journal, 315, 1689-1691. Hu, D. J., Buve, A., Baggs, J., van der Groen, G., & Dondero, T. J. (1999). What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective. AIDS, 13, 873-881. Hudson, C. N. (1999). Elective caesarean section for prevention of vertical transmission of HIV-1 infection. Lancet, 353, 1030-1031. The International Perinatal HIV Group. (1999). The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. New England Journal of Medicine, 340, 977-987. Ippolito, G., Poggio, P., & Arid, C. (1994). Transmission of zidovudine-resistant HIV during a bloody fight. Journal of American Medical Association, 272, 433-434. Ippolito, G., Puro, V., Heptonstall,J.,Jagger,J., De Carli, G., & Petrosillo, N. (1999). Occupational human immunodeficiency virus infection in health care workers: Worldwide cases through September 1997. Clinical Infectious Diseases, 28, 365 383. Jaffe, H. W., Choi, K., Thomas, P. A., Haverkos, H. W., Auerbach, D. M., Guinan, M., et al. (1983). National case-control study of Kaposi's sarcoma and Pneumocystis cariniipneumonia in homosexual men: 1. Epidemiologic results. Annals of Internal Medicine, 99, 145-151. Jaffe, H. W., Hardy, A. M., Morgan, W. M., & Darrow, W. W. (1985). The acquired immunodeficiency syndrome in gay men. Annals of Internal Medicine, 103, 622664. Jaffe, H. W., & Schochetman, G. (1998). Group O human immunodeficiency virus1 infections. Infectious Disease Clinics of North America, 12(1), 39-46. Janssen, S. W., Buve, A., & Nkengasong,J. N. (1997). The puzzle of HIV-1 subtypes in Africa. AIDS, 11, 705-712. Jochimsen, E. M. (1997). Failures of zidovudine postexposure prophylaxis. American Journal of Medicine, /02(5B), 52-57. Joint United Nations Programme on HIV/AIDS and World Health Organization. (1998, June). Report on the global HIV/AIDS epidemic, 1-75. Jones, T. S., & Vlahov, D. (1998). Use of sterile syringes and aseptic drug preparation are important components of HIV prevention among injection drug users. Journal

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

67

of Acquired Immune Deficiency Syndromes and Human Retrovirology, _/8(Suppl. 1), SI — S5. Jovaisas, E., Koch, M. A., Schafer, A., Stauber, M., & Lowenthal, D. (1985). LAV/ HTLV-III in a 20-week fetus. Lancet, 2, 1129. Kanki, P. J., Hamel, D. J., Sankale, J. L., Hsieh, C. C., Thior, I., Barin, F., et al. (1999). Human immunodeficiency virus type 1 subtypes differ in disease progression. Journal of Infectious Diseases, 179, 68-73. Kaplan, J. E. (1986). A modern-day plague. Natural History, 95, 28-33. Karlsson, I., Massavve, A., Urassa, E., Kawo, G., Msemo, G., Kazimoto, T., et al. (1997). Late postnatal transmission of human immunodeficiency virus type 1 infection from mothers to infants in Dar es Salaam, Tanzania. Pediatric Infectious Diseases Journal, 16, 963-967. Kawamura, M., Yamazaki, S., Ishikawa, K., Kwofie, T. V., Tsujimoto, H., & Hayami, M. (1989). HIV-2 in West Africa in 1966. Lancet, 1, 385. Klevens, M., Fleming, P. L., Neal, J. J., Li,J., & the Mode of Transmission Validation Study Group. Is there really a heterosexual AIDS epidemic in the United States? Findings from a multisite validation study, 1992-1995. American Journal of Epidemiology, 149, 75-84. Kuhn, L., & Stem, Z. (1997). Infant survival, HIV infection, and feeding alternatives in less-developed countries. American Journal of Public Health, 87, 926-931. Lacey, C. J. N., & Waugh, M. A. (1984). AIDS: An old disease from Africa? British Medical Journal, 289, 496. Lackrit/, E. M. (1998). Prevention of HIV transmission by blood transfusion in the developing world: Achievements and continuing challenges. AIDS, 72(Suppl. A),S81-S86. Landesman, S. H., Ginzburg, H. M., & Weiss, S. H. (1985). The AIDS epidemic. New England Journal of Medicine, 312, 521—525. Landesman, S. H., Kalish, L. A., Berns, D. N., Minkoff, H., Fox, H. E., Zorrilla, C., et al. (1996). Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. New England Journal of Medicine, 334, 1617-1623. Lane, H. C., & Fauci, A. S. (1985). Immunologic abnormalities in the acquired immunodeficiency syndrome. Annual Review of Immunology, 3, 477-500. Larson, A. (1989). Social context of human immunodeficiency virus transmission in Africa: Historical and cultural bases of East and Central African sexual relations. Rnnew of Infectious Diseases, I I , 716-731. Lashley, F. R. (1998). Clinical genetics in nursing practice (2nd ed.). New York: Springer. Latham, M. C. (1998). Breastfeeding versus formula feeding in HIV infection. Lancet, 352. 737. Lean', W. E. (1998, September 28). Older people enjoy sex, survey says. Online at New York Times, [http://www. nytimes.com/library/national/science/ 092998sci-sex.html] Lemp, G. F., Jones, M., Kellogg, T. A., Nieri, G. N., Anderson, L., Withum, D., et al. (1995). HIV seroprevalence arid risk behaviors among lesbian and bisexual

68

THE PERSON WITH HIV/AIDS

women in San Francisco and Berkeley, California. American Journal of Public Health, 85, 1549-1552. LePage, P., Van de Perre, P., Carael, M., Nsengumuremyi, F., NkurunzizaJ., Butzler, ]., & Sprecher, S. (1987). Postnatal transmission of HIV from mother to child. Lancet, 2, 400. Leroy, V., Newell, M., Dabis, F., Peckham, C., Van de Perre, P., Bulterys, M., Kind, C., Simonds, R. J., Wiktor, S., & Msellati, P., for the Ghent International Working Group on Mother-to-Child Transmission of HIV. (1998). International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet, 352, 597-600. Levine, P. H. (1985). The acquired immunodeficiency syndrome in persons with hemophilia. Annals of Internal Medicine, 103, 723-726. Levy, J. A., Hoffman, A. D., Kramer, S. M., Landis, J. A., Shimabukuro, J. M., & Oshiro, L. S. (1984). Isolation of lymphocytopathic retrovirus from San Francisco patients with AIDS. Science, 225, 840-842. Li, P. C., & Yeoh, E. K. (1996). Update on epidemiology of AIDS in Asia. AIDS Clinical Review 1995/1996, 96, 347-386. Lifson, A. R. (1988). Do alternate modes for transmission of human immunodeficiency virus exist? Journal of the American Medical Association, 259, 1353-1356. Lot, F., Seguier, J. C., Fegueux, S., Astagneau, P., Simon, P., Aggoune, M., et al. (1999). Probable transmission of HIV from an orthopedic surgeon to a patient in France. Annals of Internal Medicine, 130, 1-6. Ludlam, C. A. (1997). Viral safety of plasma-derived factor VIII and IX concentrates. Blood Coagulation andFibrinolysis (Suppl. 8(1), S19-S23. Lukashov, V. V., & Goudsmit, J. (1998). HFV heterogeneity and disease progression in AIDS: A model of continuous virus adaptation. AIDS, /2(Suppl. A), S43-S52. Maclntyre, G. G., & Lyons, S. (1996, July). The effect of breastfeeding on vertical transmission of HIV in Soweto, South Africa. Paper presented at the llth International Conference on AIDS, Vancouver. Magierowska, M., Theodorou, I., Debre, P., Sanson, F., Autran, B., Riviere, Y., et al. (1999). Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus1-infected individuals. Blood, 93, 936-941. Magura, S., Grossman, J., Lipton, D., Siddiqi, Q., Shapiro, J., Marion, I., & Amann, K. R. (1989). Determinants of needle sharing among intravenous drug users. American Journal of Public Health, 79, 459-462. Malo, A., Rommel, F., Bogner, J., Gruber, R., Schramm, W7., Goebel, F. D., Riethmuller, G., & Wank, R. (1998). Lack of protection from HFV infection by the mutant HIV coreceptor CCR5 in intravenously HIV-infected hemophilia patients. Immunobiology, 198, 485-488. Mann, J. M., Chin, J., Piot, P., & Quinn, T. (1988). The international epidemiology of AIDS. Scientific American, 259, 82-89. Mann, J. M., & Tarantola, D. J. M. (Eds.). (1996). AIDS in the world: 2. Global dimensions, social roots and responses. New York: Oxford University Press. Marcus, R., & the Cooperative Needlestick Surveillance Group. (1989,June). Healthcare workers exposed to patients infected with human immunodeficiency virus (HIV)—

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

69

United States. Paper presented at the Fifth International Conference on AIDS, Montreal. Marmor, M., Weiss, L. R., Lyden, M., Weiss, S. H., Sacinger, W. C., Spira, T. J., £ Feorino, P. M. (1986). Possible female-to-female transmission of human immunodeficiency virus. Annals of Internal Medicine, 105, 969. Martin, J. L. (1987). The impact of AIDS on gay male sexual behavior patterns in New York City. American Journal of Public Health, 77, 578-581. Maury, W., Potts, B. J., & Rabson, A. B. (1989). HIV-1 infection of first-trimester and term human placental tissue: A possible mode of maternal-fetal transmission. Journal of Infectious Diseases, 160, 583-588. McCoy, C. B., Metsch, L. R., Chitwood, D. D., Shapshak, P., £ Comerford, S. T. (1998). Parental transmission of HIV among injection drug users: Assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 7#(Suppl. 'l) ,825-829. McCutchan, F. E., Salminen, M. O., Carr, J. K., £ Burke, D. S. (1996). HIV genetic diversity. AIDS, 10(Suppl 3), S513-S520. McDermott, D. H., Zimmerman, P. A., Guignard, F., Kleeberger, C. A., Leitman, S. F., the Multicenter AIDS Cohort Study (MACS), £ Murphy, P. M. (1998). CCR5 promoter polymorphism and HfV-1 disease progression. The Lancet, 352, 866-870. Mellors, J. W., Rinaldo, C. R., Gupta, P., White, R. M., Todd, J. A., £ Kingsley, L. A. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 272, 1167-1170. Miller, B., Stansfield, S., Zack, M., Curran,J., Kaplan,]., & Schonberger, L. (1984). The syndrome of unexplained generalized lymphadenopathy in young men in New York City. Journal of the American Medical Association, 251, 242-246. Monzon, O. T., & Capellan, J. M. (1987). Female-to-female transmission of HIV. Lancet, 2, 40-41. Moore, J. P., Trkola, A., £ Dragic, T. (1997). Co-receptors for HPV-1 entry. Current Opinion in Immunology, 9, 551-562. Moor, A. C. K.. Dubbelman, T. M. A. R., VanSteveninck, J., £ Brand, A., (1999). Transfusion-transmitted diseases: Risks, prevention and perspectives. European Jon rn a I of Hem atology, 62, 1-18. Moore, R. D., £ Chaisson, R. E. (1996). Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Annals of Internal Medicine, 124, 633-642. Morris, L., Distenfeld, A., Arnorosi, E., £ Karpatkin, S. (1982). Autoimmune thrombocytopenk prupura in homosexual men. Annals of Internal Medicine, 96, 714— 717. Msamanga, C. 1., £ Fawzi, W. W (1997). The double burden of HIV infection and tuberculosis in Sub-Saharan Africa. New England Journal of Medicine, 337, 849-851. Mundy, D. C.. Schinazi, D. C., Gerber, A. R., Nahmias, A. J., £ Randall, H. W. (1987). Human immunodeficiency virus isolated from amniotic fluid. Lancet, 2, 459-460. Nahmias, A. J., W T eiss,J., Yao, X., Lee, F., Kodsi, R., Schanfield, M., et al. (1986). Evidence for human infection with an HTLV III/LAV-like virus in Central Africa, 1959. Lancet, 7(8492), 1279-1280.

70

THE PERSON WITH HIV/AIDS

National Institute of Allergy and Infectious Diseases. (1999, July 8). Researchers identify a simple, affordable drug regimen that is highly effective in preventing HIV infection in infants and mothers with disease. Press release, National Institute of Allergy and Infectious Diseases, [http://www.niaid.nih.gov/newsroom/ simple/release.htm] Nduati, R. W., John G. C., Richardson, B. A., Overbaugh, J., Welch, M., NdinyaAchola, J., Moses, S., Holmes, K., Onyango, F., & Kreiss, J. K. (1995). Human immunodeficiency virus type 1-infected cells in breast milk: Association with immunosuppression and vitamin A deficiency. Journal of Infectious Diseases, 172, 1461-1468. Newell, M. L., Gray, G., & Bryson, Y. (1997). Prevention of mother-to-child transmission of HIV-1 infection. AZDS(Suppl. A), S165-S172. Norman, C. (1985). What's in a name? Science, 230, 641. O'Brien, T. R., Winkler, C., Dean, M., Nelson, J. A. E., Carrigton, M., Michael, N. L., & White, G. C., II. (1997). HIV-1 infection in a man homozygous for CCR5A32. The Lancet, 239, 1219-1220. Osmond, D., Page, K., Wiley, J., Garrett, K., Sheppard, H. W., Moss, A. R., et al. (1998). HIV infection in homosexual and bisexual men 18 to 29 years of age: The San Francisco young men's health study. American Journal of Public Health, 84, 1933-1937. Pela, A. O., & Platt, J. J. (1989). AIDS in Africa: Emerging trends. Social Science and Medicine, 28, 1-8. Perlman, D. (1998, October 8). AIDS deaths cut in half—disease off top 10 list. San Francisco Chronicle [http://www.aegis.eom/channel/s/SC981002.html] Pezzotti, P., Phillips, A. N., Dorrucci, M., Lepri, A. C., Galai, N., Vlahov, D., & Rezza, G. (1996). Category of exposure to HIV and age in the progression to AIDS: Longitudinal study of 1199 people with known dates of seroconversion. British Medical Journal, 313, 583-586. Phair,J. P. (1999). Determinants of the natural history of human immunodeficiency virus type 1 infection. Journal of Infectious Diseases, 179(Suppl. 2), S384-S386. Piazza, M., Chirianni, A., Picciotto, L., Guadagnino, V., Orlando, R., & Cataldo, P. T. (1989). Passionate kissing and microlesions of the oral mucosa. Possible role in AIDS transmission. Journal of the American Medical Association, 261V, 244-245. Pinching, A. J., Weiss, R. A., & Miller, D. (1988). AIDS and HIV infection: New perspectives. British Medical Bulletin, 44(1), 1-19. Pitchenik, A. E., Shafron, R. D., Glasser, R. M., & Spira, T. J. (1984). The acquired immunodeficiency syndrome in the wife of a hemophiliac. Annals of Internal Medicine, 100, 62-65. Pomerantz, R. J., Kuritzke, D. R., de la Monte, S. M., Rota, T. R., Baker, A. S., Albert, D., et al. (1987). Infection of the retina by human immunodeficiency virus type I. Neiu England Journal of Medicine, 317, 1643-1647. Quillent, C., Oberlin, E., Braun, J., Rousset, D., Gonzalez-Canali, G., Metais, P., Montagnier, L., Virelizier, J., Arenzana-Seisdedos, F., & Berreta, A. (1998). HIV1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet, 351, 14-18.

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

71

Ragni, M. V., Faruki, H., & Kingsley, L. A. (1998), Heterosexual HIV-1 transmission and viral load in hemophilic patients. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 1 7 ( 1 ) , 42-45. Raymond, C. A. (1988). Study of IV drug users and AIDS finds differing infection rate, risk behaviors. Journal of the American Medical Association, 260, 3105. Reiter, G. S. (1998). Human immunodeficiency virus (HIV) in America, 1981 to 1997: Epidemiologic and therapeutic considerations. Seminars in Ultrasound, CT, and MRJ, 19, 122-127. Remafedi, G., Parsons, J. T., Schultz, J. R., & Schulz, S. L. (1997). Sexual behavior of HIV-seropositive young men with congenital coagulopathies, Hemophilia Behavioral Intervention Projects (HBIEP) Study Group. Journal of Adolescent Health, 27(4), 232-237. Rezza, G. (1998). Determinants of progression to AIDS in HIV-infected individuals: An update from the Italian Seroconversion Study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 77(Suppl. 1), S3-S6. Roger, M. (1998). Influence of host genes on HIV-1 disease progression. TheFASEB Journal, 12, 625-632. Roosendaal, G., van der Schouw, Y. T., Mauser-Bunschoten, E. P., Borleffs,J. C., &: van den Berg, H. M. (1998). Progression to AIDS in relation to clinical factors and clotting product consumption. Vox Sanguinis, 75, 261-266. Rosenberg, P. S., & Goedert, J. J. (1998). Estimating the cumulative incidence of HIV infection among persons with haemophilia in the United States of America. Statistics in Medicine^ 77(2), 155-168. Rosenzweig, R., & Fillit, H. (1992). Probable heterosexual transmission of AIDS in an aged woman. Journal of the American Geriatric Society, 40, 1261-1264. Roz.enbaum, W.. Gharakhanian, S., Garden, B., Duval, E., & Coulaud,J. P. (1988). HPV transmission by oral sex. Lancet, 1, 1395. Sarr, A. D., Hamel, D. ]., Thior, L, Kokkotou, E., Sankale,J., Marlink, R., Coil-Seek, E., Essex, M., Siby, T., Doye, I. N., Mboup, S., & Kanki, P. (1998). HIV-1 and HIV-2 dual infection: Lack of HIV-2 provirus correlates with lowCD4+ lymphocyte counts. AIDS, 12, 131-137. Schacker, T., Ryncarz, A. J., Goddard,J., Diem, K., Shaughnessy, M., & Corey, L. (1998). Frequent recoveiy of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. Journal of the American Medical Association, 280, 61-66. Scully, G. (1997). The HFV global pandemic: The development and emerging implications. Oral Diseases, 3(Suppl. 1), S1-S6. Seale, J. R. (1984). AIDS and hepatitis B cannot be venereal diseases. Canadian Medical Association Journal, 130, 1109-1110. Selik, R. M.. Castro, K. G., & Pappaioanou, M. (1988). Acquired immune deficiency syndrome (AIDS) trends in the United States, 1978-1982. American Journal of Medicine, 76, 493-500. Selik, R. M., Haverkos, H. W., & Curran,J. W. (1984). Acquired immune deficiency syndrome (AIDS) trends in the United States, 1978-1982. American Journal of Medicine, 76, 493-500. Semba, R. D., Miotti, P. G., & Chiphangwi, J. D. (1995). Infant mortality and maternal vitamin A deficiency during human immunodeficiency virus infection.

Clinical Journal of Infectious Diseases, 21, 966-972.

72

THE PERSON WITH HIV/AIDS

Serwadda, D., Mugerwa, R. D., Sewankambo, N. K., Lwegaba, A., Carswell, J. W., Kirya, G. B., et al. (1985). Slim disease in Uganda and its association with HTLVIII infection. Lancet, 2, 849-852. Simon, F., Mauclere, P., Roques, P., Loussert-Ajaka, I., Muller-Trutwin, M. C., Saragosti, S., Georges-Courbot, M. C., Barre-Sinoussi, F., & Brun-Vezinet, F. (1998). Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nature Medicine, 4(9), 1032-1036. Sol, N., Ferchal, F., Braun, J., Pleskoff, O., Treboute, C., Ansart, I., & Alizon, M. (1997). Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2. Journal of Virology, 77(11), 8237-8244. Spitzer, P. G., & Weiner, N.J. (1989). Transmission of HFV infection from a woman to a man by oral sex. New England Journal of Medicine, 320, 251. Strathdee, S., Van Ameijden, E., Mesquita, F., Wodak, A., Rana, S., & Vlahov, D. (1998). Can HIV epidemics among injection drug users be prevented? AIDS, ;2(Suppl. A),S71-S79. Theodorou, I., Meyer, L., Magierowska, M., Katlama, C., & Rouzioux, C. (1997). HFV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group [letter]. Lancet, 349(9060), 1219-1220. Thiry, L., Sprecher-Goldberger, S., Jonckheer, T., Levy, J., Van de Perre, P., Henrivaux, P., Cogniaux-LeCleree, J., & Clumeck, N. (1985). Isolation of AIDS virus from cell-free breast milk of three health virus carriers. Lancet, 2, 891-892. UNAIDS/WHO. (1998). Global HIV/AIDS and STD Surveillance. Report on the Global HIV/AIDS Epidemic, June 1998. [http://unaids.org/unaids/docum . . . 1% 5Freport/rep/rep%5html/report2.html] UNAIDS/WHO. AIDS epidemic update: December, 1998. UNAIDS Joint United Nations Programme on HIV/AIDS, 1-17. U.S. Bureau of the Census, Resident population of the United States: Middle Series Projections 1996-2000, by sex, race, and Hispanic origin, with median age. http://www.census.gov/population/projections/nation/nsrh/nprh9600.txt, accesses June 23, 1999. Vail, L. (1988). HFV infection in Zaire. New England Journal of Medicine, 319, 309. Vermund, S. H. (1997). Transmission of HIV-1 among adolescents and adults. In V. T. DeVita,Jr., S. Hellman, & S. A. Rosenberg, AIDS: Etiology, diagnosis, treatment and prevention (pp. 147-165). Philadelphia: Lippincott Raven. Vernazza, P. L., Eron,J. J., Fiscus, S. A., & Cohen, M. S. (1999). Sexual transmission of HIV: Infectiousness and prevention. AIDS, 13, 155-166. Viscarello, R. R., Cullen, M. T., DeGennaro, N. J., & Hobbins, J. C. (1992). Fetal blood sampling in human immunodeficiency virus—seropositive women before elective midtrimester termination of pregnancy. Amencan Journal of Obstetrics and Gynecology, 167(4, Pt. 1), 1075-1079. Vittecoq, D., Mettetal, J. F., Rouzioux, C., Bach, J. F., & Bouchon, J. P. (1989). Acute HIV infection after acupuncture treatments. New England Journal of Medicine, 320V, 250-251. Voelker, R. (1998). Rural communities struggle with AIDS. Journal of the Amencan Medical Association, 279, 5-6.

THE ETIOLOGY, EPIDEMIOLOGY, AND TRANSMISSION OF HIV

73

Vogt, M. W., Witt, D. J., Craven, D. E., Byington, R., Cra\vford, D. F., Schooley, R., & Hirsch, M. S. (1986). Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet, 1, 525-527. Wain-Hobson, S. (1998). More ado about HIV's origins. Nature Medicine, 4 ( 9 ) , 10011002. Walker, T. S. (1998). Microbiology. Philadelphia: W. B. Saunders. Ward, J. W7., & Duchin, J. S. (1998). The epidemiology of HIV and AIDS in the United States. AIDS Clinical Review, 1997/1998, 1-45. Webber, M. P., Schoenbaum, E. E., Gourevitch, M. N., Buono, D., & Klien, R. S. (1999). A prospective study of HIV disease in female and male drug users. AIDS, 13, 257-262. Weber, J. (1984). Is AIDS an epidemic form of African Kaposi's sarcoma?: Discussion paper. Journal of the Royal Society of Medicine, 77, 575-576. Whittle, H. C., Ariyoshi, K., & Rowland-Jones, S. (1998). HIV-2 and T cell recognition. Current Opinion in Immunology, 10(4), 382-387. Wiley, C. A., £ Achim, C. (1994). Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Annals oj Neurology, 36, 673-676. Withrington, R. H., Cornes, P., Harris,]. R. W., Seifert, M. H., Berrie, E., TaylorRobinson, D.. & Jeffries, D. J. (1987). Isolation of human immunodeficiency virus from svnovial fluid of a patient with reactive arthritis. British Medical Journal, 294, 484. Wofsy, C. B., Cohen, J. B., Hauer, L. B., Padian, N. S., Michaelis, B. A., Evans, L., & Levy, J. A. (1986). Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. Lancet, 1, 527-529. World Health Organization. (1985). Acquired immune deficiency syndrome (AIDS). Weekly Epidemiological Record, 60, 342. (1998). Global AIDS surveillance. Weekly Epidemiological Record, 73, 193-200. Wortley, P. M., & Fleming, P. L. (1997). AIDS in women in the United States. Journal of the American Medical Association, 275(11), 911-916. Zeigler,}. V., Cooper, D. A., Johnson, R. O., £ Gold, J. (1985). Postnatal transmission of AIDS-associated retrovirus from a mother to an infant. Lancet, 1, 896-897. Zhu, T., Korber, B. T., Nahmias, A.J., Hooper, E., Sharp, P. M., £ Ho, D. D, (1998). An African HlV-1 sequence from 1959 and implications for the origin of the epidemic. Nature, 391, 594—597.

This page intentionally left blank

2

The Pathogenesis of HIV Infection Janice M. Zeller and Barbara Swansan

nfection with the human immunodeficiency virus (HIV) induces defects in both cell-mediated and humoral immune responses, thus rendering the host susceptible to opportunistic infections and neoplasms. The pathogenesis of HIV infection is highly complex, involving interactions among multiple viral and host factors. In recent months, substantial progress has been made in elucidating the mechanisms underlying HIV infection and replication dynamics. In concert with the development of protease inhibitors, these findings have led to cautious optimism that sustained inhibition of HFV-1 replication will be achieved in the future. In this chapter, we summarize current knowledge pertaining to the pathogenesis of HIV infection.

I

CHARACTERISTICS OF HIV-1 Classification HIV is a retrovirus. Retroviruses demonstrate a reversal in the usual flow of genetic information during their life cycle (Stine, 1997). That is, their genetic material is contained within ribonucleic acid 75

76

THE PERSON WITH HIV/AIDS

(RNA), rather than deoxyribonucleic acid (DNA). Following entry into a target cell, they use an enzyme, reverse transcriptase, to transcribe their RNA into DNA, which is then integrated into the host genome. Using host cell enzymes, the integrated DNA, or provirus, is transcribed into messenger RNA (mRNA), which directs the synthesis of new viral particles (Pavlakis, 1997). HIV is a member of the family of retroviruses known as lentiviruses Lentiviruses typically infect cells of the immune system, resulting in immunodeficiency. They escape clearance by the immune system and cause persistent infections characterized by long incubation periods. Examples of other lentiviruses include visna virus, a neurotoxic virus that infects sheep, and simian immunodeficiency virus (SIV), a primate virus that induces an AIDS-like syndrome (Pavlakis, 1997). Viral Structure HIV is spherically shaped and measures 1/10,000 mm in diameter (Stine, 1997). It consists of an outer envelope composed of a phospholipid bilayer that is "studded" with two glycoproteins: gp41, which spans the phospholipid bilayer, and gp!20, which is attached to the top of gp41 and lies outside the viral envelope. Lying directly beneath the lipid bilayer and lining the inner surface of the virus is the pi 7 matrix protein, which helps stabilize the particle. The center of the virus is a cone-shaped core that is composed of the major capsid protein (p24). The core contains enzymes necessary for viral replication and two copies of genomic RNA bound to the nucleocapsid proteins (p9 and p7) (Hahn, 1994; Levy, 1994) (see Figure 2.1). Viral Genes The HIV provirus consists of approximately 8.5 kilobases of proteincoding information flanked on each side by identical sequences of nucleotides known as long terminal repeats (LTRs). The LTRs are produced during reverse transcription and thus are only present in the DNA copy of the viral genome (Hahn, 1994). These LTRs contain binding sites for host transcription factors and regulate the expression of viral proteins (Parslow & Hope, 1994; Stine, 1997). Similar to all known retroviruses, HIV has three genes that encode for its structural proteins: env, pol, and gag. The env gene encodes

THE PATHOGENESIS OF HIV INFECTION

FIGURE 2.1

77

HIVvirion.

Note. From The Medical Management of AIDS (5\h ed.). Edited by M. A. Sande & P. A. Volberding, 1997, Philadelphia: W. B. Saunders Company. Copyright 1997 by W. B. Saunders Company. Reproduced with permission.

for gplGO, a precursor to the envelope glycoproteins. The gplGO precursor is cleaved by a cellular protease into its subunits, gp!20 and gp41. The pol gene encodes for three viral enzymes necessary for replication: reverse transcriptase, integrase, and protease. The grtggene encodes for a polyprotein that is cleaved by the viral protease into the viral matrix (pi7), capsid (p24), and nucleocapsid proteins (p7 and p9) (Lew, 1994; Young, 1994). Additional genes, unique to HIV, encode for three proteins that regulate viral replication. One protein, Tat, binds to a region in the LTR known as the Tat responsive element (TAR). Binding of Tat to TAR has been shown to upregulate viral replication by 1,000fold (Stine, 1997), possibly by initiating and elongating proviral transcription (Folks & Hart, 1997). A second regulator}' protein, Rev, binds to the Rev regulatory element located in the env gene of the viral mRNA (Folks & Hart, 1997). Rev is involved in transporting mRNAs for the gag, pol, and env genes from the nucleus to the cytoplasm, where they are translated into proteins (Hahn, 1994). The third regulatory protein, Nef, has diverse functions. Nef has been shown to downregulate surface expression of CD4+ on infected

78

THE PERSON WITH HIV/AIDS

1911s (Aiken, Konner, Landau, Lenburg, & Trono, 1994). This downregulation of CD4+ prevents the reinfection of target cells and promotes viral spread to uninfected cells. Thus, Nef appears to confer a survival advantage to the virus (Hahn, 1994). Evidence also suggests that Nef regulates viral virulence. A small cohort of Australians infected in the 1980s with a Nef-deleted viral mutant has shown no evidence of immunodeficiency to date (Dyer et al., 1997). Furthermore, it has been shown that Nef is required for viral replication and the development of disease in macaques infected with SIV (Kestler et al., 1991). Cellular Tropism HIV strains can be categorized on the basis of their tropism, or ability to infect different cell types. Tropism is determined by variations in the V3 loop of gp!20. All viruses isolated from infected persons are capable of infecting CD4+ T lymphocytes (Fauci, 1996). Some isolated viruses are also capable of infecting macrophages and are known as macrophage tropic strains (M tropic), while other isolates only infect T lymphocytes or transformed T cell lines and are known as T cell tropic strains (T tropic). For unknown reasons, M tropic strains predominate in the early, asymptomatic stages of infection, regardless of route of transmission, while T tropic strains predominate at later stages (Fauci, 1996). HIV strains are also categorized by their ability to induce the formation of syncytia in vitro. Syncytia are clusters of fused lymphocytes that form when cell cultures are infected with certain viral strains. These viral strains, termed syncytium-inducing (SI), predominate in later stages of infection and are associated with a decline in CD4+ T lymphocyte counts and progression to AIDS. In contrast, non-syncytium-inducing (NSI) strains can be found at all stages of infection. Generally, T tropic strains are SI, whereas M tropic strains are NSI (Weiss, 1994). HIV LIFE CYCLE HIV Receptors HIV infects cells that express the CD4+ receptor on their surface. CD4+ is a 58-kd transmembrane glycoprotein that belongs to the

THE PATHOGENESIS OF HIV INFECTION

79

immunoglobulin (Ig) superfamily. CD4+ assists in T cell recognition of antigen by binding to major histocompatibility complex (MHC) class II molecules expressed on the surface of antigen-presenting cells. CD4+ cells that are targets for HIV infection include the helper subset of T lymphocytes, monocytes and macrophages (including microglial cells in the brain), and dendritic cells (follicular dendritic cells in the lymph node and Langerhans cells in the skin) (Cunningham, Dwyer, Mills, & Montagnier, 1996; Pavlakis, 1997). For years, it had been recognized that CD4+ is necessary but insufficient to permit infection of target cells and that unknown coreceptors were likely involved in viral binding and entry. Recently, it was observed that chemokines, chemoattractant cytokines released during inflammation, suppressed infection of CD4+ target cells. This observation led to the identification of chemokine receptors as coreceptors for HIV infection (Fauci, 1996). Chemokine receptors have seven transmembrane segments and are coupled to signal transducing G proteins (Feng, Broder, Kennedy, & Berger, 1996). Ligand binding activates signals that mediate leukocyte extravasation and migration (Wu et al., 1997). Two major chemokine receptors have been identified as the coreceptors for HIV infection: CXCR4, which mediates entry of T tropic strains, and CCR5, which mediates entry of M tropic strains (Unutmaz & Littman 1997). Variations in these affect resistance to HIV infection and progression to AIDS. See chapter 1 (Lane, 1997; Wu et al., 1997). Binding and Entry Upon entry into the host, HIV attaches to the CD4+ molecule via gp!20. This binding induces conformational changes in both the viral envelope and CD4+ that permit binding of other gp!20 epitopes to either CXCR4 or CCR5. This second binding event moves the viral envelope closer to the cell surface and leads to the fusion of gp41 with the target cell membrane. Following fusion, the virus enters the cell, the core uncoats, and the core contents (two strands of RNA and reverse transcriptase) are released into the cytoplasm (Levy, 1996). Reverse Transcription, Translocation, and Integration Reverse transcriptase (RT) is a polymerase that acts in concert with a second enzyme, RNAse, to copy the viral RNA into DNA. The RT

80

THE PERSON WITH HIV/AIDS

polymerase transcribes the two RNA strands into two strands of DNA, while the RNAse separates the DNA copies from the RNA (Brennan & Porche, 1997). T;«e mutations characteristic of HIV are generated during reverse transcription. The RT polymerase lacks a "proofreading" mechanism to correct for misincorporated nucleotides. These transcription errors underly the genetic diversity of viral strains worldwide, enable the virus to elude immune clearance, and select for antiretroviral-resistant mutants (Folks & Hart, 1997). The double-stranded DNA, in association with the gag matrix proteins and integrase, is transported across the nuclear pore and into the nucleus. This translocation is mediated by nuclear localization signals contained within the gag matrix proteins. Upon entry into the nucleus, the integrase enzyme trims the viral DNA, cuts the host chromosomal DNA, and inserts the viral DNA into the host's chromosomes (Folks & Hart, 1997). Some viral DNA does not become integrated into the host's chromosomes and remains in the cytoplasm. The accumulation of unintegrated DNA has been shown to be associated with cell death in animal models of retrovirus infection (Weller, Joy, & Temin, 1980). However, it is not known if this is a mechanism associated with the progression of HIV infection in humans.

Viral Transcription and Synthesis Provirus transcription and subsequent viral synthesis occurs most efficiently in activated cells. Activation stimuli, such as opportunistic pathogens or immunizations, induce the elaboration of cytokines that promote proviral transcription and subsequent viral replication. For example, cytokines activate a DNA binding protein, known as nuclear factor-kappa B (NF-KB), that is present in the cytoplasm of T lymphocytes. NF-KB binds to receptors present in the interleukin2 (IL-2) promoter gene region, thus promoting IL-2 production by activated cells. The HIV-LTR also contains receptors that can bind NF-KB, and binding of these receptors activates provirus transcription (Fauci & Rosenberg, 1994). Because HIV infection is associated with chronic immune activation, the infected host provides a permissive environment for viral replication (Pantaleo et al., 1997).

THE PATHOGENESIS OF HIV INFECTION

81

Upon cellular activation, the provirus is transcribed into strands of RNA. Some of the strands are spliced by cellular enzymes to become the messenger RNA (mRNA) that serves as the template for the synthesis of new virus particles. The strands left unspliced are the genomic RNA that will be packaged in the core of new viral particles (Stine, 1997). Following proviral transcription, the Rev protein binds to the RNA transcripts and delivers them to ribosomes in the cytoplasm. At the ribosome, the mRNA is translated into polyproteins that will serve as the structural and regulatory proteins of new virus particles. The viral polyproteins accumulate at the plasma membrane, and the two genomic RNA copies become encapsidated by the gag proteins. The viral particles begin to bud from the host cell and acquire their lipid envelopes from the plasma membrane. During and immediately after budding, the viral protease cleaves the polyproteins into individual active proteins, thus creating mature, infectious new virions (Folks & Hart, 1997; Stine, 1997). VIRAL REPLICATION DYNAMICS After entering the host, HIV is rapidly disseminated to the lymphoid tissues (Fauci, Pantaleo, Stanley, & Weissman, 1996). During this period of initial infection, also known as primary infection, there is a burst of viremia, as demonstrated by a high plasma viral load (up to 107 copies of HIV RNA per 1 milliliter of plasma), and a depletion of CD4+ T lymphocytes (Pantaleo & Fauci, 1996). After a period of a few weeks, the host develops an immune response to the virus, resulting in a down regulation of plasma viral load and a partial restoration of absolute CD4+ T lymphocyte numbers, although both parameters frequently fluctuate for the next 6 months (Ffrench, Stewart, Penny, & Lew, 1996). Viral load in regard to treatment is discussed in chapter 7. The immune response does not completely eliminate the virus from the host. Viral particles can be found in the lymphoid tissue, which serves as the reservoir for as much as 99% of the total viral burden in the body. Most of the lymphoid tissue-associated virus is contained within follicular dendritic cells (FDC) (Patel, Hale, & Haynes, 1996). Latent, yet replication-competent virus, has also been found in quiescent, CD4+ T lymphocytes

82

THE PERSON WITH HIV/AIDS

in the peripheral blood of patients who have been taking highly active antiretroviral therapy (HAART) for up to 30 months. This finding suggests that peripheral lymphocytes constitute a second, albeit smaller, viral reservoir (Finzi et al., 1997). Approximately 6 months after infection, CD4+ T lymphocyte counts and plasma viral load stabilize. The stable viral load is known as the "viral setpoint" and is predictive of long-term clinical outcomes, with higher viral load associated with more rapid progression to AIDS (Staprans & Feinberg, 1997). The initiation of antiretroviral therapy during primary HIV infection may lower the viral setpoint and thus delay disease progression, although there are insufficient data to confirm this (Carr & Cooper, 1997). See chapter 5. After the period of primary HIV infection, there is a clinically asymptomatic phase that can last for several years. During this period of clinical latency, HIV is actively and continuously replicating. It is estimated that 1.1 x 108 virus particles are produced daily, with the majority of virus produced from continuous rounds of de novo infection, rather than from chronically infected cells or latently infected cells that become activated (Wei et al., 1995). Because the half-life of virus-producing cells is only 2 days, a tremendous reconstitution of infected cells is necessary to sustain steady-state levels of viral replication. The daily turnover rate of CD4+ T lymphocytes in HIV infection is estimated to be 2.6 x 109 cells. It is hypothesized that the persistent reconstitution demands eventually exceed the immune system's finite capacity for regeneration, resulting in immunodeficiency and disease progression (Ho et al., 1995). MECHANISMS OF VIRAL ESCAPE FROM THE IMMUNE RESPONSE Shortly after infection, the host mounts vigorous, anti-HIV cell-mediated and humoral responses resulting in a decline of the initial viremic burst (Haynes, Pantaleo, & Fauci, 1996). However, for unknown reasons, these responses are insufficient to completely eliminate the virus from the infected host, although both virologic and immunologic factors are probably involved. Putative virologic factors include (1) the formation of large pools of latently infected cells, (2) the trapping of viral particles in the FDC network leading to

THE PATHOGENESIS OF HIV INFECTION

83

continuous rounds of de novo infection of resident CD4+ T lymphocytes and/or activation of these cells rendering them susceptible to infection, and (3) the continual emergence of viral mutants that can escape HlV-specific cytotoxic T lymphocyte (CTL) responses. Immunologic factors include (1) virally induced quantitative and qualitative defects in immune cells, (2) the egress of HIV-1-specific CTLs from the lymphoid tissue, the primary site of viral replication, and (3) the clonal deletion of HlV-specific CTLs (Pantaleo & Fauci, 1996). CD4+ LYMPHOCYTE DYNAMICS Naive and Memory Cells Over the course of HIV infection, there is a steady decline in the number of CD4+ lymphocytes. Phenotypic analysis of CD4+ T lymphocytes has revealed that naive cells are preferentially depleted, with a relative sparing of memory subsets. By end-stage disease, it is postulated that only memory cells remain (Lane, 1997). HAART is associated with an expansion of both naive and memory subsets, although memory subsets expand preferentially early in the course of therapy. After several months of therapy, there is a slow increase in naive cells. Therefore, although HAART is associated with clinically significant improvements in immune function, only partial restoration of the immune system is achieved in the first year (Powderly, Landay, & Lederman, 1998). Th-1 and Th-2 Responses Imbalances involving immunoregulatory subsets of CD4+ T lymphocytes have been postulated to contribute to HIV disease progression (Staprans & Feinberg, 1997). Immune responses are regulated by the helper subset of CD4+ T lymphocytes, of which there are two major phenotypes: (1) type-1 cells (Th-1) that produce interferony and induce cell-mediated immune (CMI) responses, and (2) type2 cells (Th-2) that produce interleukin-4 (IL-4) and induce humoral

84

THE PERSON WITH HIV/AIDS

responses. CMI responses activate effector cells that are capable of killing intracellular pathogens such as viruses. Humoral responses involve the elaboration of antibody to neutralize pathogens and are effective in clearing bacterial infections (Allen & Maizels, 1997). Th-1 responses appear to inhibit HIV disease progression, whereas Th-2 responses appear to be relatively ineffective (Clerici & Shearer, 1994). It has been suggested that HIV disease progression is associated with a switch from a predominantly Th-1 response to a Th-2 response. The mechanisms underlying this phenotypic switch remain unclear, although it may be influenced by the temporary upregulation of IL-4 production that occurs in the first year of HIV infection (Shearer & Clerici, 1996). Studies to confirm this hypothesis have yielded conflicting findings, calling into question the validity of this hypothesis (Allen & Maizels, 1997; Graziosi et al., 1994). HIV in Lymphoid Tissue During primary infection and throughout the period of clinical latency, the greatest concentration of HlV-infected cells is found in the lymphoid tissue. This includes the lymph nodes, adenoids, tonsils, and the spleen (Staprans & Feinberg, 1997). The high concentration of actively replicating virus in lymph nodes, and the subsequent immune activation, underlie the lymphadenopathy commonly seen in the early stages of HIV infection (Saag, 1997). Histological analysis of lymph node tissue throughout the course of HIV infection reveals characteristic changes that correlate with plasma viral load, CD4+ T lymphocyte count, and clinical status. In early HIV infection (CD4+ count > 500/mm3), virus particles are trapped by the network of follicular dendritic cells (FDC) located in lymph node germinal centers. FDCs are major antigen presenting cells in the lymph node. They can trap HIV that is bound to antibodycomplement complexes via complement receptors expressed on their surface (Patel et al., 1996). This trapping leads to immune cell activation, infection of target cells in the lymph node, and follicular hyperplasia. Moreover, trapping of virus particles by the FDC network sequesters virus in the lymph node. In the early stages of infection, viral load in the lymphoid tissue exceeds that in the plasma by one to three logs (Pantaleo et al., 1997).

THE PATHOGENESIS OF HIV INFECTION

85

As HIV infection progresses to intermediate stages (CD4+ T lymphocyte counts between 200 and 500/mm s ), plasma viral load increases to levels that are more comparable with levels found in the lymph node. Although this increase in plasma viremia reflects HIVinduced immune suppression, it also reflects progressive histopathological changes in lymphoid tissue (Pantaleo et al., 1997). During this time, lymph nodes show involution with hypocellular germinal centers, loss of FDCs, and increased vascularity. These changes lead to a gradual loss of viral trapping by the FDC network and increased plasma viral load (Patel et al., 1996). In the final stages of HIV infection (CD4+ lymphocyte counts < 200/mm s ), there is a profound destruction of normal lymph node architecture. Lymph node germinal centers are involuted and depleted of lymphocytes and FDCs. The remaining cells are predominantly histiocytes and plasma cells. These histopathological changes are associated with high plasma viral load, the development of opportunistic infections, and death (Pantaleoetal., 1997; Patel etal., 1996). PROFILES OF DISEASE PROGRESSION Typical Progressors, Rapid Progressors, Long-term Nonprogressors Although it was initially estimated that all persons who had become infected with HIV would die within a few years of exposure to the virus, it soon became clear that there was tremendous diversity in outcomes postinfection. In observing the immunological, virological, and clinical changes occurring in HFV-infected persons, three patterns of disease progression have emerged. The majority (80% to 90%) of HFV-infected persons are categorized as typical progressors. They tend to develop AIDS within 10 years of initial infection (Pantaleo et al, 1997). Rapid progressors, representing 5% to 10% of infected persons, progress to AIDS within 2 to 3 years of HIV infection. The remaining 5% of infected persons (long-term nonprogressors) remain clinically asymptomatic for 7 to 10 years following infection and show no decline in CD4+ T lymphocyte counts. To gain a better understanding of the factors that sup-

86

THE PERSON WITH HIV/AIDS

port an effective host response to HIV infection, attempts have been made to characterize the genetic, immunological, and virological correlates of disease progression in these populations (Pantaleo et al, 1997). The majority of typical progressors manifest acute clinical symptoms within 3 to 6 weeks of primary infection. During this period, high serum viral liters can be detected, but in most cases there is no indication of elevated antibody liters to HIV. At 9 to 12 weeks, individuals enter into a period of clinical latency that correlates with the appearance of both humoral and cell-mediated immune responses to the virus, reduction in plasma viremia, and resolulion of clinical symptoms. Allhough viral levels in ihe peripheral blood remain low during the period of clinical latency, active viral replication occurs within lymphoid organs. CD4+ T lymphocyle counls decline and clinical disease becomes apparenl after approximately 8 to 10 years. The onset of clinical disease occurs in the face of continuous viral replication, progressive deslruclion of lymphoid lissue, and profound immune dysregulalion. Rapid progressors differ from typical progressors in that they fail lo develop a compelenl immune response lo primary infeclion. Rapid progressors show low HIV anlibody lilers, poor suppression of HIV replication by CD8+ CTLs, and persistency high plasma viral load. Later stages of the disease are characterized by inappropriate immune activation, as evidenced by elevated serum levels of neoplerin, p2-microglobulin, and soluble IL-2 receptors. This inappropriate immune aclivation is associated with progressive exhaustion of the immune response and accelerated clinical disease progression. Long-term nonprogressors have captured the interesl of clinicians and researchers alike, as iheir clinical course may shed light on how best to promote a favorable host response to HIV. This small group of individuals has been shown to maintain stable CD4+ T lymphocyte counts for greater than 7 years postinfection, despite lack of antiretroviral iherapy. Their immune funclion remains intact, as they continue to generate slrong humoral as well as cell-mediated responses lo HIV and show no signs of inappropriate immune activation. Absolute numbers of CD8+ CTLs are higher than those seen in typical progressors, and fewer CD8+ CTLs show signs of inappropriate activation. Although long-term nonprogressors demonstrate low levels of viral load in plasma and mononuclear cells in the peripheral blood

THE PATHOGENESIS OF HIV INFECTION

87

and lymph nodes, viral replication persists. Despite the persistence of viral replication, lymph node architecture is preserved and no evidence of AIDS-associated clinical symptoms is noted for at least 7 years following primary infection. A number of factors have been proposed as contributory to the varying rates of disease progression in HIV-infected individuals. Although there is evidence that virus isolated from long-term nonprogressors is infectious and replication-competent, it is plausible that these viral strains exhibit lower levels of pathogenicity than those infecting persons with more rapidly progressing disease (Pantaleo et al., 1997). In support of this hypothesis, strains of virus bearing Nef deletions have been isolated from long-term nonprogressors (Korchhoff, Greenough, Brettler, Sullivan, & Desrosiers, 1995). Host genetic factors have also been associated with varying rates of HIV disease progression. Those genes encoded by the major histocompatability (MHC) loci, MHC class I and MHC class II, determine the strength and specificity of cellular and humoral immune responses. Certain MHC alleles have been postulated to promote long-term survival in persons with HIV infection by facilitating effective clearance of HIV-infected cells during early stages of infection (Haynes et al., 1996). Also, the expression of MHC class I antigens on HIVinfected cells may regulate their susceptibility to lysis by natural killer cells (Haynes et al., 1999b). The observation that long-term nonprogressors have strong CTL responses to certain HIV epitopes has focused attention on these cells in the design of HIV immunotherapeutic strategies (Haynes et al., 1996). Resistance to Infection Of perhaps even greater interest to the research community than long-term nonprogressors are those individuals who have been repeatedly exposed to HIV but nevertheless show no clinical evidence of chronic infection. There is reason to believe that these individuals were acutely infected at some point, as they demonstrate vigorous CTL responses to HIV antigens (Haynes et al., 1996). Although currently there is no explanation for the ability of certain individuals to effectively clear the infection, host genetics, such as that involving alleles of the CCR5 gene, may play a role (Fauci, 1996). This molecule

88

THE PERSON WITH HIV/AIDS

may be an important target in planning disease prevention strategies (Fauci, 1996). See chapter 1. CHARACTERISTICS AND MECHANISMS OF HIV-RELATED IMMUNE DEFICIENCY Decline in CD4+ Cell Numbers Virtually all components of the immune system are altered during the course of HIV infection. This may be the result of direct infection of immune cells with HIV or alternatively may occur in response to altered patterns of cytokine expression associated with the disease (reviewed in Zeller, McCain, & Swanson, 1996). The cell most markedly influenced by HIV infection is the CD4+ T lymphocyte. Functional defects in CD4+ T lymphocytes occur early in infection, even when CD4+ cell numbers remain high (Clerici & Shearer, 1992). Over the course of illness, there is a progressive decline in the ability of these cells to respond to recall antigens, followed by a loss of responsiveness to alloantigens, which is followed by a failure to respond to nonspecific activators, such as mitogens (Shearer & Clerici, 1992). The rate of decline of CD4+ T lymphocyte numbers has proven to be an important prognostic indicator of HIV-disease progression. The maintenance of an adequate pool of functionally intact CD4+ T lymphocytes is dependent upon maintaining a steady-state balance between cell loss and cell renewal (Ffrench et al., 1996). In HIV disease, reduced CD4+ T cell numbers have been attributed to impairments in cell renewal capabilities coupled with increased cell losses. Impairment in T Cell Renewal CD4+ T lymphocytes are derived from bone marrow cells that undergo maturation within the thymus gland. T lymphocytes normally encounter antigen and continue to differentiate and proliferate within peripheral lymph nodes (Janeway & Travers, 1994). Over the course of HIV infection there is evidence of direct infection and lytic destruction of thymocytes (immature T lymphocyte

THE PATHOGENESIS OF HIV INFECTION

89

precursors), as well as disruption of the stromal network within the thymus gland, which provides a microenvironment for thymocyte maturation. Additionally, as HIV disease progresses, there is marked involution and atrophy of peripheral lymphoid organs (Fauci, Pantaleo, Stanley, & Weissman, 1996; Pantaleo & Fauci, 1996). Loss of the network relevant MHC class II antigen-presenting cells within this environment is instrumental in reducing the renewal of an antigen-specific T helper cell population (Heeney, 1995). At late stages of HIV disease, pluripotent bone marrow stem cells, identified by the CD34 surface marker become infected with the virus. Although in vitro infection of CD34+ bone marrow stem cells is cytopathic, it remains uncertain whether these cells are destroyed in vivo or whether they serve as a viral reservoir in HIV-infected individuals (Fauci et al., 1996). Anergy, diminished capacity for clonal expansion following cell stimulation, may also contribute to reduced cell renewal in persons with HIV disease. It has been postulated that gp!20 from the virus binds to CD4+ on T cell surfaces, rendering these cells refractor)"' to further stimulation (Heeney, 1995). Enhanced Loss of CD4+ T Lymphocytes T cell destruction in HIV disease has been attributed to both virologic and nonvirologic mechanisms. Direct virologic mechanisms include single-cell lysis and cell fusion, resulting in syncytia formation. CD4+ T lymphocytes infected with HIV can undergo loss of viability due to disruption of cellular function and loss of membrane integrity in association with budding of newly synthesized virions (Garry, 1989). Syncytia formation occurs when gp!20 on the surface of HIV-infected cells binds to free CD4+ on uninfected cells. This process of cell engagement, which is facilitated by cell adhesion molecules (Hildreth 8c Orentas, 1989), results in membrane fusion and the generation of rnultinucleated giant cells. Although both direct cell killing and syncytia formation have been observed in HIV-infected cells in culture, it remains controversial whether these mechanisms play a major role in CD4+ T lymphocyte depletion in vivo (Pantaleo et al.," 1997). Nonvirologic mechanisms proposed to contribute to cell loss in HIV infection include apoptosis, cell stimulation by superantigens,

90

THE PERSON WITH HIV/AIDS

and cell killing by immunologic mechanisms (Pantaleo et al., 1997). Apoptosis, also referred to as programmed cell death, is a process used by multicellular organisms to maintain a homeostatic balance between cell proliferation and cell loss (Thompson, 1995). Apoptotic cell death is characterized by intracellular release of digestive enzymes, DNA fragmentation, and plasma membrane disruption (Thompson, 1995). The observation that mature T lymphocytes can undergo apoptosis following activation (Kabelitz, Phol, & Pechhold, 1993) supports the hypothesis that programmed cell death may contribute to cell loss associated with HIV infection (Ameisen, 1992). It has been reported that soluble gp 120 binding to the CD4+ receptor renders lymphocytes more susceptible to apoptosis (Oyaizu & Pahwa, 1995). Given that infection is not required for this event to occur, apoptosis may explairi, at least in part, the loss of large numbers of T lymphocytes in HIV disease, more than can be attributed to direct infection with the virus. To date, it has not been demonstrated that apoptosis is closely correlated with HIV disease progression (Meyaard & Miedema, 1995). Superantigens are molecules that have the potential to bind to antigen receptors on certain subsets of T lymphocytes (Janeway, 1991). Engagement of these receptors may lead to cell loss either by inducing anergy or by directly destroying the stimulated cell. Microbial-derived superantigens have been implicated in the pathogenesis of a number of diseases (Johnson, Torres, & Soos, 1996). Although it has been reported that certain HIV components can function as superantigens (Garcia et al., 1996), it remains controversial whether this property of the virus significantly contributes to the loss of T lymphocytes in HFV-infected individuals (Pantaleo et al., 1997). A number of immune mechanisms may contribute to the decline of CD4+ T lymphocyte numbers over the course of HIV disease. As described earlier, CTLs have been proposed to exert a beneficial role in HIV disease by controlling viral load (Pantaleo & Fauci, 1996). For example, it has been reported that intact CTL responses are more long-lived in long-term nonprogressors than in rapid progressors (Pantaleo et al., 1997). CTLs are able to reduce viral load by directly lysing cells that are the source of new virions, such as CD4+ T lymphocytes. CD8+ CTLs recognize foreign antigen on the surface of infected cells in the context of the MHC class I molecule.

THE PATHOGENESIS OF HIV INFECTION

91

Lytic destruction occurs due to CTL release of perforin, a poreforming molecule, and cytokines such as tumor necrosis factor-alpha. Alternatively CTL binding can trigger programmed cell death in HIV-infected cells (reviewed in Rowland-Jones, Tan, & McMichael, 1997). Because, under certain conditions, CTLs can lysis both HIVinfected cells and uninfected cells (Weinhold et al., 1989; Zarling et al., 1990), the potential for massive cell destruction by this mechanism is great. There is evidence that CD8+ T lymphocytes can also control viral production in HIV-infected cells using noncytotoxic mechanisms (Levy, Mackewicz, & Barker, 1996). By suppressing viral replication with a soluble factor that does not destroy cells, this mechanism may protect the host from harmful consequences of CTL-mediated cell lysis (Levy et al., 1996). The interplay of cytotoxic and noncytotoxic mechanisms utilized by CD8+ T lymphocytes in controlling HIV viral load warrants further investigation. CONCLUSION Since the early years of the HIV epidemic, tremendous progress has been made in understanding the nature of the infectious virus, the mechanisms it utilizes to decimate the immune system, and how it manages to circumvent normal host defense mechanisms. This information, taken together with current insights into the tremendous variability of the disease course as well as host and viral factors that may influence clinical outcomes, offers promise for the development of new treatment strategies. While many of these new approaches may involve the use of immune-derived products to prevent HIV entry into uninfected cells, others will focus on the development of vaccines to either prevent or attenuate the disease. Recent information that nutritional factors (Guenter et al., 1993; Snyder & Sigal, 1994) and neuroendocrine-derived products (McCain & Zeller, 1996) alter immunity and perhaps the course of HIV infection suggest that nonpharmacologic approaches to disease management should also be considered when planning treatment strategies.

THE PERSON WITH HIV/AIDS

92

REFERENCES Aiken, C., Konner, J., Landau, N. R., Lenburg, M. E., & Trono, D. (1994). Nef induces CD4 endocytosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell, 76, 853-864. Alien,]. E., & Maizels, R. M. (1997). Thl-Th2: Reliable paradigm or dangerous dogma? Immunology Today, 18, 387-392. Ameisen, J. C. (1992). Programmed cell death and AIDS: From hypothesis to experiment. Immunology Today, 13, 388-391. Brennan, C., & Porche, D.J. (1997). HIVimmunopathogenesis.yoMrna/o/fA^/liiorzation of Nurses in AIDS Care, 8, 7-22. Carr, A., & Cooper, D. A. (1997). Primary HIV infection. In M. A. Sande & P. A. Volberding (Eds.), The medical management of AIDS (5th ed., pp. 89-106). Philadelphia: W. B. Saunders. Clerici, M., & Shearer, G. M. (1992). The use of in vitro T cell immune function to monitor the course of HIV infection. In G. Janossy, B. Autran, & F. Miedema (Eds.), Immunodeficiency in HIV infection and AIDS. EC/FERS/MRC workshop on immunodeficiency in HIV-1 infections, Windsor, Surrey, 1991 (pp. 64-75). Basel, Karger. . (1994). TheThl/Th2 hypothesis of HFV infection: New insights. Immunology Today, 15, 575-581. Cunningham, A. L., Dwyer, D. E., Mills, J., & Montagnier, L. (1996). Structure and function of HIV. Medical Journal of Australia, 164, 161-165. Dyer, W. B., Geczy, A. F., Kent, S. J., Mclntyre, L. B., Blasdall, S. A., Learmont, J. C., & Sullivan, J. S. (1997). Lymphoproliferative immune function in the Sydney Bolld Bank Cohort, infected with natural n
et al. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 278, 1295-1300.

THE PATHOGENESIS OF HIV INFECTION

93

Folks, T. M., & Hart, C. E. (1997). The life cycle of human immunodeficiency virus type 1. In V. T. Devita, S. Hellman, & S. A. Rosenberg (Eds.), AIDS: Biology, diagnosis, treatment, and prevention (4th ed., pp. 29-43). Philadelphia: Lippincott-Raven. Garcia, S., Dadaglio, G., Cilote, V., Chenal, H., Bondurand, A., & Gcmgeon, M. L. (1996). Evidence for an in vivo superantigenic activity in human immunodeficiency virus-infected persons. Blood, 88, 2151-2161. Garry, R. F. (1989). Potential mechanisms for the cytopathic properties of HFV. AIDS, 3, 683-694. Graziosi, C., Pantaleo, G., Gantt, K. R., Fortin, J. P., Demarest, J. F., Cohen, O. J., Sekaly, R. D., & Fauci, A. S. (1994). Lack of evidence for the dichotomy of Thl and Th2 predominance in HIV-infected individuals. Science, 265, 193-194. Guenter, P., Mtuirahainen, N., Simons, G., Kosok, A., Cohan, G. R., Rudenstein, R., & Turner, J. L. (1993). Relationships among nutritional status, disease progression, and survival in HIV infection. Journal of Acquired Immune Deficiency Syndromes, 6, 1130-1138. Hahn, B. H. (1994). Viral genes and their products. In S. Broder, T. C. Merigan, & D. Bolognesi (Eds.), Textbook of AIDS medicine (pp. 21-43). Baltimore: Williams & Wilkins. Haynes, B. F., Pantaleo, G., & Fauci, A. S. (1996); Toward an understanding of the correlates of protective immunity to HIV infection. Science, 271, 324—327. Heeney, J. L (1995). AIDS: A disease of impaired Th-cell renewal? Immunology Today, 16, 515-520. Hildreth, J. E. K., & Orentas, R. J. (1989). Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science, 244, 1075-1078. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HFV-1 infection. Nature, 373, 123-126. Janeway, C. (1991). Mis: Makes a little sense. Nature, 349, 459-461. Janeway, C. A.. Jr., & Travers, P. (1994). Immunobiology: The immune system in health and disease. New York: Garland. Johnson, H. M., Torres, B. A., & Soos, J. M. (1996). Superantigens: Structure and relevance to human disease. Proceedings of the Society for Experimental Biology and Medicine, 212, 99-109. Kabelitz, D., Pohl, T., & Pechhold, K. (1993). Activation-induced death (apoptosis) of mature peripheral T lymphocytes. Immunology Today, 14, 338-339. Kestler, H. W.. Ringler, D. J., Mori, K., Panicali, D. L., Sehgal, P. K., Daniel, M. D., & Desrosiers, R. C. (1991). The importance of the ne/gene for maintenance of high virus loads and for development of AIDS. Cell, 65, 651-662. Korchhoff, F., Greenough, T. C., Brettler, D. B., Sullivan, L., & Desrosiers, R. C. (1995). Brief report.: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. New England Journal of Medicine, 332, 228-232. Lane, H. C. (1997). HIVpathogenesis. Improving the Management of HIV Disease, 5, 4-7. Levy, J. A. (1994). HIV and the pathogenesis of AIDS. Washington, DC: ASM Press. . (1996). Infection by human immunodeficiency virus—CD4 is not enough. New England Journal of Medicine, 335, 1528-1530.

94

THE PERSON WITH HIV/AIDS

Levy, J. A., Mackewicz, C. E., & Barker, E. (1996). Controlling HIV pathogenesis: The role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunology Today, 17, 218-224. McCain, N. L., & Zeller, J. M. (1996). Psychoneuroimmunological studies in HIV disease. Annual Review of Nursing Research, 14, 23-55. Merigan, T. C., & Bolognesi, D. (Eds.). Textbook of AIDS medicine. Baltimore: Williams & Wilkins. Meyaard, L., & Miedema, F. (1995). Programmed death of T cells in HFV infection: Result of immune activation? Current Topics in Microbiology and Immunology, 200, 213-221. Oyaizu, N., & Pahwa, S. (1995). Role of apoptosis in HIV disease pathogenesis. Journal of Clinical Immunology, 15, 217-231. Pantaleo, G., Cohen, O., Graziosi, C., Vaccarezza, M., Paolucci, S., Demarest, J. F., & Fauci, A. S. (1997). Immunopathogenesis of human immunodeficiency virus infection. In V. T. Devita, S. Hellman, & S. A. Rosenberg (Eds.), AIDS: Biology, diagnosis, treatment, and prevention (4th ed., pp. 75-88). Philadelphia: Lippincott-Raven. Pantaleo, G., & Fauci, A. S. (1996). Immunopathogenesis of HIV infection. Annual Review of Microbiology, 50, 825-854. Parslow, T. G., & Hope, T.J. (1994). Structure and expression of the HIV genome. In P. T. Cohen, M. A. Sande, & P. A. Volberding (Eds.), The AIDS knowledge base (2nd ed., pp. 3.2-1 to 3.2-9). Boston: Little, Brown. Patel, D. D., Hale, L. P., & Haynes, B. F. (1996). HIV in lymph node and thymus. In S. Gupta (Ed.), Immunology of HIV infection (pp. 95—121). New York: Plenum. Pavlakis, G. N. (1997). The molecular biology of human immunodeficiency virus type 1 regulatory genes. In V. T. Devita, S. Hellman, & S. A. Rosenberg (Eds.), AIDS: Biology, diagnosis, treatment, and prevention (4th ed., pp. 45-74). Philadelphia: Lippincott-Raven. Powderly, W. G., Landay, A., & Lederman, M. M. (1998). Recovery of the immune system with antiretroviral therapy. The end of opportunism? fournal of the American Medical Association, 280, 72-77. Rowland-Jones, S., Tan, R., & McMichael, A. (1997). Role of cellular immunity in protection against HFV infection. Advances in Immunology, 65, 277-346. Saag, M. S. (1997). Quantitation of HIV viral load: A tool for clinical practice? In M. A. Sande & P. A. Volberding (Eds.), The medical management of AIDS (5th ed., pp. 57-74). Philadelphia: W. B. Saunders. Shearer, G. M., & Clerici, M. (1992). T helper cell immune dysfunction in asymptomatic, HFV-1-seropositive individuals: The role of TH1-TH2 cross regulation. In R. L. Coffman (Ed.), Regulation and functional significance of T-Cell subsets (pp. 21-43). Basel, Karger. . (1996). Type 1 and type 2 responses in HIV infection and exposure. In S. Gupta (Ed.), Immunology of HIV infection (pp. 229-241). New York: Plenum. Snyder, B. K. & Sigal, L. H. (1994). Aging, nutrition and the immune system: B. nutrition and immunity. In L. H. Sigal & Y. Ron (Eds.), Immunology and Inflammation:. Basic mechanisms and clinical consequences (pp. 509-517). New York: McGraw-Hill.

THE PATHOGENESIS OF HIV INFECTION

95

Staprans, S. I., & Feinberg, M. B. (1997). Natural history and immunopathogenesis of HFV-1 disease. In M. A. Sande 8c P. A. Volberding (Eds.), The medical management of AIDS (5th ed., pp. 29-55). Philadelphia: W. B. Saunders. Stine, G. J. (1997). AIDS update 1997. Saddle River, NJ: Prentice Hall. Thompson, C. B. (1995). Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456-1462. Unutmaz, D., & Littman, I). R. (1997). Expression pattern of HIV-1 coreceptors on T cells: Implications for viral transmission and lymphocyte homing. Proceedings of the National Academy of Science, 94, 1615-1618. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S., & Shaw, G. M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 373, 117-122. Weinhold, K. J., Lyerly, H. K., Stanley, S. D., Austin, A. A., Matthews, T. J., & Bolognesi, D. P. (1989). HIV-1 gp!20-mediated immune suppression and lymphocyte destruction in the absence of viral infection. Journal of Immunology, 142, 3091-3097. Weiss, R. A. (1994). The virus and its target cells. In S. Broder, T. C. Merigan, & D. Bolognesi (Eds.), Textbook of AIDS medicine (pp. 15-20). Baltimore: Williams & Wilkins. Weller, S. K., Joy, A. E., & Temin, H. M. (1980). Correlation between cell killing and massive second-round superinfection by members of some subgroups of avian leukosis virus. Journal of Virology, 33, 494—506. Wu, B. L., Paxton, W. A., Kassam, N., Ruffing, N., Rottman,J. B., Sullivan, N., Choe, H., Sodroski, J., Newman, W., Koup, R. A., & McKay, C. R. (1997). CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV1, in vitro. Journal of Experimental Medicine, 185, 1681—1691. Young, J. A. T. (1994). The replication cycle of HIV-1. In P. T. Cohen, M. A. Sande, & P. A. Volberding (Eds.), The. AIDS knowledge base (2nd ed., pp. 3.1-1 to 3.1-12). Boston: Little, Brown. Zarling, J. M., Ledbetter, J. A., Sias,J., Fultz, P., Eichberg, J., Gjerset, G., & Moran, P. A. (1990). HIV-infected humans, but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected CD4+ cells. Journal of Immunology, 144, 2992-2998. Zeller, J. M., McCain, N. L., & Swanson, B. (1996). Immunological and virological markers of HIV disease progression. Journal of the Association of Nurses in AIDS Care, 7(1), 15-27.

This page intentionally left blank

3

Preventing HIV Infection Barbara Berger and Vida M. Vizgirda

Tien the HIV epidemic first emerged, little was known regarding effective disease prevention programs in general, and the finer points of transmission behaviors were yet to be elucidated. Currently, much more information is available about how these transmission behaviors interact with social, cultural, and personal factors in determining an individual's risk of HIV infection. Effective prevention programs must not only address the specific behaviors linked to transmission of HIV, but must also tailor that information to the various contexts within which these behaviors may occur. This chapter reviews the behaviors that place an individual at risk for HIV infection and ways in which context can influence transmission and adoption of risk reduction measures. Information on prevention programs will focus on those characteristics most associated with successful risk reduction and decreased HIV seroconversion. Much of the information on how to protect oneself from HIV is straightforward, but questions of skill, motivation, and access to prevention resources continue to complicate HIV prevention.

w

SEXUAL TRANSMISSION OF HIV Modes of Transmission The risk of HIV transmission during sex is entirely related to the exchange of body fluids. The relative risk of transmission appears 97

98

THE PERSON WITH HIV/AIDS

to vary with the type of activity. Body fluids known to contain and transmit HIV include ejaculate, vaginal secretions, breast milk, and blood. Although HIV has been recovered from saliva, only saliva contaminated with blood from oral lesions or gum disease has been implicated in HIV transmission (Centers for Disease Control and Prevention, 1997a). There is a theoretical possibility of HIV transmission during "passionate" kissing, although kissing in the absence of oral lesions or bleeding is considered generally safe (Marzili, 1989; Woolley, 1989). Cases of HIV transmission during oro-genital sex, with and without ejaculation, have also been reported (Edwards & Carne, 1998). Anal and vaginal intercourse are associated with higher risk of HIV transmission compared to oral sex (European Study Group on Heterosexual Transmission of HIV, 1992; Seidlin, Vogler, Lee, Lee,&Dubin, 1993;Voeller, 1991). Bleeding during intercourse has also been associated with increased risk of sexually transmitted HIV, both to male and to female partners (European Study Group; Lazzarin, Saracco, Musicco, Nicolosi, & Italian Study Group on HIV Heterosexual Transmission, 1991; Seidlin et al.). Sexual Practices Most adults are sexually active, with a range of sexual practices that may include vaginal, oral, and anal intercourse. Each of these practices carries some risk of HIV transmission if one's partner is infected, although the degree of risk differs across behaviors. For example, it appears that unprotected anal intercourse is more likely to transmit HIV than unprotected vaginal intercourse (European Study Group, 1992; Padian, Shiboski, & Jewell, 1990). Thus, in evaluating the risk associated with sexual activities, the prevalence of specific sexual behaviors must be taken in to account. Reviewing information on sexual behaviors collected by several major surveys of American health and family life, Seidman and Rieder (1994) found that 91% of males between ages 25 and 59 are heterosexually active. Of these, 25% had 20 or more lifetime partners, and 55% had 2 to 19 lifetime partners. In the National Health and Social Life Survey, Laumann, Gagnon, Michael, and Michaels (1994) interviewed a probability sample of men and women of all ages. This more inclusive sample reported an overall median of 3

PREVENTING HIV INFECTION

99

partners (median number of sexual partners for men was 6 and for women was 2), with nearly 20% reporting more than 10 lifetime sexual partners. The most important demographic predictors of multiple partners were marital status (unmarried), gender (male), age (< 30), and race (Black) (Laumann et al., 1994; Seidman & Rieder, 1994). These findings are consistent with those in adolescents ages 14 to 19 (Kegeles, Adler, &Irwin, 1988), i.e., that 53% of females and 72% of males had more than 1 sex partner over a 1-year period. Similarly, the 1995 Youth Risk Behavior Survey of 10,904 high school students (Centers for Disease Control and Prevention, 1996c) found that 52% of Black males, compared to 15% of White males, had had 4 or more sex partners in their lifetime. The number of partners for homosexual men may be higher than for exclusively heterosexual men, but not at a statistically significant level. For example, men with only female partners averaged nearly 2 partners in the past year, compared to 3 partners in the past year for men who selfidentified as homosexual or bisexual (Laumann et al., 1994). In general, the age at first intercourse has been decreasing. For example, White females born 1963-1967 had intercourse approximately one year earlier than those born 1933-1942 (Laumann et al., 1994). Laumann and colleagues found that half of Black males had had intercourse by age 15, compared with age 16 1/2 for Hispanic males and nearly 17 for White males. Half of Black females had had intercourse by age 17, compared to approximately age 18 for White and Hispanic females. By age 19, over 75% of females and over 80% of males had engaged in sexual intercourse (Seidman & Rieder, 1994). According to the Centers for Disease Control and Prevention (1996c), 9% of high school students nationwide had sex by age 13. However, in groups with higher risk of HIV infection, these figures may be even more extreme. In a survey of high risk 9to 15-year-olds living in public housing, 12% of 9-year-olds (both boys and girls) claimed to have had sex; by age 15, all boys and more than 80% of girls reported having sex (Romer et al., 1994). Among men ages 17 to 22 who had sex with men in the San Francisco area, 85% reported first having anal intercourse at or before age 19, and 22%) were age 14 or younger (Lemp et al., 1994). In this sample, younger age at first anal intercourse was also associated with higher rates of HIV infection (15.2% among those age 14 oryounger,

100

THE PERSON WITH HIV/AIDS

11.6% among 15- to 19-year-olds, and 3.8% among those age 20 and older). Nearly all adults (95% of men and 97% of women) reported having vaginal intercourse at some time in their lives (Laumann et al., 1994). The remaining 5% and 3% included those who may not yet have begun to have intercourse or who may have had no opportunity or desire to engage in vaginal intercourse. Oral sex, including fellatio (performed on a male) and cunnilingus (performed on a female), was practiced by many, though not as regularly or frequently as vaginal intercourse. While 76% to 79% of men and 67% to 73% of women reported having oral sex in their lifetimes, only 19% to 27% of men and 20% to 28% of women reported oral sex during their last sexual episode (Laumann et al.). Among men who have sex with men (MSM) and women who have sex with women (WSW), oral sex was highly prevalent within the past year (90% to 95%) (Laumann et al., 1994). The prevalence of anal intercourse is less clearly defined. Up to one quarter of heterosexuals reported having had anal intercourse (Seidman & Rieder, 1994). Similarly, Laumann and colleagues (1994) found that, across all sexually active adults, 26% of men and 20% of women reported having participated at some time in anal intercourse. For those with opposite-gender partners, 10% of men and 9% of women reported practicing anal intercourse in the past year (Laumann et al., 1994), although only 2% of men and 1% of women had done so during their last sexual encounter. These findings are consistent with Seidman and Rieder's (1994) and Voeller's (1991) conclusion that 10% is a conservative estimate of the number of sexually active Americans who engage in heterosexual anal intercourse with some regularity. Although anal intercourse is more common among MSM, it is not universally practiced even by those who identify themselves as exclusively homosexual. Of men who had male sex partners in the past year, 21% to 23% did not include anal intercourse in their repertoire of practices (Laumann et al., 1994). Factors Modifying Risk of Sexual Transmission Sexually transmitted diseases (STDs), whether ulcerative or nonulcerative (de Vincenzi, 1994; Hook et al., 1992; Laga et al., 1993; Lazzarin etal., 1991; Plummeretal., 1991) and whether existing in the person

PREVENTING HIV INFECTION

101

with HIV or in their HlV-uninfected partner (Centers for Disease Control and Prevention, 1997b), have been associated with increased risk of HIV transmission. Ulcerations that provide a portal of entry for HIV and inflammatory processes that concentrate infectable cells at a site of virus deposition or that increase the concentration of HIV being deposited may contribute to the link between STDs and HIV transmission (Levine et al., 1998). Because HIV infection has been associated with nonulcerative STDs such as chlamydia and gonorrhea in younger (adolescent) women, researchers have speculated that the immature cervical epithelium may facilitate HIV transmission in these cases (Stein, 1995). Because STDs are associated with unsafe sexual practices such as having multiple partners or unprotected intercourse (Centers for Disease Control and Prevention, 1997c), STD rates may be viewed as proxies for HIV risk behavior. The high rates of STDs among adolescents, whether from heterosexual or homosexual activity, increase concerns about HIV transmission among this population. STD rates in general decreased over the period from 1990 to 1996. However, the rates for chlamydia and gonorrhea in women remained highest among those ages 15 to 19, and for men the gonorrhea rate was highest among 20- to 24-year-olds, closely followed by 15- to 19year-olds (Centers for Disease Control and Prevention, 1997c). A link between STDs and HIV infection has been demonstrated in young MSM. Two separate studies found HIV seroprevalence rates of 23% to 25% among young MSM with a history of an STD, whereas only 3% to 6% of those with no history of STD were HIV-positive (Lemp et al., 1994; Ruiz, Facer, & Sun, 1998). Sexual transmission of HIV can also be modified by the consistent use of condoms. Studies among HFV-discordant couples (couples in which only one partner is infected with HIV) have demonstrated that using condoms with every episode of intercourse is effective in preventing HIV transmission. Deschamps, Pape, Hafner, and Johnson (1996) reported one seroconversion among 42 Haitian couples who always used condoms, compared to a seroconversion rate of 6.8/100 person-years among those who intermittently or never used condoms. De Vincenzi (1994) found 0 seroconversions among 124 couples who always used condoms in 15,000 protected vaginal and anal sexual contacts. Among those who did not consistently use condoms, HIV seroconversions occurred at a rate of 4.8/100 person-

102

THE PERSON WITH HIV/AIDS

years. De Vincenzi also found no difference in the number of seroconversions between couples who used condoms for less than half of their sexual encounters compared to those using condoms for more than 50% but not 100% of encounters. Condoms are clearly effective in preventing transmission of HIV, if used during every sexual encounter. Use of drugs, including alcohol, that affect judgment and motivation can increase the likelihood of exposure to HIV during sexual activity. Whether legal or illegal, injected, ingested, or inhaled, any substance that decreases inhibitions or alters consciousness can interfere with decision-making related to whether, how, and with whom to engage in sex. For example, heterosexual female and homosexual male respondents in Trocki and Leigh's (1991) survey of San Francisco adults reported being less likely to use a condom for vaginal or anal intercourse when feeling intoxicated. The effects of drug use on sexual behavior is a particular concern with adolescents. According to the National Institute on Drug Abuse (National Commission on AIDS, 1994), 89% of high school seniors have used alcohol, 40% reported using marijuana, and 9% have tried cocaine. Nationwide, 24.8% of sexually active high school students reported using alcohol or drugs at last sexual intercourse (Centers for Disease Control and Prevention, 1996c). Sixteen percent of Hingson, Strunin, Berlin, and Heeren's (1990) random sample of adolescents reported using condoms less often after drinking. In two studies of young MSM, both Ruiz and colleagues (1998) and Remafedi (1994) found that the prevalence of unprotected anal intercourse was significantly higher for those reporting recent drug use during sex. By increasing the likelihood that sexual activity will be unsafe, drug use increases the risk of HIV transmission. The particular sexual practices, age at onset of sexual relations, and number of sexual partners over time all influence the risk of HIV infection via sexual activity. Other significant factors include STDs, condom use, and concomitant drug use. Information about the risks associated with all types of sexual activities should be addressed with all audiences in HIV prevention programs. Methods Protecting against Sexual Transmission of HIV There are several ways to protect against sexual transmission of HIV, some of which participants will find more practical or acceptable

PREVENTING HIV INFECTION

103

than others. Which method of protection is best will depend on the people involved, their values and beliefs related to sex, the context or circumstances in which they are acting, and their access to resources. By understanding the different options for protection during sexual activity, the individual will be better able to choose and modify sexual behaviors in ways that minimize the risk of HIV transmission. Abstinence offers complete protection from HIV and other sexually transmitted diseases. While abstinence is an effective strategy and may be encouraged especially among adolescents, it is not realistic as the sole option for avoiding HIV. Abstinence is seldom a viable approach to lifelong HIV prevention. Furthermore, intending to abstain from sex without considering other possible methods of protection may leave the person entirely unprotected, should abstinence fail. Given data about sexual activity of adolescents and adults, abstinence appears not to be an option for many persons. Monogamy can prevent sexually transmitted HIV if both partners are monogamous, neither is HlV-infected, and neither partner participates in other activities (such as injection drug use) through which he or she may acquire HIV. This method of protection requires an understanding of the difference between lifetime monogamy (one partner throughout one's life) and serial monogamy (one partner at a time, but several partners over time), and recognition that HIV tests are not infallible. For example, either partner may test negative for HIV during "the window period" before antibodies are detectable, yet be infected with HIV and able to transmit it through sexual behavior to the partner. Outercoune is a term for any nonpenetrative sexual activity that involves contact with intact skin but does not result in an exchange of potentially infectious body fluids. Such activities include masturbation, frottage, petting, massage, and cuddling. Use of sex toys is safe as long as they are not shared between partners, since sharing can expose one partner to the other's secretions. For some people, outercourse can be a satisfactory alternative to more conventional penetrative sex. However, because outercourse activities may lead to penetrative sexual activity, partners must be clear about the point beyond which additional protection is required to avoid exchanging body fluids.

104

THE PERSON WITH HIV/AIDS

Barriers include the male latex condom and the dental dam, a thin latex or polyurethane film that protects the oral mucosa during cunnilingus. Latex condoms have been shown to be highly effective in preventing HIV transmission when used correctly, and experience with condoms results in greatly decreased failure rates (Gates Be Stone, 1992). In prospective studies in developed countries (Albert, Warner, Hatcher, Trussell, & Bennett, 1995; Centers for Disease Control and Prevention, 1993a) condom breakage rates ranged from 0.5% to 3.7% during vaginal and anal intercourse. Similarly, slippage rates ranged from 0.6% to 5.4%. Strategies to optimize condom performance are presented in Table 3.1. Latex allergy may limit condom use by some people. A male polyurethane condom is also available in the United States. This type of condom has been shown to be significantly more likely to break than latex condoms. In one large clinical trial, the overall condom failure rate (combining breakage and slippage) was 1.7% for latex condoms and 10.8% for polyurethane male condoms (Frezieres, Walsh, Nelson, Clark, & Coulson, 1998). However, male partners reported less discomfort and better sensation with the polyurethane condoms compared to latex condoms. The female condom is a prelubricated polyurethane sheath with an external ring, which holds the opening against the vulva, and a free internal ring, which helps position the sheath in the vagina. Laboratory studies have shown the female condom to be impervious to HIV, and 1-year pregnancy rates of 5% to 11% when used consistently and correctly have been reported (Centers for Disease Control and Prevention, 1993a; Farr, Gabelnick, Sturgen, & Dorflinger, 1994). Advantages of the female condom include a softer polyurethane material that conducts heat better than latex, the ability to put it in place prior to erection and use it with partners who may have trouble sustaining an erection, and the increased ability for women to control the use of protection when a partner refuses to wear male condoms. The female condom is also an alternative to latex condoms for people with latex hypersensitivity. The female condom is somewhat more expensive than conventional male latex condoms. Among women who have tried the female condom, its acceptability is fairly high. In Farr and colleagues' study, 80% of the women reported that they liked the female condom and would recommend

PREVENTING HIV INFECTION

TABLE 3.1 of HIV

105

Proper Use of Condoms to Prevent Sexual Transmission

About male condoms: Use latex condoms only. Lambskin or natural membrane condoms have pores through which hepatitis B virus, and possibly HIV, can pass. Condoms come in many sizes and shapes. If one type is not comfortable, try others. Protect condoms from heat. Do not leave in the car or carry in your wallet for long periods of time. Do not use after the expiration date, or if brittle, sticky, or discolored. Open the package carefully, being sure not to puncture or tear the condom. Do not unroll the condom to inspect it before use, since this is associated with increased rates of condom breakage. Use only water-soluble lubricants such as KY jelly. Avoid oil-based products, including vaseline, mineral oil, and hand lotion, since they can cause rapid (within 60 seconds) deterioration of the latex. Saliva is not recommended as a lubricant because it may contain infectious material. Some condoms come with the spermicide nonoxynol-9 already in the tip. Because high doses of nonoxynol-9 have been associated with genital irritation, it is no longer routinely recommended to prevent HIV transmission. If either partner has a rash or genital irritation, any genital contact will be unsafe. Using a male condom: Use a new latex condom with each act of oral, vaginal, or anal intercourse. Before opening the condom, inspect the wrapper for punctures or defects, and discard if not intact. Pinch 1/2 inch at the tip of the condom to squeeze air out and to leave room for the semen. Unroll the condom onto the erect penis before beginning penetrative intercourse. If uncircumcised, pull the foreskin back before putting on the condom. Use additional water-soluble lubricant on the outside of the condom if your partner is not well lubricated—sex without adequate lubrication increases the likelihood that the condom will break. Monitor the condition of the condom throughout intercourse. If the condom breaks or slips, immediately stop and put on a new condom. Change condoms during prolonged intercourse. Refrain from rough or vigorous sex. Hold on to the rim of the condom during withdrawal to avoid spilling any fluid. Dispose of the used condom in the trash. Flushing a condom down the toilet is bad for the plumbing. Wash the genital area thoroughly with soap and water to remove all secretions before cuddling. (continued)

THE PERSON WITH HIV/AIDS

106

TABLE 3.1

(continued)

Using a female condom: The female condom may be applied well before either partner is aroused, since it does not require an erect penis. Inspect the condom for tears or punctures, and discard if any defects are visible. Lubricant, either water- or oil-based, should be used, both on the outside to help hold the condom in place against the vaginal wall, and on the inside to protect against tears and to decrease displacement. To insert the female condom, pinch the inner ring at the closed end with the thumb and middle finger, and insert into the vaginal canal. Then put your index finger inside the condom and push the inner ring up behind the pubic bone, similar to a diaphragm. Be sure the sheath is not twisted. The large ring stays outside, covering the labia. Avoid penile misrouting/penetration by the penis outside the outer ring. If the female condom tears or slips, immediately stop and put on a new condom with additional lubricant. To remove the female condom, squeeze and twist the outer ring to prevent spillage, and pull gently. Dispose of the used condom in the trash, not in the toilet. Use a new female condom with each act, and remove it promptly after ejaculation. It is not recommended to use a male latex condom and the female condom at the same time, since friction between the two materials may cause tears or slippage of either condom. Adapted from Gates & Stone (1992), Centers for Disease Control and Prevention (1993a), Gollub & Stein (1993), Joffe (1993), and Reality® product information [online], available at http://www.femalehealth.com/yourquests.html.

it to friends. In a small sample of female staff and patients, 73% of respondents, and 44% of their male partners, preferred the female condom compared to male condoms (Gollub, Stein, & El-Sadr, 1995). About 15% to 20% experienced some malfunction, including displacement of the condom or "penile misrouting," that could have placed them at risk for HIV infection. In a sample of MSM using condoms for anal intercourse, 86% indicated that they would use the female condom again, and 54% preferred it to male condoms (Gibson, McFarland, Wohlfeiler, Scheer, & Katz, 1999). However, although 86% of female sex workers were willing to recommend the female condom to others, only 24% preferred it to male condoms (Witte, El-Bassel, Wada, Gray, & Wallace, 1999). Focus groups of men have demonstrated a wide range of attitudes towards the female condom (Seal & Ehrhardt, 1999), although attitudes following actual

PREVENTING HIV INFECTION

107

experience with the female condom were more positive (El-Bassel, Krishnan, Schilling, Witte, & Gibert, 1998). In general, attitudes toward the female condom appear to be more favorable among people who have experience with using the device. Although the higher failure rates with both male and female polyurethane condoms are a concern in terms of HIV prevention, these products do offer an alternative for people who are allergic to latex. Information on how to use the female condom is included in Table 3.1. Those techniques that do not reliably protect against pregnancy, such as coitus interruptus, douching after sex, and the rhythm method, are entirely ineffective against HIV. Other techniques that do prevent pregnancy may not reliably decrease the risk of contracting HIV. For example, hormonal contraceptives, including birth control pills and injectable or implantable contraceptives such as Norplant, do not protect against HIV, and may even increase the risk of transmission because of their effects on the vaginal environment (European Study Group, 1992; Plummer et al., 1991). Intrauterine devices, sterilization, and hysterectomy are other methods that prevent pregnancy but are not effective against HIV. The diaphragm and cervical cap are latex barriers that cover the cervix, acting as physical barriers to HIV infection through the cervix. However, neither the diaphragm nor the cap is considered adequate protection against HIV transmission, since HIV can also enter the body through the vaginal mucosa. Spermicides and virucides have been considered as methods of preventing sexual transmission of HFV. Using nonoxynol-9 is no longer recommended, since the vaginal irritation associated with frequent use and high doses may actually increase HIV transmission (Howe, Minkoff, & Duerr, 1994). There is some evidence that lower concentrations of nonoxynol-9 may be protective (Zekeng, Feldblum, Oliver, & Kaptue, 1993), but the role of nonoxynol-9 in preventing sexual transmission of HIV remains unclear (Wittkowski, Susser, 8c Dietz, 1999). "Partner history" refers to the past sexual and drug use activities of either participant in a sexual encounter. By knowing a potential partner's risk behaviors, people may believe they can judge how likely that person is to have become infected with HIV. Unfortunately, there is ample evidence that partners are not always forthright about their past sexual and drug experiences. Among bisexual men,

108

THE PERSON WITH HIV/AIDS

fewer than half disclosed the fact that they also had male partners to their female partners (Wold et al., 1998). In a study of sexually active HIV-seropositive men (Marks, Richardson, 8c Maldonado, 1991), 52% had not told at least one of their sexual partners, and the more partners they had, the less likely they were to disclose their HIV status. Similarly, Stein and colleagues (1998) found that 40% of their sexually active HIV-positive respondents admitted not disclosing their HIV status to all sexual partners in the preceding 6 months, and, of that 40%, 57% did not consistently use condoms. Even among men who used condoms, 13% failed to disclose condom breakage to their partners, potentially resulting in unintended pregnancy or delayed treatment for disease (Warner, Boles, & Goldsmith, 1997). Information on preventing sexual transmission of HIV is available to the general public over the Internet and through various other sources such as popular magazines and radio. Although these sources have been very helpful in getting prevention messages to the public, consumers must be aware that some safer sex information available through the media, including the Internet, may not be entirely correct. Consumers can be very confident about information from a reputable source or Internet site, such as the Centers for Disease Control and Prevention (http://www.cdc.gov), the National AIDS Clearing House (Centers for Disease Control and Prevention National AIDS Clearing House at 800-458-5231), or a university or other major medical center, but should be more skeptical of information from unknown individuals or organizations.

Safer Sex Recommendations on safer sex have been widely disseminated to the general public over the past decade. Sex practices that are considered always safe include abstinence and nonpenetrative sexual behaviors that do not involve the exchange of body fluids. Sexual behaviors that are unsafe include any of the following performed without a latex barrier: penetrative vaginal or anal intercourse, fellatio or cunnilingus, heavy petting, and sharing of sex toys. Each of these unsafe behaviors becomes safer with the use of a latex barrier such as a condom. However, if the condom or barrier fails (breaks, leaks, falls off), that activity poses a risk for HIV transmission. Increasingly

PREVENTING HIV INFECTION

109

rough sexual activities that lead to mucosal trauma or bleeding, such as "fisting" or rough anal intercourse, are considered very unsafe. Even when latex barriers are used, these activities carry some risk, since the roughness of the activity may damage the protective barrier. The range of possible sexual expressions is limited only by the human imagination, making it impossible to identify every possible behavior and its associated risk of HIV transmission. However, knowing the extremes of safe and unsafe activities, and understanding how a safer behavior can turn into an unsafe activity, allows the individual to judge the degree of risk involved with a particular act. An informed participant can determine where a given behavior would fall along the continuum from safe to unsafe, depending on the likelihood of exposure to body fluids. Motivational Aspects of Sexual Prevention Knowing how to avoid sexually transmitted HIV does not guarantee that prevention methods will be used in every sexual encounter. The reality is that condoms are not used 100% of the time. Even among couples who know they are HFV-discordant, less than 50% always used condoms (de Vincenzi, 1994; Deschamps et al., 1996). In the general U.S. population, levels of consistent condom use, though increased over rates in the 1970s and early 1980s, remain low. Studies of representative samples of adults in the United States indicate that approximately 23% to 36% of those with multiple partners consistently used condoms with their secondary partners (Binson, Dolcini, Pollack, & Catania, 1993; Catania et al., 1995; Leigh, Temple, & Trocki, 1993), and approximately 22% of these respondents always used condoms with their primary partners. Among a group of inner city women considered at risk for sexually transmitted HIV, 30% reported always using condoms and 51% reported never using condoms in the previous 6 months (Heckman et al., 1996). In the Youth Risk Behavior Survey (Centers for Disease Control and Prevention, 1996c), 54% of adolescents reported using a condom during their last sexual encounter. Similarly, nearly half of a group of runaway adolescents in New York City reported condom use at last intercourse, but less than 20% reported always using condoms (Rotheram-Borus 8c Koopman, 1991).

110

THE PERSON WITH HIV/AIDS

So what can account for these low rates of barrier protection use among people who are at some risk of sexually transmitted HIV? A number of factors interfere with consistent condom use. Although evidence of the effectiveness of condoms is available (Centers for Disease Control and Prevention, 1993a), many people believe that condoms are not effective, or not adequately effective, in preventing HIV transmission. For example, over half the respondents to a telephone survey believed condoms might fail during intercourse (Choi, Rickman, & Catania, 1994). Others, though their behavior clearly involves some risk for HIV transmission, do not consider themselves at risk for HIV, perhaps because they feel they know their partner, because they are not part of the "risk groups" identified with AIDS early in the epidemic, or because they are uninformed about how HIV can be transmitted sexually (St. Lawrence, 1993). Particularly for adolescents, who are well known for their feelings of invulnerability (Stiffman, Earls, Dore, & Cunningham, 1992), the threat posed by a virus that may not cause illness for a decade may seem too intangible to bother about (Joffe, 1993). Many people have negative attitudes toward condoms. Leonard (1990) found a general dislike of condoms among male clients of prostitutes, often to the extent of refusing intercourse if the woman insisted on a condom. In a probability sample of heterosexual adults (Choi et al., 1994), 41% believed that using a condom interferes with sensation and sexual pleasure, and 21% reported that putting condoms on was uncomfortable. Others believe that a condom makes it more difficult to maintain an erection (Ames, Atchinson, & Rose, 1995). Buying condoms is embarrassing (Choi et al., 1994; Hingson et al., 1990; Sacco, Rickman, Thompson, Levine, & Reed, 1993), particularly for women and adolescents, and may be inconvenient if stores are not open when a condom is needed (Wight, 1992). Access to condoms may also be more difficult for individuals with marginal finances, such as runaway adolescents (Rotheram-Borus & Koopman, 1991) or people in developing countries. Sexuality and sexual behavior can carry powerful, pervasive, and primal messages that tap into deeply held beliefs about sexual identity, masculinity, and power and dominance. For some men, using a condom diminishes their feelings of virility and potency (Campbell, 1995; Wight, 1992). For some, condoms are associated only with prostitutes and are not to be used with the decent women in their

PREVENTING HIV INFECTION

111

lives (Marin, Marin, & Juarez, 1988). Frank and open discussions of sexuality and condom use may also violate cultural norms calling for female naivete regarding all sexual topics (Mays & Cochran, 1988). Not using condoms for intercourse may also be considered an affirmation of the legitimacy of gay sex (Ames, Atchinson, & Rose, 1995). Women may be concerned that carrying condoms or having frank discussions about sex will be interpreted as evidence of their own promiscuity (Airhihenbuwa, DiClemente, Wingood, & Lowe, 1992; Hillier, Harrison, & Warr, 1998; Wight, 1992). When negotiating for condom use, women often find themselves at a disadvantage (Fullilove, Fullilove, Haynes, & Gross, 1990; Sacco et al., 1993; Wight, 1992). As Wight (1992) noted, gender-related power decisions can make insisting on condoms a lose-lose proposition for women—the woman can insist on condoms at the expense of the relationship, or not insist and risk being exposed to HIV. Women may find it especially difficult to negotiate condom use in abusive relationships (Wingood & DiClemente, 1997). Women who are dependent on their sexual relationship for status or financial support may see themselves as having more to lose by insisting on condoms (Wight, 1992). The effects of drugs and alcohol on judgment and motivation can interfere with condom use. Kelly and colleagues (1995) speculated that the association between patronizing bars and high-risk sexual behaviors could be attributed at least in part to the disinhibiting effects of alcohol. Among adolescents in Massachusetts, 25% reported using condoms less often when taking drugs, and 16% used condoms less often when drinking alcohol (Hingson et al., 1990). Male street youth who used marijuana daily were less likely to use condoms (Clements, Gleghorn, Garcia, Katz, & Marx, 1997). Differential condom use, that is, using condoms more often with one type of sex partner than another, occurs in various contexts. Prostitutes are more likely to insist on, or at least request, condoms with their commercial clients, while with emotionally intimate partners, the norm is not to use condoms (Campbell, 1995; McKeganey, 1994). Male sex workers in Australia, for example, demarcate work sex, casual sex, and personal sex based in part on whether a condom is used (Browne & Minichiello, 1995). As McKeganey (1994) noted, norms regarding condom use with clients may vary widely over a

112

THE PERSON WITH HIV/AIDS

fairly small geographic region, but this pattern of using condoms less often in personal as opposed to commercial sexual encounters persists. This general pattern is also seen with condom use among heterosexuals who have secondary partners in addition to a single primary partner. Typically, condoms are used more frequently with the secondary partners, though even there the level of condom use tends to be low. In a representative sample of young urban heterosexuals with multiple partners, 36% always used condoms with secondary partners, while 23% consistently used condoms with their primary partner (Binson et al., 1993). A representative national sample of African-Americans was more likely to use condoms with secondary partners compared to condom use with primary partners, though 45% reported never using condoms at all (Grinstead, Peterson, Faigeles, & Catania, 1997). Anderson et al. (1999) found that only 19% of a nationally representative sample reported using condoms in their last sexual encounter with an on-going partner, while 62% who had recently had sex outside their main relationship reported condom use. Condom use can be particularly problematic among men who have sex with both men and women. Bisexuals in Boston were more likely to engage in unprotected sex with their female partners than with male partners (Wold et al., 1998). Nongay-identifying men who had sex with men tended to deny any increased risk of HIV for themselves or for their female partners, and this was reflected in their very low rates of condom use with either male or female partners (Goldbaum, Perdue, & Higgins, 1996). One of the most difficult aspects of sexual behavior to reconcile with condom use is the desire to trust one's partner. This impulse to trust is directly at odds with consistently protecting oneself, especially from a partner who is not known to have HIV. Indeed, many people worry that merely asking to use condoms will cost them their partner's trust (Choi et al., 1994). Wight (1992) noted that as adolescents' relationships become more committed, continued use of condoms may be interpreted as distrust. Similarly, Ames and colleagues (1995) reported that for gay men, not using condoms is a sign of trust and may indicate a special, more intimate meaning to the relationship that is contradicted by insisting on condoms. Successfully changing behavior to prevent sexual transmission of HIV will require "finding

PREVENTING HIV INFECTION

113

the proper mix between protection from infection, satisfying sexual desire, and building emotional and loving bonds" (Ames etal., 1995, P- 71). INJECTING DRUG USE AND HIV TRANSMISSION Modes of Transmission HIV can be transmitted by reusing injection equipment that has previously been used by someone with HIV. Injecting drug users (IDUs) who share injection equipment such as syringes and needles, filters, and water may be at particular risk due to practices such as "backloacling," "frontloading," and "booting." Backloading and frontloading (Grund, Kaplan, Adriaans, Blanken, & Huisman, 1990) are techniques for transferring drug between two syringes in order to divide the drug or to mix two drugs together. Booting, which appears to be more common with cocaine injection compared to heroin injection (Greenfield, Bigelow, 8c Brooner, 1992), involves aspirating blood into the syringe to mix with the drug just before injecting, a practice that is believed to intensify the drug's effects. Any equipment, including spoons or bottle caps for mixing drug, cotton through which drug is filtered, or rinse water from a communal jar, can become contaminated with HIV, and can pass HIV along to the next user (Wiebel et al., 1996). Sharing these types of equipment is common. Booth, Koester, Brewster, Wiebel, and Fritz (1991) reported that "cookers" were shared by 86% of IDUs in their sample, and that 70% shared needles, similar to the 71% of IDUs in a Baltimore sample who reported sharing needles without cleaning them (Latkin, Mandell, Vlahov, Oziemkowska, & Celentano, 1996). However, IDUs who do not share any equipment or supplies can continue to inject drugs without risking HIV infection from their injection practices. Other practices in which needles could be reused, such as injecting vitamins or steroids, tattooing or body piercing, and medical care in situations in which sterile equipment is scarce (Centers for Disease Control and Prevention, 1996a), may also carry transmission risk.

114

THE PERSON WITH HIV/AIDS

Modifying Factors The actual risk of contracting HIV due to injection practices that involve sharing varies according to a number of factors. One important aspect of IDU culture is the network, the group of people involved in drug-related activities, including obtaining drugs and equipment and injecting together. Although these networks may provide emotional, financial, and informational support that the IDU cannot obtain from other sources, they may also draw the IDU into environments with greater risk for HIV transmission. An increased prevalence of HIV in the IDU's network of injectors will increase the likelihood that sharing equipment will include sharing HIV (Alcabes & Friedland, 1995). Smaller networks tend to be associated with fewer sharing partners and relatively private venues for injecting, compared to more public settings such as shooting galleries (Walters, 1989). Injecting drug use in shooting galleries has been associated with an increased risk of HIV (Celentano et al., 1991), perhaps because of the increased likelihood of using HIV-infected equipment (Latkin et al., 1996; Neaigus et al., 1994) and the increased prevalence of HIV infection in that environment. The network may also be influential in establishing and maintaining behavioral norms for its members. These norms often set expectations for sharing drugs and injection equipment, but may also include sharing other commodities such as food and housing (Grund, Kaplan, & Adriaans, 1991). These exchanges not only provide material support, but also symbolize social bonds that develop among the network members. For example, Singer (1991) refers to needle sharing as "a core rite of intensification" (p. 268) in the IDU subculture. The affective component of this type of support is also visible in Mays and Cochran's (1988) account of allowing another IDU to "wash" (diluting and injecting the residue from a recently used syringe to postpone withdrawal symptoms) as an expression of friendship and loyalty. The IDU's injection experience also appears to make a difference in injection-related HIV transmission. HIV prevalence has been found to be higher among younger and new-onset injectors in Baltimore (Alcabes & Friedland, 1995). Van Ameijden, van den Hoek, van Haastrecht, and Coutinho (1992) also reported an increased risk of HIV seroconversion among novices, that is, those who first injected

PREVENTING HIV INFECTION

115

within the previous 2 years. Grund and colleagues (1991) provide several cases illustrating how more experienced IDUs are able to anticipate problems and make adjustments to keep their injection behavior safe. Novices, on the other hand, found themselves in situations where their only alternative to unsafe injection was not to inject at all, generally not an acceptable option. The increased risk of HIV associated with failing to plan for unsafe injection conditions can be exacerbated by drug craving, the desire to inject as soon after scoring as possible (Barnard, 1993; Grund et al., 1991). Injection frequency and equipment sharing have been linked to the type of drug being injected, with cocaine tending to increase both frequency of injection and sharing, and consequently the risk of acquiring HIV (Alcabes & Friedland, 1995; Grund et al., 1991). Sharing of injection equipment occurs when an IDU has limited access to dean equipment. Where injection equipment can be purchased through pharmacies or obtained at needle exchanges, sharing is less likely (Barnard, 1993; Calsyn, Saxon, Freeman, & Whittaker, 1991). There may be a protective effect to having legal access to clean injection equipment. Nelson and colleagues (1991) found significantly lower rates of HIV infection in diabetic IDUs (9.8%) compared to their nondiabetic counterparts (24.3%). However, in most states in the United States, legal access to injection equipment is complicated by legislation that prohibits the sale, distribution, or possession of devices that can be used to inject illicit drugs (Gostin, Lazzarini, Jones, & Flaherty, 1997). Such legislation has also prevented widespread development of needle or syringe exchange programs (NEPs or SEPs) in this country. In addition, for IDUs who are incarcerated, the barriers to obtaining clean equipment may be overwhelming (Polonsksy et al., 1994). Gender may also have some effect on sharing behaviors. Women may be more reluctant to obtain clean needles and syringes from pharmacies or NEPs (Barnard, 1993) because they are afraid that being known to inject drugs could be used as a lever to take away their children. Female IDUs are also more likely to have IDUs as primary sex partners, so that sharing syringes becomes an additional expression of intimacy (Dwyer et al., 1994). Dwyer and colleagues also found that women were more likely to report being unable to inject themselves than men. As a result, women were less likely to

116

THE PERSON WITH HIV/AIDS

inject alone, leaving them vulnerable to the unsafe injection practices of others. Methods Protecting against HIV Transmission during Injection Drug Use The harm reduction or harm minimization perspective is the framework upon which many HIV prevention efforts with IDUs are based. Programs operating from this perspective work with IDUs to make their behaviors safer without requiring them to stop or reduce their drug use (Des Jarlais, Friedman, & Ward, 1993). Although harm reduction acknowledges the detrimental aspects of drug use, it does not define IDUs solely by their drug use. Instead, it sees them as individuals who will make rational choices to change specific behaviors that place them at risk. Rather than insisting on a drug-free ideal, the harm reduction approach focuses on pragmatic short-term goals to minimize the negative impact of injection drug use on the IDU and others. To be most effective, harm reduction requires a multidimensional approach, not just a single type of program (Brettie, 1991; Paone, Des Jarlais, Gangloff, Milliken, & Friedman, 1995; Stryker et al., 1995). Prevention efforts appropriate to a harm reduction approach include street outreach work teaching safer injection and safer sex techniques, NEPs, HIV counseling and testing programs, and drug treatment programs, including methadone treatment. The following set of easy-to-remember recommendations on safer injection techniques (Broadhead, 1991) incorporates harm reduction principles as it moves hierarchically from safest to least safe behaviors. Don't use drugs. If you do use drugs, don't shoot. If you do shoot, don't share equipment. If you do share, use bleach. Each of the steps of the risk reduction hierarchy that acknowledges drug use also offers an option that can make that activity safer by avoiding HIV. Clearly, in terms of HIV transmission, the riskiest injection behavior is sharing equipment, that is, injecting oneself

PREVENTING HIV INFECTION

117

with equipment that another person has already used. Yet even that behavior can be made safer by cleaning the syringe with bleach. When first developed, a typical bleaching protocol called for using full-strength bleach twice, then rinsing twice with water, with the total procedure taking less than 15 seconds (Broadhead, 1991). Different cities and outreach programs developed their own specifications for bleaching injection equipment. In 1993 questions arose regarding whether those bleach protocols were adequate to kill HIV (Centers for Disease Control and Prevention, 1993b). Responding to these concerns, Shapshak and colleagues (1994) demonstrated that both bleach concentration and exposure time were important in disinfecting syringes. Being exposed to full-strength bleach for 30 seconds was sufficient to inactivate HIV, but full-strength bleach for 15 seconds or 10% diluted bleach for 30 seconds was not. Flynn and associates (1994) had similar findings regarding use of fullstrength bleach. However, although both groups concluded that disinfecting injection equipment with full-strength bleach for at least 30 seconds effectively inactivated HIV in syringes, they concurred that using only sterile equipment is a safer practice. Flynn's group also identified corrosion of the needle and loss of smooth plunger movement after about 20 washings as disadvantages of bleaching. A further concern about cleaning with bleach was whether IDUs were following the cleaning procedures they had been taught. McCoy and associates (1994) found that 90% of IDUs who had been instructed in bleaching techniques 6 to 12 months earlier could still perform the basic steps of using bleach and rinsing with water, but only 36% completely filled the syringe with bleach twice, as they had originally been taught. When Gleghorn, Doherty, Vlahov, Celentano, and Jones (1994) videotaped IDUs performing their cleaning procedures, 58% used full-strength bleach, but 46% of those who used bleach had less than 30 seconds of contact time between the bleach and the syringe. IDUs also reported that they were cleaning for about twice as long as they actually were. Ongoing reinforcement of bleaching techniques may be necessary to maintain IDUs' skills at an effective level. Safer injection can also be accomplished by avoiding social pressures to share equipment. IDUs who have internalized HIV prevention messages against sharing injection equipment may handle requests to share bv earning a spare syringe that they are willing to give

118

THE PERSON WITH HIV/AIDS

away, since refusals to share can be interpreted as believing that the requesting IDU has HIV (Barnard, 1993). Techniques to avoid sharing include giving equipment away rather than loaning it, or denying having any syringes on hand (Barnard, 1993). These techniques give IDUs the opportunity to protect themselves without disrupting their social connection with the requesting IDU. For those who continue to inject, the safest practice is to use sterile equipment each time. Having access to sterile supplies has been shown to significantly decrease risky injection practices, and concerns that increased access to needles may encourage drug use or initiate new users have not been borne out (National Institutes of Health, 1997; Paone et al., 1995). By decreasing the time a needle is in circulation, NEPs decrease the number of IDUs who use it (Alcabes & Friedland, 1995). NEPs may also be cost-effective. Gold, Gafney, Nelligan, and Millson's (1997) economic analysis of an NEP in Hamilton estimated that the cases of HIV prevented by the NEP would result in a net saving of $1.3 million over 5 years. In many countries syringes are available at legally sanctioned NEPs or can be purchased without a prescription at pharmacies. In the United States, however, most states have some regulations prohibiting the sale and/or possession of injection equipment without a prescription (Gostin et al., 1997). Indeed, the political opposition to providing IDUs access to sterile supplies has been sufficient to outweigh the conclusions of numerous scientific panels and reports that NEPs are beneficial and warranted in HIV prevention (Lurie, 1995). Despite these obstacles, over 100 NEPs were operating in the United States in 1996 (Centers for Disease Control, 1997d). By offering other services in addition to needle exchange, such as referral to drug treatment programs, instruction in safer sex and safer injection techniques, HIV testing and counseling, tuberculosis testing, primary medical care, and STD screening and prevention, NEPs can make themselves more valuable to their IDU clients and more politically acceptable. Ultimately, the most effective approach to HIV prevention for IDUs may be to stop using drugs altogether. Drug treatment programs work with IDUs to help them stop drug use, especially injecting drug use, stop using unclean equipment, and stop high-risk sexual practices (Holtgrave et al., 1995). Longshore, Hsieh, and Anglin (1994) suggest that sexual risk reduction may be more likely as IDUs

PREVENTING HIV INFECTION

119

disengage from sex work and increase their perceived self-efficacy. IDUs who do not initially succeed in stopping all drug use may still benefit from the risk reduction practices they learn in treatment. Sex by Drug Interaction As previously discussed, use of any mood-altering substance can lessen the motivation to use risk reduction behaviors. Although alcohol may be the most common drug to impair judgment and expose its users to HIV risk, illicit drugs, particularly smokable cocaine ("crack"), have also been implicated in high-risk sexual behavior. Crack users experience brief but intense highs, followed immediately by craving for more drug (Edlin et al., 1994). In these circumstances of addiction and craving, safer sex practices are not a priority for the user. Edlin and colleagues found that crack use was widespread among both males and females, and in both sexes was associated with high-risk sexual behaviors. Nearly half of men using crack reported 50 or more sex partners, and significantly more male crack users had anal sex with other men. More than two thirds of female crack users had engaged in sex work, often without condoms. Crack use has also been associated with greater numbers of partners, less consistent condom use, higher rates of new STDs among HFV-infected women (Wilson, Minkoff, DeHovitz, Feldman, & Landesman, 1998), and increased rates of HIV infection (Chiasson et al., 1991), particularly among women (Edlin et al., 1994). Edlin and colleagues attributed this increased prevalence of HIV among crack users entirely to their high-risk sex practices. The risk of HIV infection associated with injection drug use may pose an unrecognized threat to the sexual partners of IDUs. Many male IDUs have non-IDU female sex partners (Dwyer et al., 1994; Kane, 1991). These female non-IDU partners may be unaware that their partner injects drugs until the relationship is well established (Kane, 1991). Developing rules within the relationship to minimize the intrusiveness of the partner's drug use may increase the risk of HIV by making it easier to ignore the increased potential for sexual transmission. Although there is evidence that IDUs are adopting safer injection practices, use of safer sex practices has lagged behind. In the United

120

THE PERSON WITH HIV/AIDS

States, Booth and colleagues (1991) found that unprotected sex was the norm among IDUs, with 66% reporting that they never used condoms whereas only 6% always did. Only 4% practiced both safer sex and safe injection. Among HIV-infected European IDUs, about two thirds reported using safer injection techniques and not giving away used needles, but only slightly over one third reported consistent condom use (Desenclos, Papaevangelou, & Ancelle-Park, 1993). Those who tested negative for HIV showed a similar pattern of risk reduction, with two thirds or more practicing safe injecting but less than 10% always using a condom. More recently, the proportion of IDUs in Chicago who reported injection risk behavior decreased from 100% to 14%, while those reporting high-risk sexual behaviors decreased from 71% to 45% over a 4-year period (Wiebel et al., 1996). Rhodes, Stimson, and Quirk (1996) suggested that the lack of change toward safer sex practices may be due to IDUs' perceiving less risk from sex than from injection, difficulties applying knowledge of sexual risk reduction to actual situations, and responsibility norms that are tied primarily to injection behaviors rather than sex behaviors for IDUs. OTHER METHODS OF TRANSMITTING HIV Transfusions HIV infection due to transfusing infected blood or blood products, including coagulation factors used to treat hemophilia, was a significant problem until a screening test for HIV antibody became available in 1985. The "window" period between when a person becomes infected with HIV and when that infection can be identified may narrow further as more sensitive methods of detecting HIV become feasible. Recent estimates of the risk of HIV from transfusion in the United States range from 1 in 450,000 (Lackritz et al., 1995) to 1 in 680,000 units transfused (AuBuchon, Birkmeyer, & Busch, 1997). Blood supplies in the United States, Australia, New Zealand, Canada, Japan, and western European countries are tested for HIV antibody (Centers for Disease Control, 1996a). However, people living or traveling in countries with less rigorously screened blood supplies should consider postponing elective medical procedures until they

PREVENTING HIV INFECTION

121

can be transported to a locale with reliable testing of the blood supply. Vertical (Mother-to-Child) Transmission Transmission of HIV to young children occurs almost entirely while in utero, during birth, or during breastfeeding, with most perinatal transmission taking place near or during childbirth (Centers for Disease Control and Prevention, 1998a). Before antiretroviral drugs were available, about 25% of infants born to mothers with HIV were also infected with HIV. In 1994 preliminary results from Pediatric AIDS Clinical Trials Group Protocol 076 (PACTG 076) demonstrated that, for HIV-infected mothers with CD4 counts above 200 cells/|oL who had not received antiretroviral therapy earlier in the pregnancy (Centers for Disease Control and Prevention, 1994), administering zidovudine (ZDV) to the mothers during pregnancy and delivery, and to infants for 6 weeks after birth, could decrease HIV transmission to the child. Final results from PACTG 076 showed that 22.6% of infants in the placebo group became infected, compared to only 7.6% of infants in the ZDV group, for a 66% reduction in transmission risk (Outers for Disease Control and Prevention, 1998a). PACTG 185 investigated this effect in women with low CD4 counts who were already taking antiretroviral therapy. Interim results showed a transmission rate of only 4.8%, suggesting that ZDV was also effective for preventing HIV transmission to infants of women with advanced HIV disease, CD4 counts below 200 cells/jlL, and previous ZDV therapy (Centers for Disease Control and Prevention, 1998a). The mechanism by which ZDV reduces HIV transmission to the fetus has not been fully defined. ZDV metabolism in the placenta may significantly contribute to its protective effect, even beyond its antiretroviral effect in the mother. It is still unknown whether other antiretrovirals will perform as well (Centers for Disease Control and Prevention, 1998a). Because there is a possibility of transplacental carcinogenicity due to ZDV, long-term follow-up of children is necessary. The results of PACTG 076 strongly support encouraging all pregnant women to be tested for HIV (The Institute of Medicine [1998]

122

THE PERSON WITH HIV/AIDS

has recommended routine HIV testing for all pregnant women). HIV treatment for the woman and prevention of HIV transmission to the infant are separate but related issues to consider in deciding on appropriate therapy for the pregnant woman with HIV and can raise a number of ethical questions. Ultimately, the decision about drug therapy to prevent HIV transmission should be made by the woman after full, noncoercive discussion with her provider about the known and unknown possible effects on both herself and the fetus (Centers for Disease Control and Prevention, 1998a).

Occupational Exposure to HIV In general, people's greatest risk for HIV infection tends to come from behaviors in their personal lives, not from professional activities. Nonetheless, exposures on the job can occur, especially to health care workers such as nurses and laboratory technicians. To prevent occupational exposure to HIV and other blood-borne pathogens, the Centers for Disease Control and Prevention (1998b) have developed standard precautions (formerly called universal precautions). Standard precautions call for health care workers to use gloves, safety glasses, masks, gowns, and other barriers to keep themselves from coming in contact with the blood or other body fluids of all patients, regardless of whether the patient appears to be at risk for having HIV. Standard precautions require health care workers to exercise judgment about which procedures are likely to result in exposure to blood or body fluids. Engineering changes in devices such as syringes and operating room equipment have also been developed to further minimize the likelihood of injury. When a worker is exposed to HIV, the risk of transmission depends on the type of exposure: 0.3% (3 transmissions per 1,000 injuries) with percutaneous injury, 0.1% with mucocutaneous exposure (eyes, nose, or mouth), and less than 0.1% with skin exposure (Centers for Disease Control and Prevention, 1996d). HIV transmission from percutaneous exposure is more likely when injuries are deep or involve visibly bloody equipment, or when the source patient dies of AIDS within 2 months of the exposure (Cardo et al., 1997). If skin has been exposed to HIV-infected fluid, transmission is more likely with prolonged contact over a large area of disrupted integrity

PREVENTING HIV INFECTION

123

(Centers for Disease Control, 1996d). There is, of course, no risk of HIV transmission via any of these routes if the source patient is not infected with HIV. Postexposure Prophylaxis for Occupational and Other Types of HIV Exposure. Treatment with antiretrovirals may decrease the risk of seroconversion following occupational exposure to HIV by as much as 80%, although the magnitude of the decrease has been questioned (Cardo et al., 1997). For massive exposure to blood with a high HIV titer, prompt initiation of antiretroviral therapy with ZDV, lamivudirie, and indinavir is recommended (Rachlis & Zarowny, 1998). ZDV and lamivudine may be offered for moderate exposures as well. The timeframe within which PEP must begin to be effective is not clear. Seroconversion has been known to occur despite ZDV monotherapy initiated within 30 minutes of the exposure (Jochimsen, 1997), so, if antiretroviral therapy is warranted, it should begin promptly. Although treatment may be initiated as long as 48 to 72 hours after exposure, administering the first dose within 1 hour of the exposure is strongly encouraged (Henderson, 1999). Some institutions have developed rapid response programs to achieve this goal, including on-call teams to evaluate the exposure and initiate therapy quickly (e.g., Zeh et al., 1998). The treatment period is generally 4 weeks, with HIV testing continuing for at least 6 months and preferably 1 year (Henderson). The exposed worker will need explicit counseling regarding the use of safer sex practices and other risk reduction measures to prevent possible transmission to others until lack of HIV transmission is confirmed. The National Clinicians Post-Exposure Prophylaxis Hotline (1-888-448-4911) is available 24 hours a day, every day, to help clinicians counsel and treat health care workers who have been exposed to HIV or hepatitis viruses. Recommending postexposure prophylaxis following occupational exposures raises the question of prophylaxis for other types of exposure to HIV. The per-episode risk of HIV infection from unprotected sex has been estimated to range from approximately 3% for receptive anal intercourse to 0.03% for insertive vaginal intercourse (Katz & Gerberding, 1998). Because these figures are similar to the risks related to occupational exposure and because prophylactic antiretroviral therapy is associated with decreased rates of transmission in those cases, similar antiretroviral therapy has been suggested follow-

124

THE PERSON WITH HIV/AIDS

ing known sexual exposure to HIV (Lurie, Miller, Hecht, Chesney, & Lo, 1998). Victims of rape are candidates for antiretroviral therapy even when the serostatus of the rapist is unknown, because the physical trauma often associated with rape increases the risk of transmission (Lurie et al.). Prophylaxis may also be recommended after isolated incidents of sharing injection equipment with a person known to be infected with HIV (Katz & Gerberding, 1997), or with a person of unknown serostatus in an area with HIV prevalence of 30% or more (Lurie et al.)- For individuals who intend to continue high-risk sexual or injection behavior, postexposure prophylaxis is not recommended, since in effect they would need to be on continuous antiretroviral therapy to address their on-going exposures. However, such individuals should receive explicit risk reduction counseling. Further information on postexposure prophylaxis following nonoccupational exposure is presented in Appendices 1 and 2. Antiretroviral therapy following sexual or IDU exposure remains controversial for a number of reasons (Desmond & Coker, 1998; Evans, Darbyshire, & Cartledge, 1998). Health care providers may be concerned that easy availability of postexposure prophylaxis for sexual or injection exposure will make people less vigilant in avoiding risky behaviors. Timely access to the medications is also much more difficult to arrange in the context of a nonoccupational exposure, diminishing the potential effectiveness of the therapy. Finally, widespread use of such therapy can be quite expensive, with cost estimates ranging from $136,500 to $2 million per case of HIV prevented (Lurie et al., 1998). Further evidence regarding the efficacy of postexposure prophylaxis for nonoccupational exposures and clarification of the costs, benefits, and ethical aspects of access to such therapies are needed to answer this question. Sports-related Exposure The risk of contracting HIV during athletic activities has been estimated to be less that 1 per 85 million game contacts (Mast, Goodman, Bond, Favero, & Drotman, 1995). Again, as with health care workers, the vast majority of the athlete's risk of HIV lies in activities not related to sports, including unprotected sex and sharing equipment

PREVENTING HIV INFECTION

125

used to inject performance-enhancing drugs (Centers for Disease Control and Prevention, 1996b). For sports with significant body contact, basic precautions are appropriate, including covering any open wounds to prevent leakage of blood or other fluids during play. Fresh wounds leaking blood or other fluid should be washed with soap and water and covered completely before the athlete returns to play. Anyone else exposed to the fluid should promptly wash it off with soap and water as well. Trainers or medical personnel working with injuries should wear disposable exam gloves when contact with blood or body fluids is anticipated. Strict enforcement of regulations prohibiting unsportsmanlike conduct such as biting and scratching will also minimize potential exposure to blood.

PREVENTION PROGRAMS HIV prevention efforts can take many forms, and may be most effective when using a coordinated strategy that includes a variety of approaches. Formats may include mass media campaigns, counseling and testing services, individual and community outreach programs, and school prevention programs. Mass media campaigns are appropriate for reaching a wide audience with informational messages that encourage condom use and sexual responsibility and discourage drug use. HIV counseling and testing programs can be useful in higher prevalence populations. There is evidence that seropositive individuals who know they are infected are more likely to use risk reduction techniques, although people who test negative do not appear to alter their risk behaviors (Corby &; Jamner, 1996). Outreach programs have come to form the cornerstone of HIV prevention efforts among at-risk populations who may be difficult to access through conventional means. Outreach to individuals aims to help individuals identify those behaviors that place them at risk for HIV infection and implement risk-reduction strategies. This type of outreach is often performed by peer educators who may have experience with the lifestyle of the individuals they contact. In addition to educating individuals about risk reduction, this type of outreach can help them connect with services already available in the communitv. By contrast, community outreach works with social

126

THE PERSON WITH HIV/AIDS

groups to shift social norms toward safer practices (Stimson, Eaton, Rhodes, & Power, 1994). School-based HIV prevention programs have been controversial because of fears that they would encourage early sexual activity among teenagers. Kirby and colleagues (1994) reviewed 23 studies of HIV prevention programs in schools, looking for evidence of adverse outcomes and effectiveness. Concerns that explicit HIV prevention messages would result in increased sexual activity were not borne out. All of the programs either delayed the onset of sex or had no effect. No program resulted in increased frequency of sexual activity, and some programs may have resulted in increased condom use. The programs that demonstrated the desired outcomes of increasing condom use, delaying the onset of sexual intercourse, and reducing other risk behaviors such as number of partners had several characteristics in common. First, these programs were grounded in theories of social learning and social influence. They also had a narrow focus, concentrating on reducing specific sexual risk behaviors. Successful programs relied heavily on experiential activities rather than lecture to convey their information and incorporated skills-building activities such as role playing. These programs also included discussion of how to manage social pressures toward having sex and reinforced age- and experience-appropriate values and norms against unprotected sex. School-based condom programs have not been shown to increase sexual activity, although there are indications that they may result in modest but significant increases in condom use (Guttmacher et al., 1997). A number of reviews of HIV prevention programs are available (Centers for Disease Control and Prevention, 1996e; Coates et al., 1996; Corby & Jamner, 1996; Des Jarlais, Padian, & Winkelstein, 1994; Holtgrave et al., 1995; National Institutes of Health, 1997), and their conclusions are highly consistent. HIV prevention programs can bring about behavior change that will prevent transmission of HIV, but not all prevention efforts are equally effective. Several major principles for developing effective HIV prevention programs have emerged: 1. HIV prevention programs should be targeted to well-defined audiences and should have clear objectives and interventions.

PREVENTING HIV INFECTION

2.

3.

4.

5.

6.

127

Defining the audience may require a considerable investment prior to initiating the program itself. Ethnographic studies and inclusion of community informants during development will enhance the program's cultural competence and increase its impact on risk behaviors within the community. Prevention messages should be sensitive to the audience's culture, developmentally appropriate, and linguistically specific (Holtgrave et al., 1995). HIV prevention programs should be grounded in the behavioral and social sciences, incorporating theories of behavioral change and self-efficacy. Concepts from these theories have proven to be empirically important in predicting changes in risk behavior. Information, motivation, and skills building, including condom use, accessing supplies such as condoms, negotiation skills, anticipating the need for protection, and critical thinking skills, are key elements of HIV prevention programs. The intervention should be designed with an appropriate "dosage," in terms of number, duration, and intensity, to have sufficient impact to bring about lasting behavior change. Sustained interventions appear to produce long-term behavioral changes, and more intense interventions may lead to greater risk reduction (Coates et al., 1996). The program should address community myths, such as concerns that NEPs will increase drug use or that AIDS education in schools will increase adolescents' sexual activity. In fact, the demonstrated outcomes of such programs are generally quite congruent with community values. Being prepared to address these questions with clear presentation of the research findings will make it easier for community leaders to support the program. Ongoing evaluation of the program and its impact are important in allowing modifications of the intervention that meet the community's changing needs. Recruiting people from the community to convey prevention information helps keep the message culturally appropriate, and also demonstrates that peers do support behavior changes to protect against HIV.

128

THE PERSON WITH HIV/AIDS

Vaccines The spread of HIV infection around the world provides evidence that knowledge alone is inadequate in preventing the transmission of the virus. For often complex reasons discussed earlier in this chapter, individuals may engage in behaviors that place them at risk of HIV infection. As the number of persons infected .with HIV has increased dramatically over the past two decades, scientists have searched diligently for effective treatments for HIV infection and for a safe, effective vaccine. Scientists have sought a vaccine that will either prevent infection by HIV-1 or boost the immune systems of infected individuals. Clinical trials in humans began in the United States as early as 1987 with "simple subunit vaccines" (Frey, 1999, p. 95). Over time scientific knowledge has led to the understanding that an HIV-1 vaccine needs to stimulate both cell-mediated and antibody responses. Proposed vaccines have included live viruses genetically altered to attenuate their pathogenic potential, inactivated whole viruses with various adjuvants, live vector-based (e.g., pox viruses) vaccines, DNA vaccines, HIV peptides and pseudovirions (Fauci, 1998; Letvin, 1998). Some recent vaccines have been recombinantly engineered to include the genome of multiple proteins for HIV (Frey, 1999). Because HIV-1 mutates frequently, scientists have experienced difficulty in developing one or a combination of vaccines that will overcome the generation of viruses capable of escaping immune recognition. A few vaccines have advanced to phase 3 clinical trials, but most have not advanced beyond phase I. While several vaccines have been at least partially successful in preventing HIV infection in nonhuman primates, this partial success has not been replicated in human subjects (Letvin, 1998). In a 1998 speech Fauci summarized impediments to developing an HIV vaccine to include "geographic variability of HIV subtypes, lack of a clear understanding of the correlates of protective immunity in HIV infection, the limitations of available animal models of HIV infection, and challenges of inducing mucosal immunity to prevent sexual transmission of HIV." In addition to the scientific challenges of developing a safe and effective vaccine, several other factors make developing and testing an HIV vaccine difficult. These include difficulty in finding an ade-

PREVENTING HIV INFECTION

129

quate number of volunteers for testing; concerns about the safety of those enrolled in clinical trials; social risks of testing HIV antibody positive after receiving a vaccine, depending upon the type of vaccine; concerns that volunteers in clinical trials of vaccines may be more inclined to engage in activities that place them at risk of infection because of an unwarranted belief that they are protected by their participation in the clinical trial; the enormous costs associated with development and testing of potential vaccines; and controversies related to clinical trials in underdeveloped nations (Angell, 1997; Bloom, 1998; Fauci, 1998). While a vaccine for HIV is a\op priority of the federal Office of AIDS Research (a part of the National Institutes of Health), the federal government has been criticized for inadequately funding vaccine research aimed at achieving President Clinton's goal of HIV vaccine by 2007, a goal that some scientists believe cannot be achieved (Wheeler, 1999). Until such time as a safe and effective vaccine and/or a curative treatment is available, efforts to combat the spread of HIV will feature preventive strategies discussed earlier in this chapter. This chapter has provided basic information on sources of risk for HIV infection and factors that modify that risk. After more than a decade of experience with HIV, and with no immediate prospects for an effective vaccine or cure, prevention remains the best solution to stemming the spread of HIV. WThile prevention of HIV transmission is straightfonvard in its basic requirements, the complexities of human motivation and behavior complicate the simplest HIV prevention messages. Efforts to provide the information, motivation, and equipment needed to prevent HIV must continue. Closely involving the community in these prevention efforts will enhance their acceptabilitv and effectiveness. REFERENCES Airhihenbuwa, C. O., DiClemente, R. J., Wingood, G. M., & Lowe, A. (1992). HIV/ AIDS education and prevention among African-Americans: A focus on culture. AIDS Education and Prevention, 4, 267-276. Albert, A. E., Warner, D. L., Hatcher, R. A., Trussell, ]., & Bennett, C. (1995). Condom use among female commercial sex workers in Nevada's legal brothels. America?!. Journal of Public Health, 85, 1514-1520. Alcabes, P., & Friedland, G. (1995). Injection drug use and human immunodeficiency virus infection. Clinical Infectious Diseases, 20, 1467-1479.

130

THE PERSON WITH HIV/AIDS

Ames, L. J., Atchinson, A. B., & Rose, D. T. (1995). Love, lust, and fear: Safer sex decision making among gay men. Journal of Homosexuality, 30, 53-73. Anderson,]. E., Wilson, R. W., Barker, P., Doll, L., Jones, T. S., & Holtgrave, D. (1999). Prevalence of sexual and drug-related HIV risk behaviors in the U.S. adult population: Results of the 1996 National Household Survey on Drug Abuse. Journal of Acquired Immune Deficiency Syndromes, 21, 148-156. Angell, M. (1997). The ethics of clinical research in the Third World. New England Journal of Medicine, 337, 847-849. AuBuchon, J. P., Birkmeyer, J. D., & Busch, M. P. (1997). Safety of the blood supply in the United States: Opportunities and controversies. Annals of Internal Medicine, 127, 904-909. Barnard, M. A. (1993). Needle sharing in context: Patterns of sharing among men and women injectors and HFV risks. Addiction, 88, 805-812. Binson, D., Dolcini, M. M., Pollack, L. M., & Catania, J. A. (1993). IV. Multiple sexual partners among young adults in high-risk cities. Family Planning Perspectives, 25, 268-272. Bloom, B. (1998). The highest attainable standard: Ethical issues in AIDS vaccines Science, 279, 186-188. Booth, R., Koester, S., Brewster, J. T., Wiebel, W. W., & Fritz, R. B. (1991). Intravenous drug users and AIDS: Risk behaviors. American Journal of Drug and Alcohol Abuse, 17, 337-353. Brettle, R. P. (1991). HFV and harm reduction for injection drug users. AIDS, 5, 125-136. Broadhead, R. S. (1991). Social constructions of bleach in combating AIDS among injection drug users. Journal of Drug Issues, 21, 713-737. Browne, J., & Minichiello, V. (1995). The social meanings behind male sex work: Implications for sexual interactions. British Journal of Sociology, 46, 598-622. Calsyn, D. A., Saxon, A. J., Freeman, G., & Whittaker, S. (1991). Needle-use practices among intravenous drug users in an area where needle purchase is legal. AIDS, 5, 187-193. Campbell, C. A. (1995). Male gender roles and sexuality: Implications for women's AIDS risk and prevention. Social Science and Medicine, 41, 197-210. Cardo, D. M., Culver, D. H., Cieselski, C. A., Srivastava, P. U., Marcus, R., Abiteboul, D., Heptonstall, J., Ippolito, G., Lot, F., McKibben, P. S., & Bell, D. M. (1997). A case-control study of HIV seroconversion in health care workers after percutaneous exposure. New England Journal of Medicine, 337, 1485-1490. Catania, J. A., Binson, D., Dolcini, M. M., Stall, R., Choi, K-H., Pollack, L. M., et al. (1995). Risk factors for HIV and other sexually transmitted diseases and prevention practices among US heterosexual adults: Changes from 1990 to 1992. American Journal of Public Health, 85, 1492-1499. Gates, W., & Stone, K. M. (1992). Family planning, sexually transmitted diseases and contraceptive choice: A literature update—part I. Family Planning Perspectives, 24, 75-84. Celentano, D. D., Vlahov, D., Cohn, S., Anthony, J. C., Solomon, L., & Nelson, K. E. (1991). Risk factors for shooting gallery use and cessation among intravenous drug users. American Journal of Public Health, 81, 1291-1295.

PREVENTING HIV INFECTION

131

("enters for Disease Control and Prevention. (1993a). Update: Barrier protection against HIV infection and other sexually transmitted diseases. Morbidity and Mortality Weekly Report, 42, 589-591, 597. . (1993b). Use of bleach for disinfection of drug injection equipment. Morbidity and Mortality Weekly Report, 42, 418-419. . (1994). Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. Morbidity and Mortality Weekly Report, 43(RR-11), 1-19. . (1996a). CDC travel information: HIV/AIDS prevention [online], [http:// www.cdc.gov/travel/hivaids.htm] . (1996b). HIV'/AIDS and sports [online], [http://www.epibiostat.ucsf.edu/ capsweb/toolbox/HrV&sports.html] . (1996c). Youth risk behavior surveillance—United States, 1995. Morbidity and Mortality Weekly Report, 45(SS-4), 1-84. . (1996d). Provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. Morbidity and Mortality Weekly Report, 45, 1-6. . (1996e). Community-level prevention of human immunodeficiency virus infection among high-risk populations: The AIDS Community Demonstration Projects. Morbidity and Mortality Weekly Report, 45(RR-6), 1-24. . (1997a). Transmission of HIV possibly associated with exposure of mucous membrane to contaminated blood. Morbidity and Mortality Weekly Report, 46, 620623. Centers for Disease Control and Prevention. (1997b). Gonorrhea among men who have sex with men—selected sexually transmitted diseases clinics, 1993-1996. Morbidity and Mortality Weekly Report, 46, 889-892. . (I997c). Sexually transmitted disease surveillance 1996: STDs in adolescents and young adults [online]. [http://wonder.cdc.gov/wonder/STD/ STDD016.PCW.html] . (1997d). Update: Syringe-exchange programs—United States, 1996. Morbidity and Mortality Weekly Report, 46, 565-568. . (1998a). Public Health Service Task Force recommendations for the vise of antiretioviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Morbidity and Mortality Weekly Report, 47(No. RR-2), 1-30. . (1998b, May). Universal precautions for prevention of transmission of HIV and other bloodborne infections [online], [http://www.cdc.gov/ncidod/ blood/hip/ universa.htm j Chiasson, M. A., Stoneburner, R. L., Hildebrandt, D. S., Ewing, W. E., Telzak, E. E., & faffe, H. W. (1991). Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack). AIDS, 5, 1121-1126. Choi, K.-H., Rickman, R., & Catania, J. A. (1994). What heterosexual adults believe about condoms [Letter to the editor]. New England Journal of Medicine, 331, 406407. Clements, K., Gleghorn, A., Garcia, D., Katz, M., & Marx, R. (1997). A risk profile of street youth in Northern California: Implications for gender-specific human immunodeficiency virus prevention. Journal of Adolescent Health, 20, 343-353.

132

THE PERSON WITH HIV/AIDS

Coates, T. J., Aggleton, P., Gutzwiller, F., Des Jarlais, D., Kihara, M., Kippax, S., Schechter, M., & van den Hoek, J. A. R. (1996). HIV prevention in developed countries. Lancet, 348, 1143-1148. Corby, N. H., & Jamner, M. S. (1996). HIV prevention interventions: What works and what doesn't? [online]. [http://hivinsite.ucsf.edu/prevention/ evaluating_programs/2098.33 14.html] de Vincenzi, I., for the European Study Group on Heterosexual Transmission of HIV. (1994). A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. New England Journal of Medicine, 331, 341-346. Des Jarlais, D. C., Friedman, S. R., & Ward, T. P. (1993). Harm reduction: A public health response to the AIDS epidemic among injecting drug users. Annual Review of Public Health, 14, 413-450. Des Jarlais, D. C., Padian, N. S., & Winkelstein, W. (1994). Targeted HIV-prevention programs. New England Journal of Medicine, 331, 1451-1453. Deschamps, M.-M., Pape, J. W., Hafner, A., & Johnson, W. D. (1996). Heterosexual transmission of HIV in Haiti. Annals of Internal Medicine, 125, 324-330. Desenclos, J.-C., Papaevangelou, G., & Ancelle-Park, R., for the European Community Study Group on HIV in Injecting Drug Users. (1993). Knowledge of HIV serostatus and preventive behaviour among European injecting drug users. AIDS, 7, 1371-1377. Desmond, N. M., & Coker, R. J. (1998). Should preventive an tire tro viral treatment be offered following sexual exposure to HIV? The case for. Sexually Transmitted Infections, 74, 144-145. Dwyer, R., Richardson, D., Ross, M. W., Wodak, A., Miller, M. E., & Gold, J. (1994). A comparison of HIV risk between women and men who inject drugs. AIDS Education and Prevention, 6, 379-389. Edlin, B. R., Irwin, K. L., Faruque, S., McCoy, C. B., Word, C., Serrano, Y., Inciardi, J. A., Bowser, B. P., Schilling, R. F., Holmber, S. D., & Multicenter Crack Cocaine and HIV Infection Study Team. (1994). Intersecting epidemics—Crack cocaine use and HIV infection among inner-city young adults. New England Journal of Medicine, 331, 1422-1427. Edwards, S., & Carne, C. (1998). Oral sex and the transmission of viral STIs. Sexually Transmitted Infections, 74, 6-10. El-Bassel, N., Krishnan, S. P., Schilling, R. F., Witte, S., & Gilbert, L. (1998). Acceptability of the female condom among STD clinic patients. AIDS Education and Prevention, 10, 465-480. European Study Group on Heterosexual Transmission of HIV. (1992). Comparison of female to male and male to female transmission of HIV in 563 stable couples. EM], 304, 809-813. Evans, B., Darbyshire, J., & Cartledge, J. (1998). Should preventive antiretroviral treatment be offered following sexual exposure to HIV? Not yet! Sexually Transmitted Infections, 74, 146-148. Farr, G., Gabelnick, H., Sturgen, K., & Dorflinger, L. (1994). Contraceptive efficacy and acceptability of the female condom. American Journal of Public Health, 84, 1960-1964.

PREVENTING HIV INFECTION

133

Fauci, A. (1998, July 22). HIV vaccine research: Considerations for the new millennium. 32nd National Immunization Conference, Atlanta, Georgia. Flynn, N., Jain, S., Keddie, E. M., Carlson, }. R., Jennings, M. B., Haverkos, H. W., Nassar, N., Anderson, R., Cohen, S., & Goldberg, D. (1994). In vitro activity of readily available household materials against HIV-1: Is bleach enough? Journal of Acquired Immune Deficiency Syndromes, 7, 747-753. Frey, S. (1999). HIV vaccines. Infectious Disease Clinics of North America, 13(1), 95-112. Frezieres, R. G., Walsh, T. L., Nelson, A. L., Clark, V. A., & Coulson, A. H. (1998). Breakage and acceptability of a polyurethane condom: A randomized, controlled study. Family Planning Perspectives, 30, 73-78. Fullilove, M. T.. Fullilove III, R. E., Haynes, K., & Gross, S. (1990). Black women and AIDS prevention: A view towards understanding the gender rules. Journal of Sex Research, 27, 47-64. Gibson, S., McFarland, W., Wohlfeiler, D., Scheer, K., & Katz, M. H. (1999). Experiences of 100 men who have sex with men using the Reality condom for anal sex. AIDS Education and Prevention, 11, 65-71. Gleghorn, A. A., Doherty, M. C., Vlahov, D., Celentano, D. D., & Jones, T. S. (1994). Inadequate bleach contact times during syringe cleaning among injection drug users. Journal of Acquired Immune Deficiency Syndromes, 7, 767-772. Gold, M., Gafni, A., Nelligan, P., & Millson, P. (1997). Needle exchange programs: An economic evaluation of a local experience. Canadian Medical Association Journal, 157, 255-262. Goldbaum, G., Perdue, T., & Higgins, D. (1996). Non-gay-identifying men who have sex with men: Formative research results from Seattle, Washington. Public Health Reports, / / / ( S u p p l . 1), 36-40. Gollub, E. L., & Stein, Z. (1993). Commentary: The new female condom—Item 1 on a women's AIDS prevention agenda. American Journal of Public Health, 83, 498-500. Gollub, E. L.. Stein, Z., & El-Sadr, W. (1995). Short-term acceptability of the female condom among staff and patients at a New York City hospital. Family Planning Perspectives, 27, 155-158. Gostin, I.. O., Lazzarini, Z., Jones, T. S., & Flaherty, K. (1997). Prevention of HIV/ AIDS and other blood-borne diseases among injection drug users: A national survey on the regulation of syringes and needles. Journal of the American Medical Association, 277, 53-62. Greenfield, L.. Bigelow, G. E., & Brooner, R. K. (1992). HIV risk behavior in drug users: Increased blood "booting" during cocaine injection. AIDS Education and Prevention, 4, 95-107. Grinstead, O. A., Peterson, J. L., Faigeles, B., & Catania, J. A. (1997). Antibody testing and condom use among heterosexual African Americans at risk for HIV infection: The National AIDS Behavioral Surveys. AmericanJournal of Public Health, 87, 857-859. Grund, J.-P. ( ., Kaplan, C. D., & Adriaans, N. F. P. (1991). Needle sharing in the Netherlands: An ethnographic analysis. American Journal of Public Health, 81, 1602-1607.

134

THE PERSON WITH HIV/AIDS

Grund,J.-P. C., Kaplan, C. D., Adriaans, N. F. P., Blanken, P., & HuismanJ. (1990). The limitations of the concept of needle sharing: The practice of frontloading. AIDS, 4, 819-821. Guttmacher, S., Lieberman, L., Ward, D., Freudenberg, N., Radosh, A., & Des Jarlais, D. (1997). Condom availability in New York City public high schools: Relationships of condom use and sexual behavior. American Journal of Public Health, 87, 1427-1433. Heckman, T. G., Sikkema, K. J., Kelly, J. A., Fuqua, R. W., Mercer, M. B., Hoffmann, R. G., Winett, R. A., Anderson, E. S., Perry, M. J., Roffman, R. A., Solomon, L. J., Wagstaff, D. A., Cargill, V., Norman, A. D., & Crumble, D. (1996). Predictors of condom use and human immunodeficiency virus test seeking among women living in inner-city public housing developments. Sexually Transmitted Diseases, 23, 357-365. Henderson, D. K. (1999). Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. Journal of the American Medical Association, 281, 931-936. Hillier, L., Harrison, L., & Warr, D. (1998). "When you carry condoms all the boys think you want it": Negotiating competing discourses about safe sex. Journal of Adolescence, 21, 15-29. Hingson, R. W., Strunin, L., Berlin, B. M., & Heeren, T. (1990). Beliefs about AIDS, use of alcohol and drugs, and unprotected sex among Massachusetts adolescents. American Journal of Public Health, 80, 295-299. Holtgrave, D. R., Quails, N. L., Curran, J. W.( Valdiserri, R. O., Guinan, M. E., & Parra, W. C. (1995). An overview of the effectiveness and efficiency of HIV prevention programs. Public Health Reports, 110, 134-146. Hook, E. W., Cannon, R. O., Nahmias, A. J., Lee, F. F., Campbell, C. H., Glasser, D., & Quinn, T. C. (1992). Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. Journal of Infectious Diseases, 165, 251-255. Howe, J. E., Minkoff, H. L., & Duerr, A. C. (1994). Contraceptives and HIV. AIDS, 8, 861-871. Jochimsen, E. M. (1997). Failures of zidovudine postexposure prophylaxis. American Journal of Medicine, 102(5S), 52-55. Joffe, A. (1993). Adolescents and condom use. American Journal of Diseases of Children, 147, 746-754. Kane, S. (1991). HIV, heroin and heterosexual relations. Social Science and Medicine, 32, 1037-1050. Katz, M. H., & Gerberding, J. L. (1997). Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. New England Journal of Medicine, 336, 1097-1100. . (1998). The care of persons with recent sexual exposure to HIV. Annals of Internal Medicine, 128, 306-312. Kegeles, S. M., Adler, N. E., & Irwin, C. E. (1988). Sexually active adolescents and condoms: Changes over one year in knowledge, attitudes and use. American Journal of Public Health, 78, 460-461.

PREVENTING HIV INFECTION

135

Kelly, J. A., Sikkema, K. J., Winett, R. A., Solomon, L. J., Roffman, R. A., Heckman, T. G., Stevenson, L. Y, Perry, M. J., Norman, A. D., & Desiderate, L. J. (1995). Factors predicting continued high-risk behavior among gay men in small cities: Psychological, behavioral, and demographic characteristics related to unsafe sex. Journal of Consulting and Clinical Psychology, 63, 101-107. Kirby, D., Short, L., Collins, J., Rugg, D., Kolbe, L., Howard, M., Miller, B., Sonenstein. F., & Zabin, L. S. (1994). School-based programs to reduce sexual risk behaviors: A review of effectiveness. Public Health Reports, 109, 339-360. Lackritz, E. M., Satten, G. A., Aberle-Grasse, J., Dodd, R. Y., Raimondi, V. P.Janssen, R. S., Lewis, W. F., Notari, E. P., & Petersen, L. R. (1995). Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. New England Journal of Medicine, 333, 1721-1725. Laga, M., Manoka, A., Kivuvu, M., Malele, B., Tuliza, M., Nzila, N., Goeman, J., Behets, F., Batter, V,, Alary, M., Heyward, W. L., Ryder, R. W., & Piot, P. (1993). Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: Results from a cohort study. AIDS, 7, 95-102. Latkin, G., Mandell, W., Vlahov, D., Oziemkowska, M., & Celentano, D. (1996). People and places: Behavioral settings and personal network characteristics as correlates of needle sharing. Journal of Acquired Immune Deficiency Syndromes and Human Retnnnrology, 13, 273-280. Laumann, E. ()., Gagnon, J. H., Michael, R. T., & Michaels, S. (1994). The social organization of sexuality. Chicago: University of Chicago Press. Lazzarin, A., Saracco, A., Musicco, M., Nicolosi, A., & Italian Study Group on HIV Heterosexual Transmission. (1991). Man-to-woman sexual transmission of the human immunodeficiency virus. Archives of Internal Medicine, 151, 2411-2416. Leigh, B. C., Temple, M. T., & Trocki, K. F. (1993). The sexual behavior of US adults: Results from a national survey. American Journal of Public Health, 83, 1400-1408. Lemp, G. F., Hirozawa, A. M., Givertz, D., Nieri, G. N., Anderson, L., Lindegren, M. L., Janssen, R. S., & Katz, M. (1994). Seroprevalence of HIV and risk behaviors among young homosexual and bisexual men: The San Francisco/Berkeley Young Men's Survey. Journal of the American Medical Association, 272, 449-454. Leonard, T. L. (1990). Males clients of female street prostitutes: Unseen partners in sexual disease transmission. Medical Anthropology Quarterly, 4, 41-55. Letvin, N. (1998). Progress in the development of an HIV-1 vaccine. Science, 250(5371). 1875-1880. Levine, W. C., Pope, V., Bhoomkar, A., Tambe, P., Lewis, J. S., Zaidi, A. A., Farshy, C. E., Mitchell, S., & Talkington, D. F. (1998). Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted disease. Journal of Infectious Diseases, 177, 167-174. Longshore, D., Hsieh, S. C., & Anglin, M. D. (1994). Reducing HIV risk behavior among injection drug users: Effect of methadone maintenance treatment on number of sex partners. International Journal of the Addictions, 29, 741-757. Lurie, P. (1995). When science and politics collide: The federal response to needleexchange programs. Bulletin of the New York Academy of Medicine, 72, 380-396. Lurie, P., Miller, S., Hecht, F., Chesney, M., & Lo, B. (1998). Postexposure prophylaxis after nonoccupational HIV exposure: Clinical, ethical, and policy considerations. Journal of the American Medical Association, 280, 1769-1773.

136

THE PERSON WITH HIV/AIDS

Marin, B. V., Marin, G., & Juarez, R. (1988, August). Prevention of AIDS in the Latino Community: Cultural Issues. Paper presented at the Annual Convention of the American Psychological Association, Atlanta. Marks, G., Richardson, J. L., & Maldonado, N. (1991). Self-disclosure of HIV infection to sexual partners. American Journal of Public Health, 81, 1321-1323. Marzili, T. J. (1989). The biologic possibility of HIV transmission during passionate kissing [Letter to the editor ].Journalof the American Medical Association, 262, 22302231. Mast, E. E., Goodman, R. A., Bond, W. W., Favero, M. S., & Drotman, D. P. (1995). Transmission of blood-borne pathogens during sports: Risk and prevention. Annals of Internal Medicine, 122, 283-285. Mays, V. M., & Cochran, S. D. (1988). Issues in the perception of AIDS risk and risk reduction activities by Black and Hispanic/Latina women. American Psychologist, 43, 949-957. McCoy, C. B., Rivers,]. E., McCoy, H. V., Shapshak, P., Weatherby, N. L., Chitwood, D. D., PageJ. B., Inciardi,J. A., & McBride, D. C. (1994). Compliance to bleach disinfection protocols among injecting drug users in Miami, journal of Acquired Immune Deficiency Syndromes, 7, 773-776. McKeganey, N. P. (1994). Prostitution and HIV: What do we know and where might research be targeted in the future? AIDS, 8, 1215-1226. National Commission on AIDS. (1994). Preventing HIV/AIDS in adolescents. Journal of School Health, 64(1), 39-51. National Institutes of Health. (1997). NIH Consensus Statement: Interventions to prevent HIV risk behaviors [online], [http://odp.od.nih.gov/consensus/ cons/104/ 104_intro.htm] Neaigus, A., Friedman, S. R., Curtis, R., Des Jarlais, D. C., Furst, R. T., Jose, B., Mota, P., Stepherson, B., Sufian, M., Ward, T., & Wright, J. W. (1994). The relevance of drug injectors' social and risk networks for understanding and preventing HFV infection. Social Science and Medicine, 38, 67-78. Nelson, K. E., Vlahov, D., Cohn, S., Lindsay, A., Solomon, L., & Anthony, J. C. (1991). Human immunodeficiency virus infection in diabetic intravenous drug users. Journal of the American Medical Association, 266, 2259-2261. Padian, N. S., Shiboski, S. C., & Jewell, N. P. (1990). The effect of number of exposures on the risk of heterosexual HIV transmission. Journal of Infectious Diseases, 161, 883-887. Paone, D., Des Jarlais, D. C., Gangloff, R., Milliken, J., & Friedman, S. R. (1995). Syringe exchange: HIV prevention, key findings, and future directions. International Journal of the Addictions, 30, 1647-1683. Plummer, F. A., Simonsen, J. N., Cameron, D. W., Ndinya-Achola, J. O., Kreiss, J. K., Gakinya, M. N., Waiyaki, P., Cheang, M., Piot, P., Ronald, A. R., & Ngugi, E. N. (1991). Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. Journal of Infectious Diseases, 163, 233-239. Polonsky, S., Kerr, S., Harris, B., Gaiter, J., Fichtner, R. R., & Kennedy, M. G. (1994). HIV prevention in prisons and jails: Obstacles and opportunities. Public Health Reports, 109, 615-625. Rachlis, A. R., & Zarowny, D. P. (1998). Guidelines for antiretroviral therapy for HIV infection. Canadian Medical Association Journal, 158, 105-114.

PREVENTING HIV INFECTION

137

Remafedi, G. (1994). Predictors of unprotected intercourse among gay and bisexual youth: Knowledge, beliefs, and behavior. Pediatrics, 94, 163-168. Rhodes, T., Stirnson, G. V., & Quirk, A. (1996). Sex, drugs, intervention, and research: From the individual to the social, Substance Use and Misuse, 31, 375-407. Romer, D., Black, M., Ricard, I., Feigelman, S., Kaljee, L., Galbraither, J., Nesbit, R., Hornik, R. C., & Stan ton, B. (1994). Social influences on the sexual behavior of youth at risk for HIV exposure. American Journal of Public Health, 84, 977-985. Rotheram-Bonis, M. J., & Koopman, C. (1991). Sexual risk behaviors, AIDS knowledge, and beliefs about AIDS among runaways. American Journal of Public Health, 81 206-208. Ruiz, J., Facer, M., & Sun, R. K. (1998). Risk factors for human immunodeficiency virus infection and unprotected anal intercourse among young men who have sex with men. Sexually Transmitted Diseases, 25, 100-107. Sacco, W. P., Rickman, R. L., Thompson, K., Levine, B., & Reed, D. L. (1993). Gender differences in AIDS-relevant condom attitudes and condom use. AIDS Education and Prevention, 5, 311-326. Seal, D. W., £ Ehrhardt, A. A. (1999). Heterosexual men's attitudes toward the female condom. AIDS Education and Prevention, 11, 93-106. Seidlin, M., Vogler, M, Lee, E., Lee, Y. S., & Dubin, N. (1993). Heterosexual transmission of HIV in a cohort of couples in New York City. AIDS, 7, 1247-1254. Seidman, S. N., & Rieder, R. O. (1994). A review of sexual behavior in the United States. American Journal of Psychiatry, 151, 330-341. Shapshak, P., McCoy, C. B., Shah, S. M., Page,]. B., Rivers, J. E., Weatherby, N. L., Chitwood, D. D., & Mash, D. C. (1994). Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. Journal of Acquired Immune Deficiency Syndromes, 7, 754-759. Singer, M. (1991). Confronting the AIDS epidemic among IV drug users: Does ethnic culture matter? AIDS Education and Prevention, 3, 258-283. St. Lawrence,}. S. (1993). African-American adolescents' knowledge, health-related attitudes, sexual behavior, and contraceptive decisions: Implications for the prevention of adolescent HIV infection. Journal of Consulting and Clinical Psychology^, 61, 104-112. Stein, M. D., Freedberg, K. A., Sullivan, L. M., Savetsky,J., Levenson, S. M., Hingson, R., & Samet, ]. H. (1998). Sexual ethics: Disclosure of HIV-positive status to partners. Archives of Internal Medicine, 158, 253-257. Stein, Z. A. (1995). Editorial: more on women and the prevention of HIV infection. American Journal of Public Health, 85, 1485-1488. Stiffman, A. R., Earls, F., Dore, P., & Cunningham, R. (1992). Changes in acquired immunodeficiency syndrome-related risk behavior after adolescence: Relationships to knowledge and experience concerning human immunodeficiency virus infection. Pediatrics, 89, 950-956. Stimson, G. V., Eaton. G., Rhodes, T., & Power, R. (1994). Potential development of community oriented HIV outreach among drug injectors in the UK. Addiction, 89, 1601-1611. Stryker, }., Coates, T. J., DeCarlo, P., Haynes-Sanstad, K., Shriver, M., & Makadon, H. J. (1995). Prevention of HIV infection: Looking back, looking ahead. Journal of the Amen can Medical Association, 273, 1143-1148.

138

THE PERSON WITH HIV/AIDS

Trocki, K. F. , & Leigh, B. C. (1991). Alcohol consumption and unsafe sex: A comparison of heterosexuals and homosexual men. Journal of Acquired Immune Deficiency Syndromes, 4, 981-986. Van Ameijden, E. J. C., van den Hoek, J. A. R., van Haastrecht, H. J. A., & Coutinho, R. A. (1992). The harm reduction approach and risk factors for human immunodeficiency virus (HIV) seroconversion in injecting drug users, Amsterdam. American Journal of Epidemiology, 136, 236-243. Voeller, B. (1991). AIDS and heterosexual anal intercourse. Archives of Sexual Behavior, 20, 233-276. Warner, D. L., Boles, J., & Goldsmith, J. (1997). Disclosure of condom breakage to sexual partners [Letter to the editor]. Journal of the American Medical Association, 278, 291-292. Walters, J. K. (1989). Observations on the importance of social context in HIV transmission among intravenous drug users. Journal of Drug Issues, 19, 9-26. Wheeler, D. (1999, March 26). As AIDS continues to spread, some scientists are pessimistic about developing a vaccine. The Chronicle of Higher Education, A21. Wiebel, W. W., Jimenez, A., Johnson, W., Ouellet, L., Jovanovic, B., Lampinen, T., Murray, J., & O'Brien, M. U. (1996). Risk behavior and HIV seroincidence among out-of-treatment injection drug users: A four-year prospective study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 12, 282-289. Wight, D. (1992). Impediments to safer heterosexual sex: A review of research with young people. AIDS Care, 4, 11-23. Wilson, T. E., Minkoff, H., DeHovitz, J. Feldman, J., Landesman, S. (1998). The relationship of cocaine use and human immunodeficiency virus serostatus to incident sexually transmitted diseases among women. Sexually Transmitted Diseases, 25(2), 70-75. Wingood, G. M., & DiClemente, R. J. (1997). The effects of an abusive primary partner on the condom use and sexual negotiation practices of African-American women. American Journal of Public Health, 87, 1016-1018. Witte, S., El-Bassel, N., Wada, T., Gray, O., & Wallace, J. (1999). Acceptability of female condom use among women exchanging street sex in New York City. International Journal of STD & AIDS, 10, 162-168. Wittkowski, K., Susser, E., & Dietz, K (1999). The protective effect of condoms and nonoxynol-9 against HIV infection. American Journal of Public Health, 89, 109-110. Wold, C., Seage III, G. R., Lenderking, W. R., Mayer, K. H., Cai, B., Heeren, T., & Goldstein, R. (1998). Unsafe sex in men who have sex with both men and women. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 17, 361-367. Woolley, R. J. (1989). The biologic possibility of HIV transmission during passionate kissing [letter]. Journal of the American Medical Association, 262, 2230. Zeh, J., Wong, M. T., Torterella, F. J., Kaatz, J. S., Allen, P., Kaplowitz, L. G., & Weiir-Wiggins, C. (1998). The PEP team: A multidisciplinary team approach to provide continuous coverage for post-exposure prophylaxis in an urban university hospital setting (abstractno. 60200). International Conference on AIDS, 12,1035. Zekeng, L., Feldblum, P.J., Oliver, R. M., & Kaptue, L. (1993). Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS, 7, 725-731.

4

Promoting Wellness in Persons with HIV Infection Susan L. Keller

nfection with the human immunodeficiency virus (HIV) results in the progressive deterioration of the human immune system. The immunopathogenesis of HIV results from the gradual loss of CD4+ T lymphocytes in untreated persons infected with the virus. CD4+ T lymphocytes are crucial to maintaining appropriate immunological responses to a wide array of pathogens as well as malignant neoplasms. Deterioration of the human immune system results in severe immunosuppression with the subsequent development of opportunistic infections and neoplasms (Fauci & Rosenberg, 1994; Glaser, Rabin, Chesney, Cohen, & Natelson, 1999). Although, scientific understanding of the behavior of HIV has advanced substantially since the initial reports of AIDS nearly 20 years ago, the precise mechanism whereby HIV causes the depletion of these lymphocytes has yet to be fully understood. The specific clinical course of HIV disease is difficult to predict. Expression of the continuum of HIV disease is dependent on both host and viral factors, as described in chapters 1, 2, and 5. The progression of the immune system deterioration as a result of HIV infection varies considerably from person to person and is not con-

I

139

140

THE PERSON WITH HIV/AIDS

stant throughout the course of HIV disease (Feinberg, 1996). Factors such as host genetic immunity (Kaslow et al., 1996), age (Darby, Ewart, Giangrande, Spooner, & Rizza, 1996), exposure to environmental antigens or common infections (Stanley et al., 1996; Staprans et al., 1995), and ongoing viral replication and mutation (BarreSinoussi, 1996; Ho et al., 1995; Wei, et al., 1995) may affect the rate of progression of HIV disease. In the absence of effective antiviral therapy, a common pattern of the course of HIV infection has been recognized progressing along a continuum from asymptomatic illness to episodes of severe morbidity (Pantaleo & Fauci, 1997). HIV infection typically advances through stages of acute HIV infection and clinical latency to clinically apparent disease. The result of infection with HIV is most often acquired immunodeficiency syndrome (AIDS), the final stage of HIV disease (Ho et al., 1995; Wei et al., 1995). Progression of HIV is not necessarily linear in nature. Persons living with HIV disease often experience periods of well-being interspersed with episodes of severe morbidity. Advancements in understanding modes of transmission, clinical manifestations, and treatment approaches have successfully led to prolonged life through slowed disease progression and reduced risk of opportunistic illness in many persons infected with HIV. Most specifically, recent development and short-term success of highly active antiretroviral therapy (HAART) agents have contributed to the hope of transforming a once definitively fatal illness into a chronic condition that can remain stable with therapy for many years (Feinberg, 1996). However, despite these advancements, knowledge of the long-term benefits of HAART on HIV disease progression is still not known, and HIV disease must still be considered an eventually fatal illness. Persons with HIV disease continue to experience morbidity that may affect the progression of their disease and/or diminish their quality of life. In addition, development of opportunistic disease is associated with a risk of mortality independent of CD4+ count (Chaisson, Gallant, Keruly, & Moore, 1998). Therefore, efforts to reduce morbid episodes through a "wellness" or a health-promoting self-care approach to living with HIV should be recommended throughout the course of the disease.

PROMOTING WELLNESS IN PERSONS WITH HIV INFECTION

141

HIV DISEASE AS CHRONIC ILLNESS AND HEALTH PROMOTION Chronic illness as defined in Donnelly (1993, p. 3) is "a condition not cured by medical intervention and requiring periodic monitoring and supportive care to reduce the degree of illness and to maximize the person's functioning and responsibility for self-care." Bennett (1988) defined chronic disease as one with silent pathology progression and variable asymptomatic periods, as well as a lack of symptoms not reflecting the severity of pathology. Based on these definitions. HIV disease could be considered a chronic illness. Health can be measured by an individual's "sense of well-being," resulting from "reducing unnecessary suffering, illness and disability" and "an improved quality of life" (U.S. Department of Health and Human Services [HHS], 1992, p. 6). Therefore, if health and illness are defined as two interrelated but distinct concepts, it is reasonable to consider health maintenance and health promotion for individuals who are living with HIV disease (Irish, 1989). Health promotion activities are "efforts to enhance positive health and prevent ill-health, through the overlapping spheres of health education, prevention, and health protection" (Downie, Fife, & Tannahill, 1990, p. 59). By utilizing social and personal resources individuals develop skills to effect change in their lives. Persons must be "empowered to define, seek, and find conditions, resources and processes to be an effective agent in meeting the significant needs" (Jones & Meleis, 1993, p. 12). Cognitive perceptions of health, personal characteristics (who they are), coping responses (what they do in certain situations), and availability of resources (personal and social) directly influence individuals' health promotion behaviors, health care seeking, and acceptance of health interventions (Jones & Meleis, 1993). Persons living with HIV experience physical and psychosocial manifestations associated with their disease. Issues including alterations in self-concept, social support, self-efficacy, coping mechanisms, hope, uncertainty, symptom distress, and access to resources mav all be related to participation in health-promoting behaviors. Persons with HIV disease should be encouraged to adopt practices minimizing the effects of "cofactors" that may, although unproven, enhance the progression to clinical disease (Bartlett 8c Finkbeiner,

142

THE PERSON WITH HIV/AIDS

1993; Lang, 1993). These purported cofactors include malnutrition, repeated exposure to HIV or other pathogens through exposureprone sexual practices or injecting drug use, chronic infections, stress, and recreational drug and alcohol use (Flaskerud, 1992). Participation in health-promoting self-care activities are recommended for persons living with HIV disease (Bartlett & Finkbeiner, 1993; Maclntyre, Holzemer, & Philippek, 1997). These activities include regular medical care and adherence to recommended therapy, proper nutrition, exercise, adequate rest, smoking and other recreational drug cessation, stress management, sobriety, and safer sexual practices (Bartlett & Finkbeiner, 1993; Flaskerud, 1992; Irish, 1989; Jewett & Hecht, 1993; Lang, 1993; Maclntyre & Holzemer, 1997). Persons with HIV disease may not extend their lives by practicing health promoting self-care. No proven cause-and-effect relationship exists between health-promoting self-care activities and prolonged life with HIV infection. It has been suggested, however, that these strategies pose few risks and may restore a measure of self-control for persons infected with HIV (Lang, 1993). These interventions may improve an HIV-infected person's quality of life by enhancing overall health and immunity, thus reducing the risk of opportunistic disease or minimizing the effects of illness when they occur (Jewett & Hecht, 1993). Adopting a wellness approach to HIV disease, in conjunction with appropriate medical management, may have an effect on the morbidity experienced by these persons. Fries (1983, 1988, 1989a, 1989b) described a "compression of morbidity hypothesis," stating: If the morbid period may be defined as that period from the onset of chronic infirmity until death, and if the time of occurrence of such morbid events can be postponed, and if life expectancy is relatively constant, then morbidity will be compressed into a shorter period of time. (1989a, p. 208)

Compressing morbidity may enhance a person's quality of life by reducing the number of morbid episodes experienced before death. Fries (1989b) envisioned that health promotion interventions offer the dividend of reduction in the population illness burden on society. Health promotion strategies may also reduce medical utilization and thus expenditures. Health promotion interventions for persons with HIV disease attempt to aid in the reduction of illness episodes, thereby potentially reducing health service utilization, as well as

PROMOTING WELLNESS IN PERSONS WITH HIV INFECTION

143

enhancing the quality, although not necessarily the quantity, of their lives. Participation in certain self-care behaviors (i.e., safer sexual practices) may also reduce the transmission of HIV to uninfected persons. Self-care behaviors may also include use of alternative (or complementary) therapies such as vitamin supplements, traditional Chinese herbs, and massage, even though the benefits of some of these treatments remain unproven (Freeman 8c Maclntyre, 1999). COFACTORS OF HIV DISEASE As stated previously, persons with HIV disease should be encouraged to adopt practices minimizing the effects of "cofactors" that may, although unproven, enhance the progression to clinical disease (Bartlett & Finkbeiner, 1993). The effects of specific behaviors, including nutrition, exercise, smoking, alcohol use, and unsafe sexual behavior, on HFV disease have been examined in the literature. Nutrition Nutrition has an influence on susceptibility to infection and immune response (Gorman, 1993). Infection with HIV may affect an individual's metabolism by increasing resting energy expenditure and caloric requirements. This impact reportedly often begins in the early, asymptomatic stages of HIV disease (Grunfeld et al., 1992; Hommes, Romijn, Endert, & Sauerwein, 1991; Niyongabo et al., 1997). Malnutrition often significantly contributes to HIV morbidity and mortality (Babameto & Kotler, 1997), occurs frequently, and has been shown to predict patient survival independent of CD4+ count (Ott et al., 1995; Suttman et al., 1995). A loss of just 10% of baseline weight in the year prior to developing AIDS may result in reduced survival (Palenicek et al., 1995). HIV-related wasting (Chlebowski, Grosvenor, & Lillington, 1995) and low serum albumin levels (Guenter, Muurahainen, & Simons, 1993) have been shown to be more significantly related to mortality than CD4+ count. Specific micronutrient deficiencies, such as vitamins A, E, and B12, may accelerate progression to AIDS (Liang, Chung, Araghiniknam, Lane, & Watson, 1996; Tang, Graham, Chandra, 8c Saah, 1997). Higher dietary nutrient

144

THE PERSON WITH HIV/AIDS

intake may be related to higher CD4+ T lymphocytes, which is inversely related to AIDS risk even when adjusted for health status (low CD4+ counts and symptoms) at baseline (Abrams, Duncan, & Hertz-Picciotto, 1993). Persons with HIV disease should be assessed thoroughly, including medical and diet history, physical assessment with anthropometric measures, and laboratory studies, to fully understand their nutritional status (Casey, 1997; Walsek, Zafonte, & Bowers, 1997). Effective dietary counseling leading to increased nutrient intake may improve quality of life, reduce the incidence of nutritional deficiencies, and aid in maintaining satisfactory weight during hypermetabolic states (Dowling, Mulcahy, & Gibney, 1990). Nutritional assessment and counseling should start early and continue throughout the course of HIV disease to detect early signs of malnutrition. Nutritional counseling should include information on healthy eating principles (what nutrients are important and frequency of eating), a healthy eating plan (what and how much to eat), managing nutrition-related symptoms (dealing with poor appetite, nausea, vomiting, diarrhea, stomatitis), foodborne disease prevention (storage, preparation, dining out), and alternate nutritional methods when necessary (nutritional supplements, enteral or parental support) (American Dietetic Association/Canadian Dietetic Association, 1997; Casey, 1997; Walsek et al., 1997). Early intervention to limit nutritional deficiencies may improve survival and quality of life in persons with HIV (Niyongabo et al., 1997).

Smoking Suggestions that cigarette smoking may alter immune response or modify host response to HIV infection have led to scientific studies yielding conflicting results. Cigarette smoking has been reported as increasingly prevalent in HlV-infected gay men and possibly associated with high-risk sexual behavior (Burns et al., 1991; Penkower et al., 1991; Royce & Winkelstein, 1990). Most early studies examining the effect of cigarette smoking on lymphocyte profiles in HIV-infected persons determined no direct correlation between cigarette smoking and a fall in CD4+ lymphocytes or progression of HIV

PROMOTING WELLNESS IN PERSONS WITH HIV INFECTION

145

disease (Burns et al., 1991; Park et al, 1992; Royce 8c Winkelstein, 1990). Nieman, Fleming, Coker, Harris, and Mitchell (1993) challenged these findings. Their study consisted of a retrospective, case series analysis of HIV-seropositive persons without an AIDS diagnosis whom the researchers initially saw for an asymptomatic respiratory assessment but then subsequently developed AIDS. The study concluded that progression to AIDS and the incidence of Pneumocystis carinii pneumonia was significantly related to smoking habit. These findings may have been due to the detrimental effect of smoking on the local pulmonary defense rather than on systemic immunocompromise. Unfortunately, this study has been criticized for its lack of betweengroup control for individuals' CD4+ count and duration of HIV infection upon entry to the study (Park, Margolick, & Munoz, 1993). More recent findings concur with earlier findings in revealing no correlation between cigarette smoking and HIV disease progression (Conley et al., 1996; Galai et al., 1997). Despite conflicting arguments surrounding cigarette smoking and progression of HIV disease, agreement does exist regarding the detrimental effect of cigarette smoking on a person's health. Cigarette smoking reduces the number of alveolar macrophages necessary for initiating cellular immune response against invading pathogens in the lung (Twigg, Soliman, & Spain, 1994). Cigarette smoking is associated with the incidence of malignancies and increased respirator)' tract bacterial infections, including influenza and varicella pneumonia (Burnsetal., 1991). In persons with HIV disease, smoking cigarettes may lead to an increased risk of oral lesions (including mucosal ulceration, oral candidiasis, and hairy leukoplakia) and bacterial pneumonia (Burns et al., 1996; Conley et al., 1996; Galai et al., 1997; Palacio, Hilton, Canchola, & Greenspan, 1997; Palmer et al., 1996; Rogers, 1997; Tumbarello et al., 1998). Smoking cigarettes may also act as an exogenous factor stimulating the activitation of HIV in the local lung tissue, thereby having a direct negative impact on lung function (Rich, 1998). HIV-positive smokers have reduced carbon monoxide diffusing capacity than HIV-positive nonsmokers even when free of other HFV-related lung disease (McCabe et al., 1997). Women smokers may have five times the risk of developing human papilloma virus (HPV)-related genital warts compared to nonsmokers (Feldman, Chirgwin, Dehovitz, & Minkoff, 1997).

146

THE PERSON WITH HIV/AIDS

Presence of HPV-related genital warts may increase the risk of cervical carcinoma in HIV-infected women. Finally, cigarette smoking by HIV-infected pregnant women may result in an increased risk for perinatal HIV transmission (Burns et al., 1994; Turner, Hauck, Fanning, & Markson, 1997). Based on these findings, efforts to assist persons with HIV disease in smoking cessation behavior change are warranted.

Alcohol Similar to smoking, alcohol use and its resultant effect on HIV progression is unclear. Overall, heavy alcohol consumption has been associated with altered lymphocyte production and function (Dunne, 1989). Moderate to heavy alcohol use has been reported to suppress cellular immune function and response. Skin testing in a homogeneous sample of moderate to heavy drinkers revealed depressed response to seven delayed hypersensitivity antigens. This depression was noted to be reversible within 8 to 10 weeks of abstinence from alcohol (Tonnesen, Kaiser, Nielsen, & Pedersen, 1992). Alcohol intake has been shown to have an impact on immune functioning in general population samples and has been duplicated in persons known to be infected with HIV (Avins et al., 1994; Bagasra et al., 1996; Fong, Read, Wainberg, Chia, & Major, 1994). More recent evidence shows that chronic alcohol consumption leads to a significant decrease in CD4+ count (Pol, Artru, Thepot, Berthelot, & Nalpas, 1996) and increased viral replication (Bagasra et al., 1996) in persons with HIV disease. Decreases in CD4+ count were reversible with alcohol cessation (Pol et al., 1996). Despite this evidence, the role of alcohol consumption in HIV disease progression continues to be disputed (Dingle Be Oei, 1997). There may be a relationship between alcohol consumption and sexual practice. Using alcohol may make an individual more susceptible to unsafe sexual practices (Bagasara et al., 1996; Boscarino et al., 1995; Clark, Kissinger, Bedimo, Dunn, & Albertin, 1997; Dermen, Cooper, & Agocha, 1998; Malow, McMahon, Cremer, Lewis, & Alferi, 1997; Seage et al., 1998; Shillington, Cottier, Compton, & Spitznagel, 1995; Woods et al., 1996); however, this assertion has been refuted (McManus & Weatherburn, 1994). Messiah, Bloch, and Blin (1998)

PROMOTING WELLNESS IN PERSONS WITH HFV INFECTION

147

reported that alcohol consumption may help identify individuals in at-risk situations but does not predict that these individuals will participate in unsafe sexual practices while using alcohol (see also chapter 3). Alcohol consumption can also complicate HIV disease management. Alcohol abuse may delay entry to primary care for some HIVinfected individuals (Samet et al., 1998). Alcohol may directly interact with certain antiretrovirals, leading to an increased risk of pancreatitis and liver dysfunction. Reducing alcohol consumption reduces the risk of these complications (Whitfield, Bechtel, & Starich, 1997). Other complications related to alcohol include nutritional deficiencies, enhanced malabsorption, gastritis, and esophagitis (McManus & Weatherburn, 1994). Exercise Exercise has a direct impact on immune responsiveness; however, this response is dependent on many factors including intensity, duration, and mode of exercise, body temperature, and hydration status (Eichner 8c Calabrese, 1994; Nieman, 1997). Although in many studies regular exercise has not been shown to significantly enhance or reduce CD4+ lymphocytes in persons living with HIV disease (LaPerriere etal., 1997; Nieman, 1997), in at least one study exercise was shown to increase concentrations of circulating CDS cells in persons with HIV (Phillips et al., 1997). Loss of muscle mass early in the progression of HIV disease may be a result of decreased physical activity (Evans, Roubenoff, & Shevitz, 1998). The physical benefits of regular exercise such as increased cardiopulmonary fitness, improved muscle function, and weight gain have been demonstrated in HIV-positive individuals. Physical exercise may improve mood states, reduce psychological stress, and increase active coping behaviors (LaPerriere et al., 1997). In addition, prescribed exercise regimens can significantly increase neuromuscular strength and cardiorespiratory fitness in persons with HIV disease, including symptomatic individuals, without negative effects on immune status (MacArthur, Levine, & Birk, 1993; Rigsby, Dishman, Jackson, Maclean, &: Raven, 1992; Stringer, Berezovskaya, O'Brien, Beck, & Casaburi, 1998). When combined with appropriate protein intake,

148

THE PERSON WITH HIV/AIDS

resistance exercise may increase energy intake, nitrogen balance, and functional capacity in persons with HIV/AIDS (Evans et al., 1998). Finally, all of the above mentioned benefits of physical exercise may have a dramatic effect on the feelings of negative body image, stress, anxiety, and depression many HIV-positive individuals experience. It should be noted, however, that HIV-seropositive individuals, without AIDS, have exhibited exercise dysfunction as demonstrated by exercising to a significantly lower workload and lower ventilatory anaerobic threshold when compared to an otherwise similar group of HFV-seronegative individuals (Johnson et al., 1990). In addition, persons with HIV disease with a history of bronchopulmonary complications exhibit reduced exercise capacity when compared to those without a history of such complications (Pothoff, Wasserman, & Ostmann, 1994). Sexual Behavior Informing sexual partners of one's seropositive status and practicing protective sexual behaviors are recommended and in some states mandated for persons with HIV disease. The benefits of these behaviors include both reducing transmission of HIV to others and reducing acquisition of virologically different HIV by those already infected. Encouraging clients to protect themselves from different strains of virion is increasingly important with recent evidence supporting sexual transmission of multidrug-resistant virus, including protease inhibitor (Hecht et al., 1998). Health providers are challenged to consider this evidence as not simply anecdotal but instead utilize it as an opportunity for education with their clients (Cohen & Fauci, 1998). Despite the recommendations, knowledge of HIV-seropositive status in conjunction with knowing the benefits of practicing risk-reduction behaviors may not lead to reductions in risky sexual behavior (DiScenza, Nies, & Jordan, 1996). Persons with HIV disease may not alter their sexual practices or may do so inconsistently (Posner & Marks, 1996). Forty percent of individuals receiving HIV care in an urban center asked about whether they had disclosed their HIV status to sexual partners reported they had not disclosed. More than half of these individuals

PROMOTING WELLNESS IN PERSONS WITH HIV INFECTION

149

also reported using condoms inconsistently. Participants with greater numbers of sexual partners disclosed less frequently (Stein et al., 1998). Changing sexual behavior presumably for one's lifetime is difficult. Unprotected sexual behavior may be related to sexual impulsivity, substance use, sexual enjoyment, communication difficulties, or low individual intentions to change risk behavior (Hays et al., 1997; Kalichman, Kelly, & Rompa, 1997). Sexual behavior is most often viewed as pleasurable, and changing this behavior may lead to feelings of loss of pleasure or desirability and obviously requires the ability to negotiate with others. Nursing interventions must assist individuals with HIV disease to acquire not only the information required to change sexual behavior but also the support and skills to do so (Cole, 1997). Encouraging clients to consistently disclose their HIV seropositivity and implement safer sex practices with sexual partners may require multiple intervention episodes in order to produce the desired outcome (DeRosa 8c Marks, 1998). (See also chapter 3.) HEALTH-PROMOTING BEHAVIOR AND PERSONS WITH HIV DISEASE While documentation exists on the effects of specific behaviors on HIV disease, there is continued debate regarding the effect of these behaviors on HIV disease progression. Despite differences in opinion and results of scientific study, persons infected with HIV should be encouraged to participate in a wellness-oriented approach to their disease (Maclntyre, Holzemer, & Philippek, 1997). It is possible to be well and to maintain a healthy approach to the disease experience (Ardell, 1984; Fender, 1987). A few studies have reported the adoption of health-promoting behaviors by HIV-infected persons. See Table 4.1 for a summary of the literature on this approach to living with HIV. Many persons living with HFV disease are working to promote or maintain their health through self-care behaviors. Self-care behaviors reported by people with HIV include focusing on proper nutrition, hygiene, stress reduction, nontraditional medicine, and symptom surveillance, reduction in alcohol consumption, and an increase in

TABLE 4.1

Living with HIV Disease: A Summary of Research on Health Promotion

Citation

Purpose

Sample

Design

Findings

Allan, 1990

Describe self-care activities used by HIV+ men

11 gay, HIV+ men

Qualitative, naturalistic

5 clusters of self-care: diet, exercise, stress reduce, lifestyle change, attitude adjust; accounted for most help-seeking, mainly health maintenance/ disease prevention; reduced uncertainty, increased control

Barroso, 1995

Describe self-care activities of long-term survivors of AIDS

14 men, 6 women with AIDS for at least 3 years

Qualitative, naturalistic

Self-care activities reported: discontinuing negative health habits, undertaking health-promoting activities, being responsible for one's health, decreasing stress

Carson, 1993

Determine behaviors related to hardiness among persons with HIV

100 persons, HIV+, ARC, AIDS

Comparative, descriptive

Increased hardiness related to increased perception of physical, emotional, spiritual health; > 50% of sample report health-promoting behaviors (HPB); increased HPB related to increased hardiness

Gloersen et al., 1993

Identify processes that enhanced AIDS patients states of well-being

16 PWAs (persons with AIDS)

Qualitative, grounded theory

Grimes & Cole, 1996

Examine factors contributing to life quality in persons with HIV disease

83 persons with HIV/AIDS

Descriptive

Self-help is influenced negatively by dependency and positively by enabling skill; enabling skill mediates negative effects of dependency on self-help

TABLE 4.1

(continued)

Citation

Purpose

Sample

Design

Findings

Kelly, 1991

Evaluate specific situational/social context factors and coping methods r/t sexual risk taking

470 gay men

Descriptive

Increased risk taking related to exclusive relation with partner, known HIV status, difficulty w/safe sex, younger age, less education, increased # partners; resisters coping related to self-guidance, fear/worry, benefits of safety/health

Kendall, 1996

Identify meaning of wellness in men with HIV/ AIDS

29 gay men

Qualitative, grounded theory

Need for intimacy and sense of community; feeling connected to others promoted sense of being well

Kendall et al., 1989

Identify factors enhancing well-being in persons with AIDS

3 men "doing well" with AIDS

Qualitative, naturalistic

"Doing well" themes: autonomy or mastery over disease, existential, spiritual journey toward understanding, self-acceptance, staying active and involved, positive thinking

Lovejoy & Moran, 1988

Describe select behaviors, beliefs, and info needs of gay/bisexual men with ARC/AIDS

30 gay/bisexual men w/ ARC/AIDS

Descriptive

Beliefs: sexual behavior hazardous, use sex to relieve tension, use unsafe sex under influence ETOH/drugs; HPB: used more often in recent years, stress reduce, nutrition, sleep, less ETOH, safer sex; info needs: immune building (continued)

TABLE 4.1

(continued)

Citation

Purpose

Sample

Design

Findings

Lovejoy, Moran, & Paul, 1988

Describe self-care behaviors and info needs of HIV+ men w/wo AIDS

178 gay/bisexual men, HIV+; self-selected convenience sampling

Descriptive

SC (self-care) = nutrition, hygiene, stress reduce, nontraditional medicine, surveillance; increased use of SC after diagnosis; most frequent: less drugs/stimulants; want ways to build immune/ health

Lovejoy, Morgenroth, Paul, Freeman, & Christianson, 1992

Describe potential predictors/patterns of info seeking after diagnosis w/ HIV; describe info seeking networks

60 HIV+ gay men attending outpatient clinic; self-selected convenience sampling

Descriptive

High use of 39/81 SC behaviors; info sources = friends, MD, media; use of SC before/after diagnosis + r/t info seeking; those performing before most likely to perform after

Lovejoy, Paul, Freeman, & Christianson, 1991

Identify patterns of selfcare/symptom distress; potential correlates of frequent use of self-care

162 gay/bisexual men receiving outpatient services

Descriptive

Increased frequency of self-care behaviors after diagnosis w/HIV; self-care related to use prior to HIV diagnosis, AIDS diagnosis, feeling "connected," feeling close to friends; self-care negatively related to lack of control

TABLE 4.1

(continued)

Citation

Purpose

Sample

Design

Findings

Siegel & Krauss, 1991

Identify challenges of living daily with HIV infection before AIDS and adaptive tasks

55 HIV+ gay men

Secondary analysis of qualitative study

3 challenges: dealing with shortened life span, reactions to stigmatizing illness, developing strategies to maintain health; adaptation: assume responsibility, influence course of infection, follow healthy lifestyle, maintain vigilance

Sowell et al., 1997

Describe self-care activities of women with HIV

27 women with HIV/AIDS from urban and rural settings

Qualitative

Seven categories of self-care identified: special dietary and nutrition practices, choosing not to use medically prescribed therapies, spiritual reliance and rituals, staying active, cognitive strategies, self-education, and healthy lifestyles

Valente, Saunders, & Uman, 1993

Examine relationships among perceived impact of HIV status, psychological distress, and changes in self-care

220 men, 20 women with known HIV or at risk for HIV

Comparative descriptive

Symptoms related to depression related to unhealthy behaviors; hopelessness related to unhealthy behaviors

154

THE PERSON WITH HIV/AIDS

the use of safer sexual practices (Allan, 1990; Lovejoy, Moran, & Paul, 1988; Lovejoy & Moran, 1988; Sowell et al., 1997). These persons, in particular gay men, also identified sexual behavior as a means of tension relief and confessed to a failure in safer sexual practices when under the influence of alcohol (Lovejoy & Moran, 1988). Health-promoting activities may be used to reduce uncertainty toward the future and/or to enhance a sense of control in one's life (Allan, 1990). Persons with HIV disease may believe they can affect the course of their disease by taking responsibility for their wellbeing (Siegel & Krauss, 1991), and such "self-help" may improve their quality of life (Grimes & Cole, 1996). Health-promoting and protective activities may enhance a sense of well-being among persons with HIV and provide them with the ability to further accept and positively face their illness by relating mind and body (Gloerson et al., 1993). Enhancing psychological well-being may reduce the risk of mortality associated with a depressive affect (Mayne, Vittinghoff, Chesney, Barrett, & Coates, 1996). Persons living with AIDS for more than 2 years have reported using health-promoting activities as a means by which they "reconstructured his or her own life within the context of HIV disease" (Barroso, 1995, p. 49) and actually contributed to why they thought they had survived longer than expected (Remien, Rabkin, & Williams, 1992). A wellness-oriented approach to living with HIV may lead to a sense of psychological and spiritual growth (Dunbar, Mueller, Medina, & Wolf, 1998). Some individuals with HIV believe their positive attitude and healthy approach to living with their disease is as influential on their lack of disease progression as biological factors or use of pharmaceutical therapy (Troop et al., 1997). These beliefs highlight the importance of developing partnerships with patients in their treatment plan in order to serve them in the most holistic manner possible. Approaching persons with HIV as individuals with their own set of beliefs and values will convey a sense of respect for their life experience, an experience that is truly their own and that the nurse cannot fully feel or understand. Unfortunately, individuals adopting this approach to living with their disease may encounter negative attitudes from traditional Western medicine health providers regarding the benefits of "complementary medicine." Some health providers have deemed such an approach as unproven and questionable regarding its benefit on HFV disease

PROMOTING WELLNESS IN PERSONS WITH HIV INFECTION

155

outcomes. These attitudes were in direct contrast to their patients' beliefs regarding their nonconventional treatment approaches (MacIntyre et al., 1997). Negative attitudes or a lack of understanding toward an individual's approach to his or her disease experience potentially broadens the gap of acceptance in the patient-provider relationship. PREDICTORS OF HEALTH-PROMOTING BEHAVIORS IN PERSONS WITH HIV INFECTION Less is known about what motivates persons with HIV disease to practice health-promoting behaviors. Simply knowing you are living with a serious illness does not necessarily lead to changing or adopting new behaviors. Health providers should not be naive to this fact. The factors influencing a wellness-oriented approach to living with HIV disease are often individualized, diverse and complex. Lovejoy and colleagues (1991) described the self-care behaviors and the relationship between self-care and symptom distress of homosexual/bisexual men. Their study examined patterns of symptom distress, mood states, individual characteristics, and their relationship to self-care. Previous participation in -self-care behaviors was reported as significantly related to continued participation in these behaviors after diagnosis with HIV. Other identified potential correlates to self-care included becoming aware of an AIDS diagnosis, feeling connected to the environment, and feeling close to friends. Increased frequency of certain self-care behaviors was related to being informed of an HIV-seropositive status. Behaviors that showed significant increases following an HIV diagnosis were stress reduction, information seeking, and symptom surveillance. However, certain positive health behaviors remained unchanged or decreased after learning of HIV status such as smoking cessation, refraining from going to bathhouses, reducing alcohol use, and exercise. Persons participating in positive health behaviors prior to their HIV diagnosis have been shown to continue these behaviors after learning their seropositive status (Lovejoy et al., 1992). Positive perceptions of hope and social support may influence a person with HIV to adopt health-promoting behaviors (Keller, 1995). Presence of HIV-related symptoms, feelings of depression, and a sense of

156

THE PERSON WITH HIV/AIDS

hopelessness may result in participation in unhealthy behaviors (Valente et al., 1993). Feelings of intimacy with others, a sense of community, and feeling connected to others in an era of uncertainty may influence feelings of well-being (Kendall, 1996). Such social interaction and relationships may offer a protective influence on health outcomes. Finally, providing health-promotion education sessions through structured wellness programs may result in positive behavior change (Gifford, Laurent, Gonzales, Chesney, & Lorig, 1998; RotheramBorus & Miller, 1998). Wellness programs have demonstrated increased self-efficacy and reduced health service utilization among participants (Watt, Verma, & Flynn, 1998). RECOMMENDATIONS FOR NURSING PRACTICE Persons are living longer with HIV infection than ever before. Encouraging these individuals to stay well and reduce their risk for morbid episodes is increasingly important. Although participation in positive self-care may not impact longevity in persons with HIV/ AIDS, it may enhance quality of life, reduce illness episodes (thus reducing health resource utilization), and reduce the transmission of HIV to others. Nurses must act as facilitators of their clients' realization of health potential. However, influencing behavior change is extremely complex. By understanding the factors influencing their clients' health behavior, nurses can develop health-promotion interventions based on identified antecedents to a specific health outcome. Health-promotion interventions must be appropriate and acceptable to those to whom the intervention is directed. By giving patients the opportunity to be active participants in their own care, nurses can help to foster a sense of personal responsibility in those patients. Nurses are challenged to enhance their knowledge of factors influencing participation in positive health behaviors by their clients in order to assist in the development of appropriate health-promotion interventions. Understanding who their clients are, what they do in certain situations, and the availability of their personal and social resources can assist nurses in serving clients "where they are." Simply instructing someone to "take care of yourself is usually insufficient

PROMOTING WELLNESS IN PERSONS WITH HIV INFECTION

157

in producing a desired outcome. Nurses must understand the array of factors influencing health behavior and direct health-promotion interventions toward those factors. Such understanding can lead to the development of interventions aimed at enhancing clients' beliefs and perceptions of living with HIV disease, which may empower them to take care of themselves. The challenge to nurses is to discern methods of fostering positive perceptions of living with HIV among their clients. Nursing interventions must focus on the factors influencing the decision to adopt strategies to promote, maintain, and restore health among persons with HIV disease. Serving clients in a holistic manner may help them to develop strategies that will facilitate integration of positive health behaviors into their daily lifestyle. Due to the increasing recognition of asymptomatic HIV infections as a result of widespread HIV testing and because persons are living longer with HIV disease, greater numbers of persons with HFVrelated disease are seeking health care. In an era of limited health care resources, care of persons with HIV disease must emphasize health maintenance, health enhancement, and prevention of hospitalization (Agency for Health Care Policy and Research, 1994). Individuals with HIV disease must be empowered to participate in healthpromoting self-care activities that may promote and enhance their health or quality of life. The challenge nurses face in facilitating this approach to living with HIV disease is enormous. Yet trying to empower clients to stay well is important not only from a resource standpoint but also from the hope that one day there will be successful development of longevity-producing treatments or even a cure and that they will live to reap the benefits. REFERENCES Abrams, B., Duncan, D., & Hertz-Picciotto, I. (1993). A prospective study of dietary intake and acquired immune deficiency syndrome in HlV-seropositive men. Journal of Acquired Immune Deficiency Syndromes, 6, 949-958. Agency for Health Care Policy and Research. (1994). Evaluation and Management of Early HW Infection. U.S. Department of Health and Human Services, Publication No. 94-0572. Allan, J. (1990). Focusing on living, not dying: A naturalistic study of self-care among seropositive gay men. Holistic Nursing Practice, 4, 56-63.

158

THE PERSON WITH HIV/AIDS

American Dietetic Association/Canadian Dietetic Association. (1997). Nutrition intervention in the care of persons with HIV infection. HIV Hotline, 7, 7-10. Ardell, D. (1984). High level wellness. New York: Bantam. Avins, A., Woods, W., Lindan, C., Hudes, E., Clark, W., & Hulley, S. (1994). HIV infection and risk behaviors among heterosexuals in alcohol treatment programs. Journal of the American Medical Association, 7, 515-518. Babameto, G., & Kotler, D. (1997). Malnutrition in HIV infection. Gastroenterology Clinics of North America, 26, 393-415. Bagasra, O., Bachman, S., Jew, L., Tawadros, R., Cater, J., Boden, G., Ryan, I., & Pomerantz, R. (1996). Increased human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells induced by ethanol: Potential immunopathogenic mechanisms. Journal of Infectious Diseases, 173, 550-558. Barre-Sinoussi, F. (1996). HIV as the cause of AIDS. The Lancet, 348, 31-35. Barroso, J. (1995). Self-care activities of long-term survivors of acquired immunodeficiency syndrome. Holistic Nursing Practice, 10, 44-53. Bartlett.J., & Finkbeiner, A. (1993). The guide to living with HIV infection. Baltimore: Johns Hopkins University. Bennett, J. (1988). Helping people with AIDS live well at home. Nursing Clinics of North America, 23, 731-748. Boscarino, J., Avins, A., Woods, W., Lindan, C., Hudes, E., & Clark, W. (1995). Alcohol related risk factors associated with HIV infection among patients entering alcohol treatment: Implications for treatment. Journal of Studies on Alcohol, 56, 642-653. Burns, D., Hillman, D., Neaton, J., Sherer, R., Mitchell, T., Capps, L., Vallier, W., Thurnerr, M., & Gordin, F. (1996). Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 13, 374-383. Burns, D., Kramer, A., Yellin, F., Fuchs, D., Wachter, H., DiGioia, R., Sanchez, W., Grossman, R., Gordin, F., Biggar, R., & Goedert, J. (1991). Cigarette smoking: A modifier of human immunodeficiency virus type 1 infection? Journal of Acquired Immune Deficiency Syndromes, 4, 76-83. Burns, D., Landesman, S., Muenz, L., Nugent, R., Goedert, J., Minkoff, H., Walsh, J., Mendez, H., Rubinstein, A., & Willoughby, A. (1994). Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4 levels. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 7, 718-726. Carson, V. (1993). Prayer, meditation, exercise, and special diets: Behaviors of the hardy person with HIV/AIDS. Journal of the Association of Nurses in AIDS Care, 4, 18-28. Casey, K. (1997). Malnutrition associated with HIV/AIDS: 2. Assessment and intervention. Journal of the Association of Nurses in AIDS Care, 8, 39-48. Chaisson, R., Gallant, J., Keruly, J., & Moore, R. (1998). Impact of opportunistic disease on survival in patients with HIV infection. AIDS, 12, 29-33. Chlebowski, R., Grosvenor, M., & Lillington, L. (1995). Dietary intake and counseling, weight maintenance, and the course of HIV infection. Journal of the American Dietetic Association, 95, 428-435.

PROMOTING WELLNESS IN PERSONS WITH HIV INFECTION

159

Clark, R., Kissinger, P., Bedimo, A., Dunn, P., & Albertin, H. (1997). Determination of factors associated with condom use among women infected with human immunodeficiency virus. International Journal ofSTD & AIDS, 8, 229-233. Cohen, O., & Fauci, A. (1998). Transmission of multidrug-resistant human immunodeficiency virus—The wake up call. New England Journal of Medicine, 339, 341-343. Cole, F. (1997). The role of self-esteem in safer sexual practices. Journal of the Association oj Nurses in AIDS Care, 8, 64-70. Conley, L., Bush, T., Buchbinder, S., Penley, K.,Judson, F., & Holmberg, S. (1996). The association between cigarette smoking and selected HIV-related medical conditions. AIDS, 10, 1121-1126. Gorman, L. C. (1993). The role of nutrition in sickness and in health. Medical Clinics of North America, 77, 711-724. Darby, S. C., Ewart, D. W., Giangrande, P. L., Spooner, R., & Rizza, C. (1996). Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. The Lancet, 347, 1573-1579. Dermen, K., Cooper, M., & Agocha, V. (1998). Sex-related expectancies as moderators of the relationship between alcohol use and risky sex in adolescents. Journal of Studies on Alcohol, 59, 71-77. DeRosa, C. J., & Marks, G. (1998). Preventive counseling of HIV-positive men and self-disclosure of serostatus to sex partners: New opportunities for prevention. Health Psychology, 17, 224-231. Dingle, G., & Oei, T. (1997). Is alcohol a cofactor of HIV and AIDS? Evidence from immunological and behavioral studies. Psychological Bulletin, 122, 56-71. DiScenza, S., Nies, M., & Jordan, C. (1996). Effectiveness of counseling in the health promotion of HIV-positive clients in the community. Public Health Nursing, 13, 209-216 Donnelly, G. (1993). Chronicity: Concept and reality. Holistic Nursing Practice, 8, 1-7. Dowling, S., Mulcahy, F., & Gibney, M. (1990). Nutrition in the management of HIV antibody positive patients: A longitudinal study of dietetic outpatient advice. European Journal of Clinical Nutrition, 44, 823-829. Downie, R., Fife, C., & Tannahill, A. (1990). Health promotion: Models and values. Oxford: Oxford University Press. Dunbar, H., Mueller, C., Medina, C., & Wolf, T. (1998). Psychological and spiritual growth in women living with HIV. Social Work, 43, 144-154. Dunne, F. (1989). Alcohol and the immune system. British Medical Journal, 298, 543544. Eichner, E. R., 8c Calabrese, L. (1994). Immunology and exercise: Physiology, pathophysiology, and implications for HIV infection. Medical Clinics of North America, 78, 377-388. Evans, W.,Roubenoff, R., &Shevitz, A. (1998). Exercise and the treatment of wasting: Aging and human immunodeficiency virus infection. Seminars in Oncology, 25, 112-122. Fauci, A., & Rosenberg, Z. (1994). Immunopathogenesis. InS. Broder.T. Merigan, & D. Bolognesis (Eds.), Textbook of AIDS medicine (pp. 55-75). Baltimore: Williams 8c Wilkins.

160

THE PERSON WITH HIV/AIDS

Feinberg, M. B. (1996). Changing the natural history of HIV disease. The Lancet, 348, 239-246. Feldman, J., Chirgwin, K., Dehovitz, J., & Minkoff, H. (1997). The association of smoking and risk of condyloma acuminatum in women. Obstetrics and Gynecology, 89, 346-350. Flaskerud, J. H. (1992). HIV disease and levels of prevention. Journal of Community Health Nursing, 9, 137-150. Fong, I., Read, S., Wainberg, M., Chia, W., & Major, C. (1994). Alcoholism and rapid progression to AIDS after seroconversion. Clinical Infectious Disease, 19, 337-338. Freeman, E., & Maclntyre, R. (1999). Evaluating alternative treatments for HIV infection. Nursing Clinics of North America, 34(1), 147-162. Fries, J. F. (1983). The compression of morbidity. Milbank Memorial Fund Quarterly, 61, 397-419. . (1988). Aging, illness, and health policy: Implications of the compression of morbidity. Perspectives in Biology and Medicine, 31, 407-428. . (1989a). The compression of morbidity: Near or far? The Milbank Quarterly, 67, 208-231. . (1989b). Health promotion and the compression of morbidity. The Lancet, 1, 481-483. Galai, N., Park, L., Wesch.J., Visscher, B., Riddler, S., & Margolick.J. (1997). Effect of smoking on the clinical progression of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 14, 451-458. Gifford, A., Laurent, D., Gonzales, V., Chesney, M., &Lorig, K. (1998). Pilot randomized trial of education to improve self-management skills of men with symptomatic HIV/AIDS. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18, 136-144. Glaser, R., Rabin, B., Chesney, M., Cohen, S., & Natelson, B. (1999). Stress-induced immunomodulation./oimza/ of the American Medical Association, 281, 2268-2270. Gloersen, B., Kendall, J., Gray, P., McConnell, S., Turner, J., & Lewkowicz.J. (1993). The phenomena of doing well in people with AIDS. Western Journal of Nursing Research, 15, 44-58. Grimes, D., 8c Cole, F. (1996). Self-help and life quality in persons with HIV disease. AIDS Care, 8, 691-699. Grunfeld, C., Pang, M., Shimizu, L., Shigenaga,J.Jensen, P., & Feingold, K. (1992). Resting energy expenditure, caloric intake and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. American Journal of Clinical Nutrition, 55, 455-460. Guenter, P., Muurahainen, N., & Simons, G. (1993). Relationships among nutritional status, disease progression and survival in HIV infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 6, 1130-1138. Hays, R., Paul, J., Ekstand, M., Kegeles, S., Stall, R., & Coates, T. (1997). Actual versus perceived HIV status, sexual behaviors and predictors of unprotected sex among young gay and bisexual men who identify as HIV-negative, HIV-positive, and untested. AIDS, 11, 1495-1502. Hecht, F., Grant, R., Petropoulos, C., Dillon, B., Chesney, M., Tian, H., Hellman, N., Bandrapalli, M., Digilio, L., Branson, B., &Kahn,J. (1998). Sexual transmission of

PROMOTING WELLNESS IN PERSONS WITH HIV INFECTION

161

an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. Nein England Journal of Medicine, 339, 307-311. Ho, D., Neumann, A., Pereison, A., Chen, W., Leonard, J., & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 373, 123-126. Hommes, M., Romijn, ]., Endert, E., & Sauerwein, H. (1991). Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage. Ammcan Journal of Clinical Nutrition, 54, 311-315. Irish, A. (1989). Maintaining health in persons with HIV infection. Seminars in Oncology Nursing, 5, 302-307. Jewett, J., & Hecht, F. (1993). Preventive health care for adults with HIV infection. Journal of the American Medical Association, 269, 1144—1153. Johnson,}., Anders, G., Blanton, H., Hawkes, C., Bush, B., McAllister, C., & Matthews, ]. (1990). Exercise dysfunction in patients seropositive for the human immunodeficiency virus. American Review of Respiratory Disease, 141, 618-622. Jones, P., & Meleis, A. (1993). Health is empowerment. Advances in Nursing Science, 75, 1-14. Kalichman, S., Kelly, J., & Rompa, D. (1997). Continued high-risk sex among HIV seropositive gay and bisexual men seeking HIV prevention sendees. Health Psychology, 16, 369-373. Kaslow, R. A., Carrington, M., Apple, R., Park, L., Munoz, A., Saah, A., Goedert, J., Winkler, C., O'Brien, S., Rinaldo, C., Betels, R., Blattner, W., Phair, J., Erlich, H., & Mann, D. (1996). Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Medicine, 4,405-411. Keller, S. (1995). Predictors of self-care activities among persons with HIV infection. Unpublished thesis, Indiana University. Kelly, ]., Kalichman, S., Kauth, M., Kilgore, H., Hood, H., Campos, P., Rao, S., Brasfield, T., & St. Lawrence, J. (1991). Situational factors associated with AIDS risk behavior lapses and coping strategies used by gay men who successfully avoid lapses. American Journal of Public Health, 81, 1335-1338. Kendall, J. (1994). Wellness spirituality in homosexual men with HIV infection. Journal o/ the Association of Nurses in AIDS Care, 5, 28-34. . (1996). Human association as a factor influencing wellness in homosexual men with human immunodeficiency virus disease. Applied. Nursing Research, 9, 195-203. Kendall,]., Gloersen, B., Gray, P., McConnell, S., Turner, J., & West, J. (1989). Doing well with AIDS: Three case illustrations. Archives of Psychiatric Nursing, 3, 159-165. Lang, C. (1993). Positive steps. Nursing Times, 89, 54-56. LaPerriere, A., Klimas, N., Fletcher, M., Perry, A., Ironson, G., Perna, F., & Schneiderman, N. (1997). Change in CD4 cell enumeration following aerobic exercise training in HIV-1 disease: Possible mechanisms and practical applications. International Journal of Sports Medicine, 18, S56-S61. Liang, B., ("hung, S., Araghiniknam, M., Lane, L., & Watson, R. (1996). Vitamins and immunomodulation in AIDS. Nutrition, 12, 1-7.

162

THE PERSON WITH HIV/AIDS

Lovejoy, N., & Moran, T. (1988). Selected AIDS beliefs, behaviors and informational needs of homosexual/bisexual men with AIDS or ARC. International Journal of Nursing Studies, 25, 207-216. Lovejoy, N., Moran, T., & Paul, S. (1988). Self-care behaviors and informational needs of seropositive homosexual/bisexual men. Journal of Acquired Immune Deficiency Syndromes, 1, 155-161. Lovejoy, N., Morgenroth, B., Paul, S., Freeman, E., & Christiansen, B. (1992). Potential predictors of information seeking behavior by homosexual/bisexual (gay) men with a human immunodeficiency virus seropositive health status. Cancer Nursing, 15, 116-124. Lovejoy, N., Paul, S., Freeman, E., & Christiansen, B. (1991). Potential correlates of self-care and symptom distress in homosexual/bisexual men who are HIV seropositive. Oncology Nursing Forum, 18, 1175-1185. MacArthur, R., Levine, S., & Birk, T. (1993). Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. Medicine and Science in Sports and Exercise, 25, 684-688. Maclntyre, R., & Holzemer, W. (1997). Complementary and alternative medicine and HIV/AIDS: 2. Selected literature review. Journal of the Association oj Nurses in AIDS Care, 5(2), 25-38. Maclntyre, R., Holzemer, W., & Philippek, M. (1997). Complementary and alternative medicine and HIV/AIDS: 1. Issues and context. Journal of the Association of Nurses in AIDS Care, 8 ( 1 ) , 23-31. Malow, R., McMahon, R., Cremer, D., Lewis, J., & Alferi, S. (1997). Alcohol and drug abuse. Psychosocial predictors of HIV risk among adolescent offenders who abuse drugs. Psychiatric Services, 48, 185-187. Mayne, T., Vittinghoff, E., Chesney, M., Barrett, D., & Coates, T. (1996). Depressive affect and survival among gay and bisexual men infected with HIV. Archives of Internal Medicine, 156, 2233-2238. McCabe, R., Baron, J., Griffin, R., Omogbehin, M., Snashall, P., & Seed, W. (1997). Effects of smoking and clinical status on lung function in human immunodeficiency virus (HIV)-seropositive subjects. Respiratory Medicine, 91, 221-229. McManus, T., & Weatherburn, P. (1994). Alcohol, AIDS, and immunity. British Medical Bulletin, 50, 115-123. Messiah, A., Bloch, J., & Blin, P. (1998). Alcohol or drug use and compliance with safer sex guidelines for STD/HFV infection. Results from the French National Survey on Sexual Behavior among heterosexuals. Sexually Transmitted Diseases, 25, 119-124. Nieman, D. (1997). Exercise immunology: Practical applications. International Journal of Sports Medicine, 18, S91-S100. Nieman, R., Fleming,]., Coker, R., Harris, W., & Mitchell, D. (1993). The effect of cigarette smoking on the development of AIDS in HIV-1 seropositive individuals. AIDS, 7, 705-710. Niyongabo, T., Bouchard, O., Henzel, D., Melchior,J., Samb, B., Dazza, M., Ruggeri, C., Begue, J., Couland, J., & Larouze, B. (1997). Nutritional status of HFVseropositive subjects in an AIDS clinic in Paris. European Journal of Clinical Nutrition, 51, 637-640.

PROMOTING WELLNESS IN PERSONS WITH HIV INFECTION

163

Ott, M, Fischer, H., Polat, H., Helm, E., Frenz, M., Caspary, W., & Lembcke, B. (1995). Bioelectrical impedence analysis as a predictor of survival in patients with human immunodeficiency virus infection. Journal of Acquired Immune Deficiency Syndromes and, Human Retrovirology, 9, 20-25. Palacio, H., Hilton, J., Canchola, A., & Greenspan, D. (1997). Effect of cigarette smoking on HIV-related oral lesions. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 14, 338-342. Palenicek, J., Graham, N., He, Y., Hoover, D., Oisha, J., Kingsley, L., & Saah, A. (1995). Weight loss prior to clinical AIDS as a predictor of survival. Multicenter AIDS Cohort Study Investigators. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 10, 366-373. Palmer, G., Robinson, P., Challacombe, S., Birnbaum, W., Croser, D., Erridge, P., Hodgson, T., Lewis, D., McLaren, A., & Zakrzewska,J. (1996). Aetiological factors for oral manifestations of HIV. Oral Diseases, 2, 193-197. Pantaleo, G., & Fauci, A. (1997). Introduction: Recent advances in the pathogenesis of human immunodeficiency virus infection. Springer Seminars inlmmunopathology, 18, 253-256. Park, L., Margolick, J., Giorgi, J., Ferbas, J., Bauer, K., Kaslow, R., Munoz, A., & the Multicenter AIDS Gohort Study. (1992). Influence of HIV-1 infection and cigarette smoking on leukocyte profiles in homosexual men. Journal of Acquired Immune Deficiency Syndromes, 5, 1124-1130. Park, L., Margolick, J., & Munoz, A. (1993). Cigarette smoking, leukocyte profiles, and HFV-1 progression. Journal of Acquired Immune Deficiency Syndromes, 6, 11751176. Fender, N. J. (1987). Health promotion in nursing practice (2nd ed.). Norwalk, CT: Appleton & Lange. Penkower, L., Dew, M., Kingsley, L., Becker, J., Satz, P., Schaerf, F., & Sheridan, K. (1991). Behavioral, health, and psychosocial factors and risk for HIV infection among sexually active homosexual men: The Multicenter AIDS Cohort Study. American Journal of Public Health, 81, 194-196. Phillips, E., Ottaway, C., Freedman, J., Kardish, M., Li, J., Singer, W., & Fong, I. (1997). The effect of exercise on lymphocyte redistribution and leucocyte function in asymptomatic HIV-infected individuals. Brain, Behavior, and Immunity, 11, 217-227. Pol, S., Artru, P., Thepot, V, Berthelot, P., & Nalpas, B. (1996). Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients. AIDS, 10, 1293-1294. Posner, S., & Marks, G. (1996). Prevalence of high-risk sex among HFy positive gay and bisexual men: A longitudinal analysis. American Journal of Preventive Medicine,

12, 472-477. Pothoff, G., Wasserman, K., & Ostmann, H. (1994). Impairment of exercise capacity in various groups of HIV-infected patients. Respiration, 61, 80-85. Remien, R., Rabkin, J., & Williams, J. (1992). Coping strategies and health beliefs of AIDS long-term survivors. Psychology and Health, 6, 335-345. Rich, E. (1998). Activation-inactivation of HIV-1 in the \\ing.JournalofBiomedical Science, 5, 1-10.

164

THE PERSON WITH HIV/AIDS

Rigsby, L., Dishman, R., Jackson, A., Maclean, G., & Raven, P. (1992). Effects of exercise training on men seropositive for the human immunodeficiency virus1. Medicine and Science in Sports and Exercise, 24, 6-12. Rogers, R. (1997). Recurrent aphthous stomatitis: Clinical characteristics and associated systemic disorders. Seminars in Cutaneous Medicine and Surgery, 16, 278-283. Rotheram-Borus, M., & Miller, S. (1998). Secondary prevention for youths living with HIV. AIDS Care, 10, 17-34. Royce, R., & Winkelstein, W. (1990). HIV infection, cigarette smoking and CD4 Tlymphocyte counts: Preliminary results from the San Francisco Men's Health Study. AIDS, 4, 327-333. Samet, J., Freedberg, K., Stein, M., Lewis, R., Savetsky, J., Sullivan, L., Levenson, S., & Hingson, R. (1998). Trillion virion delay: Time from testing positive for HFV to presentation for primary care. Archives of Internal Medicine, 158, 734-740. Seage, G., Mayer, K., Wold, C., Lenderking, W., Goldstein, R., Cai, B., Gross, M., Heeren, T., & Hingson, R. (1998). The social context of drinking, drug use, and unsafe sex in the Boston Young Men Study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 17, 368-375. Shillington, A., Cottier, L., Compton, W., & Spitznagel, E. (1995). Is there a relationship between heavy drinking and HIV high risk sexual behaviors among general population subjects? International Journal of the Addictions, 30, 1453-1478. Siegel, K., & Krauss, B. (1991). Living with HIV infection: Adaptive tasks of seropositive gay men. Journal of Health and Social Behavior, 32, 17-32. Sowell, R., Moneyham, L., Guillory, J., Seals, B., Cohen, L., & Demi, A. (1997). Selfcare activities of women infected with human immunodeficiency virus. Holistic Nursing Practice, 11, 18-26. Stanley, S. K., Ostrowski, M. A., Justement, J. S., Gantt, K., Hedayati, S., Mannix, M., Roche, K., Swartzentruber, D., Fox, C., & Fauci, A. (1996). Effect of immunization with a common recall antigen in viral expression in patients infected with human immunodeficiency virus type I. New England Journal of Medicine, 334,12221230. Staprans, S. I., Hamilton, B. L., Foolansbee, S. E., Elbeik, T., Barbosa, P., Grant, R., & Feinberg, M. (1995). Activation of virus replication after vaccination of HIV-1 infected individuals. Journal ofExperimental Medicine, 182, 1727-1737. Stein, M., Freedburg, K., Sullivan, L., Savetsky, J., Levenson, S., Hingson, R., & Samet, J. (1998). Sexual ethics. Disclosure of HIV-positive status to partners. Archives of Internal Medicine, 158, 253-257. Stringer, W., Berezovskaya, M., O'Brien, W., Beck, C., & Casaburi, R. (1998). The effect of exercise training on aerobic fitness, immune indices, and quality of life in HFV+ patients. Medicine and Science in Sports and Exercise, 30, 11-16. Suttman, U., Ockenga, J., Selberg, O., Hoogestraat, L., Deicher, H., & Muller, M. (1995). Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients./owraa/ of Acquired Immune Deficiency Syndromes and Human Retrovirology, 8, 239-246. Tang, A., Graham, N., Chandra, R., & Saah, A. (1997). Low serum vitamin B-12 concentrations are associated with faster human immunodeficiency virus type 1 (HIV-l) disease progression. Journal of Nutrition, 127, 345-351.

PROMOTING WELLNESS IN PERSONS WITH HIV INFECTION

165

Tonnesen, H., Kaiser, A., Nielsen, B., &Pedersen, A. (1992). Reversibility of alcoholinduced immune depression. British Journal of Addiction, 87, 1025-1028. Troop, M., Easterbrook, P., Thornton, S., Flynn, R., Gazzard, B., & Catalan, J. (1997). Reasons given by patients for "non-progression" in HIV infection. AIDS Care, 9, 133-142. Tumbarello, M.. Tacconelli, E., deGaetano, K., Ardito, F., Pirronti, T., Gauda, R., & Ortona, L. (1998). Bacterial pneumonia in HIV-infected patients: Analysis of risk factors and prognostic indicators. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18, 39-45. Turner, B., Hatick, W., Fanning, T., & Markson, L. (1997). Cigarette smoking and maternal-child HIV transmission. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 14, 327-337. Twigg, H., Soliman, D., & Spain, B. (1994). Impaired alveolar macrophage accessory cell function and reduced incidence of lymphocyte alveolitis in HIV-infected patients who smoke. AIDS, 8(5), 611-618. U.S. Department of Health and Human Services. (1992). Healthy people 2000: National health promotion and disease prevention objectives. Boston: Jones and Bartlett. Valente, S., Saunders, }., & Uman, G. (1993). Self-care, psychological distress, and HIV disease. Journal of the Association of Nurses in AIDS Care, 4, 15-25. Walsek, G., Zafonte, M., & Bowers,]. (1997). Nutritional issues and HIV/AIDS: Assessment and treatment strategies. Journal of the Association of Nurses in AIDS Care, 8, 71-80. Watt, D., Verma, S., & Flynn, L. (1998). Wellness programs: A review of the evidence. Canadian Medical Association Journal, 158, 224-230. Wei, X., Ghosh, S., Taylor, M., Johnson, V., Emini, E., Deutsch, P., Lifson, J., Bonhoeffer, S., Nowak, M., Hahn, B., Saag, M., & Shaw, G. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 373, 117-122. Weissman, G.. Melchior, L., Huba, G., Smereck, G., Needle, R., McCarthy, S.,Jones, A., Genser, S., Cottier, L., & Booth, R. (1995). Women living with drug abuse and HIV disease: Drug abuse treatment access and secondary prevention issues. Journal of Psychoactive Drugs, 27, 401-411. Whitfield, R., Bechtel, L., & Starich, G. (1997). The impact of ethanol and Marinol/ marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/clideoxycytidine, or dideoxyinosine therapy. Alcoholism, Clinical, and Experimental Research, 21, 122-127. Woods, W., Avins, A., Lindan, C., Hudes, E., Boscarino, J., & Clark, J. (1996). Predictors of HIV-related risk behaviors among heterosexuals in alcoholism treatment. Journal of Studies on Alcohol, 57, 486-493.

This page intentionally left blank

5

The Clinical Spectrum of HIV Infection and Its Treatment Felissa R. Lashley

he effects of HIV on the immune system (as discussed in chapters 1 and 2) render the affected individual susceptible to a variety of opportunistic conditions, including infections and neoplasms, many of which were rarely seen before 1980, as well as more vulnerable to common pathogens. HIV-infected persons can show a broad continuum of effects ranging from acute infection through an asymptomatic state through full-blown AIDS. The exact nature of the opportunistic conditions (OIs) that occur and the organ systems that are affected in each person vary and can result in unique, complicated presentations. The clinical presentations seen most commonly in developed countries are often different than those that are most common in developing countries. This is in part due to differences in the infections that are prevalent and endemic, socioeconomic conditions, and access to medical care of varying levels, among other reasons. The signs and symptoms seen in patients with HIV infection depend upon the nature of the underlying opportunistic infection or neoplasm and the organ systems directly or indirectly affected. These signs and symptoms may result not only from one condition but can

T

167

168

THE PERSON WITH HIV/AIDS

be due to a combined variety of infections and neoplasms, such as Pneumocystis carinii pneumonia (PCP) and Kaposi's sarcoma (KS). The onset of signs and symptoms may be abrupt or gradual. Some patients with full-blown AIDS may present with a combination of dermatologic, gastrointestinal, pulmonary, neurologic, ophthalmologic, and/or musculoskeletal conditions. As knowledge of the effects of HIV infection has evolved, clinicians have become much more experienced in anticipating and applying prophylaxis and preventive measures to delay or avoid opportunistic conditions resulting from immunosuppression. Early treatment that takes into account and monitors viral load and CD4+ cell counts is aimed at maintaining immune function and possibly eliminating HIV. Immune function is a major determinant of whether specific infections and neoplasms develop and the stage of the illness when they develop. The combination of protease inhibitors and other drugs in a regimen known as highly active antiretroviral therapy (HAART), as discussed in chapter 7, has positively affected the natural history of many HIV-related opportunistic infections, particularly cryptosporidiosis, microsporidiosis, Kaposi's sarcoma, progressive multifocal leukoencephalopathy, those caused by Molluscum contagiosum, Mycobacterium avium complex, and cytomegalovirus (CMV) infections and provided benefits even without other measures (Sepkowitz, 1998). Both host and environmental factors play a role in which OIs tend to be more frequently observed in persons with HIV infection. Behaviors associated with the epidemiologic groups of men who have sex with men and injecting drug use may increase to vulnerability to certain types of OIs and other conditions in HIV infection. For example, HIV-infected persons who inject drugs are more likely to develop bacterial endocarditis than men who have sex with men (MSM) because malnutrition and exposure play roles in disease development. On the other hand, MSM are more likely to develop KS due to human herpes virus 8 (HHV-8), a sexually transmitted agent (Jones, Hanson, Dworkin, Kaplan, & Ward, 1998). It must be remembered that HIV-infected persons may engage in overlapping, multiple behaviors and therefore may be at risk for developing opportunistic conditions for a variety of reasons, including socioeconomic status, living conditions, the geographic region of residence, and access to health care.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 169

One way the clinician may be able to detect a particular OI or HlV-related condition early is to monitor the CD4+ T-cell count. The degree of immune depression as reflected by the CD4+ Tcell count can be used to assess the HFV-infected person for those conditions observed to occur more frequently at those levels. For example, CMV retinitis is most frequently observed when the CD4+ count is < 50 cells/mm3. Therefore, although a general ophthalmologic examination is called for at higher levels of CD4+ cell counts, the clinician should be especially alert for CMV retinitis when a given patient has a CD4+ cell count approaching 50 cells/mm3. A listing of conditions noted to be particularly prevalent at various CD4+ cell counts are listed in Table 5.1. These are not meant to be absolute and do not preclude an HIV-infected person from developing a given condition at any CD4+ cell count level but can be used as a guide. Prophylaxis is a major force in the total management of HIV infection. The Centers for Disease Control and Prevention (CDC) strongly recommend strategies to prevent first episodes of diseases for the following: Toxoplasma gondii, Mycobacterium tuberculosis (MTB), Mycobaclerium avium complex (MAC), Streptococcus pneumoniae and varicella zoster virus (VZV) infections, and Pneumocystis carinii pneumonia (PCP), and generally recommends prophylaxis for hepatitis A and B, Streptococcus pneumoniae, and influenza (Centers for Disease Control and Prevention, 1997; USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). Prophylaxis for recurrence in adults is recommended as a standard of care for PCP, toxoplasmosis, MAC, CMV, Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, and Salmonella. If frequent or severe, prophylaxis is indicated for Candida and herpes simplex virus. These are discussed later in this chapter. Major therapeutic efforts have centered on therapy aimed at the HIV itself, and these treatments are discussed in chapter 7. Therapeutic approaches depend, to a large extent, on what infections and/ or neoplasms are manifested. Many of the signs and symptoms of various manifestations require complex and exhausting nursing care often taking place in long-term care settings or the home, as discussed in chapters 6 and 10. Current approaches to treatment can be conceptualized as follows:

170

THE PERSON WITH HIV/AIDS

TABLE 5.1 Selected Opportunistic Infections and Conditions Frequently Associated with CD4+ Cell Count Categories* CD4+ Cell Count Range

Condition

> 500 cells/mm3

Bronchitis Sinusitis HIV-associated myositis

200 to 500 cells/mm3

Oral candidiasis Oral hairy leukoplakia Bacterial pneumonia Anemia Autoimmune thrombocytopenic purpura Herpes zoster Pulmonary TB Kaposi's sarcoma

> 100 to < 200 cells/mm3

Pneumocystis carinii pneumonia HIV-associated nephropathy Progressive multifocal leukoencephalopathy Peripheral neuropathy Microsporidiosis Molluscum contagiosum

50 to 100 cells/mm3

Pseudomonas pneumonia Cytomegalovirus CMV retinitis Disseminated histoplasmosis Aspergillosis Primary CMS lymphoma Toxoplasmosis Bacillary angiomatosis Disseminated coccidioidosis Esophageal candidiasis HIV-associated wasting Disseminated Mycobacterium avium complex

*These are meant only as a guide. Conditions may appear at other CD4+ cell counts. Sources: Carmichael, 1997; Jung & Paauw, 1998; Reiter, 1998.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 171

1. Prophylactic therapy aimed at the prevention of opportunistic infections (OIs) and their reoccurrence 2. Therapy aimed at the treatment of OIs 3. Therapy aimed at the treatment of neoplasms 4. Therapy aimed at combating HIV itself by eliminating it or by preventing reactivation or progression 5. Strengthening the person's own immunocompetence 6. Therapy aimed at combating the side effects of treatment modalities 7. Combinations of these approaches In order to fully understand the clinical consequences of HIV infection on the body, this chapter will present information in the following ways. First, information about the major infecting organisms and malignancies will be presented. Then, each organ system will be considered for the effects that are manifested. The usual current therapies will be discussed, generally in conjunction with the clinical condition for which they are most commonly used. In general, information on clinical conditions presented in this chapter and the usual therapies relates to adults in developed countries. CLASSIFICATION SYSTEMS On May 23, 1986, the CDC published a classification system for HIV infection. This system delineated inclusive definitions and classifications that were used for patient care, health planning, public health strategies, prevention and control activities, and epidemiologic studies (Centers for Disease Control, 1986). This classification was revised, and the 1993 version classifies HIV-infected persons on the basis of CD4+ T cell count or percent in three ranges and three clinical categories resulting in a matrix of nine mutually exclusive categories (Centers for Disease Control and Prevention, 1992). These are shown in Table 1.1 (see chapter 1). The CD4+ T-cell categories are Category I Category 2 Category 3

> 500 cells/jlL or mm3 200-499 cells/jiL or mm3 < 200 cells/|lL or mm 3

THE PERSON WITH HIV/AIDS

172

The clinical categories for adults or adolescents are A, B, and C. Clinical categories are divided into A, B, and C (see Table 1.2, chapter 1). Category A consists of one or more of the following Asymptomatic HIV infection Persistent generalized lymphadenopathy (PGL) Acute or primary HIV infection with accompanying illness or history of acute HIV infection (Centers for Disease Control and Prevention, 1992) Category B consists of "symptomatic conditions" not included in category C (Centers for Disease Control and Prevention, 1992). Examples of conditions in clinical category B are listed in Table 1.2 (see chapter 1). Category C includes the clinical conditions listed in the AIDS surveillance case definition as shown in Table 1.3 (see chapter 1). Once a person has had a category C condition, the person remains in category C.

PRIMARY HIV INFECTION Symptomatology of primary HIV infection or acute retroviral syndrome was first described in 1985 (Cooper et al., 1985; Ho et al., 1985). Early in the epidemic, this syndrome was often diagnosed as some type of nonspecific flulike or mononucleosislike illness and its significance in relation to HIV was not appreciated. From 50% to 95% of HFV-infected persons show at least one symptom or sign during this time while the others remain asymptomatic. However, if symptoms are mild, they may not be recognized. The time period from HIV infection to the onset of acute illness has been reported to range from 5 days to 30 days or longer, with the typical period being about 14 days (Quinn, 1997; Schacker, 1997; Vanhems & Beaulieu, 1997). The clinical signs and symptoms may typically include fever, fatigue, pharyngitis, weight loss, myalgias, headache, arthralgias, mucosal ulcerations, rash, and lymphadenopathy, although others may occur. Lymphadenopathy often develops in the second week of the illness and may be limited to axillary, occipital, and cervical nodes or may be generalized. The rash that may be seen is usually erythema-

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 173

tons and maculopapular, most commonly affecting the face or trunk. Headaches can occur that are often retro-orbital, and acute encephalopathy or aseptic meningitis may be seen. Depression, irritability, photophobia, and cognitive changes may be seen. These probably represent the initial involvement of the central nervous system. Those who are symptomatic appear to have a more rapid progression to AIDS (Cohen, Sande, & Volberding, 1998; Perrin & Yerly, 1998; Schacker, 1997; Schacker, Hughes, Shea, Coombs, & Corey, 1998; Vanhems & Beaulieu, 1997). During primary HIV infection patients may be very infectious with high viral levels (Quinn, 1997). The time of primary HIV infection now is viewed as an opportunity to influence the rate of disease progression or to possibly "abort" HIV infection. Early, aggressive antiviral therapy may affect host response and influence the long-term outcomes (Schacker et al., 1998), although studies spanning a 3-year period have not yet yielded definitive results on this treatment approach. It is also thought that during this acute time the person's immune system is relatively intact, and the infecting virus tends to be relatively homogenous, meaning the infected individual may be more susceptible to antiretroviral therapy (Cohen et al., 1998). Thus, early recognition of the syndrome and diagnosis are important. In addition, postexposure prophylaxis for persons having nonoccupational exposures to HIV has been recommended by the CDC and is outlined in Appendix 1 (Centers for Disease Control and Prevention, 1998). Diagnosis may be confirmed by detection of HIV RNA or p24 antigen, because tests looking for HIV antibodies will usually be negative or indeterminate as seroconversion progresses during this period (Quinn, 1997). Reasons to intervene early in acute/primary HIV infection are: to suppress the initial burst of viral replication and decrease the magnitude of viral dissemination throughout the body to decrease the severity of acute disease to potentially alter the initial viral "set point," which may ultimately affect the rate of disease progression to possibly reduce the rate of viral mutation due to the suppression of viral replication (Centers for Disease Control and Prevention, 1998, p. 56), thereby reducing the problem of the virus developing resistant forms to prevent the virus from establishing sequestered reservoirs

174

THE PERSON WITH HIV/AIDS

Potential disadvantages have also been identified. These include expense, issues of adherence to therapy and diminution of perceived risk, early emergence of resistant strains, and unpleasant side effects of the medications used (Burman, Reves, & Cohn, 1998). Thus, how early to begin therapy in HIV infection and how aggressive that therapy should be are not subjects of uniform agreement (Burman et al., 1998; Corey & Schacker, 1999; Walker & Basgoz, 1998). If diagnosis of primary HIV infection is made, the patient should be examined for sexually transmitted diseases and hepatitis A and B; if the latter are not evident, vaccination may be considered. Additionally, baseline CD4+ T-cell counts should be taken, HIV viral loads should be assessed regularly, and the person should be monitored for the occurrence of HIV seroconversion. The goal of therapy early in the infection is to suppress plasma HIV RNA levels to below detectable levels with a combination of two nucleoside reverse transcriptase inhibitors (NRTIs), such as zidovudine, ddl, ddC, stavudine, or lamivudine, and one protease inhibitor (see chapter 7) (Cohen et al., 1998; Centers for Disease Control and Prevention, 1998). In one report, after beginning treatment for primary HIV infection before seroconversion, a patient voluntarily discontinued treatment and evidenced a later second acute syndrome with rebound viremia (Daar et al., 1998). At this time of early diagnosis, the long-term treatment plan as known should be discussed with the HIV-infected person, and preventive aspects such as maintaining wellness and avoiding transmission should be emphasized. Aspects of adherence should be discussed (see chapter 7). Adverse prognostic signs at primary infection include persistent symptoms (especially if lasting more than 14 days), neurologic involvement, acquisition of infection from a person with late-stage HIV disease, infection with a virulent viral strain such as SI, persistent p24 antiginemia, higher HIV RNA viremia following seroconversion, persistently low CD4+ T cell count, and other immunological parameters (Sande & Volberding, 1997). THE COURSE OF HIV INFECTION AND THE PROGRESSION TO AIDS Following initial infection, the most usual clinical course for the HIV-infected person is to enter an essentially asymptomatic phase as

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 175

described above. Some, however, do develop persistent generalized lymphadenopathy (PGL) before other symptoms or disorders develop. Over time, the individual's chances for developing symptoms increases, particularly as the immune system is compromised, but the appearance of symptoms is influenced by many factors, including those related to the HIV, other organisms to which the person is exposed and their characteristics, host characteristics (including genetic factors, relative state of immunity, nutritional status), and environmental factors governing exposure and other parameters. After transmission of HIV, the organism establishes infection, initially replicating in CD4+ T lymphocytes, macrophages, and probably dendritic cells. HIV is transported to lymphoid tissue, where it replicates. An immune response is mounted. As HIV replicates, it may also mutate, making the population of HIV more genetically diverse. HIV RNA appears, followed by HIV antigens, and eventually antibodies appear and may be detected. During the immune response to HIV, some specific CD4+ cells and possibly CD8+ cell clones are lost that might be effective in controlling HIV (Cohen etal, 1998). After transmission, establishment of infection, and an initial immune system response, a "set point" is established. This is defined as a relatively constant steady state level of plasma HIV RNA resulting from a rate of HIV replication approximately equal to the rate of viral destruction (Cohen etal., 1998). An acute syndrome, described earlier, may accompany this process and may be seen within weeks of the primary infection and immune response. HIV antigen falls from peak levels early in the infection to undetectable levels. The set point usually remains stable. CD4+ cell counts drop initially, then rise to the set point. When plasma virus levels fall to virtually undetectable levels after treatment, HIV may still persist in resting memory CD4+ T cells forming a latent reservoir (Finzi, Blankson, Siciliano, et al., 1999). HIV may have a period where it is replicating rapidly and being destroyed in lymphoid tissue and is not really latent. PGL may reflect some of this activity (Cohen et al., 1998). The CDC definition of PGL includes patients with lymph node enlargement of 1 cm or greater at two or more extrainguinal sites that persist for more than 3 months in the absence of a concurrent illness other than HIV that explains these findings (Centers for Disease Control, 1986). PGL

176

THE PERSON WITH HIV/AIDS

began to be described in the literature in the early 1980s when it was seen in homosexual males. The nodes most frequently affected, in decreasing order of frequency, are cervical, axillary, inguinal, supraclavicular, infraclavicular, and popliteal. PGL may persist for several years, even in the absence of other symptoms. Discomfort may result from pressure caused by the enlargement. After primary HIV infection, the patient usually becomes asymptomatic and usually remains so through the early stage of HIV disease, which has been defined by Cohen and colleagues (1998) as the period from the establishment of the set point to a CD4+ T cell count < 500 cells/mm3. In this early stage, dermatological abnormalities such as seborrheic dermatitis or folliculitis or idiopathic aphthous ulcers may appear, particularly as CD4+ cell counts slowly decline over time (Cohen etal., 1998; DeVita, Hellman, & Rosenberg, 1997). During the middle or intermediate stage of disease, the CD4+ cell count is between 200 and 500 cells/mm3. While the person may still be relatively asymptomatic, intermittent conditions such as candidiasis of the mouth or herpes zoster infections may be seen. There may be episodes of recurrent herpes simplex virus (HSV) or the occurrence of diarrhea. Persons are also at higher risk for TB and bacterial infections such as sinusitis (Cohen, Sande, & Volberding, 1998; DeVita, Hellman, & Rosenberg, 1997). As disease advances to CD4+ cell counts below 200 mm3, the CDC's definition of AIDS is met (Centers for Disease Control and Prevention, 1992). DeVita and colleagues (1997) call the stage of 50 to 200 CD4+ cells/mm3 late stage disease, whereas Cohen and associates (1998) call it advanced HIV disease. At this stage there is substantial risk for PCP, esophageal candidiasis, T. gondii encephalitis, C. neoformans infections, cryptosporidiosis, isosporiasis, TB, KS, B cell lymphomas, and neurological disorders. Individuals with CD4+ cell counts below 50 cells/mm3 are said to have late stage (Cohen et al., 1998) or advanced stage disease (DeVita et al., 1997). The risk of MAC, CMV, cryptococcal meningitis, PML, and disseminated fungal diseases become more likely. DeVita and colleagues (1997) include a terminal stage in their progression. This stage represents an inability to successfully treat symptoms and comfort becomes a primary goal. Gates, Chesney, and Cohen (1997) simply separate phases of HIV infection into primary, which encompasses early and

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 177

acute phases, and chronic, which is defined as occurring after the viral set point is established. Although development from initial infection to AIDS-defining illness can be 10 to 12 years or more, some persons (known as nonprogressors) have been symptom free for about 15 to 20 years, whereas others show symptoms relatively quickly (rapid progressors). Conditions usually associated with progression are oral candidiasis, oral hairy leukoplakia, and herpes zoster (Cohen et al., 1998; DeVita et al., 1997). Diseases commonly associated with various CD4+ cell count categories were shown in Table 5.1. Reduction of CD4+ cell counts below 200 mm3 results in the probability of developing OIs of 33% 1 year later and 56% 2 years later (Klepser & Klepser, 1997). The stages described above are influenced by prophylaxis, treatment, and factors pertaining to the host, organism, and environment. INFECTIONS Opportunistic infections have been one of the hallmarks of AIDS. Many of these infections are ones that were rarely described in humans before the advent of the AIDS epidemic. Many of the infections seen represent the reactivation of previously acquired latent infections but can also represent primary infection, or infections with organisms that usually cause little or no pathogenicity in the immunocompetent host. The most frequent causes of infection in persons with AIDS are parasitic, viral, and fungal organisms, although bacteria, particularly the mycobacteria, are also problematic and becoming more so. The person with HIV infection is likely to have multiple infections that are either simultaneous or consecutive and are caused by different organisms. Fungal, parasitic, and viral infections are frequently not curable; rather, treatment is aimed at controlling acute episodes. Long-term suppressive therapy even over a lifetime may be needed, and response is often delayed. Treated individuals are prone to experience increased frequency and severity of side effects of medications. The frequency of specific fungal and parasitic infections in persons with AIDS in a specific geographic area depends on the endemicity of the organism in that area. Thus, more cases of coccidioidomycosis will be seen in persons with HIV infection in the Southwest because more cases occur in non-HIV-

178

THE PERSON WITH HIV/AIDS

infected persons in that region. In persons with HIV infection/AIDS, infections may show a different disease presentation, have atypical locations, have more rapid progression, be more severe, be more likely to be disseminated, and have a high density of organisms than in those without HIV infection, although this is not always the case in early stages when CD4+ cell counts are relatively high. There are differences in the patterns and prevalence of infections seen in developed and developing countries. In comparison to developed countries, the spectrum of opportunistic infection in developing countries may differ. For example, Pneumocystis carinii pneumonia, cytomegalovirus, and disseminated MAC are seen far less frequently than in Western populations, while skin diseases, intestinal complications (including severe diarrhea), tuberculosis, Toxoplasma gondii encephalitis, and cryptococcal meningitis occur more frequently (Karp & Neva, 1999). "Slim disease," a type of wasting syndrome, was recognized in Africa before its significance in relation to HIV infection was understood (Serwadda et al., 1985). Ideal treatment of OIs in persons with HIV infection includes prevention of infections, treatment of active infections, and prevention of recurrences (secondary prophylaxis). When prophylaxis should be used depends on several factors, including the incidence of the disease in the patient's community, how severe the disease is, efficacy of the regimen, simplicity of regimen, frequency and type of side effects, cost, potential adherence of the patient, and risk of emergence of drug-resistant pathogens (Carmichael, 1997). In 1995 an extensive document on prophylaxis of infections in persons with HIV infection was published (Centers for Disease Control and Prevention, 1995), and these were updated in 1997 and 1999 (Centers for Disease Control and Prevention, 1997; USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). Recommendations for prophylactic medication for initial occurrences and for recurrences of OFs in adults and adolescents are given in Appendices 2 and 3, respectively. Nonpharmacological preventive measures are given in Appendix 4 and in the USPHS/IDSA document. These appendices should be consulted for specific information related to each infection discussed below. The major parasitic, fungal, viral, and bacterial infections seen in HIV infection are described below and their therapy briefly discussed.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 179

PARASITIC INFESTIONS The appearance of pneumonia caused by what was then considered a protozoan, Pneumocystis carinii, in previously healthy male homosexuals was one of the events that initially drew attention to what was later recognized as AIDS (Centers for Disease Control, 1981a, 1981b). In the immunocompetent person, opportunistic parasitic infections are generally self-limiting. In HFV-infected individuals, the relative prevalence of various parasitic infections depends upon geographic factors and upon the prevalence of the organism in the population. Significant morbidity and mortality for HIV-infected persons have resulted from opportunistic parasitic infections, especially from Toxoplasma gondii (central nervous system lesions), Cryptosporidiumparvum, and hospora belli (diarrhea and malabsorption), Enterocytozoon bienuesi and Encephalitowon intestinalis (microsporidiosis resulting in diarrhea), and Strongyloides stercoralis (strongyloidosis). Other parasitic illnesses causing a lesser incidence of morbidity in the United States include Cydospora cayetanensis (Ackers, 1997).

Cryptosporidiosis Cryptosporidiosis is caused by the protozoan parasite Cryptosporidium parvum (Lew, Poles, & Dieterich, 1997) and is now known to be one of the most common enteric infections (Griffiths, 1998). It is an enteric protozoan infection seen in animals since 1907 but not described in humans until the 1970s (Rose, 1997). Person-to-person contact is the most important mode of transmission, but other routes include fecal contamination of the environment, including water and food, and animal-human contact (Griffiths, 1998; Rose, 1997). In the United States, the groups at highest risk of infection are children in day care centers, animal handlers, foreign travelers, and immunocompromised persons, including those with malnutrition and HIV infection (Atkins, Caceres, & Cleary, 1998; Rose, 1997). This infection has also been spread nosocomially from health care workers. Differences exist in prevalence rates for cryptosporidial enteritis for persons with AIDS in developed and developing countries. In the United States the organism can be found in up to 20% of persons with HIV, whereas in developing countries such as Africa

180

THE PERSON WITH HIV/AIDS

and Haiti it is approximately 50% (Lew et al., 1997; Manabe et al., 1998). North American outbreaks have occurred from contamination of drinking water in cities such as Milwaukee (1993), Las Vegas (1994), and Gainesville, Florida (1995), and associated with swimming pools in Vancouver (1990) and Los Angeles County (1988). The mortality rates in Milwaukee and Las Vegas for patients with AIDS were 68% and 52.6%, respectively (Perz, Ennever, & LeBlancq, 1998; Rose, 1997). Cryptosporidiosis affects immunocompromised and immunocompetent persons differently. The latter have a self-limited illness with varying degrees of watery diarrhea, cramping abdominal pain, malaise, anorexia, and weight loss. Nausea, vomiting, and low-grade fever may be present. Symptoms commonly resolve within 5 to 14 days (Kartalija & Sande, 1999; Lew et al., 1997). In persons with AIDS, however, cryptosporidiosis manifests with choleralike diarrhea with bowel movements of up to 20 or more per day. The volume of watery stool lost is often as much as 10 to 20 liters per day but is more usually 3 to 6 liters per day. The exact mechanism of the diarrhea is unclear. In persons with AIDS the symptoms mentioned above are more severe and wasting may be life threatening (Atkins et al., 1998). Involvement of the gall bladder and biliary tree has also been recognized. Effects may include cholecystitis, biliary stenosis, and obstruction. There have been reports of cryptosporidial colonization of the lungs and stomach (Ventura et al., 1998). Diagnosis is based on the identification of parasitic oocysts in fecal specimens using various stains and microscopy, or monoclonal immunofluorescent stain and enzyme-linked immunosorbent assays (ELISA) for detection of antibodies in the stool. Intestinal biopsy is rarely used due to cost, invasiveness, and false negative results (Atkins et al., 1998). There is still no effective specific treatment for cryptosporidiosis but HAART decreases symptoms (Kartalija & Sande, 1999). Limited therapeutic success has been reported with diclazuril and letrazuril, and paromomycin may be used. There have been mixed reports on the effectiveness of antidiarrheal agents, including morphine sulfate, in reducing stool volumes and for antisecretary therapy with somatostatin analogues such as octreotide. Some reports have indicated usefulness of hyperimmune bovine colostrum. Immunomodulators such as interleukin-2 may improve symptoms (Atkins et al., 1998; Carr, Marriott, Field, Vasak, & Cooper, 1998; Lew et al.,

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 181

1997). Preventive and prophylactic measures are listed in Appendices 2, 3, and 4. Especially important is avoiding contact with feces, handwashing after handling pets, gardening, or before eating, and avoiding ingesting river, lake, or swimming pool water or unpasteurized juices. Isosporiasis Isosporiasis is caused by the protozoan Isospora belli. This parasite is ubiquitous in animals and has been the cause of several outbreaks of diarrhea in institutions in the United States. It is endemic in parts of South America, Africa, and Asia. It has been found in approximately 0.2% of U.S. patients with AIDS in developed countries, as opposed to 15% to 18% of AIDS patients in developing countries such as Haiti and Africa (Atkins et al., 1998; Kartalija & Sande, 1999). Clinically, the immunocompetent person generally demonstrates a self-limited enteritis, whereas those who are immunocompromised as in AIDS show chronic intermittent disease. Symptoms are very similar to those of cryptosporidiosis. Diagnosis is based on identification of I. belli oocysts from stools or more rarely by intestinal biopsy (Atkins et al., 1998). Isosporiasis responds to treatment with oral trimethoprim-sulfa-methoxazole (TMP-SMZ) or pyramethamine-sulfadiazine, and other therapies may also be successful. The use of antiretroviral therapy including a protease inhibitor may result in improvement due to improved immunity (Atkins et al., 1998; Carr et al., 1998; Kartalija & Sande, 1999). Recurrences are common, and ongoing drug regimens may be needed for prophylaxis (Lew et al., 1997; Kartalija & Sande, 1999). Preventive and prophylactic measures are listed in Appendices 2, 3, and 4. Toxoplasmosis Toxoplasmosis is caused by the protozoan Toxoplasma gondii and is a common infection in both animals and humans. It is an obligate intracellular parasite. The route of transmission is believed to be oral-fecal from contamination by feline feces or from eating food infected with the organism, such as unwashed vegetables or un-

182

THE PERSON WITH HIV/AIDS

dercooked or raw meat. HIV-infected persons should avoid contact with cat litter, cleaning horse stables, or sandboxes to reduce exposure to T. gondii. T. gondii infection is the m<-v common cause of focal encephalitis in persons with AIDS (Boyer, Remington, & McLeod, 1998; Lynfield & Guerina, 1997; Walker, 1998). It also crosses the placenta and can infect the fetus, causing various manifestations including microcephaly, mental retardation, and chorioretinitis in infected infants (Feigen & Cherry, 1998; Lashley, 1998). Toxoplasmosis in HIV-infected persons most often results from reactivation of previously acquired latent infection; therefore, those countries and geographic locations with higher general population prevalence can be expected to see a higher prevalence of toxoplasmic encephalitis in persons with AIDS. Thus, HIV-infected persons who have antibodies to T. gondii should be considered at risk for the development of toxoplasmic encephalitis. In countries where seroprevalence of T. gondii is high, toxoplasmic encephalitis is often a presenting symptom of AIDS (Subauste, Wong, & Remington, 1997). Encephalitis due to T. gondii is one of the most common neurological diseases in AIDS. The major features in clinical presentation are fever, headache, and focal neurologic deficits, including hemiparesis, seizures, and altered mental status. The latter may include confusion, lethargy, psychosis, global cognitive impairment, delusions, or coma. In addition to hemiparesis, other focal neurologic deficits may include ataxia, aphasia, movement disorders, and visual field loss (Blumenthal et al., 1999; Subauste et al., 1997). Noninvasive tests currently available lack specificity; thus, definitive diagnosis can only be made by detection of the organism from brain tissue obtained at either an open or a closed brain biopsy. Such lesions, however, are often inaccessible. While biopsy is the only method currently available to definitively distinguish toxoplasmosis from other causes, the high morbidity and mortality rates, coupled with the possibility of false negative results, often means that in practice clinicians initiate therapy based on positive serologic findings, clinical picture, and/or magnetic resonance imaging (MRI) or CT scan data. PCR and molecular testing using cerebrospinal fluid (CSF) are being increasingly used in diagnosis (Cohen, 1997). T. gondii may also infect the lung after dissemination. Typical symptoms include fever, cough, hypoxemia, lymphadenopathy, and skin rash, and it may resemble PCP. The lungs may be involved even

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 183

when neurologic disease is not evident. The eye is another major site of infection. Other affected sites involved after dissemination are the heart, adrenal glands, liver, stomach, colon, pancreas, and testes, with necrosis occurring in these organs (Subauste et al., 1997). It is considered that the presence of extraneural toxoplasmosis means concurrent central nervous system disease. Treatment of toxoplasmosis is accomplished with a combination ofpyrimethamine (a diaminopyrimidine antimicrobial) andsulfadiazine. Clindamycin may also be used (Goldschmidt & Dong, 1999). Improvement is often seen within 10 to 14 days, but there is a high rate of relapse and therapy is generally continued for 4 to 6 weeks. The side effects of pyrimethamine (leukopenia, thrombocytopenia, and anemia) are related to an altered metabolism of folate, so folinic acid (leucovorin) is given concomitantly or added when blood counts so indicate. There is also a high frequency of complications in about 40% to 45% of patients manifested by bone marrow suppression or rash necessitating discontinuation of therapy. Treatment often lasts 3 to 6 months, although the optimal duration is unknown. Therapy is often necessary for the lifetime of the patient. Some drugs that have shown promise against toxoplasmic encephalitis in animal experiments or early clinical trials include roxithromycin, clarithromycin, azithromycin (macrolide antibiotics with relatively long halflives), and the hydroxynapthoquinone atovaquone (Klepser 8c Klepser, 1997; Lynfield & Guerina, 1997). Prophylaxis against toxoplasmosis is indicated, especially when the CD4+ count is < 100 cells/ mm' or if a prior episode has occurred (see Appendices 2 and 3). Nonpharmacological preventive measures have also been described (see Appendix 4 and Lashley, 1998; USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). Especially important are good handwashing, avoiding raw or undercooked meat, and avoiding cat litter. Microsporidiosis Microsporidiosis is caused by a unicellular spore-producing protozoan, and disease in humans appears most commonly due to Enterocytozoon bieneusi, with a smaller number resulting from Encephalitozoon intestinalis (Carr et al., 1998; Sobottka et al., 1998). Prior to the

184

THE PERSON WITH HIV/AIDS

emergence of AIDS, microsporidiosis was rarely described in humans, although it was well known in both invertebrate and vertebrate animals (Carr et al., 1998). In the United States, especially, microsporidiosis is almost never seen in immunocompetent persons. In humans, transmission is believed to occur by the fecal-oral or urinary-oral route and may be food or waterborne (Kartalija & Sande, 1999). The prevalence in persons with AIDS ranges from 7% to 50% (Didier, 1998). Disease effects in clinical cases of AIDS in the United States include reports of myositis, intestinal infections, cholecystitis, peritonitis, and hepatitis. Keratoconjunctivitis (suggesting direct inoculation) and disseminated disease have also been reported (Didier, 1998). Microsporidia are regarded as one of the leading causes of diarrhea in HIV-infected persons (Sobottka et al., 1998). Symptoms depend on the site of infection. In persons with small intestine infection, symptoms include the occurrence of persistent watery diarrhea, weight loss, and abdominal pain. Malabsorption results (Kotler & Orenstein, 1998). Albendazole (a microtubule inhibitor) is used in treatment but is not as effective against E. bieneusi as other species of microsporidia. Fumagillin (an antibiotic) is used especially to treat keratoconjunctivitis topically. TNP-470 (a fumagillin analogue) holds promise (Didier, 1998). For prevention, see Appendices 2, 3, and 4. Strongyloides stercoralis Strongyloides stercoralis is an intestinal worm or a nematode with a worldwide distribution that is endemic in many tropical and subtropical regions, including the southeastern United States (Karp & Neva, 1999; Wehner & Kirsch, 1997). Usually larvae penetrate the skin, then migrate to the lungs, where they ascend the trachea and are swallowed. They mature in the gut. Larvae migrate from bowel to lung, where they can cause pneumonia. The migration of the larvae can cause gram negative bacteremia and shock. Infections may be acute or chronic, and they may be localized to a specific system or become disseminated. In persons without AIDS, infections tend to be either asymptomatic or mild after causing self-limited vomiting and diarrhea. In heavy abdominal infection, abdominal pain, weight loss, and diarrhea may be seen. Eosinophilia and symptoms specific

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 185

to the respiratory tract may also be seen, and 5. stercoralis may cause adult respiratory distress syndrome (Wehner & Kirsch, 1997). Diagnosis is by detection of larvae in stool or tissues. S. stercoralis is considered potentially lethal in persons with AIDS because it can cause a hyperinfection syndrome. Dissemination to the lung and brain is also possible. Pruritus, urticaria, and a rash may also occur transiently. S. stercoralis can live in the heart with only occasional symptoms. Unexplained enterobacteremia or meningitis may indicate disseminated disease; therefore, strongyloidiasis should be considered in patients from endemic areas with nonspecific skin, pulmonary, and gastrointestinal symptoms, particularly with eosinophilia (Karp & Neva, 1999; Schneider & Rogers, 1997). Thiabendazole is used for treatment, and it is important to completely eradicate the parasite (Wehner & Kirsch, 1997). Cyclospora cayetanensis Cyclospora cayetanensis came to attention in the United States after an outbreak caused by imported raspberries in 1996 (Centers for Disease Control and Prevention, 1996a). Prior to this occurrence, the first major human outbreak causing diarrhea and cramping was noted in Chicago in a medical residence (Huang et al., 1995). The organism is a spore-forming, round to ovoid protozoa and may be waterborne (Brown & Rotschafer, 1999; Ortega, Sterling, & Gilman, 1998). These protoza may cause self-limiting diarrhea in immunocompetent persons and severe protracted diarrhea in those who are immunocompromised. Symptoms include watery diarrhea, malaise, myalgia, anorexia, weight loss and vomiting and fever in some. Asymptomatic carriage has been reported (Atkins et al., 1998). Diagnosis is made after finding the organism in the stool. Prophylaxis for HlV-infected persons with TMP-SMZ appears to prevent recurrences (Atkins et al., 1998; see Appendices 2 and 3). Treatment is also with trimethoprim-sulfamthoxazole (TMP-SMZ) (Brown & Rotschafer, 1999; Ortega et al.,1998; Soave, Herwaldt, & Relrnan, 1998).

Other Parasitic Diseases In addition to the parasites listed above, other parasitic diseases are being increasingly identified in persons with AIDS. Some, such as

186

THE PERSON WITH HIV/AIDS

Giardia lamblia, are more commonly seen in homosexual males and children in day care than in the general population, but they are not particularly associated with HIV infection and therefore are not discussed here. Disorders such as leishmaniasis are relatively uncommon in developed countries, although they may be encountered in persons with AIDS who were born in a developing country often causing visceral leishmaniasis. Trypanosoma cruzi or Chagas' disease may be responsible for some AIDS-related brain disease (Karp &Neva, 1999). FUNGAL DISEASES Fungal diseases are important OIs in persons with HIV infection, and their frequency of occurrence can vary greatly with geography since many are endemic whereas others (e.g., Candida) are ubiquitous. Fungal infections such as cryptococcosis and infection with Penicillium marneffei are particularly prevalent in Southeast Asia (Kaplan et al., 1996; Karp & Neva, 1999), a region where specific disease associations with HIV infection are still being newly recognized. The major fungal infections are discussed here. The most important, Pneumocystis carinii, was previously considered a parasite. Pneumocystis carinii Pneumocystis cariniiis a unicellular organism, having some characteristics of a protozoan parasite and others of a fungus. Based on recent nucleotide sequence analysis, it appears most closely related to fungi but with some differences (Deresinski, 1997; Kaneshiro, 1998; Santamauro & Stover, 1997). It is almost exclusively seen in persons who are immunosuppressed (e.g., those receiving chemotherapy or immunosuppressive therapy or in HIV infection). Most normal children demonstrate antibody to P. carinii by 4 years of age, probably due to subclinical infection. Clinical illness from P. carinii was not described until the early 1950s (Hughes & Anderson, 1998). Before extensive prophylactic efforts, it was the most common life-threatening opportunistic infection seen in patients with AIDS and often resulted from reactivation of earlier latent infection (Cavert, 1997a).

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 187

Before vigilant prophylaxis, PCP was the presenting opportunistic infection seen in about 60% to 65% of persons with AIDS. Earlier in the epidemic about 75% to 85% of persons with AIDS eventually developed PCP (Santamauro & Stover, 1997). Far fewer cases are now seen but PCP is still the most common AIDS-defining illness to occur first in the United States (Centers for Disease Control and Prevention, 1999). The most common expression of P. carinii is as pneumonia (PCP). Extrapulmonary pneumocystis is relatively rare. Sites of extrapulrnonary infection when they occur most often include lymph nodes, adrenal glands, liver, choroid of the eye, external and middle ear, thyroid, kidney, spleen, skin, gastrointestinal sites, and mediastinum and disseminated disease (Kaplan et al., 1995; Kroe, Kirsch, & Jensen, 1997; Santamauro & Stover, 1997). In one series Telzak, Cote, and Gold (1990) found an incidence of 2.5% of extrapulrnonary pneumocystis at autopsy. The most frequent presenting symptoms of PCP are relatively nonspecific—fever, nonproductive dry cough, tachypnea, and shortness of breath, which may be seen initially only on exertion (Cavert, 1997a). Persons who smoke or have complicating bacterial infection may have sputum production. Spontaneous pneumothorax may occur, and any patient with AIDS and pneumothorax should be investigated for PCP (Santamauro & Stover, 1997). Chest x-rays may show diffuse alveolar or interstitial infiltration distributed throughout the lung, but other changes such as patchy asymmetric infiltrates or discrete areas of pneumonia have been noted, especially when disease is more severe (Santamauro & Stover, 1997; Walsh, Rolfe, & Rumbak, 1999). Hopewell (1988) reported that 5% to 10% of patients with AIDS and later shown to have PCP have normal chest x-rays. Some radiologic patterns have changed over time (Boiselle et al., 1999). Pulmonary function testing results show nonspecific changes that may typically include reduced vital capacity, total lung capacity, and single breath diffusing capacity for carbon monoxide. Definitive diagnosis of PCP is based on finding the organism in pulmonary secretions or lung tissue. In experienced hands, sputum induction using hypertonic saline mist inhalation is a noninvasive, inexpensive method of diagnosis, but a negative result does not exclude PCP. Indirect immunofluorescent staining using monoclonal antibodies on induced sputum has improved the technique.

188

THE PERSON WITH HIV/AIDS

A direct fluorescence test using monoclonal antibodies performed on sputum is widely available, and molecular and PCR testing has potential to also be so. Bronchoalveolar lavage (BAL) may also be sufficient for diagnosis before attempting more invasive procedures such as fiberoptic bronchoscopy with or without bronchoalveolar lavage and transbronchial biopsy. Open lung biopsies are rarely necessary for diagnosis (Hughes & Anderson, 1998; Kroe et al., 1997; Santamouro & Stover, 1998; Walsh, Rolfe, & Rumbak, 1999). Once HIV infection is diagnosed, chemoprophylaxis against PCP is indicated if the person has a history of orophayngeal candidiasis, PCP, a fever above 37.7° C > 2 weeks, and/or a CD4+ lymphocyte count < 200/|LiL (Centers for Disease Control and Prevention, 1997; Kaplan, Masur, Holmes, Wilfert, Sperling, & Baker, 1995). Standard prophylactic therapy for persons with HIV infection includes TMPSMZ (Bactrim or Septra) given orally. TMP-SMZ is a combination of antimicrobials resulting in a synergistic effect. SMZ inhibits the incorporation of PABAinto folic acid, while TMP (a diaminopyrimidine) prevents the reduction of dihydrofolate to tetrahydrofolate, thus acting on sequential steps in the pathway of a bacterial enzymatic reaction. TMP-SMZ also may confer cross-protection against some bacterial infections and toxoplasmosis (Centers for Disease Control and Prevention, 1997; USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). Unfortunately, there is a high frequency (up to 65%) of adverse reactions to TMP-SMZ in AIDS patients that may include anemia, neutropenia, dermatitis, thrombocytopenia, altered sense of taste, nausea, pruritis, stomatitis, headache, depression, and renal disease. Folate deficiency can occur, particularly in the chronically ill. For those who cannot tolerate TMP-SMZ, alternative recommended prophylaxis includes dapsone alone, dapsone and pyrimethamine, and leucovorin, atovaquone, or aerosolized pentamidine administered by the Respirgard nebulizer (Centers for Disease Control and Prevention, 1997; El-Sadret et al., 1999; Goldschmidt & Dong, 1999). (See also Appendices 2, 3, and 4.) Aerosol pentamidine is not effective against extrapulmonary P. carinii. Children with a history of PCP may require lifelong chemoprophylaxis to prevent recurrence. Before starting dapsone and certain other sulfa-based drugs, persons should be tested for glucose6-phosphate-dehydrogenase deficiency to prevent hemolysis (Cohen

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 189

et al., 1998; Lashley, 1998). A detailed discussion may be found in Lashley (1998). Regimens for treatment of acute infection may include oral or intravenous preparations of TMP-SMZ, depending on disease severity. Dapsone alone has been shown to be nearly as effective as TMPSMZ. Other drug combinations include dapsone-trimethoprim, clindamycin-primaquirie, and atovaquone. Corticosteroids may be used as an adjunct in the absence of contraindications and with certain other criteria (Deresinski, 1997; Hughes, 1998). Adverse reactions to pentamidine isethionate, particularly when given parenterally, have included hypoglycemia followed by hyperglycemia, leukopenia, anorexia, altered taste, pancreatitis, orthostatic hypertension, elevated creatinine, and renal failure. Too rapid intravenous administration can be followed by severe reactions such as dizziness, breathlessness, vomiting, facial flushing, headache, prolongation of the QT interval, tachycardia, and even sudden death (Cohen et al., 1998). The finding of some studies have indicated that especially when treated with HAART, PCP prophylaxis may not need to be lifelong (Furrer et al., 1999; Masur & Kaplan, 1999; Weverling et al., 1999). Candidiasis Candidiasis (also called candidosis) is caused by members of the genus Candida, most often Candida albicans. In HFV-infected persons, non-albicans strains accounted for 3.4% of oropharyngeal isolates in the late 1980s, but by 1990 they accounted for 16.8% (Darouiche, 1998). More recently other species such as C. krusei and S. tropicalis are responsible for infection in a small percent of cases (Cartledge, Midgley, & Gazzard, 1999; Burden & Elewski, 1997). Candida is considered to be part of the normal flora of the gastrointestinal tract, including the oral cavity, and mucocutaneous regions. In immunocompetent persons, the organism is prevented from proliferating by other microorganisms in the normal flora and by immunoregulatory mechanisms. In the normal vagina of nonpregnant women, the incidence of C. albicans is about 5%; in pregnant women or those taking oral contraceptives, the incidence can be as high as 30% (Rippon, 1988). Up to 60% of healthy persons may

190

THE PERSON WITH HIV/AIDS

harbor C. albicans'm the mouth (Sweet, 1997). Although C. albicans is not considered to be part of the normal flora of the skin, it is often isolated from folds, especially in moist areas such as between the fingers or under the breasts (Rippon, 1988). A number of factors have been identified in which the equilibrium between the human host and C. albicans is altered and opportunistic infection can occur. These include age, physiologic alterations, metabolic alterations, antibiotic administration, decreased immunocompetence, steroid administration, and invasive techniques that break natural barriers such as indwelling catheters and central lines or chronic injections (Hughes & Flynn, 1998; Rippon, 1988). Candidiasis of the oral cavity and esophagus is found in up to 90% of the HIV-infected persons, making it the most common fungal infection (Darouiche, 1998). Less frequently, vulvo-vaginal (in women) or anal infection is seen. Oral candidiasis may be first seen when the CD4+ T-cell count falls to 200 to 500 cells/mm3 and is an indicator of progression to AIDS. Esophageal candidiasis meets criteria for an AIDS diagnosis. Persons with AIDS do not commonly have systemic candidiasis, because granulocytes are the major defense against it as opposed to mucosal surfaces, where T cells are the major defense; however, it may be nosocomially acquired and cause severe illness in late-stage AIDS (Launay et al., 1998). Oropharyngeal candidiasis occurs in up to 90% of persons with HIV infection in the United States at some point in their illness (Darouiche, 1998). Oropharyngeal candidiasis maybe seen in several forms primarily of three major types: (1) pseudomembranous (usually synonymous with thrush), (2) erythematosus (atrophic), and (3) angular cheilitis (Phelan, 1997). The most common is pseudomembranous candidiasis. In this form, white curdlike removable plaques can be seen on the oral mucosa. These can be removed, leaving behind an erythematous or bleeding surface. The erythematous form manifests as smooth red areas in the oral cavity or the dorsal surface of the tongue, where patchy depapillation may be seen, and are easy to miss on inspection. Candida infection also can produce redness and cracking at the edges of the mouth (angular cheilitis) (Greenspan & Greenspan, 1997; Phelan, 1997). Diagnosis is by potassium hydroxide (KOH) preparation of a smear from the oral lesion or other staining techniques. Treatment for oral candidiasis can vary. Topical therapy includes nystatin sus-

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 191

pension or oral pastilles or clotrimazole troches. Oral fluconazole, itraconazole, and ketoconazole can also be used. The angular cheilitis usually responds to topical antifungal agents such as nystatin and clotrimazole creams. Oral candidiasis usually responds well to therapy, especially early in HIV infection (Phelan, 1997). Esophageal candidiasis is accompanied by dysphagia, painful swallowing (odynophagia), and retrosternal pain without swallowing, although the latter may be due to lesions from other organisms (Minamoto & Rosenberg, 1997). Occasionally patients initially show esophageal perforation or upper gastrointestinal bleeding. Yellowishwhite plaques may be seen in the esophagus. The practical approach to HFV-infected patients with oral candidiasis and esophageal symptoms is to initiate empiric treatment for esophageal candidiasis and not perform endoscopy, although it may be done in order to confirm a potential AIDS diagnosis by biopsy. Treatment usually involves administration of fluconazole or ketoconazole and may require amphotericin B (a systemic antifungal agent with potentially severe toxicity that is not effective orally) in refractory cases (Goldschmidt & Dong, 1999; Minamoto & Rosenberg, 1997). Definitions of what is refractory may vary (Fictenbaum & Powderly, 1998). Despite therapy, esophageal lesions may persist and make obtaining adequate nutrition by normal methods difficult and painful, thereby resulting in inadequate nutrition and loss of weight. Routine primary prophylaxis against candidiasis is not currently recommended because treatment remains generally effective despite some reports of fluconazole-resistant strains. For recurrence, particularly for esophageal candidiasis, fluconazole or itraonazole may be considered for suppression (USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999; Greenspan & Shirlaw, 1997). Vaginal candidiasis may occur frequently in those women who do not have HIV infection, as well as those who do. It is the second most common vaginal infection in those who are non-HIV-infected (Sobel et al., 1998). Thus, clinicians may miss this indication of underlying immunodeficiency, which is often a presenting manifestation of HIV disease in women. Common symptoms include vulvovaginal pruritus, burning, and a white or sometimes yellow, thick vaginal discharge usually without odor. Suspicion of HIV infection should be aroused in women who have vaginal candidiasis that is recurrent or refractory to treatment (Cohen & Durham, 1993; Minkoff et

192

THE PERSON WITH HIV/AIDS

al., 1999; Wright & Johnson, 1997). Sobel (1992) defines recurrent vaginal candidiasis as "the occurrence of at least four mycologically proven symptomatic episodes within 12 months, with the exclusion of other common vaginal pathogens" (p. S148), whereas others counsel that one should be suspicious of HIV infection in women who have more than two episodes within 6 months or persistence of candidiasis after two treatment courses. Severe vaginal candidiasis is an HIVassociated symptomatic disorder. See Appendixes 2, 3, and 4.

Cryptococcosis (Cryptococcus neoformans) C. neoformans, the cause of cryptococcosis, is a yeast that is encased in a capsule. Pigeons appear to be the chief vector, and the organism is found in pigeon dung and in the debris of pigeon roosts as well as soil contaminated with pigeon and chicken droppings (Buchanan & Murphy, 1998). In humans, inhalation of the organism can cause primary infection in the lung. Relatively recently it has been recognized that many healthy individuals experience mild or subclinical cryptococcal disease with the discovery of old healed lesions found on routine autopsies. In New York City alone there are an estimated 15,000 subclinical cases per year (Rippon, 1988). C. neoformans is considered to be the third most common life-threatening fungal infection in persons with AIDS, developing in an estimated 5% to 10% of patients in the United States and up to 30% in patients in Africa (Aberg & Powderly, 1998; Oursler et al., 1999). The prevalence in children with AIDS may be about 1% (Abadj et al., 1999). In HIV disease, the major clinical pictures are pulmonary, central nervous system, and skin lesions, and may result from dissemination. In HIVinfected persons, cryptococcosis may result from acute infection, reactivation of an earlier infection, or both (Hajjeh et al., 1999). Although the lung is the usual primary infection site, C. neoformans has a predilection for the central nervous system. It can also affect the skin, mucous membranes, bone marrow, blood, genitourinary tract, and viscera. Over 75% of cases of crypococcosis occur when the CD4+ count falls below 50 cells/mm3 (Aberg & Powderly, 1998). In persons with cryptococcosis complicating AIDS, disseminated disease can occur in up to 50% (Grant & Armstrong, 1988). C. neoformans is the third most common infectious agent (after HIV itself

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 193

and T. gondii) causing neurological disease in patients with AIDS. Meningitis is the most common manifestation seen and may occur as either the initial opportunistic infection or as a later complication. Manifestation of cryptococcal meningitis may be either subtle or acute. Fever, headache, and altered sensorium, which may persist for weeks, are the most common symptoms. Papilledema may occur. Seizures, photophobia, meningismus, and focal neurologic defects are less common. Some patients only demonstrate fever and malaise, with or without headache; thus, it is suggested that persons who are at risk for AIDS or who are known to have HIV infection be evaluated for cryptococcal meningitis and other central nervous system diseases in the presence of persistent fever with or without headache (Minamoto & Rosenberg, 1997). While CT scanning or MRI may be used to detect space-occupying lesions in persons with HIV infection and central nervous system dysfunction, in cryptococcosis the CT scan is usually normal or nonspecifically abnormal. Studies of the cerebrospinal fluid obtained by lumbar puncture may show only mild non-specific abnormalities such as in the white blood cell count or protein and glucose levels, but usually specific tests for cryptococcal antigen are positive. Cryptococcal antigen in the serum may indicate systemic disease, or the organism may be detected in tissue or the cerebrospinal fluid (Minamoto & Rosenberg, 1997). The usual therapy is high-dose parenteral amphotericin B alone or with oral 5-flucytosine (an orally active antifungal agent with relatively low toxicity), with serum levels being monitored for optimum effectiveness. Fluconazole therapy may follow. Side effects of amphotericin B include fever, chills, nausea, vomiting, renal dysfunction, and necrosis, while flucytosine can cause rash, hepatitis, diarrhea, or bone marrow depression. Treatment failure and relapse are common, and long-term suppressive therapy is usually indicated often with fluconazole. Patients receiving it should be monitored for liver function abnormalities and disease. Despite treatment, mortality from cryptococcal meningitis is high in persons with AIDS (Cohen et al., 1998; Klepser & Klepser, 1997; Larsen, 1999). C. neoformans may cause pulmonary disease, and the lung is usually the portal of entry for the organism. Signs and symptoms may include cough, fever, malaise, tachypnea, shortness of breath, pleuritic pain, and focal or diffuse infiltrates on radiograph (Aberg & Powderly,

194

THE PERSON WITH HIV/AIDS

1998). Cutaneous manifestations occur and vary greatly and is a sign of dissemination. When Cryptococcus attacks the adrenal glands, adrenal insufficiency may arise (Cohen et al., 1998). Primary prophylaxis is indicated only in unusual circumstances, and prophylaxis with fluconazole is recommended after an initial episode (USPHS/ IDSA Prevention of Opportunistic Infections Working Group, 1999). (See Appendices 2, 3, and 4.) Smoking and certain outdoor occupations have been associated with an increased risk of cryptococcosis (Hajjeh et al., 1999).

Histoplasmosis Disseminated histoplasmosis has been recognized recently as an important opportunistic infection in AIDS and is included in the case definition of AIDS. It is caused by Histoplasma capsulatum and is a major endemic mycosis in the Caribbean, Central America, and South America and in river valleys in the United States, especially in the central and eastern areas (Minamoto & Rosenberg, 1997; Walker, 1998). In the United States it is endemic in the Midwest, where 85% to 90% of the population has been infected by 20 years of age. In most cases infection is asymptomatic (Walker, 1998). H. capsulatum is widely distributed in the soil and grows in association with fecal material from birds (including chickens) and bats. In immunocompetent persons, primary infection occurs by inhalation of spores. Cells are then distributed by the blood to other organs. In the immunocompetent person the organisms are usually sequestered or destroyed by the immune system, and the lung lesions heal. Occasionally infection is associated with high fever and pneumonia. In persons with AIDS, histoplasmosis may be a primary infection or reactivation of a latent one. Persons may have acquired primary infection when residents in an endemic area or merely while traveling in one. Clinical manifestations of disseminated histoplasmosis typically include fever, lymphadenopathy, hepatosplenomegaly, weight loss, cough, and pulmonary infiltration. Occasionally neurological manifestations such as meningitis present (Sande & Volberding, 1997). In persons with AIDS, unusual manifestations may also be present, including endocarditis or central nervous system (CNS) involvement

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 195

(Minamoto & Rosenberg, 1997). Diagnosis is made through culture of tissue, especially bone marrow. Antigen to H. capsulatum has been detected in blood and urine specimens by radioimmunoassay or ELISA (Minamoto & Rosenberg, 1997). Therapy is less successful in persons with AIDS than in other immunocompromised conditions. The mortality rate is very high, and relapses are quite common. At present, the therapy of choice is amphotericin B, followed by itraconazole or fluconazole. Lifelong maintenance therapy is necessary to prevent relapse (Cohen et al., 1998). Primary prophylaxis is not routinely indicated, but prophylaxis usually with itraconazole is indicated to prevent recurrence (USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). (See Appendices 2, 3, and 4.) Coccidioidomycosis Coccidioidomycosis is caused by the fungus Coccidioides immitis. This organism is endemic in the southwestern United States, especially in Arizona, California, and New Mexico. It is also commonly found in Mexico and Central and South America. Disseminated Coccidioidomycosis is rare in immunocompetent persons. In persons with AIDS, it is usually the result of reactivation of latent infection, although primary infection is possible (Minamoto & Rosenberg, 1997). Infection is acquired by exposure to contaminated soil. Inanimate objects, such as packages from endemic areas, can also carry the infection (Galgiani, 1999; Meunier, 1988). In the immunocompetent person, most infection is asymptomatic or an upper respiratory infection may be noticed. However, as many as 35% to 40% will develop symptomatic pulmonary infections, and a small number will develop a pulmonary nodule or cavity or disseminated disease (Kirkland & Fierer, 1996). In one series of 170 patients with HIV infection living in Arizona, 25% developed Coccidioidomycosis (Ampel, Dols, & Galgiani, 1993). In persons with AIDS, diffuse and focal pulmonary disease, meningitis, cutaneous lesions, and/or disseminated disease may be seen. The clinical presentation includes fever, malaise, weight loss, and cough. Severe, disseminated Coccidioidomycosis is more common in persons with CD4+ T cells < 200 jl/L. Pulmonary involvement is usually present and is manifested

196

THE PERSON WITH HIV/AIDS

on chest x-ray. Treatment with fluconazole or itraconazole can be effective in non-meningeal infections (Kirkland & Fierer, 1996). Meningeal infection is involved in about one third to one half of cases of disseminated coccidioidomycosis. Usually this meningitis is either subclinical or chronic, but it can present as an acute illness in the immunodeficient patient. Treatment with amphotericin B, either intravenously or intrathecally, is necessary in mehingeal infections (Kirkland & Fierer, 1996). Acute therapy is followed by longterm maintenance therapy usually with fluconazole, itraconazole, or, if necessary, amphotericin B (Lortholary, Denning, & Dupont, 1997). Prophylaxis against recurrence is recommended for life (USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). (See Appendices 2, 3, and 4.) Other Fungi Penicillium marneffei, causing penicilliosis, is considered to be an emerging pathogen. It is most common in Southeast Asia, such as Thailand and Taiwan, and parts of China. In HIV-infected persons in those areas it is the third most common OI after extrapulmonary TB and cryptococcosis. It has been suggested by some to be an addition to the list of AIDS indicator diseases for HIV-infected persons who visit or live in these areas (Duong, 1996; Hung et al., 1998). Symptoms of P. marneffei infection may include nonspecific clinical manifestations such as fever, anemia, weight loss, hepatosplenomegaly, and lymph adenopathy. It has a predilection for the skin and lungs and may disseminate. Skin lesions include papules, a generalized papular rash, and abscesses or nodules. If the respiratory tract is involved then a nonproductive cough may be seen. Diagnosis is by culture, and PCR techniques are also available. Treatment for severe disease is amphotencin B usually followed by itraconazole for life (Cooper & McGinnis, 1997; Duong, 1996; Kantipong, Panich, Pongsurachet, & Watt, 1998; Karp & Neva, 1999). Aspergillosis may result from several organisms, but Aspergillus fumigatus is most common. Aspergillus fumigatus is an opportunistic mold that appears to be increasing in infection prevalence. It is ubiquitous, even being found in Antarctica. It is found in the soil,

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 197

decaying vegetation, bird droppings, and air conditioning vent dust, as well as in pepper, spices, and marijuana. Clinical patterns vary with patient condition and organism source. In AIDS, it is most often seen in the late stages, and the lung is the most common site of infection. Symptoms include hemoptysis, arid it may be mistaken for TB (Denning, 1998; Walker, 1998). Mortality is high in immunosuppressed persons. Treatment typically is amphotericin B followed by itraconazole (Denning, 1998). Other fungal infections causing disease in HIV-infected persons less often include blastomycosis, the fusarium species Mucorales, Sporothrix schenckii, and even Saccharomyces cerevisae (Durden & Elewski, 1997; Minamoto & Rosenberg, 1997). Newer antifungal agents are being developed (Terrell, 1999).

VIRAL DISEASES The herpesvirus group of DNA viruses is ubiquitous and contains more than 70 identified members classified within three subfamilies, Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae (Walker, 1998). Those that are the most important in disease manifestation, especially in persons with HIV infection, are cytomegalovirus (CMV), herpes simplex virus (HSV) types 1 and 2, varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and human herpesvirus type 8, which is discussed under Kaposi's sarcoma. They share the property of persistence in latent form with the potential of reactivation after initial infection. Susceptibility of cells to primary herpesvirus infection depends on a variety of factors including, age, immune factors, and unique viral features. Reactivation of the latent virus may depend on imrnunocompetence and stress-related factors (Cavert, 1997b). Primary infection, the latent stage, and reactivation with the same virus can involve different cell types. Actual disease manifestations can therefore vary. The JC virus is a human polyomavirus associated with progressive multifocal leukoencephalopathy (PML), a demyelinating disease. It is considered an opportunistic pathogen in humans, as is parvovirus B19 and papillomavirus (Cavert, 1997b). The aforementioned viruses and others seen more rarely are discussed below in regard to their manifestations in persons with AIDS.

198

THE PERSON WITH HIV/AIDS

Cytomegalovirus (CMV) CMV belongs to the Herpesviridae family of DNA viruses and the subfamily betaherpesvirus (Cohen et al., 1998; Demmler, 1998). CMV is ubiquitous, and most people are infected sometime in their life. Primary CMV infection in immunocompetent persons is usually benign and can be acquired at any age, although it occurs most frequently in childhood (Cavert, 1997b). In developed countries, by 50 years of age, about half of the population are seropositive for CMV. CMV seroprevalence in adults ranges between 50% and 80% (Belshe, 1991; Cohen et al., 1998). In developing countries, CMV infection occurs earlier, and about 90% of children are CMV-seropositive by school age (Belshe, 1991). Congenitally acquired CMV has severe effects and is a major problem in the United States and elsewhere. About 1 % of newborns are infected with CMV. Thousands of infants are born each year with symptomatic CMV disease (mental retardation, blindness, and/or deafness), many of whom die early. Of the additional asymptomatic infants born with CMV each year, about 15% later develop severe problems (e.g., deafness and neurological deficits), many of whom require major therapeutic interventions and/or custodial care. Prevention during pregnancy is important, including good handwashing, which helps reduce spread (Demmler, 1998; Lashley, 1998). CMV may be shed in oropharyngeal secretions such as saliva, cervical secretions, semen, urine, and breast milk for prolonged periods of time even if the person is asymptomatic (Belshe, 1991). Persons who are immunocompromised, especially due to defects in cellular immune response, either iatrogenically (e.g., chemotherapy, transplant recipients) or because of disease, can experience reactivation of latent CMV. Persons immunocompromised by HIV are no exception. Although severe primary CMV infection can occur in persons with HIV, the majority of infection results from reactivation of previously acquired CMV. As many as 90% or more of persons with AIDS develop active CMV infection, and, before the use of protease inhibitors, 20% to 40% of persons with AIDS developed CMV end-organ disease, particularly when CD4+ cell counts were below 50 cells/mm3 (Cheung & Teich, 1999; Jacobson, 1998). In persons with AIDS, CMV infection may be manifested in a variety of organs including the eye, esophagus, colon, lung, liver,

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 199

brain, and adrenal glands. In addition, systemic CMV infection is often present, and multiple organs are often simultaneously involved (Cheung & Teich, 1999; Demmler, 1998); moreover, CMV may further contribute to imrnunosuppression caused by HIV. In HFV-infected persons suspected of having CMV infection, diagnosis is generally made by isolation of virus through tissue culture, detection of virus antigens by direct fluorescence or ELISA, or through molecular techniques and by use of CMV antibodies through serology (Belshe, 1991). Chorioretinitis is the most common opportunistic infection of the eye in persons with AIDS, often occurring when CD4+ T-lymphocyte counts fall below 50 cells/mm 3 (Cheung & Teich, 1999; Cohen et al., 1998; Cunningham & Margolis, 1998; Greenwood & Graham, 1997); therefore, persons with AIDS should have ophthalmologic examinations at regular intervals. Signs and symptoms of CMV retini tis depend on the location of the lesions. Often retinitis begins unilaterally but becomes bilateral because of the presence of CMV in the blood. Sometimes persons are initially asymptomatic but may complain of floaters, loss of peripheral vision, blurred vision, unilat eral visual field loss, or decreased visual acuity (Cohen et al., 1998; Greenwood & Graham, 1997). The ophthalmologic examination shows a perivascular whitish colored retinal infiltrate that may be accompanied by hemorrhage or a diffuse fluffy yellow white infiltrate with or without hemorrhage. These lesions have been described as "cottage cheese and ketchup" appearance and enlarge in a "brushfire" pattern (Demmler, 1998). Chemoprophylaxis against CMV disease in adults who are CMV seropositive and who have a CD4+ T lymphocyte count of < 50/mm3 is usually with oral ganciclovir. Trials attempting prophylaxis against CMV retinitis using ganciclovir have been reported (Jacobson, 1998). For treatment, ganciclovir, either orally or IV in combination with foscarnet (Foscavir), is usually the firstline choice. Maintenance therapy for the rest of the individual's life is necessary, as ganciclovir (Cytovene) is virostatic, not virocidal, and thus CMV is not eliminated. Reactivation is common. Cidofovir (Vistide) shows effectiveness when given IV (Jacobson, 1998). For CMV retinitis, ganciclovir may be administered through ocular injection or by means of intravitreal implant impregnated with ganciclovir and sometimes intravitreal foscarnet is used (Cavert, 1997b; Cheung & Teich, 1999; Greenwood & Graham, 1997; Martin et al.,

200

THE PERSON WITH HIV/AIDS

1999). Oral ganciclovir may be given along with the implant (Martin etal., 1999). In persons with AIDS and pulmonary infection, CMV is detected alone quite infrequently and is associated with other pulmonary pathogens in many cases. Signs and symptoms resemble those of interstitial pneumonitis and include shortness of breath, dyspnea on exertion, hypoxemia, and a nonproductive cough (Demmler, 1998). Ganciclovir is less effective in treating CMV pneumonia than in treating CMV retinitis. In the gastrointestinal (GI) tract, CMV can cause colitis, gastritis, enteritis, ulceration, esophagitis, small bowel obstruction and perforation, and hepatitis. About one third of all persons with AIDS have CMV infection somewhere in the GI tract (Lew et al., 1997), typically resulting in diarrhea and cramping abdominal pain with as many as 20 liquid stools per day, weight loss, possible fever, anorexia, and malaise. Although most have a prolonged disease course, some show rapid disease progression, including perforation of the colon or hemorrhage. Diagnosis is often by biopsy, which shows intranuclear inclusions of CMV on histologic examination and other typical findings. Persons with esophagitis or gastritis due to CMV may present with dysphagia and substernal or epigastric pain. Ulcers may be demonstrated (Cohen et al., 1998). CMV may cause hepatitis and biliary disease, which may only become evident at autopsy (Cheung & Teich, 1999). Ganciclovir and foscarnet are used in treatment (Cheung & Teich, 1999). CMV also can infect the central nervous system, and in patients with AIDS, radiculop'athy may be found. Encephalitis, often in combinations with other pathogens, may occur. Symptoms of encephalitis may include altered mental state, headache, difficulty concentrating, personality changes, fever, and somnolence. Only brain biopsy gives confirmation of the diagnosis, but newer molecular biology techniques applied to CSF analysis are promising (Roullet, 1999). Radiculopathy symptoms include pain and weakness of the legs, spasticity, areflexia, urinary retention, and hypoesthesia (Cohen et al., 1998). CMV prophylaxis is often used for patients with CD4+ cell counts < 50mm3, usually with oral ganciclovir. (See Appendices 2, 3, and 4 for information on prevention and prophylaxis.) Herpes Simplex Virus Types 1 and 2 (HSV-1 and HSV-2) The herpes simplex virus (HSV) is classified within the alphaherpesvirus subfamily. There are two types, HIV-1 and HSV-2, that share

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 201

approximately 50% of their DNA in common but which have some different biological properties and are antigenically distinct (Belshe, 1991; Walker, 1998). In general, HSV-1 is responsible for oral-facial lesions, visceral infections in the immunocompromised persons, and encephalitis, whereas HSV-2 is associated with genital tract infections and neonatal disease, although overlap exists (DeVita et al., 1997). Primary infection with HSV-1 is most likely acquired during the first decade of life, although as many as half of adults in upper socioeconomic classes of developed countries may lack HSV-1 antibodies. Primary HSV-2 infection is more likely to be acquired in the adolescent or adult years (Cavert, 1997b; Walker, 1998). About 25% of the general U.S. population is seropositive for HSV-2. Rates are higher for those who are more sexually active; in males with HIVinfection the rate for HSV-2 infection ranges from 50% to 80%, while for HIV-1 infection it is more than 90% (Cavert, 1997b). Primary infection of epithelial cells with HSV-1 is most often asymptomatic; however, in some, painful blisters and ulcerated lesions ("fever blisters," "cold sores") occur in the mucous membranes of the mouth and may involve the pharynx, lips, tongue, and palate. Fever, malaise, and regional lymphadenopathy may also occur. Symptoms generally last under 3 weeks, and the disease is self-limiting (DeVita et al., 1997). After primary infection, experts believe that HSV travels through sensory nerves to sensory nerve ganglia, such as sacral and trigeminal ganglia, where it becomes latent. Reactivation of HSV-1 can occur with asymptomatic shedding of the virus or with visible lesions, often on the lips and sometimes on the nose or eyes. Recurrent disease frequently follows stressful events that can include emotional stress, hormonal changes, fever, ultraviolet light exposure, and decreased cellular immunity, and may be related to decreased CD8+ cell surveillance. The HSV latency cycle consists of primary infection at a peripheral site where the virus replicates, travels via axons to neuronal cell bodies in sensory or autonomic ganglia where latency is established and maintained in neurons, and reactivation from latency with travel via the axon to the periphery, where replication and viral shedding may occur. HSV-1 can be responsible for genital herpes infection as well, although less commonly than HSV-2 (Cavert, 1997b; DeVita et al., 1997; Posavad, Koelle, & Corey, 1998; Sacks, 1999; Walker, 1998). Viral shedding of

202

THE PERSON WITH HIV/AIDS

lesions can occur asymptommatically, and counseling should include information on prevention of transmission. Primary infection with HSV-2 most commonly is manifested as genital herpes, although HSV-2 has also been implicated in oral infections. Genital herpes has become one of the most prevalent sexually transmitted diseases in the United States. Signs and symptoms associated with primary infection include systemic symptoms such as malaise, fever and headache, dysuria, pain and tenderness in the affected area, lymphadenopathy, and vesicular lesions on the genitalia, which become ulcerated. In women, vaginal and cervical lesions may be present, while in homosexual men, perianal lesions and proctitis may occur. Lesions on the buttocks or thighs may also be present. Lesions may be present for 2 to 3 weeks. In some cases, primary infection may be asymptomatic (DeVita et al., 1997; Sacks, 1999). After primary infection, HSV-2 typically establishes latency in sacral ganglia, and recurrent infection may follow viral reactivation by the appropriate stimuli, as discussed above. Recurrent HSV-2 infection tends to be milder than primary infection, and tingling and burning sensations often precede lesions. HSV-2 infection of the fetus or the neonate may occur transplacentally, by passage through the birth canal or sometimes because of invasive fetal monitoring (Jackson & Soper, 1997). Asymptomatic shedding occurs especially around the time of a symptomatic episode (Sacks, 1999). Because most people have been infected with primary HSV before acquiring HIV infection, reactivation of the virus is usually responsible for clinical symptoms. Most frequently, mucocutaneous lesions are seen that originally may be local. Perianal HSV infection was one of the early reported opportunistic infections in persons with AIDS. Severe proctitis may also be present, the signs and symptoms of which include severe anorectal pain, perianal lesions that become ulcerated, constipation, itching, and neurological symptoms, which include impotence and neurogenic bladder (Sande & Volberding, 1997). HSV may also produce esophageal lesions and ulcerations that may be associated with difficult and painful swallowing; however, esophagitis in persons with AIDS is more commonly due to CMV and Candida (Sande & Volberding, 1997). HSV encephalitis may also occur but is infrequent and can be hard to distinguish from

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 203

encephalitis caused by Cryptococcus neoformans and Toxoplasma gondii. The encephalitis may be acute or subacute (Sande & Volberding, 1997). HSV-1 is also associated with herpes simplex keratitis (a common cause of blindness). Oral lesions consisting of many palatal or gingival vesicles that ulcerate are common in HIV infection. Although healing usually occurs, recurrences are common (Cohen et al., 1998). Diagnosis is usually made on clinical grounds or on viral isolation from tissue. Treatment with acyclovir (Zovirax) is generally effective, although if recurrences are frequent and severe, long-term suppressive therapy may be necessary. In acyclovir-resistant HSV infections, foscarnet may be used but has a greater toxicity risk. Other drugs that may be used are valacyclovir and famciclovir (Balfour, 1999; Sacks, 1999). Newer approaches include nucleoside analogs and antisense compounds, as well as a HSV vaccine (Sacks, 1999).

Varicella-Zoster Virus (VZV) Varicella-zoster virus (VZV) is also an alphaherpesvirus. Primary infection with VZV usually occurs in childhood in the form of chicken pox, which is a worldwide illness. Recurrent VZV infection results in herpes zoster (shingles) and is most often seen in adults (Wright & Johnson, 1997). VZV probably is acquired by respiratory route, multiplies in the respiratory tract and local lymph nodes, is released into the blood, and is disseminated throughout the body. Varicella (chicken pox) usually begins with fever, headache, and malaise that precede a rash that develops sequentially into vesicles, pustules, and scabs that are widely distributed on the body. Ninety percent of chicken pox cases are in children under 10 years of age, and lesions heal without complications by the second week in most cases. In adults, varicella is often more severe and complicated, with varicella pneumonia, purpura, specific organ involvement (e.g., orchids, pancreatitis) , and neurologic (encephalitis, polyneuritis) complications seen (DeVita et al., 1997). Most persons with AIDS will have had primary infection with HZV in the form of chicken pox in childhood, and therefore primary varicella is not common. After initial infection, VZV invades the peripheral nerves and moves into the dorsal root ganglia, where it becomes latent. Under

204

THE PERSON WITH HIV/AIDS

conditions of immunosuppression such as stress, aging, chemotherapy, and others listed above, the latent VZV reactivates as zoster (shingles). A nonimmune person who is exposed to VZV usually develops varicella (chicken pox), but the reverse is not usual. When VZV reactivates, the virus travels to the distal nerve branches and the skin, where lesions typically appear in the skin area supplied by the affected nerve. Before the rash is seen, persons may have malaise, fever, and increased sensation in the area of the subsequent rash. The rash is maculopapular with vesicle development and crusting. In herpes zoster, the rash is usually restricted to one to three dermatomes usually being local and segmented. In persons with AIDS, however, the rash is often more generalized. Neuralgia is often severe and persistent (DeVita et al., 1997; Sande & Volberding, 1997). Up to 15% of persons with HIV develop herpes zoster at some time (Geusau & Tshachler, 1997). If zoster remains localized, the dermatome site affected can determine the effects. The trunk is the most frequent site. Involvement of the ophthalmic branch of the trigeminal nerve can result in eye involvement, with effects on the cornea, eyelid, retina, conjunctiva, and uvea, leading to blindness (Cohen et al., 1998; DeVita et al., 1997; Sande & Volberding, 1997). Posttherpetic neuralgia can persist for months or even years. Treatment is usually with oral acyclovir, valcyclovir, or famciclovir. IV therapy may be necessary in severe central nervous system involvement, for example (Balfour, 1999; Cavert, 1997b). Analgesic agents and topical creams may prove helpful, but most have not been optimally effective. Primary prophylaxis against VZV is recommended as a standard of care in certain instances (USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). (See Appendices 2, 3, and 4.) Epstein-Barr Virus (EBV) The Epstein-Barr virus belongs to the gammaherpesvirus subfamily. Members of this subfamily have a very narrow host range, grow in lymphocytes, and are capable of inducing transformation to malignancy (Walker, 1998). EBV is distributed widely throughout the world. In countries that are less developed and/or have a high population density, 80% to 100% of children demonstrate antibodies

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 205

to EBV by 3 to 6 years of age. In more developed countries, such as the United States, infection may occur in later childhood in persons of lower socioeconomic status, while it may occur later (i.e., in adolescence or young adulthood) in persons of higher socioeconomic status. By 30 years of age, 80% to nearly 95% or more of persons worldwide show EBV seropositivity (Feigin & Cherry, 1998; Walker, 1998). There are two strains, type 1 and type 2. Type 2 is most commonly seen in Africa and has become endemic in HIVpositive homosexuals, whereas type 1 is most prevalent in developed countries among the general population (Yao et al., 1998). Primary infection that occurs early in childhood is usually asymptomatic. When primary infection occurs in later childhood, adolescence, or young adulthood, the most common outcome is infectious mononucleosis (Feigin & Cherry, 1998). EBV appears to initially infect B lymphocytes. EBV causes infection and replicates in the epithelial cells of the oropharynx, nasopharynx, and the salivary glands. EBV is disseminated by the blood and the lymphoreticular system and eventually usually becomes latent. EBV is known to cause infectious mononucleosis (Feigin & Cherry, 1998; Walker, 1998) and has been suspected of contributing to chronic fatigue syndrome. EBV was originally identified in tumor cells from a patient with Burkitt's lymphoma. It continues to be etiologically implicated in endemic Burkitt's lymphoma in Africa and some cases elsewhere, especially in immunocompromised persons, and in nasopharyngeal carcinoma, in which case it may require a genetic susceptibility factor as well (Rickinson, 1998; Walker, 1998), such as a chromosomal translocation. See Lashley (1998) for more details. EBV has been associated with oral hairy leukoplakia in adults with HIV and with lymphocytic interstitial pneumonitis in HlV-infected children, leiomyosai comas in children with AIDS, and, as mentioned above, lymphomas. Oral hair)' leukoplakia (HL) is characterized by whitish thickening or plaques seen on the oral mucosa, especially on the lateral surface of the tongue. In contrast to lesions caused by Candida they are difficult to remove. (The term "hairy" refers to projections that extend outward from the surface of the lesion and are evident on microscopic examination. It may not require treatment.) High doses of oral acyclovir or valciclovir may be used for treatment, and, if not successful, topical treatment such as podophyllin solution or retinoin may be used; however, hairy leukoplakia

206

THE PERSON WITH HIV/AIDS

tends to return when treatment stops (Greenspan & Shirlaw, 1997). Because hairy leukoplakia is so frequently an indication of HIV infection or immunodeficiency, the underlying reason for its appearance should be investigated. HL is listed in the B category of the 1993 CDC criteria for AIDS and appears more frequently as the CD4+ cell count declines, being a harbinger of disease progression (Centers for Disease Control and Prevention, 1992; Cohen et al., 1998).

The JC Virus The JC virus (JCV) is a member of the genus polyomavirus, of the Papovavirus family. It was first isolated from the brain tissue of a person with progressive multifocal leukoencephalopathy and was first named in 1971 (Clifford et al., 1999; Richardson, 1988; Walker, 1998). This DNA virus has several types and subtypes (Agostini et al., 1998). Primary infection occurs in childhood, and JC antibody seroprevalence worldwide is between 60% and 80%. It appears that primary infection is subclinical or inapparent, and its nature and the mode of transmission remain unelucidated. It is suspected that viremia does occur, since JCV reaches the urinary tract, the brain, and other organs (Walker, 1998). It is not clear whether other factors are needed in addition to immunosuppression to allow JCV to cause progressive multifocal leukoencephalopathy (PML). PML is a demyelinating disease of the central nervous system that was first recognized in 1958. Lesions occur in both gray and white matter. Demyelination occurs as a result of infection of the oligodendrocytes (Sadler & Nelson, 1997b). It is ultimately reported in about 5% of patients with AIDS. Clinically the disease in persons with AIDS is similar to that in other immunocompromised patients. Common symptoms include mental status alterations, headaches, cognition difficulties, ataxia, focal neurologic signs, visual problems, and hemiparesis (Cavert, 1997b). Diagnosis is through detection of JCV DNA, especially in the cerebrospinal fluid, often by PCR (Lafon et al., 1998). The prognosis is poor, and survival after PML onset is often a matter of a few weeks or months. To date, specific therapy has been ineffective but HAART therapy that reduces viral load has

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 207

resulted in longer survival periods (Clifford et al., 1999; Hall et al., 1998). Molluscum contagiosum Molluscum contagiosumis a member of the family Poxviridae (poxvirus) (Walker, 1998). Infection results in pearly or flesh-colored papules with a central white curdlike umbilicated core that may be located on the skin or mucous membranes. Lesions are often present on the trunk, extremities, genitalia, and the face, and spread by direct contact as well as possibly indirectly through fomites such as towels (Geusau & Tschachler, 1997; Walker, 1998). Lesions can cluster multiply, with secondary infection possible. In persons with AIDS, lesions often spread in sheets, especially across the face. It is thought that seeding may spread them. Because of their rapid multiplication in persons with AIDS, immediate treatment is desirable. Even in immunocompetent persons resolution of the lesions can take months to years. Sometimes physical methods such as cautery, curettage, and cryotherapy are used to remove the lesions. Lesions may be seen in up to 20% of HFV-infected persons (Geusau & Tschachler, 1997; Walker, 1998). Parvovirus Parvovirus B19 belongs to the family Paruoviridae. It is a nearly ubiquitous virus; infections are acquired in childhood (80% before age 15 years), and about half are asymptomatic. Infection results in various illnesses including erythema infectiosum in childhood (Walker, 1998). In HlV-infected persons, red cell aplasia can occur from parvovirus B19 infection. IV immunoglobulin has been used in treatment. Parvovirus infection should be considered in persons with HIV-infection who have severe anemia (Cavert, 1997b).

Human Papillomaviruses Human papillomaviruses (HPV) belong to the family Papovaridae. They are responsible for many kinds of warts, including common

208

THE PERSON WITH HIV/AIDS

skin warts and those affecting anogenital, oral, and cervical areas such as condyloma acuminatum. Over 85 types are known (Walker, 1998; Wright & Johnson, 1997). Human papillomavirus infection may be the most common sexually transmitted disease (Cavert, 1997b). Certain HPV subtypes such as 16, 18, and 31 are associated with cervical intraepithelial neoplasia, which can lead to cervical cancer in women (Walker, 1998). Recognition of the risk that HIV infection and immunosuppression pose for cervical cancer in women eventually led to its being classified as an AIDS-defining condition in the 1993 definition (Centers for Disease Control and Prevention, 1992). Byrne, Taylor-Robinson, Munday, and Harris (1989) reported that 95% of HIV-infected women in their clinic showed clinical or subclinical evidence of HPV infection. While results from other studies vary, HIV-infected women are much more likely to have HPV infection than those who are HIV negative (Hankins et al., 1999). Younger women are more likely to have HPV (Palefsky et al., 1999). Cryotherapy is effective for common warts, and some respond to tretinoin. Topical podophyllin is effective for mucosal warts (Wright & Johnson, 1997). Orally, in addition to causing warts, HPV is sometimes found in conjunction with hairy leukoplakia (Noyer & Simon, 1997). Hepatitis Viruses Hepatitis may result from hepatitis virus types A through E, which are members of different classes. Hepatitis B and C may be particularly transmitted in similar ways to HIV (Alter, Mast, Moyer, & Margolis, 1998; Walker, 1998). The efficacy of transmission of hepatitis B and C appears increased in HIV infection, but other results of coinfection are unclear if present (Casey, Cohen, & Hughes, 1996; DeVita et al., 1997). Primary prophylaxis against both hepatitis A and B is generally recommended in susceptible persons (USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). Hepatitis C was discovered in 1989 and is now considered a major cause of chronic liver disease, especially cirrhosis and liver failure (Younossi & Canute, 1999). (See Appendices 2, 3, and 4.) The various forms of hepatitis have similar symptoms but often no symptoms are present. Symptoms may include fatigue, fever,

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 209

muscle aches, loss of appetite, nausea, vomiting, and vague abdominal pain. In some cases, jaundice, dark urine, and light colored stools may be seen. Hepatitis B and C have the potential to progress to chronic liver disease while this is not true of Hepatitis A (Focus on Hepatitis, 1999; Newell & Nelson, 1999).

BACTERIAL INFECTIONS Opportunistic bacterial infections were originally considered less important in complicating HIV infection than other microorganisms. However, this is no longer true, and they are now recognized for their true contribution to morbidity and mortality. CDC first listed recurrent bacterial pneumonias in the 1993 case definition of AIDS. The bacterial infections that are most important are those caused by mycobacteria such as Mycobacterium avium complex and Mycobacterium tuberculosis. Others discussed in this section are Nocardia, Bartonella, Salmonella, Haemophilus influenzae, Pseudomonas aeroginosa, and Rhodococcus equi. Certain other bacterial diseases cause pneumonia, bronchitis, and sinusitis in HIV-infected persons but are not actually considered opportunistic. Some of these are discussed briefly at the end of this section. Bacterial infections may also be secondary and follow other OIs such as after CMV infection of the lungs or GI tract or after perianal HSV ulcers (Kovacs, Leaf, & Simberkoff, 1997).

Mycobacterium Avium Complex (MAC) and Other Atypical Mycobacteria Mycobacteria other than M. tuberculosis are sometimes referred to as potentially pathogenic environmental mycobacteria (PPEM). Mycobacterium avium and Mycobacterium intracellulare are atypical mycobacteria that, although distinguishable from each other by DNA and certain other techniques, are very similar in many respects. Mycobacterium avium complex (MAC) is a complex of the two species. The PPEM include MAC and other mycobacteria such as M. kansaii and M. gordonae. MAC is ubiquitously distributed in soil and water (French, Benator, & Gordin, 1997). The laboratory often classifies

210

THE PERSON WITH HIV/AIDS

the environmental mycobacteria according to growth rate and pigmentation according to the Runyon classification. MAC belongs to Runyon Group III, which is nonpigmented (Walker, 1998). Like many of the other infections now seen frequently in persons with HIV infection, few cases of disseminated MAC were reported before the early 1980s. Data from skin tests indicate that approximately 40 million persons in the United States have been infected by environmental mycobacteria, and MAC is virtually endemic in the southeastern United States. Before the AIDS epidemic, the typical patient was a middle-aged male who had slowly progressive pulmonary MAC disease in addition to previously existing pulmonary disease (Griffith, 1988), or one in which immunosuppression from predisposing causes such as hematologic malignancies allowed disseminated MAC to make an appearance. MAC appears to be the most frequent systemic bacterial infection seen in persons with AIDS, affecting 15% to 40% (French et al., 1997). There appears to be some type of interaction between HIV and MAC (Havlir etal., 1998). In persons without HIV infection, who develop MAC, pulmonary involvement is most common. Disseminated MAC is seen most often when CD4+ cell counts are below 50 cells/mm3. Clinically, the person with disseminated MAC and HIV infection demonstrates systemic symptoms that include high, swinging fever, weight loss, malaise, anorexia, weakness, myalgia, and night sweats. Cough and headache may be present. If MAC has invaded the colon and small intestine, then diarrhea and abdominal pain and malabsorption may also be seen, resulting in a "wasting" type of syndrome (French et al., 1997). MAC is frequently cultured from the sputum and may be present in pulmonary secretions and tissue. It is believed, however, that MAC alone rarely causes severe pulmonary disease in persons with AIDS. Diagnosis is made on the basis of blood culture, and, if necessary, cultures of sputum, bone marrow, or lymph nodes. Effective therapy may be difficult, and standard antituberculosis drugs when used alone are usually ineffective. Multidrug approaches include clarithromycin or azithromycin combined with ethambutol, often with rifabutin as well. Immunomodulators may also be used (Benson, 1998). Other atypical mycobacteria are now seen in conjunction with persons with AIDS. These include Mycobacterium kansasii, Mycobacterium gordonae, and Mycobacterium xenopi. The most frequently reported of these has been M. kansaii, causing both pulmonary and

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 211

disseminated infection in persons with HIV. In general, the symptoms are similar to MAC (French et al., 1997). Prophylaxis for life as a standard of care is recommended after an initial infection with MAC or other atypical mycobacteria in all HIV-infected persons after disseminated disease and as primary prophylaxis for those with CD4+ cell counts < 50 mm3 (USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). (See Appendices 2 and 3.) Mycobacterium Tuberculosis Beginning in 1984, the rate of decline of tuberculosis (TB) cases in the United States slowed. By 1986 the number of U.S. cases had increased. This trend continued to accelerate until 1993, when a decline began but that was not back to pre-AIDS rates (Centers for Disease Control, 1988; Centers for Disease Control and Prevention, 1994). This increase has been attributed to HIV-related defective cell-mediated immunity. Infectious diseases are the leading cause of death in the world, and among infectious diseases, TB is the major cause of death. TB is increasing worldwide, with about 8.8 million new cases each year and 3 million deaths per year. Worldwide nearly 6 million persons are infected with both HIV and TB, and 90% to 95% of them live in developing countries (Cohen & Durham, 1995; Daley, 1998; Schluger, 1999). Extrapulmonary and disseminated TB have been AIDS-defming illnesses, based on the 1987 CDC surveillance definition, but it was not until 1993 that pulmonary TB was added to the expanded surveillance definition (Centers for Disease Control and Prevention, 1987, 1992). This addition was because pulmonary TB is the most common type in HIV-infected persons and in recognition of the strong epidemiologic link between HIV infection and TB (Centers for Disease Control and Prevention, 1992). Many people acquire tuberculous infection, but in 90% of cases the immune system contains the tubercule bacilli. Active pulmonary TB results from uncontained primary infection, reactivation of a past, latent endogenous infection, or resurgence following a recent exogenous reinfection (Cohen & Durham, 1995). Like many other infections associated with AIDS, it was believed that most cases of AIDS-assodated tuberculosis were the result of reactivation of latent

212

THE PERSON WITH HIV/AIDS

infection rather than from the progression of a primary recent infection. The use of recent molecular techniques have now indicated that in HIV-infected persons, primary infection may account for up to 40% of new cases in urban areas of developed countries (Schurmann, Nightingale, Bergmann, & Ruf, 1997). Some populations that have a higher background prevalence of tuberculosis even in the absence of HIV infection are injecting drug users, immigrants from countries with endemic tuberculosis, and economically disadvantaged inner city residents who often are members of racial/ethnic minorities. Thus, when persons from those populations are infected with HIV, they will also show a higher tuberculosis rate in contrast to White, middle-class homosexuals infected with HIV (Cohen & Durham, 1995). The increase in the tuberculosis case rate is particularly notable in areas in the United States that also have a high HIV infection prevalence. Tuberculosis has been reported in approximately 4% of patients with AIDS in California, 15% in New York City, and 8% in Florida, while in most states less than 3% of reported AIDS cases were associated with TB (Daley, 1998). A diagnosis of tuberculosis often precedes the diagnosis of AIDS. The affected site and manifestations of TB in HIV infection depend on the status of the person's immune system. Persons with HIV infection whose immune system is relatively intact present with clinical symptoms of HlV-associated tuberculosis that are similar to tuberculosis without HIV infection and include such constitutional symptoms as fever, night sweats, weight loss, anorexia, cough, and malaise (Telzak, 1997). Persons with pulmonary tuberculosis may have a cough with sputum production, dyspnea, and chest pain. As the CD4+ cell counts fall, TB may present in atypical ways and include extrapulmonary sites in 40% to 80% of cases (Telzak, 1997). Concomitant pulmonary disease may be present. Therefore, diagnosis of TB at an extrapulmonary site should prompt evaluation for pulmonary TB. Common indicators of extrapulmonary TB include lymphadenitis, disseminated disease and bacteremia, intra-abdominal disease, including the liver and urinary tract, and central nervous system disease, particularly meningitis (Cohen & Durham, 1995). The symptoms seen relate to the specific extrapulmonary sites involved. The frequency of drug-resistant and multidrug-resistant TB (MDR TB), which originally was thought to be due to the AIDS epidemic,

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 213

has also increased and is particularly prevalent in certain geographic areas such as New York City. MDR-TB has been defined as "a case of tuberculosis caused by a strain of M. tuberculosis resistant to two or more antituberculosis drugs" (Riley, 1993, p. S442). However, geography and failed drug treatment due to incorrect therapy or nonadherence are more important in MDR-TB than AIDS. Nosocomial spread is a particular problem in MDR-TB, and the largest outbreaks have occurred in hospitals. Tuberculin skin testing for screening for TB is often a part of standard primary care for the HIV-infected person in the absence of TB-related symptoms. Interpretation of the Mantoux test is based on induration. Five or more millimeters induration is considered positive for persons with HIV disease. Because of the immunosuppression associated with HIV infection, anergy may be encountered; thus, a negative skin test may not accurately reflect actual status, and anergy testing may be recommended but is somewhat controversial. Therefore, it is important to maintain a high index of suspicion for tuberculosis in all persons with HIV infection. Preventive therapy may be considered for persons who are HIV infected and anergic who are from a group or region in which the prevalence of tuberculous infection is 10% or higher (Telzak, 1997). At the present time, persons with AIDS-associated tuberculosis respond well to standard antituberculosis chemotherapy. It is important that susceptibility testing precede treatment. Directly observed therapy is generally recommended, and ways to enhance adherence are an important component of treatment (Cohen, 1997; Cohen & Durham, 1995). Generally, the medication regimen for treatment consists of isoniazid, rifampin, pyrazinamide, and/or ethambutol for 2 months, followed by 4 months of rifampin and isoniazid. Sometimes streptomycin may be added as a supplement (Daley, 1998). Because of the increased risk of tuberculosis in HFV-seropositive persons, it is also important that health care workers protect themselves against transmission and instruct patients on appropriate precautions for household contacts. For those with tuberculosis infection, recommendations for preventive therapy with isoniazid (unless medically contraindicated) with pyridoxine for a minimum of 9 months in persons with HIV infection and a positive tuberculin test; however, a 2-month course of therapy of rifampin and pyrazinamide appears to be an effective alternative (Centers for Disease Control

214

THE PERSON WITH HIV/AIDS

and Prevention, 1998). Rifampin is used less often because of interactions with protease inhibitors (Schluger, 1999) and newer recommendations reflect this. For a review of drugs used in TB and interactions with drugs used in HIV therapy, see Pozniak et al. (1999). Detailed information about TB may be found in the reference by Cohen and Durham (1995) and treatment information is in CDC, 1998 (USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). (See Appendices 2 and 3 for other information on prevention and prophylaxis.)

Nocardiosis Nocardiosis is caused by the Nocardia species, especially Nocardia asteroides. This organism is partially acid fast and has gram-positive staining properties. These bacteria resemble fungi because of their branched, filamentous hyphaelike morphology (Walker, 1998). Distribution is worldwide. Nocardia's natural habitat is the soil, and the organism probably enters the body by inhalation of aerosolized organisms. It is also found in muddy water and rotting vegetables. Nocardiosis is generally considered an opportunistic infection because most infected persons have a serious underlying disease, although this is not essential for infection. Nocardiosis is estimated to occur in 0.3% of patients with AIDS (Kovacs et al., 1997). Most primary infections occur in the lung, with disseminated systemic disease possible. The clinical picture may vary from inapparent infection to severe pulmonary and disseminated disease. Ectopic foci may develop through blood-borne distribution after pulmonary infection (Walker, 1998). In the lung, solitary nodules, localized pneumonitis, or lung abscesses are possible. Clinical findings vary with the organ system involved and can include fever, chills, cough with sputum production, malaise, weakness, weight loss, and/or dyspnea. The most frequent sites of hematogenous spread are the central nervous system, causing brain abscess; the skin, causing infection of subcutaneous tissue; the bones; and the kidney. Other organs that may be affected are the heart, bones, spleen, liver, eyes, and lymph nodes. Prolonged therapy is necessary, sometimes for a year or more, and relapses are frequent. TMP-SMZ or a sulfonamide and/or a selected antibiotic such as

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 215

ceftriaxone or amikacin are drugs of choice. Despite therapy, overall mortality is high, about 50% (Kovacs et al., 1997).

Bartonella (formerly Rochalimaea) Infections Bacillary angiomatosis and hepatic bacillary peliosis result from Bartonella henselae and B. quintana infection. These are gram-negative bacilli (Brouqui et al., 1999; Cohen et al., 1998). In immunocompetent hosts, B. henselae causes cat scratch disease, which is characterized by a lesion and lymphadenopathy that may be due to granuloma formation and be associated with fever. It typically resolves within 2 to 4 months (Walker, 1998). Bacillary angiomatosis (BA) is not usually seen in HIV infection until the CD4+ cell count is below 100 cells/mm3 (Spach & Koehler, 1998). A hallmark of BA is cutaneous or subcutaneous lesions. Subcutaneous lesions may appear as nodules with or without reddened overlying skin. They can erode through the surface. Cutaneous BA may appear as papular and red with a vascular appearance and bleed when traumatized. Other appearances are possible, and occasionally they appear as dry, scaly, hyperkeratotic or plaquelike and may be confused with Kaposi's sarcoma. Lymphadenopathy may be present, and lesions in the gastrointestinal tract, respiratory tract, central nervous system, larynx, oral areas, anal region, bones, endocardium, and perineum can occur, as can bacteremia (Cohen et al., 1998; Loutit, 1998; Spach & Koehler, 1998). Signs and symptoms depend on the site affected. Bacillary peliosis, or the formation of venous lakes within the liver or splenic parenchyma, has been associated with Bartonella (Spach & Koehler, 1998). Symptoms and signs include hepatosplenomegaly, thrombocytopenia, and/or pancytopenia. Diagnosis is by biopsy, and in some cases, an enzyme immunoassay or indirect fluorescence antibody test can detect Bartonella antibodies. PCR techniques are in use in certain situations. Treatment is usually erythromycin or doxycycline. If these are not possible, tetracycline, clarithromycin, azithromycin, and/or minocycline maybe used. Treatment needs to be long term (at least 2 months), and relapse is common. Prevention includes avoidance of interaction with cats that can lead to scratches, control of flea and louse infestation, and washing any scratches

216

THE PERSON WITH HIV/AIDS

immediately (Cohen et al., 1998; Spach & Koehler, 1998). (See Appendices 2, 3, and 4 for other prevention information.) Rhodococcus equi Rhodococcus equi (formerly classified with the Corynebacterid) is a grampositive bacillus with many fungilike characteristics (Walker, 1998). The first case of R. equi infection in humans was reported in 1967 in a person who was immunocompromised due to steroid therapy for chronic hepatitis (Golub, Falk, & Spink, 1967), and in 1986, the first reported case in an HIV-infected person was described (Sarnies, Hathaway, & Echols, 1986). The most common resulting disease from infection is pneumonia, and fever, cough, chest pain, dyspnea, and later, hemoptysis and weight loss may be seen. Extrapulmonary infection may occur in about one quarter of cases and most commonly include subcutaneous, renal, pelvic, and brain abscesses as well as osteomyelitis. Dissemination may occur. Various combinations of antibiotics are used, and therapy should be long term, with at least two antibiotics used to which the organism is susceptible. Mortality in HIV-infected persons has been reported from 25% to 55% (Cohen et al., 1998; Hamrock et al., 1999). Haemophilus influenzae Haemophilus influenzae is one of the most common bacterial infections in HIV-infected persons (Cohen et al., 1998). It is a gram-negative rod with several biotypes. The main determinant of virulence is the capsule, and those with capsule type b (Hib) disseminate. H. influenzae carriage in the upper respiratory tract is common (seen in 35% to 85% of adults, and 60% to 90% of children); however, only about 0.4% of adults and 5% of all children carry Hib. In day care centers, up to 60% of children may carry Hib (Walker, 1998). In HIV-infected adults, pneumonia, sinusitis, and meningitis may be seen. Dissemination may occur. Symptoms in HIV-positive persons do not differ from those found in HIV-negative persons (Cohen et al., 1998; Walker, 1998). The treatment choices are second- or third-generation cephalosporins, doxycycline, or fluoroquinolones (Barrett, Brei-

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 217

man, Mandell, & File, 1998). A vaccine is available for some types, and infants should be immunized as well as certain others at risk. Pseudomonas aeroginosa

Pseudomonas aeroginosa has been long known as an opportunistic and nosocomial pathogen. The annual incidence of these infections in HlV-infected persons, particularly in those in which the CD4+ cell counts are below 100 mm 3 , appears to be increasing (Cohen et al., 1998). P. aeroginosa is a ubiquitous gram-negative rod found in soil, water, and vegetation, primarily causing infections in those who are immunocompromised or who have indwelling catheters. It may be carried on the skin and in the GI tract or throat in about 3% of the general population (Walker, 1998). In persons with AIDS, the most frequent syndromes seen are pneumonia, characterized by fever and a productive cough, and bacteremia, although a malignant form of otitis externa has been seen. Diagnosis relies on organism detection. Treatment depends on susceptibility of the organism, and combination therapy with an antipseudomonal beta lactam with an aminoglycoside or fluoroquinolone is usual. Relapses are relatively frequent (Cohen et al., 1998). Staphylococciis aureus

StaphyLococcus aureus are pyogenic gram-positive cocci occurring in clusters (Lowy, 1998). It is a normal resident of the nose and bowel of 30% to 50% of the general population but is considered a top cause of nosocomial infection (Walker, 1998). It is considered one of the most common bacterial infections with patients with AIDS and causes local and invasive infections. Pyogenic skin infections, such as folliculitis, are a common manifestation (Kovacs et al., 1997). Bacteremia may be followed by endocarditis or other responses (Cohen et al., 1998; Lowy, 1998). Symptoms depend on the affected site, and treatment depends on susceptibility of the infecting organism. HIV-positive persons are similar to HIV-negative persons in relation to symptomatology, diagnosis, and treatment. The reduction of iatrogenic opportunities such as indwelling vascular catheters may decrease the opportunities for infection.

218

THE PERSON WITH HIV/AIDS

Salmonella The Salmonella species is divided into seven subgroups, and there are nine serogroups based on cell surface antigens encompassing more than 2,000 serotypes (Cohen et al., 1998; Walker, 1998). Salmonella infections in persons with AIDS are usually due to the following serotypes: S, typhimurium, S. dublin, S. newport, and S. enteritidis. Common manifestations in persons with AIDS include diarrhea (seen in more than half of the cases of salmonellosis), fever, chills, and bacteremia (Cohen et al., 1998). Diagnosis depends on isolation of the organism. Antibacterial therapy is usually successful insofar as resolution of symptoms is concerned, but relapse upon discontinuation of therapy is common (Cohen et al., 1998). Salmonellosis frequently precedes the diagnosis of AIDS. Antibiotic treatment depends on organism susceptibility and classically includes chloramphenicol, ampicillin, amoxicillin, and TMP-SMZ. In AIDS, ceftriaxone and ciprofloxacin may be effective. Prevention includes not eating uncooked or partly cooked eggs, meat, poultry, and seafood, or using unpasteurized milk or dairy products. Handling animals such as reptiles and turtles has been associated with some cases of salmonellosis. Prophylaxis is recommended if previous bacteremia has occurred (USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999). (See Appendices 2 and 3 for more information.)

Other Bacteria Some of the bacterial organisms that have been described as causing increased problems in persons with AIDS include Listeria, Shigella, Campylobacter, Streptococcus pneumoniae, and Clostridium difficile. The proliferation of these organisms is associated with either T or B cell defects. Endocarditis due to a variety of bacterial pathogens has been described more frequently in injecting drug users who are HIVinfected than in those who are not HIV-infected. Other frequently encountered intestinal bacterial infections in HIV infection may be due to Shigella and Campylobacter. Manifestations include severe diarrhea, cramping, nausea, and fever. Colitis with bloody diarrhea

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 219

may result from the toxin produced by Clostridium difficile. Treatment is with oral vancomycin or metronidazole. Bacteremia due to usually enteric pathogens is seen even more frequently than intestinal complications in conjunction with AIDS. Recurrences are common (Casey, Cohen, & Hughes, 1996). Campylobacterspp may cause bacteremia in patients with HIV infection with varying incidence (Pigrau, Almirante, Pahissa, & Bartolome, 1996). Bacterial pneumonias are seen in persons with HIV infection more commonly than in the general population and have become the most common pulmonary infection in AIDS (Afessa, Green, Chiao, & Frederick, 1998). The major implicated organisms include Haemophilus influenza?., Streptococcus pneuinoniae, P. aeroginosa, R. equi, and N. asteroides. The incidence of bacterial pneumonias appears higher among injecting drug abusers and in some foreign-born persons with AIDS than other groups. The signs and symptoms of pneumonia in HIV-infected persons is not usually different from persons without HIV infection. However, bacteremia is much more frequent. Treatment depends on the organism involved and its antimicrobial susceptibility (Kovacs et al., 1997).

MALIGNANCIES Malignancies are frequent in many immunodeficiency states, both congenital and acquired, as well as in HIV disease (Lashley, 1998; Sande & Volberding, 1997). The most frequent malignancies associated with HIV infection are Kaposi's sarcoma and non-Hodgkin's lymphomas, especially of the central nervous system. In the 1993 case definition of AIDS, the CDC added invasive cervical cancer to the list of AIDS-defming conditions that already included Kaposi's sarcoma and Burkitt's lymphoma, immunoblastic lymphoma, and primary lymphoma of the brain (Centers for Disease Control, 1992). Other malignancies described with increased frequency in AIDS vary and include Hodgkin's disease, multiple myeloma, seminoma, brain cancer, anorectal carcinoma, testictilar cancer, and small-cell carcinoma of the lung (Goedert et al., 1998; Katariya & Thurer, 1999; Sande & Volberding, 1997).

220

THE PERSON WITH HIV/AIDS

Kaposi's Sarcoma In 1981 an unusual disseminated form of Kaposi's sarcoma (KS) was reported among young homosexual men (Centers for Disease Control, 1981b). Prior to this, KS in the United States was essentially considered a relatively indolent disease of older men or as a sequelae of immunosuppressant therapy (Friedman-Kien, 1988). A review of the literature has detected reported cases not encompassed in the preceding categories among American-born young single men as early as 1977 and in Europe in 1976 among travelers returning from endemic areas of KS in Africa, but not earlier (Biggar, Nasca, & Burnett, 1988; Schwartz, 1988). Speculation existed for some time that KS might be due to a transmissible agent, and at one time Epstein-Barr virus was among the leading candidates. Eventually, it was found that certain viral DNA fragments were present in KS lesions not only from KS associated with AIDS but the other types as well as such primary effusion lymphoma and HIV-associated Castleman's disease. This virus is called the Kaposi's sarcoma-associated herpesvirus or human herpesvirus 8 (HHV-8) (Chang et al., 1994; Jaffe & Pellett, 1999; Kemeny, Gyulai, Kiss, Nagy, & Dobozy, 1997; Oksenhendler et al., 1998). HHV-8 is now used more frequently because sequences of this virus are found in other types of tumors as well.-Despite this, HIV may be a cofactor in KS (Cohen et al., 1998; Kemeny et al., 1997). Sexual transmission of HHV-8 appears likely, especially among homosexual men. In children, the risk of HHV-8 infection correlates with the HHV-8 status of their mothers, and it has been suggested that horizontal transmission such as that occurring in EBV infection may occur (Jaffe & Pellett, 1999). KS is the most frequently observed malignancy among persons with AIDS; however, there has been a recent decrease in incidence in the United States. In 1981 KS was seen in 44% of homosexual males with AIDS and continues to be most prevalent in that group (Friedman-Kien, 1988). KS is more frequent among homosexual and bisexual men with AIDS than among hemophiliacs. It appears likely that HHV8 is sexually transmitted (Boshoff & Moore, 1998). Types ofKS. In 1872, Moriz Kaposi, a Hungarian physician practicing in Vienna, first described the idiopathic multiple pigmented

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 221

sarcomas on the lower extremities that became known as classic Kaposi's sarcoma (Iscovich et al., 1999). Today, four types are generally recognized: 1. Classic KS 2. Endemic African KS 3. latrogenic KS (also called KS in immimosuppressed non-AIDS patients or renal transplant associated KS) 4. AIDS-KS Each will be described below. Classic KS was the first type recognized. It is seen most frequently in males between the ages of 50 and 80 years who are of eastern and southern European extraction, particularly Ashkenazic Jews and Italians (Greenblatt, 1998; Sung, Louie, & Park, 1997). This concentration in ethnic groups, but not in families, led to the speculation of genetic susceptibility to KS. The ratio of males to females is 10:1 to 15:1. All forms of KS are more frequent in men than women. Women who develop KS may be estrogen deficient (Clayton & Clayton, 1997; Sung et al., 1997), and KS may be more aggressive when it does occur in women (Nasti et al., 1999). The most common presentation in classic KS is that of asymptomatic single or multiple lesions appearing usually on the lower extremities, especially the ankles or soles of the feet. These lesions may appear as a reddish, purple, or brown patch, placque, or nodule. Classic KS usually runs a rather indolent course over 10 to 15 years or more, with slow enlargement of the original lesions and the gradual appearance of additional ones. A multifocal origin is more common than true metastasis. Additional lesions tend to be close to the original ones but may appear on conjunctiva or oral mucosa, and, over a long period of time, visceral lesions can occur. Skin lesions may become hyperpigmented, and chronic venous stasis and lymphedema complicate the picture. While not common, local invasion of lymph nodes, tissue, and bone can occur. Up to one third of KS patients may develop second primary malignancies, usually lymphoproliferative disorders such as non-Hodgkin's lymphoma or Hodgkin's disease. Treatment of classic KS with radiation, surgical excision of lesions, or electrocauterization with curettage has generally been successful. Systemic chemotherapy has been used in more

222

THE PERSON WITH HIV/AIDS

advanced cases. Most persons with classic KS have died from other causes (Sung et al., 1997). Endemic African KS began to receive attention in 1961 but had been noticed before, both in 1934 and.1950. In 1961 it was reported that KS accounted for about 9% of all cancers in black Ugandan males. In addition, the geographical distribution of KS in Africa appears to parallel that of Burkitt's lymphoma (Krigel & FriedmanKien, 1988). Within this type there have been several clinical subtypes identified. The first is similar to classic KS, although it tends to occur in a younger age group, usually 25 to 40 years of age. Lesions tend to be nodules and/or plaques. Death can occur within 5 to 8 years. The second pattern of endemic African KS includes florid and inflltrative types that are more aggressive. Rapid progression is seen, with lesions growing into tumors that invade the subcutaneous tissue and bone. This may be called infiltrative-aggressive KS. If not treated, death can occur in about a year. Another pattern of endemic KS occurs in children or occasionally in young adolescents with a male to female ratio of 3:1. This lymphadenopathic form is disseminated and aggressive and usually does not have cutaneous manifestations. Generalized lymphadenopathy and visceral organ involvement are prominent. The prognosis is very poor, with a reported fatality rate of 100% within 3 years of diagnosis (Sung et al., 1997). KS in immunosuppressed patients is usually due to iatrogenic immunosuppression and was first described in 1969 in association with a renal transplant. This is still the most frequent group in whom it is seen, but it also occurs in persons with lymphoma, myeloma, systemic lupus erythematosus, rheumatoid arthritis, hemolytic anemia, and other disorders in which therapy with immunosuppressive agents such as cyclosporine, azathioprine, prednisone, and cyclophosphamide is initiated. In these patients, KS may remain localized to the skin or show widespread mucocutaneous and visceral organ dissemination. The ratio of males to females is about 2.3:1. The average time for development of KS after transplant is about 16 months. Therapy is difficult because of already existing immunosuppression, and about 30% of transplant patients are reported to die with generalized KS. In some iatrogenically suppressed patients, reduction or discontinuation of immunosuppressants has resulted in regression of KS (Sung et al., 1997).

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 223

AIDS-related or associated KS was reported in this country in association with what we now know to be AIDS as described above (Centers for Disease Control, 1981). Persons with KS may have systemic symptoms such as fatigue, weight loss, diarrhea, and/or intermittent fevers, or KS may be the first sign of AIDS in an otherwise asymptomatic individual, which occurs in about 15%. KS has steadily declined in the United States since the 1980s in connection with HIV infection (Tulpule & Matheney, 1998). Clinical Staging of KS. Various staging systems are used in KS. One staging system for AIDS-related KS has been developed and tested by the AIDS Cooperative Treatment Group, also known as TIS [ Junior (tumor extent), immune Function (measured by CD4+ cell count), and Systemic illness (the presence of associated systemic illnesses)]. In this system, a good prognosis is reflected by tumors confined to the skin and/or lymph nodes (and/or nonnodular sarcoma confined to the palate), CD4+ cell count > 150 mm3; a Karnofsky performance rating of > 70, no history of opportunistic infection or thrush, and no weight loss, fever, or night sweats. A poor prognosis is predicted by any of the following: tumor-associated edema or ulceration, extensive oral KS, gastrointestinal and/or pulmonary KS, and/or other visceral KS; CD4+ cell count < 150 mm3; the presence of opportunistic infection or thrush; symptoms of weight loss, fever, or night sweats; a Karnofsky performance rating of < 70; or the presence of another related illness, such as lymphoma or dementia (Kroll & Shandera, 1998; Krown, Testa, & Huang, 1997). Clinical Aspects ofKS in AIDS. Clinically, KS lesions can vary from flat macular patches to papules, plaques, and elevated nodules that range in color from faint pink to dark purple to bluish brown and are hyperpigmented in dark-skinned persons. Lesions that appear first are often faint, flat patches of discolored skin. In the absence of any clinical suspicion of HIV infection initial lesions may be overlooked or misdiagnosed, depending on their appearance, as such conditions as hemangiomas, insect bites, nevi, melanomas, or bruises. However, in contrast to classic KS, lesions grow in size and number very quickly and are widespread (Krown, 1997). While usually oval, sometimes cutaneous lesions follow a distribution pattern along skin cleavage lines (Langer's lines). A multicentric

224

THE PERSON WITH HIV/AIDS

distribution pattern of multiple primary tumors may be seen. The most frequent skin sites affected include the face, especially the tip of the nose, the ears, the penis, and the chest, back, or abdomen, in contrast to the extremities, as seen in classic KS (Greenblatt, 1998). The size of the lesions vary from a few millimeters to several centimeters in diameter. They are generally painless and nonpruritic. As the disease progresses, KS lesions may progress from macule to plaque to nodule to fulminating lesion (Greenblatt, 1998; Kroll & Shandera, 1998; Krown, 1997). Because the skin lesions are often visible and difficult to conceal in AIDS-associated KS, the potential of social stigma is added to other problems. KS can also cause lymphatic obstruction leading to lymphedema especially of the face and legs that can cause considerable discomfort (Kroll & Shandera, 1998; Krown, 1997). AIDS-related KS also shows predilection for other sites such as the oral cavity, lymph nodes, gastrointestinal tract, and the lung. The liver, adrenal glands, and heart may also be affected, as well as many other organ systems. The nervous system is not often involved, but focal neurologic deficits may be seen. At autopsy, gastrointestinal involvement may be seen in as many as 80% of AIDS-related KS cases (Krown, 1997). In the oral cavity, KS lesions may present only as a discoloration and can be overlooked (Wiebe & Epstein, 1997). Recognition of KS lesions in the oral cavity should prompt an examination of the gastrointestinal tract for additional lesions. KS can cause obstructive lesions most often in the upper GI tract resulting in impaired swallowing, intussception, obstruction, perforation, disturbed motility, or even lymphatic blockade with exudative enteropathy. Hemorrhage may be a sequelae. Diarrhea is not generally caused by KS (Clayton & Clayton, 1997). In about 20% to 50% of cases, KS lesions occur in the respiratory tract. Dyspnea, shortness of breath, wheezing, hemoptsis, and pleural effusion may be seen (Tulpule & Matheney, 1998). The diagnosis may be accomplished by bronchoscopy since radiography may show nonspecific changes. Pulmonary involvement is ominous, with a median survival of 3 months after it occurs (Katariya & Thurer, 1999; Tulpule & Matheney, 1998). The spindle cells, considered to be the tumor cells, secrete large amounts of vascular endothelial growth factor, an angiogenic agent. Tumor progression is linked to its ability to develop new blood vessels (angiogenesis) (Boshoff, 1998). Definitive diagnosis of KS

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 225

skin lesions is by biopsy, usually punch biopsy. Treatment may be local or systemic. Therapy must be considered in light of the already existing immunosuppression. For small lesions, intralesional injection of vinblastine or alpha interferon is sometimes used. Localized radiation therapy and surgical removal of skin lesions has been successful. Systemic chemotherapy is also used, especially for multiple lesions or extracutaneous disease. Taxol (given IV), liposomal daunorubicin and doxorubicin are used in chemotherapy (Tulpule & Matheney, 1998). Newer approaches are based on new understanding of the lesion and includes use of inhibitors of angiogenesis (e.g., fumagillin derivatives), inhibitors of basic fibroblast growth factor (e.g., pentosan polysulfate), inhibitors of tumor necrosis factor (e.g., thalidomide), inhibitors of interleukin 1 (IL-1 receptor antagonist), inhibitors of interleukin 6, inhibitors of invasion (e.g., tissue inhibitor of matrix rnetalloproteinase 2), (3 human chorionic gonado tropin, and inhibitors of HHV-8 such as cidofovir or foscarnet (Katariya & Thurer, 1999; Kroll & Shandera, 1998). Death is most often due to the acquisition of opportunistic infection. When death results directly from KS, it is most often due to gastrointestinal hemorrhage, perforation of the gut, cardiac tamponade, adrenal insufficiency, or bulky tumors obstructing the respiratory tract. HIV-asso elated Malignant Lymphomas Aggressive B-cell non-Hodgkin's lymphoma (NHL) is believed to occur in between 5% and 13% of all HFV-infected persons (Kaplan, 1998). The malignant lymphomas are relatively frequent in immunodeficiency and immunosuppression from various sources. Most of these are NHLs that are concentrated in extranodal locations, are of B cell origin, and are often polyclonal. Most are intermediate and high-grade small noncleaved. Histology includes diffuse large cell immunoblastic subtypes and other diffuse large cell lymphomas (Katariya & Thurer, 1999; Straus, 1997). EBV has been implicated in NHL but may not be essential for its development (Goedert et al., 1998). NHLs may be classified as systemic, those that affect the CNS and primary effusion types. Extranodal presentations occur in more than two thirds. The sites most affected are the bone marrow, meninges, and GI tract, while pleural, pericardial, and peritoneal effusions

226

THE PERSON WITH HIV/AIDS

have been more recently described. Systemic presentation may include symptoms relating to the extranodal sites such as GI disease, which can be found from the oral cavity to the anorectal area, with the stomach being one of the more common sites (Kaplan, 1998; Straus, 1997). Beginning in 1980, a sizable increase in the occurrence of lymphomas in never-married males was noted. Primary lymphoma of the CNS has been considered a defining criteria for AIDS since the beginning of the epidemic. Patients often present with confusion, lethargy, memory loss, cranial nerve palsies, hemiparesis, headache, or seizures. Sometimes the initial symptoms are more subtle, with only personality changes evident. On radiology, lesions may resemble toxoplasmosis (Kaplan, 1998). There may be an initial response to radiation therapy, but results are not sustained. With systemic malignant lymphomas, patients frequently present with systemic symptoms such as persistent unexplained fever, night sweats, weight loss, and/or lymphadenopathy. Specific symptoms depend on the sites involved. For example, those with extranodal disease of the gastrointestinal tract often present with complaints of abdominal pain, an abdominal mass, or a recent history of gastrointestinal bleeding. The CNS is also a common extranodal site for systemic lymphomas (Kaplan, 1998). Treatment is difficult, but combination chemotherapy with or without radiation may be used and protocols with anti-IL-6 antibodies and IL-2 are being used (Kaplan, 1998; Katariya £ Thurer, 1999). Hodgkin's Disease Hodgkin's disease is also occasionally associated with HIV infection and is not an AIDS-defining illness. It may be slightly increased in frequency above the general population in persons with HIV disease and may have a different natural history (Kaplan, 1998; Straus, 1997). Invasive Cervical Cancer Invasive cervical cancer was added as an AIDS-defining diagnosis in the 1993 AIDS definition, and is more common in HIV-infected

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 227

women than noninfected women. Cervical dysplasia and cervical cancer in situ were added to category B conditions (Centers for Disease Control and Prevention, 1992; Chin, Sidhu, Janssen, & Weber, 1998). Cervical intraepithelial neoplasia (CIN), therefore, is an HlV-associated condition and may precede cervical cancer. HPV is implicated in the etiology of both CIN and invasive cervical cancer, and HPV DNA is found in lesions. HPV types 16 and 18 are most commonly found in cervical cancer. More advanced CIN is associated with more advanced immunosuppression, especially below 200 cells/ mm 3 (Cohen et al., 1998; Goedert et al, 1998; Walker, 1998). In HlV-infected women, CIN may recur (Fruchter et al., 1996). The CDC has recommended that a complete gynecological examination be part of the baseline for HlV-infected women. If negative, the examination should be repeated in 6 months. If squamous epithelial lesions are seen, colposcopy may be indicated (Centers for Disease Control and Prevention, 1993). THE NERVOUS SYSTEM AND HIV INFECTION Neurological complications accompanying AIDS were noted early in the epidemic. However, it was not until reports were published in 1985 that the impact of HIV on the nervous system began to be appreciated (Black, 1985; Carne et al., 1985; Levy, Bredesen, & Rosenblum, 1985; Shaw et al., 1985). At autopsy, evidence of central nervous system disease in patients with AIDS were noted in 80% to 90% (Cohen, 1997). Astrocytes and microglia in the CNS are thought to be reservoirs for HIV (Allbright et al., 1999; Brack-Werner, 1999). It is generally accepted that neurologic signs and symptoms occur in 40% to 60% of HIV-infected persons at some time in the course of their illness and may be the presenting manifestation in 10% to 20% (Cohen, 1997). Symptomatology is probably underreported because some manifestations can be subtle. As HIV-infected persons survive longer, more minor cognitive motor disorders (MCMD) are seen. However, the functional mental and neurological status of persons who are asymptomatic and HIV seropositive, how they should be measured, and what testing and physical and laboratory abnormalities mean on a practical level are still the subject of discussion. It is now appreci-

228

THE PERSON WITH HIV/AIDS

ated that HIV is neurotropic and can invade the nervous system early in infection, resulting in involvement of both the central and peripheral nervous systems. This involvement can be latent or overt. Among the earliest noticeable manifestations of central nervous system (CNS) involvement are those seen in acute primary HIV infec tion due to acute aseptic meningitis or encephalopathy. These include fever, headache, meningeal signs, and cranial nerve involvement (Cohen, 1997). Neurological dysfunction can result from any of the following alone or in combination: 1. 2. 3. 4. 5. 6. 7.

Direct infection with HIV Opportunistic infections Primary or metastatic neoplasms Cerebrovascular etiologies Metabolic encephalopathies Complications secondary to therapy Factors as yet unknown

These are shown in Table 5.2. Multiple neurological dysfunctions are common in persons with AIDS, thereby complicating diagnosis and treatment. Also complicating direct organic effects are those effects that are emotional or psychological, such as anxiety and depressive reactions to the diagnosis of HIV. AIDS Dementia Complex (ADC) AIDS dementia complex (ADC), also known as HIV-associated dementia and HFV-1-associated cognitive/motor complex, is the most common cause of neurological dysfunction in adults with HIV and is believed due to HIV itself rather than to another pathogen (Kolson, Lavi, & Gonzalez-Scarano, 1998). ADC is characterized by cognitive, motor, and behavioral disturbances and may be divided into late and early symptomatology (Cohen, 1997; Navia, 1997). Early symptoms are summarized in Table 5.3. Cognitive impairment may be noticed first (McArthur, 1997). Early cognitive impairment may be manifested by difficulty in concentration, slowed processing, and memory impairment, especially recall. Affected persons may forget

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 229

TABLE 5.2

Selected HIV-related Central Nervous System Disorders

Primary infection with HIV AIDS dementia complex Aseptic meningitis Vacuolar myelopathy HIV encephalopathy of childhood Opportunistic infections Cerebral toxoplasmosis Progressive multifocal leukoencephalopathy Cytomegalovirus encephalitis Cryptococcal meningitis Herpes simplex encephalitis Varicella zoster encephalitis Coccidioidal meningitis Neoplasms Primary CMS lymphoma Other metastatic lymphomas Other Metabolic encephalopathies (e.g., secondary to hypoxia, sepsis) Cerebrovascular disorders (e.g., infarcts, thrombi, emboli) Secondary to therapy Sources: Dalakas, Wichman, and Sever (1989); Levy, Bredesen, and Rosenblum (1985); Navia and Price (1986); Blumenthal et al. (1999).

TABLE 5.3 Early Symptoms of AIDS Dementia Complex/HIV-associated Dementia Cognitive Difficulty in concentration Slowness in thinking and response Memory impairment and forgetfulness Easily distracted Behavioral Social withdrawal Apathy Personality changes Motor Clumsiness of gait Difficulty with fine motor movements Poor balance and coordination Sources: Navia and Price (1986); Price (1997).

230

THE PERSON WITH HIV/AIDS

appointments, have difficulty in reading a book and remembering the theme, lose track of conversations or their train of thought, and exhibit verbal' and/or mental slowness that is noticed by others. Early behavioral dysfunction may include personality changes, social withdrawal, apathy, and occasionally depression. The apathy, plus mental slowing, may be mistaken for depression. Early motor function impairment may include clumsiness, fine tremors, lower extremity hypertonia, poor balance and coordination, and difficulty with fine motor movements. Affected persons may drop items, have difficulty with writing or eating, and have an increased tendency to trip and fall. Sensorium is usually intact (Cohen, 1997; Navia, 1997). These features worsen as the disease progresses. Later manifestations include worsening of the cognitive impairment that eventually can include mutism, global dementia, and vacant staring. The person may manifest organic psychosis and be unaware of the illness. Extremity weakness increases, with paraparesis, ataxia, tremors, and seizures becoming evident. Urinary and fecal incontinence complicate the picture. In the final stages, patients usually become vegetative, cannot leave their beds, stare vacantly, and are capable, at best, of only simple interactions. Patients may retain consciousness, and even those who exhibit hypersomnolence may be aroused easily unless metabolic or systemic disease complicates the picture (Cohen, 1997; Navia, 1997; Price & Brew, 1988b). Price and Brew (1988a) proposed a clinical staging system for AIDS dementia complex that is summarized in Table 5.4. Another proposed classification is that of the World Health Organization/ American Academy of Neurology, which has two categories: (1) HIV1-associated cognitive/motor complex with the subcategories of HIVassociated dementia for those with primarily cognitive presentations and HPv^-1-associated myelopathy for those with primarily myelpathic presentations, and (2) HIV-1-associated minor cognitive/motor disorder for those with minimal impairment. The former category corresponds to ADC stages 2 through 4, whereas the latter corresponds to ADC stage 1. There is no equivalent for ADC stages 0 and 0.5 (Price, 1997). Bedside mental status testing does not always reveal early abnormalities. Several groups have developed test batteries. A core battery of tests was assembled to assess neurocognitive performance by Sidtis, Gatsonis, and Price (1993). A composite score, the neuropsychologi-

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 231

TABLE 5.4 Clinical Staging of the AIDS Dementia Complex Stage

Characteristics

Stage 0 (normal)

Normal mental and motor function.

Stage 0.5 (equivocal/ subclinical)

Absent, minimal, or equivocal symptoms without impairment of work or capacity to perform ADL. Mild signs (snout response, slowed ocular or extremity movements) may be present. Gait and strength are normal.

Stage 1 (mild)

Able to perform all but the more demanding aspects of work or ADL but with unequivocal evidence (signs or symptoms that may include performance on neuropsychological testing) or functional intellectual or motor impairment. Can walk without assistance.

Stage 2 (moderate)

Able to perform basic activities of self-care but cannot work or maintain the more demanding aspects of daily life. Ambulatory but may require a single prop.

Stage 3 (severe)

Major intellectual incapacity (cannot follow new or personal events, cannot sustain complex conversation, considerable slowing of all output) or motor disability (cannot walk unassisted, requiring walker or personal support, usually with slowing and clumsiness of arms).

Stage 4 (end stage)

Nearly vegetative. Intellectual and social comprehension and output are at a rudimentary level. Nearly or absolutely mute. Paraparetic or paraplegic, with urinary and fecal incontinence.

ADL = activities of daily living Sources: Navia (1997); Price (1997); Price and Brew (1988a).

cal Z score (NPZ-8), is generated. Lower NPZ-8 scores correlate with a higher ADC stage (Navia, 1997; Navia et al., 1998). An HIVdementia scale developed at Johns Hopkins University has also been used as a rapid screening test (McArthur, 1997; Power, Seines, Grim, & McArthur, 1995). Development of cognitive impairment is in part related to the degree of immune suppression as reflected by the CD4+ cell count. The incidence rate of ADC reported in a Multicenter AIDS Cohort Study by Janssen, Nwanyanwu, Selik, and Stehr-Green (1992) indi-

232

THE PERSON WITH HIV/AIDS

cated that in AIDS patients with a CD4+ cell count < 200/mm3 and < 100/mm3 the incidence of ADC increased threefold and sevenfold, respectively. Yet even patients with counts above 500 cells/mm3 could show cognitive impairment. It is believed that there are other contributing factors such as differences in strains of infecting HIV, genetic factors, and other disease processes (Navia, 1997). The issue of whether or not asymptomatic HIV-infected individuals develop neurologic impairment is somewhat unresolved, although subclinical infection of the nervous system may be found and CSF abnormalities may be seen even in the absence of symptoms (Navia, 1997; Price, 1997). McArthur (1997) believes that about 30% of HIV-seropositive patients fall in the latter category, which is insufficient to interfere with usual activities of daily living. Radiological findings using MRI show diffuse cerebral atrophy and abnormalities in the white matter. Single photon emission computed tomography (SPECT) measures regional blood flow in the brain and indicates that changes in cerebral blood flow occur early in persons with HIV infection. HIV may be recovered from macrophages. Other tests such as CSF analysis should be done to rule out other possible causes. Management is difficult, and strategies that improve immune function and decrease viral load such as use of antiretroviral agents and protease inhibitors have been used. Nimodipine (a calcium channel antagonist) and selegiline have shown promise in phase 1 clinical trials (McArthur, 1997). Vacuolar Myelopathy Myelopathies in HIV infection can be divided into segmental and diffuse types. Segmental types are rare. Vacuolar myelopathy, a diffuse form, mainly affects the lateral and dorsal columns of the thoracic spinal cord, affecting up to 30% of patients with AIDS. It may occur in conjunction with ADC or alone (Cohen, 1997; Price, 1997). It may result from neurotoxic effects of cytokines (Tyor et al, 1993). Vacuolar degeneration results in a loss of myelin from the spinal cord that chiefly affects the white matter. The vacuoles result from edema within the myelin sheath. Pathologically, vacuolar myopathy resembles degeneration caused by vitamin B12 deficiency (Cohen, 1997). Clinical features include leg weakness, gait ataxia, inconti-

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 233

nence, upper motor neuron signs, and posterior column deficits that evolve over a period of weeks to months. Dementia is a very frequent association. Development of vacuolar myelopathy has occurred rarely as part of seroconversion when primary HIV infection occurs (Cohen, 1997). Miscellaneous Central Nervous System Disorders Other central nervous system disorders are also common with HIV infection. These are often due to opportunistic infections and/or neoplasms. The most frequent CNS complications due to infectious agents are toxoplasmic encephalitis, cryptococcal meningitis, and CMV or herpes simplex encephalitis. Others include progressive multifocal leukoencephalopathy caused by the JC virus, intracerebral candidiasis, abscesses, or meningoencephalitis due to C. immitis or M. tuberculosis, and herpes simplex encephalitis (Ammassari et al., 1998; Blumenthal etal., 1999; Cohen, 1997; Roos, 1998). These were discussed earlier. Neurosyphilis due to Treponema pallidum may cause neurological disease in HIV-positive patients as well (Cohen, 1997). Other opportunistic infections can affect the central nervous system, but do so infrequently. Among the neoplasms affecting the CNS, primary CNS lymphoma is most frequently seen in patients with AIDS. Systemic lymphomas, especially due to non-Hodgkin's lymphoma or Burkitt's lymphomas can invade the meninges and other parts of the nervous system. Spinal cord compression may also be seen. The 1993 CDC revised criteria for AIDS now allows for an AIDS diagnosis in HlV-seropositive patients with systemic lymphoma. Metastasis of Kaposi's sarcoma to the CNS in persons with AIDS occurs but is rare (Blumenthal et al., 1999; Centers for Disease Control and Prevention, 1992; Kaplan, 1998; Straus, 1997). Metabolic encephalopathies may affect the CNS either alone or in combination with another disorder. These can result from systemic illnesses experienced by persons with AIDS. Examples of these are generalized sepsis and hypoxia secondary to pneumonia. These may cause a decrease in alertness (Price & Brew, 1988b). Cerebrovascular complications can also affect the CNS. Most frequently described are infarcts, transient ischemic attacks, hemorrhage due to neoplasias that frequently occurred within the tumor,

234

THE PERSON WITH HIV/AIDS

and cerebral vasculitis. In some cases, the cause can be identified, such as hemorrhage secondary to thrombocytopenia, but in others, the explanation is not evident. Lastly, CNS complications can arise as a result of therapy. These include both neurological and psychiatric side effects and may follow chemotherapy for neoplasms, antiviral therapy, or therapy for specific symptoms. The clinical presentations vary with the pharmacological agent.

Neuromuscular Manifestations of HIV Infection Although the CNS effects associated with HIV infection and AIDS have received more attention, awareness of the effects of HIV on the peripheral nervous system and of neuromuscular manifestations has increased. Neuromuscular disorders may be seen at any stage of HIV infection and may be the only indication of such infection. They may also coincide with acute illness and seroconversion, but this is less likely. The major neuromuscular disorders seen in HIV infection are the peripheral neuropathies (e.g., acute inflammatory demyelinating polyneuropathy or chronic inflammatory demyelinating polyneuropathy, mononeuropathy multiplex, and sensory neuropathy) and inflammatory and noninflammatory myopathies such as polymyositis (Price, 1997). Neuropathies may also be due to viruses such as varicella zoster causing herpes zoster, as discussed earlier. Acute inflammatory demyelinating polyneuropathy (AIDP) in persons with HIV infection is very similar to theGuillain-Barre syndrome, which often follows other viral diseases. It may have the same autoimmune pathogenesis, although other causes are possible. While AIDP is found in patients without HIV infection, its occurrence should alert clinicians to consider HIV infection as a diagnosis. Symptoms include ascending flaccid paralysis. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a progressive sensorimotor polyneuropathy. Patients often present with a subacute onset of sensorimotor deficit occurring over a period of 1 to 2 months. Weakness and sensory loss are prominent symptoms. On testing, reflexes generally are reduced, cerebrospinal fluid protein is usually elevated, and there is evidence of demyelination (Cohen, 1997; Sadler & Nelson, 1997a). For both AIDP and CIDP, corticosteroids, immune globin,

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 235

and plasmapheresis have proved useful. Spontaneous remission has also occurred (Cohen, 1997). Mononeuropathy multiplex may have several forms. Sometimes it can be due to multifocal CMV infection of the nerve, and in other cases an autoimmune vasculitis may be the cause (Price, 1997). This has been seen rarely, and usually the legs or feet have been affected, with sensory or motor deficits in the distribution of multiple spinal, cranial, or peripheral nerves. Footdrop and paresthesias have been prominent (Dalakas et al., 1989). One of the most common neuropathies seen in persons with AIDS is a distal symmetric polyneuropathy that is predominately sensory. It occurs in about 30% to 35% of HlV-infected adults (Cohen, 1997; McArthur, 1997; Sadler & Nelson, 1997a). Severe, painful paresthesias occur, which patients may describe as walking on broken glass or feeling as if their feet have been set on fire (McArthur, 1997). Symptoms often begin on toes or the soles of the feet, with numbness, burning or a pins-and-needles sensation. Some patients can walk only on their heels, because the soles become so tender. This may progress to involvement of the entire foot, with contact hypersensitivity becoming a major problem. Ankle and knee jerk reflexes are diminished. Weakness of the feet may be seen. The hands can also be affected, and a glove and stocking distribution can occur. This polyneuropathy can continue throughout the course of HIV disease, causing disability. The direct cause is unknown, but possibilities include direct infection of neurons of the dorsal root ganglia by HIV, CMV infection, the elaboration of cytokines, or toxic, metabolic, or nutritional factors that are not yet identified (Swanson, Zeller, & Paice, 1998). Although many physicians do not view the polyneuropathy as a serious complication of AIDS, it is very troubling and disabling to affected patients, and various therapies should be tried to obtain success. These include analgesics and tricyclic antidepressants (Cohen, 1997; McArthur, 1997; Sadler & Nelson, 1997a). Human nerve growth factor is being tested in a clinical trial (McArthur, 1997). Lumbosacral polyradiculopathy, is usually seen when the CD4+ cell count falls below 50 cells/mm3, which occurs in about 2% of persons with AIDS. It often manifests with radiating low back pain followed by an asymmetric flaccid paraparesis with decreased or absent reflexes. Sphincter dysfunction leading to both fecal and

236

THE PERSON WITH HIV/AIDS

urinary incontinence is an accompaniment. Motor deficits are more prominent than sensory ones. CMV has been associated with this disorder, but its role is not clear. Cidofovir, ganciclovir, and foscarnet have been used without much success, and death is usually the sequela of this syndrome (Cohen, 1997; Sadler & Nelson, 1997a). The most frequent myopathy seen in AIDS is polymyositis or inflammatory myopathy. It generally presents with subacute proximal muscle weakness, sometimes in association with skin rash. Muscle enzymes are elevated, especially creatine kinase. The cause is unknown but may result from direct HIV invasion of the muscles, by organisms such as CMV, or by an immune-mediated mechanism (Cohen, 1997; Dalakas & Pezeshkpour, 1988). Myopathy suggestive of mitochondrial involvement has been associated with zidovudine, and discontinuing it may cause resolution (Cohen, 1997).

CONSTITUTIONAL SYMPTOMS AND HIV WASTING SYNDROME HIV wasting syndrome was recognized as an AIDS-defining condition in 1987. It was defined as "findings of profound involuntary weigh loss > 10% of baseline body weight plus either chronic diarrhea (at least two loose stools per day for 30 days or more) or chronic weakness and documented fever for 30 days or more, intermittent or constant in the absence of a concurrent illness or condition other than HIV infection that could explain the finding" (Centers for Disease Control, 1987, p. 12S; Centers for Disease Control and Prevention, 1993). There is now some controversy over whether it should be defined as 5% or 10% of usual weight and whether body composition such as lean muscle mass should be included (Corcoran & Grinspoon, 1999). Currently, due to the introduction of effective therapies, wasting is most often seen in developed countries in advanced AIDS rather than earlier. A variety of etiologies have been identified as possibly causing or contributing to wasting. These include metabolic alterations, anorexia, malabsorption, hypogonadism, and excessive cytokine production. Wasting may be seen less frequently since the initiation of protease inhibitors in therapy (Corcoran & Grinspoon, 1999). A significant relationship has been observed between weight loss, dis-

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 237

ease progression, and survival in persons with HIV infection. Those with depleted body cell mass have an increased risk of mortality. Among metabolic alterations identified are increased resting expenditure, altered rates of protein turnover, and lipid clearance and disposal alterations. Anorexia can result from many causes such as oral and esophageal lesions and ulcers, nausea, and taste alterations from medications. Decreased testosterone levels and impotence are found in men with HIV infection, and this affects lean body mass. GI disease, discussed earlier, can lead to diarrhea, malabsorption, and weight loss and be due to a variety of pathogens. Malabsorption may occur even without diarrhea. Cytokines may contribute to energy balance disturbances in HIV disease (Cohen et al., 1998). Detailed assessments need to be conducted when a patient is at risk for wasting and/or malnutrition. These include history, laboratory data review, anthropometric tests, physical examination, dental check, and psychosocial data analysis such as lifestyle habits and preferences. Details regarding assessments and interventions can be found in Casey (1997) and Corcoran and Grinspoon (1999). While not part of this definition, many persons with HIV wasting syndrome also have drenching night sweats and anorexia. Diagnostic evaluation is particularly important for persons with constitutional symptoms because identification of an underlying infectious cause allows therapy for those diseases that are treatable. Many of the interventions that increase the comfort of the patient are nursing ones and are discussed in chapter 6. OTHER ORGAN SYSTEMS IN HIV INFECTION AND AIDS Another useful way to consider the clinical spectrum of manifestations of HIV infection and AIDS is by organ system. In order not to repeat much of the earlier information given in this chapter, the reader will, when appropriate, be referred to earlier sections. The nervous system has been considered separately above because of its particular importance in HIV infection. Gastrointestinal (GI) Tract and Intra-Abdominal Sites The GI tract is a common site for expression of HFV-related signs and symptoms. It is often a site of entry through anal intercourse,

238

THE PERSON WITH HIV/AIDS

and for infants the GI tract may serve as a portal of entry for HIV via the ingestion of material during the intrapartum period or by breastfeeding (Veazey & Lackner, 1998). GI effects may arise most commonly from the direct effect of HIV on the gut opportunistic infections neoplasms A summary of the most frequent HIV-related gastrointestinal disorders are presented in Table 5.5. Esophageal symptoms may be seen in about a third of patients with AIDS (Clayton & Clayton, 1997). Candida, HSV, MAC, and CMV are the most frequent infectious causes of esophagitis in persons with AIDS. Idiopathic aphthous ulcers may also be seen, and lesions may also be produced by certain medications and Kaposi's sarcoma. Esophageal candidiasis and HSV lesions are more frequently seen when the CD4+ cell count is > 200 mm3, while CMV and idiopathic ulcers are observed when it falls below 100 cells/mm3 (Cohen et al., 1998). Disease affecting the esophagus is often a major source of discomfort for the patient, resulting in dysphagia (difficult swallowing) and odynophagia (pain on swallowing). Lesions may also be produced by certain medications and Kaposi's sarcoma. Acid reflux into the esophagus can cause heartburn, regurgitation, and discomfort (Casey et al., 1996; Truitt & Tami, 1999). Episodic retrosternal pain not associated with swallowing may also be prevalent (Noyer & Simon, 1997). Any of the causes of discomfort and difficult swallowing may lead to decreased intake of food and resultant nutritional deficiencies, further complicating any that might result from other causes. The stomach is less frequently affected in HlV-infected persons than the rest of the gastrointestinal (GI) tract, and GI problems that arise are often not AIDS-related (Cello, 1997). While uncommon, mucosal ulcerations due either to cytomegalovirus or to herpes simplex virus may be seen. Kaposi's sarcoma lesions may be seen but is not often symptomatic, and the stomach was the most frequently affected organ when visceral disease was present. Gastric lymphomas and Kaposi's sarcoma lesions can cause obstruction, perforation,

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 239

TABLE 5.5 Selected HIV-related Gastrointestinal Disorders Site/process Esophagus Esophagitis

Stomach Hepatobiliary Cholecystitis Hepatic disease

Intestinal Tract Obstruction Ulceration

Diarrhea

Anorectal

Most frequent causes/pathogens

Candida Herpes simplex virus Cytomegalovirus Mycobacterium avium complex Esophageal acid-peptic reflux Ulcerations from medications Kaposi's sarcoma lesions Kaposi's sarcoma (rare) Cytomegalovirus ulcers (rare) Cytomega lovirus Cryptosporidium spp. Mycobacterium avium complex Cytomegalovirus hepatitis Kaposi's sarcoma Intrahepatic lymphoma Cryptococcus neoformans hepatitis Disseminated herpes virus Disseminated histoplasmosis Kaposi's sarcoma Lymphomas Cytomegalovirus Kaposi's sarcoma Toxoplasma Lymphomas Cryptosporidium parvum Isospora belli Mycobacterium avium complex Strongyloides stercoralis Salmonella spp. Campylobacter jejuni Unknown origin, direct HIV affect? Herpes simplex virus ulcerations Kaposi's sarcoma Squamous cell Carcinoma Lymphomas Perirectal abscess Condyloma acuminatum Candida albicans infection

240

THE PERSON WITH HIV/AIDS

and hemorrhage occasionally. Symptoms seen that may be related to gastric disease include nausea, early satiety, vomiting, and hematemesis (Cello, 1997). Both the upper and lower intestines are commonly affected in AIDS. Many of the responsible agents affect both sites. Diarrheal syndromes develop in more than 30% to 60% of persons with AIDS in developed countries and about 90% in developing countries (Framm & Soave, 1997; Karp & Neva, 1999; Lew et al., 1997; Veazey & Lackner, 1998). In many cases, no causative organism can be found to be responsible for the diarrhea. It is believed that the direct effect of HIV itself on the cells of the gut is sufficient for symptom production. A variety of organisms are known to produce diarrhea and are listed below. However, the resulting severe diarrhea, in addition to discomfort, often causes malabsorption, weight loss, wasting, electrolyte and fluid imbalances, and malnutrition, and is a major source of morbidity. Diarrhea may remain a chronic problem throughout the course of HIV disease (Framm & Soave, 1997). Major findings of small bowel infection include large-volume choleralike diarrhea, cramping abdominal pain, bloating, and weight loss that may or may not be accompanied by anorexia or malaise. Malabsorption occurs, particularly in chronic infections. The exact symptoms depend on the infecting organisms, host factors, and duration of illness. In large bowel infections, typical symptoms include abdominal pain, frequent small-volume diarrhea, tenesmus (rectal urgency), cramping in the left lower quadrant, and blood in the stool. Some organisms cause ulcerations. Several microorganisms that commonly affect the bowel in persons with HIV disease include Cryptosporidium spp., Isospora belli, microporidia, Strongyhides stercoralis, cytomegalovirus, Mycobacterium avium complex, Salmonella spp., Giardia, and Campylobacter jejuni. CMV is common in the ileum, where it can result in perforation. Other agents may also be responsible, and lymphomas and Kaposi's sarcomas of the intestine may contribute to chronic diarrhea and/or obstruction (Cello, 1997; Clayton & Clayton, 1997; Framm & Soave, 1997; Kartalija & Sande, 1999). Therapy for diarrhea in patients with AIDS has been difficult and complicated, in part, by infection with multiple organisms. Cytomegalovirus commonly causes colitis that, in addition to the diarrhea, causes troubling abdominal pain. Mucosal ulceration with perforation of the colon is not infrequent (Kartalija & Sande, 1999;

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 241

Redvanly & Silverstein, 1997). Lesions due to Kaposi's sarcoma and/ or lymphomas may become large arid cause both ulcerations and obstruction with hemorrhage. Protein-losing enteropathy has been reported secondary to KS. MAC is commonly found in the colon, often in association with systemic disease. Adenovirus infection of the colon has been noted. Also seen may be pseudomembranous colitis (Cello, 1997; Clayton & Clayton, 1997; Cohen et al., 1998). Anorectal disorders are frequently found. In one series, Barrett, Callahan, and Orkin (1998) found the following disorders occurred most frequently: condylomas, fistulas, fissures, abscesses, ulcers, and neoplasms. In the anorectal region, vesicular eruptions that progress to ulcerative lesions due to HSV can cause considerable pain and discomfort. CMV can also cause anal and perianal ulcers. The perianal ulcerations seen may be deep and extensive. These lesions further complicate irritation due to diarrhea. HPV may cause anal warts. KS lesions, as well as squamous cell carcinomas, may also appear rectally (El-Attar & Evans, 1999). Most persons with HIV disease have some type of liver malfunction, with 80% showing abnormal liver function tests (especially alkaline phosphate), and enlargement of the liver or jaundice occurs in about half (Cello, 1997; Cohen et al., 1998). In the liver, lesions can be caused by infiltration of microorganisms, most commonly MAC, C. neoformans, cytomegalovirus, and Histoplasma capsulatum, and by KS and lymphomas. Hepatitis due to Bartonella infection has been more recently recognized and is described earlier in this chapter. Fungal infections are seen most often when disseminated disease is present, particularly that due to C. neoformans, Histoplasma capsulatum, Candida, and Coccidioides immitis. Hepatitis B and C may coexist with HIV infection, causing hepatitis and leading to further complications. Cholecystitis also occurs, particularly secondary to cytomegalovirus and Cryptosporidium spp. as well as other biliary tract disease. Depending on the pathology, jaundice may be seen (Cello, 1997; Clayton & Clavton, 1997; Cohen et al., 1998; Ventura et al., 1997; Younossi & Canute, 1999). The pancreas has not been extensively studied in HIV infection, but some abnormalities, particularly pancreatitis and pancreatic duct problems, have been noted. Pancreatic lesions may result from medications used in therapy of HIV or associated conditions. These include ddl (pancreatitis, glucose intolerance), ddC (pancreatitis), pentamidine (pancreatitis, hypoglycemia,

THE PERSON WITH HIV/AIDS

242

hyperglycemia, or diabetes mellitus), and TMP-SMZ (pancreatitis). Infectious processes due to MAC, CMV, C. neoformans and other fungi, and Toxoplasma, causing severe necrosis, maybe seen (Cappell, 1997; Hofbauer & Heufelder, 1996).

The Oral Cavity Oral manifestations associated with HIV infection have been prominent since candidiasis was discussed in the first reports of the epidemic (Centers for Disease Control, 1981a, 1981b). Since then, a variety of other oral findings have been reported in connection with HIV infection. The most important of these are summarized in Table 5.6. Oral candidiasis is probably the most frequent disorder seen in HIV infection, found in about 75% of patients with AIDS (Noyer & Simon, 1997), and has been discussed fully earlier. The World Health Organization and the EC-Clearinghouse on oral problems related to HIV infection classified oral manifestations of HIV infections into three groups: 1. Lesions strongly associated with HIV infection 2. Lesions less commonly associated with HIV infection

TABLE 5.6

Major Oral Disorders Manifested in HIV Infection

Disorder

Etiology

Candidiasis (thrush) HIV-associated gingivitis HIV-associated periodontitis Oral hairy leukoplakia Warts Recurrent aphthous ulcers Vesicles/ulcerations

Candida albicans Unclear, may be bacterial Unclear, may be bacterial Epstein-Barr virus—associated Human papilloma virus Cause unknown Herpes simplex complex and varicella zoster viruses Kaposi's sarcoma

Purple or red raised macules, papules, or nodules Mucosal ecchymoses Xerostomia Masses/swelling

Autoimmune thrombocytopenic purpura CMV infection of salivary glands Lymphomas

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 243

3. Lesions possibly associated with HIV infection ("Classification and diagnostic criteria . . . ," 1993). Presumptive and definitive criteria for diagnosis were also given. Those conditions considered by this report to be strongly associated with HIV infection were erythematous and pseudomembranous candidiasis, hairy leukoplakia, KS, non-Hodgkin's lymphoma, and certain types of periodontal disease such as lineal gingival erythema, necrotizing ulcerative gingivitis, and necrotizing ulcerative periodontitis. Those considered less commonly associated with HIV infection were necrotizing stomatitis, salivary gland disease such as dry mouth and swelling of the salivary glands, thrombocytopenic purpura, ulceration not otherwise specified, HSV, and VZV ("Classification and diagnostic criteria . . . ," 1993). In HlV-infected persons there has been a notable increase of both gingivitis and periodontitis that are unlike those seen in non-HIVinfected persons. There is a rapidly progressing severe form called necrotizing ulcerative periodontitis (Cohen et al., 1998). This HIVassociated gingivitis and periodontitis often show a distinctive red marginal line (linear gingival erythema) on the gums; general gingival reddening; spontaneous bleeding, especially at night; severe oral pain that may not be easily ameliorated by analgesics; gingival necrosis; and exposure and destruction of supporting bone. Teeth loosen and may be lost. An additional hallmark is the extremely rapid progression and destruction (Cohen et al., 1998). Periodontal disease is believed due to bacteria. Recurrent aphthous ulcers are not uncommon in the immunocompetent population, but these are being seen increasingly in persons who are HIV-infected. These are manifested as crops of ulcers on the oral and oropharyngeal mucosa, where they can interfere with both speech and swallowing. The cause is unknown. KS may be manifested in the mouth with erythematous slightly bluish macules or swellings that may or may not be ulcerated. They are most common on the palate and gingival and dorsal surface of the tongue. NonHodgkin's lymphoma manifests in the mouth as firm, rubbery, pink, or reddened swelling with or without ulceration on the gingiva and palate (Wiebe & Epstein, 1997). Other oral disorders presented in Table 5.6 are discussed elsewhere in this chapter.

244

THE PERSON WITH HIV/AIDS

The Skin, Hair, and Nails Skin lesions appear commonly in people with or without HIV infection; however, common conditions are seen even more frequently in those with HIV infection. As the CD4+ cell count drops, unusual disorders and unusual manifestations of common disorders may be observed. Cutaneous manifestations of HIV infection may be due to infectious agents, neoplasms, as the result of various medications used in treatment, and unknown factors. Included in the unknown category are the effects of HIV, both direct and indirect, through its effects on the immune system. More than 90% of HIV-infected persons show skin manifestations of the illness at some time, and they may be the reason for seeking medical attention (Geusau & Tschachler, 1997). Any type of skin condition that may be seen in persons who are HFV-uninfected can occur in those who are infected. Many such manifestations have been observed. A selection of these is shown in Table 5.7. Opportunistic conditions with skin manifestations such as Kaposi's sarcoma, candidiasis, herpes simplex virus ulcers, herpes zoster (shingles) due to varicella zoster virus, autoimmune thrombocytopenic purpura, and Molluscum contagiosum have already been discussed in this chapter. Many of the skin disorders seen in conjunction with HIV infection differ from disorders seen in those who are HIV seronegative by virtue of severity, unusual locations, and rapidity of progression, particularly as immunosuppression progresses. For example, HIV ulcers, instead of presenting as small blisters, tend to be large chronic oral or anogenital ulcers (Geusau & Tschachler, 1997). Lesions may occur due to skin infestation of organisms such as MAC and tuberculosis. In developing countries, lesions from infections such as leishmaniasis may occur. A maculopapular rash with a truncal distribution is often the first skin manifestation of HIV infection when it occurs during acute infection with HIV (Geusau & Tschachler, 1997), and is thought to be due to HIV itself. As discussed earlier in this chapter, fungal, viral, and bacterial organisms most commonly cause skin lesions in developed countries. The most common bacterial skin infections seen in AIDS are due to Staphylococcus aureus, which is responsible for many pyogenic lesions in both HIV and non-HIV-infected persons, MAC, extrapulmonary M. tuberculosis, and syphilis. Bacillary

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 245

TABLE 5.7 Selected Cutaneous Manifestations Seen in HIV Infection Manifestation

Possible etiology*

Red, purple, blue, brown nodules, patches, macules, plaques Vesicles, usually crusting following dermatomes Seborrheic dermatitis Pruritic maculopapular rash (chronic), especially of trunk and abdomen Warts, facial, hands, feet Anogenital condylomata Psoriasis Telangiectasia Perioral vesicles, ulcers Nail abnormalities Petechiae, purpura, ecchymoses Pearly papules with core, especially on face Alopecia areata Premature aging of skin Hair—graying and thinning Pruritus

Kaposi's syndrome

Angular cheilitis Folliculitis Dry skin Vascular proliferative lesions

Varicella zoster virus Pityrosporium orbiculare ?HIV Human papilloma virus Human papilloma virus ?HIV ?HIV, amyl and butyl nitrite Herpes simplex virus ?HIV, various fungi Thrombocytopenia Molluscum contagiosum ?HIV ?HIV ?HIV ?HIV, scabies, lymphoma, miscellaneous skin diseases Candida albicans Staphylococcus aureus ?HIV, nutritional deficits Bartonella henselae, B. quintana

*?HIV = the cause is believed to be a result of HIV infection because of either direct effect or depressed and deranged immune function.

angiomatosis, similar to cat scratch fever, is caused by members of the Bartonella group. Seborrheic dermatitis is said to occur in 40% to 80% or more of patients with AIDS in contrast to under 5% of the general population. In appearance it is a scaly erythematous eruption seen on the face, upper arms, scalp, and sometimes the trunk. Sometimes a butterfly pattern is seen on the face. It is often an early manifestation, and although the cause is uncertain, the fungi, Malassezia furfur in the asexual form, and Pityrosporium orbiculare in the sexual form, with a trend to using the former designation, has been implicated. This

246

THE PERSON WITH HIV/AIDS

eruption responds to topical antifungal agents such as ketoconazole and steroids (Geusau & Tschachler, 1997; Walker, 1998). Psoriasis also occurs in persons with AIDS. Whether or not it is more frequent in those who are HIV-infected when compared with those who are not is not clear; however, it may be more severe and difficult to treat. It may be associated with other conditions and symptoms such as with arthritis in Reiter's syndrome. Treatment is often with cyclosporine, topical steroids, synthetic retinoids, and sometimes ultraviolet B radiation (Ray & Gately, 1994; Sande & Volberding, 1997; Wong & Shumack, 1996). Folliculitis occurs in about 20% of persons with HIV infection. The skin eruptions may resemble acne vulgaris. The papular lesions may be intensely itchy and occur in sheets. The etiology is unknown, but sometimes Staphylococcus aureus or M. furfur may be involved, and it may respond to antifungal therapy in some cases (Ray & Gately, 1994). Dry skin is also commonly seen in persons with AIDS. It may accompany diarrhea and malabsorption, and therefore may be due to nutritional deficiencies seen more commonly as CD4+ cell counts drop (Wong & Shumack, 1996). Insect bite reactions such as to mosquitoes, fleas, and spiders can be more severe in persons with AIDS. Scabies, a mite infestation often spread by close contact, may also be more severe. Prevention of insect bite reactions may include eliminating insects from the environment, protecting the person by use of repellents, and blocking the reaction to the bite with regular antihistamine therapy if this is a problem (Sande & Volberding, 1997). Sensitivity reactions to drugs used to treat HIV or its complications may manifest with dermatologic effects as well and can be more severe in persons with HIV, often progressing to systemic reactions. Pruritus that is associated with drug therapy or not seems to occur more severely in HIV-infected persons with skin conditions (Wong & Shumack, 1996). The hair and nails have also been noted to be affected. Premature aging changes of both the hair and skin have also been noted with AIDS. These are particularly noticeable as thinning and graying of hair and loss of facial fat. In Black patients, straightening of previously curly hair has been described (DeVita et al., 1997). Fungal infections of the nails, or onychomycosis when affecting the toenails tend to be relatively common and refractory to treatment (Loveland, 1998).

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 247

Nail changes can also result from associated therapy such as dark lines seen with zidovudine treatment or blue lunae that are more common in darker skinned persons (Casey et al., 1996).

The Eyes Ocular manifestations of some type are estimated to occur in about 70% to 80% or more of persons with AIDS at some time. These may include disorders affecting the adnexa including the eyelids, conjunctiva, and lacrimal drainage system; the cornea, iris, anterior chamber, retina, choroid, optic nerve or head, and/or the orbit (Cunningham & Margolis, 1998; Hodge, Seiff, & Margolis, 1998). CMV retinitis, as discussed previously in this chapter, is the most common ocular opportunistic infection in HIV-infected persons. It is detected in 30% to 40% of persons with HIV infection in developed countries. It is a poor prognostic sign, does not respond well to therapy, and, if the optic nerve is involved, can lead to blindness (Cheung & Teich, 1999; Cunningham & Margolis, 1998). Cotton wool spots of HIV-retinopathy may be seen (DeVita et al., 1997). Other ocular infections may be caused by toxoplasmosis, varicella zoster virus, herpes simplex virus, certain fungi, Pneumocystis carinii, and syphilis (Hodge et al., 1998). VZV can cause a vesiculobullous dermatitis, herpes zoster ophthalmicus, which is said to affect 5% to 15% of HIV-infected persons. This often follows the distribution of the ophthalmic branch of the trigeminal nerve and can lead to conjunctivitis, keratitis, uveitis, or blepharitis. Treatment is with acyclovir or famciclovir. HSV can also threaten the eye causing keratitis, retinitis, or blepharitis (Cunningham & Margolis, 1998). Visual loss without retinopathy can also occur (Plummer et al., 1999). Kaposi's sarcoma can affect the eyelid or conjunctiva, where it is sometimes mistaken for hemorrhage, but does not usually invade the eye itself (Cohen et al., 1998). Microvascular changes in the conjunctiva occur in 70% to 80% of HIV-positive persons. The cause is not known, and speculation includes direct effects of HIV and HIV-related immune complex deposition. Iridocyclitis maybe caused by CMV or VZV. Other eye involvement can result from T. gondii infection, threatening the retina. Many skin rashes such as M. contagiosum may involve the eyelids (Cunningham & Margolis, 1998).

248

THE PERSON WITH HIV/AIDS

Respiratory Tract The respiratory tract is commonly involved in persons with AIDS and is the most frequent system causing death due to AIDS-associated conditions (Afessa et al., 1998). About 70% of persons with AIDS have some AIDS-related respiratory episode (McGuinness, 1997). Trends in pulmonary complications of HIV have changed in recent years. A major factor in those changes has been widespread PCP prophylaxis. Thus, while PCP was formerly the most frequent AIDSrelated respiratory condition, it is now secondary. Bacterial pneumonia is now the most common pulmonary infection seen in AIDS and may be community-acquired or nosocomial (Afessa et al., 1998; Tumbarello et al., 1998). Organisms most likely to cause bacterial pneumonia in persons with AIDS are MAC and other atypical mycobacteria, Pseudomonas aeroginosa, Staphylococcus, and Streptococcus haemophilus. Cryptococcus neoformans, Toxoplasma gondii, and CMV also frequently affect the lung, as does tuberculosis. VZV infection can result in varicella pneumonia, but VZV is not a common cause of pulmonary disease in AIDS. In epidemic KS, pulmonary involvement may be seen in up to 50% of cases. AIDS-related lymphoma is less likely to cause pulmonary disease in persons with AIDS (McGuinness 1997). Other agents may be involved, and for some, the frequency depends on geographic location of the patient. These include HSV, Candida, Histoplasma capsulatum, and Coccidioides immitis, especially when infection is disseminated such as in nocardiosis. Most of these disorders are discussed in detail earlier in this chapter. Sinusitis and bronchitis, usually due to bacteria, may be seen in the middle or intermediate stages of HIV disease (DeVita et al., 1997).

Renal Complications Renal complications of HIV infection have become increasingly evident. These include acute renal failure, chronic renal disease, and HIV-associated nephropathy, which is characterized by proteinuria and glomerulosclerosis. This syndrome results in rapid deterioration of renal function leading to end-stage renal disease within weeks. The renal failure may follow acute tubercular necrosis (Sande & Volberding, 1997). Renal insufficiency due to drugs, such as ketoco-

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 249

nazole and megestrol, used in the treatment of HlV-related conditions, may occur (Gripshover & Aron, 1997). Cardiac Involvement In recent years more has become known about cardiac involvement in AIDS (Cardoso, 1999). Estimates of morbidity range from 6% to 7% (Yunis Sc Stone, 1998). The most important cardiac problems are pericardial disease, pulmonary hypertension, myocardial involvement, valvular abnormalities, and vascular lesions. Similar to findings related to other systems, effects on the heart are due to HIV itself, OIs, Kaposi's sarcoma, and the treatment of HIV and its complications. Some conditions are detected only on autopsy, whereas others cause clinically relevant disease (Cheitlin, 1997; Yunis & Stone, 1998). Among pericardial disease, pericardial effusion has been detected in up to 49% of patients at autopsy, many of whom were asymptomatic (Chen et al., 1999; Yunis & Stone, 1998). Pericarditis may be due to viruses, especially CMV and HSV; bacteria, especially MAC, Nocardia, Staphylococcus, and M. tuberculosis; and fungi, especially Cryptosporidium and Aspergillus. Myocarditis, with or without cardiomyopathy, was found at autopsy in 46% to 52% of patients (Cohen et al., 1986; Raul, Fishbein, & Siegel, 1991). Cardiac effects may also be due directly to HIV or to autoimmune reaction in addition to infectious agents (Barbaro, Di Lorenzo, Grisorio, & Barbarini, 1998). Drugs commonly used for the treatment of opportunistic conditions in AIDS may affect the heart. For example, TMP-SMZ and pentamidine can cause QT prolongation (Michaels, Lederman, MacGregor, & Cheitlin, 1997). Ganciclovir and amphotericin B can cause ventricular tachycardia and ventricular arrhythmia, respectively. Alpha inter feron and doxirubicin can cause dilated cardiomyopathy, and zidovudine can cause myocarditis and dilated cardiomyopathy. Rheumatic and Musculoskeletal Conditions Various rheumatologic pictures have been described in HIV infection. Musculoskeletal disorders affect 0.15% to 12% of HIV-infected persons. The spectrum of such diseases include septic arthritis, pyo-

250

THE PERSON WITH HIV/AIDS

myositis, arthralgia, and Reiter's syndrome (Barzilai et al., 1999; Cuellar, 1998). Reiter's syndrome is an asymmetric arthritis usually involving a few joints, especially in the sacroiliac joints, the knees, hips, and ankles often in association with mucocutaneous manifestations and eye involvement. Ligament and tendon inflammation may also be associated. Reiter's syndrome is closely associated with HLAB27 and has a substantial genetic component. Whether the connection is a direct biologic one, or whether the development of Reiter's syndrome occurs due to the immunodeficiency in HIV infection, is not currently clear (Lashley, 1998; Vassilopoulos et al., 1997; Weitzul&Duvic, 1997).

Gynecologic Conditions A variety of gynecological conditions appear in HIV-infected women. (See also chapter 11.) Some of these are coincident to HIV and may be the result of other concurrent sexually transmitted diseases or conditions, whereas others result directly from immunodeficiency. In the 1993 case definition of AIDS, invasive cervical cancer was added (Centers for Disease Control and Prevention, 1992). The most frequently appearing gynecologic conditions in women with HIV infection are pelvic inflammatory disease, cervical dysplasia, and neoplasia, including cervical interstitial neoplasia (GIN), and invasive cervical cancer and vaginal fungal infections, especially candidiasis (Cohen, 1993). Vaginal candidiasis has been discussed above. Cervical cancer has been shown to be caused by the human papillomavirus, particularly types 16,18, and 31 (Richart et al. 1998; Walker, 1998). It is more common in women with HIV, particularly when invasive (Chin et al., 1998). Cervical cancer was discussed earlier. Pelvic inflammatory disease, for which about one million women a year are treated, affects women who are HIV-infected. The Centers for Disease Control (1991) published guidelines for prevention and management that are still used. Organisms causing PID are most often Chlamydia trachomatis and Neisseria gonorrheae, and standard treatments are used. HIV-infected women may have more complications than non-HIV-infected women; however, unless disease is advanced, they both respond to treatment (Cohen et al., 1998). One study looked at menstrual disorders in HIV-infected women, and

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 251

amenorrhea was noted in 7% of HIV-infected women and 5% of HFV-negative control women (Cohen et al., 1998). Other disorders discussed earlier such as herpes simplex ulcers affecting the genital area may be harder to treat in women with HIV infection. Advanced immunosuppression results in more and more severe gynecologic complications (Greenblatt et al., 1999; Watts et al., 1999). In one study, women with HIV who had CD4+ cell counts below 500 mm 3 did not have an increased frequency of sexually transmitted diseases (Minkoff et al., 1999). Endocrine Disorders Endocrine disorders may be due to HIV infection itself, OIs, neoplasms, the medications used in treatment, or factors related to stress and nutrition (Hofbauer & Heufelder, 1996). The most commonly reported endocrine abnormality described in HIV is adrenal insufficiency. Adrenal abnormalities have been noted in 37% to 88% of patients with AIDS at autopsy. Most frequently these have been due to CMV, MAC, C. neoformans, histoplasmosis, or Kaposi's sarcoma (Gripshover & Aron, 1997). Various thyroid abnormalities have also been described, particularly in late HIV disease. CMV inclusions in the thyroid gland have been found, and thyroiditis can occur most often with MAC, MTB, or C. neoformans (Hofbauer & Heufelder, 1996). Some drugs that have been shown to affect function in HIV infection were discussed under the GI tract above. In addition, the following are a few examples how drugs may affect the endocrine system of HIV-infected persons: interferon (panhypopituitarism, autoimmune thyroid disorder, hypothyroidism), rifampin (increased cortisol clearance, hypothyroidism), cyclophosphamide (hypogonadism and many other gonadal manifestations), and megestrol (adrenal insufficiency, Cushing's syndrome) (Hofbauer & Heufelder, 1996). Other endocrine abnormalities may be reported as more information becomes available. In addition to endocrine problems listed above, hypogonadism may occur in about 30% of HIV-infected men, and androgen levels may be low. The hypogonadism can lead to sexual dysfunction, decreased sense of well-being, lower quality of life, and may be related to wasting (Dobs, 1998).

252

THE PERSON WITH HIV/AIDS

Other Organ Systems and Disorders More than half of HIV-infected persons have related findings in the head and neck region. This includes odds externa of the external auditory canal, often due to Pseudomonas aeroginosa, and odds media in which the responsible organisms are similar to those in the nonHIV infected population. Sensorineural hearing loss, often of high frequencies, may relate to OIs, malignancies, central nervous system infections, or iatrogenic causes. Sinusitis, both acute and chronic, may be seen, and the responsible organisms for acute sinusitis are similar to the general population. In chronic sinusitis, common pathogens include Staphylococcus, Pseudomonas, and anaerobes, and may often be due to fungi such as Aspergillus, Cryptococcus, or Candida. Oropharyngeal or laryngeal candidiasis may experience hoarseness. Xerostomia may be present in 6% to 10% of the HIV-infected population, possibly due to cytomegalovirus infection (Truitt & Tami, 1999). Fever of unknown origin may occur in HIV-infected persons in the United States, and one study showed that the most common diagnoses were disseminated Mycobacterium avium complex infection, PCP, cytomegalovirus, disseminated histoplasmosis, and lymphoma. Many times multiple causes were present and FUO occurred in the late stages of disease (Armstrong, Katz, & Kazanjian, 1999). Various hematologic disorders have been described in HIV disease and are common manifestations of advanced disease. The most common is cytopenia—anemia, thrombocytopenia, and leukopenia. Anemia may result from a variety of causes including iron deficiency, due to infection such as Parvovirus B19, as a sequelae of certain drugs, or due to hemolysis, and bone marrow suppression (Bain, 1999). Anemia may lead to fatigue. See chapter 6. Thrombopenia may result from decreased production or HIV-associated immune destruction (Coyle, 1997). In 1982 investigators reported a clustering of immune or autoimmune thrombocytopenic purpura (AITP) in young homosexual males (Morris et al., 1982). Signs and symptoms associated with AITP include petechiae, easy bruisability with ecchymoses, and platelet counts below 100,000/mm3. Its prevalence is estimated to be between 5% and 10%. AITP is thought to result from either deposition of circulating immune complexes onto platelets or specific andplatelet antibodies. Either process leads to their destruction. The chief risk of AITP is hemorrhage into sites other than

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 253

the skin, but this does not usually occur until platelet levels are substantially decreased (Coyle, 1997). Leukopenia may consist of lymphopenia and/or neutropenia from HIV-related causes or from drug reactions or infection. Drugs commonly causing toxicity related to the hematologic system that are used in the treatment of HIV infection and associated conditions include zidovudine, ganciclovir, TMP-SMZ, alpha interferon, flueytosine, amphotericin B, pyrimethamine, and many of the antineoplastic drugs. Others, such as dapsone and pentamidine, are less commonly implicated (Coyle, 1997). Lipodystrophy has been described in HIV infection more recently and may develop secondary to hypercortisolism, be due to the HIV infection itself, or be secondary to therapy, especially the use of protease inhibitor therapy. The median time for development is 6 to 12 months after therapy begins. Signs and symptoms may include a "buffalo hump," central obesity, and intra-abdominal fat deposition (often called "protease pouch") that may cause abdominal cramping or pain. The pathogenesis is not well delineated, and treatment has included recombinant human growth hormone, discontinuation of protease inhibitors, and ketoconazole therapy (Williamson, Reboli, & Manders, 1999). Also see chapter 6. It is likely that all of the organ involvement due to HIV infection has not yet been elucidated. As patients with AIDS live longer, other conditions will undoubtedly be described. CONCLUSION Infection with HIV renders the person susceptible to a variety of infections and neoplasms as well as to the direct effects of HIV itself, immune derangement, the body's autoimmune responses, and biochemical changes. These can produce unusual infections and atypical clinical pictures for more common infections and conditions. Side effects from medications may add to the constellation. AIDS is truly a multisystem disease producing complicated clinical pictures. REFERENCES Abadj, J., Nachman, S., Kressel, A. B., & Pirofski, L. (1999). Cryptococcosis in children with AIDS. Clinical Infectious Diseases, 28, 309-313.

254

THE PERSON WITH HIV/AIDS

Aberg.J. A., & Powderly, W. G. (1998). Cryptococcal disease: Implications of recent clinical trials on treatment and management. AIDS Clinical Review, 1997/1998, 229-248. Ackers, J. P. (1997). Gut coccidia—Isospora, Cryptosporidium, Cyclospora, and Sarcocystis. Seminars in Gastrointestinal Disorders, 8(1), 33-44. Afessa, B., Green, W., Chiao, J., & Frederick, W. (1998). Pulmonary complications of HIV infection. Chest, 113, 1225-1229. Agostini, H. T., Shishido-Hara, Y., Baumhefner, R. W., Singer, E. J., Ryschkewitsch, C. F., & Stoner, G. L. (1998). JC virus type 2: Definition of subtypes based on DNA sequence analysis of ten complete genomes. Journal of General Virology, 79, 1143-1151. Albright, A. V., Shieh, J. T., Itoh, T., Lee, B., Pleasure, D., O'Connor, M. J., et al. (1999). Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. Journal of Virology, 75,205-213. Allen, M. H. (1990). Primary care of women infected with the human immunodeficiency virus. Obstetrics and Gynecology Clinics of North America, 77(3), 557-569. Alter, M. J., Mast, E. E., Moyer, L. A., & Margolis, H. S. (1998). Hepatitis C. Infectious Disease Clinics of North America, 12(1), 13-27. Ammassari, A., Scoppettuolo, G., Murri, R., Pezzotti, P., Cingolani, A., Del Borgo, C., De Luca, A., Antinori, A., & Ortona, L. (1998). Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18(4), 365-371. Ampel, N. M., Dols, C. L., & Galgiani, J. N. (1993). Coccidioidomycosis during human immunodeficiency virus infection: Results of a prospective study in a coccidiodal endemic area. American Journal of Medicine, 94, 234-240. Armstrong, W. S., Katz,J. T., & Kazanjian, P. H. (1999). Human immunodeficiency virus-associated fever of unknown origin: A study of 70 patients in the United States and review. Clinical Infectious Diseases, 28, 341-345. Atkins, J. T., Caceres, E., & Cleary, T. G. (1998). Cryptosporidiosis, Cyclospora infec tion isosporiasis, and microsporidiosis. In Ralph D. Feigin & James D. Cherry (Eds.), Textbook of pediatric infectious diseases (4th ed., vol. 2, pp. 2413-2431). Philadelphia: W. B. Saunders. Bain, B. J. (1999). Pathogenesis and pathophysiology of anemia in HIV infection. Current Opinion in Hematology, 6, 89-93. Balfour, H. H.Jr. (1999). Antiviral drugs. New England Journal of Medicine, 340,12551268. Barbaro, G., Di Lorenzo, G., Grisorio, B., Barbarini, G., & the Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS Investigators. (1998). Cardiac involvement in the acquired immunodeficiency syndrome: A multicenter clinicalpathological study. AIDS Research and Human Retroviruses, 14(12), 1071-1077. Barrett, J. G., Breiman, R. F., Mandell, L. A., & File, T. M. (1998). Communityacquired pneumonia in adults: Guidelines for management. Clinics for Infectious Diseases, 26(4), 811-838. Barrett, W. L., Callahan, T. D., & Orkin, B. A. (1998). Perianal manifestations of human immunodeficiency virus infection: Experience with 260 patients. Diseases of the Colon and Rectum, 41, 606-612.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 255

Barzilai, A., Varon, D., Martinowitz, U., Heim, M., & Schulman, S. (1999). Characteristics of septic arthritis in human immunodeficiency virus-infected haemophiliacs versus other risk groups. Rheumatology, 38, 139-142. Belshe, R. B. (Ed.). (1991). Textbook of human virology (2nd ed.). St. Louis: Mosby Year Book. Benson, C. A. (1998). Disseminated Mycobacterium avium complex infection: Implications of recent clinical trials on prophylaxis and treatment. AIDS Clinical Revieiv, 1997/1998, 271-287. Biggar, R. J., Nasca, P. C., & Burnett, W. S. (1988). AIDS-related Kaposi's sarcoma in New York City in 1977. New England Journal of Medicine, 318, 252. Black, P. H. (1985). HTLV-III, AIDS, and the brain. New England Journal of Medicine, 313, 1538-1540. Blumenthal, D. T., Razier,J. J., Rosenblum, M. K., Bilsky, M. H., Hariharan, S., & Abrey, L. E. (1999). Primary intracranial neoplasms in patients with HIV. Neurology, 52, 1648-1651. Boiselle, P. M., Crans, C. A. Jr., & Kaplan, M. A. (1999). The changing face of Pneumocystis carinii pneumonia in AIDS patients. American Journal of Roentgenology, 172, 1301-1309. Boshoff, C. (1998). Kaposi's sarcoma: Coupling herpesvirus to angiogenesis. NatiLre, 391, 24-25. Boshoff, C., £ Moore, P. (1998). Kaposi's sarcoma—associated herpesvirus: A newly recognized pathogen. In P. Volberding & M. Jacobson (Eds.), AIDS clinical review, 1997-1998 (pp. 323-340). New York: Marcel Dekker. Bowen, E. F., Wilson, P., Atkins, M., Madge, S., Griffiths, P. D., Johnson, M. A., & Emery, V. C. (1995). Natural history of untreated cytomegalovirus retinitis. Lancet, 346, 1671-1673. Bowersox, J. (1998). Short-course TB prophylaxis effective in HIV-infected individuals. National Institutes of Health, February 11, 1-3. Boyer, K. M., Remington, J. S., & McLeod, R. L. (1998). Toxoplasmosis. In R. D. Feigin & J. D. Cherry (Eds.), Textbook of pediatric infectious diseases (4th ed., vol. 2, pp. 2473-2490). Philadelphia: W. B. Saunders. Brack-Werner, R. (1999). Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS, 13, 1-22. Brouqui, P., Lascola, B., Roux, V., & Raoult, D. (1999). Chronic Bartonella quintana bacteremia in homeless patients. New England Journal of Medicine, 21, 184-189. Brown, G. H., & Rotschafer,J. C. (1999). Cyclospora: Review of an emerging parasite. Pharmacotherapy, 19, 70-75. Buchanan, K. L., & Murphy, J, W. (1998). What makes Cryptococcus neoformans a pathogen? Emerging Infectious Diseases, 4 ( 1 ) , 71-83. Burman, W. )., Reves, R. R., & Cohn, D. L. (1998). The case for conservative management of early HIV disease. Journal of the American Medical Association, 280, 93-95. Byrne, M. A., Taylor-Robinson, D., Munday, P. E., & Harris, J. W. (1989). The common occurrence of human papillomavirus infection and intrepithelial neoplasia in women infected by HIV. Att)S, 3, 379-382.

256

THE PERSON WITH HIV/AIDS

Cappell, M. S. (1997). The pancreas in AIDS. Gastroenterology Clinics of North America, 26, 337-365. Cardoso, J. S. (1999). Cardiac involvement in immunodeficiency virus infection. Review of Portuguese Cardiology, 18, 217-220. Carmichael, C. (1997). Prevention and treatment of common HlV-associated opportunistic complications. Primary Care, 24(3), 561-574. Game, C. A., Tedder, R. S., Smith, A., Sutherland, S., Elkington, S. G., Daly, H. M., Preston, R. E., & Craske, J. (1985). Acute encephalopathy coincident with seroconversion for anti-HTLV-III. Lancet, 2, 1206-1208. Carr, A., Marriott, D., Field, A., Vasak, E., & Cooper, D. A. (1998). Treatment of HFV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet, 351, 256-261. Cartledge, J. D., Midgley, J., & Gazzard, B. G. (1999). Non-albicans oral candidosis in HIV-positive patients. Journal of Antimicrobial and Chemotherapy, 43, 419-422. Casey, K. M. (1997). Malnutrition associated with HIV/AIDS: 2. Assessment and intervention. Journal of the Association of Nurses in AIDS Care, 8, 39-48. Casey, K., Cohen, F., & Hughes, A. (Eds.). (1996). ANAC's Core Curriculum for HIV/ AIDS Nursing. Philadelphia: Nursecom. Gates, W., Chesney, M. A., & Cohen, M. S. (1997). Primary HIV infection—A public health opportunity. American Journal of Public Health, #7(12), 1928-1930. Cavert, W. (1997a). Preventing and treating major opportunistic infections in AIDS. Postgraduate Medicine, 102(4), 125-140. . (1997b). Viral infections in human immunodeficiency virus disease. Medical Clinics of North America, 81(2), 411-426. Cello, J. P. (1997). Gastrointestinal manifestations of AIDS. In M. Sande & P. Volberding (Eds.), The medical management of AIDS (5th ed., pp. 181-195). Philadelphia: W. B. Saunders. Centers for Disease Control. (1981a). Kaposi's syndrome and pneumocystis pneumonia among homosexual men—New York and California. Morbidity and Mortality Weekly Report, 31, 507-515. . (1986). Tuberculosis, final data—United States, 1986. Morbidity and Mortality Weekly Report, 36, 817-820. . (1987). Revision of the CDC surveillance case definition for the acquired immunodeficiency syndrome. Morbidity and Mortality Weekly Report, 36(Suppl. IS), 1S-15S. Centers for Disease Control and Prevention. (1991). Outbreaks of diarrheal illness associated with cyanobacteria (blue-green algae)-like bodies—Chicago and Nepal, 1989 and 1990. Morbidity and Mortality Weekly Report, 40, 325. . (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report, 41 (No. RR-17), 1-19. . (1993). Expanded tuberculosis surveillance and tuberculosis morbidity— United States, 1993. Morbidity and Mortality Weekly Report, 43(20), 695-697. . (1994). Expanded tuberculosis surveillance and tuberculosis morbidity— United States, 1993. Morbidity and Mortality Weekly Report, 43, 361-366.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 257

. (1996a). Outbreaks of Cydospora cayetanensis infection—United States, 1996. Morbidity and Mortality Weekly Report, 45(25), 549-551. . (1996b). USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary. Morbidity and Mortality Weekly Report, 44, 1-34. . (1997). 1997 USPH/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Morbidity and Mortality Weekly Report, 47(No. RR-12), 1-46. . (1998). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report, 47, 43-82. . (1999). Surveillance for ATDS-defming opportunistic illnesses, 1992-1997. Morbidity and Mortality Weekly Report, 48(No. SS-2), 1-22. Chang, Y, Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., & Moore, P. S. (1994), Identification of herpes virus-like DNA sequences in AIDSassociated Kaposi's sarcoma. Science, 266, 1865-1869. Cheitlin.M. (1997). Cardiovascular complications of HIV infection. InM. A. Sande& P. A. Volberding (Eds.), The medical management of AIDS (5th ed, pp. 247-256). Philadelphia: W. B. Saunders. Chen, Y., Brennessel, D., Walters, J., Johnson, M., Rosner, F., & Raza, M. (1999). Human immunodeficiency virus-associated pericardial effusion: Report of 40 cases and review of the literature. American Heart Journal, 137, 516-521. Cheung, T. W., & Teich, S. A. (1999). Cytomegalovirus infection in patients with HIV infection. The Mount Sinai Journal of Medicine, 66, 113-122. Chin, K. M., Sidhu,J. S.,Janssen, R, S., & Weber, J. T, (1998). Invasive cervical cancer in human immunodeficiency virus-infected and uninfected hospital patients. Obstetrics and Gynecology, 92(1), 83-87. Classification and diagnostic criteria for oral lesions in HIV infection. (1993)./ourna/ of Oral Pathology and Medicine, 22, 289-291. Clayton, F., & Clayton, C. (1997). Gastrointestinal pathology in HIV-infected patients. Gastroenterology Clinics of North America, 26(2), 191-240. Clifford, D. B., Yiannoutsos, C., Glicksman, M. S., Simpson, D. M., Singer, E. J., Piliero, P.J., et al. (1999). HAART improves prognosis in HIV-associated progressive multiibcal leukoencephalopathy. Neurology, 52, 623-625. Cohen, B. A. (1997). Neurologic complications of HIV infection. Primary Care, 24(3), 575-595. Cohen, F. (1997). Adherence to therapy in tuberculosis. Annual Review of Nursing Research, 75, 153-184. Cohen, F., & Durham, J. D. (Eds.). (1995). Tuberculosis: A sourcebook for nursing practice. New York: Springer. Cohen, P. T., Sande, M. A., & Volberding, P. A. (Eds.). (1998). The AIDS knowledge base (3rd ed.). [Online.] [http://hivinsite.ucsf.edu/akb/1997/] San Francisco: University of California, San Francisco and the San Francisco General Hospital. Cooper, C. R., & McGinnis, M. R. (1997). Pathology of Penidllium mameffei: An emerging acquired immunodeficiency syndrome-related pathogen. Archives of Pathology and Laboratory Medicine, 121, 798-804.

258

THE PERSON WITH HIV/AIDS

Cooper, D. A., Gold, J., Maclean, P., Donavan, B., Finlayson, R., Barnes, T. G., Michelmore, H. M, Brooke, P., & Penny, R. (1985). Acute AIDS retrovirus infection definition of a clinical illness associated with seroconversion. Lancet, 1, 537-540. Corcoran, C., & Grinspoon, S. (1999). Treatments for wasting in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine, 340, 1740-1750. Corey, L., & Schacker, T. (1998). Characteristics of primary HIV infection. Annals of Internal Medicine, 130, 80-81. Coyle, T. E. (1997). Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Medical Clinics of North America, 81, 449-470. Cuellar, M. L. (1998). HIV infection-associated inflammatory musculoskeletal disorders. Rheumatological Diseases in Clinics of North America, 24(2), 403-421. Cunningham, E. T., & Margolis, T. P. (1998). Ocular manifestations of HIV infection. New England Journal of Medicine, 339(4), 236-244. Dalakas, M. C., & Pezeshkpour, G. H. (1988). Neuromuscular diseases associated with human immunodeficiency virus infection. Annals of Neurology, 2J(Suppl.), S38-S48. Dalakas, M., Wichman, A., & Sever, J. (1989). AIDS and the nervous system. Journal of the American Medical Association, 261, 2396-2399. Daley, C. L. (1998). Current issues in the pathogenesis and management of HFVrelated tuberculosis. AIDS Clinical Review, 1997/1998, 289-321. Darouiche, R. O. (1998). Oropharyngeal and esophageal candidiasis in immunocompromised patients: Treatment issues. Clinical Infectious Diseases, 26, 259-274. Daar, E. S., Bai, J., Hausner, M., Majchrowicz, M., Tamaddon, M., & Giorgi, J. (1998). Acute HIV syndrome after discontinuation of an tire tro viral therapy in a patient treated before seroconversion. Annals of Internal Medicine, 128(10), 827828. Demmler, G. J. (1998). In R. D. Feigin &J. D. Cherry (Eds.), Textbook of pediatric infectious diseases (4th ed., vol. 2, pp. 1732-1751). Philadelphia: W. B. Saunders. Denning, D. W. (1998). Invasive aspergillosis. Clinical Infectious Diseases, 26, 781-805. Deresinski, S. C. (1997). Treatment of Pneumocystis camm pneumonia in adults with AIDS. Seminars in Respiratory Infections, 12(2), 79-97. Detecting CMV retinitis: Know what to look for. (1996, March). Common Sense About AIDS, pp. 1-2. DeVita, V. TJr., Hellman, S., & Rosenberg, S. (Eds.). (1997). AIDS: Etiology, diagnosis, treatment and prevention (4th ed.). Philadelphia: Lippincott. Didier, E. S. (1998). Microsporidiosis. Clinical Infectious Diseases, 27, 1-8. Dobs, A. S. (1998). Androgen therapy in AIDS wasting. Bailliere's Clinical Endocrinology and Metabolism, 12(B), 379-390. Duong, T. A. (1996). Infection due to Penicillium marneffei, an emerging pathogen: Review of 155 reported cases. Clinical Infectious Diseases, 23, 125-130. Durden, F. M., & Elewski, B. (1997). Fungal infections in HIV-infected patients. Seminars in Cutaneous Medicine and Surgery, 16(3), 200-212.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 259

El-Attar, S. M., & Evans, D. V. (1999). Anal warts, sexually transmitted diseases, and anorectal conditions associated with human immunodeficiency virus. Primary Care, 26(1), 81-99. El-Sadr, W. M., Murphy, R. L., Yurik, T. M., Luskin-Hawk, R., Cheung, T. W., Balfour, H. R., et al. (1998). Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. New England Journal of Medicine, 339, 18891895. Feigin, R. D., & Cherry, J. D. (Eds.). (1998). Textbook of pediatric infectious diseases (4th ed.). Philadelphia: W. B. Saunders. Fichtenbaum, R. J., & Powderly, W. G. (1998). Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clinical Infectious Diseases, 26(3), 556-565. Finzi, D., Blankson,J., Siliciano,J., Margolick,J. B., Chadwick, K., & Pierson (1999). Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine, 5, 512-517. Framm, S. R., & Soave, R. (1997). Agents of diarrhea. Medical Clinics of North America, 81, 427-447. Friedman-Kien, A. E. (1988). AIDS-related Kaposi's sarcoma. Recent Results in Cancer Research, 112, 27-36. French, A. L., Senator, D. A., & Gordin, F. M. (1997). Nontuberculousmycobacterial infections. Medical Clinics of North America, 81, 361-379. Fruchter, R. G., Maiman, M., Sedlis, A., Bartley, L., Camilien, L., & Arrastia, C. D. (1996). Multiple recurrences of cervical intraepithelial neoplasia in women with human immunodeficiency virus. Obstetri.es and Gynecology, 3, 338-344. Furrer, H., Egger, M., Opravil, M., Bernasconi, E., Hirschel, B., Battegay, M., et al. (1999). Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. New England Journal of Medicine, 340, 1301-1306. Galgiani, J. N. (1999). Coccidioidomycosis: A regional disease of national importance. Annals of Internal Medicine, 130, 293-300. Geusau, A., & Tschachler, E. (1997). HIV-related skin diseases. Journal of the Royal College of Physicians of London, 31(4), 374-378. Goedert, J. J., Cote, T. R., Virgo, P., Scoppa, S. M., Kingma, D. W., Gail, M. H., Jaffee, E. S., & Biggar, R. J. (1998). Spectrum of AIDS-associated malignant disorders. The Lancet, 351, 1833-1839. Goldschmidt, R. H., & Dong, B. J. (1999). Treatment of AIDS and HIV-related conditions—1999. Journal of The American Board of Family Pratice, 12, 71-94. Golub, B., Falk, G., & Spink, W. W. (1967). Lung abscess due to Corynebacterium equi: Report of first human infection. Annals of Internal Medicine, 66, 1174-1177. Goodrich, J., &: Khardori, N. (1997). Cytomegalovirus: The taming of the beast? The Lancet, 350, 1718-1719. Grant, 1. H., & Armstrong, D. (1988). Fungal infections in AIDS: Cryptococcosis. Infectious Disease Clinics of North America, 2(2), 457-464.

260

THE PERSON WITH HIV/AIDS

Greenblatt, R. M. (1998). Kaposi's sarcoma and human herpesvirus-8. Infectious Disease Clinics of North America, 12(1), 63-82. Greenblatt, R. M., Bacchetti, P., Barkan, S., Augenbraun, M., Silver, S., Delapenha, R., et al. (1999). Lower genital tract infections among HIV-infected and highrisk uninfected women: Findings of the Women's Interagency HIV study (WIHS). Sexually Transmitted Diseases, 26, 143-151. Greenspan, D., & Shirlaw, P. J. (1997). Management of the oral mucosal lesions seen in association with HIV infection. Oral Disease, 3(Suppl. 1), S229-S234. Greenspan, J. S., & Greenspan, D. (1997). Oral complications of HIV infection. In M. Sande & P. Volberding (Eds.), The medical management of AIDS (5th ed., pp. 169-180). Philadelphia: W. B. Saunders. Greenwood, J., & Graham, E. M. (1997). The ocular complications of HIV and AIDS. International Journal of STD and AIDS, 8, 358-365. Griffith, D. E. (1988). Environmental mycobacteria: An increasing problem. Hospital Practice, 23(5), 125-149. Griffiths, J. K. (1998). Human cryptosporidiosis: Epidemiology, transmission, clinical disease, treatment and diagnosis. Advances in Parasitology, 40, 37-85. Griffiths, P. D. (1998). Studies of viral co-factors for human immunodeficiency virus in vitro and in vivo. Journal of General Virology, 79, 213-220. Gripshover, B. M., & Aron, D. C. (1997). Status of endocrine disease with HIV infection. Current Therapy in Endocrinology and Metabolism, 6, 210-215. Hall, C. D., Dafni, U., Simpson, D., Clifford, D., Wetherill, P. E., Cohen, B., McArthur, J., Hollander, H., Yainnoutsos, C., Major, E., Miller, L., & Timpone, J. (1998). The AIDS Clinical Trials Group 243 Team. New England Journal of Medicine, 338(19), 1345-1351. Hamrock, D., Azmi, F. H., O'Donnell, E., Gunning, W. T., Phillips, E. R., & Zaher, A. (1999). Infection by Rhodococcus equi in a patient with AIDS: Histological appearance mimicking Whipple's disease and Mycobacterium avium-intracellulare infection. Journal of Clinical Pathology, 52, 68-71. Hankins, C., Coutlee, F., Lapointe, N., Simard, P., Tran, T., Samson, J., etal. (1999). Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Medical Association Journal, 160, 185-191. Hajjeh, R. A., Conn, L. A., Stephens, D. S., Baughman, W., Hamill, R., Graviss, E., et al. (1999). Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Journal of Infectious Diseases, 179, 449-454. Havlir, D. V. (1998). Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: A case control study. Journal of Infectious Diseases, 777(3), 595-599. Havlir, D. V., Haubrich, R., Hwang, J., Dunne, M. W., Currier, J., Forthal, D., et al. (1998). Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: A case control study. California Collaborative Treatment Group. Journal of Infectious Disease, 177, 595-599. Heyworth, M. F. (1996). Parasitic diseases in immunocompromised hosts. Cryptosporidiosis, isosporiasis, strongyloidiasis. Gastroenterology Clinics of North America, 25(3), 691-707.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 261

HFV-related conditions, focus on: Hepatitis Feburary (1999). HIV Frontline, 6-8. Ho, D. D., Sarngadharan, M. G., Resnick, L., Dimarzo-Veronese, F., Rota, T. R., & Hirsch, M. S. (1985). Primary human T-lymphotropic virus type III infection. Annals of Internal Medicine, 103, 880-883. Hodge, W. G., Seiff, S. R., & Margolis, T. P. (1998). Ocular opportunistic infection incidences among patients who are HIV positive compared to patients who are HIV negative. Ophthalmology, 705(5), 895-900. Hofbauer, L. G., & Heufelder, A. E. (1996). Endocrine implications of human immunodeficiency virus infection. Medicine, 75, 262-278. Hopewell, P. G. (1988), Diagnosis of Pneumocystis carinii pneumonia. Infectious Disease Climes of North America, 2(2), 409-418. Huang, P., Weber, J. T., Sosin, D. M., Griffin, P. M., Long, E. G., Murphy, J.J., et al. (1995). The first reported outbreak of diarrheal illness with Cyclospora in the United States. Annals of Internal Medicine, 123(6), 409-414. Hughes, W. T. (1998). Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: A review. Clinical Infectious Diseases, 29, 191-204. Hughes, W. T., & Anderson, D. C. (1998). Pneumocystis carinii pneumonia. In R. D. Feigin & J. D. Cherry (Eds.), Textbook of pediatric infectious diseases (4th ed., vol. 2, pp. 2490-2499). Philadelphia: W. B. Saunders. Hung, G. G., Hsueh, P. R., Chen, M. Y., Hsiao, G. H., Chang, S. C., & Luh, K. T. (1998). Invasive infection caused by Penicillium marneffei: An emerging pathoge in Taiwan. Clinical Infectious Diseases, 26, 202-203. Iscovich, J., Boffetta, P., Winkelmann, R., & Brennan, P. (1999). Classic Kaposi's sarcoma as a second primary neoplasm. International Journal of Cancer, 80, 178182. Jackson, S. L., & Soper, D. E. (1997). Sexually transmitted diseases in pregnancy. Obstetric and Gynecological Clinics in North America, 24(3), 631-644. Jacobson, M. A. (1997). Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. New England Journal of'Medicine, 337, 105114. Jacobson, M. S. (1998). Cytomegalovirus retinitis: New developments in prophylaxis and therapy. AIDS Clinical Review, 1997/1998, 249-269. Jaffe, H. W., & Pellett, P. E. (1999). Human herpesvirus 8 & Kaposi's sarcoma—some answers, more questions. The New England Journal of Medicine, 340, 1912-1913. Janssen, R. S., Nwanyanwu, O. G., Selik, R. M., & Stehr-Green,J. K. (1992). Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology, -12(8), 1472-1476. Jones, J. L., Hanson, D. L., Dworkin, M. S., Kaplan, J. E., & Ward, J. W. (1998). Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996. TheJournal of Infectious Diseases, 178, 114-120. Jung, A. G., & Paauw, D. S. (1998). Diagnosing HIV-related disease: Using the GD4 count as a guide. Journal of General Internal Medicine, 13, 131-136. Kaneshiro, E. S. (1998). The lipids of Pneumocystis carinii. Clinical Microbiology Reviews, 1 1 ( 1 ) , 27-41.

262

THE PERSON WITH HIV/AIDS

Kantipong, P., Panich, V., Pongsurachet, V., & Watt, G. (1998). Hepatic penicilliosis in patients without skin lesions. Clinical Infectious Diseases, 26, 1215-1217. Kaplan,]. E., Hu, D. J., Holmes, K. K., Jaffe, H. W., Masur, H., & De Cock, K. M. (1996). Preventing opportunistic infections in human immunodeficiency virusinfected persons: Implications for the developing world. American Journal of Tropical Medicine and Hygiene, 55, 1-11. Kaplan, J. E., Masur, H., Holmes, K. K., McNeil, M. M., Schonberger, L. B., & Navin, T. R. (1995). USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Introduction. Clinical Infectious Diseases, 27(Suppl. 1), S1-S11. Kaplan, J. E., Masur, H., Holmes, K. K., Wilfert, C. M., Sperling, R., & Baker, S. A. (1995). USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: An overview. Clinical Infectious Diseases, 2J?(Suppl. 1), S12-S31. Kaplan, L. D. (1994). HIV-associated lymphoma. In P. Volberding and M. Jacobson (Eds.), AIDS clinical review, 1993/1994 (pp. 145-166). New York: Marcel Dekker. Kaplan, L. D. (1998). HIV-associated lymphoma. AIDS Clinical Review, 1997/1998, 349-373. Karp, C. L., & Neva, F. A., (1999). Tropical infectious diseases in human immunodeficiency virus-infected patients. Clinical Infectious Diseases, 28, 947-965. Kartalija, M., & Sande, M. A. (1999). Diarrhea and AIDS in the era of highly active an tire tro viral therapy. Clinical Infectious Diseases, 28, 701-707. Kaul, S., Fishbein, M. C., & Siegel, R. J. (1991). Cardiac manifestations of acquired immune deficiency syndrome: A 1991 update. American Heart Journal, 122, 535— 544. Kemeny, L., Gyulai, R., Kiss, M., Nagy, F., & Dobozy, A. (1997). Kaposi's sarcoma— associated herpesvirus/human herpesvirus-8: A new virus in human pathology. Journal of the American Academy of Dermatology, 37(1), 107-113. Kirkland, T. N., & Fierer, J. (1996). Coccidioidomycosis: A reemerging infectious disease. Emerging Infectious Diseases, 2(3), 192-199. Klepser, M. E., &Klepser, T. B. (1997). Drug treatment of HFV-related opportunistic infections. Drugs, 53(1), 40-73. Koehler, J. E. (1997). Bacillary angiomatosis and other unusual infections in HIVinfected individuals. In M. A. Sande & P. A. Volberding (Eds.), The medical management of AIDS (5th ed., pp. 363-380). Philadelphia: W. B. Saunders. Kolson, D. L., Lavi, E., & Gonzalez-Scarano, F. (1998). The effects of human immunodeficiency virus in the central nervous system. Advanced Virus Research, 50, 147. Kotler, D. P., & Orenstein, J. M. (1998). Clinical syndromes associated with microsporidiosis. Advances in Parasitology, 40, 321-349. Kovacs, A., Leaf, H. L., & Simberkoff, M. S. (1997). Bacterial infections. Medical Clinics of North America, 81, 319-343. Krigel, R. L., & Friedman-Kein, A. E. (1988). Kaposi's sarcoma in AIDS: Diagnosis and treatment. In V. T. DeVita,Jr., S. Hellman, & S. A. Rosenberg (Eds.), AIDS: Etiology, diagnosis, treatment, and prevention (2nd ed., pp. 245-261). Philadelphia: Lippincott.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 263

Kroe, D. M, Kirsch, C. M., & Jensen, W. A. (1997). Diagnostic strategies for Pneumocystis carinii pneumonia. Seminars in Respiratory Infections, 12(2}, 70-78. Kroll, M. H., & Shandera, W. X. (1998). AIDS-associated Kaposi's sarcoma. Hospital Practice, 33(4), 85-102. Krown, S. E. (1997). Acquired immunodeficiency syndrome—associated Kaposi's sarcoma. Medical Clinics of North America, 81(2), 471-494. Krown, S. E., Testa, M. A., & Huang, J. (1997). AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS clinical trials group staging classification. Journal of Clinical Oncology, 15(9), 3085-3092. Kushagra, K., & Thurer, R. J. (1999). Malignancies associated with the immunocompromised state. Chest Surgery Clinics of North America, 9, 63-77. Lafon, M. E., Dutronc, H., Dubois, V., Pellegrin, I., Barbeau, P., Ragnaud, J. M., Pellegrin, J. L., & Fleury, H. J. (1998). JC virus remains latent in peripheral blood B lymphocytes but replicates actively in urine from AIDS patients. Journal of Infectious Diseases, 177(6), 1502-1505. Larsen, R. A. (1999). Editorial response: A comparison of itraconazole versus fluconazole maintenance therapy for AIDS-associated crytococcal meningitis. Clinical Infectious Diseases, 28, 297-298. Lashley, F. R. (1998). Clinical genetics in nursing practice (2nd ed.). New York: Springer. Launay, O., Lortholary, O., Bouges-Michel, Jarrousse, B., Bentata, M., & Guillevin, L. (1998). Candidemia: A nosocomial complication in adults with late-stage AIDS. Clinical Infectious Diseases, 26, 1134-1141. Levy, R. M., Bredesen, D. E., & Rosenblum, M. L. (1985). Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience at UCSF and review of the literature. Journal of Neurosurgery, 62, 475-495. Lew, E. A., Poles, M. A., & Dieterich, D. T. (1997). Diarrheal diseases associated with HIV infection. Gastroenterology Clinics of North America, 26(2), 259-290. Lortholary, O., Denning, D. W., &Dupont, B. (1999). Endemic mycoses: A treatment update. Journal of Anticrobial?? and Chemotherapy, 43, 321-331. Loutit, J. S. (1998). Bartonella infections: Diverse and elusive. Hospital Practice, 33(12), 37-49. Loveland, L. ]. (1998). Onychomycosis in HIV-positive patients. Clinical Podiatric Medicine and Surgery, 15, 305-315. Lowy, F. D. (1998). Staphy loco ecus aureus infections. New England Journal of Medicine, 339, 520-532. Lynfield, R., & Guerina, N. G. (1997). Toxoplasmosis. Pediatrics in Review, 18(3), 7583. Manabe, Y. C., Glark, D. P., Moore, R. D., Lumadue, J. A., Dahlman, H. R., Belitsos, R. C., Chaisson, R. E., & Sears, C. L. (1998). Cryptosporidiosis in patients with AIDS: Correlates of disease and survival. Clinical Infectious Diseases, 27, 536-542. Marshall, M. M., Naumovitz, D., Ortega, Y, & Sterling, C. R. (1997). Waterborne protozoan pathogens. Clinical Microbiological Review, 10(1), 67-85. Martin, D. F., Kuppermann, B. D., Wolitz, R. A., Palestine, A. G., Li, H., Robinson, C. A., & the Roche Ganciclovir Study Group. (1999). Oral ganciclovir for patients

264

THE PERSON WITH HIV/AIDS

with cytomegalovirus retinitis treated with a ganciclovir implant. New England Journal of Medicine, 340, 1063-1070. McArthur, J. C. (1997, August 15). NeuroAIDS: Diagnosis and management. Hospital Practice, pp. 73-97. McGuinness, G. (1997). Changing trends in the pulmonary manifestations of AIDS. Radiological Clinics of North America, 35, 1029-1082. Meunier, F. (1988). Fungal infections in the compromised host. In R. H. Rubin & L. S. Young (Eds.), Clinical approach to infection in the compromised host (2nd ed., pp. 193-220). New York: Plenum Medical Books. Michaels, A. D., Lederman, R. J., MacGregor, J. S., & Cheitlin, M. D. (1997). Cardiovascular involvement in AIDS. Current Problems in Cardiology, 22(3), 115148. Minamoto, G. Y, & Rosenberg, A. S. (1997). Fungal infections in patients with acquired immunodeficiency syndrome. Medical Clinics of North America, 81(2), 381-409. Minkoff, H. L., Eisenberger-Maityahu, D., Feldman,]., Burk, R., & Clark, L. (1999). Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus. American Journal of Obstetrics & Gynecology, 180, 824-836. Mussi-Pinhata, M. M., Yamamoto, A. Y, Figueiredo, L. T., Cervi, M. C., & Duarte, G. (1998). Congenital and perinatal cytomegalovirus infection in infants born to mothers infected with human immunodeficiency virus. Journal of Pediatrics, 132, 285-290. Nasti, G., Serraino, D., Ridolfo, A., Antinori, A., Rizzardini, G., Zeroli, C., et al. (1998). AIDS-associated Kaposi's sarcoma is more aggressive in women: A study of 54 patients. JournalofAcquired Immune Deficiency Syndromes and Human Retrovirology, 20, 337-341. Navia, B. A. (1997). Clinical and biologic features of the AIDS dementia complex. Neuroimaging Clinics of North America, 7(3), 581-592. Navia, B. A., Dafni, U., Simpson, D., Tucker, T., Singer, E., McArthur, J. C., Yiannoutsos, C., Zaborski, L., & Lipton, S. A. (1998). A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology, 51, 221-228. Navia, B. A., & Price, R. W. (1986). Central and peripheral nervous system complications of AIDS. Clinics in Immunology and Allergy, 6(3), 543-558. Newell, A., & Nelson, M. (1998). Infectious hepatitis in HIV-seropositive patients. International Journal ofSTD & AIDS, 9, 63-69. Noyer, C. M., & Simon, D. (1997). Oral and esophageal disorders. Gastroenterology Clinics of North America, 26, 241-257. Ockenga, J., & Manns, M. P. (1999). The impact of body composition analysis in HIV-infected patients: Quantifying therapeutic effects. AIDS, 13, 279-280. Oksenhendler, E., Cazals-Hatem, D., Schulz, T., Barateau, V., Grollet, L., Sheldon, J., Clauvel, J., Sigaux, F., & Agbalika, F. (1998). Transient angiolymphoid hyperplasia and Kaposi's sarcoma after primary infection with human herpes virus 8 in a patient with human immunodeficiency virus infection. New England Journal of Medicine, 338, 1585-1590.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 265

Ortega, Y. R., Sterling, C. R., & Oilman, R. H. (1998). Cydospora cayetanensis. Advances m Parasitology, 40, 399-418. Oursler, K. K., Moore, R. D., & Chaisson, R. E. (1999). Risk factors for cryptococcal meningitis in HIV-infected patients. AIDS Research and Human Retroviruses, 15, 625-631. Palefsky, J. M., Minkoff, H., Kalish, L. A., Levine, A. Sacks, H. S., Garcia, P., et al. (1999). Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. Journal of the National Cancer Institute, 91, 226-234. Perrin, L., & Yerly. S. (1998). Clinical presentation, virological features, and treatment perspectives in primary HIV-1 infection. AIDS Clinical Review, 19971998, 67-92, Perz, J. F,, Ennever, F. K., & LeBlancq, S. M. (1998). Cryptosporidium in tap water: Comparison of predicted risks with observed levels of disease. American Journal of Epidemiology, 747(3), 289-301. Phelan, J. A. (1997). Oral manifestations of human immunodeficiency virus infection. Medical Clinics of North America, 57(2), 511-531. Pigrau, C., Almirante, B., Pahissa, A., & Bartolome, R. (1996). Campylobacter spp. bac.tere.mia in AIDS patients. Journal of Acquired Immune Deficiency Syndrome in Human Reirovirology, 8, 51-57. Plummet, D. J., Marcotte, T. D., Sample, P. A., Wolfson, T., Heaton, R. K., Grant, I., et al. (1999). Neuropsychological impairment-associated with visual deficits in HIV infection. Investigative Ophthalmology & Visual Science, 40, 435-462. Poles, M. A., Lew, E. A., £ Dieterich, D. T. (1997). Diagnosis and treatment of hepatic disease in patients with HIV. Gastroenterology Clinics of North America, 26, 291-321. Posavad, C. M., Koelle, D. M., & Corey, L. (1998). Tipping the scales of herpes simplex virus reactivation: The important responses are local. Nature Medicine, 4, 381-382, Powderly, W. G. (1994). New developments in the treatment of Cryptococcal disease in AIDS. In P. Volberding & M. A. Jacobson (Eds.), AIDS clinical review 1993/ 1994 (pp. 113-128). New York: Marcel Dekker. Power, C., Seines, O. A., Grim, J. A., & McArthur.J. C. (1995). HIV dementia scale: A rapid screening test. Journal of Acquired Immune Deficiency Syndrome in Human Retivvirology, 8, 273-278. Pozniak, A. L., Miller, R., & Ormerod, P (1999). The treatment of tuberculosis in HIV-infected persons. AIDS, 13, 435-445. Price, R. W. (1997). Managementof the neurologic complications of HIV-1 infection and AIDS. In M. A. Sande & P. A. Volberding (Eds.), The medical management of AIDS (5th ed., pp. 197-216). Philadelphia: W. B. Saunders. Price, R. W., & Brew, B. (1988a). The AIDS dementia complex. Journal of Infectious Diseases, 158, 1079-1083. . (19881)). Management of the neurologic complications of HIV infection and AIDS. In M. A. Sande & P. A. Volberding (Eds.), The medical management of AIDS (pp. 111-126). Philadelphia: W. B. Saunders.

266

THE PERSON WITH HIV/AIDS

Quinn, T. C. (1997). Acute primary HIV infection. Journal of the American Medical Association, 278(1), 58-62. Ray, M. C., & Gately, L. E. (1994). Dermatologic manifestations of HIV infection and AIDS. Infectious Disease Clinics of North America, 8, 583-605. Redvanly, R. D., & Silverstein,J. E. (1997). Intra-abdominal manifestations of AIDS. Radiologic Clinics of North America, 35, 1083-1125. Reiter, G. S. (1999). Clinical correlates of human immunodeficiency virus (HFV)related immunosuppression. Seminars in Ultrasound, CT, and MR, 19, 128-132. Richardson, E. P., Jr. (1988). Progressive multifocal leukoencephalopathy 30 years later. New England Journal of Medicine, 318, 315-318. Richart, R. M., Masood, S., Syrjanen, K. J., Vassilakos, P., Kaufman, R. H., Meisels, A., etal. (1998). Human papillomavirus: International Academy of Cytology Task Force Summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Acta Cytol, 42, 50-58. Rickinson, A. B. (1998). Epstein-Barr virus in action in vivo. New England Journal of Medicine, 338, 1461-1463. Riley, L. W. (1993). Drug resistant tuberculosis. Clinical Infectious Diseases, l7(Suppl. 2),S442-S446. Rippon, J. W. (1988). Medical Mycology (3rd ed.). Philadelphia: W. B. Saunders. Roos, K, L. (1998). Pearls and pitfalls in the diagnosis and management of central nervous system infectious diseases. Seminars in Neurology, 18(2), 185-196. Rose, J. B. (1997). Environmental ecology of Cryptosporidium and public health implications. Annual Review of Public Health, 18, 135-161. Roullet, E. (1999). Opportunistic infections of the central nervous system during HIV-1 infection. Journal of Neurology, 246, 237-243. Sacks, S. L. (1999). Improving the management of genital herpes. Hospital Practice, 34(2), 41-49. Sadler, M., & Nelson, M. (1997a). Peripheral neuropathy in HIV. International Journal of STD and AIDS, 8, 16-22. . (1997b). Progressive multifocal leukoencephalopathy in HIV. International Journal of STD and AIDS, 8, 351-357. Salahuddin, S. Z., Groupman, J. E., Markam, P. D., Sarngadharan, M. G., Redfield, R. R., McLane, M. F., et al. (1984). HTLV-III in symptom-free seronegative persons. Lancet, 2, 1418-1420. Sarnies,J. H., Hathaway, B. N., & Echols, R. M. (1986). Lung abscess due to Corynebacterium equi.—Report of the first case in a patient with acquired immune deficiency syndrome. American Journal of Medicine, 80, 685-688. Sande, M. A., & Volberding, P. A. (Eds.). (1997). The medical management of AIDS (5th ed.). Philadelphia: W. B. Saunders. Santamauro, J., & Stover, D. E. (1997). Pneumocystis carinii pneumonia. Medical Clinics of North America, 81(2), 299-318. Schacker, T. (1997). Primary HIV infection: Early diagnosis and treatment are critical to outcome. Postgraduate Medicine, 102(4), 143-151. Schacker, T. W., Hughes, J. P., Shea, T., Coombs, Rr W., & Corey, L. (1998). Biological and virologic characteristics of primary HFV infection. Annals of Internal Medicine, 128(8), 613-620.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 267

Schambelan, M., Sellmeyer, D. E., & Grunfeld, C. (1997). Endocrinologic manifestations of HIV infection. In M. A. Sande & P. A. Volberding (Eds.), The medical management of AIDS (5th ed., pp. 257-267). Philadelphia: W. B. Saunders. Schluger, N. W. (1999). Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. Clinical Infectious Diseases, 28,130—135. Schneider, J. H., & Rogers, A. I. (1997). Strongyloidiasis. The protein parasitic infection. Postgraduate Medicine, 102(3), 177-184. Schurmann, D., Nightingale, S. D., Bergmann, F., & Ruf, B. (1997). Tuberculosis and HIV infection: A review. Infection, 25, 274-280. Schwartz, R. A. (1988). Skin cancer. New York: Springer-Verlag. Sepkowitz, K. A. (1998). Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet, 351, 228-230. Shaw, G. M., Harper, M. E., Hahn, B. H., Epstein, L. G., Gajdusek, D. C., Price, R. W., Navia, B. A., Petito, C. K., O'Hara, C. J., Groopman,J. E., Cho, E., Oleske, J. M., Wong-Staal, F., & Gallo, R. C. (1985). HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science, 227, 177-181. Sidtis, J. J., Gatsonis, C., & Price, R. W. (1993). Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial. AIDS Clinical Trials Group. Annals of Neurology, 33, 343-350. Sidtis, J. J., & Price, R. W. (1990). Early HW-1 infection and the AIDS dementia complex. Neurology, 40, 323-326. Soave, R. (1988). Cryptosporidiosis and isosporiasis in patients with AIDS. In M. A. Sande & P. A. Volberding (Eds.), The medical management of AIDS (pp. 259-269). Philadelphia: Saunders. Soave, R., Herwaldt, B. L., & Relman, D. A. (1998). Cyclospora. Infectious Disease Clinics of North America, 12(1), 1-12. Sobel, J. D. (1992). Pathogenesis and treatment of recurrent vulvo-vaginal candidiasis. Clinical Infectious Diseases, 14(Suppl. 1), S148-S153. Sobel, J. D., Faro, S., Force, R. W., Foxman, B., Ledger, W. J., Nyirjesy, P. R., & Reed, B. D. (1998). American Journal of Obstetrics and Gynecology, 178, 203-211. Sobottka, I., Schwartz, D. A., Schottelius, J., Visvesvara, G. S., Pieniazek, N. J., Schmetz, C., Kock, N. P., Laufs, R., & Albrecht, H. (1998). Prevalence and clinical significance of intestinal microsporidiosis in human immunodeficiency virus—Infected patients with and without diarrhea in Germany: A prospective coprodiagnostic study. Clinical Infectious Diseases, 26, 475-480. Spach, D. H., & Koehler, J. E. (1998). J5mtone//a-associated infections. Infectious Disease Clinics of North America, 12(1), 137-155. Straus, D.J. (1997). Human immunodeficiency virus—Associated lymphomas. Medical Clinics of North America, 81(2), 495-510. Subauste, C. S., Wong, S. Y., & Remington, J. S. (1997). AIDS-associated toxoplasmosis. In M. A. Sande & P. A. Volberding (Eds.), The medical management of AIDS (5th ed., pp. 343-362). Philadelphia: W. B. Saunders. Sung, J. C. Y., Louie, S. G., & Park, S. Y. (1997). Kaposi's sarcoma: Advances in tumor biology and pharmacotherapy. Pharmacotherapy, 17, 670-683. Swanson, B., Zeller, J. M., & Paice, J. A. (1998). HIV-associated distal symmetrical polyneuropathy: Clinical features and nursing management.Journalof the Association of Nurses in AIDS Care, 9(2), 77-80.

268

THE PERSON WITH HIV/AIDS

Sweet, S. P. (1997). Selection and pathogenicity of Candida albicans in HIV infection. Oral Diseases, 5(Suppl. 1), S88-S95. Telzak, E. E. (1997). Tuberculosis and human immunodeficiency virus infection. Medical Clinics of North America, 81(2), 345-360. Telzak, E. E., Cote, R. J., & Gold, J. W. M. (1990). Extrapulmonary Pneumocystis carinii infections. Reviews of Infectious Disease, 12, 380-386. Terrell, C. L. (1999). Antifungal agents. Part II. The azoles. Mayo Clinic Proceedings, 74, 78-100. Tompkins, L. S. (1997). Of cats, humans and Bartonella. New England Journal of Medicine, 355(26), 1916-1917. Truitt, T. O., & Tami, T. A. (1999). Otolaryngologic manifestations of human immunodeficiency virus infection. Medical Clinics of North America, 83(1), 303315. Tulpule, A., & Matheney, S. C. (1998). AIDS-related malignancies. Primary Care, 25, 473-482. Tumbarello, M., Tacconelli, E., de Gaetano, K., Ardito, F., Pirronti, T., Cauda, R., & Ortona, L. (1998). Bacterial pneumonia in HIV-infected patients: Analysis of risk factors and prognostic indicators. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18, 39-45. Tyor, W. R., Glass, J. D., Baumrind, N., McArthur.J. C., Griffin,]. W., & Becker, P. S. (1993). Cytokine expression of macrophages in HrV-1-associated vacuolar myelopathy. Neurology, 43, 1002-1009. USPHS/IDSA. Prevention of Opportunistic Infections Working Group. 1999 guidelines for the prevention of opportunistic infections in persons infected with the human immunodeficiency virus. May 14, 1999, Draft #5, pl-49. Vanhems, P., & Beaulieu, R. (1997). Primary infection by type 1 human immunodeficiency virus: Diagnosis and prognosis. Postgraduate Medical Journal, 73, 403-408. Vaz, A., Pineda-Roman, M., Thomas, A. R., & Carlson, R. W. (1998). Coccidioidomycosis: An update. Hospital Practice, 33(9), 105-120. Veazey, R. S., & Lackner, A. A. (1998). The gastrointestinal tract and the pathogenesis of AIDS. AIDS, 72(Suppl. A), S35-S42. Ventura, G., Cauda, R., Larocca, L. M., Riccioni, M. E., Tumbarello, M., & Lucia, M. B. (1997). Gastric cryptosporidiosis complicating HIV infection: Case report and review of the literature. European, Journal of Gastroenterology and Hepatology, 9, 307-310. Wald, A. (1999). New therapies and prevention strategies for genital herpes. Clinical Infectious Diseases, 28(Supp\. 1), S4-14. Wali, R. K., Drachenberg, C. I., PapadimitriouJ. C., Keay, S., & Ramos, E. (1998). HIV-1-associated nephropathy and response to highly active antiretroviral therapy. The Lancet, 352, 783-784. Walker, B. D., & Basgoz, N. (1998). Treat HIV-1 infection like other infectionsTreat it. Journal of the American Medical Association, 280(1), 91-95. Walker, T. S. (1998). Microbiology. Philadelphia: W. B. Saunders. Walsh, F. W., Rolfe, M. W., & Rumbak, M. J. (1999). The initial pulmonary evaluation of the immunocompromised patient. Chest Surgery Clinics of North America, 9(1), 19-35.

THE CLINICAL SPECTRUM OF HIV INFECTION AND ITS TREATMENT 269

Watts, D. H., Spino, C., Zaborski, L., Katzenstein, D., Hammer, S., & Benson, C. (1999). Comparison of gynecologic history and laboratory results in HIV-positive women with CD4+ lymphocyte counts between 200 and 500 cells/microl and below 100 cells/microl. Journal of Acquired Immunodeficiency Syndromes and Human Retrovirology, 20, 455-462. Wehner,J. H., & Kirsch, C. M. (1997). Pulmonary manifestations of strongyloidiasis. Seminars in Respiratory Infection, 72(2), 122-129. Weiss, L. M., £ Vossbrinck, C. R. (1998). Microsporidiosis: Molecular and diagnostic aspects. Advances in Parasitology, 40, 351-395. Weitzul, N. F., & Duvic, M. (1997). HIV-related psoriasis and Reiter's syndrome. Seminars in Cutaneous Medicine and Surgery, 16(3), 213-218. Weverling, G. J., Mocroft, A. M., Ledergerber, B., Kirk, O., Gonzales-Lahoz, J., & Monforte, A., et al. (1999). Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HFV-1 infection. The Lancet, 353, 1293-1297. Whitcup, S. M. (1996). Ocular manifestations of AIDS. Journal of the American Medical Association, 275, 142-144. Wiebe, C. B., & Epstein, J. B. (1997). An atlas of HIV-associated oral lesions: A new classification and diagnostic criteria. Journal of the Canadian Dental Association, 63, 298-294. Williamson, K., Reboli, A. C., & Manders, S. M. (1999). Protease inhibitor—induced lipodystrophy. Journal of The American Academy of Dermatology, 40, 635-636. Wong, D., & Shumack, S. (1996). HIV and skin disease. Medical Journal of Australia, 164, 352-356. Wright, S. W., & Johnson, R. A. (1997). Human immunodeficiency virus in women: Mucocutaneous manifestations. Clinics in Dermatology, 15, 93-111. Yao, Q. Y., Groom-Carter, D. S., Tierney, R. J., Habeshaw, G., Wilde, J. T., & Hill, F. G. (1998). Epidemiology of infection with Epstein-Barr virus types 1 and 2: Lessons from the study of a T-cell-immunocompromised hemophilic cohort. Journal of Virology, 72, 4352-4363. Young, L. H. (1996). Therapy for cytomegalovirus retinitis: Still no silver lining. Journal of the American Medical Association, 275, 149-150. Younossi, Z. M., & Canuto, P. E. (1998). Hepatitis C update: Implications of the blood transfusion "lookback." Cleveland Clinic Journal of Medicine, 65, 412-421. Yunis, N. A.. & Stone, V. E. (1998). Cardiac manifestations of HIV/AIDS: A review of disease spectrum and clinical management. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18, 145-154.

This page intentionally left blank

6

Symptom Management in HIV/AIDS Anthony J. Adinolfi

ersons with HIV disease may experience multiple and complex physical, cognitive, emotional, and social symptoms during the course of their illness (Fantoni et al., 1997; Newshan & Sherman, 1999; Whalen, Antani, Carey, & Landefeld, 1994). Symptom management offers complex challenges to health care providers (Hench, Anderson, Grady, & Ropka, 1995; Lietzau, 1996). Commonly experienced symptoms include fatigue, dizziness, anorexia and weight loss, nausea and vomiting, dysphagia, diarrhea, cough, dyspnea, pain (including myalgias), fever, pruritis, sleep disturbances (including night sweats), and psychological distress (Capaldini, 1999; Cella, Mo, & Peterman, 1997; Fantoni et al., 1997; Newshan & Sherman, 1999; van Servellen & Aguirre, 1995). The type, number, and severity of symptoms can serve as indirect measures of immune functioning and indicators of disease progression (McCain et al., 1998). Once the diagnosis of HIV infection is made, a plan of care may be developed by one or more experts in HIV care; however, ongoing care may be provided by a primary care provider such as a nurse practitioner or family physician. The initial encounter should include risk assessment, including social behaviors such as travel, drug use, sexual history (with discussion of prevention of transmission); medi-

P

271

272

THE PERSON WITH HIV/AIDS

cal history including medications, vaccinations, illnesses; travel history; dietary history; information about living arrangements, including pets and family or roommates. A physical examination and initial laboratory profile should also be obtained during this initial encounter. The comprehensive physical examination should include a general assessment and focus on specific organ systems known to be most often affected in HIV infection. The CD4+ cell count and viral load may guide this examination to some degree (see chapter 5). Specific areas to be examined include evaluation of the oral cavity; skin; a general eye examination; assessment of neurocognitive functioning, including a cranial nerve examination and reflex testing; general abdominal assessment and cardiovascular and respiratory assessments. The anorectal areas should be examined carefully as should the genitalia for HIV-related conditions. Women should have a baseline pelvic examination with a Pap test (see chapters 5 and 11). Symptoms such as diarrhea, fever, and the like (to be discussed below) should be specifically asked about. Signs such as lymphadenopathy should be specifically looked for. Basic laboratory determinations include complete blood count, standard chemistry, tests for syphilis, toxoplasmosis, hepatitis, and cytomegalovirus. Testing for tuberculosis should also be initiated. The results of the assessment form the basis for the total plan of care and may point out special areas for prevention and prophylaxis (see Appendices 2-4), and the relevant information should be communicated to the patient. Appropriate vaccinations (e.g., for hepatitis A) should be given. It is important to establish good rapport with the HlV-infected person at this visit because the relationship with the primary provider will be a long-term, ongoing one necessitating mutual trust and respect (Goldschmidt & Dong, 1999; Kirton, Ferri, & Eleftherakis, 1999). Some symptoms are directly related to the opportunistic infections and other conditions of HIV disease (see chapter 5), whereas others may stem from treatments for HIV disease and related conditions. The severity of symptoms influences the quality of life of persons living with HIV disease. Persons experiencing multiple HIV diseaserelated symptoms often have greatly reduced physical and social functioning and emotional well-being (Cunningham et al., 1998). For these reasons, care providers should aggressively screen and treat patients for common HIV disease-related symptoms.

SYMPTOM MANAGEMENT IN HIV/AIDS

273

Nurses have the opportunity to help patients make positive changes in their lives and to help them achieve the highest levels of wellness possible, including the management of symptoms. This chapter describes common symptoms experienced by persons living with HIV disease and the subjective and objective evaluation of these symptoms and related nursing interventions. SYMPTOMS COMMONLY EXPERIENCED BY PERSONS LIVING WITH HIV DISEASE Although some symptoms are more common than others in persons living with HIV disease, the symptoms any individual may experience, and their severity, are dependent on individual constitutional factors stage and severity of disease, and treatment approaches, among other factors. The following symptoms/conditions experienced by persons living with HIV disease are not listed in order of importance, frequency, or severity. Fatigue Fatigue is commonly experienced by persons with HIV infection and AIDS (Horn & Fan try, 1995) and is one of the most undertreated problems experienced by patients with HIV infection and AIDS (Delmonte, 1997). Unfortunately, little empirical research has focused on its prevalence or characteristics among persons living with HIV disease (Breitbart, McDonald, Rosenfeld, Monkman, &: Passik, 1998). Because fatigue cannot be accurately measured, it may be ignored or not taken seriously by health care providers because it is not life-threatening. Fatigue is described subjectively as low energy, exhaustion, tiredness, and/or sleepiness resulting in changes in daily life activities and quality of life. Immune function may be negatively influenced by fatigue. Fatigue is sometimes included in the listing of constitutional symptoms of AIDS. As HIV disease worsens, fatigue often becomes more pronounced. In persons for whom depression is a cause of fatigue, somatic complaints are often prominent (Lyketsos et al., 1996).

274

THE PERSON WITH HIV/AIDS

The presence of fatigue has been associated with the number of HIV-related physical symptoms, medical treatments of HFV-related medical disorders, anemia, and pain (Bartlett, 1997; Breitbart et al., 1998). Common factors associated with fatigue include the following (Casey, Cohen, & Hughes, 1996; Goroll, May, & Mulley, 1995): Inadequate nutritional status (not having the ability to obtain food, prepare food, nausea, vomiting, diarrhea). Problems of the circulatory system (possibly anemia or cardiac complications). There is a direct correlation between severe anemia (hematocrit < 20) and fatigue (Garoll et al., 1995). Cardiopulmonary disease has a hallmark symptom of exertional dyspnea leading to fatigue. Infections or malignancies. Many cancers can cause fatigue. Infections include mononucleosis, viral hepatitis, cytomegalovirus infection, and possible virus-triggered chronic fatigue syndrome. Tuberculosis, subacute bacterial endocarditis, parasitic disease, and Lyme disease also cause fatigue. HIV infection that causes AIDS dementia may be a cause of fatigue (Delmonte, 1997). Fever. Fever is one of the most common symptoms associated with AIDS (Casey et al., 1996; Holtzclaw, 1998; Jones, 1998). Fever may stem from iatrogenic causes (i.e., drug treatment) or an infectious process. Fever may also occur in the absence of a known infection, particularly in advanced disease in the presence of systemic and constitutional symptoms (Jones, 1998). Malaise, muscle aches, headaches, loss of appetite, and fatigue often accompany fever. Psychological stress. The patient may be experiencing stress related to his or her condition, to stressors of everyday living (financial, social), or as a result of depression, anxiety, or other psychological disorders. Physiological stress. An increase in physical activity that is more than the person is capable of can cause fatigue. Medication side effects. Drugs that are usually used to treat depression, anxiety, and insomnia have side effects, including sedation, and may actually worsen a patient's condition (Goroll et al., 1995). These drugs include antidepressants, minor tranquilizers, and hypnotics. Also, antihypertensives and antihista-

SYMPTOM MANAGEMENT IN HIV/AIDS

275

mines penetrate the nervous system, leading to tiredness. The use of ziclovudine (AZT) has been implicated in causing myopathy, leading to fatigue (Delmonte, 1997). Disturbances of sleep. Sleep apnea or other sleep disorders may cause a person to be fatigued. Endocrine dysfunction. Hypothyroidism, hyperthyroidism, Addison's disease, panhypopituitarism, hypogonadism, and poorly controlled diabetes mellitus may cause fatigue. Metabolic disorders. An early symptom of chronic renal failure may be fatigue. Chronic HIV infection. Fatigue may worsen in the course of the disease. Subjective Evaluation Ask questions regarding when the patient has the most energy and when he or she is most fatigued (Is he or she fatigued at rest or during activities, during the early part of the day or the end of the day, or does weather/environmental factors have a role?) Ask what a routine day is like for the patient. Ask if there are associated symptoms (i.e., shortness of breath, tachycardia, appetite changes, depression). Ask, "How is your life overall?" (Interactions with others, financial matters, family and social support, access to health care) Ask if he or she is taking any drugs (prescription, over-thecounter, vitamins, recreational). Assess sleep habits and environment (Cohen et al., 1996; Lashley, 1998; Nokes et al., 1999). Objective Assessment Obtain vital signs and carefully observe the patient's demeanor and affect and their presenting complaint. Perform a physical assessment—a thorough general, skin, respiratory, cardiac, and neurologic assessment, carefully noting any pallor, dizziness, weakness of muscles, and diaphoresis.

276

THE PERSON WITH HIV/AIDS

Review laboratory tests (should have a baseline CBC to rule out anemia; may want to evaluate chemistries to assess heart, liver, and kidney function). Evaluate the laboratory test results to identify a pathologic cause of fatigue (e.g., renal dysfunction, anemia). If the patient is febrile, refer to primary caregiver for further workup to identify potential pathogen.

Nursing Interventions Agree on a plan to combat fatigue to ensure the patient's sense of ownership of the plan and to increase adherence to the plan. The nurse should not develop a plan without input from the patient and possibly the patient's caregiving team. Assist the patient to identify, describe, and anticipate fatigue (Lee, Portillo, & Miramontes, 1999). Ask the patient what fatigue means to him or her. By identifying a pattern of fatigue, activities and appointments may be scheduled to reduce fatigue (e.g., housework, exercise, health care appointments). Environmental factors identified as contributing to fatigue have the potential to be altered to reduce it (e.g., room-darkening shades to allow the patient to rest during the day). Help the patient to make a schedule that includes adequate rest periods. Evaluate the social environment and social support. If support is inadequate or ineffective, refer the patient to a social work or case manager. Also, a referral to a support group may help the patient put fatigue into perspective. Counsel the patient regarding activity expenditure, including nutrition information. If more information is necessary, refer the patient to an occupational therapist, physical therapist, and/ or nutritionist. Assist the patient in following prescribed treatment for infections and for antiretroviral medication adherence, identifying any side effects of medications. Also, assist the patient in scheduling medications if a side effect of a medication is causing fatigue (e.g., taking the medication at night to avoid fatigue, if possible).

SYMPTOM MANAGEMENT IN HIV/AIDS

277

Treat fever while preventing or controlling energy-consuming shivering (Holtzclaw, 1998). Help the patient explore complementary therapies. Patients may be disillusioned with standard Western medical practices and choose alternatives to standard medical treatment (Abrams, 1997). Assist patient in implementing sleep hygiene measures (Cohen etal., 1996; Lashley, 1998). Anemia Anemia is the most common cytopenia in AIDS and increases in severity as HIV infection progresses. Although the incidence of anemia seen in persons with HIV disease varies according to the level of hemoglobin and hematocritused to define anemia, approximately 10% to 20% of patients are anemic at the initial presentation, and 70% to 80% become anemic as their disease progresses (Doweiko & Groopman, 1998). The exact causes of anemia in persons with HIV disease cannot always be pinpointed, thereby complicating the determination of the most appropriate medical treatment. The anemia results from impaired erythropoiesis caused directly or indirectly by the HIV infection and myelosuppression from numerous causes (Mitsuyasu, 1998). Hematologic disorders also occur in HIV disease because of decreased production of precursor cells in the bone marrow and increased peripheral destruction of the differentiated cells (Ownby, 1995). Anemia in the HIV-positive patient can be attributed to many different factors. Anemia can be caused by malignancies (e.g., Kaposi's sarcoma, lymphoma, Hodgkin's disease), which can lead to chronic iron deficiency that occurs with chronic blood loss (Hambleton, 1997). Nutritional deficiencies, especially low intake of vitamin B12 and folate and decreases in serum iron and iron-binding capacity, which occurs with malabsorption, can also cause anemia. Infections contributing to anemia include Mycobacterium avium complex, Mycobacterium tuberculosis, and fungal infections (cryptococcosis, histoplasmosis, coccidioidomycosis) (Hambleton, 1997), and the parvovirus B19 (Levine, 1997), causing an anemia of chronic disease (Delmonte, 1997). See chapter 5. Medications used to treat HIV

278

THE PERSON WITH HIV/AIDS

infection and opportunistic infections can also cause anemia in a significant percentage of persons with HIV disease (Mitsuyasu, 1998). Anemia causes a deficit in oxygen transport and an increase in cardiac workload that leads to fatigue, which in turn leads to a decrease in the quality of life. Treatment of even mild to moderate anemia can improve overall functioning and quality of life, especially important as persons with HIV disease live longer, more productive lives (Cella et al., 1997). Anemia has been associated with decreased survival (Moore, Keruly, & Chaisson, 1998). Recovery from anemia can significantly lower the risk of death in persons with HIV disease (Mitsuyasu, 1998). Compensatory mechanisms (peripheral vascular dilation, increased tissue extraction of oxygen, and increased cardiac output) from anemia are handled well by the hearts of most AIDS patients (Hughes et al., 1992). Medical treatments vary according to the causes of the anemia but may include direct treatment of opportunistic diseases; vitamin B12 and folk acid replacement; change of antiretroviral and other medications; and administration of red blood cells/whole blood, immunoglobulin, corticosteroids, and/or recombinant erythropoietin (Epogen or Procrit) (Mitsuyasu, 1998). The signs and symptoms of anemia include the following (Hughes etal., 1992): fatigue dyspnea on exertion tachycardia and feelings of the heart "beating hard" exercise intolerance dizziness, headaches irritability, difficulty sleeping difficulty concentrating cold intolerance gastrointestinal problems (indigestion, anorexia) menstrual problems (in women) male sexual dysfunction systolic ejection murmur pallor

SYMPTOM MANAGEMENT IN HIV/AIDS

279

Subjective Evaluation Assess mental status Obtain a very detailed history regarding possible loss of blood (menstruation, rectal bleeding). Ask if there is a family history of anemia and determine the country of origin of relatives. Obtain a detailed history of medication usage. Drugs that possibly could cause anemia include, but are not limited to, trimethoprim, sulfamethoxazole, sulfadiazine, pyrimethamine, amphotericin B, 5-flucytosine, ganciclovir, antineoplastics (e.g., adriamycin, methotrexate, vinblastine, cyclophosphamide, paclitaxol, and liposomal doxorubicin), alpha interferon, zidovudine, and dapsone (Bain, 1999; Northfelt & Mitsuyasu, 1992). Other drugs that can cause myelosuppression include didanosine, lamivudine, stavudine, foscarnet, and pentamidine (Levine, 1997). Objective Evaluation Evaluate volume status to rule out dehydration, fluid overload. Evaluate for blood loss. If blood loss is suspected from the gastrointestinal tract, stool should be examined for occult blood. Document the pads and/or tampons of menstruating women. For patients with bleeding disorders, check the urine, stool, and emesis for occult blood (Ownby, 1995). Evaluate laboratory tests: CBC, reticulocyte count, blood smear morphology, serum B12, folate, iron. Nursing Interventions Assess the above mentioned subjective and objective data and report abnormalities to the primary care provider. Provide patient education to help the patient recognize signs and symptoms of anemia. Provide nutrition information regarding foods that are rich in iron and vitamins or refer to a nutritionist/dietitian.

280

THE PERSON WITH HIV/AIDS

Encourage the patient to reduce fatigue by resting between tasks and using adjunctive techniques to conserve energy. Encourage the patient to rest as much as possible. If the patient has difficulty sleeping, the primary care provider should be notified. Encourage the patient to ask for help in managing activities of daily living. Review with the patient the possible side effects and potential interactions of the drugs that they are taking. If the primary care provider makes any changes with the drug, dose, or schedule, review with the patient. If a transfusion is ordered, review the policy and procedure for transfusion and be familiar with the administration and potential complications of administering blood. Review with the patient the procedure and be willing to answer questions about transfusions. If recombinant human erythropoietin is used to treat anemia, be familiar with dosage, administration, and potential side effects (Goodnough, Monk, & Andriole, 1997). HIV Wasting Syndrome, Weight Loss, and Changes in Fat Distribution Wasting Syndrome and Weight Loss. Persons with HIV disease often experience weight loss and changes in fat distribution. The HIV wasting syndrome was included by the Centers for Disease Control (CDC) as an AIDS-defining condition in 1987 (Centers for Disease Control, 1987). It is a weight loss that is involuntary, resulting in > 10% decrease in baseline body weight plus either chronic diarrhea (at least two loose stools per day for more than 30 days) or chronic weakness and fever that is documented, lasting > 30 days, intermittent or constant. These conditions (diarrhea and chronic weakness) occur in the absence of a concurrent illness or condition other than HIV infection that would justify the findings. Changes in the definition of wasting, one that is time dependent with lesser losses of weight, have been proposed (Kotler, Shevitz, & Fenton, 1998). Wasting generally predicts impending complications (Grunfeld, 1995). Problems with the gastrointestinal system are common, not only in

SYMPTOM MANAGEMENT IN HIV/AIDS

281

patients with AIDS but also in patients with HIV infection (Kotler, 1998). The HIV wasting syndrome causes significant morbidity and mortality in patients with HIV and AIDS (Coodley, Loveless, & Merrill, 1994). Weight loss due to wasting is associated with a rapid decline in the overall health of HlV-infected patients, increased risk of hospitalization, increased risk of developing an opportunistic infection, decreased quality of life, and decreased survival (Coodley et al., 1994; Kotler et al., 1998). While many factors can contribute to weight loss and wasting in HIV disease, the central negative energy balance that occurs stems from a reduction in energy intake rather than increased energy expenditure (Macallan et al., 1995). According to Smigelski (1998), the body uses many nutrients faster than they can be replaced. In some patients food supplements must be taken on a regular basis; moreover, the intestines may be damaged with progressive HIV disease and need help with rebuilding. Recommendations by Smigelski are included in the section on nursing interventions. Rapid weight loss may be a harbinger of infection (Schambelan, Sellmeyer, & Grunfeld, 1997). Often there are one or more infectious processes that can cause the wasting syndrome. One of the most common causes of wasting is infection with Mycobacterium avium complex (MAC) (see chapter 5). MAC usually occurs when the CD4+ lymphocyte count drops to below 75 cells/mm3. It is important to monitor the CD4+ count, along with the viral load, to anticipate potential problems that may occur. If the CD4 count is low, the clinician should pursue a diagnostic workup. The weight that is lost to wasting syndrome is usually that of lean body mass, predominantly muscle protein, rather than fat (Hellerstein, Kahn, Mudie, & Viteri, 1990). According to Coodley and colleagues (1994), wasting may occur more commonly in HFV-infected women due to a delay in diagnosis, different modes of HIV transmission, or delayed access to knowledgeable health care providers, rather than a biologic reason based on gender. A number of factors can contribute to weight loss and wasting. Some of the most common include the following: Altered metabolism. An error in metabolism may cause a failure to switch to fatty acid oxidation, thus sparing carbohydrates

282

THE PERSON WITH HIV/AIDS

and protein oxidation, causing a paradoxical conservation of adipose tissue and muscle protein depletion (Hellerstein et al., 1990). Pathogens. Chronic diarrhea can result when cryptosporidiosis occurs. It is thought that cryptosporidiosis accounts for about 10% of the diarrhea in persons with AIDS (Kotler, 1998). Microsporidia, Isospora belli, Giardia lamblia, cytomegalovirus, Mycobacterium avium complex, and others may also cause diarrhea, leading to weight loss (Kotler, 1998). Decreased oral intake. Some HIV-infected patients have a decreased oral intake that may cause significant weight loss leading to HIV wasting syndrome. There are some studies reporting that HIV-infected patients take in more calories but that this increased intake of calories did not correlate with weight loss (Sharkey, Sharkey, Sutherland, & Church, 1992). According to Goroll et al. (1995), other causes of decreased oral intake include (1) gastrointestinal inflammation/ulceration (Smigelski [1998] states that the gut is damaged in HIV infection and with the introduction of antibiotics for treatment of infections. He recommends that the gut be protected and reconditioned, using antioxidants, amino acids, and vitamins.), (2) depression and bereavement, (3) anxiety, (4) poor dentition, (5) taste disturbances, (6) esophageal disease, (7) peptic ulcer disease, (8) drug therapies (digitalis, quinidine, amphetamines, NSAIDS, antitumor agents), (9) hypercalcemia, (10) alcoholism, (11) prodrome of viral hepatitis, (12) hypokalemia, (13) uremia, (14) malignancy, (15) chronic congestive heart failure, (16) chronic inflammatory disease, (17) anorexia nervosa, and (18) dementia. Nausea and vomiting (N&V). Persons with AIDS frequently report nausea and vomiting as a troublesome symptom that can lead to weight loss, discomfort, and distress (Capili & Anastasi, 1998). Pharmacologic agents and infectious diseases are the most common causes of N&V. Other causes are HIV-associated visceral neuropathy, endocrine dysfunction (adrenal insufficiency and pancreatic dysfunction), and conditioned aversions (known as "ANV") (Capili & Anastasi, 1998). Social isolation and poverty. Patients may not have the resources to purchase, store, or prepare nutritious meals. Lack of money

SYMPTOM MANAGEMENT IN HIV/AIDS

283

to purchase essential foods, no kitchen appliances (refrigerator, stove, microwave), no one to assist with shopping for food and food preparation, isolation from family and friends, lack of meal delivery programs, and lack of meal programs that take into account social needs and cultural differences can reflect this social isolation and poverty (Casey et al., 1996). With the increasing number of persons with AIDS from disenfranchised groups, these issues require interventions not only from health care clinicians but also from social workers and case managers to assure adequate resources. Early satiety. The feeling of being full and no interest in eating anymore. Dyspepsia. Dyspepsia may occur because the stomach may be infected with disseminated infections such as cytomegalovirus, mycobacterium avium complex, fungi, or tumor (Roller, 1998), and/or low-grade pancreatitis. Malabsorption. As the CD4+ cell count decreases and immune system damage occurs, diarrhea and HIV wasting increases. AIDS itself can be a cause of malabsorption. Some opportunistic infections cause malabsorption (bacterial, parasitic, viral organisms play a role). According to Goroll and associates (1995), other causes of altered absorption include cholestasis, pancreatic insufficiency, postgastrectomy, small bowel disease, blind loop syndrome, drugs (e.g., cholestyramine, cathartics), neoplastic conditions (such as Kaposi's sarcoma), and HIV enteropathy. Other possible causes may include pancreatic insufficiency, medication-induced diarrhea, protein calorie malabsorption leading to mucosal atrophy, gluten enteropathy, and intestinal autonomic neuropathy (Coodley et al., 1994). Malabsorption and diarrhea occur without an identifiable pathogen. Cytokines. Certain cytokines, in particular tumor necrosis factor (TNF), may be responsible for wasting and weight loss in patients with AIDS (Grunfeld & Feingold, 1992). Endocrine abnormalities. Changes in endocrine function, especially gonadal, adrenal, and thyroid function, could lead to weight loss and wasting. Diabetes mellitus is a cause of weight loss (Gorroll et al., 1995). A drop in testosterone can lead to a reduction in lean body mass and may lead to wasting syndrome.

284

THE PERSON WITH HIV/AIDS

Changes in Fat Distribution. Changes in body fat distribution have been linked to the use of antiretroviral therapy, especially protease inhibitors (e.g., indinavir and ritonavir/saquinavir), although other factors may be involved (Henry, Melroe, & Huebsch, 1998; James, 1998a; Kotler, 1998; Melroe, Kopaczewski, Henry, & Huebsch, 1999). The redistribution of fat is believed to be related to changes in lipid metabolism (referred to as lipodystrophy) and includes several patterns of observable fat redistribution: dorsocervical ("buffalo hump"), bilateral symmetrical lipomatosis (occurring at specific sites such as the neck), visceral obesity, and breast enlargement (Lo, Mulligan, Tai, Algren, & Schambelan, 1998). HIV-infected persons may experience regional fat accumulation or depletion (Kotler, Ro senbaum, & Wang, 1998). The fat redistribution may lead to increased fat in both subcutaneous and visceral compartments and can include decreased fat in the extremities and increased fat in the peritoneal cavity. Affected individuals with an increased waist size usually experience an increase in weight. High triglycerides, high cholesterol, and an increase in blood glucose have been associated with lipodystrophy, possible resulting from more than one cause. Increased lipid levels in some persons with HIV disease may pose an increased risk of coronary artery disease. The underlying biochemical mechanisms of lipodystrophy are not yet fully understood, although several theories have been advanced and are of intense scientific interest. Fat redistribution may be reversed after it has occurred, although success is not assured. This reversal may be achieved in some cases with a change in antiretroviral therapy. Recombinant growth hormone (GH) has also been used to achieve decreases in buffalo hump and truncal lipodystrophy although relapses can occur if treatment is halted. Use of GH can cause a variety of side effects, including arthralgia and worsening diabetes. Other treatment approaches for lipid abnormalities in persons with HIV disease include diet, exercise, and lipid-lowering drugs (e.g., gemfibrozil and/or atorvastatin) (James, 1998b). Subjective Evaluation Ask the patient about his or her diet history, using a 3-day recall. Specific tools are available through a nutritionist or dietitian.

SYMPTOM MANAGEMENT IN HIV/AIDS

285

Ask the patient to describe any pattern of nausea and vomiting and related treatment. Ask the patient to describe his or her appetite, including favorite and least favorite foods. Ask the patient what his or her "normal" weight was before the weight loss. Ask the patient if he or she noticed muscle-wasting (e.g., has clothing become looser, does he or she feel less strong than before onset of weight loss). Obtain a diet recall from the patient, paying particular attention to intake of protein-rich foods. Does the patient have adequate access to food, cooking/storage facilities, and the energy to shop and prepare the food? Does the patient have any religious or cultural restrictions regarding the diet? Does the patient have any other signs or symptoms that would cause him or her to lose weight (e.g., diarrhea, vomiting, abdominal pain, pain/difficulty swallowing, oral lesions, loss of appetite, taste/smell changes, and nausea)? Does the patient take medications that interfere with the intake of food? (e.g., having to take certain medications on an empty stomach and having to wait between doses of medications to eat). Obtain a thorough listing of all the drugs that the patient is taking, including over-the-counter drugs. Objective Evaluation Assess general appearance. Assess muscle strength. Check height and weight to include pre-illness baseline and current weight. Assess vital signs. Perform a physical examination with particular attention to the mouth (e.g., exudate, lesions, dentition, erythema, edema), abdomen (tenderness, hypo/hyperactive bowel sounds), and neurologic system. Collect appropriate blood/stool samples as ordered by the primary care provider to rule out infections.

286

THE PERSON WITH HIV/AIDS

Perform a nutritional assessment: 1. Conduct anthropometric measurements as ordered. 2. Arrange for laboratory testing, to include serum albumin, prealbumin, transferrin, electrolytes, iron, total iron-binding capacity, triglycerides, calcium, phosphorus, magnesium, alkaline phosphatase, bilirubin, SCOT, hemoglobin and hematocrit, zinc, white blood cell count with differential, retinol-binding protein, HIV staging tests (viral burden and CD4+ lymphocytes), stool cultures, and other appropriate tests (Casey, 1997; Casey et al., 1996).

Nursing Interventions Treat opportunistic infection (s) with appropriate medication as ordered by the primary care provider. Review results of lipid profile before implementation of protease inhibitors. Administer medications aimed at stimulating appetite and/or improving weight gain. 1. Megestrol acetate (Megace) is the most studied agent that stimulates appetite leading to weight gain (Casey, 1997). The standard dose is 400 to 800 mg per day as oral suspension and leads to a weight gain that is mostly fat. Adverse effects can include GI upset, impotence, rash, breakthrough bleeding, decreased libido, hypertension, hyperglycemia, and alopecia (Bartlett, 1998). 2. Thalidomide (Thalomid) was approved by the Food and Drug Administration (FDA) in July 1998 for treatment of the debilitating and disfiguring lesions associated with erythema nodosum leprosurn (ENL), a complication of Hansen's disease, commonly known as leprosy. Because of thalidomide's potential for causing birth defects, the FDA invoked unprece dented regulatory authority to tightly control the marketing of thalidomide in the United States (Lashley, 1998). A System for Thalidomide Education and Prescribing Safety (STEPS) oversight program has been initiated that includes limiting

SYMPTOM MANAGEMENT IN HIV/AIDS

287

authorized prescribers and pharmacies, extensive patient education about the risk associated with thalidomide, and a 100% patient registry. This oversight program is designed to help ensure a zero tolerance policy for thalidomide exposure during pregnancy. Thalomid's manufacturer, the Gelgene Corporation, has reported that administration of Thalomid in patients with AIDS-associated weight loss for up to 6 months afforded statistically significant increases in body weight. The side effects of thalidomide include sedation, nausea, neuropathy, and rash (Bartlett, 1998). Thalidomide may also promote the healing of oral aphthous ulcers. 3. Dronabinol (Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (THC), an active ingredient in marijuana that was first approved in 1985 for nausea and vomiting associated with cancer chemotherapy. The dose is 2.5 to 5.0 mg/bid orally (Bartlett, 1998). Some patients do not like to take this drug because they experience a "high" that makes them feel uneasy. (See www.marinol.com for additional patient information.) 4. Recombinant growth hormones, such as Serostim produced by Serono Laboratories, has the potential to increase lean body mass. Growth hormones have to be given as a subcutaneous injection daily and are very expensive ($280/day or $l,750/week) (Bartlett, 1998). 5. Testosterone cypionate or testosterone enathate. Hypogonadism is an acquired endocrine deficiency state characterized by loss of testosterone (Grinspoon et al., 1998). Hypogonadism occurs in many men with advanced HIV disease. Men with hypogonadism may experience diminished energy and libido, increased fat around the abdomen, and decreased muscle in the arm and legs. Testosterone deficiency may contribute to the catabolic state and loss of lean body mass associated with the AIDS wasting syndrome. Testosterone has been shown to increase lean body mass and improve libido, mood, appetite, and energy (Bartlett, 1998). Testosterone is given intramuscularly, usually at the does of 100 to 400 mg IM every two weeks. The patient can be instructed to administer the injection at home. Side effects include balding, acne, gynecomastia, virilizing to women,

288

THE PERSON WITH HIV/AIDS

and testicular atrophy (Bartlett, 1998). Continuous use of high doses of any anabolic steroid can cause a hepatitis, leading to liver failure. The FDA has granted orphan drug status to an anabolic steroid, oxandrolone (trade name Oxandrin), for use in treating HIV-related wasting. Other related drugs include oxymetholone (Anadrol-50) and nandrolone decanoate (Deca Durabolin).

Encourage small, frequent meals throughout the day to include food high in calories and protein. Administer/assist with procurement of nutritional supplements to promote weight gain and improve nutritional status. Administer enteral feedings as ordered by the primary care provider. Administer parenteral nutrition as ordered and observe for side effects and complications. Help patient identify causes of inadequate nutrition intake, especially nausea and vomiting, and develop a plan appropriate to these causes. This may require a referral to a nutritionist/ dietitian. Instruct the patient in methods to decrease feeling of satiety, including small, frequent meals on small plates. Instruct the patient and his or her caregiving team that nutrition is a very important component in the process of increasing weight gain and plays an important role in the quality of life of the patient. Encourage exercise and fresh air to stimulate the appetite. Short walks in the home leading up to short walks outdoors not only help the appetite but may increase the quality of life of the patient. Encourage the intake of foods that are high in protein and rich in other nutrients. These foods include, but are not limited to instant breakfast drinks, milk shakes, cottage cheese, cheese, fish, chicken, peanut butter, and nutrition bars. Instruct the patient and members of the caregiving team on how to protect the patient from certain microbes that could lead to illness. These include:

SYMPTOM MANAGEMENT IN HIV/AIDS

289

1. Keep hot foods hot and cold foods cold until ready to eat. 2. Wash produce thoroughly before eating. 3. Avoid raw or undercooked eggs (e.g., Caesar salad dressing), poultry, meat (e.g., steak tartar), or fish (e.g., sushi). 4. Cook meats, poultry, and fish until no longer pink, so that the internal temperature reaches > 165° F. 5. Thaw meats, poultry, and fish in the refrigerator or microwave. 6. Clean utensils, cutting boards, knives, and counters after cutting raw meats, poultry, and fish. 7. Use pasteurized dairy products only. 8. Never swallow water directly from lakes or rivers (even during swimming or skiing). 9. During outbreaks or advisories, boil water for one minute before drinking, tooth brushing, or making ice. The use of a submicron filter and/or bottled water may also reduce the risk of water-borne microbes (Centers for Disease Control and Prevention, 1995). The International Food Information Council has an Internet site (http://ificinfo.health.org) that includes information on food safety, as does the federal government's Consumer Information Center (http:/ /www. pueblo, gsa. gov). To avoid food and water-borne illnesses when traveling to foreign countries, it is recommended that persons with HIV disease: 1. Eat steaming-hot foods. 2. Eat foods that can be peeled by the traveler. 3. Drink bottled water (especially carbonated) beverages; beer and wine are usually safe. 4. Drink hot tea or coffee. 5. Boil water for > 1 minute before drinking or using to brush teeth. 6. Avoid untreated tap water or ice made from tap water. 7. Avoid undercooked meats, poultry, fish. 8. Avoid unpasteurized milk and dairy products.

290

THE PERSON WITH HIV/AIDS

9. Avoid swimming in water that may be contaminated by sewage or feces. 10. Avoid direct contact with soil and sand in areas where fecal contamination is likely (e.g., wear shoes, and use towels on the beach to avoid exposure) (Centers for Disease Control and Prevention, 1995). Assist patient with identifying complementary treatments for wasting. Smigleski (1998) recommends a program that includes a multivitamin, high-potency B vitamin, antioxidants (including N-acetyl cysteine, vitamin C, vitamin E, selenium, beta-carotene), minerals (magnesium and zinc), and amino acids (Lglutamine). This regimen is controversial, although it merits exploration and consideration. Other nutritional supplements that Smigelski (1998) recommends investigating for weight loss include co-enzyme Q10, L-carnitine, probotics ("friendly bacteria") , alpha-lipoic acid, milk thistle, and evening primrose oil. A referral to a "nontraditional" dietitian or nutritionist may be an option for patients who continue to lose weight, even with interventions usually beneficial. Although nurses do not have to recommend or endorse such supplements, they should assist the patient in evaluating options available to them. Gastrointestinal Symptoms: Diarrhea As their immune systems deteriorate, persons with HIV infection have increased susceptibility to frequently occurring, treatment-resistant organisms. Diarrhea is a common problem for persons with AIDS, occurring in 30% to 60% of persons with AIDS in industrialized countries and in as many as 90% of persons with AIDS in Haiti or Africa (Framm & Soave, 1997). The diarrhea experienced by persons with AIDS may respond to treatment, although it is often chronic, debilitating, and associated with wasting and cachexia, leading to significant morbidity (Framm & Soave, 1997). Cause can be established in approximately 50% to 80% of persons with chronic diarrhea (Henry, Holzemer, Weaver, & Stotts, 1999). If left untreated, AIDS-associated diarrhea confers a significant risk of death. An estimated 44% to 85% of pathogens that cause

SYMPTOM MANAGEMENT IN HIV/AIDS

291

diarrhea in persons with AIDS can be identified (Wilcox et al., 1996), although in 25% to 50% of these individuals the pathogen cannot be identified (Framm & Soave, 1997). The diarrhea, which may involve the small bowel, large bowel, or both, is caused by bacteria, parasites, mycobacteria, and viruses (Cello, 1997, p. 185). Other causes of diarrhea include antiretroviral agents (e.g., didanosine, saquinavir, ritonavir, and nelfinavir) and other medications used to treat opportunistic infections, such as clindamycin, ciprofloxacin, ofloxacin, clarithromycin, azithromycin (Bartlett, 1997; Lee, 1997; Sanford, Gilbert, Moellering, & Sande, 1997). Diarrhea may also be caused by villous atrophy due to malnutrition or repeated bowel infections, low serum albumin levels, zinc deficiency or excess, inadequate or absent digestive enzymes or bile salts, or lactose intolerance (Casey et al., 1996). Patients may also experience associated symptoms, such as abdominal pain, urgency, perianal discomfort, and fecal incontinence (Melson & Tripodi, 1997). Subjective Evaluation Obtain the history of diarrhea-associated symptoms: 1. Obtain the patient's full description of symptoms (flatus, abdominal pain/cramping, bloating). 2. Discern the pattern of diarrhea (estimate the number of bowel movements each day, when it started, how long it has lasted). 3. Ask patient if he or she has kept a stool diary. 4. Ask the patient to describe the appearance of stool (black, red-tinged, frothy, foul-smelling). 5. Ask the patient to estimate the volume of each stool. Obtain a diet history (food intake and preparation styles). Obtain the patient's travel history (recent travel to mountainous areas, Eastern European countries, and developing countries). Ask the patient to recount antibiotic use in the past 3 months. Inquire about prescription and over-the-counter medication use. Obtain a history of anal-oral sex.

292

THE PERSON WITH HIV/AIDS

Inquire whether or not the patient works at a day care center or custodial institution. Ask the patient to describe the impact of diarrhea on his or her quality of life. Objective Assessment Measure weight. Assess the skin integrity/turgor. Obtain and review a complete blood count with differential, CD4 lymphocyte count, viral load, and serum electrolytes. Obtain (or instruct the patient in obtaining) stool samples for examination of the stool for ova and parasites X 3, for fecal leukocytes and occult blood of stool, for stool culture and sensitivity, and/or for Clostridium difficile toxin culture if the patient has had recent treatment with antibiotics. Perform a physical exam, to include inspection of the abdomen, perineum, and rectum: 1. 2. 3. 4.

Perform Perform Perform Perform

auscultation for bowel sounds, bruits. percussion for dullness, tympany. light palpation of the entire abdomen. deep palpation of the entire abdomen.

Nursing Interventions Home remedies. Home remedies have their place in slowing down mild diarrhea. The patient should be instructed to try dietary changes to allow the gut to rest. This would include eating bananas, apples, rice, and toast and drinking weak tea. The patient and his or her family and supportive community must be informed that some dangerous organisms can be transmitted during routine food preparation. It is known that Salmonella is found in poultry and can be transmitted to humans. Patients should be instructed to use separate utensils (or wash in hot water) between cutting poultry and cutting vegetables (especially raw). Keeping the counters, sinks, and refrigerator

SYMPTOM MANAGEMENT IN HIV/AIDS

293

clean also can help prevent infections. Patients should also be reminded that good handwashing is the best way to prevent the transmission of potentially harmful organisms. Dietary changes. According to Casey and associates (1996) and Bartlett (1997), a high-protein, high-calorie diet, served in small portions, containing foods that are high in soluble fiber, low in fat, and lactose- and caffeine-free should be followed. Also, liquid nutrition, such as Gatorade, can be used to replace essential electrolytes lost to diarrhea. Fluids such as juices, broth, and water are equally important. Other more sophisticated liquid supplements are available. For patients with lactose intolerance, lactase enzyme replacement pills prior to ingesting lactose-containing foods should be used. Some patients benefit from pancreatic enzymes or bile salts. A referral to a dietitian would be appropriate if available. Pharmacologic interventions: 1. Antimotility agents such as paregoric, loperamide, and diphenoxylate hydrochloride (Bartlett, 1997) may play a role in decreasing the frequency, number of stools, and volume of stools after pathogenic organisms are ruled out. Specific antimicrobial agents should be administered depending on the organism. Listed below are diarrhea-causing organisms and agents commonly used for treatment. BACTERIA Salmonella. Third-generation cephalosporins (e.g., Suprax, Rocephin, Fortaz), fluoroquinolones (ciprofloxacin, floxin), ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (TMP/SMZ) (Framm & Soave, 1997). Amoxicillin may also be used (Melson & Tripodi, 1997). A course of antibiotics should continue for more than 2 weeks. Shigella. Intravenous third-generation cephalosporins, fluoroquinolones (Framm & Soave, 1997).

294

THE PERSON WITH HIV/AIDS

Campylobacter. Erythromycin (Melson & Tripodi, 1997). Fluoroquinolones (Framm & Soave, 1997). Vibrio species. Fluoroquinolones, tetracycline (Framm & Soave, 1997). Clostridium difficile. Discontinue antibiotics; start oral or intravenous metronidazole and oral vancomycin (Framm & Soave, 1997). Escherichia coli. Possible ciprofloxacin (Framm & Soave, 1997). Mycobacteria. Mycobacterium avium complex. At least two agents. Macrolides (azithromycin and clarithromycin), ethambutol, rifabutin, ciprofloxacin, and ofloxacin (Framm & Soave, 1997). VIRUSES Cytomegalovirus. Intravenous ganciclovir or intravenous foscarnet (Framm & Soave, 1997). Herpes simplex. Acyclovir (Melson & Tripodi, 1997). PROTOZOA Cryptosporidiumparvum.Paramomycm, octreotide, azithromycin, symptomatic treatment with nutritional supplements and antidiarrheal agents (Bartlett, 1998). hospora belli. TMP/SMZ. Microsporidia. Albendazole, symptomatic treatment with nutritional supplements and antidiarrheal agents (Bartlett, 1998). Giardia lamblia. Metronidazole (Bartlett, 1998). Entamoeba histolytica Metronidazole, iodoquinol, or paramomycin (Bartlett, 1998).

Related Nursing Interventions Educate the patient and the caregiver regarding: 1. Proper collection of specimens (stool collection). 2. Dietary precautions and dietary changes. 3. Which antidiarrheal agents to take and when to take them.

SYMPTOM MANAGEMENT IN HIV/AIDS

295

Give antidiarrheals on a schedule rather than as necessary (Casey et al., 1996). If patient is receiving treatment at home, educate regarding frequency, amount, and side effects of drugs. Educate patient and caregiver about what to report to health care provider (e.g., stool counts, description of stools, abdominal cramping, bloody stools, vomiting). Maintain adequate hydration. 1. Encourage the administration of appropriate fluids by mouth if the patient is able to take fluids by mouth. 2. Administer intravenous fluids as ordered. Check for signs of rehydration. Administer antimicrobial agents as ordered. Assess for efficacy, side effects, and adverse responses. Administer antidiarrheal agents as ordered. Assess efficacy of these agents. Maintain adequate skin integrity 1. Encourage patient to use warm, wet cloths (or disposable baby wipes) or gentle warm water rinses, after each stool. 2. Offer the patient sitz baths. 3. Apply an appliance that collects fecal matter if stools are watery, frequent, or if the patient is unable to go to the toilet. Recommend the patient to a case management specialist, dietitian, or nutritionist as needed. Gastrointestinal Symptoms: Oral Candidiasis Oral candidiasis is the most common complication caused by an infectious agent to develop in patients with HIV infection (Kotler, 1998) (see chapter 5). As many as 75% of persons with AIDS will develop oral candidiasis during their disease course. Oral candidiasis usually causes thrush, a whitish coating on the tongue, which may cause a patient to have difficulty with food intake, as the thrush is often painful. The organisms that cause thrush include C. albicans, C

296

THE PERSON WITH HIV/AIDS

krusei, C. parapilosis, and C. tropicalis (Bartlett, 1998). If left untreated, Candida may invade the esophagus and cause substernal pain and greater difficulty with swallowing, leading to weight loss. The oral lesions of candidiasis in persons with HIV infection can assume four forms: (1) pseudomembranous lesions, which manifest as white plaques on inflamed base of palate, buccal mucosa, or tongue; (2) erythematous or atrophic lesions, which are spotty or confluent red patches; (3) hyperplastic or "candidal leukoplakia," which are white lesions that will not wipe off but respond to treatment with antifungal agents; and (4) angular chelitis, which causes fissures at the corner of the mouth (Bartlett, 1998).

Subjective Evaluation Collect a drug history. Ask the patient to disclose any previous treatment for candidiasis. Determine those foods the patient is eating (e.g., spicy foods). Ask the patient to describe any symptoms associated with the candidiasis. Objective Evaluation Conduct a thorough examination of the mouth. Any white exudate should be scraped off gently and applied to a slide with potassium hydroxide and observed under a microscope to look for budding yeast (Candida). If a microscope is not available, a specimen should be prepared according to the instructions of the facility where the patient is being seen and sent to a laboratory.

Treatment For the initial infection with Candida, fluconazole 100 mg poq day for 10 to 14 days is recommended (Bartlett, 1998). Other options include clotrimazole troches 10 mg, 5 times per day,

SYMPTOM MANAGEMENT IN HIV/AIDS

297

or nystatin 500,000 units swished in the mouth and gargled 5 times per day. In patients who are given a systemic medication for treatment of thrush, it is important to monitor their liver function tests, as the azole drugs are metabolized by the liver. It is also important to know what medications the patients is taking, as there are drug interactions associated with azole therapy. Advise the patient to avoid foods that would aggravate the mouth soreness. Pain Pain is one of the most frequent symptoms occurring in HIV disease. In one study, from 30% to 62% of HIV patients in 34 treatment facilities in France exhibited pain (Larue, Fontaine, & Colleau, 1997). In another study, 226 of 366 ambulatory AIDS patients reported persistent or frequent pain (Breitbart et al., 1996). Pain is frequently underestimated and undertreated. Even when pain is accurately assessed, health care providers may prescribe and administer inadequate analgesia. One reason for this undertreatment is concern about the addictive potential of opiates and other medications used for pain relief or their side effects. Other reasons include inadequate assessment of pain and inadequate knowledge of the most effective ways to treat pain. Sometimes patients inadvertently contribute to this problem by not reporting pain they are experiencing. Reasons for this reticence include not wanting to be labeled as a "bad" patient, not wanting to distract the health care provider from other aspects of their care, fear of addiction, and not wanting to be a burden to others. Sociocultural parameters may also play a role in how and if pain is expressed. In a 1996 study by Breitbart and colleagues, those least likely to express HlV-related pain were women, less educated patients, and injecting drug users. Patients may also not have the financial resources for all of their needs and try to reduce pain medication to save money. In HIV infection pain may arise from a variety of causes including those related to HIV and associated symptoms and those related to HIV treatments. It may also be due to another condition that the person with HIV disease has that is not related to HIV such as

298

THE PERSON WITH HIV/AIDS

"slipped" disc. When possible, both the pain and its causes should be treated as well as the pain itself. Sources of pain related to HIV and its complications include peripheral neuropathy; skin lesions due to herpes zoster (shingles) and other ulcerations; arthralgia; myalgia; lesions of the mouth or anus from conditions such as herpes lesions or Candida; esophagitis; pressure from lesions or tumors, such as Kaposi's sarcoma and lymphomas; headache from such conditions as meningitis or encephalitis or due to zidovudine; or abdominal pain due to conditions such as pancreatitis. Treatment such as inserting a central venous access device may cause acute pain. These conditions have been discussed elsewhere in this book. Peripheral neuropathy pain, which is described as burning, tingling, numbness and may be extremely tender to the touch, is discussed in chapter 5. Although most approaches to treating peripheral neuropathy have been disappointing, tricyclic antidepressants and anticonvulsants have been used in addition to such traditional approaches as application of heat and ice locally. Recombinant nerve growth factor is being used experimentally to control pain, and topical lidocaine gel may be useful. Assessment of pain in HIV infection follows the same basic principles as in other disorders, particularly cancer pain. It is important to assess such parameters as location of pain, type of pain (i.e., burning, shooting), intensity of pain, onset, duration, precipitating factors, any factors that appear to ameliorate pain, time of day pain occurs, and any description of the pain the patient provides. The effect of the pain on physical, emotional, and social functioning should be ascertained. A variety of tools are available to assess pain, including the visual analogue scale, the numerical rating scale, and the Brief Pain Inventory (Jacox et al., 1994). The choice depends on the client (age and so forth) and type of pain. It is important for the nurse to be consistent in the use of a pain assessment tool and to note pain relief following a measure that is implemented for that purpose. Whatever the plan of pain relief, the patient and the family or caregiver must understand that plan and be able to participate in modifying it if necessary. Important principles in pain relief include believing that the patient has pain, accepting the patient's self-report of pain, and anticipating pain and treating it before it occurs, such

SYMPTOM MANAGEMENT IN HIV/AIDS

299

as when a painful procedure is performed. Preventing pain is preferable to treating it after it has occurred. Pain is a subjective experience. Pain relief in HIV disease uses both pharmacologic and nonpharmacologic approaches. When using drug therapy, it is often important to implement regular doses rather than "p.r.n." (as necessary) doses in order to establish early pain control. Drugs used in the treatment of pain fall into three basic groups: opioids (e.g., morphine, fentanyl, codeine), nonopioids (e.g., nonsteroidal antiinflammatory agents, acetaminophen); and other drugs that act more indirectly (i.e., corticosteroids, antidepressants). Topical preparations such as lidocaine, menthol, capsaicin, and benzocaine may be useful for certain types of pain (e.g., lidocaine is available in a viscous solution to treat painful mouth lesions). The World Health Organization has devised an analgesic ladder that illustrates pain control and that is said to be 85% to 90% effective in controlling cancer pain (W7orld Health Organization Expert Committee, 1990). Other nonpharmacologic therapies may also be used. These include relaxation, hypnosis, therapeutic touch, music therapy, yoga, application of heat or cold, massage, mental imagery, biofeedback, transcutaneous electrical nerve stimulation (TENS), acupuncture, and prayer. Combinations of a variety of pharmacologic and nonpharmacologic approaches may be used; however, no person should be denied the benefit of pharmacologic pain relief if it is available and safe. Fever Fever is often defined as an oral temperature greater than 100.1° F (Jones, 1998). In persons with HIV disease fever is one of the most frequently reported symptoms (Holtzclaw, 1998). Fever may occur at any time in seropositive persons and can be low grade, moderate, or high. The. causes of fever are not always ascertainable but are often seen in conjunction with other symptoms that suggest one or more infections, drug reactions, or malignancies. A low-grade fever is often present in persons with advanced HIV disease (Jones, 1998). HIV-infected persons may have febrile periods that are noninfectious in origin. Fever at night may or may not be accompanied by sweating, which, when present, can be profuse. Some drugs used to

300

THE PERSON WITH HIV/AIDS

treat HIV disease or opportunistic infections may also cause fever (Holtzclaw, 1998). Serological and microbiological tests may not always pinpoint the causes of fever, even when other signs and symptoms suggest an infectious process. Geographical setting and local disease prevalence are often valuable in determining possible causes of fever (Collazos & Martinez, 1997). Common infectious causes of fever in hospitalized patients include Pneumocystis carinii pneumonia, tuberculosis, histoplasmosis, cryptococcosis, and Mycobacterium avium complex (Barat et al., 1996). Assessment of individuals with fever includes monitoring of body temperature and hydration status. Key assessment-related interventions include assessing oral temperature if fever is suspected, assessing skin temperature and elasticity, assessing the oral cavity, maintaining a cool environment, monitoring intake and output, and checking specific gravity of urine. Nursing interventions for fever are aimed promoting comfort and averting or reducing the complications of fever. Common nursing interventions for fever include providing liquids orally or intravenously, administering antipyretics, and using a cooling blanket. Interventions that produce febrile shivering (e.g., sponge baths), energy expenditure, and patient discomfort have been discouraged (Casey et al., 1996). In individuals for whom fever is a recurring symptom, nurses may need to teach the patient how to read a thermometer, maintain a fever diary, and ingest adequate fluids. Psychological Responses Living with HIV disease can be stressful. Living with HIV disease can be stressful and can cause distress for people living with HIV. Many changes associated with HIV disease such as multiple losses (job, family support, body image, and body function), illness and disease (and the accompanying "roller coaster" of periods of good health and bad health), side effects from medications, economic hardship and isolation from regular social interactions. The progressive nature of HIV disease can lead to increased stress (Robinson, Mathews, Witek-Janusek, 1999). Other stressors include living with uncertainty and dealing with the stigma and discrimination still associated with HIV and AIDS.

SYMPTOM MANAGEMENT IN HIV/AIDS

301

This psychological stress may be intensified by the complex medical regimens and physical conditions and symptoms often accompanying HIV disease. Moreover, a significant number of persons living with HIV also are dealing with abuse of substances, including alcohol, cannabis, and cocaine (McDaniel, Fowlie, Summerville, Farber, & Cohen-Cole, 1995). Although the advent of more effective medical treatments has prolonged the lives of many HFV-infected persons, some now face what has been termed "the Lazarus syndrome," which has been likened to the situation of survivors following the aftermath of the Holocaust (France, 1998). While the relationship among stress, immune function, and HIV progression is not fully understood (Robinson et al., 1999), most clinicians treating persons with HIV disease urge their patients to learn means to cope with and reduce stress in their lives (Leipart, 1998). Plausible pathways to stress-induced HIV progression have been proposed, although these remain unproven (Kemeny, 1994; McCain & Zeller, 1996; Robinson et al., 1999). Research indicates that stress management training can buffer HIV disease-related psychological distress over time (McCain, Zeller, Cella, Urbanski, 8c Novak, 1996). Persons living with HIV disease experience a range of negative psychological responses to their condition. The most common of these are affective disorders, adjustment disorders, anxiety, hypochondriasis. and sexual dysfunction. Moreover, persons who are HIVinfected may experience increased stress at critical times, including when they learn they are HIV seropositive, when disclosing their diagnosis to others, when facing major health crises, and when undergoing major changes as a result of their condition. In addition, some persons living with HIV disease may require hospitalization for psychosis as a result of severe stress, reaction to medication used to treat their HIV disease, and organic brain disease secondary to HIV infection and other related conditions (Zegans 8c Coates, 1994). The individual's ability to cope effectively with the stressors of HIV disease is influenced by a range of factors, including the stage of psychological development; premorbid personality; availability of coping resources; previous experience in coping with loss, stress, and serious illness; and access to professional care. Mental health treatment for psychological distress includes supportive, interpersonal, cognitive-behavioral, and group therapy. Per-

302

THE PERSON WITH HIV/AIDS

sons living with HIV disease should be considered candidates for pharmacotherapy, with the choice of drug(s) to treat psychological distress taking into account the severity of symptoms and other medications being taken. Commonly, when antidepressants or anxiolytic agents are used, a low dose of the drug is prescribed because of concerns about drug interactions, a higher risk of side effects, and tolerability. Antidepressants (e.g., the SSRIs—fludxetine, paroxetine, and sertraline), stimulants, and testosterone have been used successfully to treat major depression in the HIV-seropositive population. Individuals taking an tire troviral agents who are also taking psychotropic medications need careful initial and ongoing evaluations for possible drug interactions and side effects. Subjective Evaluation Assess the individual's mental health status at regular intervals using the structured approach found in a number of neurological assessment tools. Key areas of assessment include changes in: Interpersonal relationships with significant others Social support Recreational activities Loss of job, income Sexual functioning Sleep patterns Appetite/food intake Energy level Motor function Sense of happiness/pleasure/hopelessness Ability to concentrate Cognition changes, particularly changes in memory Speech patterns Other areas of assessment include: Presence of suicidal thoughts/plan for committing suicide Physical symptoms, including those associated with anxiety disorders (dry mouth, dizziness, fast heart rate, shortness of

SYMPTOM MANAGEMENT IN HIV/AIDS

303

breath, frequent urination, nausea, light-headedness, trouble swallowing, sweating Presence of intrusive thoughts, excessive worry Methods used to cope with stress Assess use of legal or illegal substances: Type of substance Amount Frequency of use Route of use Side effects Objective Evaluation Assess/observe for: The individual's affect Appearance, including weight loss or gain Level of alertness Pattern of speech to detect changes in cognition (conduct an assessment of cognition if warranted) Motor activity for slowing, agitation, trembling, irritability, vigilance/scanning Recurrent thoughts about worthlessness, guilt, sadness, or death Signs of substance use (alcohol on breath, needle marks) Side effects of any psychotropic medications Nursing Intervention Refer individual for possible medical intervention if anxiety and depression are interfering with ability to function or diminishing quality of life. Arrange for immediate psychiatric intervention if client is suicidal. Ensure that client is well educated regarding any psychotropic medications he or she may be taking.

304

THE PERSON WITH HIV/AIDS

Refer substance-using clients to sources of treatment. If appropriate, facilitate referral to a therapist who is competent to work with the client's issues. Make client aware of organizations he or she may join to assist in coping with HIV-seropositive status and/or loss. Provide client with information regarding other sources of assistance, including special HIV/AIDS treatment centers, crisis centers, and Internet resources. (See the list of selected Interne sites at the end of this chapter.)

CONCLUSION Individuals with HIV disease can experience a wide range of physiological and psychological symptoms that interfere with functioning and the overall quality of life. The identification and successful treatment of symptoms can greatly improve the quality of life of persons with HIV disease. Nurses play important roles in administering medical treatments for symptom control and in helping patients and their significant others to manage HlV-related symptoms. Although much information is available to help nurses and patients to manage these symptoms, research is needed to determine those nursing and medical interventions that are most effective.

REFERENCES Abrams, D. (1997). Alternative therapies for HIV. In M. Sande & P. Volberding (Eds.), The medical management of AIDS (pp. 143-158). Philadelphia: W. B. Saunders. Bain, B. J. (1999). Pathogenesis and pathophysiology of anemia in HIV infection. Current Opinion in Hematology, 6, 89-93. Barat, L., Gunn, J., Steger, K., Perkins, C., & Craven, D. (1996). Causes of fever in patients infected with human immunodeficiency virus who were admitted to Boston City Hospital. Clinical Infectious Disease, 23, 320-328. Bartlett, J. G. (1997). The Johns Hopkins Hospital 1997 guide to medical care of patients with HIV infection. Baltimore: Williams & Wilkins. Breitbart, W., McDonald, M., Rosenfeld, B., Monkman, N., & Passik, S. (1998). Fatigue in ambulatory AIDS patients. Journal of Pain and Symptom Management, 15, 159-167.

SYMPTOM MANAGEMENT IN HIV/AIDS

305

Breitbart, W., Rosenfeld, B. D., Passik, S. D., McDonald, M. V., Thaler, H., & Portenoy, R. K. (1996). The undertreatmentof pain in ambulatory AIDS patients. Pain, 65, 243-249. Capaldini, L. (1999). Symptom management guidelines. In P. T. Cohen, M. A. Sande, & P. A. Volberding (Eds.), A textbook on HIV disease from the University of California, San Francisco, and the San Francisco General Hospital (3rd ed.) (pp. 277-282). Philadelphia: Lippincott Williams & Wilkins. (Available athttp:// hivinsite.ucsf.edu/akb/ 1997/index.html). Capili, B., & Anastasi, J. (1998). A symptom review: Nausea and vomiting. Journal of the Association of Nurses in AIDS Care, 9(6), 47-56. Casey, K. (1997). Malnutrition associated with HIV/AIDS: 2. Assessment and interventions. Journal of the Association of Nurses in AIDS Care, 8(5), 39-48. Casey, K., Cohen, F., & Hughes, A. (Eds.). (1996). Management of common symptoms, signs, and other responses to HIV infection/AIDS. In ANAC's core curriculum for HIV/AIDS nursing (199-277). Philadelphia: Nursecom. Cella, D., Mo, F., & Peterman, A. (1997). Anemia, fatigue, and quality of life in people with cancer and HIV infection. Rehabilitation in Oncology, 75(2), 18, 21. Cello,]. (1997). Gastrointestinal tract manifestations of AIDS. In M. Sande & P. Volberding (Eds.). The medical management of AIDS (pp. 181-195). Philadelphia: W. B. Saunders. Centers for Disease Control. (1987). Council of State and Territorial Epidemiologists, AIDS Program, Center for Infectious Diseases. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morbidity and Mortality Weekly Report, 36 (Suppl. 1), 3S-15S. Centers for Disease Control and Prevention. USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons infected with human immunodeficiency virus: A summary. Morbidity and Mortality Weekly Report 1995, 44(No. RR8), 30-33. Cohen, F. L., Ferrans, C. E., Vizgirda, V., Kunkle, V., & Cloninger, L. (1996). Sleep in men and women infected with human immunodeficiency virus. Holistic Nursing Practice, 10(4), 33-43. Collazos, M., 8c Martinez, E. (1997). Fever of unknown origin in the HIV-infected patient: New scenario for an old problem. Scandanavian Journal of Infectious Disesase, 29, 327-326. Coodley, G., Loveless, M., & Merrill, T. (1994). The HIV wasting syndrome: A review. Journal of Acquired Immune Deficiency Syndromes, 7, 681-694. Cunningham, W., Shapiro, M., Hays, R., Dixon, W., Visscher, B., George, W., Ettl, M., & Beck, K. (1998). Constitutional symptoms and health-related quality of life in patients with symptomatic HIV disease. American Journal of Medicine, 104(2), 129-136. Delmonte, L. (1997, January). HIV/AIDS-related fatigue. Gay Men's Health Crisis Treatment, http://www.thebody.com/gmhc/issues/jan97.htmlttfatigue Dossey, B., & Guzzetta, C. (1995). Holistic nvirsing practice. In B. Dossey, L. Keegan, C. Guzzetta, Be L. Kolkmeier (Eds.), Holistic nursing: A handbook for practice (pp. 5-36). Gaithersburg, MD: Aspen.

306

THE PERSON WITH HIV/AIDS

Doweiko.J., & Groopman, J. (1998). Hematologic manifestations of HIV infection. In G. Wormser (Ed.), AIDS and other manifestations of HIV infection (pp. 541-557). Philadelphia: Lippincott-Raven. Fantoni, M., Ricci, F., Del Borgo, C., Izzi, I., Damiano, F., Moscati, A., Marasca, G., Bevilacqua, N., & Del Forno, A. (1997). Multicentre study of the prevalence of symptoms and symptomatic treatment in HIV infection. Journal of Palliative Care, 13(2), 9-13. Framm, S., & Soave, R. (1997). Agents of diarrhea. Medical Clinics of North America, 81(2), 427-447. France, D. (1998, October 6). Holding AIDS at bay, only to face "Lazarus Syndrome." New York Times, p. BIO. Goldschmidt, R., & Dong, B. (1999). Treatment of AIDS and HlV-related conditions—1999. Journal of the American Board of Family Practice, 12(1), 71-94. Goodnough, L., Monk, T., & Andriole, G. (1997). Current concepts: Erythropoietin therapy. New England Journal of Medicine, 336, 933-938. Goroll, A., May, L., & Mulley, A. (1995). Evaluation of weight loss. In A. Goroll, L. May, & A. Mulley (Eds.), Primary care medicine (pp. 38-42). Philadelphia: Lippincott. Grinspoon, S., Corcoran, C., Askari, H., Schoenfeld, D., Wolf, L., Burrows, B., et al. (1998, July). Effects of androgen administration in men with the AIDS wasting syndrome: A randomized, double-blind placebo-controlled trial. Annals of Internal Medicine, 129(1), 18-26. Grunfeld, C. (1995). What causes wasting in AIDS? New England Journal ofMedicine, 333, 123-124. Grunfeld, C., & Feingold, K. (1992). Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. New England Journal of Medicine, 327, 337. Hambleton,J. (1997). Hematologic complications of HTV infection. In M. Sande & P. Volberding (Eds.), The medical management of AIDS (pp. 239-246). Philadelphia: W. B. Saunders. Hellerstein, M. K., Kahn, J., Mudie, H., & Viteri, F. (1990). Current approach to the treatment of human immunodeficiency virus-associated weight loss: Pathophysiologic considerations and emerging management strategies. Seminars in Oncology, 17(6 Suppl. 6), 17-33. Hench, K, Anderson, R., Grady, C., & Ropka, M. (1995). Investigating chronic symptoms in HIV: An opportunity for collaborative nursing research. Journal of the Association of Nurses in AIDS Care, 6(3), 13-17. Henry, K., Melroe, H., & Huebsch, J. (1998). Atorvastatin and genfibrozil for protease-inhibitor-related lipid abnormalities. The Lancet, 352(9133), 1031. Henry, S., Holzemer, W., Weaver, K., & Stotts, N. (1999). Quality of life and self-care management strategies of PLWAs with chronic diarrhea. Journal of the Association of Nurses in AIDS Care, 10, 46-54. Herrington, A., Herrington, J., & Church, C. (1997). Pharmacologic options for the treatment of cachexia. Nutrition in Clinical Practice, 12, 101-113. Hewitt, D. J., McDonald, M., Portenoy, R. K, Rosenfeld, B., Passik, S., & Breitbart, W. (1997). Pain syndromes and etiologies in ambulatory AIDS patients. Pain, 70, 117-123.

SYMPTOM MANAGEMENT IN HIV/AIDS

307

Holtzclaw, B. (1998). Managing fever in HIV disease. Journal of the Association of Nurses in AIDS Care, 9(4), 97-101. Horn, J., & Fantry, L. (1995). Ambulatory care of the HIV-infected patient. In L. Barker, J. Burton, & P. Zieve (Eds.), Principles of ambulatory medicine (pp. 408-432). Baltimore: Williams & Wilkins. Hughes, A., Angell, J., Bundrock, G., Hinds, C., Katz, A., Taylor, R., Williams, A., & Emanuele, T. (1992). Understanding and managing anemia in the HIV-infected patient. Ruritan, NJ: Ortho Biotech. Jacox, A., Can, D. B., Payne, R., Berde, C. B., Brietbart, W., Cain.J. M., etal. (1994). Management of cancer pain, Clinical Practice Guideline No. 9. (AHCPR Pub. No. 94-5-0592). Rockville, MD: Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service. James, J. (1998a, September 18). Lipodystrophy research coordination needed, AIDS Treatment News, 303. [http://w\vw.immunet.org/immunet/atn.nsf/homepage] James,}. (1998b, October 2). Successful standard treatment for lipid abnormalities: Experience with 44 patients. AIDS Treatment News, 304. [http://www.immunet. org/immunet/atn.nsf/homepage] Jones, S. (1998). Nursing practice for HIV/AIDS fever care: A descriptive study. Journal of the Association of Nurses in AIDS Care, 9(5), 53-60. Kemeny, M. (1994). Stressful events, psychological responses and progression of HIV infection. In R. Glaser and J. Kiecolt-Glaser (Eds.), Handbook on stress and immunity (pp. 245-266). San Diego: Academic Press. Kirton, C., Ferri, R., & Eleftherakis, V. (1999). Primary care and case management of persons with HIV/AIDS. Nursing Clinics of North America, 34(1), 71-94. Kotler, D. (1998). The gastrointestinal and hepatobiliary systems in HIV infection. In G. Wormser (Ed.), AIDS and other manifestations of HTVinfection (pp. 505-527). Philadelphia: Lippincott-Raven. Kotler, D., Rosenbaum, K., & Wang, J. (1998). Alterations in body fat distribution in HIV-infected men and women [Abstract 32173]. 12th Wo rid AIDS Conference, Geneva, Switzerland. Kotler, D., Shevitz, A., & Fenton, M. (1998). Update on wasting, metabolism and altered body shape in HIV/AIDS, [http://www.healthcg.com/hiv/tuftswasting/print.asp] Larue, F., Fontaine, A., & Colleau, S. M. (1997). Underestimation and undertreatrnent of pain in HFV disease: Multicentre study. British Medical Journal, 314, 23-28. Lashley, F. R. (1998). Sleep alterations. In M. E. Ropka & A. B. Williams (Eds.), PI W nursing and symptom management (pp. 471-483). Sudbury, MA: Jones and Bartlett Publishers. Lee, B. (1997). Drug interactions and toxicities in patients with AIDS. In M. Sande & P.Volberding (Eds.), The medical management of AIDS (pp. 125-142). Philadelphia: W. B. Saunders. Lee, K, A., Portillo, C., & Miramontes, H. (1999). The fatigue experience for women with HIV. Journal of Obstetric, Gynecologic & Neonatal Nursing, 28, 193-200. Levine, A. (1997). Hematologic manifestations of HIV disease. Golden, CO: Healthcare Communications Group.

308

THE PERSON WITH HIV/AIDS

Lietzau.J. (1996). Teaching symptom management of HIV/AIDS using algorithms. Cancer Nursing, 19, 263-268. Lo, J., Mulligan, K., Tai, V., Algren, H., & Schambelan, M. (1998). Buffalo hump in men with HIV-1 infection. The Lancet, 351, 867-870. Lyketsos, C., Hoover, D., Guccione, M., Dew, M., Wesch, J., Bing, E., & Treisman, G. (1996). Changes in depressive symptoms as AIDS develops. American Journal of Psychiatry, 153(11], 1430-1437. Macallan, D., Noble, C., Baldwin, C., Jebb, S., Prentice, A., Coward, A., Sawyer, M., McManus, T., & Griffin, G. (1995). Energy expenditure and wasting in human immunodeficiency virus infection. New England Journal of Medicine, 333, 83-88. McCain, N., Lyon, D., Higginson, R., Settle, J., Robins, J., & Fisher, E. (1998). Revision of the HIV center medical staging scale. Journal of the Association of Nurses in AIDS Care, 9(5), 19-23. McCain, N., & Zeller,J. (1996). Psychoneuroimmunological studies in HIV disease. Annual Review of Nursing Research. New York: Springer. McCain, N., Zeller, J., Cella, D., Urbanski, P., & Novak, R. (1996). The influence of stress management training in HIV disease. Nursing Research, 45, 246-253. McDaniel, S., Fowlie, E., Summerville, M., Farber, E., & Cohen-Cole, S. (1995). An assessment of rates of psychiatric morbidity and functioning in HIV disease. General Hospital Psychiatry, 17, 346-352. Melchior, J. C., Salmon, D., Rigaud, D., Leport, C., Bouvet, E., Detruchis, P., et al. (1991). Resting energy expenditure is increased in stable, malnourished HFVinfected patients. American Journal of Clinical Nutrition, 53, 437-441. Melroe, H., Kopaczewski, B., Henry, K., & Huebsch, J. (1999). Lipid abnormalities associated with protease inhibitors. Journal of the Association of Nurses in AIDS Care, 10, 22-30. Melson, S., & Tripodi, J. (1997, February). Infectious diarrhea in HIV: Coping with the many causes. Internal Medicine, pp. 54-63. Mitsuyasu, R. (1998). The importance of treating anemia in HIV disease. Clinical Care Options for HIV: HIV Updates, Experts' Column. (Available at http:// www.healthcg.com/hiv/updates/oct98). Moore, R., Keruly, J., & Chaisson, R. (1998). Anemia and survival in HIV infection. Journal of Human Acquired Immune Deficiency Syndromes and Human Retrovirology. Newshan, G., & Sherman, D. W. (1999). Palliative care: Pain and symptom management in persons with HIV/AIDS. Nursing Clinics of North America, 34(1), 131-145. Nokes, K. M., Chidekel, J. H., & Kendrew, J. (1999). Exploring the complexity of sleep disturbances in persons with HIV/AIDS. Journal of the Association of Nurses in AIDS Care, 10(3), 22-29. Northfelt, D., & Mitsuyasu, R. (1992). Hematologic complications of HIV infection. In V. DeVita, S. Hellman, & S. Rosenberg (Eds.), AIDS etiology, diagnosis, treatment and prevention (pp. 337-345). Philadelphia: Lippincott. Ownby, K. (1995). Management of the hematological manifestations of HIV infection and AIDS. Journal of the Association of Nurses in AIDS Care, 6(4), 9-15. Robinson, F. P., Mathews, H., & Witek-Janusek. (1999). Stress and HFV disease progression: A psychoneuroimmunological framework. Journal of the Association of Nurses in AIDS Care, 10(1), 21-31.

SYMPTOM MANAGEMENT IN HIV/AIDS

309

Ropka, M. E., & Williams, A. B. (Eds.). (1998). HIV nursing anaI symptom management (pp. 471-483). Sudbury, MA: Jones and Bartlett Publishers. Sanford, J., Gilbert, D., Moellering, R., & Sande, M. (1997). The Sanford guide to HIV/AIDS therapy. Vienna, VA: Antimicrobial Therapy. Schambelan, M., Sellmeyer, D., & Grunfeld, C. (1997). Endocrinologic manifestations of HIV infection. In M. Sande & P. Volberding (Eds.), The medical management of AIDS (pp. 257-267). Philadelphia: W. B. Saunders. Sharkey, S., Sharkey, K., Sutherland, L., & Church, D. (1992). Nutritional status and food intake in human immunodeficiency virus infection. Journal of Acquired Immune Deficiency Syndromes, 5, 1091-1098. Srnigelski, C. (1998, March). Vitamin and mineral supplements for HIV infection. In Supportive care nursing. Symposium conducted at the Bristol-Myers Squibb Oncology/Immunology Visiting Faculty Program, Miami, Florida. Sotrel, A., & LaGuardia, J. (1998). Pathology and pathogenesis of HIV-1 infections and other nervous system and skeletal muscle diseases associated with AIDS. In G. Wormser (Ed.), AIDS and other manifestations of HW infection (pp. 627-686). Philadelphia: Lippincott-Raven. Sowell, R., Lowenstein, A., & Spicer, T. (1998). Nursing perspectives in care of persons with HIV infection. In G. Wormser (Ed.), AIDS and other manifestations of HIV injection (pp. 785-798). Philadelphia: Lippincott-Raven. van Servellen, G., &: Aguirre, M. (1995). Symptoms, symptom management, and psychological morbidity among persons with HIV disease. AIDS Patient. Care, 9, 134-139. Whalen, C., Antani, M., Carey, J., & Landefeld, C. (1994). An index of symptoms of infection with human immunodeficiency virus: Reliability and validity. Journal of Clinical Epidemiology, 47(5), 537-546. W7ilcox, C., Schwartz, D., Cotsanis, G., & Thompson, S. (1996). Chronic unexplained diarrhea in human immunodeficiency virus infection: Determination of the best diagnostic approach, Gastroenterology, IJ0(30). World Health Organization Expert Committee. (1990). Cancer pain relief and. palliative care: Report of a WHO expert committee (Technical Report Series No. 804). Geneva, Switzerland: Author. Wormser, G.. & Horowitz, L. (1998). Care of the adult patient with HIV infection. In G. Wormser (Ed.), AIDS and other-manifestations of HIV infection (pp. 289-337). Philadelphia: Lippincott-Raven. Zegans, L., & Coates, T. (Eds.). (1994). Psychiatric manifestations of HIV disease. Psychiatric Clinics of North America. Philadelphia: W. B. Saunders.

This page intentionally left blank

7

The Medical Treatment of HIV Disease Susan L. Wightman and Michael K. Klebert

rarnatic advances in the medical treatment of HIV disease have been achieved since 1995. These advances resulted from a better understanding of HFV-1 pathogenesis, the development of new antiretroviral therapies, and the availability of newer methods to measure HIV in the blood. Fourteen drugs are approved to treat HIV-1 infection (see Table 7.1), with several new therapies under investigation in clinical trials. In an attempt to ensure that clinicians and all people with HIV have access to the most recent information, the National Institutes of Health periodically convenes a panel of experts to define the scientific basis of and provide guidelines for treating HIV disease. Much of this chapter will be based on the two most recently published documents that resulted from this process: "Report of the NIH Panel to Define Principles of Therapy of HIV Infection" and "Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents." The goal of this chapter is to assist nurses and their patients in understanding treatment options so that effective antiretroviral therapy is initiated before extensive and irreversible immune system damage occurs. Congruent with that objective, the appropriate use of antiretroviral drugs to suppress HIV replication will be reviewed as well as the importance of establishing patient-provider relationships to encourage patient

D

311

312

TABLE 7.1

THE PERSON WITH HIV/AIDS

Licensed Anti-HIV Drugs

Short name

Generic name

Brand name

Drug class

AZT 3TC d4T ddC ddl ABC SQV

Zidovudine Lamuvidine Stavudine Zalcitabine Didanosine Abacavir Saquinavir

NRTI NRTI NRTI NRTI NRTI NRTI

IDV NFV RTV AMP NVP DLV DMP

Indinavir Nelfinavir Ritonavir Amprenavir Nevirapine Delavirdine Efavirenz

Retrovir Epivir Zerit HMD Videx Ziagen Invirase/ Fortovase Crixivan Viracept Norvir Agenerase Viramune Rescriptor Sustiva

PI PI PI PI PI NNRTI NNRTI NNRTI

NRTI = nucleoside reverse transcriptase inhibitor PI = protease inhibitor NNRTI = non-nucleoside reverse transcriptase inhibitors Source: Adapted from Panel on Clinical Practices for Treatment of HIV Infection (1999).

adherence to complicated drug regimens. Because this is a rapidly evolving field of science, frequent updates are expected with respect to the availability of new agents or new information on the use of existing agents. Updates are available from the Centers for Disease Control and Prevention National AIDS Clearinghouse (800-4585231) and are posted on the World Wide Web's HIV INSITE (http://hivinsite.ucsf.edu/medical/). BACKGROUND HIV replication leads to immune system damage and progression to AIDS (Mellors et al., 1995). Antiretroviral therapy (ART), when used appropriately, offers HFV-infected persons the best chance of slowing or preventing irreversible disease progression (Saag et al., 1996). No clear threshold is known beyond which immune function loss is truly irreversible; therefore, ART should be initiated, whenever

THE MEDICAL TREATMENT OF HIV DISEASE

313

possible, before serious immunosuppression occurs (Connors et al, 1997). The primary goal of ART therapy is to completely suppress HIV replication in order to maintain normal immune function, improve the quality of life, and extend life. Highly active antiretroviral therapy (HAART), which is the current standard of care for HIV disease, is the most effective means to accomplish maximal viral suppression. HAART is typically the combination of a three-drug therapy that includes two NRTIs and one protease inhibitor or two NRTIs and one NNRTI. Prior to 1997, antiretroviral therapy was recommended only for those HFV-infected individuals with symptomatic HIV disease and/ or CD4+ T cell counts less than 500. Although there are impressive immunologic, virologic, and clinical responses seen with protease inhibitor-containing regimens initiated in moderately advanced disease, the restoration of CD4+ T cells typically is incomplete with respect to number and proportions of naive versus memory cells (Connors, 1997). VIRAL LOAD TESTS AND CD4+ T CELL COUNTS USED TO GUIDE CLINICAL PRACTICE The rate of HIV disease progression is directly related to the magnitude of viral replication (Mellors et al., 1997). Plasma HIV-1 RNA level (viral load) is the best measurement of the magnitude of viral replication, whereas CD4+ T cell counts indicate the extent of immune damage already suffered (Enger et al., 1996). Together, they provide important information about the virologic and immunologic status of the individual and the risk of disease progression to AIDS. Decisions about when to initiate therapy or when to change a treatment regimen should be based on the viral load, CD4+ T cell counts, and the individual's clinical status. The viral load measures the amount of HIV presumed to be actively replicating in the blood and is reported as the number of copies of HIV found per ml of plasma. Three different techniques are currently used to measure the amount of HIV RNA in plasma, but the Roche assay, often referred to as RT-PCR (quantitative polymerase chain reaction), is the only one with Federal Drug Adminis-

314

THE PERSON WITH HIV/AIDS

tration (FDA) approval, while the Organon and Chiron (branchedchain DNA; bDNA—about 50% lower results than PCR) assays are only available in clinical trials. The RT-PCR assay can quantify the RNA copy number between 400 and 500,000 copies per ml of plasma. Anything less than 400 is too low to be measured and is considered "undetectable" virus, but this does not imply that the virus has been eliminated. An "ultrasensitive" assay has been developed that lowers the limit of detection to around 40 copies per ml. Plasma viral load does not indicate the concentration of virus in lymphoid tissues and other body compartments. Several studies have indicated that viral load is closely linked to the risk of disease progression and illness (Mellors et al., 1995). Viral load testing is the essential parameter in decisions to initiate or change an tire troviral therapies. Measurement of plasma HIV RNA levels (viral load) should be included in the initial evaluation of a newly diagnosed HIV infection. The current recommendation of the Panel on Clinical Practices for Treatment of HIV Infection (1999) (referred to hereafter as "the Panel") is to monitor the viral load every 3 to 4 months in all patients and every time a switch in therapy is done. It is important to keep in mind that plasma HIV RNA levels obtained within the first 6 months of initial HIV infection do not accurately predict an individu al's risk of disease progression (Schacker, Hughes, Shea, & Corey, 1997). These levels may initially be high and will stabilize after approximately 6 to 9 months of initial infection and may remain fairly stable for months to years in many individuals. In addition, viral load tests should not be done during or after immunizations, acute infections, or tuberculin skin tests, as these can cause transient increases of viral load that may last for several weeks (NIH Panel to Define Principles of Therapy of HIV Infection, 1998). CD4+ T cell counts should also be measured at the time of diagnosis and generally every 3 to 6 months thereafter, according to the individual circumstances. A normal CD4+ T cell count is 800 to 1,200 cells/mm3. When the CD4+ T cell count drops below 200, the risk of opportunistic infections increases dramatically. Baseline viral load and CD4+ T cell counts should be measured on two occasions (within 1 to 2 weeks of each other) to ensure accuracy of measurement before initial treatment decisions are made (Saag et al., 1996).

THE MEDICAL TREATMENT OF HIV DISEASE

315

Testing viral load is recommended immediately prior to and again at 4 weeks after initiation of or changes to antiretroviral therapy. This time frame allows the clinician to evaluate the initial effectiveness of drug therapy, since most individuals adhering to a potent antiretroviral regimen should have a large decrease (> 10-fold or 1 Iog10) in viral load by 2 to 8 weeks (Panel, 1999). If response is less than desirable, the Panel suggests that the clinician reassess the individual for adherence, rule out malabsorption, consider repeat viral load testing, and consider a change in drug regimen. Viral load testing should be repeated every 3 to 4 months or during a clinical event or decline in CD4+ T cells in order to evaluate the continuing effectiveness of therapy. Viral loads should be undetectable after 6 months of optimal therapy. Interpreting the results of viral load must be done with caution: The intrassay variability is approximately 0.2 log and the biologic variability of the tests is approximately 0.3 log; therefore, sustained changes in the plasma HIV RNA levels > 0.5 log (i.e., greater than three-fold) are considered significant. One isolated value is difficult to interpret. Tests should be repeated using the same method, as comparison of results between different methods is not valid. WHEN SHOULD THERAPY BE STARTED? The question of when to begin treatment is very difficult to answer. Decisions to begin treatment should be individualized, taking into account the risk of disease progression (HIV RNA level) and the degree of immunodeficiency (CD4+ T cell count). No study has determined specifically when is the best time to start. It is believed that initiating triple-drug combination treatment as early as possible offers the best chance for total and long-lasting virologic response. This should be balanced, however, against the side effects and the impact on quality of life of that therapy. It seems reasonable that the sooner therapy is started, the more likely the immune system of the individual is going to be protected from the progressive damage of ongoing viral replication. However, no long-term benefit has yet been demonstrated in individuals with more than 500 CD4+ T cells. While clinical benefits of combination therapy with two nucleoside analogues have been demonstrated for HIV-infected individuals with

316

THE PERSON WITH HIV/AIDS

advanced HIV disease and immunosuppression (less than 500 CD4+ T cells/mm3), there is only theoretical benefit to treating individuals with more than 500 CD4+ T cells. Adding a protease inhibitor to the combination of nucleoside analogues has been shown to decrease the risk of death and opportunistic infections by more than 50% in individuals with less than 200 CD4+ T cells (Hammer et al., 1997). The decision to begin therapy is complex and must include careful counseling and education to enable the individual to make a choice based on the benefits and risks of initiating treatment (see Table 7.2). Factors that the physician and asymptomatic individual must consider in deciding when to initiate therapy include (1) willingness of the individual to begin therapy; (2) the degree of existing immunodeficiency; (3) the risk of disease progression as determined by the level of plasma HIV RNA; (4) the potential benefits and risks of initiating therapy in asymptomatic individuals; and (5) the likeli-

TABLE 7.2 Potential Risks and Benefits of Early Initiation of Antiretroviral Therapy in the Asymptomatic HIV-lnfected Patient Potential benefits Control of viral replication and mutation Reduction of viral burden Prevention of progressive immunodeficiency; potential maintenance or reconsti tution of a normal immune system Delayed progression to AIDS and prolongation of life Decreased risk of selection of resistant virus Decreased risk of drug toxicity Possible decreased risk of viral transmission Potential risks Reduction in quality of life from adverse drug effects and inconvenience of current maximally suppressive regimens Earlier development of drug resistance Transmission of drug-resistant virus Limitation in future choices of antiretroviral agents due to development of resistance Unknown long-term toxicity of antiretroviral drugs Unknown duration of effectiveness of current antiretroviral therapies Source: Adapted from Panel (1999).

THE MEDICAL TREATMENT OF HIV DISEASE

317

hood, after counseling and education, of adherence to the prescribed treatment regimen (Panel, 1997). Table 7.3 summarizes the Panel recommendations for the initiation of ART. In general, all individuals with symptoms of HIV disease or AIDS should be treated regardless of HIV RNA or CD4+ T cell count. Any asymptomatic individual with more than 20,000 (RTPCR) copies of HIV RNA/ml of plasma or less than 500 CD4+ Tcells/mm 3 are at risk of disease progression and should be offered therapy. However, due to the complexities of the treatment regimens and risk of drug resistance due to nonadherence to the regimen, any recommendation for therapy should be based on the readiness of the individual for treatment (Panel, 1999). If the risk of disease progression is low, one may benefit from delaying treatment. New drugs are in development, and new information is continuously evolving about how to use the currently available drugs. Many experts will delay ART in persons with CD4+ T cells > 500/mm3 and HIV RNA less than 20,000 (RT-PCR) but will continue to observe clinical status along with monitoring viral load and CD4+ T cell counts every 3 months. Although it is not currently recommended to initiate ART in this population, some experts will take

TABLE 7.3

Guidelines for Treatment Initiation

Status/CD4+ T cell count and HIV RNA

Recommendation

Symptomatic HIV disease (AIDS, thrush, unexplained fever) CD4+ T cells/RNA any value

Treat

Asymptomatic CD4+ T cells < 500/mm3 or HIV RNA > 10,000 (bDNA) or > 20,000 (RT-PCR)

Treatment should be offered

Asymptomatic CD4+ T cells > 500/mm3 and HIV RNA < 10,000 (bDNA) or < 20,000 (RT-PCR)

Many experts would delay therapy and observe; however, some experts would treat

Source: Adapted from Panel (1999).

318

THE PERSON WITH HIV/AIDS

a therapeutically aggressive approach and treat the individual if any HIV RNA is detected. Others will initiate ART if the HIV RNA is greater than 5,000 to 10,000 copies. Both approaches to initiating ART in the asymptomatic patient are acceptable. In all cases an inexperienced clinician must keep in mind that this is a complex and rapidly evolving field requiring the consultation of clinicians with experience in treating HIV-infected persons. Health care workers should keep in mind the two distinct approaches to initiation of treatment and the rationale for each. They should keep in mind that the ability to maintain long-term adherence to a complex treatment regime is a major challenge, especially in asymptomatic patients at an early stage of disease (Carpenter et al., 1997). Drugs must be taken as prescribed, probably for life. Failure to do so may result in drug-resistant virus, the major obstacle to the long-term efficacy of antiretroviral therapy. However, drug resistance can be delayed or possibly prevented by the proper use of potent agents to suppress HIV replication. Once the decision to initiate treatment is made by the individual and clinician, treatment should be aggressive with the goal of therapy to completely suppress viral replication to undetectable viral levels or at least less than 5,000 copies. If viral replication is completely suppressed, resistance to therapy is less likely to develop and the benefits of therapy could be sustained over time. New and aggressive regimens continue to be tested in ongoing clinical trials through the national AIDS Clinical Trials Group (ACTG) Network. These trials offer an option to individuals to be treated in a very controlled environment with close monitoring of health status and virologic end points.

RESISTANCE AND ADHERENCE Treatment for HIV infection cannot be fully discussed without addressing two very important components: viral resistance to drug therapy and adherence to a treatment regimen. A key element in HIVpathogenesis is the rapid level of productive infection characterized by a high rate of virus turnover. Current estimates suggest that at least 10 billion HIV particles are produced and destroyed each

THE MEDICAL TREATMENT OF HIV DISEASE

319

day and that the plasma virus half-life is about 6 hours (Ho et al., 1997). The high rate of viral replication and the ability of HIV to reorganize its amino acid chain lead to the rapid emergence of drugresistant virus, the primary reason for the loss of antiretroviral activity. The development of resistance is greatly increased after incomplete suppression of HIV replication due to inadequate treatment or interruptions in treatment (Katzenstein, 1997). Resistance can be delayed by the use of potent combination regimens that drive HIV RNA levels below the level of detection. Genotype testing is available to test for drug sensitivity; however, the utility of these tests is under clinical investigation. If viral load begins to climb following a decline, resistance to drug therapy must be suspected. In order for antiretrovirals to be effective, and to minimize the risk of resistance, it is important that these drugs be prescribed and taken in accordance with the products' approved labeling. Underdosing, nonadherence, or partial adherence with dosing regimens for these drugs may result in the development of resistant strains of HIV that will not be susceptible to treatment. Scrupulously following prescribed directions for protease inhibitors appears to have more clinical importance than with the nucleoside analogues. The implications for the development of drug resistance extend beyond the loss of treatment efficacy and include transmission of HIV that is resistant to therapy. Data already suggest transmission of resistant virus with 16% of all newly diagnosed HIV infections resistant to AZT and 2% to 3% resistant to 3TC. Although adherence to treatment regimens is not a new challenge for patients and their caregivers, the term has surfaced in more recent years to describe a patient's actions relative to medications or therapy. It is preferred over the previously coined term compliance, as its meaning more accurately reflects a person's actions: to be consistent; to hold fast, be attached or stick to steady or faithful attachment (from Webster's Third Neiv International Dictionary, 1994). Patients with HIV infection experience a great challenge of adhering to potent combination antiretroviral regimens. Currently available, effective antiretroviral therapy regimens require that patients take multiple medications that may have specific dietary requirements, storage and handling conditions, and different dosing schedules at specific times of the day. When combined with additional medica-

320

THE PERSON WITH HIV/AIDS

tions for treatment or prophylaxis of opportunistic infections or other HFV-related conditions, the number of pills can easily exceed 25 per day. This complicated regimen is difficult for even the most serious individual. Persons with unstable living situations or limited social support may have particular difficulty adhering to the recommended antiretroviral therapy regimens. The most frequent cause, however, for nonadherence is the individual 'just forgets the pills," which is seen most frequently in the asymptomatic individual. Adherence is so critically linked to resistance that if circumstances impede adherence to the most effective treatment regimens now available, therapy is unlikely to be of long-term benefit to the individual. If resistance occurs to one or more drugs in an individual's regimen, the drug combination may lose its ability to suppress HIV replication and decrease viral load. As a result, therapy may fail (NIH, 1998). Clinicians and patients must understand that treatment is truly complex, with considerations of drug interaction, adverse reactions, resistance, cross-resistance, monitoring, treatment failure, and determining which options are available when treatment fails. Patients must be aware of the need to take the complete dose on schedule to lessen the risk of potential drug resistance. Patients should be cautioned against modifying dosages in any way to "expand" their prescription. Decisions made by health care practitioners and HPV-infected clients regarding initiation of ART should be guided not only by the client's plasma HIV RNA level and CD4+ T cell count, but also by the client's readiness and understanding of the implications of initiating therapy. The combination of antiretroviral drugs used when therapy is initiated or changed needs to be carefully chosen since it will influence all future therapy options due to potential cross-resistance. Each of the antiretroviral drugs used in combination therapy should always be used according to optimum schedules and dosages. The use of combinations of potent antiretroviral drugs to maximally suppress HIV replication provides the best approach to avoid the inherent tendency of HIV to generate drug-resistant variants. Clinicians must help individuals understand that adherence is the most critical factor for the success of therapy. Nurses can play a crucial role in helping clients adhere to complex treatment regimens. Adherence can be promoted through extensive patient educa-

THE MEDICAL TREATMENT OF HIV DISEASE

321

tion about the goals and rationale for therapy before it is initiated. Expert clinicians believe it is better to evaluate, counsel, and educate clients extensively before the initiation of ART, even if it means a limited delay in initiating treatment. Clinicians and patients can do more harm than good if antiretroviral therapy is initiated before the patient is ready and thus is not adherent to taking the drugs as prescribed. Should antiretroviral drug resistance develop as a result of underdosing or irregular dosing of antiretroviral drugs, subsequent administration of drugs on a regular schedule is unlikely to accomplish effective suppression of HIV replication (NIH, 1998). Furthermore, if clinicians do not fully understand the lack of adherence of their patients, they may mistakenly believe that higher viral loads are due to drug failure as opposed to the patient's not taking the drugs as prescribed. In these situations, a physician may prescribe a completely different drug regimen based on inaccurate information, further limiting future choices. Nurses, counselors, case managers, social workers, and other health care providers must work with HlV-infected clients to assess if they are ready and able to commit to a regimen of antiretroviral therapy. Because health care providers are not always able to predict accurately who will be adherent, caution should be taken to avoid making generalizations about populations or any specific group of people. Such assessment should be made on an individual basis. Chesney (1997) explains that adherence to a drug regimen involves a sequence of complex cognitive and behavioral skills. Interventions to help clients adhere to treatment range from simple to complex. As noted by Chesney, adherence involves not only following a drug regimen but also remaining in treatment, in clinical trials, and in the health care system. More realistic strategies to help patients learn to integrate behaviors to enhance adherence to a drug regimen are listed in Table 7.4. Tools that may improve adherence include flexibility and individualization of the therapeutic regimen; education about potential and expected side effects; positive reinforcement; and support from family members, the community, and other health care providers (Williams & Friedland, 1997). The creative use of tools and reminders such as pagers, voice messages, watch alarms, pillboxes, and calendars mav also be of value.

322

TABLE 7.4

THE PERSON WITH HIV/AIDS

Strategies for Improving Adherence to ART

Clarify the regimen Self-monitor adherence with a personalized diary Tailor the regimen to individual lifestyles Facilitate interaction with clinic staff Identify and remove personal barriers to adherence Refer patients with special needs Enhance self-efficacy Create a social environment conducive to adherence Source: Adapted from Chesney (1997).

ANTIRETROVIRAL AGENTS There are currently two classes of antiretroviral drugs: reverse transcriptase inhibitors (RTI) and protease inhibitors (PI). The classes refer to the type of replication inhibition that each induces. The first class of antiretroviral drugs licensed was the reverse transcriptase inhibitors. These drugs interfere with reverse transcriptase, a necessary enzyme critical in transcribing RNA into DNA within the HIV replication cycle. RTIs are further broken into two classes: nucleoside RTIs (NRTIs) (see Table 7.5) and nonnucleoside RTIs (NNRTIs) (see Table 7.6). Nucleoside inhibitors bind to viral DNA, preventing reverse transcription. NNRTIs attach themselves directly to reverse transcriptase downstream from the catalytic site, disrupting the completion of the DNA chain. Both RTIs share a common antiretroviral effect by inhibiting the HIV enzyme reverse transcriptase. Licensed Ms include zidovudine, didanosine, zalcitabine, stavudine, abacavir, and lamivudine. Licensed nonnucleoside inhibitors include nevirapine, efavirenz, and delavirdine. Protease inhibitors are medications that inhibit the HIV protease enzyme, thereby preventing cleavage and release of mature, infectious viral particles. Five Pis (saquinavir, ritonavir, indinavir, amprenavir, and nelfinavir) have been approved by the FDA, and others are in development. Cross-resistance between RTIs and Pis is nonexistent since the enzyme targets are different. However, NNRTIs significantly alter levels of Pis when they are prescribed together; therefore, the use of these two classes simultaneously should be done cautiously.

TABLE 7.5

At a Glance—Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Abacavir (1592U89)

Generic name

Zidovudine (AZT, ZDV)

Didanosine (ddl)

Zalcitabine (ddC)

Stavudine (d4T)

Lamivudine (3TC)

Trade name

Retrovir

Videx

HIVID

Zerit

Epivir

Dosing recommendations

200 mg tid or 300 mg bid or with 3TC as Combivir one bid

> 60 kg: 200 mg bid < 60 kg: 125 mg bid

0.75 mg tid

> 60 kg: 40 mg bid < 60 kg: 30 mg bid

150 mg bid < 50 kg: 2 mg/ kg bid

300 mg bid

Food effect

Take without regard to meal

Levels decrease 55%. Take 1/2 hour before or 1 hour after meal

Take without regard to meals

Take without regard to meals

Take without regard to meals

Take without regard to meals Alcohol increases abacavir levels 41%; no effect on alcohol

Oral bioavailability

60%

Tablet: 40% Powder: 30%

85%

86%

86%

83%

(continued)

TABLE 7.5

(continued)

Generic name

Zidovudine (AZT, ZDV)

Didanosine (ddl)

Zalcitabine (ddC)

Stavudine (d4T)

Lamivudine (3TC)

Trade name

Retrovir

Videx

HMD

Zerit

Epivir

Serum half-life Intracellular halflife Elimination

1.1 hour 3 hours

1.6 hour 25-40 hours

1 .2 hour 3 hours

1.0 hour 3.5 hours

3-6 hours 12 hours

1 .5 hours 3.3 hours

Metabolized to AZT glucuronide (GAZT); renal excretion of GAZT Bone marrow suppression: anemia and/or neutropenia; subjective complaints: Gl intolerance, headache, insomnia, asthenia

Renal excretion 50%

Renal excretion 70%

Renal excretion 50%

Renal excretion unchanged

Renal excretion of metabolites 82%

Pancreatitis; peripheral neuropathy; nausea; diarrhea

Peripheral neuropathy; stomatitis

Peripheral neuropathy

Allergic-type reaction with rash and fever, nausea, headache, asthenia, diarrhea, insomnia, dizziness, vomiting, and pain

Nausea, fever, rash, malaise, fatigue, vomiting, pain and rash, decreased serum carnitine*

Adverse events

Abacavir (1592U89)

NA = Not available "Patients who develop signs and symptoms of hypersensitivity should discontinue abacavir as soon as hypersensitivity reaction is suspected. Abacavir should not be restarted because more severe symptoms will recur within hours and may include life-threatening hypertension and death. Source: Panel (1999).

TABLE 7.6

At a Glance-Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Generic name

Nevirapine

Delavirdine

Efavirenz

Trade name

Viramune

Rescriptor

Sustiva

Form

200 mg tabs

100 mg tabs

50, 100, 200 mg capsules

Dosing recommendations

200 mg po qd x 14 days, then 200 mg po bid

400 mg po tid or (Four 100 mg tabs in > 3 oz water to produce slurry). Separate dosing with ddl or antacids by 1 hour

600 mg po HS

Food effect

Take without regard to meals

Take without regard to meals

Avoid taking after high fat meals. Levels increase 50%

Oral bioavailability

> 90%

85%

NA

Serum half-life

25-30 hours

5.8 hours

40-55 hours

Elimination

Metabolized by cytochrome p450; 80% excreted in urine (glucuronidated metabolites, < 5% unchanged), 10% in feces

Metabolized by cytochrome p450; 51% excreted in urine (< 5% unchanged), 44% in feces

Metabolized by cytochrome p450; 14-34% excreted in urine; 16-61% in feces

(continued)

TABLE 7.6

(continued)

Generic name

Nevirapine

Delavirdine

Efavirenz

Trade name

Viramune

Rescriptor

Sustiva

Drug interactions

Induces cytochrome p450 enzymes

Inhibits cytochrome p450 enzymes

Induces the CYP3A pathway

The following drugs have suspected interactions that require careful monitoring if coadministered with nevirapine: rifampin, rifabutin, oral contraceptives, protease inhibitors, triazolam, and midazolam

Not recommended for concurrent use: terfenadine, astemizole, alprazolam, midazolam, cisapride, rifabutin, rifampin, triazolam, ergot derivatives, amphetamines, nifedipine, anticonvulsants (phenytoin, carbamazepine, phenobarbitol) Delavirdine increases levels of clarithromycin, dapsone, quinidine, warfarin, indinavir, saquinavir Antacids and didanosine: separate administration by > 1 hour Rash, headaches

May reduce indinavir levels

Adverse events NA = Not available Source: Panel (1999).

Rash, increased transaminase levels, hepatitis

Lightheadedness, dizziness, rash, teratogenic in monkeys

THE MEDICAL TREATMENT OF HIV DISEASE

327

Nucleoside Reverse Transcriptase Inhibitors (NRTI) Zidovudine (AZT, Retrovir) was the first antiretroviral medication approved for use against HIV. A pivotal study in 1987 indicated prolonged survival and reduced opportunistic infections with zidovudine use (Fischl et al., 1987). Zidovudine inhibits the HIV enzyme reverse transcriptase, causing premature viral DNA chain termination. Zidovudine is rapidly absorbed with peak serum concentrations occurring within one half hour to 90 minutes and a serum half-life of 3 hours. Due to first-pass metabolism, the average oral bioavailability is 60% to 65%. CNS penetration is 60% of serum levels. The pharmacokinetics of AZT in children 6 months through 12 years of age are similar to those observed in adult patients (Facts and Comparisons, 1999). Granulocytopenia and anemia are the most frequent hematologic adverse events in adult and pediatric patients. Platelet count can be both increased arid decreased by AZT. Nausea, severe headache, insomnia, and myalgia occur in at least 5% of patients. Hepatomegaly with steatosis, hepatitis, pancreatitis, lactic acidosis, sensitization reactions, hyperbilirubinemia, vasculitis, and seizures are rare reactions (Facts and Comparisons, 1999). Concomitant ganciclovir or interferon alpha therapy has resulted in hematologic toxicity. Probenecid may increase zidovudine levels by inhibiting glucuronidation and/or by reducing renal excretion. Some patients on concomitant probenecid therapy have developed flulike symptoms consisting of myalgia, malaise, and/or fever and maculopapular rash. Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine. In methadone maintenance patients the zidovudine blood levels increased without any adverse clinical effects. Atovaquone decreased zidovudine clearance by 24% in HFV-infected patients, resulting in a small increase in plasma zidovudine with no clinically significant effects noted. Neurotoxicity has been reported in one case following concomitant acyclovir. Valproic acid decreased the urinary excretion ratio of zidovudine and its primary metabolite without affecting zidovudine plasma half-life; however, this interaction may increase zidovudine bioavailability and these patients should be monitored for possible zidovudine-related adverse effects. Lamivudine (3TC) is safely administered in conjunction with zidovudine. Caution should be ob-

328

THE PERSON WITH HIV/AIDS

served with drugs that affect the renal excretion or hepatic blood flow and decrease clearance. Drugs that are nephrotoxic, cytotoxic, or myelosuppressive (e.g., amphotericin B, co-trimoxazole, dapsone, doxorubicin, flucytosine, interferon, pentamidine, vinblastine, vincristine) should be used with caution during zidovudine therapy (Facts and Comparisons, 1999). Adults typically receive zidovudine 600 mg per day in divided doses, usually bid. Pediatric dosing for children between 3 and 12 years of age is 180 mg/m2. This dosing should not exceed 200 mg every 6 hours. Pregnant women beyond 14 weeks gestation should receive 100 mg five times a day. While in labor the woman should receive intravenous zidovudine 2 mg/kg (total body weight) over 1 hour, then a continuous infusion of 1 mg/kg per hour until the umbilical cord is tied. The neonate should receive 2 mg/kg of oral zidovudine within 12 hours of birth and every 6 hours through the sixth week of birth. Infants unable to swallow at birth may be given zidovudine intravenously 1.5 mg/kg over 30 minutes every 6 hours (Facts and Comparisons, 1999). Dosing is altered for significant anemia (> 25% decrease from baseline values) and/or significant neutropenia (> 50% decrease from baseline). The drug may be withheld pending resolution of bone marrow suppression. For less severe anemia or neutropenia, dose reduction may be instituted. Transfusion may be necessary for more severe anemia. Persons in end-stage renal disease on dialysis should be dosed at 100 mg every 6 to 8 hours (Facts and Comparisons, 1999). Didanosine (ddl, Videx) is rapidly absorbed but is affected by acidic conditions. Optimal bioavailability is achieved by dosing 30 minutes to 1 hour before meals. Tablets achieve 40% bioavailability and the powder formulation achieves 30% bioavailability. The intracellular half-life of the drug is 12 hours. The metabolism of ddl is not understood. It is presumed that the drug is metabolized like endogenous purines. Renal excretion accounts for 50% of the drug (Facts and Comparisons, 1999). The most serious side effect of ddl is pancreatitis, which has been fatal in some cases. The use of didanosine in patients with prior histories of pancreatitis, alcohol consumption, or hypertriglceridemia is not recommended. The incidence of pancreatitis is between 2% and 9% and dose related. In patients complaining of abdominal

THE MEDICAL TREATMENT OF HIV DISEASE

329

pain, nausea, vomiting, and elevated amylase and lipase levels, didanosine should be held until the diagnosis of pancreatitis is excluded. Peripheral neuropathy was reported in 17% to 20% of the patients in AIDS Clinical Trials Group (ACTG) protocols 116A and 116B/ 117 and is the most common dose-limiting toxicity with this drug. Peripheral neuropathy is more common in persons with prior histories of peripheral neuropathy and among those receiving neurotoxic medications. Symptoms include tingling, burning, or aching in the lower extremities, particularly the feet. Onset is typically mild but can become quite painful. Interruption of therapy usually results in gradual diminution of symptoms over several weeks. Other adverse events seen with didanosine include diarrhea and gastrointestinal discomfort. Didanosine also contains 36.5 mg of phenylalanine per tablet (Facts and Comparisons, 1999). Caution should be used in the administration of didanosine with neurotoxic medications as well as medications associated with pancreatic disease. Medications that require an acidic environment to work or be absorbed should be taken 2 hours before or after didanosine administration. Examples of these types of drugs include dapsone, ketoconazole, and ranitidine. Delavirdine should be taken 1 hour before didanosine (Facts and Comparisons, 1999). The current dosing pattern of ddl is every 12 hours. The dose is based on weight. Individuals weighing more than 60 kg should receive 200 mg tablets or 250 mg buffered powder bid. Persons weighing less than 60 kg should receive 125 mg (100 mg + 25 nig) tablets or 167 mg buffered powder bid. Pediatric formulations are constituted by pharmacists to produce either a 20 mg/ml or a 10 mg/ml oral solution. Tablets should be chewed thoroughly with frequent sips of water or thoroughly crushed and dissolved in at least 4 oz of water before consumption. Powder is mixed with approximately 4 oz of drinking water, stirred to mix completely (2 to 3 minutes), and consumed immediately (Facts and Comparisons, 1999). Resistance to didanosine is at the amino acids 174 and ml84. Hydroxyurea (Hydrea) is an antineoplastic agent that shows promise when combined with ddl. The cytotoxic effects of this drug when used as a cancer treatment may be due to immediate inhibition of DNA synthesis sparing synthesis of ribonucleic acid or of protein (Facts and Comparisons, 1999). Hydroxyurea is thought to allow the increased uptake of nucleoside analogues. Trials of this drug in

330

THE PERSON WITH HIV/AIDS

combination with ddl and other nucleosides are ongoing. Hydroxyurea is dosed at 500 mg bid. The major toxicity of this drug is bone marrow suppression (leukopenia, anemia, and thrombocytopenia). Gastrointestinal symptoms of stomatitis, anorexia, nausea, vomiting and constipation as well as rash are less common (Facts and Comparisons, 1999). Zalcitabine (ddC, HTVID) bioavailability is 80% when administered on an empty stomach and drops to 39% when administered with food. The serum half-life is 1.2 hour. The intracellular half-life is 3 hours. CNS penetration is 20% of serum levels. Zalcitabine is largely excreted (70%) via the renal system (Facts and Comparisons, 1999). Adverse effects seen with Zalcitabine include peripheral neuropathy, pancreatitis, hepatic toxicity, and stomatitis. In patients complaining of abdominal pain, nausea, and vomiting with elevated amylase and lipase levels zalcitabine should be held until the diagnosis of pancreatitis is excluded. Peripheral neuropathy has been seen in 30% to 33% of patients with advanced HIV disease receiving zalcitabine. Peripheral neuropathy is more common in persons with prior histories of peripheral neuropathy and among those receiving neurotoxic medications. Symptoms include tingling, burning, or aching in the lower extremities, particularly the feet. Onset is typically mild but can become quite painful. Interruption of therapy usually results in gradual diminution of symptoms over several weeks. Oral ulcers of a severe nature occur in up to 3% of persons taking the drug. Probenicid and cimetidine both increase levels of zalcitabine when administered together. Maalox decreases absorption and metaclopromide, within 4 hours of dosing, decreases bioavailability by 10%. In persons with renal impairment, zalcitabine should be administered with care due to decreased drug clearance (Facts and Comparisons, 1999). The usual dose for adults is 0.75 mg administered orally three times a day. The recommended zalcitabine dose reduction for impaired renal function is based on creatinine clearance rate. Creatinine clearance (Crcl) rates of 10 to 40 ml/min warrant 0.75 mg bid, while Crcl rates < lOml/min would take 0.75 mg once a day. The safety and effectiveness of zalcitabine has not been established in children, neonates, or pregnancy (Facts and Comparisons, 1999).

THE MEDICAL TREATMENT OF HIV DISEASE

331

Stavudine (d4T, Zerit) oral bioavailability is 86%. Its serum halflife is 1 hour. The intracellular half-life is 3.5 hours. CNS penetration is approximately 30% to 40% of serum values. The metabolism of stavudine is not well understood. Renal excretion accounts for 50% of the drug (Facts and Comparisons, 1999). The major clinical toxicity of stavudine is peripheral neuropathy occurring in 19% to 24% of patients with advanced disease and about 13% of patients with less advanced disease. Symptoms include tingling, burning, or aching in the lower extremities, particularly the feet. Onset is typically mild but can become quite painful. Interruption of therapy usually results in gradual diminution of symptoms over several weeks (Facts and Comparisons, 1999). In ACTG 290 stavudine added to a zidovudine regimen demonstrated no increase in CD4+ T cells and by 36 weeks an average drop of 57 cells/mm3 compared to baseline. This apparent antagonism argues against combining the drugs. Dose and administration of stavudine is based on weight. Persons weighing > 60 kg should receive 40 ing orally bid. Persons weighing < 60 should be dosed at 30 mg orally bid. Dosing should be as close to 12 hours apart as possible but may be taken without regard to food intake. The recommended starting dose for pediatric patients weighing more than 30 kg is identical to adult dosing. Pediatric patients weighing less than 30 kg should receive 2 mg/kg/day (Facts and Comparisons, 1999). Lamivudine (3TC, Epivir) is labeled for use in combination with zidovudine against HIV infection. Lamivudine is rapidly absorbed, achieving oral bioavailability at 86%. The serum half-life is 3 to 6 hours. The intracellular half-life is 12 hours. CNS penetration is 10% of serum levels (Facts and Comparisons, 1999). Lamivudine is generally well tolerated with minimal toxicity. In clinical trials that combined lamivudine and zidovudine against zidovudine controls, the additive toxicity of lamivudine was negligible. Nausea, anorexia, cramping, and headache were reported more frequently in the combination group (Facts and Comparisons, 1999). Lamivudine is typically dosed at 150 mg orally every 12 hours in combination with zidovudine for individuals over the age of 12. Adults weighing < 50 kg are dosed at 2 mg/kg twice daily. The dose for pediatric populations 3 months to 12 years of age is 4 mg/

332

THE PERSON WITH HIV/AIDS

kg orally twice a day in combination with zidovudine (Facts and Comparisons, 1999). Combivir is a new FDA-approved combination drug consisting of zidovudine 300 mg and lamivudine 150 mg. The drug is prescribed at one tablet by mouth twice a day. The profile of this drug is identical to the profile of its constituents. Abacavir (Ziagen) is recently licensed nucleode inhibitor. Abacavir is dosed at 300 mg bid and is associated with mild rash and GI symptoms. Abacavir has been associated with fatal hypersensitivity reactions. Clinicians are advised to discontinue abacavir in patients developing signs of hypersensitivity reaction and to avoid restarting the drug following such a reaction (Panel, 1999).

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) Nevirapine (Viramune), a nonnucleoside reverse transcriptase inhibitor, is rapidly absorbed with > 90% oral bioavailability. The serum half-life of the drug is between 25 and 30 hours. Nevirapine readily crosses the blood-brain barrier with about 45% of serum levels available. Nevirapine is hepatically metabolized by the cytochrome P450 system, the same enzyme that metabolizes many other drugs, including the protease inhibitors. Eighty percent of nevirapine is excreted in the urine and 10% in feces (Facts and Comparisons, 1999). The most common clinical toxicity of nevirapine is rash, occurring in about 17% to 37% of patients in clinical trials. Severe or lifethreatening rashes were seen in 7.6% of patients, and about a quarter of these required hospitalization. Rashes are usually mild to moderate, presenting as maculopapular erythmatous eruptions most often found on the chest, back, face, and extremities. Most rashes occur in the first 28 days of therapy (Facts and Comparisons, 1999). Caution is urged with the administration of nevirapine to patients taking rifampin, rifabutin, or oral contraceptives and protease inhibitors (Facts and Comparisons, 1999). Dosing of nevirapine is designed to minimize the incidence of rash. The typical recommendation for adults is 200 mg orally once a day for 14 days, then escalating to 200 mg orally bid. The use of nevirapine in pediatric, neonatal, and pregnant populations is not yet known (Facts and Comparisons, 1999).

THE MEDICAL TREATMENT OF HIV DISEASE

333

Delavirdine (Rescriptor) was licensed in April 1997 as a combination agent with other antiretroviral agents. Delavirdine is rapidly absorbed with 85% of the drug bioavailable. Serum half-life is 5.8 hours. CNS penetration is poor. The cytochrome P450 system and possibly the CYP2D6 hepatically metabolize Delavirdine. Fifty-one percent is excreted in the urine and 44% in the feces (Facts and Comparisons, 1999). The most common clinical toxicity seen is rash developing in about 18% to 50%) of clinical trial participants. The rash is usually diffuse, maculopapular, erythmatous, and often pruritic. Severe rash occurred in 3.6% of clinical trial participants. In most instances, the rash occurred within the first 3 weeks of therapy in persons with lower CD4+ T cell counts. The rash typically lasts less than 2 weeks and does not require dose modification or discontinuation of delavirdine. The rash is usually confined to the trunk and upper extremities (Facts and Comparisons, 1999). Several drugs are contraindicated for administration with delavirdine. These include terfanidine, astemizole, alprazolam, midazolam, cisapride, rifabutin, and rifampin. Drugs that decrease delavirdine blood levels include phenytoin, rifabutin, rifampin, carbamazepine, and phenobarbitol. Delavirdine increases the levels of clarithromycin, dapsone, rifabutin, ergot alkaloids, dihydropyrides, quinidine, warfarin, indinavir, and saquinavir (Facts and Comparisons, 1999). Antacids and ddl can both reduce absorption of delavirdine and should both be dosed at least an hour apart (Morse et al., 1997). Dosing is 400 mg orally three times a day. Food plays no part in absorption. The drug currently has no indications for patients under the age of 16 or pregnant or nursing mothers (Facts and Comparisons, 1999). Efavirenz (Sustiva) is a NNRTI approved for combination with other antiretroviral medications. Efavirenz induces CYP3A metabolism that decreases the blood levels of indinavir and saquinavir. It increases the levels of nelfmavir. The half-life of efavirenz is 40 to 50 hours, allowing for once a day dosing at 600 mg orally. There have been reports of delusions and inappropriate behavior mostly seen in patients with a history of mental illness or substance abuse. Severe acute depression has been reported in a few cases. Close monitoring of these patients is recommended. Additionally, about 52% of patients beginning efavirenz experience CNS and psychiatric

334

THE PERSON WITH HIV/AIDS

symptoms including dizziness, impaired concentration, abnormal dreams, somnolence and insomnia (Facts and Comparisons, 1999). Bedtime dosing or dosing at 300 mg bid is recommended to minimize CNS side effects (Rozenbaum, 1997).

PROTEASE INHIBITORS Protease inhibitors comprise the second class of antiretroviral drugs (see Table 7.7). The most potent antiretroviral weapons to date, protease inhibitors are also most prone to the rapid development of resistant HIV viral strains, are associated with drug-specific intolerance, and penetrate poorly into the CNS. The effects of protease inhibitors have been most dramatic when combined with other antiretrovirals, specifically RTIs. The protease inhibitors are partially metabolized by the cytochrome P450 oxidase system and have a potential for serious interactions with a large number of commonly prescribed drugs metabolized by the same pathway. Saquinavir (Invirase, Fortovase) was the first protease inhibitor licensed by the FDA. The first formulation of saquinavir, Invirase, was hampered by poor bioavailability at 4%. The use of Invirase is only indicated with ritonavir (Panel, 1999). The new formulation Fortovase provides about 40% bioavailability. Bioavailability is optimal when taken with a high-fat meal. Saquinavir has poor CNS penetration. The serum half-life of the drug is 1 to 2 hours. The route of metabolism is via the biliary P450 cytochrome 3A4 system (Facts and Comparisons, 1999). Adverse effects of saquinavir are usually mild. Side effects most commonly reported include diarrhea, nausea and vomiting, headache, and elevations of transaminase enzymes (Facts and Comparisons, 1999). Because saquinavir inhibits cytochrome P450, drugs metabolized via the same mechanism are likely to cause alterations in metabolism of the drug. Ritonavir, another protease inhibitor, extensively inhibits the metabolism of saquinavir, increasing plasma levels (up to 20 times). This fact has been exploited by some in an effort to enhance antiretroviral regimens. Ketoconazole also increases saquinavir levels about three times. Grapefruit juice also increases saquinavir levels. Additionally, rifampin, rifabutin, phenobarbitol, phenytoin, dexa-

TABLE 7.7

At a Glance—Protease Inhibitors (Pis)

Generic name

Indinavir

Saquinavir

Ritonavir

Nelfinavir

Amprenavir

Trade name

Crixivan

Invirase/ Fortovase

Norvir

Viracept

Agenerase

Form

200 and 400 mg caps

SQV 200 mg caps FTV

100 mg caps 80 mg/ml oral sol

250 mg tablets

1 50 mg or 200 mg capsules

Dosing recommendations

800 mg q8 hours Separate dosing with ddl by 1 hour

SQV 400 mg bid with ritonavir; not recommended otherwise FTV 1,200 mg tid

600 mg bid Separate dosing with ddl by 2 hours

750 mg tid

1 ,200mg bid

Food effect

Levels decrease 77%, take 1 hour before or 2 hours after meals. May take w/skim milk or lowfat meal

Levels increase 6-fold, take with a large meal.

Levels increase 15%, take with food if possible, this may improve tolerability

Levels increase 2-3 fold, take w/ meal or snack

With or without food; avoid excessive alcohol

Oral bioavailability

60%

SQV 4% FTV 40%

60%

70% increases with food

Serum half-life

1 .5 to 2 hours

1 to 2 hours

1 .5 to 2 hours

3.5 to 5 hours

Route of metabolism

P450 cytochrome

P450 cytochrome

P450 cytochrome

P450 cytochrome

(continued)

TABLE 7.7

(continued)

Generic name

Indinavir

Saquinavir

Ritonavir

Nelfinavir

Amprenavir

Trade name

Crixivan

Invirase/ Fortovase

Norvir

Viracept

Agenerase

Adverse events

Nephrolithiasis, nausea, vomiting, headache, increased indirect hyperbilirubinemia

Mild diarrhea, nausea, vomiting, headache, and transaminase elevations

Nausea, vomiting, diarrhea, headache, dizziness, parasthesias, vasodilation, pharyngitis, altered taste, elevated liver enzymes, cholesterol and triglycerides

Diarrhea, astenia, nausea, vomiting, depressions, mild fatigue, rash and elevations in LFTs and triglycerides

Diarrhea, rash, headache

TABLE 7.7 (continued) Generic name

Indinavir

Saquinavir

Ritonavir

Nelfinavir

Amprenavir

Trade name

Crixivan

Invirase/ Fortovase

Norvir

Viracept

Agenerase

Contraindicated medications

Rifampin, terfanidine, astemizole, cisapride, midazolam, and ergot alkaloids

Midazolam, triazolams, rifampin, rifabutin

Amiodarone, astemizole, bepridil, bupropione, cisapride, clozapine, encainide, flecanide, meperidine, piroxicam, propafenone, propoxyphene, quinidine, rifabutin, alprazolam, terfanidine, alprazolam, clorazepate, diazepam, estazolam, flurazepam, midazolam, triazolam, and zolpidem

Terfanidine, astemizole, cisapride, midazolam, triazolam, rifampin

Astemizole, terfenadine, cisapride, rifampin, midazolam, triazolam, migraine meds

Storage

Room temp

SQV Room temp FTV Refrigerate or store at room temp for up to 3 months

Refrigerate capsules, oral solution should not be refrigerated

Room temp

Room temp

Source: Panel (1999).

338

THE PERSON WITH HIV/AIDS

methasone, and carbamazepine all decrease saquinavir levels (Facts and Comparisons, 1999). Invirase dosing is 600 mg tid orally. Fortovase is orally dosed at 1200 mg TID. There is no available dosing information for pediatric, neonatal and pregnant populations (Facts and Comparisons, 1999). Ritonavir (Norvir) is absorbed well, achieving 70% oral bioavailability. The serum half-life is between 3 and 5 hours. Ritonavir achieves near complete inhibition of the hepatic cytochrome P450 CYP3A, CYP2D6, and CYP2C9/19 systems, which can produce large increases in plasma concentrations of certain hepatically metabolized, commonly used drugs (Facts and Comparisons, 1999). Table 7.8 illustrates some drugs that can be dose modified. The list of PI and NNRTI drug interactions is lengthy and is summarized in Table 7.9. Ritonavir has been associated with numerous adverse events. Some of these may be reduced when the medication is taken with food. The side effects include nausea, vomiting, diarrhea, circumoral and extremity paresthesias, asthenia, taste perversion, and increased elevations in triglycerides, transaminases, CPK, and uric acid (Facts and Comparisons, 1999). The recommended dosing of ritonavir for adults is 600 mg by mouth twice a day with meals. A graduated dose increase (Day 1-2: 300 mg bid; day 3-5: 400 mg bid; day 6-13: 500 mg bid; day 14: 600 mg bid) may reduce adverse events (Panel, 1999). Pediatric dosing guidelines recommend 400 mg/m2. The child is started on 250 mg/ m2 and gradually increased (2- 3-day intervals) by 50 mg/m2 steps to full dose or the highest tolerated dose (Facts and Comparisons, 1999). Indinavir (Crixivan) oral bioavailability is about 60% when administered in a fasting state. The serum half-life is 1.5 to 2 hours. The route of metabolism is via the cytochrome P450 system (Facts and Comparisons, 1999). Major side effects of indinavir include nephrolithiasis (4%), nausea, vomiting, and headache. Increased indirect hyperbilirubinemia has been noted (Facts and Comparisons, 1999). Several drugs should not be given concurrently with indinavir. These include rifampin, terfanidine, astemizole, cisapride, traxolam, midazolam, and ergot alkaloids. Indinavir levels are increased by ketoconazole. Rifampin and rifabutin reduce indinavir levels. Didanosine will reduce indinavir absorption unless taken at least 2 hours apart (Facts and Comparisons, 1999).

TABLE 7.8

At a Glance—Protease Inhibitor Drug Interactions Requiring Dose Modifications Indinavir

Ritonavir

Saquinavir

Nelfinavir

Fluconazole

No dose change

No dose change

No data

No dose change

Ketoconazole and itraconzole

Decrease dose to 600 mg q8h

Increases ketoconazole > 3-fold; dose adjustment required

Increases saquinavir levels 3-fold; no dose change

No dose change

Rifabutin

Reduce rifabutin to half dose: 150 mg qd

Consider alternative drug

Not recommended

Reduce rifabutin to half dose: 150 mg qd

Rifampin

Contraindicated

Unknown*

Not recommended

Not recommended

Oral contraceptives

Modest increase OrthoNovum levels; no dose change

Ethinyl estradiol levels decreased; use alternative or additional contraceptive method

No data

Ethinyl estradiol and norethindrone levels decreased; use alternative or additional contraceptive method

Miscellaneous

Grapefruit juice reduces indinavir levels by 26%

Desipramine increased 145%, reduce dose Theophylline levels decreased, dose increase

Grapefruit juice increases saquinavir levels

'Rifampin reduced ritonavir 35%. Increased ritonavir dose or use of ritonavir in combination therapy is strongly recommended. The effect of ritonavir on rifampin is unknown. Used concurrently, there may be increased liver toxicity. Therefore, patients on ritonavir and rifampin should be monitored closely. Source: Adapted from Panel (1998).

o TABLE 7.9 At a Glance—Drug T Transcriptase Inhibitors Drug affected

Indinavir

Indinavir (IDV)

Ritonavir

No data

Saquinavir (SQV)

Levels: SQV T 4-7x; IDV no effect Dose: No data

Ritonavir

Saquinavir

Nelfinavir

Nevirapine

Delavirdine

Efavirenz

Levels: IDV t 2-5x Dose: Limited data

Levels: IDV no effect; SQV T 4-7x Dose: No data

Levels: IDV t 50%; NFV t 80% Dose: No data

Levels: IDV

Levels: RTV no effect; SQV T 20x Dose: SQV 400 mg bid + RTV: 400 mg bid

Levels: RTV no effect; NFV T 1 .5x Dose: No data

Levels: RTV 4, 11% NVP no effect Dose: Standard

Levels: IDV t 40% Dose: IDV 600 mg q 8h Levels: RTV T 70% Dose: No data

Levels: IDV t 36% Dose: IDV 1000 mg q 8h RTV t 18% EFV?21% Dose: RTV 600 mg bid

Levels SQV T 3-5x NFV t 20% (with FTV) Dose: Standard NFV FTV 800 mg tid

Levels: SQV i 25% NVP no effect Dose: No data

Levels: SQV T 5x DLV no effect Dose: Standard (monitor transaminase levels) FTV 800 mg tid

Levels: I SQV 62% EFV 1 12 Coadministration not recommended

Levels: SQV T 20x; RTV no effect Dose: SQV 400 mg bid + RTV bid

I 28%

Dose: Standard

TABLE 7.9

(continued)

Drug affected

Indinavir

Ritonavir

Nelfinavir (NFV)

Levels: NFV T 80% IDV T 50% Dose: No data

Levels: NFV t 1.5x RTV no effect Dose: RTV 400 mg bid NFV 500-750 mg bid

Saquinavir

Nelfinavir

Nevirapine

Delavirdine

Efavirenz

NVF T 10% NVP no effect Dose: Standard

Levels: NFV T 2x DLV I 50% Dose: No data (monitor for neutropenic complications) No data

Levels: T 15%-24% Dose: Standard

Nevirapine (NVP)

No data

Delavirdine (DLV)

No data

Source: Adapted from Panel (1998, 1999).

No data

342

THE PERSON WITH HIV/AIDS

The currently recommended adult dosing of indinavir is 800 mg (two 400 mg capsules) every 8 hours with water but at least 1 hour prior to or 2 hours after a meal. Adequate hydration is critical to reduce the risk of nephrolithiasis, and daily oral intake of 48 oz of liquid a day is strongly recommended (Facts and Comparisons, 1999). Nelfmavir (Viracept) is a protease inhibitor shown to be highly effective against HIV. The oral bioavailability of nelfinavir is 20% to 80%. The serum half-life is 3.5 to 5 hours. Nelfinavir is excreted via the liver and the P450 system including several isofofms of CYP3A. The major clinical toxicity of nelfinavir is diarrhea that was mild to moderate among clinical trial participants (Facts and Comparisons, 1999). Nelfinavir use of the cytochrome P450 mechanism is responsible for numerous administration difficulties with other medications. Several drugs should not be administered with nelfinavir. These include rifampin, triazolam, midazolam, ergot alkaloid, terfanidine, astemizole, and cisapride. Nelfinavir levels are decreased by rifampin and rifabutin. Nelfinavir decreases the levels of ethinyl estradiol and norethindrone. Nelfinavir increases the levels of ketoconazole and saquinavir. Didanosine, ritonavir, and saquinavir increase nelfinavir levels, but there is currently no safety or efficacy data on these combinations. Additionally, if used together, nelfinavir and didanosine must be taken at different times, with nelfinavir being taken at least 2 hours before or 1 hour after didanosine (Facts and Comparisons, 1999). The adult dosing of nelfinavir is 750 mg (three 250 mg capsules) three times a day by mouth. Optimal absorption is obtained when taken with food. Nelfinavir is dosed for pediatric populations from ages 2 to 13 at 20 to 30 mg/kg per dose three times a day accompanied with food. A powder formulation is available for those unable to tolerate capsules (Facts and Comparisons, 1999). Amprenavir, sold as Agenerase, is a newly approved protease inhibitor for use in combination with other AIDS medications. Amprenavir is dosed twice a day in eight 150 mg capsules (total 16 capsules per day). There is a liquid formulation available for children. Amprenavir may be taken with or without food. Taking Amprenavir with high fat meals is discouraged because fat can decrease medication absorption. Side effects include nausea, diarrhea, and rash. In about 1%

THE MEDICAL TREATMENT OF HIV DISEASE

343

of patients, Amprenavir can also cause life-threatening skin reactions (Murphy & Gallant, 1997; Schooley, 1996). Antiretroviral regimens should include at least one agent that penetrates well into the cerebrospinal fluid (CSF). Zidovudine and stavudine (d4T) have the highest levels of CSF penetration. Lamivudine, delavirdine, and protease inhibitors penetrate poorly, whereas nevirapine achieves adequate levels. WHAT TREATMENT REGIMEN(S) SHOULD BE STARTED? The goal of HIV therapy is to reduce virus in the plasma to undetectable levels. In order to achieve this, one should begin with the simultaneous initiation of combinations of antiretroviral drugs with which the individual has not yet been treated and that are not cross-resistant with any other antiretroviral agents with which the individual has been treated previously (NIH, 1998). The best chance for durable suppression of HIV replication includes treatment with two nucleoside analogue reverse transcriptase inhibitors (NRTIs) and one potent protease inhibitor (see Table 7.10). Recent data with the use of efavirenz (an NNRTI) in place of the PI has shown efavirenz to compare favorably to a Pi-containing regimen. All of these drugs should be started at the same time. Initial nucleoside TABLE 7.10

Initial Antiretroviral Triple-Therapy Options

Nucleoside analogue reverse transcriptase inhibitors

Protease inhibitors

ZDV + ddl d4T + ddl ZDV + ddC ZDV + 3TC d4T + 3TC

Indinavir Nelfinavir Ritonavir Ritonavir + Saquinavir

QQI + o I \-/

Nonnucleoside reverse transcriptase inhibitors Nevirapine 'Delavirdine Efavirenz

(choose one from each column) 'Less likely to provide sustained virus suppression, or data inadequate. Source: Adapted from Panel (1998, 1999).

344

THE PERSON WITH HIV/AIDS

combinations include AZT + 3TC, AZT + ddl, AZT + ddC, D4t + 3TC, or D4T + ddl. A protease inhibitor, such as indinavir, nelfinavir, ritonavir, amprenavir, a combination of ritonavir/saquinavir, or the NNRTI efavirenz may be added to this combination. Alternative regimens include substituting nevirapine, or delavirdine or efavirenz, NNRTIs, for the protease inhibitor. Regimens consisting of two NRTIs alone are less effective and should be used only if more potent treatment is not possible (due to lack of commitment to drug adherence, cost, access, etc). Monotherapy with any one drug is not recommended except to prevent perinatal transmission (Carpenter et al., 1997) because viral resistance usually emerges within weeks to months with one-drug therapy (Saag et al., 1996). Agreement is lacking regarding the "right order" in using these drugs. There are several ongoing clinical trials that are designed to answer the questions Which protease inhibitor should be used first? Should we use an NNRTI first, then, if failure occurs, switch to a protease inhibitor? Not all individuals can tolerate or adhere to a triple combination therapy, nor will all individuals achieve undetectable virus. An effective drug regimen should be able to reduce viral load by about 99% after 4 to 8 weeks of treatment (Panel, 1998). So if the viral load is 100,000 copies at initiation of treatment, it should be reduced to about 1,000 copies after 4 to 8 weeks of treatment. However, the maximal response to PI therapy may not be observed for 3 to 4 months (Carpenter et al., 1997), and it could take up to 6 months or 1 year to achieve undetectable levels. Once undetectable, HIV activity has been effectively reduced or even stopped. At this point, it is more difficult for the virus to become resistant to therapy or cause illness and disease progression. Although immune restoration remains an area of much needed study, several studies have shown increases in CD4+ T cells and improved health with fewer opportunistic infections (Hammer et al., 1997). If complete viral suppression is not possible, partial viral suppression of more than one-half log reduction in viral load is a reasonable secondary goal of therapy, and any regimen that can achieve that, including double nucleoside therapy, is preferred to no therapy (Panel, 1998). Individuals maintained on an antiretroviral regimen should not have the antiretroviral therapy discontinued during an acute opportunistic infection and/or malignancy, unless there are concerns re-

THE MEDICAL TREATMENT OF HIV DISEASE

345

garding drug toxicity, intolerance, or drug interactions. Additional reasons for temporarily discontinuing antiretroviral therapy include intolerable side effects, first trimester pregnancy when the patient so elects, and unavailability of drug. If the need should arise, it is recommended that all antiretroviral agents be stopped simultaneously, rather than continuing one or two agents, to minimize the emergence of viral resistance (Panel, 1998). Although viral load will probably rise when treatment is stopped, the virus won't have had a chance to become resistant to any of the drugs, so they may be effective again when treatment is restarted. Repeated dose reductions and interruptions in treatment could lead to drug resistance and should be avoided in the protease and nonnucleoside classes of agents (Carpenter et al., 1997; Saag et al., 1996). If viral suppression has been adequately achieved in patients who are intolerant or experiencing side effects, there can be substitution for the offending drug, preferably using an agent in the same class with a different side effect or tolerance profile (Panel, 1998). CONSIDERATIONS FOR CHANGING ART Resistance is a key factor in maintaining viral suppression and the benefits associated with it. Whereas there is precise criteria for treatment failure, changing therapy while plasma HIV RNA levels are relatively low may limit the degree of viral resistance that may emerge and may increase the opportunity for successful resuppression with an alternative regimen (Carpenter et al., 1997). In addition to side effects, drug toxicities, or drug interactions a change in therapy may be indicated if the combination is not having a strong enough antiHIV effect. Guidelines that should prompt consideration for changing therapy include (1) lack of an initial response of less than a log (10-fold) reduction of the viral load by 8 weeks following initiation of therapy; (2) failure to reach undetectable viral load after 6 months of treatment; (3) detection of virus after initial complete suppression of viral load, which suggests development of resistance; and (4) persistent decline of CD4+ T cells or clinical deterioration (Carpenter et al., 1997; Panel, 1998). Currently, there are only 14 antiretroviral drugs available, and some experts caution against changing treatments too quickly. A

346

THE PERSON WITH HIV/AIDS

three-fold increase in viral load, which should be confirmed with a second test, is reason to consider changing treatment. Once the decision is made to change the regimen, there are additional factors to consider such as prior an tire tro viral treatment, available options, expected cross-resistance, potential drug interactions, cost, and access (Carpenter et al., 1997). In the case of treatment failure, all drugs in the regimen should be changed or at least two of the drugs be substituted with others with no expected cross-resistance (Panel, 1998). This is frequently difficult to achieve in the an tire troviral experienced individual. If this is the case, a second combination might include two new NRTI drugs, a new NNRTI, and a new protease inhibitor (Panel, 1997). Another option may be a combination that includes two protease inhibitors. Clinicians and patients need to discuss how the drugs were taken to determine if they were taken as prescribed and to rule out any other reasons the treatment isn't working. When treatment failure has occurred because of nonadherence, the individual reasons for nonadherence must be explored. SPECIAL CONSIDERATIONS Acute Primary HIV Infection Although often not diagnosed in the primary care setting, most experts endorse on the basis of theoretical considerations and potential benefits of the treatment of acute (recent) HIV infection (Panel, 1998). A treatment regimen should include a combination of two NRTIs and one potent protease inhibitor. The duration of therapy is unknown, but the Panel (1999) recommends at least 1 year of treatment with repeat monitoring. The goal of therapy is to reduce viral replication and dissemination. Postexposure Prophylaxis The CDC's most recent guidelines for high-risk occupational or accidental exposure to HIV should be followed (Centers for Disease Control and Prevention, 1996). Recommendations for prophylaxis

THE MEDICAL TREATMENT OF HIV DISEASE

347

post high-risk sexual exposure have been issued by the Centers for Disease Control and Prevention. (See chapter 1.) ART in the HIV-Infected Pregnant Woman Guidelines for ART in pregnant HlV-infected women are the same as for nonpregnant adults (Panel, 1999); however, the regimen should include AZT prophylaxis per the ACTG protocol 076 (Centers for Disease Control and Prevention, 1994). When AZT is administered according to protocol, it reduces the risk of perinatal transmission by 66% (Connor et al., 1994). (See chapters 11 and 12.) Women who have not yet initiated ART may wish to delay therapy until after 10 to 12 weeks gestation since the fetus is most susceptible to harmful effects of drugs during this period. Because there is little data for combination therapy during pregnancy, no specific recommendations can be made. In general, HAART regimens containing zidovudine (AZT/ZDV) and lamivudine (3TC), about which there is the largest amount of data, are reasonable. Efavirenz is contraindicated in pregnancy due to teratogenicity in primates (Panel, 1999). The Panel (1997) recommends that women who are already on ART and who become pregnant be encouraged to continue the regimen if they are at high risk for disease progression. Women who are at low risk for disease progression might consider stopping ART for the first trimester of pregnancy. In this case, all drugs should be stopped at once to lower the chance of drug resistance. It is imperative that decisions to initiate or continue therapy are fully discussed, delineating the benefits and potential risks of ART to the woman arid her fetus based on limited available data on treatment of HIV during pregnancy. CONCLUSION Viral load test results in conjunction with CD4+ T cell counts strengthen the clinicians ability to predict disease progression and are essential tools to monitoring the effects of ART. Highly active antiretroviral therapy (HAART) is recommended early in the disease

348

THE PERSON WITH HIV/AIDS

process before immune system damage occurs. However, long-term benefits of this approach have not been confirmed through clinical trials. The limited number of antiretroviral medications currently available, access/availability of these medications, and the readiness of the patient to commit to treatment must balance enthusiasm for early treatment. Viral load is used as a parameter to initiate therapy but should be individualized based on clinical status and CD4+ T cell counts. The goal of therapy is to attain and maintain undetectable viral load. Currently, triple combination therapy from two different categories of agents, NRTIs plus a PI or NNRTI, is the most likely method to achieve undetectable virus. Adherence is key to the success of therapy. Development of resistance due to inadequate dosing is of major concern. If intolerable adverse effects develop at the time of initiation of treatment, gradual dosing may be successful. However, if toxicity cannot be tolerated for any protease inhibitor, the medication should be stopped rather than continued at a lower dose. When treatment fails, at least two drugs should be changed at the same time. The number of antiretroviral agents and other categories of drugs affecting distinct viral targets will likely increase during the next few years. Because of the increasing complexity of HIV treatment, primary care clinicians may benefit from consultation with an HIV specialist. REFERENCES ACTG 290 Executive Summary. (1997). Carpenter, C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. ML, Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schooley, R. T., Thompson, M. A., Villa, S., Yeni, P. G., & Volberding, P. A. (1997, June). Antiretroviral therapy for HIV infection in 1997, updated recommendations of the International AIDS Society—USA. Journal of'the American Medical Association, 227, 1962-1969. Centers for Disease Control and Prevention. (1994). Recommendations of the U.S. public health service task force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. Morbidity and Mortality Weekly Report, 43(RR-11), 1-21. . (1996). Update: Provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. Morbidity and Mortality Weekly Report, 45(22), 468-480. Chesney, M. A. (1997). Adherence to drug regimens: A learned skill. Improving the Management of HIV Disease. International AIDS Society—USA, 5(3), 12.

THE MEDICAL TREATMENT OF HIV DISEASE

349

Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., et al. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Croup Protocol 076 study Group. New England Journal of Medicine, 331,1173-1180. Connors, M., Kovacs.J. A., Krevath, S., Gea-Banacloche, J. C., Sneller, M. C., Flanigan, M., et al. (1997). HIV infection induces changes in CD4+ T cell phenotype and depletions within the CD4+ T cell repertoire that are not immediately restarted by antiviral or immune-based therapies. Nature Medicine, 3, 533-540. Crespo-Fierro, M. (1997). Compliance/adherence and care management in HIV disease. Journal of the Association of Nurses in AIDS Care, 5(4), 43-54. Enger, C., Graham, N., Peng, Y., Chmiel, J. S., Kingsley, L. A., Betels, R., & Munoz, A. (1996). Survival from early, intermediate and late stages of HIV infection. Journal of the American Medical Association, 275, 1329-1334. Erice, A., Mayers, D. Z., Strike, D. G., Sannerud, K. J., McCutchen, F. E., Henry, K., & Balfour, H. H., Jr. (1993). Brief report: Primary infection with zidovudineresistant human immunodeficiency virus type 1. New England Journal of Medicine, 328(16), 1192-1193. Facts and Comparisons. (1999, June Update). St. Louis, MO: Facts and Comparisons Division of J. B. Lippincott Company. Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom.J. M., Groopman, J. E., Mildvan, D., & Schooley, R. T., for the 016 study team AIDS Clinicals Trials Group. (1987). The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New England Journal of Medicine, 317(4), 185-191. Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, C. M., Currier, J. S., Eron, J. J., Jr., Feinberg, J. E., Balfour, H. H., Deyton, L. R., Chodakewitz, J. A., & Fischl, M. A., for the AIDS Clinical Trials Group 320 Study Team. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. New England Journal of Medicine, 337, 725-733. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 373, 123-126. Katzenstein, D. A. (1997). Adherence as a particular issue with protease inhibitors. Journal of the Association of Nurses in AIDS Care, Special Issue: Adherence Issues in HW Therapeutics, 8, 10-17. Mellors, J. W., Kingsley, L. A., Rinaldo, C. R., Hoo, B. S., Kokko, R. P., & Gupta, P. (1995). Quantltation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine, 112, 573-579. Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., et al. (1997). Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine, 124, 946-954. Mellors, J. W., Rinaldo, C. R.,Jr., Gupta, P., White, R. M., Todd, J. A., & Kingsley, L. A. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 272, 1167-1170.

350

THE PERSON WITH HIV/AIDS

Morse, G. D., Fischl, M. A., Shelton, M. J., Cox, S. R., Driver, M., DeRemer, M., & Freimuth, W. W. (1997, January). Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy, 41, 169-174. Murphy, R. L., & Gallant, J. E. (1997). Antiretroviral Therapy CME - HIV Clinical Management Series. Medical Education Collaborative and Health Care Communications Group, No. 3. Available at http://www.medscape.com/Medscape/HIV/ ClinicalMgmt/CM.v03/public/i ndex-CM.v03.html [1998, December 24] NIH Panel to Define Principles of Therapy of HIV Infection. (1998). Report of the NIH panel to define principles of therapy of HIV infection. Morbidity and Mortality Weekly Report, 47(Suppl. No. RR-5), 1-38. Panel on Clinical Practices for Treatment of HIV Infection. (1998). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report, 47(Suppl. No. RR-5), 43-81. Panel on Clinical Practices for Treatment of HIV Infection. (1999). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at http://hivinsite.ucsf.edu/rnedical/tx_guidelines/2098.3a62.html [1999, May 5] Rozenbaum, W. (1997, January). AVANT 1: A randomized, double-blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV infection. 4th Conference on Retroviruses and Opportunistic Infections. Washington DC, January 22-26 (Abstract 368). Saag, M. S., Holodniy, M., Kuritzkes, D. R., O'Brien, W. A., Coombs, R., Poscher, M. E., et al. (1996). HIV viral load markers in clinical practice. Nature Medicine, 2, 625-629. Schacker, T., Hughes, J., Shea, T., & Corey, L. (1997, January). Viral load in acute and very early HIV infection does not correlate with disease progression. 4th Conference on Retroviruses and Opportunistic Infections. Washington DC, Jan 22-26 (Abstract 475, 152). Schooley, R. T. (1996, September). Preliminary data on the safety and antiviral efficacy of the novel protease inhibitor 141W94 in HrV-infected patients with 150-400 CD4 cells/mm3. 36th Interscience Conference on Antimicrobial Agents and chemotherapy. New Orleans, September 15-18, 2E (Abstract LB07a). Williams, A., & Friedland, G. (1997). Adherence, compliance and HAART. AIDS Clinical Care, 9(7), 51-54.

8

Principles of Infection Control Barbara Russell

I he basis of currently accepted principles of infection control can be found in the Old Testament of the Bible. If one reads through the chapters of the third book of Moses, called Leviticus, written long before the discovery of microbes, one can find several references to those principles. The following provides an illustration and establishes the points to be further discussed.

T

Biblical Reference

Modern Principle

Individuals returning to the camps were held at the outer edges for several days.

Standard (which incorporates the concepts of universal precautions) and transmissionbased precautions Hand washing

Multiple use of phrases referring to "the cleansing of flesh." Clothing or items touched by a "soiled" body were to be washed or burned.

Disinfection/sterilization

Before discussing how to apply these principles to a specific setting where health care is provided, whether outpatient clinic, hospital, 351

352

THE PERSON WITH HIV/AIDS

or home, it is important to review another set of principles, specifically those that deal with how an individual acquires an infectious or communicable disease. The following represent the essential elements: the presence or source of an appropriate dose of infecting organisms, a route of transmission applicable to the infection or disease caused by that organism, and a susceptible host. Organisms (e.g., bacteria, viruses, fungi, or protozoa) can be present in individuals as well as the environment. When an individual is the source of one or more organisms, he or she may be incubating or demonstrating effects of the disease caused by the specific organism or may simply be a carrier of the organism. Environmental sources can include contaminated items, food, water, air, or insects carrying a specific organism. The major routes of transmission include direct or indirect contact, ingestion, inhalation, and vector-borne. "Direct" refers to a physical transfer of organisms between two individuals or via translocation of a person's endogenous flora, while "indirect" involves personal contact with a contaminated item. "Ingestion" implies the eating or drinking of contaminated food or liquids, while "inhalation" is the breathing in of air or dust particles containing the infectious agent. "Vector-borne" implies being bitten by an insect such as a mosquito or tick that is carrying the infectious agent. Susceptible hosts include individuals exposed to vaccine-preventable disease to which they have not received the vaccine or in whom protection has waned. More commonly susceptible hosts are those individuals with underlying medical conditions such as diabetes mellitus, HIV, and neoplastic processes. The use of immunosuppressive agents, corticosteroids, irradiation, surgical procedures, and age are some of the major factors that can add to a person's inability to resist infection, thus increasing his or her level of susceptibility to infection or other disease.The following provides an example of each type of transmission previously described. Infection/ disease

Causative agent

Route of transmission

Lyme disease

Borrelia burgdorferi (Spirochete bacterium)

Bites acquired from ticks carrying the organism

PRINCIPLES OF INFECTION CONTROL

Pulmonary tuberculosis

Shigellosis

Chicken pox

Herpes zoster (shingles)

HIV/AIDS

353

Inhalation of air recently contaminated following the uncovered cough of an individual with an active infection Shigella—a member Ingestion of contamiof the Enterobacteria- nated food ceae family of bacteria Varicella virus Susceptible individual (one who has not previously had vaccine or illness) via direct contact with person in infectious stage Varicella virus Individual's own dormant virus manifests itself due to immunosuppression (acute or chronic) Human immunode- Direct exchange of inficiency virus fectious body fluids, specifically semen, vaginal fluids, and blood, during sexual intercourse; indirect exchange of blood through purposeful or accidental sharing of needles Mycobacterium tuberculosis

TRANSMISSION OF HIV IN A HEALTH CARE SETTING Currently, knowledge about transmission of HIV in any setting where health care is being provided should be reviewed before planning and implementing approaches to prevent and control the spread of it and other infectious organisms. To date, there continues to be no documentation of HIV being casually acquired by any individual in or outside of health care. The only recorded information involving

354

THE PERSON WITH HIV/AIDS

transmission of HIV from an infected heath care provider to a patient involves an American dentist and a French orthopedic surgeon (Gerberding, 1996; Robert et al., 1995). The first cases of health care providers in the United States acquiring HIV occupationally, primarily through needlestick injuries, were noted in 1985. In 1987 three cases of nonpercutaneous transmission were reported, which led the Centers for Disease Control and Prevention (CDC) to develop and release guidelines that described "universal precautions" (Centers for Disease Control, 1987). Since that time and through December 1998 the CDC has documented specific information on 54 cases (47 by percutaneous exposures, 5 by mucocutaneous exposure, 1 where both types of exposure were noted, and 1 where exposure type was unknown) of occupationally acquired HIV infection (see Table 8.1). The Occupational Safety and Health Administration (OSHA) is seeking additional ways to reduce the estimated 600,000 injuries that occur annually among health care workers (HCWs) from needles and other "sharps" ("OSHA Seeks," 1998). As a result of the information gleaned from these reports and a case-control study of HCWs' occupational exposure to HIV, the CDC TABLE 8.1 Health Care Workers with Documented Occupationally Acquired AIDS/HIV Infection, by Occupation through December 1998 Occupation

Number of cases

Clinical laboratory technician Nurse Physician Nonclinical laboratory technician Surgical technician Autopsy technician Health aide/attendant Housekeeper/maintenance worker Respiratory therapist Dialysis technician

16 22 6 3 2 1 1 1 1 1

Total

54

Source: Centers for Disease Control and Prevention. (1999, June). Preventing occupational HIV transmission to health care workers. CDC Update, 1-3. [http://www.cdc.gov/nchstp/ hiv_aids/pubs/facts/hcw.htm]

PRINCIPLES OF INFECTION CONTROL

355

has developed a profile of the type of exposure, without intervention with postexposure prophylaxis, that could increase the likelihood of acquiring an infection with HIV. Risk factors include a deep injury with a needle containing visible blood after being removed from the vein or artery of a patient more likely to be in the terminal stages of AIDS rather than the early stages of the infection. This last factor implies a correlation with the source individual's viral load at the time of the exposure. Another study has concluded that factors associated with increased needlestick injuries to nurses include recapping of needles and temporary work assignments, while workin in hospitals with professional nurse practice models and taking precautions to avoid blood contact were linked to fewer injuries (Aiken, Sloane, & Klocinski, 1997). It is meaningful to note that health care providers are at greater risk of acquiring other blood-borne diseases, specifically hepatitis B and C, when the blood or a bloody body substance of an infected individual enters their bodies through the same type of exposures described here (McClinsey, 1999). The Centers for Disease Control (1987, 1995) estimates that the approximate risk of a susceptible health care provider acquiring a specific bloodborne pathogen after percutaneous exposure to blood containing the virus is as follows: hepatitis B, 30.0%; hepatitis C, 3.0%; and HIV, 0.3%. Between 1991 (when OSHA issued its blood-borne pathogens standard) and 1995, new hepatitis B infections among HCWs declined from 5,000 to 800 annually. Because of better workplace safety precautions, the incidence rate of hepatitis B infections among HCWs is now lower than the incidence for the general U.S. population ("OSHA Seeks," 1998). The most important way to prevent percutaneous injuries in the workplace is to be prudent in using, handling, and disposing of sharp objects (e.g., needles and scalpels) that could be contaminated with potentially infectious material. This includes, when available, the proper and consistent use of safety devices on all patients in all settings. When conventional devices are used, the user should avoid recapping needles, instead immediately disposing of needles in an appropriate container. If such disposal is not possible, recapping should be done using a one-handed scoop up method followed by a tightening of the cap at its base. Sharp objects, whether used or unused, should be discarded in a rigid container, preferably one approved for biohazardous/biomedical waste. In a home setting, if

356

THE PERSON WITH HIV/AIDS

a rigid container is not available, a resealable metal can, plastic soda bottle, or milk jug to which a 1:10 household bleach solution is added should be substituted. Local regulations for disposal should be consulted. Mucocutaneous exposures that are usually caused by splashing or direct contact with blood or a bloody substance can be prevented by using personal protective equipment (PPE) and by protecting open cuts or wounds on the HCW. An HCW with an open cut or wound on an exposed portion of his or her body should avoid direct patient contact until healing occurs. When contact cannot be avoided, the exposed area should be covered by an appropriate dressing, in addition to the indicated PPE such as gloves and/or an impervious gown. Whenever performing a task or procedure where splashing is predictable (e.g., irrigating a wound or emptying a receptacle containing body substances), the face should be protected by wearing a face shield or goggles and a mask, and the arms and trunk should be covered by an impervious gown. When an exposure occurs, the following steps should be taken: 1. Immediately wash the affected area with soap and water. The use of an antiseptic such as alcohol is not contraindicated. Do not use bleach, as it is a caustic agent. Rinse exposed eyes and mucous membranes by flushing with water. 2. Report the exposure to a supervisor and follow the supervisor's instructions. The exposure should be assessed according to institutional policy to determine the need for HIV postexposure prophylaxis (PEP). Figures 1.1 and 1.2, Steps 1-3 reflect the Centers for Disease Control and Prevention's (1998) recommendations (see Figures 1.1 and 1.2). 3. Follow-up for exposure to hepatitis B and C viruses should also be considered following CDC recommendations. The CDC funds a 24-hour hotline (888-448-4911) to assist practitioners providing care to exposed individuals. PREVENTING THE TRANSMISSION OF INFECTIOUS AGENTS IN HEALTH CARE SETTINGS The intent of appropriately applying the previously described modern principles of infection control is twofold:

PRINCIPLES OF INFECTION CONTROL

357

1. To prevent the transmission of potentially infectious agents from or via a health care provider/worker to a patient/client. 2. To prevent the transmission of potentially infectious agents from a patient/client to a health care provider/client. These are applied irrespective of what is or is not known regarding organisms an individual may be harboring. Guidelines developed by the Centers for Disease Control and Prevention (1987,1997,1998) and the Hospital Infection Control Practices Advisory Committee (1995) can serve as excellent information resources. Their recommendations, intended primarily for acute care hospitals, can be adapted to any setting where care is provided. In its most recent guidelines (Garner, 1996) the Hospital Infection Control Practices Advisory Committee introduced the terms standard precautions and transmission-based precautions.

Standard Precautions Standard precautions integrate the properties of universal precautions, which were originally described by the CDC's 1987 guidelines aimed at reducing the risk of transmission of blood-borne pathogens (e.g., HIV, hepatitis B, and hepatitis C) and body substance isolation (BSI), which was designed by a group of independent practitioners to reduce the risk of transmission of any pathogen that might be present in moist body substances. Standard precautions apply to blood and all body fluids and secretions, except sweat, and to nonintact skin and mucous membranes. They are designed to reduce the transmission of potentially infectious agents from both recognized and unrecognized sources and therefore are used with all patients/ clients. Key component include the following. 1. Don gloves when direct contact with blood, body fluids, nonintact skin, or mucous membrane is anticipated. Change gloves between procedures on the same individual to avoid the translocation of organisms. Remove gloves before touching noncontaminated equipment, anything in the environment, or going to another person.

358

THE PERSON WITH HIV/AIDS

2. Wash hands after removing gloves or after inadvertent contact with blood, body fluids, nonintact, skin or mucous membrane when gloves not worn. 3. Don face protection, such as a mask and goggles, and a gown when performing procedures that could create a splash of blood, body fluids, excretions, or secretions. 4. Be sure the environment is properly cleaned and any linen or equipment used is cleaned and correctly reprocessed before using on another individual. Discard single-use items properly. 5. In a hospital setting only patients who are fecally incontinent or have extremely poor hygiene should be housed in a private room.

Transmission-based Precautions The three categories of transmission-based precautions described below are designed to be used with individuals suspected or known to be infected with infectious agents of epidemiological importance or transmitted via airborne or droplet transmission. These precautions may be used singularly or in combination but are intended to supplement standard precautions. Droplet Precautions. In addition to standard precautions, a surgical-type mask should be worn when working within 3 feet of the infected person. Airborne Precautions. Respiratory protection should be worn when entering the room of a person known or suspected of having a disease such as measles (rubeola), chicken pox (varicella), or pulmonary tuberculosis (TB). Persons immune to measles or chicken pox do not need to wear respiratory protection. When caring for an individual suspected, diagnosed, and/or under treatment for tuberculosis, a specific type of respiratory protection, referred to as N95 or HEPA respirators, should be worn. Use of the protective device should be continued regardless of the setting (i.e., hospital, clinic, home) until the individual is rendered noninfectious. Contact Precautions. These primarily apply to persons who have draining wounds not contained by dressings and/or an organism

PRINCIPLES OF INFECTION CONTROL

359

that is resistant to antibiotics commonly used for treatment. CDC guidelines should be consulted for more specific details. Hand Washing The practice of hand washing remains the single most important procedure for preventing the transfer of infection-causing agents whose common route of transmission is through direct contact. Hand washing with a bland or lotion-based soap product is generally done to remove low-level contamination. Examples include After removing gloves Between routine patient/client contacts After coughing or sneezing Before and after using the bathroom Before and after eating Hand washing with a product that contains an antimicrobial agent such as chlorhexidine, PCMX, triclosan, or povidine-iodine should be used in situations including but not limited to the following: Before participating in an invasive procedure (i.e., insertion of a central line) When multiresistant organisms are present (e.g., methicillinresistant Staphylococcus aureus, vancomycin-resistant£nteroeom£s) In areas where scrubbing is indicated (e.g., surgery or special care nurseries) When dealing with a cluster or outbreak of infections When caring for a child with a viral illness and/or diarrhea Before caring for particularly susceptible clients, such as those who are severely immunocompromised Regardless of what type product is used, the following steps should be followed: Wet hands and apply soap. Work up a lather using friction, one hand against the other, for at least 10 to 15 seconds.

360

THE PERSON WITH HIV/AIDS

Rinse thoroughly under running water. Dry hands thoroughly. Turn faucet off avoiding direct contact (i.e., with a paper towel or tapping against handle with wrist). Products containing 70% ethanol alcohol are referred to as an alcohol-based hand rinse. They can be used when running water is not available or when washing with an antimicrobial agent is indicated but not accessible. When used in the latter situation, the alcohol product should be applied following a hand wash with lotion soap.

CONCLUSION Table 8.2 summarizes the major components of an effective infection control program, many of which were discussed in this chapter. Table 8.3 provides a summary of guidelines for handling medical equipment intended for reuse. These components were extrapolated from samples of guidelines utilized by the two referenced sources and are adaptable to any setting. Table 8.4 provides examples of transmission-based precautions. Microbes, especially those that are or may become pathogenic, will continue to cause infections; therefore, the principles of infection control and prevention should be utilized by all individuals, in all health care settings. Providers of health care need to be knowledgeable about protecting their patients/clients and themselves. Additional information can be obtained from the listed references as well as from infection control professionals, specialty organizations such as the Association for Professionals in Infection Control and Epidemiology and the Society for Healthcare Epidemiology of America, or directly from the Centers for Disease Control and Prevention in Atlanta.

PRINCIPLES OF INFECTION CONTROL

361

TABLE 8.2 Components of an Effective Infection Control Program 1. Extraordinary care should be taken to prevent needlestick injuries and/or trauma from sharp objects contaminated with potentially infectious material: a. b. c. d.

Dispose of used needles/sharps in designated puncture-resistant plastic or metal containers. Avoid recapping, bending, or clipping needles before discarding. Used instrument trays should be cleaned up by the user. Whenever possible use safety devices consistently and properly. All needlestick injuries, lacerations, or abrasions with body substancecontaminated materials should be washed immediately and reported to a supervisor for direction to the designated health care provider for appropriate follow-up.

2. Hands should be washed thoroughly before and after all patient care activities, when contaminated with any body substance, and following removal of gloves. 3. Gown, gloves, mask, and protective eye wear are not routinely required. a. b.

c.

Gown—when clothing may be soiled with any body substance. Gloves—for all contact with body substances, specimens, items contaminated with body substances, and during all invasive procedures. Gloves should be changed between each patient contact and when they are torn or punctured. Mask and protective eye wear (glasses or goggles)—during all procedures that are likely to generate droplets of body substances.

4. A single room is recommended for patients with diarrhea, fecal incontinence, wound drainage not contained by dressings, noncompliant behavior, and/or infection transmitted via the airborne or droplet route. 5. Resuscitation equipment should be available in all areas where the need for resuscitation is predictable. Mouth-to-mouth resuscitation is not recommended. 6. A luer-lock syringe should be used when any body substance is aspirated from a patient. 7. All specimens collected from patients should be considered contaminated and should be transported in designated specimen racks or leak-resistant plastic bags. 8. All soiled (reusable) instruments should be rinsed and placed in a designated transport container before sending to central supply for reprocessing. 9. All spills of body substances should be cleaned up immediately using a detergent disinfectant approved by the Infection Control Committee. A 1:10 household bleach solution is acceptable. 10. All used linen should be considered contaminated, and therefore minimal handling is recommended. Linen should be placed in a laundry bag that is securely closed. (continued)

362

THE PERSON WITH HIV/AIDS

TABLE 8.2 (continued) 11. Trash that meets the following criteria should be handled as biohazardous/ biomedical ("red bag trash"): a. Used (disposable) needles, syringes, and other sharps. b. Dressing materials contaminated with body substances, especially blood. c. Used blood or blood product transfusion bags and tubing. d. Contents of all containers from suction/vacuum equipment. e. From the following areas: operating rooms, hemodialysis, clinical and research laboratories, and endoscopic rooms (i.e., Gl laboratory and bronchoscopy room). Refer to state and local regulations. Source: Veterans Administration Medical Center, New York, NY 10010; Baptist Hospital of Miami, Miami, FL 33176.

TABLE 8.3

Handling of Medical Devices/Equipment for Reuse

Use of device

Method of reprocessing

Contact with intact skin

Decontaminate (clean) only (use intermediate or low-level germicide, wipe with alcohol, or simply clean with soap and water) (items such as stethoscopes, tabletops, etc.).

Contact with mucous membrane

Decontaminate, then preferably sterilize, at a minimum- to high-level disinfection by soaking in an EPA-approved chemical agent following the manufacturer's instructions regarding timing, etc. (items such as endoscopes, laryngoscopes, etc.).

Penetrate skin

Decontaminate and sterilize by use of cold sterilization (12° F) or preferably by heat, steam, or gas following the recommendations of the sterilizer's manufacturer (items such as needles, surgical instruments, etc.).

It is critical that all equipment to be disinfected or sterilized be cleaned first to assume removal of all organic matter.

PRINCIPLES OF INFECTION CONTROL TABLE 8.4

363

Examples of Transmission-based Precautions

Clinical syndrome or condition Meningitis Rash or exanthems, generalized, etiology unknown Petechial/ecchymotic with fever Vesicular Maculopapular with coryza and fever Respiratory infections Cough/fever/upper lobe pulmonary infiltrate in an HIV-negative patient or a patient at low risk for HIV infection Cough/fever/pulmonary infiltrate in an lung location in an HlV-infected patient or a patient at high risk for HIV infection Paroxysmal or severe persistent cough during periods of pertussis activity Respiratory infections, particularly bronchiolitis and croup, in infants and young children Risk of multidrug-resistant microorganisms History of infection or colonization with multidrug-resistant organisms Skin, wound, or urinary tract infection in a patient with a recent hospital or nursing home stay in a facility where multidrug-resistant organisms are prevalent Skin or wound infection Abscess or draining wound that cannot be covered

Potential pathogens

Type of precautions

Neisseria meningitidis

Droplet

Neisseria meningitidis Varicella

Droplet

Rubeola (measles)

Airborne and contact Airborne

Mycobacterium tuberculosis

Airborne

Mycobacterium tuberculosis

Airborne

Bordetella pertusis

Droplet

Respiratory syncytial or parainfluenza virus

Contact

Resistant bacteria Resistant bacteria

Contact

Staphyloccus aureus, Group A Streptoccoccus

Contact

Contact

364

THE PERSON WITH HIV/AIDS

REFERENCES Aiken, L., Sloane, D., & KIocinski,J. (1997). Hospital nurses' occupational exposure to blood: Prospective, retrospective and institutional reports. American Journal of Public Health, 87, 103-107. Centers for Disease Control. (1987). Recommendations for prevention of HIV transmission in health care settings. Morbidity and Mortality Weekly Report, 36(2S), 1S-18S. Centers for Disease Control and Prevention. (1995). Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HlV-infected blood—France, United Kingdom, and United States, January 1988-August 1994. Morbidity and Mortality Weekly Report, 44, 929-933. . (1997). Recommendations for follow-up of health care workers after occupational exposure to hepatitis C virus. Morbidity and Mortality Weekly Report, 46, 603606. -. (1998). Public Health Service guidelines for the management of health-care worker exposures to HFV and recommendations for postexposure prophylaxis. Morbidity and Mortality Weekly Report, 47(No. RR-7), 1-33. [http://www.cdc.gov/ epo/mmwr/mmwr.html] Garner, J. S. (1996). Hospital Infection Control Practices Advisory Committee: Guidelines for isolation precautions in hospitals. Infection Control Hospital Epidemiology, 17, 53-80. Gerberding, J. (1996). The infected health care provider. New England Journal of Medicine, 334, 594-996. Hospital Infection Control Practices Advisory Committee. (1995). Recommendations for preventing the spread of vancomycin resistance. American journal of Infection Control, 23, 87-94, Infection Control Hospital Epidemiology, 76,105-113, and Morbidity and Mortality Weekly Report, 44(No. RR-12), 1-13. OSHA seeks information on additional ways to eliminate or greatly reduce needlestick injuries. (1998, September). OSHA National News Release. [http://www. osha.media/oshanews/Sept98/needles.html] Robert, L., Chamberland, B., Cleveland, J., Marcus, R., Gooch, B., & Srivastava, P. (1995). Investigation of patients of health care workers infected with HIV. Annals of Internal Medicine, 122, 653-657.

RECOMMENDED RESOURCES American Hospital Association. (1992). OSHA's final bloodbornepathogens standard: A special briefing (No. 155904). Chicago: Author. American Society for Healthcare Central Services. (1990). Recommended practices for central service: Sterilization. Chicago: American Hospital Association. American Society for Healthcare Central Services. (1990). Recommended practices for central service: Decontamination. Chicago: American Hospital Association.

PRINCIPLES OF INFECTION CONTROL

365

Bell, D. (1997). Occupational risk of human immunodeficiency virus infection in healthcare workers: An overview. American Journal of Medicine, 102(5S), 9-15. Bond, W. W., Ott, B. J., Franke, K. A., & McCracken, J. E. (1991). Effective use of liquid chemical germicides on medical devices: Instrument design problems. In S. Block (Ed.), Disinfection, sterilization, and preservation (4th ed., pp. 1097-1106). Philadelphia: Lea and Febiger. Busch, M. P., & Satten, G. A. (1997). Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. American Journal of Medicine, 702(Suppl. 5B), 117-124. Cardo, D. M., Culver, D. H., Ciesielski, C. A., Srivastava, P., Marcus, R., Abiteboul, D., et al. (1997). A case-control study of HFV seroconversion in health care workers after percutaneous exposure. New England Journal of Medicine, 337, 14851490. Centers for Disease Control. (1988). Update: Universal precautions for prevention of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health care settings. Morbidity and Mortality Weekly Report, 37(24), 337-378. (1990). Guidelines for preventing the transmission of tuberculosis in healthcare settings, with special focus on HIV-related issues. Morbidity and Mortality Weekly Report, 39(RR-17), 1-29. (1990). Nosocomial transmission of multi-drug-resistant tuberculosis to health-care workers and HFV-infected patients in an urban hospital—Florida. Morbidity and Mortality Weekly Report, 39, 718-722. -. (1990). Possible transmission of human immunodeficiency virus to a patient during an invasive dental procedure. Morbidity and Mortality Weekly Report, 39(29), 489-493. (1990). Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. Morbidity and Mortality Weekly Report, 39(No. RR1), 1-14. (1991). Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure prone invasive procedures, Morbidity and Mortality Weekly Report, 40(No. RR-8), 1-9. Centers for Disease Control and Prevention. (1994). Guidelines for preventing the transmission of tuberculosis in health-care facilities. Morbidity and Mortality Weekly Report, 43(RR-13), 1-132, and Feder-al Register, 59(208), 54242-54303. (1996). Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. Morbidity and Mortality Weekly Report, 45, 468-472. (1997). Immunization of health-care workers: Recommendations of the Advisor)7 Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). Morbidity and Mortality Weekly Report, 46(No. RR-18), 1-42. (1997). Transmission of HIV possibly associated with exposure of mucous membrane to contaminated blood. Morbidity and Mortality Weekly Report, 46, 620623.

366

THE PERSON WITH HIV/AIDS

(1998). Guideline for infection control in health care personnel. Published simultaneously in American Journal of Infection Control, 26, 289-354, and Infection Control and Hospital Epidemiology, 19, 407-463. Ciesielski, C. A., & Metier, R. P. (1997). Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. American Journal of Medicine, 102(Suppl 5B), 115-116. Department of Labor, Occupational Safety and Health Administration. (1992). Occupational exposure to bloodborne pathogens; final rule. Federal Register, 56(235), 64175-64182. Ehrenkranz, N. J. (1992). Bland soap handwash or hand antisepsis? The pressing need for clarity. Infection Control Hospital Epidemiology, 13, 299-301. Fahey, B. J., Koziol, D. E., Banks, S. M., & Henderson, D. K. (1991). Frequency of nonparenteral occupational exposures to blood and body fluids before and after universal precautions training. American Journal of Medicine, 90, 145-153. Flynn, N., Pollett, S., Vanhorne, J., Elvebakk, R., Harper, S., & Carlson,]. (1987). Absence of HIV antibody among dental professionals exposed to infected patients. Western Journal of Medicine, 146(4), 439-442. Garner, J., & Favaro, M. (1985). Guidelines for handwashing and hospital environmental control. Atlanta: Centers for Disease Control. Institute of Medicine. (1992). Emerging infections: Microbial threats to health in the United States (1st ed.). Washington, DC: National Academy Press. Jackson, M. (1984). From ritual to reason—with a rational approach for the future: An epidemiologic perspective. American Journal of Infection Control, 12(4), 213220. Jackson, M. M., & Lynch, P. (1991). An attempt to make an issue less murky: A comparison of four systems for infection precautions. Infection Control Hospital Epidemiology, 12, 448-450. Larson, E. L. (1995). 1992, 1993, and 1994 Association for Professionals in Infection Control and Epidemiology Guidelines Committee: APIC guideline for handwashing and hand antisepsis in health care settings. AmericanJournal of Infection Control, 23, 251-269. Lynch, P., Cummings, M. J., Roberts, P. L., Herriott, M. J., Yates, B., & Stamm, W. E. (1990). Implementing and evaluating a system of generic infection precautions: Body substance isolation. American Journal of Infection Control, 18, 1-12. Lynch, P., Jackson, M. M., Cummings, M. J., & Stamm, W. E. (1987). Rethinking the role of isolation practices in the prevention of nosocomial infections. Annual on Internal Medicine, 107, 243-246. Maki, D. G., Alvarado, C., & Hassemer, C. (1986). Double-bagging of items from isolation rooms is unnecessary as an infection control measure: A comparative study of surface contamination with single and double bagging. Infection Control, 7, 535-537. McClinsey, S. (1999). Considerations for postexposure prophylaxis and prevention. Nursing Clinics of North America, 34(1), 213-225. Pugliese, G., & Hunstiger, C. A. (1992). Central services,, linens, and laundry. In J. V. Bennett & P. S. Brachman (Eds.), Hospital infections (3rd ed.) (pp. 335-344). Boston: Little, Brown.

PRINCIPLES OF INFECTION CONTROL

367

Ridzon, R., Gallagher, K., Ciesielski, C., Mast, E., Ginsberg, M., Robertson, B., et al. (1997). Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. New England Journal of Medicine, 336, 919-922. Rutula, W. A. (1990). Association for Professionals in Infection Control guidelines for selection and use of disinfectants. American Journal of Infection Control, 18, 99117. Tokars, J. L., Marcus, R., Culver, D. H., Schable, C., McKibben, P., Bandea, C., & Bell, D. (1993). Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Annual on Internal Medicine, 118, 913-919. Valenti, W. (1989). Infection control and the pregnant health care worker. AIDS. Patient Care, ?(2), 12-16.

This page intentionally left blank

9

Testing and Counseling Richard S. Feni

"bile testing for the presence of the human immunodeficiency virus (HIV) antibody has complex social, ethical, legal, and health implications (Roland, Fine, & Volberding, 1998), early detection of an individual's HIV seropositive status has potential advantages that include early intervention and management. It should be noted, however, that self-knowledge of one's seropositive status does not necessarily translate into healthy behaviors and lifestyle modification. In fact, being informed of a positive antibody status may cause an individual to feel overwhelmed, isolated, depressed, and even suicidal if this diagnosis is confirmed without adequate counseling and support. It is important to note that these feelings are not limited to persons who test seropositive. Gay men, for example, who have experienced multiple unresolved losses to the pandemic may experience survivor guilt and grief for testing HIV negative while losing so many friends and partners. HIV antibody testing should be performed by a nurse or other health care worker who has had additional education and training in HIV counseling and testing issues. The public health departments of many states have established training programs that offer basic HIV/AIDS information, critical counseling aspects, and information about local resources networking to health care workers. Many federally funded AIDS training and education centers also offer testing related education to health professionals (Centers for Disease Con trol and Prevention, 1999).

w

369

370

THE PERSON WITH HIV/AIDS

Testing for the presence of the HIV antibody can be done on either serum or oral mucosal transudate (OMT). The test on either sample determines the presence in the sample of HIV-1 antibodies produced by the immune system (Ferri, 1998). HIV-1 is the most commonly identified human immunodeficiency virus found in the population of the United States. HIV-2 is also a retrovirus that is antigenically similar to HIV-1 but has a distinct and different epidemiological pattern. HIV-2 is seen primarily in West Africa and is spread through heterosexual behavior (Centers for Disease Control, 1992). To date, there are only several dozen cases of HIV-2 infection reported in the United States. This fact underscores the need for a comprehensive nursing pretest assessment. The nurse needs to determine if the client has traveled to areas endemic for HIV-2 and engaged in any unsafe sexual activity or needle use. If so, the nurse may want to consider obtaining antibody testing for both HIV-1 and HIV-2 antibodies. The two separate tests can be performed from the same sample. This section will outline HIV antibody counseling and testing, test results reliability, the risk and benefits of HIV antibody testing, pretest counseling standards of care, posttest counseling standards of care, interpretation of test results, and testing of special populations. MAJOR ISSUES IN HIV ANTIBODY COUNSELING AND TESTING There have been significant advances in the understanding of the pathogenicity of HIV infection since it was first identified in 1983. The development of critical laboratory methods used to diagnosis HIV seropositivity has become standard (Centers for Disease Control and Prevention, 1998). It is important for nurses to have comprehensive understanding of these methods in order to educate and counsel clients appropriately. Serum Testing Methods HIV is a retrovirus composed of several distinct elements, including core proteins (p24, p!8), envelope glycoproteins (gp!20, gp41 [to-

TESTING AND COUNSELING

371

gether they are designated as gp!60]), and viral polymerases (see chapter 2). Antibodies are formed after infection to most of the major viral proteins (gp!20, gp41, gp!60, p24). Commonly the types of antibody test for HIV serodiagnosis include the enzyme-linked immunosorbent assay (ELISA), Western blot, immunofluorescence, radioimmuno-precipitation, and hemagglutination. These tests do not directly measure the presence of the virus but, rather, the antibodies formed to the various viral proteins. When more direct testing for the presence of HIV is required (e.g., testing of infants), techniques such as polymerase chain reaction (PCR) or viral culture can be used (See chapter 12 and Palumbo et al., 1999). The ELISA test has a greater than 99% sensitivity and specificity rate (Centers for Disease Control, 1989). The standard procedure for HIV serum testing is to test the sample using the ELISA method and if there is a positive response to test the same sample again utilizing the ELISA method. If the second test is negative, then the test is considered negative. If, however, the second test is positive, a third test, usually the Western blot, is conducted on the same serum sample for confirmation. The Western blot identifies very specific components of the HIV, which makes it a highly specific test. Test Sensitivity A test is considered sensitive when it has the capacity to identify all specimens that have HIV antibody in them (Janssen et al., 1998). Specimens that are missed are considered falsely negative. Because the ELISA has a 99% sensitivity, 99 out of 100 tests should be correctly identified as having the HIV antibody.

Test Specificity A test is considered specific when it has the capacity to identify all specimens that do not have HIV antibody in them (Janssen et al., 1998). Specimens that are missed are considered falsely positive. The ELISA has a 99% specificity. Therefore, 99 out of 100 tests will be correctly identified as not having the HIV antibody.

372

THE PERSON WITH HIV/AIDS

Oral/Urine Testing Methods The oral test for the HIV antibody is highly accurate and offers the nurse the virtual elimination of the risk of occupational exposure to infection via accidental needlestick (Ferri, 1998). It also offers clients who may have increased anxiety over needles or who pose vein puncture challenges to be tested, thereby circumventing these barriers. Currently, one HIV oral test, OraSure©, has been approved for oral testing. This product does not test for antibodies on saliva but, rather, on OMT. OMT is derived from the transudation of interstitial fluid across the buccal and gingival mucosae and is comprised of a mixture of parotid, submandibular, sublingual, and salivary fluid mixed with sloughed epithelial cells and bacteria. Therefore, it is important for the nurse or counselor to reinforce that oral test is not done on saliva and that there is very low risk in acquiring HIV infection via saliva. The OraSure test measures antibodies on the complex OMT. The oral test utilizes the same algorithm of ELISA and Western blot as does the serum test. The oral test has proven to be equal in its test sensitivity and specificity as serum testing. Another oral test known as Ana-Sal™ and developed by Americare Health Scan, has been approved for use in three South American countries. According to the manufacturer, this test detects HIV-1, -2, and subtype O, producing results that are more than 99% consistent with conventional blood tests. A urine-based test, whose sensitivity and specificity are less than that of serum and saliva-based tests, is available for office use (Roland et al., 1998). Home HIV Testing In 1996 the Confide home testing kit became available nationwide in the United States (Tamborland & Kunz, 1996). The Confide test requires the user to prick a finger with a lancet and blot his or her blood on a special piece of paper that is number coded, then mailed to the company. Pretest counseling is supplied via a brochure that comes with the kit. After a specified period of time, the user calls a toll-free number and provides a 14-digit PIN number to obtain test results, at which time the results and posttest counseling are provided. While unapproved home-test kits are frequently advertised

TESTING AND COUNSELING

373

in newspapers, magazines, and via the Internet, their sensitivity and specificity cannot be scientifically verified. Clients should be urged to avoid testing with unapproved products. Home HIV testing has been controversial without any sense of agreement in the HIV community. For example, the National Association of People with AIDS has opposed home collection devices, while the Association of Nurses in AIDS Care has supported home collection and testing. Rapid HIV Antibody Testing A rapid HIV test is a screening test that can be performed with a rapid test result available in 5 to 30 minutes. At present there is only one commercially available test in the United States—the Single Uses Diagnostic System for HFV-1 (SUDS) (Centers for Disease Control and Prevention, 1998). The need for such a test can be highlighted by the fact that many individuals who go for HIV testing do not return to receive their results or follow-up counseling. In 1996 26% of persons who tested HIV positive and 33% of those who tested HIV negative did not return to learn their results (Centers for Disease Control and Prevention, 1998). However, while the advantage may be in identifying HIV positive individuals without loss to follow-up, the rapid HIV test presents unique clinical and counseling challenges. When utilizing the rapid HIV test in practice, it is important to develop a language and understanding that is different from standard HIV testing. Unlike the standard serum or OMT sample that can be termed "positive" when HIV-1 is detected, the rapid HFV test is termed "reactive." A reactive rapid HIV test must be confirmed with the traditional confirmatory tests, a process that typically takes I to 2 weeks. When communicating a reactive rapid HIV test result, the nurse or counselor should present the results as "the test being reactive." Clients should be informed that there is a possibility that they are HIV positive but will need to have a confirmatory test. The rapid HIV test has the same sensitivity and specificity of the ELISA. The predictive value of a negative test result is high, and persons testing negative do not have to return for a second visit if there have been no risk behaviors within the past 25 days. (This is

374

THE PERSON WITH HIV/AIDS

the "window period" when antibodies to HIV may be developing after a recent exposure.) The positive predictive value for the rapid HIV test is low; therefore, every reactive rapid HIV test must be confirmed by a Western blot or immunofluorescence assay (IFA) (Centers for Disease Control and Prevention, 1998). It is important to remember that a reactive rapid HIV test is more likely to represent a true positive if the client has engaged in some risk behaviors.

Who Should Be Tested? The Centers for Disease Control and Prevention (1994) has recommended guidelines for HIV counseling, testing, and referral. Those who may wish to consider testing for HIV antibodies are provided in Table 9.1 ("Getting Tested," 1999).

Anonymous vs. Confidential Testing When an individual decides to be tested for HIV antibody status, there can be a varied range of emotions, from mild curiosity to extreme emotional distress. The degree of this variance is often difficult to assess; thus, counselors should advocate for the protection of those seeking testing in the most comprehensive manner available. Such protections may include advocating for anonymous counseling and testing when possible. Anonymous testingis offered to individuals without a client's identity being known to those providing such services. Certain American populations (e.g., gay, bisexual, transgendered people, persons of color, and injection drug users) linked to the HIV pandemic have historically experienced discrimination and, to a lesser extent, stigmatization; thus, individuals seeking testing for the HIV antibody may also experience discrimination and stigmatization. The level of discrimination resulting from testing may range from ostracism to loss of employment or even physical violence. Anonymous test sites are typically staffed with personnel trained to meet the complex and varied needs of all clients. Confidential testing is done with the client's identity known but protected. There are several reasons for confidential HIV antibody

375

TESTING AND COUNSELING

TABLE 9.1 Getting Tested Those for whom HIV Testing is Recommended

Those for Whom HIV Testing is Considered Appropriate

Those who consider themselves at risk of HIV infection Women of childbearing age who are at risk Persons attending clinics for sexually transmitted diseases and drug abuse Spouses and sex- or needle-sharing partners of injection drug users Women seeking family planning services Tuberculosis patients Individuals who received blood components between 1977 and mid-1985

Persons with symptoms of HIV-related conditions Persons with past or current histories of injection drug use Past or current partners of persons who are or are believed to be HIV infected Persons with past or current histories of multiple sex partners Persons with histories of sexually transmitted diseases in the past ten years Victims of rape or sexual assault Inmates in correctional facilities Sex partners of hemophiliacs and others who received blood products before mid-1985 Pregnant women Newborns Sexually active adolescents or adolescents using drugs Men with past or current histories of sex with men Anyone else who wants to be tested

Source: Ferri, R. S. (1999, June/July). Getting tested (Editorial). HIV Frontline, Issue 37, 1.

testing, the first being to confirm the underlying cause of a medical condition for which an individual is seeking treatment. If the individual is HIV seropositive, appropriate medical intervention can be instituted for both the specific medical condition and the HIV disease. Individuals may also seek confidential testing if anonymous testing is unavailable. In addition, confidential testing is done when an individual donates blood at a blood collection site. Confidential testing is performed is for the military, Peace Corps, and Job Corps personnel. However, "routinely" performed HIV testing can have serious consequences that need to be considered. Because confidential testing allows for the identification and tracing of the individual tested, a seropositive result may place the person at risk for discrimination. Also, routine confidential testing can place the client who

376

THE PERSON WITH HIV/AIDS

was not anticipating a positive result, but receives one, at great emotional risk. A number of states are presently considering the mandatory reporting of all HIV-positive test results by a unique identification number. This number would be a code that would provide demographics but keep the person's identity confidential. This system has the potential to provide a more realistic portrait of the HIV epidemic in the United States.

Informed Consent For both anonymous and confidential testing the client must provide informed consent prior to testing. Informed consent is a basic right of clients and is essential to the construct of autonomy. Only with full understanding of HIV antibody testing and the consequences of such testing are clients able to make informed decisions about testing options. The HIV antibody test is not a routine blood test and should not be performed without the client's explicit understanding and consent. The decision to test should be solely that of the individual and should not be coerced in any manner (American Nurses Association, 1991). The doctrine of informed consent includes three basic principles: (1) the person must be informed of the nature, purpose, and risks of the test/treatment, (2) the person is competent to understand, and (3) the person agrees to participate without duress or coercion (Gostin, 1992). These principles should be viewed as a part of a human rights framework and a standard of professional practice, the latter including pre- and posttest counseling and client education on the significance and implications of testing.

Mandatory vs. Voluntary Testing Mandatory testing of certain populations (e.g., health care workers) has been widely debated in the popular press and professional literature (Centers for Disease Control, 1992). The value of implementing mandatory testing has generally not been supported by those charged to develop and implement policy in this area, although mandatory testing has been legislated for some populations (e.g., immigrants

TESTING AND COUNSELING

377

entering the United States, some prisoners, sex workers, and military personnel). Many experts have convincingly argued that the testing of health care workers is unwarranted inasmuch as the risk of unintentional transmission of HIV infection from health care worker to patient approaches zero. However, mandatory HIV testing remains politically appealing. The American Nurses Association (ANA) has adopted a position that opposes mandatory testing. The ANA "opposes perpetuation of the myth that mandatory testing and mandatory disclosure of the HIV status of patients and/or nurses is a method of preventing the transmission of HIV disease, and therefore does not advocate mandatory testing or mandatory disclosure of HIV status" (American Nurses' Association, 1991). The ANA position has been supported by the Association of Nurses in AIDS Care (1996). Many public health experts assert that there are no compelling reasons to mandatorily test all persons for HIV infection, maintaining that compulsory testing will have an adverse effect on those who are at the most significant risk for being infected, possibly causing them to avoid HIV testing out of concern for repercussions that might infringe upon their civil liberties. While knowing one's HIV seropositivity status may allow for early medical intervention, the decision to seek such testing must remain an individual right. Mandatory testing, which has been broadly condemned by human rights and professional health organizations, violates human rights and may negatively impact on the public's health. Even "routine" testing, which has been suggested for all pregnant women, should allow for refusal without coercion or surreptitious testing, a recognition of every person's autonomy.

COUNSELING AND TESTING GUIDELINES Standard counseling and testing guidelines have been developed in order to provide the client with an informed understanding and one-on-one counseling and education (United States Department of Health and Human Services, 1994). The advent of home collection devices raises some concerns about how these guidelines will be implemented in home testing situations.

378

THE PERSON WITH HIV/AIDS

HIV Antibody Testing Pretest Guidelines I. II.

Introduce yourself by name and title. Give a brief overview of what the pretest session will consist of. A. Explain the test is done by collecting a blood or saliva sample to detect the HIV antibody that causes AIDS. B. Explain that there is a window period of approximately 25 days from time of exposure to HIV to when it is detectable in the sample. This means if the client has experienced a risk behavior in the past 25 days he or she will need to retest even if he or she is antibody negative. C. Discuss issues of disclosure with the client. Individuals have been discriminated against simply for getting tested; therefore, they should carefully consider to whom they disclose their testing issues. D. Introduce the concept of partner notification. If the client should test antibody positive, what would be his or her method of informing past and present sex and/or needleusing partners? (Many states have anonymous partner notification programs through their local departments of health.) E. Let the client know if there is a fee involved. F. Let the client know how long it will take for the test results to be processed. G. Explain and reinforce the specific paperwork that the client is required to bring back to the postcounseling session in order to obtain test results. II. Perform a risk assessment. A. Ask the client why he or she wants to be tested today. A client may elect not to disclose this information and should never be coerced. B. Inquire about all sexual practices in a nonjudgmental manner. These include recent or past history of unprotected (insertive and receptive) oral, anal, or vaginal intercourse; fisting; water sports; oral/anal sex (analingus); sex for money, shelter, or drugs; and exposure to unwanted/ forced sex. Education about how to reduce the harm of the client's at risk behaviors should be performed.

TESTING AND COUNSELING

III.

IV.

379

C. Inquire about the client's substance use. Has the client ever been intoxicated from alcohol or drugs while engaging in sex? Is the client a needle user? Does the client know how to clean needles and use needles safely? D. Inquire if the client has had a blood product transfusion prior to 1978. Explain the test and test results. A. Reinforce the concept of the window period. B. The test is for antibodies to HIV, not for AIDS. C. A negative test result means that HIV antibodies were not found. This can mean that the person is uninfected if he or she has not engaged in any unsafe practices in the window period. If the client is not certain of this, the negative test result could mean that the antibodies are present but not yet detectable in the sample. In this case, the client should be encouraged to be tested again at the end of the window period. D. A positive test means that the client has been exposed to HIV and is infected with the virus. It does not mean that the client has AIDS. E. An indeterminate test result indicates that the presence or absence of the HIV antibody could not be determined. Indeterminate results are usually related to one of three events: (1) the client is in the process of converting to a positive antibody status; (2) the client may have had a prior inoculation that is cross reacting with the HIV antibody test; or (3) a prior medical condition, such as arthritis or autoimmune disease, is affecting the HIV test. Clients who test indeterminate for HIV should be encouraged to retest in 6 to 8 weeks. F. Explain how the test (enzyme-linked immunosorbent assay, or ELISA) is done in order to address issues of accuracy. If the first ELISA is positive for HIV antibodies, then a second ELISA is done. If possible, a third test is performed on the sample to further confirm the positive result by the Western blot test. Transmission A. Explain how the virus is transmitted and detail the risk behaviors associated with transmission.

380

THE PERSON WITH HIV/AIDS

B. HIV is a blood-borne virus that enters a noninfected person's bloodstream from the blood, semen, vaginal fluid, or menstrual blood of an infected person. HIV has also been found in preejaculate and breast milk. C. HIV can be absorbed into the body via any mucous membrane. Disruption of skin integrity and lesions increase the possibility of infection. D. The receptive partner is at greater risk for infection than the insertive partner. Both are at risk if latex barrier protection is not utilized. E. Female-to-female transmission of HIV is possible since the virus can enter into the bloodstream through vaginal mucous membranes or interrupted vaginal tissue. F. Needle users who share needles are at high risk for contracting HIV regardless of the substance being used. Infected blood can be left in the core of the needle, on cotton balls, or in the cooker. G. Blood product recipients prior to 1985 may be at risk of HIV infection. H. Occupational exposure risk is increased for health care workers, firefighters, and police and emergency personnel who come into contact with blood. The known cases of occupationally acquired HIV infection documented since the beginning of the epidemic is very low. V. Risk assessment and reduction (see also chapters 3 and 4) A. Explore with the client his or her risk behaviors. B. Discuss sexual risk reductive options that include 1. Abstinence 2. Fantasy 3. Phone sex 4. Computer sex 5. Safe use of sex toys 6. Sex without penetration (mutual masturbation) 7. Use of latex condoms and water-based lubricant for anal and vaginal intercourse C. Emphasize that the use of alcohol or recreational drugs may impair judgment. Discuss alcohol/substance use risk reduction. Encourage abstaining from alcohol/substance use. Encourage treatment. Encourage clients not to have sex under the influence of alcohol/substance use.

TESTING AND COUNSELING

381

D. Discuss needle use risk reduction, including abstaining from drug use, using only clean needles, and never sharing needles or engaging in injection drug use. Encourage drug treatment. E. When appropriate, discuss occupational exposure risk reduction, and review universal precautions standards. VI. Testing options A. Reinforce the concept that HIV antibody testing is never an emergency. If the client is experiencing clinical symptoms, the client may be better served by testing in a primary care setting. The nurse/counselor may have to assist with health care referrals. B. If the client is ambivalent about the test, the nurse may want to defer testing until the client can make a clear decision. C. If the test is to be anonymous, the nurse may have to schedule the client for sequential pretest counseling sessions to help manage anxiety. D. If the test is be confidential, the nurse can enlist other mental health resources to help the client. Appropriate release of information forms needs to be completed. VII. Preparing for test results A. Discuss the need to have a support person during the counseling session. B. Assess if the client has disclosed to anyone his or her need to be tested. C. Ask the client to prepare for getting test results by considering bringing a support person to the posttest session. A sexual partner may not be the most appropriate choice, since the partner will have his or her own risk issues. VIII. Testing negative A. Ask the client what it would mean if he or she tested negative. Do not presume universal pleasure at a negative test result. Some reactions of people who test negative include 1. Profound grief 2. Feeling of immunity to HIV 3. Confirmation of need for safer sex/needle practices 4. Survivor guilt

382

IX.

X.

THE PERSON WITH HIV/AIDS

B. Contract with the client a plan of action if the test is negative. C. Review the concept of the window period. D. Validate risk reduction skills. Testing positive A. Ask the client what it would mean if he or she tested positive. Do not presume universal despair at testing positive. Some reactions of people who test positive include 1. Relief at confirming a diagnosis 2. Validation of symptoms 3. Extreme sadness Describe how the test results will be given. A. If the test is anonymous, explain the need for the client to return with documented code numbers, since he or she will be matched to the laboratory report. B. Test results should only be given in person. C. Test results should be given in a private and confidential setting.

HIV Antibody Counseling and Testing Posttest Guidelines I. II.

III.

Introduce or reintroduce yourself by name and title. Ask the client if he or she wants to be informed of the test results. A. Allow the client to verbalize how he or she is feeling. B. Ask the client if he or she is ready for the test results. 1. If no, allow client to process feelings and continue counseling. More than one posttest counseling session may be needed before the client is ready for the test results. Some clients may decide not to return to learn of their antibody status. 2. If yes, give the test results promptly. Test results A. For anonymous test results, the client and counselor must match the client code number on the lab report. B. After confirming that the numbers match exactly, read the test results to the client. C. Assess to see if the client understands the test results.

TESTING AND COUNSELING

383

D. If the client has brought a support person to the session, it may be appropriate to suggest that the support person be brought into the session with the client's permission. IV. Negative results A. Effective posttest counseling is done when it is tailored to reason (s) for which the client sought testing. Place the testing and risk/harm reduction in the context of the client's life. B. Negative test results do not mean lifelong immunity to HIV infection. C. Negative results do not mean that the person can stop safer sex/needle practices. D. Review the need to retest if the negative test result is in the 6-month window period. E. Discuss psychosocial issues for people who test HIV negative. Include survivor guilt and being part of a discordant (one person is antibody positive, while the other is antibody negative) couple. F. Review safe sex and needle practices. G. Discuss harm reductive issues specific to the client. V. Positive results A. When giving a positive test result, it is important for the nurse to stay both physically and emotionally with the client. B. Assess verbal and nonverbal cues from the client to determine his or her needs. C. Some common reactions to testing HIV positive include 1. Silence 2. Sadness 3. Crying 4. Anger 5. Resentment 6. Fear of illness 7. Concern for partners/family D. Assist the client in developing a plan for the next 24 hours, and assist in obtaining support persons. The nurse may contract with the client to call or return for counseling the next day if there is concern over the client's emotional state.

384

THE PERSON WITH HIV/AIDS

E. Assess suicidal ideation. If the client expresses any suicidal thoughts, these must be taken seriously. The client's safety is more important than the testing process. The nurse should have established linkage with emergency mental health counselors. F. Provide the client with local resources contacts. G. Discuss disclosure issues, focusing on whom the client is going to tell first. H. Arrange for follow-up counseling and support as appropriate. I. Discuss the need for primary care linkage. Provide the client with a list of local HIV/AIDS primary care providers. J. Discuss the basics of HIV infection and health issues with the client. It may be beneficial to give the client written materials since the emotional reaction to testing positive may interfere with comprehension and communication. IMPLICATIONS FOR NURSING PRACTICE Many nurses are in key clinical positions to incorporate and promote effectively primary and secondary prevention messages into their practices. Nurses, especially those whose role includes that of HIV antibody counselor, need to advocate for their patients and provide appropriate support to facilitate antibody testing. Early intervention is essential for healthy persons living with HIV. Nurses should also advocate for health promotion and disease prevention in persons testing positive for the HIV antibody. This may be especially important with the advent of more sophisticated therapies such as combination antiretroviral regimes that include drug regimens that extend life expectancy. As persons with HIV live longer, they will require more health promotion information and health status monitoring. Health information that needs to be provided to people living with HIV includes risk reduction practices. Persons with HIV need to be counseled not to have unprotected sex or share needles with other individuals, including with those who are also HIV positive. Exposing an individual to the virus repeatedly may cause the development of more virulent strains of the virus and expose the individual to minor infections (Levy, 1993).

TESTING AND COUNSELING

385

Counseling and testing may unveil some late-stage disease, and the nurse must advocate and provide management of pain, basic hygiene, fluids, and comfort (Butters et al., 1993). Newly diagnosed late-stage disease may require crisis intervention, spiritual counseling, and psychosocial support for the client, the family, and the caregivers. CONCLUSION The testing and counseling of people for the presence of the HIV antibody is complex and requires knowledge, skill, and compassion. These elements are intrinsic to the practice of nursing. Nurses are the key health care providers—whether in the role of clinician, educator, primary care provider, or researcher—to advocate for the client. Nursing must also safeguard the client from harm caused by inappropriate antibody testing procedures and coercion. The ultimate decision to be tested for the presence of HIV infection must rest with the individual. REFERENCES American Nurses Association. (1991). Position statement on mandatory HIV antibody testing. Washington, DC: Author. . (1994). Nursing and HIV/AIDS. Washington, DC: Author. Association of Nurses in AIDS Care. (1996). Position statement on HIV antibody testing. Washington, DC: Author. Butters, E., Higginson, I., George, R., et al. (1993). Palliative care for people with HIV/AIDS: Views of patients, carers and providers. AIDS Care, 5(1), 105-116. Centers for Disease Control. (1988). Update: Serological testing for antibody to human immunodeficiency virus. Morbidity and Mortality Weekly Report, 36, 833-840. . (1989). Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. Morbidity and Mortality Weekly Report, 38. 1-7. . (1992). Testing from antibodies to human immunodeficiency virus type 2 in the United States. Morbidity and Mortality Weekly Report, 41, 1-9. Centers for Disease Control and Prevention. (1994). Update: Investigations of patients who have been treated by HIV-infected health-care workers. Morbidity and Mortality Weekly Report, 41, 344-346. . (1994). HIV counseling, testing and referral guidelines, http:// www.cdc.gov/nchstp/hiv_aids/ testing, htm

386

THE PERSON WITH HIV/AIDS

. (1998, March). Rapid HIV tests: Issues for program and clinic managers, 1-5. . (1999). Anonymous or confidential HIV counseling and voluntary testing in federally funded testing sites—United States, 1995-1997. Morbidity and Mortality Weekly Report, 48, 509-513. Ferri, R. S. (1998). Oral mucosal transudate testing for HIV-1 antibodies: A clinical update. Journal of the Association of Nurses in AIDS Care, 9, 68-72. Ferri, R. S. (1999, June/July). Getting tested (Editorial). HIV Frontline, Issue 37, 1 Gostin, L. (1992). A human rights framework for evaluating AIDS policies: Consent, confidentiality, and antidiscrimination. In V. Devita, S. Hellman, & S. Rosenberg (Eds.), AIDS: Etiology, diagnosis, treatment and prevention (pp. 498-498). Philadelphia: Lippincott. Janssen, R., Satten, G., Stramer, S., Rawal, B., O'Brien, T., Weiblen, B., Hecht, F., Jack, N., Cleghorn, F., Kahn, J., Chesney, M., & Busch, M. (1998). New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. Journal of the American Medical Association, 280, 42-48. Levy, J. (1993). The transmission of HIV and factors influencing progression to AIDS. Journal of the American Medical Association, 95, 86-98. Lovejoy, N. C., Paul, S., & Freeman, E. (1991). Potential correlates of self-care and symptoms distress in homosexual/bisexual men who are HIV seropositive. Oncology Nursing Forum, 18(7), 1175-1185. Palumbo, P. E., Raskino, C., Fiscus, S., Pahwa, S. S., Schutzbank, T., & Spector, S. A. (1999). Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children. Journal of Infectious Diseases, 179, 576-583. Roland, M., Fine, R., & Volberding, P. (1998). Indications for use of HIV-antibody testing. The AIDS Knowledge Base [http://hivinsite.ucsf.edu/akb/1997/02indic/index.htm]. Tamborland, T., & Kunz, D. (1996). Home HIV testing: The need for regulation. Caring, 8, 52-55. United States Department of Health and Human Services. (1994). HIV counseling, testing, and referral standards and guidelines. Washington, DC: Author.

10

Principles of HIV/AIDS Case Management Demetrius Porche

he prevalence and complexity of human immunodeficiency virus (HIV) infection and AIDS have challenged the existing health care delivery system. In addition, medical advances have changed HIV disease from a state of acute illness to a chronic condition with multiple episodes of acute illness, thereby requiring health care professionals to provide comprehensive health care services to a diverse client population across multiple settings. To meet the comprehensive HIV health care needs of infected clients, case management has been proposed as a model for delivering highquality, cost-effective health care. The purpose of this chapter is to familiarize health care professionals with the historical development of case management, describe case management and the case management process, and review case management models and the outcomes of case management services.

T

HISTORICAL DEVELOPMENT OF CASE MANAGEMENT Case management has historical roots in public health nursing and social work. Case management began after World War II as a mechanism to provide care across the health care continuum for psychiatric and elderly clients (Twyman & Libbus, 1994). Throughout the 1960s 387

388

THE PERSON WITH HIV/AIDS

and 1970s, there was continued recognition that health care was increasing in complexity due to medical discoveries and advances in technology. Additionally, health care services were becoming increasingly fragmented and lacked continuity under the fee-for-service model. During the 1980s, diagnostic related groups (DRGs) were presented as a mechanism to control the escalation of health care costs and to force restructuring and reform of the health care delivery system. Prospective payment systems became the norm for financing health care. Consequently, case management continued to evolve as a strategy to respond to increasing health care costs while ensuring access to health care services in a prospective payment system. HIV case management began in 1986 with the multisite HIV/ AIDS demonstration projects funded by the Robert Wood Johnson Foundation, the Health Resources and Service Administration (HRSA), and the United States Public Health Service. Nine projects were initially funded in the 11 communities of Atlanta; Dallas; Fort Lauderdale; Jersey City, New Jersey; Miami; New Orleans; New York City; Newark, New Jersey; Seattle; West Palm Beach, Florida; and Nassau County, New York (Fleishman, Mor, & Piette, 1991). Since that time case management practices have continued to evolve in the acute and community-based health care settings as an essential component of the health care delivery system. The Ryan White Comprehensive AIDS Resources Emergency (CARE) Act of 1990 formalized case management as a central service in HIV/AIDS care through federal legislation (Sowell, 1995). CASE MANAGEMENT DEFINITION AND MODELS Case management has been proposed as a health care delivery model to ameliorate several health care system problems. Health care professionals advocate case management as a strategy for monitoring and coordinating the delivery of health care services to individuals with complex health care needs (Nickel et ai., 1996). HIV health care providers agree that case management is designed to decrease fragmentation of health care, to maximize appropriate utilization of scarce resources, to coordinate care across multiple settings, and to monitor the utilization, quality, and effectiveness of health care

PRINCIPLES OF HIV AIDS CASE MANAGEMENT

389

services; however, there remains a lack of consensus regarding the definition of case management due to the diversity of case management models in practice. The American Nurses Association (ANA) has defined case management as the "provision of quality care along a continuum, decreased fragmentation of care across many settings, enhancement of the quality of life, and cost containment" (ANA, 1988, pp. 1-2). Wolfe (1997) defines case management as "a collaborative process that assesses, plans, implements, evaluates, and coordinates options and services to ensure cost-effective care based on the needs of particular clients'1 (p. 24). A literature review identified that case management referred to diverse phenomena such as "a patient care delivery system, a professional practice model, a group of activities that a nurse performs within an organization setting, or a separate service provided by private practitioners" (Goodwin, 1994, p. 29). The Association of Nurses in AIDS Care (ANAC) adopted a statement about the nurse as HIV/AIDS case manager. They view case management as hospital, community, or payor based (Kirton, Ferri, & Eleftherakis, 1999). Regardless of the case management definition that delineates the scope of case management practice, there are four main models of case management: (1) the hospital model of discharge planning, (2) the traditional case management model, (3) the direct care model, and (4) the gap-filling model (Beilman, Sowell, Knox, & Phillips, 1998; Benjamin, Lee, & Solkowetz, 1988). The hospital model of discharge planning involves brief monitoring of the patient during an acute care hospital stay. In a traditional model of case management, the client is contacted as early as possible and provided planning, coordination of sendees and care, and monitoring of his or her illness throughout the hospital stay and into the community setting. The direct care model includes the coordinating functions in the traditional model with the provision of care directly to the client. Traditional services are provided in the gap-filling model, with the additional ability to purchase extra resources or services that are needed by the client. The functions of HIV case management are implemented using a model developed in acute care or community-based organizations based on one of the four models or a hybrid of one of these models.

390

THE PERSON WITH HIV/AIDS

Case management functions occur 24 hours a day. Primary functions of a case manager are negotiation of services and treatments with health care organizations or insurers; communication with health care providers, clients, families, and information systems; coordination of care across multiple settings (from the acute care setting into the community) to avoid duplication of services and overutilization of resources; and education and counseling. In addition, the case manager facilitates multidisciplinary assessments, collective planning, evaluation, and documentation of client outcomes in terms of the cost and quality of HIV care (More & Mandell, 1997). The case manager functions are accomplished through the implementation of a systematic process. CASE MANAGEMENT PROCESS Case management is a collaborative and multidisciplinary process that parallels the nursing process framework. Table 10.1 presents the case management process (More & Mandell, 1997; Strassner, 1996). Identification or case finding of HFV-infected clients who are eligible for case management services can be achieved by several methods. One method is that HFV-infected clients with high-risk diagnosis are case managed. Another method is that all clients admitted with an HIV/AIDS diagnosis may be case managed either due to the high acuity diagnosis or the high volume of clients with this diagnosis (Cohen & Cesta, 1994). The identification process involves screening out those HIV-infected clients who do not meet the established criteria for a particular level of case management services. TABLE 10.1

Case Management Process

Offer case finding and screening Provide a comprehensive assessment Conduct assessment analysis and problem identification/diagnosis Develop plan of care Coordinate and implement plan of care Monitor plan of care, client's response, cost, and quality of services Revise plan of care, as necessary Evaluate program and client outcomes Document case management functions

PRINCIPLES OF HIV/AIDS CASE MANAGEMENT

391

Each identified client is comprehensively assessed. This assessment minimally includes a history, an evaluation of the client's physical, emotional, and psychological needs, and a review of financial resources and assets. This assessment is ongoing to identify any current or potential problems that may occur throughout the coordination of care. The case manager also assesses the available resources in the community that can potentially meet the HIV-infected client's needs. Identification of available resources requires that the case manager is knowledgeable about internal and external resources available. From the comprehensive assessment, the client's problem/ diagnosis is individualized. Highest priority problems are those that probably will respond to an intervention, fall within the client or significant other's level of capability, match available resources, and are high-risk, high-volume, or high-acuity problems. Table 10.2 presents several problems that HIV case managers may encounter. The case management plan of care should be developed within a multidisciplinary team to address priority problems. The client should be the central focus of any case management model. Most case management models provide case managers with the authority and responsibility to implement the plan of care in collaboration TABLE 10.2

Potential HIV Disease Case Management Problems

Lack of knowledge regarding HIV disease and therapeutic regimen Compliance with prescribed regimen Substance use Lack of family or support system Family conflict Inadequate finances Inadequate or lack of housing Child care issues, such as day care, guardianship Stigmatization of the disease and homophobia HIV dementia Inadequate resources available in the community Homemaker/housekeeping needs Legal consultation Counseling Individual Bereavement Family planning

392

THE PERSON WITH HIV/AIDS

with the client. During the implementation, the case manager is responsible for negotiating health care services, matching needs with available services, providing referrals, coordinating the multidisciplinary health care team, and, in some institutions, providing direct care to the client (Birmingham, 1996; Strassner, 1996). The case manager continually monitors the implementation of the plan of care for the expected outcomes. Expected outcomes of case management are cost effectiveness, quality services, and clinical improvement. The client's care can be managed through routine telephone follow-up calls, home visits, and conferences with the physician and/or health care personnel. COMMUNITY-BASED CASE MANAGEMENT Community-based organizations increasingly are becoming providers of health care services to HIV-infected clients in some communities (Grier & Sowell, 1993). Community-based case management is case management services provided by a community-based organization. These services vary among community-based organizations, depending on an organization's mission and philosophy. Communitybased case management is an effective mechanism to coordinate services within the broader context of an organized community (Indyk, Belville, Lachapelle, Gordon, & Dewart, 1993). It is dependent on a community with viable HIV resources and services (Sowell, 1995). Typical community-based case management services provided by community-based organizations are HIV testing and counseling, advocacy, referrals, coordination of health care services, housing placement, medical services (early intervention care), legal consultation, volunteer services, and community education and outreach. Clients rated community education and outreach as important functions of community-based case management (Sowell, 1995). A comparison of hospital and community-based case management programs for persons with AIDS identified that these programs provide services to a different population mix. Hospital-based case managers had a higher percentage of clients whose primary risk factor for HIV was intravenous drug use. Hospital case managers also manage HIV clients with more needs for long-term care, housing, trans-

PRINCIPLES OF HIV/AIDS CASE MANAGEMENT

393

portation, and psychological counseling. Community-based case managers in community-based organizations had a higher percentage of clients who were homosexual or bisexual. Clients receiving community-based case management need more emotional support, volunteers, and legal consultation. Often clients report being case managed through both settings (Piette, Fleishman, Mor, & Dill, 1990)"

INTEGRATED CASE MANAGEMENT Changes in health care reform and the chronicity of HIV disease require that health care professionals develop organized integrated systems of care to reduce waste and inefficiencies while focusing on primary care and improving quality care and client outcomes (Czerenda & Best, 1994). Integrated, organized health care delivery systems require a management culture that supports the goals of integrated health care delivery systems. A desired outcome of integrated health care delivery systems is effective, cost-efficient, and safe client care along a continuum (Czerenda & Best, 1994; Sowell & Meadows, 1994). Comprehensive HIV care requires integration of a client's physical, psychological, emotional, spiritual, and financial needs into a coordinated plan of care (Sowell & Grier, 1995). Integrated case management is a health care delivery model to provide integrated HIV care within an integrated health care deliver)7 system. A cornerstone of integrated case management is an interdisciplinary approach. Integrated HIV case management is a collaborative effort among physicians, nurses, social workers, pastoral counselors, substance abuse specialists, and community-based volunteers. These caregivers participate in the coordination and planning of care between the hospital and community-based agencies. Integrated case management uses vertical integration of health care organizations in one health care delivery system to meet the client's needs. The various professionals and organizations function as a single unit in the coordination of services. The assigned case manager of the respective agency is responsible for coordinating all individuals from the other respective organizations that are involved in the HFVinfected client's care.

394

THE PERSON WITH HIV/AIDS

RECONSTRUCTION CASE MANAGEMENT Some HlV-infected individuals are experiencing a "Lazarus syndrome" as a result of successful HIV pharmacologic therapies, such as highly active antiretroviral therapy (Gregonis, 1997). Those who previously were too ill to work or near death now find they are potentially capable of returning to work or their normal lifestyle. Improved health among HlV-infected individuals poses new challenges for the HIV case manager, who must understand that even with better medical treatments, the HIV-infected client's future health remains uncertain. The present case management programs need reconstruction to meet the HIV-infected client's needs and maximize his or her potential abilities. Case managers need to assist the client in planning for the future while continuing to acknowledge the ongoing need for HIV treatment and social support services (Sowell, 1997). Critical decisions that the case manager and client will encounter are how to assist clients in returning to work without compromising their health benefits, how to coordinate a work schedule with the spiraling episodes between health and illness, and how to remove a client from disability temporarily without jeopardizing future disability benefits. Advances in the treatment of HIV infection has posed new challenges for the case manager to reconstruct case management programs that focus on advocacy information programs and social support services for individuals who are "healthy" but continue to progress along an unpredictable disease trajectory with periods of disability.

PREVENTION CASE MANAGEMENT The Centers for Disease Control and Prevention (CDC) originally funded prevention case management (PCM) for HIV in 1992 (National Center for HIV, STD, & TB Prevention et al, 1997). Prevention case management initially included health education and risk reduction activities through cooperative agreements with communitybased organizations. Guidelines for PCM were published by the CDC in 1995 and revised in 1997. Currently, HIV prevention case management is a hybrid intervention that combines individual HIV risk reduction interventions with

PRINCIPLES OF HIV/AIDS CASE MANAGEMENT

395

case management principles. Behavioral interventions are designed for HIV-positive and HIV-negative individuals who are experiencing difficulty in initiating and/or sustaining practices that limit the potential transmission of HIV. Prevention case management consists of intensive, individualized supportive prevention counseling. Table 10.3 outlines essential components of PCM. The interaction between the client and case manager in PCM focuses on helping the individual to prioritize his or her risk of HIV infection in light of other compounding problems that may exist within that person's life. Clients at risk for HIV infection may trivialize HIV prevention behaviors because of multiple problems or the need to meet some basic human needs. Basic human needs that may distract a client from focusing on HIV prevention strategies are listed in Table 10.4. PCM engages a client in meeting some basic needs while providing HIV prevention education and counseling (National Center for HIV, STD, & TB Prevention et al., 1997). Prevention case management TABLE 10.3 Essential Components of Prevention Case Management Complete HIV and STD behavioral risk assessment Complete HIV and STD medical assessment Complete psychosocial needs assessment Risk reduction counseling and education Referral to community-based organizations for services

TABLE 10.4 Basic Needs that Interfere with Prevention Interventions Lack of money Lack of child care Lack of housing Lack of transportation Lack of communication devices such as telephones Active substance use Poor physical health Poor mental health Criminal history Lack of skills

396

THE PERSON WITH HIV/AIDS

programs address the client's individual needs while providing prevention interventions. For example, a PCM case manager may focus on a drug-dependent client's psychosocial and mental health needs while providing risk reduction education and counseling on safer sex practices (El-Bassel et al., 1997). Independent Case Management Services Independent case management is the provision of case management services through the hiring of a case manager. Independent case managers are hired by clients or insurance companies to complete a specific case management project (Wolfe, 1997). Clients may hire an independent case manager to coordinate and negotiate their HIV care with all HIV providers and the insurance company. Clients can also hire independent case managers to provide unbiased education regarding potential therapies that will facilitate their decision making. Referrals to independent case managers can be located in the telephone directory and through physicians and communitybased organizations. HIV-infected clients frequently cannot afford to hire independent case management services; they often rely on personal associations with health care professionals to function in the independent case manager role. Some HIV-infected clients may be forced to rely heavily on a community-based organization's services to decrease the cost to the insurer, regardless of the client's inconvenience. Likewise, insurers may contract with an independen case manager within the local community to ensure that an HIVinfected client utilizes only approved and cost-effective services in that community. EVALUATION OF CASE MANAGEMENT OUTCOMES Case management programs are evaluated against the outcomes of cost and quality care. One retrospective review (Sowell et al., 1992) of 150 men who died of AIDS did not identify a significant difference between total days hospitalized, number of admissions, or the average length of stay among patients who were and were not case managed;

PRINCIPLES OF HIV/AIDS CASE MANAGEMENT

397

however, the services provided to clients with AIDS who were case managed were less expensive. Another significant finding in this study was that case managed clients lived significantly longer between the time of diagnosis and death, and between their first AIDS-related hospitalization and death, compared to men who were not case managed. This finding potentially implies that case management may affect an AIDS client's length of life. An AIDS case management model implemented by the Missouri Department of Health was not effective in reducing the number of inpatient hospital days in AIDS patients (Twyman & Libbus, 1994). These findings support earlier findings by Benjamin (1988), who also failed to confirm that case management decreased the amount of hospital care. In contrast, The Caring Center research project, a nurse-directed health care facility for clients living with HIV/AIDS in Denver, Colorado, identified a reduction in the number of primary care provider, clinic, and emergency room visits by 42% in the HFV-infected and 50% in the AIDS clients who were case managed (Leenerts, Koehler, 8c Neil, 1996). This decreased use of HIV health care services resulted in an estimated savings of $1,590,384 in 1993. Seventythree percent of these clients reported that the self-care skills learned from nurses increased their independence at home. Controversy remains in relation to the cost savings of case management in HIV/ AIDS care; however, there is increasing evidence that HIV/AIDS clients who are case managed report an increase in their quality of life and survival statistics (Leenerts et al., 1996; Nickel et al., 1996; Sowell et al., 1992).

CONCLUSION Case management has emerged as a method of monitoring and overseeing the delivery of high-quality, cost-effective care whose outcomes can be measured. With the introduction of more effective medical treatments, the needs of HIV-infected persons must be reevaluated on an ongoing basis. Case management provides a mechanism for such evaluation and provision of services.

398

THE PERSON WITH HIV/AIDS

REFERENCES American Nurses Association. (1988). Nursing case management. Washington, DC: Author. Beilman, J., Sowell, R., Knox, M., & Phillips, K. (1998). Case management at what expense? A case study of the emotional cost of case management. Nursing Case Management,3'(2), 89-95. Benjamin, A. (1988). Long-term care and AIDS: Perspectives from experience with the elderly. The Millbank Quarterly, 66(3), 415-433. Benjamin, A., Lee, P., & Solkowetz, S. (1988). Case management for persons with Acquired Immune Deficiency Syndrome in San Francisco. Health Care Financing Review (Annual Suppl.), 69-73. Birmingham, J. (1996). How to apply CMSA's standards of practice for case management in a capitated environment. Journal of Case Management, 2(5), 9-22. Cohen, E., & Cesta, T. (1994). Case management in the acute care setting: A model for health care reform. Journal of Case Management, 3(3), 110-115. Czerenda, A., & Best, L. (1994). Tying it all together: Integrating a hospital-based health care system through case management education. Journal of Case Management, 3(2), 69-73. El-Bassel, N., Schilling, R., Irwin, K., Faruque, S., Gilbert, L., Von Bargen,J., Serrano, Y., & Edlin, B. (1997). Sex trading and psychological distress among women from the streets of Harlem. American Journal of Public Health, 87, 66-70. Fleishman, J., Mor, V., & Piette, J. (1991). AIDS case management: The client's perspective. Health Services Research, 26(4), 447-470. Goodwin, D. (1994). Nursing case management activities: A study of nursing staff involvement. Journal of Nursing Administration, 24(2), 29-34. Gregonis, S. (1997). Magic Johnson and Lazarus—The new syndrome [Editorial]. Journal of the Association of Nurses in AIDS Care, 8(5), 50-51. Grier, J., & Sowell, R. (1993). Standards and evaluation in community-based case management. Journal of the Association of Nurses in AIDS Care, 4(1), 32-33. Indyk, D., Belville, R., Lachapelle, S., Gordon, G., & Dewart, T. (1993). A communitybased approach to HIV case management: Systematizing the unmanageable. Social Work, 38(4), 380-387. Kirton, C. A., Ferri, R. S., & Eleftherakis, V. (1999). Primary care and case management of persons with HIV/AIDS. Nursing Clinics of North America, 34(1), 71-94. Lennerts, M., Koehler, J., & Neil, R. (1996). Nursing care models increase care quality while reducing cost. Journal of the Association of Nurses in AIDS Care, 7(4), 37-49. More, P., & Mandell, S. (1997). An evolving practice: Nursing case management. New York: McGraw-Hill. National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, & Department of Health and Human Services. (1997). HIV prevention case management: Literature review and current practice. Atlanta: Author. Nickel, J., Salsberry, P., Caswell, R., Keller, M., Long, T,, & O'Connell, M. (1996). Quality of life in nurse case management of persons with AIDS receiving home care. Research in Nursing and Health, 19, 91-99.

PRINCIPLES OF HIV/AIDS CASE MANAGEMEN

399

Piette, J., Fleishman,],, Mor, V., & Dill, A. (1990). A comparison of hospital and community base management programs for persons with AIDS. Medical Care, 25(8), 746-755. Sowell, R. (1995). Community-based HIV case management: Challenges and opportunities. Journal of the Association of Nurses in AIDS Care, 6(2), 33-40. . (1997). Reconstruction case management. Journal of the Association of Nurses in AIDS Care, 8(6], 43-45. Sowell, R., 8c Grier, J. (1995). Integrated case management: The AIDS Atlanta model. Journal of Case Management, 4 ( 1 ) , 15—21. Sowell, R., Gueldner, S., Killeen, M., Lowenstein, A., Fuszard, B., & Swansburg, R. (1992). Impact of case management on hospital charges of PWAs in Georgia. Journal of the Association of Nurses in AIDS Care, 3(2), 24-31. Sowell, R., & Meadows, T. (1994). An integrated case management model: Developing standards, evaluation, and outcome criteria. Nursing Administration Quarterly, 75(2), 53-64. Strassner, L. (1996). The ABCs of case management: A review of the basics. Nursing Case Management, 1 ( 1 ) , 22-30. Twyman, D., & Libbus, K. (1994). Case-management of AIDS clients as a predictor of total inpatient hospital days. Public Health Nursing, 11(6), 406-411. Wolfe, G. (1997). The case manager's role in adherence. Journal of the Association of Nurses in AIDS Care, S(Suppl), 24-28.

This page intentionally left blank

11

HIV Infection in Women Mary Jo Hoyt and Susan Holman

IDS has increasingly affected women since its recognition in 1981 when the first case was described in a woman (Centers for Disease Control, 1981). Women are estimated to constitute at least 40% of AIDS cases worldwide, mainly in developing countries (Levine, 1997). As the numbers of women diagnosed with HIV infection and AIDS have increased rapidly in the 1990s, health care providers have had to respond to the issues of HIV in families. AIDS in women is a family disease, often with multiple family members from different generations infected and certainly affected by the disease. This chapter will outline major issues of HIV and AIDS in women, including epidemiology, prevention, the unique clinical manifestations, gynecological and reproductive concerns, and social and psychological issues that women and their families face. Nurses can play a significant role in helping women and their families deal with HIV and AIDS (Sowell, Moneyham, & Aranda-Naranjo, 1999). Nursing considerations for women with HIV will also be discussed.

A

EPIDEMIOLOGY Women can acquire HIV infection through various routes of transmission, including injection drug use (IDU), sex with an infected partner, and receiving infected blood products. To date in the United States and other developed countries, most cases of AIDS in women 401

402

THE PERSON WITH HIV/AIDS

are associated directly or indirectly with IDU. In 1997IDU accounted for about 44% of reported AIDS cases in U.S. women, followed by heterosexual contact (about 39%) (Centers for Disease Control and Prevention, 1997b). The incidence of woman-to-woman transmission of HIV is low, although three cases have been reported in the literature. Larger studies of lesbians with HIV have found that, in an overwhelming majority of cases, other risk factors, including transfusions, IDU, and sex with men, were present and could not be ruled out as the mode of disease acquisition (Centers for Disease Control and Prevention, 1997a; Chu & Wortley, 1995; Petersen et al., 1992). In one study, protective barrier use during oral sex was reported as follows: always, 26%; sometimes, 31%; and never, 43% (Kennedy et al., 1998). Younger bisexual women were more likely to report having sex with men, including bisexual men, than older ones, and this was more likely for Black women ("Lesbians' HIV Risk . . . " 1997). Although IDU is a major source of HIV transmission due to sharing of contaminated equipment, women who use nonintravenous drugs may be at increased risk of acquiring HIV. Women using nonintravenous drugs, especially crack cocaine, may exchange sex for drugs, often with men who object to using condoms. In these situations, or because drugs lower inhibitions, they may be more likely to engage in unprotected sex. Also, their sex partners may be current or former IDUs. HIV and AIDS in women disproportionately affects some racial and ethnic minority groups. African-American and Hispanic women represent nearly 80% of women with Centers for Disease Control and Prevention-defined AIDS (Centers for Disease Control and Prevention, 1997b). The majority of women with AIDS are between 15 and 44 years of age, the primary childbearing years. As of December 1997, there were 92,242 women in the United States with AIDS. Overall in the United States, 1.7 per 1,000 women giving birth in 1991 were infected with HIV (Gwinn, Wasser, Fleming, Karon, & Petersen, 1993). There was significant geographic variability in the rates of HIV seroprevalence, from 6/1,000 in the Northeast to 0.5/1,000 in the Midwest (Wasser, Gwinn, & Fleming, 1993). These findings correlate with the geographic variability seen in women diagnosed with AIDS, where the majority diagnosed live in large cities, principally in the Northeast. However, the number of women with AIDS is increasing

HIV INFECTION IN WOMEN

403

in rural areas and smaller communities, particularly in the Southeast (Voelker, 1998). More information about the epidemiology of HIV/ AIDS in women can be found in chapter 1. PREVENTION ISSUES Women are at risk of acquiring HIV for various reasons. Power imbalances in relationships may make it difficult to negotiate "safe" sexual relationships. These include economic, gender, and culturalbased imbalances. Drug use may increase a woman's exposure to unsafe situations and decrease the ability to negotiate safer ones. Also, a lack of a sense of vulnerability or risk for HIV, particularly among women who are unaware of a partner's current or past risk behaviors, may place a woman at risk for HIV. Prevention efforts targeted to women must be multidimensional because no single strategy will work with this heterogeneous group. Different subgroups may require distinct and discrete prevention efforts. Several tenets should underlie all prevention efforts targeted to women. Prevention messages, whether delivered verbally or in educational material, should be culturally sensitive and provided in understandable language. Sexual partners should be included whenever possible to reinforce prevention messages. Prevention efforts should also address the general empowerment of women to facilitate their ability to negotiate safer practices, to obtain addiction treatment services, or to leave relationships that put them at risk. Levine (1997) lists major risk factors for heterosexual transmission of HIV to women: presence of another sexually transmitted disease, lack of circumcision, cervical ectopy, intercourse during menses, and high viral load in the HIV-positive sexual partner. Other risk factors include prevalence of HIV in the population, engagement in high-risk sexual behavior at an early age, an increased number of sexual partners, host immunogenetic factors, and hormonal and other local effects in the female genital tract (Fowler, Melnick, & Mathieson, 1997). Prevention efforts should take place at multiple points on the health care continuum. Offering continuing general prevention messages such as public service announcements and having educational pamphlets available in waiting rooms where women receive services

404

THE PERSON WITH HIV/AIDS

for themselves or their children can reach large numbers of women. Individualized prevention messages require more time and expense but may be more effective in reducing risk behavior. Such individualized prevention efforts include discussions of risk and implementation of safer sex practices during patient education sessions and HIV pretest counseling. HIV counseling and testing are increasingly common in health care settings that provide care for women, particularly in prenatal clinics. The components of HIV pretest counseling provide a basis for every one-to-one interaction that focuses on the prevention of HIV. The discussion of risk reduction is an important part of HIV counseling, both pre- and posttest. Prevention plans should be individualized and developed in collaboration with each woman. Assuming heterosexuality may inhibit open communication and the development of appropriate prevention plans. Providers should discuss, encourage, and refer drug users to addiction treatment services to increase their ability to make safe choices. Barriers to condom use should be assessed with heterosexual/bisexual women. Prevention is discussed further in chapter 3. CLINICAL MANIFESTATIONS AND TREATMENT Natural History of HIV in Women Data on the natural history of HIV infection in women are limited because initial epidemiologic an'd natural history studies of HIV disease concentrated on all-male cohorts. However, studies examining the transmission of HIV and the progression of HIV-related disease in women are under way. Major ongoing studies include the Women's Intragency HIV Study, the HIV Epidemiology Research Study, and the Women and Infants Transmission Study. The first two studies will help to identify the nature and rate of HIV progression, characterize manifestations of HIV disease, and assess the effects of therapeutic regimens on health and survival in HIV-positive women. The third will further examine perinatal HIV transmission. Some information on clinical manifestations and natural history of HIV in women is available from small studies. In contrast to early

HIV INFECTION IN WOMEN

405

reports, findings from several prospective studies suggest that there are no pathophysiologic reasons why HIV-infected women should fare differently in terms of disease progression and survival than infected men (Carpenter, Mayer, Fisher, Desai, & Durand, 1989; Carpenter et al., 1991). Other factors, including differential access to and use of health care, lower socioeconomic status, poor social support, the milieu of the drug culture, homelessness, and domestic violence, may more commonly adversely affect health status and survival in women. Small studies have indicated that women also experience some clinical manifestations of HIV infection that are unique to them or are more prevalent than in men. Women may be more likely to experience esophageal candidiasis as a first AIDS-defming event than men (Carpenter et al., 1989, 1991; Fleming, Ciesielski, Byers, Castro, & Berkelman, 1993), and this may occur at a higher CD4+ cell count than seen in men. Women may also be at increased risk for bacterial pneumonia than men (Carpenter et al., 1991), but others find equal distribution between heterosexual men and women (Cohen, Sande, &Volberding, 1998). Women with AIDS can develop Kaposi's sarcoma (KS) but do so rarely (Cohen etal., 1998; Haverkos, Brotman, & Morgan, 1990). However, an unusual form of KS presenting as a vulvar mass in a woman has been reported (Macasaet, Duerr, Thelms, Vernon, & Unger, 1995). Gynecologic Manifestations of HIV Studies examining the clinical, non-AIDS-defming features of HIVrelated disease in women have frequently identified fungal and viral infections, in particular of the genital tract, as the most prevalent disease manifestations, often preceding a diagnosis of AIDS (Carpenter et al., 1991). Although studies have found no association between HIV infection and bacterial vaginosis, Trichomonas vaginitis, syphilis, chlamydial infection, or gonorrhea, vaginal candidiasis is more common in HIV-infected women, and recurrent candidal vaginitis that is difficult to treat is a common sentinel symptom of HIV infection (Augenbraun & McCormack, 1994; Cohen 8c Durham, 1993) (see chapter 5). Genital ulcer disease, which is associated with transmission and acquisition of HIV-infection, is also prevalent, with a rate

406

THE PERSON WITH HIV/AIDS

of 14% in one population of HIV-infected women (LaGuardia et al., 1995). Herpes simplex virus is the most common pathogen causing genital ulcer disease in women, and shedding, even in HIV-infected women without genital symptoms, was found in one study to be nearly four times greater than viral shedding found in HIV-negative women with HSV (Augenbraun et al., 1995). Recurrent episodes of genital herpes simplex virus infections are typical in HIV-infected women, and suppressive therapy is often warranted (Cotton & Watts, 1997). Idiopathic genital ulcers may also be seen (Cohen et al., 1998). Although there does not appear to be an increased prevalence of pelvic inflammatory disease in HIV-infected women, the course of the disease appears to be more severe, and thus more likely to result in chronic sequelae such as menorrhagia, dysmenorrhea, and dysparunia (Hoegsberg et al., 1990). However, HIV-infected women generally respond to the usual therapy (Cotton & Watts, 1997). As has been found for HIV-infected men, biological false-positive nontreponemal tests for syphilis are more common in HIV-infected women, especially in injection drug users (Augenbraun et al., 1994). Cervical intraepithelial neoplasia (GIN), the precursor to cervical cancer, occurs with increased frequency and severity among women with immunodeficiency. Studies from several centers have now established that women who are immunodeficient because of HIV have high rates of abnormal Pap smears and GIN and that the prevalence of both increases as immunodeficiency becomes more severe (Cotton & Watts, 1997). Based on these and other data, invasive cervical cancer was added to the 1993 AIDS surveillance case definition (Centers for Disease Control and Prevention, 1992; see chapter 1). The incidence of invasive cervical cancer in HIV-infected women has not yet been established, but it is believed to be low. The question of whether Pap smears are adequately sensitive in detecting cervical cytological abnormalities in HIV-infected women has been raised (Fink et al., 1994; Maiman et al., 1991). Later studies have generally refuted this. In one prospective, blinded study, the sensitivity and specificity of Pap tests in HFV-seropositive women were 81% and 87%, respectively (Wright, Ellerbrock, Chiasson, Van Devanter, & Sun, 1994). In this study, 20% of the 398 HIV-positive women compared to 4% of the 357 HIV-negative women had colposcopically confirmed GIN. GIN was independently associated with

HIV INFECTION IN WOMEN

407

human papillomavirus (HPV) infection, HIV infection, CD4+ lymphocyte count less than 200/mm3, and age greater than 34 years. Currently, there is little information on the treatment of GIN in HIV-positive women, and recommendations for treatment do not differ from those of HlV-negative women. However, one study showed recurrent or persistent GIN following loop excision in 56% of HIV-positive women, compared with 13% in women of unknown serostatus (Wright, Koulos, Schnoll, Swanbeck, Ellerbrock, Chiasson, & Richart, 1994); a second study showed 62% recurrence in infected women versus 18% in uninfected women (Fruchter et al., 1996). HIV-positive women with abnormal cervical cytology require close follow-up and frequent colposcopic evaluation because of the theoretical increased risk of progression to carcinoma in situ or invasive cervical cancer associated with immunosuppression. The risk of treatment failure may increase as immunosuppression increases. There are little data available to date on menstrual irregularities in HIV-positive women. Although a high prevalence of oligomenorrhea and amenorrhea have been described, menstrual symptoms in these studies may have been attributable to substance misuse, which has a significant effect on the hypothalamus and is associated with menstrual cycle disturbances. A theoretical mechanism for a higher prevalence of amenorrhea and oligomenorrhea in the absence of substance misuse in HIV-positive women is endocrine abnormalities. Endocrine abnormalities and gonadal failure are well documented in men infected with HIV, but one controlled study published on the effects of HIV infection and immunosuppression on menstrual symptoms in the absence of confounding variables did not confirm a higher prevalence of menstrual symptoms in HlV-seropositive women (Shah et al., 1994). Nonetheless, other studies suggest that about one third of HlV-infected women had either excessive menstrual bleeding or amenorrhea (Ellerbrock et al., 1996). In general, vaginitis in HIV-positive women is treated with similar regimens as in HlV-negative women (see Table 11.1). However, treatment should be initiated promptly and should be aggressive, with full-dose therapy preferred over short-course treatment, as sometimes used in uninfected women. Vaginal pathogens may predispose women to increased frequency of herpes simplex virus outbreaks or recurrences of genital warts (Denenberg, 1993). When

THE PERSON WITH HIV/AIDS

408

TABLE 11.1 Treatment for Vaginitis and Related Conditions Condition

Symptoms

Treatment

Bacterial vaginosis

Odorous, frothy, vaginal discharge

Trichomonas infection

Copious, itchy vaginal discharge

Metronidazole 500 mg po BID x 7 days Avoid alcohol Alternative: Augmentin 500 mg po TID x 7 days or Metrogel cream BID x 5 days Metronidazole 250 mg po TID or 500 mg po BID x 7 days Avoid alcohol

Yeast/Candida/ vaginal thrush

Itchy, clumpy discharge with rash and irritation

Mucopurulent cervicitis (MPC)

Asymptomatic, or purulent discharge

Antifungal creams or suppositories HS x 7-14 days; repeat as needed Add fluconazole 100 mg or 150 mg lendula cream, Vitamin E oil, or wheat germ oil. Daily sets of Kegel exercises to increase circulation Treat as for STD: Rocephin 250 mg IM stat followed by doxycycline 100 mg BID x 7 days

Prevention and Comfort Treat female partners with same regimen Goldenseal sitz bath (1 Tbsp. of Goldenseal powder in warm bath)

Treat all partners Garlic suppositories x 12 H QD for 2-3 weeks, if metronidazole is contraindicated

409

HIV INFECTION IN WOMEN

TABLE 11.1 (continued) Condition

Symptoms

Treatment

Herpes simplex virus genital infection

Painful blister-like sores with swollen tender inguinal nodes and fever, malaise

Acyclovir 200 mg po 5 x day for 1 0 days during outbreak Acyclovir 400 mg BID for maintenance if needed

Prevention and Comfort Daily therapeutic vitamins Zinc oxide to new sores, goldenseal sitz baths

Source: Denenberg, R. (1993). Gynecological care manual for HIV-positive women. Durant, OH: Essential Medical Information Systems.

vaginal candidiasis is recurrent, or when systemic antibiotics are prescribed, prophylaxis should be employed. Genital warts are an expression of certain types of the human papillomavirus (HPV). Clinically apparent genital warts are called condyloma acuminata. The incidence of warts appears to be significantly increased in HIV-infected women (Chirgwin, Feldman, Augenbraun, Landesman, & Minkoff, 1995). Condyloma may occur relatively early in HIV disease and may become florid and respond inadequately to treatment. The lesions appear as white or gray fleshy clusters. Because HPV is also associated with GIN, all cases should be evaluated by Pap smear for cervical cytological abnormalities. Treatment of genital warts may be attempted with trichloroacetic or bichloroacetic acid, applied at weekly intervals, with surrounding tissue protected with Vaseline, A&D ointment, or antibiotic ointment. Six to eight treatments may be required to produce a remission. Aldara cream may be applied three times a week by the patient, which has been a successful treatment for women with small condyloma. Experimentally, 5-rluorouracil (5-FU or Efudex-5%) cream and alpha-interferon injections are being investigated as alternative treatments. Podophyllin is not recommended, as it usually fails to induce remission, and it cannot be used inside the vagina because of the risk of neurotoxicity upon systemic absorption. PREGNANCY AND REPRODUCTIVE CONCERNS Immune function is somewhat altered by pregnancy, and the function of the T lymphocytes, also affected by HIV infection, may be

410

THE PERSON WITH HIV/AIDS

compromised. Studies have shown decreases in T4 cells, altered T4to-T8 ratios, and decreased B cells during pregnancy (Bailey, Herrod, Younger, & Shaver, 1985; Glassman, Bennet, Christopher, & Self, 1985). Such studies support the theory of a decrease in cell-mediated immunity during pregnancy, making a pregnant woman more susceptible to some viral, bacterial, and fungal infections. Therefore, there has been concern that pregnancy-induced depression of cellmediated immunity could enhance the relative immune incompetence of HIV-infected women. Initially, reports of pregnant women with AIDS supported such a concern. Studies of pregnant women with AIDS or symptomatic HIV disease showed a greater than expected disease progression than seen in nonpregnant patients, suggesting that pregnancy was responsible for disease acceleration (Minkoff, DeRegt, Landesman, & Schwarz, 1986; Minkoff, Nanda, Menez, & Fikrig, 1987). More recently, prospectively designed controlled studies have found that pregnancy has either no effect or only a minor effect on the course of HIV disease, including viral load (Berrebi et al., 1990; Bigger, Pahwa, Landesman, & Goedert, 1988; Burns et al., 1998; Helfgott, Lai, O'Sullivan, & Yasin, 1995). Optimal therapeutic regimens for the health of the mother during a pregnancy complicated by HIV infection have yet to be determined. Generally, the recommendation is that therapies potentially beneficial to women should not be withheld during pregnancy unless an adverse maternal, fetal, or neonatal effect is known and outweighs the potential maternal benefits of therapy (Sperling & Stratton, 1992). The pregnant woman should make decisions regarding an acceptable level of maternal, fetal, or neonatal risk after risk-benefit discussions with her primary care provider.

Vertical HIV Transmission Vertical transmission of HIV infection from mother to child is the most common route of acquisition of pediatric HIV infection. Worldwide, an estimated 500,000 million infants are perinatally infected with HIV annually, mostly in developing countries (Centers for Disease Control, 1998b). Significant variation in perinatal transmission rates have been reported around the world, with the lowest rates

HIV INFECTION IN WOMEN

411

reported in Europe, intermediate rates in the United States (generally 25% to 30% without treatment), and highest rates in Africa. This variation in transmission rates is probably related both to methodological differences between studies and to differences in factors associated with the increased risk of transmission (Working Group on Mother-to-Child Transmission of HIV, 1995). Why certain children born to HFV-infected women are infected, while others are spared with apparently no adverse effects, remains a puzzling question (Lazuriago & Sullivan, 1998). Studies suggest that transmission occurs both early and late in pregnancy, but there is still uncertainty about the mechanism and timing of transmission. Evidence that early intrauterine transmission can occur has been garnered from reports in which HIV was isolated in tissue and organs of fetuses electively aborted from HIV-infected women. However, fetal studies can be difficult because of the risk of contamination with maternal blood. In many studies, the proportion of fetuses infected was higher than the transmission rate expected from knowledge of surviving infants, indicating that the virus identified may in reality have been that of the mother, rather than the fetus (Mano & Chermann, 1991; Soeiro, Rubinstein, Rashbaum, & Lyman, 1992). Prolonged rupture of the amniotic membranes may also increase the risk of vertical HIV-1 transmission (Landesman et al., 1996). During delivery, the infant has prolonged and extensive direct contact with secretions from the vagina and cervix and, in certain circumstances, with maternal blood. It is believed that about 50% of perinatal transmission occurs during the intrapartum period (Minkoff & Mofenson, 1994). Because HIV has been isolated in vaginal and cervical secretions, the infant could be infected through ingestion of HIV-containing blood and fluids, or through colonization on the skin and mucosal surfaces. A series showing that second-born twins had a lower risk of infection than first-born twins (Goedert, Duliege, Amos, Felton, & Biggar, 1991) and studies showing lower risk of transmission with cesarean delivery (European Collaborative Study, 1988, 1991, 1992) support this hypothesis. Other studies have not found differences in HIV transmission between vaginal and cesarean deliveries (Bryson, 1996; Landesman et al., 1996), although one important recent study suggests that HIV-infected women who have elective caesarean section, in the presence of zidovudine therapy, can dramatically reduce the likelihood of transmission to their newborns

412

THE PERSON WITH HIV/AIDS

(Mandelbrot et al., 1998). A meta-analysis of 15 prospective cohort studies conducted from 1982 through 1996 suggests that elective cesarean delivery performed before labor and rupture of fetal membranes, even when the patient did not receive zidovudine therapy, is strongly associated with a lower risk of vertical transmission of HIV (International Perinatal HIV Group, 1999). Studies have also found a significant association between an increased risk of HIV transmission and obstetrical events during labor and delivery that resulted in potential maternal blood exposure to the infant, particularly the use of fetal scalp electrodes, abruption, episiotomy, and second-degree or greater severe laceration (Boyer et al., 1994; Bryson, 1996; European Collaborative Study, 1992). Maternal risk factors for transmission, including clinical, viral, and immunological characteristics, have also been investigated. Symptomatic illness or the presence of AIDS-defining conditions are inconsistently associated with an increased risk of transmission to the child. In contrast, laboratory markers of maternal stage of disease during pregnancy have consistently been associated with an increased risk of transmission. Among immunological markers, low counts of CD4+ cells, a low percentage of CD4+ cells, and a low CD4/CD8 ratio have often been associated with an increased risk of transmission. Numerous reports have found a strong association with p24 antigenemia (Kuhn & Stein, 1995), and one study found that maternal HIV RNA levels were highly predictive of perinatal transmission risk (Dickover et al., 1996). A high maternal plasma concentration of virus during pregnancy has been suggested as a risk factor for transmission of HIV from an untreated mother to the infant (Garcia et al., 1998; Sperling et al., 1996), a finding that has led to calls for early detection and treatment of HIV infection in pregnant women. Vitamin A deficiency in women may predispose to increased transmission (Nduati et al., 1995). There have been documented cases of breast milk transmission, often following seroconversion in women who received HlV-infected blood transfusions postpartum (Lepage et al., 1987; Van de Perre et al., 1991; see also chapters 1 and 3). Evidence also suggests that HIV can be transmitted via breastfeeding in those women who were already infected at the time of the pregnancy, with the added risk associated with breastfeeding varying among studies. Although breastfeeding is encouraged in developing countries, where benefits

HIV INFECTION IN WOMEN

413

can outweigh the risk, breastfeeding infants of HFV-infected women in industrialized countries is strongly discouraged (Centers for Disease Control and Prevention, 1998; see also chapters 1 and 3). Prenatal diagnosis of fetal HIV infection via amniocentesis, chorionic villus sampling, or fetal blood sampling is, as yet, not feasible, latrogenic infection of a healthy fetus as a result of the procedure, as well as contamination of the test results by maternal blood, is considered a risk and is not currently recommended. Antiretroviral Therapy during Pregnancy In 1994 the AIDS Clinical Trials Group (ACTG) Protocol 076 provided strong evidence that the administration of zidovudine (ZDV) to HIV-infected pregnant women and their newborns can significantly reduce the risk of perinatal transmission of HIV. ACTG 076 was a multicenter, randomized, placebo-controlled trial of the efficacy and safety of ZDV in reducing the risk of maternal-infant HIV transmission (Connor et al., 1994). Women enrolled in this study were HIV infected, had not had antiretroviral therapy during the pregnancy, were between 14 weeks and 34 weeks gestation, and were asymptomatic with CD4+/mm 3 lymphocyte counts above 200. Participants were treated with ZDV in a combination of antepartum (oral), intrapartum (IV), and newborn (oral) therapy. Treatment with ZDV reduced the risk of perinatal transmission from 25.5% to 8.3%. ZDV was well tolerated by mothers and infants. The only observed short-term infant toxicity was anemia. The majority of maternal adverse effects were judged to be related to labor and delivery, and there were overall increases in CD4+ lymphocyte counts from baseline in treated women (Connor et al., 1994). Although extremely promising, the results of the trial also raised important questions, including clarifying the mechanism of ZDV action, the timing of transmission, the effectiveness of the regimen in women with clinical characteristics that differ from those of the women in the trial, and the long-term effects of exposure to ZDV during pregnancy for the future health of both the mother and the child. Recent advances in the treatment of HIV infection have raised many issues regarding antiretroviral therapy in pregnancy. One concern centers on the use of ZDV monotherapy (as in ACTG 076)

414

THE PERSON WITH HIV/AIDS

during pregnancy, since monotherapy is no longer recommended for treatment of HIV. Treatment of HIV with one drug generally creates viral mutants that confer drug resistance. ZDV monotherapy may be considered for pregnant women who are clinically asymptomatic, have high CD4+ counts, and low viral loads; however, for pregnant women with a CD4+ count lower than 500, a high viral load, or HIV-related symptoms, consideration is given to the use of highly active retroviral therapy (HAART). It should be noted, however, that in developing countries, where women often cannot afford HAART, even a short course of therapy with ZDV alone has been shown to reduce vertical transmission of HIV by as much as 38% (Dobis, Msellati, Meda, Welffens-Ekra, You, Manigart, et al., 1999); moreover, a 1999 joint United States-Uganda study has concluded that "a single oral dose of the antiretroviral drug nevirapine (NVP) given to HIVinfected women in labor and another to her baby within three days of birth reduces the transmission rate by half compared to similar short course of AZT" (National Institute of Allergy and Infections Diseases, 1999, p. 1). Definitive evidence proving the safety of newer antiretroviral agents when used during pregnancy is lacking, although no apparent adverse outcomes have been attributed to the drugs that are now widely used in the developed world. With so many unanswered questions, appropriate, thorough, and understandable counseling is crucial to ensure that HIV-infected women understand the benefits, risks, and uncertainties of the therapy. The United States Public Health Service Task Force (Centers for Disease Control and Prevention, 1998b) guidelines for antiretroviral therapy in pregnancy include recommendations that provide a basis for such a discussion between an HIV-infected woman and her health care provider. These recommendations state that women should be informed of (1) the significant benefit and short-term safety of the ZDV regimen in ACTG protocol 076, (2) the special characteristics of the ACTG 076 patients and knowledge gaps regarding different individual clinical situations, (3) the unknown theoretical long-term risks of ZDV for the woman and her infant, and (4) the potential for perinatal HIV transmission despite use of the ZDV regimen. Information should be presented in a noncoercive manner, using language linguistically and educationally appropriate for the patient. A decision by the woman not to receive treatment should not result in punitive action or denial of care (Centers for Disease Control

HIV INFECTION IN WOMEN

415

and Prevention, 1994). More recently the CDC has published recommendations for the use of antiretroviral drugs in HlV-infected pregnant women to decrease perinatal HIV transmission (Centers for Disease Control and Prevention, 1998). These include varying treatment recommendations based on different clinical situations. These are shown in Table 11.2. HIV Counseling and Testing in Pregnancy The availability of effective methods to reduce the risk of perinatal transmission has important implications for HIV counseling and testing of women of childbearing age. Ideally, women should know their HIV status before becoming pregnant. Women who are pregnant or are contemplating pregnancy cannot benefit from ZDV therapy or from other methods to reduce the risk of HIV transmission to their infants (i.e., not breastfeeding) unless they are aware of their own HIV status. Thus, sites serving women of childbearing age should counsel and offer voluntary HIV testing to women, including adolescents, regardless of whether they are pregnant. Because specific services must be offered to HIV-infected pregnant women, the U.S. Public Health Service recommends routine HIV counseling and voluntary testing of all pregnant women so that interventions to improve the woman's health and the health of her infant can be offered in a timely and effective manner. Routine HIV testing of all pregnant women has been recommended by the Institute of Medicine (Lear)7, 1998). In developing countries, and among many disenfranchised women in developed countries, women are less likely to know their HIV status and therefore may not take advantage of early prenatal care or antiretroviral therapy (if available to them) or know that they should consider an alternative to breastfeeding. Information should be provided to women regarding (1) early interventions to improve survival rates and quality of life for HIVinfected persons, (2) strategies to reduce the risk of perinatal HIV transmission, and (3) management of HIV infection in pregnant women and perinatally exposed or infected children. HFV-related counseling also includes information on the risk of acquiring HIV infection associated with sexual activity and injection drug use. All counseling, including written materials, should be linguistically, cul-

416

THE PERSON WITH HIV/AIDS

TABLE 11.2 Clinical Scenarios and Recommendations for the Use of Antiretroviral Drugs to Reduce Perinatal HIV Transmission Clinical scenario

Recommendations*

Scenario 1: HIV-infected pregnant women who have not received prior antiretroviral therapy

HIV-1-infected pregnant women must receive standard clinical, immunologic, and virologic evaluation. Recommendations for initiation and choice of antiretroviral therapy should be based on the same parameters used for persons who are not pregnant, although the known and unknown risks and benefits of such therapy during pregnancy must be considered and discussed. The three-part zidovudine (ZDV) chemoprophylaxis regimen should be recommended for all HIV-infected pregnant women to reduce the risk for perinatal transmission. The combination of ZDV chemoprophylaxis with additional antiretroviral drugs for treatment of HIV infection should be (1) discussed with the woman; (2) recommended for infected women whose clinical, immunologic, and virologic status indicates the need for treatment; and (3) offered to other infected women (although in the latter circumstance, it is not known if the combination of antenatal ZDV chemoprophylaxis with other antiretroviral drugs will provide additional benefits or risks for the infant). Women who are in the first trimester of pregnancy may consider delaying initiation of therapy until after 10-12 weeks' gestation.

Scenario 2: HIV-1-infected women receiving antiretroviral HIV-infected women receiv- therapy in whom pregnancy is identified after the ing antiretroviral therapy dur- first trimester should continue therapy. ing the current pregnancy For a woman receiving antiretroviral therapy in whom pregnancy is recognized during the first trimester, the women should be counseled regarding the benefits and potential risks of antiretroviral administration during this period, and continuation of therapy should be considered. If therapy is discontinued during the first trimester, all drugs should be stopped and reintroduced simultaneously to avoid the development of resistance.

HIV INFECTION IN WOMEN

TABLE 11.2

417

(continued)

Clinical scenario

Recommendations* If the current therapeutic regimen does not contain ZDV, the addition of ZDV or substitution of ZDV for another nucleoside analogue antiretroviral is recommendation after 14 weeks' gestation. ZDV administration is recommended for the pregnant women during the intrapartum period and for the newborn—regardless of the antepartum antiretroviral regimen.

Scenario 3: HIV-infected women in labor who have had no prior therapy

Scenario 4: Infants born to mothers who have received no antiretroviral therapy during pregnancy or intrapartum

Administration of intrapartum intravenous ZDV should be recommended along with the 6-week ZDV regimen for the newborn. In the immediate postpartum period, the woman should have appropriate assessments (e.g., CD4+ cell count and HIV-1 RNA copy number) to determine whether antiretroviral therapy is recommended for her own health. The 6-week neonatal ZDV component of the ZDV chemophylactic regimen should be discussed with the mother and offered for the newborn. ZDV should be initiated as soon as possible after delivery—preferably within 12-24 hours of birth. Some clinicians may choose to use ZDV in combination with other antiretroviral drugs, particularly if the mother is known or suspected to have ZDV-resistant virus. However, the efficacy of this approach for prevention of transmission is unknown, and appropriate dosing regimens for neonates are incompletely defined. In the immediate postpartum period, the woman should undergo appropriate assessment (e.g., CD4+ cell count and HIV-1 RNA copy number) to determine if antiretroviral therapy is required for her own health.

'Discussion of treatment options and recommendations should be noncoercive, and the final decision regarding the use of antiretroviral drugs is the responsibility of the woman. A decision to not accept treatment with ZDV or other drugs should not result in punitive action or denial of care. Use of ZDV should not be denied to a woman who wishes to minimize exposure of the fetus to other antiretroviral drugs and who therefore chooses to receive only ZDV during pregnancy to reduce the risk for perinatal transmission. Source: Centers for Disease Control and Prevention. (1998). Public Health Service Task Force recommendations for the viral, antiretroviral drugs in pregnancy women infected with HIV-1 for maternal health and for reducing perinatal HIV transmission in the United States. Morbidity and Mortality Weekly Report, 47(RR-No. 2), 16-17.

418

THE PERSON WITH HIV/AIDS

turally, educationally, and age appropriate for individual patients. HIV testing of pregnant women and their infants should be voluntary. Testing should be obtained in accordance with prevailing legal requirements. Women who test positive for HIV or who refuse testing should not be denied prenatal or other health care services, reported to child protective service agencies because of refusal to be tested or because of their HIV status, or discriminated against in any other way. Because about 5% of American women do not receive prenatal care and thus may not have been tested and treated for HIV infection, it has been suggested that such women could be offered rapid HIV testing during labor (Minkoff & O'Sullivan, 1998). Those advocating this approach note that such rapid testing would allow for the possibility of a course of intrapartal and neonatal antiretroviral therapy. Both medical and ethical issues would need to be resolved, however, before such testing and treatment could be provided to this population of women. HIV counseling and testing is discussed further in chapter 9.

Reproductive Decision Making Multiple factors influence the pregnancy decisions of women with HIV infection. Although the results of such clinical trials as ACTG 076 may have an as yet undocumented impact, most studies have found that HIV-positive women make reproductive decisions that are similar to those of HIV-negative women, and that the presence of HIV infection is only one factor that influences decision making about pregnancy (Hollier et al., 1998; Johnstone et al., 1990; Selwyn et al.,1989; Sunderland, Minkoff, Handte, Moroso, & Landesman, 1992). Strong ethical feelings against abortion, the desire to have a child, the desire to please a partner, a fear of revealing HIV status to the partner, a denial of infection, a perception of low or acceptable risk, barriers to contraceptive and/or abortion service, the cultural importance of motherhood, a psychological inability to make a decision, and heavy drug use that makes planning and carrying out abortion impossible are all considerations or potential influences on pregnancy-related decision making for HlV-infected women (Cohen, 1994; Cohen & Durham, 1993).

HIV INFECTION IN WOMEN

419

When offering counseling to women, it is important to recognize that children are central to many women's psychological well-being. The potential influential factors noted above must be considered, and unfounded assumptions about the influence of HFV-infection status on reproductive decision making should be avoided. Counseling about pregnancy decisions should be nondirective and should include current information about the risks of perinatal transmission and the maintenance of maternal health during pregnancy.

Contraception For an HIV-positive woman, selection of a contraceptive method is influenced by the method's efficacy in preventing both pregnancy and transmission of disease. Although the condom has usefulness in preventing both transmission of sexually transmitted disease and pregnancy, a blanket prescription for its use fails to address a woman's need to have a method of contraception and protection over which she has control. A full spectrum of contraceptive and reproductive choices should be available to HIV-infected women. Evaluating a woman's needs on the basis of her sexual practices and her relationship with her partner or partners is essential in determining whether a particular method will be appropriate and successful. Barrier methods (condoms, diaphragms, cervical caps, and vaginal sponges) are recommended because they offer the benefit of protection against several of the pathogens that cause STDs in addition to preventing pregnancy, especially when used with a spermicide such as nonoxynol-9. Nonoxynol-9, however, can cause vaginal irritation with frequent use (Cohen et al., 1998). The use of oral contraceptives and hormonal implants in HIV-positive women has not been well studied, and there are conflicting data regarding hormonal effects on immunosuppression (Allen, 1990; Baker etal, 1985). Currently, there is no documented evidence that these contraceptives contribute to the progression of HIV disease. Intrauterine devices (lUDs), however, are contraindicated in HIV-positive women because of an increased risk of HIV/STD transmission to the woman or her partner and because of an increased risk of pelvic inflammatory disease (Sinei, Morrison, Sekadde-Kigondu, Allen, & Kokonya, 1998). A

420

THE PERSON WITH HIV/AIDS

female condom is available but has not yet found wide acceptability (Cohen et al, 1998).

ACCESS TO CARE AND TREATMENT The medical care of women with HIV disease includes an intertwining of the management of HIV and non-HIV medical problems, health maintenance, and psychosocial needs. Unless gender-specific data for prophylactic and treatment strategies are available, women with HIV need at least the same HIV medical management that men need, including antiretroviral therapies, medications for the prevention of opportunistic infections, and immunological monitoring. Other needs for women with HIV include psychological and psychiatric services, gynecological and obstetrical care, access to pharmaceutical and other research, and substance-use treatment. They may also need child care, parenting assistance, and related financial and legal advice. Significant obstacles exist for many women in need of comprehensive HIV services. Socioeconomic and lifestyle barriers that commonly affect women include lack of transportation and lack of child care, jobs without sick leave or health care benefits, and active drug use that creates a disorganized lifestyle and inability to follow through with health care needs. A sense of a stigmatized lifestyle causes many women to shy away from contact with mainstream providers. Dependence on unsupportive or abusive partners may make compliance and follow-through with health care virtually impossible (Kirkham &Lobb, 1998). Women also face psychosocial and cultural barriers to comprehensive HIV care that may differ from those of men. For example, women often serve as the primary caregivers for children, partners, and members of the extended family or "family of choice." Other members of the family may be HIV infected. Whether family members are sick or well, caregiving responsibilities often take priority over personal health care needs and may consume all the time and energy available, so that health care services are sought only in the case of acute illness or crises. Finally, the health care environment is often insensitive to the needs of women. Clinic hours may conflict with child care needs,

HIV INFECTION IN WOMEN

421

and waits are often long, with no access to child care for young children. Scheduling is often fragmented, with pediatric care, gynecological care, case management, and primary care provided in separate areas and at separate times. Health care providers are often insensitive to HIV issues in women, with an inappropriately low index of suspicion for HIV infection in women at risk, discomfort or lack of attention to HIV prevention issues for women, an assumption of heterosexuality and ignorance of HIV issues for lesbians and bisexual women, and a bias against providing care for drug-using women. The same barriers exist for women who might benefit from participation in HIV/AIDS research protocols. Inner city women may not perceive study participation as providing any benefit for themselves, their families, or their community. Barriers to women's participation in research are both blatant and subtle and exist on societal, institutional, and personal levels (Kelly & Cordell, 1996). However, women must be included in research trials because research findings from male cohorts cannot be generalized to women with any certainty. NURSING CONSIDERATIONS Nurses, whether they work in HIV-specific settings or in general care settings, can improve the quality of care for at-risk or HlV-infected patients by incorporating the following strategies into their practice: 1. Thorough drug and sexual histories are important and form a basis for prevention and counseling. Become familiar and comfortable with commonly used slang for drug and sexual behaviors. Avoid assumptions and ask all questions of all patients. Incorporate risk reduction into appropriate education sessions with patients regardless of the care setting. For example, a nurse working in an asthma clinic serving large numbers of teens and young adults should discuss sex and drug prevention strategies as a part of teaching. 2. Know where to refer patients for HIV counseling and testing and be knowledgeable about HIV-specific services for referral as needed. 3. Assess HIV-infected women's support systems and need for primary medical services (including gynecological), psychoso-

422

4. 5.

6.

7.

THE PERSON WITH HIV/AIDS

cial services such as social work or support groups, and addiction treatment services. Facilitate the coordination of appointments, including those of other family members, when possible. Develop a comprehensive and ongoing plan for educating HIVinfected women about perinatal HIV transmission, effective birth control, initiating and maintaining safer sex practices, and the importance of regular gynecological checkups even in the absence of symptoms. Discuss the availability of and rationale for clinical drug trials and other HIV research. Explore patient attitudes toward participation in research. Assess barriers to adherence with appointments and intervene when possible. For example, make appointments to coincide with school hours; arrange transportation for very ill patients.

CONCLUSION Well into the 21st century, HIV prevention and care will remain a significant part of the health care of women. Nurses can and should be actively involved in the prevention of HIV in women through ongoing education and counseling. In order to provide appropriate nursing care of women with HIV, or at risk of HIV infection, nurses must acquire and maintain a current knowledge and skill base. REFERENCES Allen, M. (1990). Primary care of women infected with the human immunodeficiency virus. Obstetrics and Gynecology Clinics of North America, 17(3), 557-569. Augenbraun, M. H., DeHovitz,J., Feldman.J., Clarke, L., Landesman, S., & Minkoff, H. (1994). Biologic false positive syphilis tests in HIV infected women. Clinical Infectious Diseases, 19, 1040-1044. Augenbraun, M., Feldman, J., Landesman, S., Zenilman, J., Clarke, L., & Minkoff, H. (1995). Genital shedding of herpes simplex virus type 2 in HIV seropositive women. Annals of Internal Medicine, 123, 845-847. Augenbraun, M. H., & McCormack, W. M. (1994). Sexually transmitted diseases in HIV-infected persons. Infectious Disease Clinics of North America, 5(2), 439-448. Bailey, K., Herrod, H., Younger, R., & Shaver, D. (1985). Functional aspects of Tlymphocytes subsets in pregnancy. Obstetrics and Gynecology, 66(2), 211-215.

HIV INFECTION IN WOMEN

423

Baker, D., Hameed, N., Tejani, P., Milch, J., Thomas, A., Monheit, G., & Dattwyler, R. (1985). Lymphocytic subsets in women on low-dose oral contraceptives. Contraception, 32(4), 377-382. Berrebi, A., Kobuch, W., Fuel, J., Tricoire, J., Herne, P., Grandjean, H., & Pontonnier, G. (1990). Influence of pregnancy on human immunodeficiency virus disease. European Journal of Obstetrics and Gynecology, 37, 211-217. Bigger, R. J., Pahwa, S., Landesman, S., & Goedert, J. (1988, June). Helper and suppressor lymphocyte changes in HIV infected mothers and their infants. Paper presented at the Fourth International Conference on AIDS, Stockholm. Boyer, P., Dillon, M., Navaie, M., Deveikis, A., Keller, ML, O'Rourke, S., & Bryson, Y. (1994). Factors predictive of maternal-fetal transmission of HIV-1: Preliminary analysis of zidovudine given during pregnancy and/or delivery. Journal of the American Medical Association, 271, 1925-1930. Bryson, Y. J. (1996). Perinatal HIV-1 transmission: Recent advances and therapeutic interventions. AIDS, ^0(Suppl. 3), S33-S42. Burns, D., Landesman, S., Minkoff, H., Wright, D., Waters, D., Mitchell, R., Rubinstein, A., Willoughby, A., & Goedert, J. (1998). The influence of pregnancy on human immunodeficiency virus type 1 infection: Antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. American Journal of Obstetrics and dynecology, 178, 355-359. Carpenter, C., Mayer, K., Fisher, A., Desai, M., & Durand, L. (1989). Natural history of acquired immunodeficiency syndrome in women in Rhode Island. American Journal of Medicine, 86, 771-775. Carpenter, C., Mayer, K., Stein, M., Leibman, B., Fisher, A., & Fiore, T. (1991). Human immunodeficiency virus infection in North American women: Experience with 200 cases and a review of the literature. Medicine, 70, 307-323. Centers for Disease Control. (1981). Follow-up on Kaposi's sarcoma and Pneumocystis pneumonia. Morbidity and Mortality Weekly Report, 31, 697-698. Centers for Disease Control and Prevention. (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report, 41 (No. RR17), 1-19. . (1998a). Administration of zidovudine during later pregnancy and delivery to prevent perinatal HIV transmission—Thailand, 1996-98. Morbidity and Mortality Weekly Report, 47, 151-154. . (1998b). Public Health Service Task Force recommendation for use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 in the United States. Morbidity and Mortality Weekly Report, 47(No. RR-17), 1-30. Centers for Disease Control and Prevention. (1994). Recommendations of the U.S. Public Health Service task force on the use of zidovudine to reduce of perinatal transmission of human immunodeficiency virus. Morbidity and Mortality Weekly Report, 43(No. RR-11), 1-20. . (1997a, July). HIV/AIDS and women who have sex with women (WSW) in the United States. Facts, 1-2. . (1997b). HIV/AIDS surveillance report. Year End Edition, 9(2), 1-43.

424

THE PERSON WITH HIV/AIDS

. (1998). Administration of Zidovudine during late pregnancy and delivery to prevent perinatal transmission—Thailand, 1996-1998. CDC Update, 47(8), 151-154. Chirgwin, K. D., Feldman,J., Augenbraun, M., Landesman, S., & Minkoff, H. (1995). Incidence of venereal warts in HIV infected and un-infected women. Journal of Infectious Diseases, 172, 235-238. Chu, S. Y., & Wortley, P. M. (1995). Epidemiology of HIV/AIDS in women. In H. Minkoff, J. A. DeHovitz, & A. Duerr (Eds.), HIV in women (pp. 2-12). New York: Raven Press. Cohen, F. L. (1994). Research on families and pediatric human immunodeficiency virus disease: A review and needed directions. Journal of Behavioral and Developmental Pediatrics, 15(3), S34-S42. Cohen, F. L., & Durham,]. (Eds.). (1993). Women, children, and HIV/AIDS. New York: Springer. Cohen, P. T., Sande, M. A., & Volberding, P. A. (Eds.). (1998). The AIDS knowledge base (3rd ed.). San Francisco: University of California, San Francisco and the San Francisco General Hospital. [http://hivinsite. ucsf. edu/akb/1997/] Connor, E., Sperling, R., Gelber, R., Kiselev, P., Scott, G., O'Sullivan M., et al. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New England Journal of Medicine, 331,11731187. Denenberg, R. (1993). Gynecological care manual for HJTV positive women. Durant, OH: Essential Medical Information Systems. Dickover, R., Garratty, E., Herman, S., Sim, M. S., Plaeger, S., Boyer, P., Keller, M., Deveikis, A., Stiehm, R., & Bryson, Y. (1996). Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: Effect of maternal zidovudine treatment on viral load. Journal of the American Medical Association, 275, 599-605. Dobis, F., Msellati, P., Meda, N., Wellfens-Ekra, C., You, B., Manigart, O., et al. (1999). 6 month efficacy, tolerance, and acceptability of a short regiment of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'lvoire and Burkina Faso: A double-blind placebo-controlled multicentre trial. Lancet, 353, 786-792. Dunn, D., Newell, M., Ades, A., & Peckham, C. (1992). Risk of human immunodeficiency virus type 1 transmission through breastfeeding. The Lancet, 339, 585-588. Ellerbrock, T. V., Wright, T. C., Bush, T. J., Dole, P., Brudney, K., & Chaisson, M. A. (1996). Characteristics of menstruation in women infected with human immunodeficiency virus. Obstetrics and Gynecology, 87, 1030-1034. European Collaborative Study. (1988). Mother to infant transmission of HIV infection. Lancet, 2, 1039-1042. . (1991). Children born to women with HIV infection: Natural history and risk of transmission. The Lancet, 337, 253-260. . (1992). Risk factors for mother-to-child transmission of HIV-1. The Lancet, 339, 1007-1012. Fink, M. J., Fruchter, R. G., Maiman, M., Kelly, P., Sedlis, A., Webber, C. A., & Chen, P. (1994). The adequacy of cytology and colposcopy in diagnosing cervical neoplasia in HIV seropositive women. Obstetrics and Gynecology, 55, 133-137.

HIV INFECTION IN WOMEN

425

Fleming, P., Ciesielski, C., Byers, R., Castro, K., & Berkelman, R. (1993). Gender differences in reported AIDS-indicative diagnoses. Journal of Infectious Diseases, 168, 61-67. Fowler, M., Melmick, S., & Mathieson, B. (1997). Women and HIV: Epidemiology and global overview. Obstetrics and Gynecology Clinics of North America, 24(4), 705729. [Available on AIDSLINE, http://www.aegis.com/pubs/aidsline/1998/ apr/m9840694.html] Fruchter, R. G., Maiman, M., Sedlis, A., Bartley, L., Camilien, L., & Arrastia, C. D. (1996). Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstetrics and Gynecology, 87, 338-344. Garcia, P., Kalish, L., Pitt, J., Quinn, T., Burchett, S., Hanson, C., Minkoff, H., Jackson, B., Move, ]., & Lew. J. (1998). Maternal human immunodeficiency virus (HIV) RNA level correlates with risk but does not predict the timing of the perinatal transmission. American Journal of Obstetrics and Gynecology, Z75(1S), 2S. Glassman, A. B., Bennet, C., Christopher,}., & Self, S. (1985). Immunity during pregnancy: Lymphocyte subpopulation and mitogen responsiveness. Annals of Clinical Laboratory Science, 15, 357-362. Goedert, J. J., Duliege, A. M., Amos, E. L, Felton, S., & Biggar, R.J. (1991). High risk of HIV-1 infection in first-born twins. The Lancet, 338, 1471-1475. Gwinn, M., Wasser, S., Fleming, P., Karon, J., & Petersen, L. (1993,June). Increasing prevalence of HIV infection among childbearing women, United States, 1989-1991. Abstract presented at the 9th International Conference on AIDS, Berlin. Haverkos, H., Brotman, D., & Morgan, W. (1990). Kaposi's sarcoma in patients with AIDS: Sex, transmission mode, and race. Riomedicine and Pharmacotherapy, 44, 461-466. Hoegsberg, B., Abulafia, O., Sedlis, A., Feldman,J., Desjarlais, D., Landesman, S., & Minkoff, II. (L990). Sexually transmitted diseases and human immunodeficiency virus infection among women with pelvic inflammatory disease. American Journal of Obstetrics and Gynecology, 163, 1135-1139. Hollier, L., Ramus, R., Stuart, G., Corley, C., McElwee, B., & Wendel, G. (1998). Effect of the ACTG 076 trial results on reproductive choices in HIV positive women. American Journal of Obstetrics and Gynecology, 178(IS), 210S. International Perinatal HIV Group. (1999). The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a metal-analysis of 15 prospective studies. New England journal of Medicine, 340, 977-987. Johnstone, F., Brettle, R., MacCallum, L., Mok, J., Peutherer, J., & Burns, S. (1990). Women's knowledge of their HIV antibody state: Its effect on their decision whether to continue the pregnancy. British Medical Journal, 300, 23-24. Kelly, P. J., & Cordell, J. R. (1996). Recruitment of women into research studies: A nursing perspective. Clinical Nurse Specialist, 10(1), 25-28. Kennedy, M., Moore, ]., Schuman, P., Schoenbaum, E., Ziesler, S., Rompalo, A., & Chu, S. Y. (1998). Sexual behavior of HIV-infected women reporting recent sexual contact with women, fournal of the American Medical Association, 280, 29-30. Kirkham, C., & Lobb, D. (1998). The British Columbia positive women's survey: A detailed profile of 110 HIV-infected women. Canadian Medical Association Journal, 158, 317-323.

426

THE PERSON WITH HIV/AIDS

Kuhn, L., Stein, Z., Thomas, P., Singh, T., & Tsai, W. (1994). Maternal-infant HIV transmission and circumstances of delivery. American Journal of Public Health 84, 1110-1115. LaGuardia, K., White, M., Saigo, P., Hoda, S., McGuinness, K., & Ledger, W. (1995). Genital ulcer disease in women infected with human immunodeficiency virus. American Journal of Obstetrics and Gynecology, 172, 553-562. Landesman, S., Kalish, L., Burns, D., Minkoff, H., Fox, H., Zorilla, C., Garcia, P., Fowler, M., Mofenson, L., & Tuomala, R. (1996). Obstetrical.factors and the transmission of human immunodeficiency virus type 1 from mother to child. New England Journal of Medicine, 334, 1617-1623. Lazuriago, K., & Sullivan, J. (1998). Prevention and treatment of pediatric HIV infection. Journal of the American Medical Association, 280, 17-18. Leary, W. (1998, October 15). Medical panel urges HIV tests for all pregnant women. New York Times, p. A24. Lepage, P., Van de Perre, P., Carael, M., Nsengumuremyi, F., Nkurunziza.J., Butzler, J., & Sprecher, S. (1987). Postnatal transmission of HIV from mother to child. The Lancet, 2, 400. Lesbians' HIV risk may be underestimated. (1997, February 14). Reuters New Media. [Available at http://www.aegis.com/news/re/1997/re970258.html] Levine, A. (1997). Women and HIV. Clinical Care Options for HIV. Health Care Communications Group, Inc. [http://www.aegis.com/pubs/hcg/1997/ hg971002.html] Macasaet, M. A., Duerr, A., Thelmo, W., Vernon, S. D., & Unger, E. R. (1995). Kaposi's sarcoma presenting as a vulvar mass. Obstetrics and Gynecology, 86, 695697. Maiman, M., Tarricone, N., Vieira, J., Suarez, J., Serur, E., & Boyce, J. (1991). Colposcopic evaluation of HIV-seropositive women. Obstetrics and Gynecology, 78, 84-88. Mandelbrot, L., LeChenadec, J., Berrebi, A., Bongain, A., Benifla, J., Delfraissy, J., Blanche, S., & Mayaux, B. (1998). Perinatal HFV-1 transmission: Interaction between zidvudine prophylaxis and mode of delivery in the French perinatal cohort. Journal of the American Medical Association, 280, 55-60. Mano, H., & Chermann.J. C. (1991). Fetal HFV-1 infection of different organs in the second trimester. AIDS Research and Human Retroviruses, 7, 83-88. Minkoff, H. L., DeRegt, R. H., Landesman, S., & Schwarz, R. (1986). Pneumocystis carinii pneumonia associated with acquired immunodeficiency syndrome in pregnancy: A report of three maternal deaths. Obstetrics and Gynecology, 67, 284-287. Minkoff, H., Nanda, D., Menez, R., & Fikrig, S. (1987). Pregnancies resulting in infants with acquired immunodeficiency syndrome or AIDS related complex. Obstetrics and Gynecology, 69, 285-289. Minkoff, H., & Mofenson, L. (1994). The role of obstetrical interventions in prevention of pediatric HIV infection. American Journal of Obstetrics and Gynecology, 171, 1167-1175. National Institute of Allergy and Infectious Diseases. Researchers identify a simple, affordable drug regimen that is highly effective in preventing HIV infection in infants of mothers with the disease. (1999, July 8). Press Release, National Insti-

HIV INFECTION IN WOMEN

427

tute of Allergy and Infectious Diseases. http://www.niaid.nih.gov/newsroom/ simple/release.htm. Nduati, R. W., John, G. C., Richardson, B. A., Overbaugh, J., Welch, M., NdinyaAchola, J., Moses, S., Holmes, K., Onyango, F., & Kreiss,J. K. (1995). Human immunodeficiency virus type 1-infected cells in breast milk: Association with immunosuppression and vitamin A deficiency. Journal of Infectious Diseases, 172, 1461-1468. Petersen, L. R., Doll, L , White, C., Chu, S., & the HIV Blood Donor Study Group. (1992). No evidence for female to female transmission among 96,000 female blood donors. Journal of Acquired Immune Deficiency Syndromes, 5, 853-855. Selwyn, P., Carter, R., Schoenbaum, E., Robertson, V., Klein, R., & Rogers, M. (1989). Knowledge of HIV antibody status and decisions to continue or terminate pregnancy among intravenous drug users. Journal of the American Medical Association, 261, 3567-3571. Shah, P. J., Smith, R., Jr., Wells, C., Barton, S., Kitchen, V., & Steer, P. (1994). Menstrual symptoms in women infected by the human immunodeficiency virus. Obstetrics ant! Gynecology, 83, 397-400. Sinei, S., Morrison, C., Sekadde-Kigondu, C., Allen, M., & Kokonya, D. (1998). Complications of use of intrauterine devices among HIV-infected women. The Lancet, 351, 1238-1241. Soeiro, R., Rubinstein, A., Rashbaum, W. K., & Lyman, W. D. (1992). Maternofetal transmission of AIDS: Frequency of human immunodeficiency virus type 1 nucleic acid sequences in human fetal DNA. Journal of Infectious Diseases, 166, 699703. Sowell, R., Moneyham, L., & Aranda-Naranjo, B. (1999). The care of women with AIDS. Nursing Clinics of North America, 34(1), 179-199. Sperling, R., & Stratton, P. (1992). Treatment options for human immunodeficiency virus-infected pregnant women. Obstetrics and Gynecology, 79, 443-448. Sperling, R. S.. Shapiro, D., Coombs, R., Todd, J., Herman, S., McSherry, G., O'Sullivan, M., Van Dyke, R., Jimenez, E., Rouzioux, C., Flynn, P., Sullivan, J., & the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. (1996). Maternal viral load zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. New England Journal of Medicine, 335, 1621-1628. Sunderland, A., Minkoff, H., Handle,J., Moroso, G., & Landesman, S. (1992). The impact of influence of human immunodeficiency virus serostatus on reproductive decisions of women. Obstetrics and Gynecology, 7, 1027-1031. Van de Perre, P., Simonon, A., Msellati, P., Hitimana, D. G., Vaira, D., Bazubagira, A., et al. (1991). Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. New England Journal of Medicine, 325, 593-598. Voelker, R. (1998). Rural communities struggle with AIDS. Journal of the American Medical Association, 279, 5-6. Wasser, S., Gwinn, M., & Fleming, P. (1993). Urban-nonurban distribution of HIV infection in childbearing women in the United States. Journal of Acquired Immune Deficiency Syndromes, 6, 1035-1042.

428

THE PERSON WITH HIV/AIDS

Working Group on Mother-to-Child Transmission of HIV. (1995). Rates of motherto-child transmission of HIV-1 in Africa, America, and Europe: Results from 13 perinatal studies. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 8, 506-510. Wright, T., Ellerbrock, T., Chiasson, M. A., Van Devanter, N., Sun, X. W., & the New York Cervical Disease Study. (1994). Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: Prevalence, risk factors, and validity of Pap smears. Obstetrics and Gynecology, 84, 591-597. Wright, T. C., Koulos, J., Schnoll, F., Swanbeck, J., Ellerbrock, T. V., Chiasson, M. A., & Richart, R. M. (1994). Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: Outcome after loop electrosurgical excision. Gynecological Oncology, 55, 253-258.

12

HIV Disease in Children Wendy M. Nehring

ediatric HIV infection is a multisystem, multigenerational chronic illness that affects not only the individual infant or child, but his or her expanded network of family, friends, and community (American Academy of Pediatrics, Committee on Pediatric AIDS, 1999; Lesar & Maldonado, 1997). This disease offers the interdisciplinary health care team a dynamic pathophysiologic and psychosocial challenge that is unlike any other chronic illness. Recent immunologic and treatment discoveries have increased and altered our understanding of the pathogenesis and the management of this disease in infants and children. The future looks promising that perinatal transmission rates will continue to decrease and children already infected will live longer and better lives. This chapter provides a review of current knowledge regarding the diagnosis, natural history, clinical symptomatology, Centers for Disease Control and Prevention (CDC) classification system, immunologic and multisystem effects, management of the disease emphasizing antiretroviral therapy, primary care, and family and environmental issues.

P

PEDIATRIC EPIDEMIOLOGY As of December 1998, 8,461 infants and children below the age of 13 years had been diagnosed with AIDS in the United States and its territories (CDC, 1998c) since the pediatric form of the disease was 429

430

THE PERSON WITH HIV/AIDS

first described in 1983 (Ammann et al., 1983; Oleske & Minnefor, 1983). This is in contrast to an estimated 1.5 million infants and children with AIDS and 3 million infants and children with HIV infection worldwide. There have also been 3,423 adolescents, 13 to 19 years of age, diagnosed with AIDS in the United States and its territories. About 90% of the infants and children with HIV infection worldwide are living in developing countries (CDC, 1997b, 1999; Cervia, 1999). A supplemental problem is the estimated 10 million children in the world who have been or will be orphaned this decade due to the disease (Mann, 1992). Pediatric HIV infection continues to disproportionately affect greater numbers of African-American and Latino infants, children, and adolescents (CDC, 1999a). Pediatric HIV-1 infection is presently the fifth leading cause of death in infants and children 1-4 years of age, the seventh leading cause of death in the United States for children 1 to 14 years, and rates as first or second leading cause of death in African-American and Latino children living in cities where the disease is most prevalent (e.g., Newark, New Jersey and New York City) (Chu, Buehler, Oxtoby, & Kilbourne, 1991; Colling, 1999; Ickovics, Morril, Beren, Walsh, & Rodin, 1994). Among adolescents and young adults, ages 15 to 24 years, AIDS is the sixth leading cause of death (Lindegren, Hanson, Miller, Byers, & Onorato, 1994). Further epidemiologic data concerning pediatric HIV infection is found in chapter 1. At the end of December 1998, 91% of children in the United States infected with AIDS had acquired the virus through motherto-infant vertical transmission. The remaining children with AIDS acquired the virus through blood transfusion, components, or tissue (4%); hemophilia/coagulation disorder (3%); and unidentified causes (2%). In the near future, virtually all infants and children who become infected with HIV will have acquired it through vertical transmission, although transmission through transfusions remains a problem globally for children (Lackritz, 1998). The majority of adolescents, ages 13 to 19 years, were most often diagnosed with AIDS due to infusion of infected blood products for treatment of hemophilia/coagulation disorder (22%), heterosexual contact (23%), and homosexual contact (21%) (CDC, 1998c). Furthermore, because breastfeeding by a mother with HIV infection increases the risk of her infant's acquiring the virus through this route, breastfeeding by these mothers is discouraged in the

HIV DISEASE IN CHILDREN

431

United States and other developed countries. In developing countries, due to the results of recent research (Bobat, Moodley, Coutsoudis, & Coovadia, 1997; Leroy et al., 1998) on long-term breastfeeding, which found that 5% of infants born to HIV-positive mothers who breastfed acquired the disease through this route, recommendations by UNAIDS, UNICEF, and the World Health Organization (WHO) have significantly changed. Currently, the recommendation by these world organizations is to formula-feed when safe alternatives are available and affordable. This may be difficult given the low income, poor sanitation, and safe water available to many of these women and their children, as well as the stigma of being labelled as HIV-positive if seen bottle-feeding (WHO, 1998). Leroy and her colleagues (1998) recommend further research to determine when transmission is most likely to occur from breastfeeding. HIV type 2 (HIY-2) was originally identified in 1986 in Africa. This form of the virus is rare in children worldwide with only seven cases identified, one being coinfected with HIV type 1 (HIV-1). This information in this chapter will be restricted to a discussion of HIV1 infection in infants and children. For further information on the seven cases of HIV-2, see Faye, Burgard, Crosnier, Retbi, and Blanche (1997). It is important to note that the American Academy of Pediatrics, Committee on Pediatric AIDS (1998b) has advocated for the inclusion of pediatric HIV infection (as opposed to AIDS) in the surveillance of infants and children with AIDS. This inclusion would allow for accurate surveillance of perinatal exposure, diagnosis of HIV infection, diagnosis of AIDS, and death. These reasons alone would seem to outweigh any arguments, such as cost over the long term, against initiating this additional surveillance. Currently in all states, however, only the incidence of AIDS is documented in infants and children. The reporting of HIV infection in infants and children is mandated in 32 states and the U.S. Virgin Islands (CDC, 1998c). In most of these areas, incidence of perinatal exposure to HIV has also been documented. If all of the states and U.S. territories would document incidence at each of the four time points, then better reporting of the impact on infants, children, and their families, better evaluation of current and needed medical and social resources, and more specific and indepth approaches to prevention could be

432

THE PERSON WITH HIV/AIDS

undertaken (American Academy of Pediatrics, Committee on Pediatric AIDS, 1998b).

PREVENTION OF PERINATAL HIV INFECTION Considerable progress has been made in recent years in developing prevention strategies for vertical transmission of HIV infection from mother to infant. These advances are classified into (1) new understanding in virologic and immunologic changes after infection with the HIV virus; (2) the success of the Pediatric AIDS Clinical Trials Group (PACTG) 076 protocol to employ zidovudine (ZDV, earlier referred to as AZT) during pregnancy, during labor, and in the infant postnatally; (3) early initiation of antiretroviral therapy in infants identified as HIV positive with prophylaxis for Pneumocystis carinii pneumonia (PCP) beginning at 4 to 6 weeks of life; and (4) recommendations by the United States Public Health Service and other professional health care organizations recommending HIV counseling and HIV testing with consent in pregnant women (CDC, 1994b; Connor et al., 1994; Working Group on Antiretroviral Therapy and Medical Management of HFV-Infected Children, 1999). Researchers have more recently reported on the safety of zidovudine on the infant up through 18 months (Sperling et al., 1998; Italian Register for HIV Infection in Children, 1999), the use of HIV hyperimmune immuno-globulin in combination with zidovudine to prevent transmission (Stiehm et al.,1999), the efficacy of using shortened regimens of zidovudine in mothers and their infants to prevent transmission (Wade et al., 1998), and that chorioanmionitis was a risk factor for transmission even with the use of zidovudine (Van Dyke et al., 1999). Specifically, in cases where the maternal HIV status of the mother is not known before her infant is born, then HIV counseling with the mother should be undertaken as soon as possible and HIV testing of the infant be done quickly after maternal consent. For infants who are wards of the state, abandoned, and/ or born positive for drug exposure, procedures to acquire consent for HIV testing are recommended (CDC, 1998a). Currently, in the absence of intervention, approximately 25% of infants born to mothers with HIV infection (range = 13% to 50%) will become infected through vertical transmission. With increased efforts at prevention,

HIV DISEASE IN CHILDREN

433

this percentage is likely to decrease drastically (Bryson, 1996;Jenkins, 1996). For a detailed discussion of the prevention of HIV infection in women and their children, see chapter 3. CDC CLASSIFICATION SYSTEM FOR CHILDREN LESS THAN 13 YEARS WITH HIV INFECTION Since 1983 the definition of pediatric HIV infection in children less than 13 years of age has undergone much discussion and revision. The latest revision was in 1994 and takes into account the age-specific virologic, and immunologic changes, as well as clinical symptomatology that differentiates pediatric from adult expression of the disease (see Table 12.1) (CDC, 1994a). In other words, children experience recurrent bacterial infections, failure to thrive, encephalopathy, and lymphocytic interstitial pneumonitis, whereas the high incidence of Kaposi's sarcoma and lymphomas in adults is rare in children. DIAGNOSIS OF PEDIATRIC HIV INFECTION Viral diagnostic assays can be used to accurately diagnose the majority of infants with HIV infection by one month of age and in nearly all infants by their sixth month. DNA or RNA polymerase chain reaction (HIV PCR) or the detection of HIV by culture are the tests most widely used today with the best sensitivity and specificity (Palumbo et al, 1998; Palumbo et al., 1999). HIV DNA PCR is the preferred method of virologic analysis due to sensitivity, specificity, cost, and time to results (Working Group on An tire tro viral Therapy and Medical Management of HIV-Infected Children, 1999). At-risk (exposed) or known infected infants should have their blood tested by either one of these methods as soon as possible after birth. Although New York state began mandatory testing of all newborns in February 1997, controversy continues whether HFV testing in infants should be mandatory (Cervia, 1999; Cynn, 1999). If the results of the HIV PCR or HIV culture test is found to be positive, then verification of the finding should be done as soon as the result is available with a repeat test. An initial diagnostic test can be done by 48 hours of age because approximately 40% of infected

434

THE PERSON WITH HIV/AIDS

TABLE 12.1 1994 Revised HIV Pediatric Classification System: Clinical Categories* Category N: Not symptomatic Children who have no signs or symptoms considered to be the result of HIV infection or who have only one of the conditions listed in category A. Category A: Mildly symptomatic Children with two or more of the following conditions but none of the conditions listed in categories B and C: Lymphadenopathy (> 0.5 cm at more than two sites; bilateral = one site) Hepatomegaly Splenomegaly Dermatitis Parotitis Recurrent or persistent upper respiratory infection, sinusitis, or otitis media Category B: Moderately symptomatic Children who have symptomatic conditions other than those listed for category A or category C that are attributed to HIV infection. Examples of conditions in clinical category B include but are not limited to the following: Anemia (< 8 gm/dL), neutropenia (< 1,000/mm3), or thrombocytopenia (< 100,000/mm3) persisting > 30 days Bacterial meningitis, pneumonia, or sepsis (single episode) Candidiasis, oropharyngeal (i.e., thrush) persisting for > 2 months in children age > 6 months Cardiomyopathy Cytomegalovirus infection with onset before age 1 month Diarrhea, recurrent or chronic Hepatitis Herpes simplex virus (HSV) stomatitis, recurrent (i.e., more than two episodes within 1 year) HSV bronchitis, pneumonitis, or esophagitis with onset before age 1 month Herpes zoster (i.e., shingles) involving at least two distinct episodes or more than one dermatome Leiomyosarcoma Lymphoid interstitial pneumonia (LIP) or pulmonary lymphoid hyperplasia complex Nephropathy Nocardiosis Fever lasting > 1 month Toxoplasmosis with onset before age 1 month Varicella, disseminated (i.e., complicated chicken pox)

HIV DISEASE IN CHILDREN

TABLE 12.1

435

(continued)

Category C: Severely symptomatic Children who have any condition listed in the 1987 surveillance case definition for acquired immunodeficiency syndrome, with the exception of LIP (which is a category B condition). Serious bacterial infections, multiple or recurrent (i.e., any combination of at least two culture-confirmed infections within a 2-year period, of the following types: septicemia, pneumonia, meningitis, bone or joint infection, or abscess of an internal organ or body cavity (excluding otitis media, superficial skin or mucosal abscesses, and indwelling catheter-related infections) Candidiasis, esophageal or pulmonary (e.g., bronchi, trachea, lungs) Coccidiomycosis, disseminated (at site other than or in addition to lungs or cervical or hilar lymph nodes) Cryptococcosis, extrapulmonary Cryptosporidiosis or isosporidiosis with diarrhea persisting > 1 month Cytomegalovirus disease with onset of symptoms at age > 1 month (at a site other than liver, spleen, or lymph nodes) Encephalopathy (at least one of the following progressive findings present for at least 2 months in the absence of a concurrent illness other than HIV infection that could explain the findings: failure to attain or loss of developmental milestones or loss of intellectual ability, verified by standard developmental scales or neuropsychological tests; impaired brain growth or acquired microcephaly demonstrated by head circumference measurements or brain atrophy demonstrated by computerized tomography or magnetic resonance imaging (serial imaging is required for children < 2 years of age); acquired symmetric motor deficit manifested by two or more of the following: paresis, pathologic reflexes, ataxia, or gait disturbances. Herpes simplex virus infection causing a mucocutaneous ulcer that persists for > 1 month or bronchitis, pneumonitis, or esophagitis for any duration affecting a child > 1 month of age Histoplasmosis, disseminated (at site other than or in addition to lungs or cervical or hilar lymph nodes) Kaposi's sarcoma Lymphoma, primary, in brain Lymphoma, small, noncleaved cell (e.g., Burkitt's) or immunoblastic or large cell lymphoma of B cell or unknown immunologic phenotype Mycobactehum tuberculosis, disseminated or extrapulmonary Mycobacterium, other species or unidentified species, disseminated (at a site other than or in addition to lungs, skin, or cervical or hilar lymph nodes) Mycobacterium avium complex or Mycobacterium /cans/7, disseminated (at site other than or in addition to skin, lungs, or cervical or hilar lymph nodes) Pneumocystis carinii pneumonia (continued)

436

THE PERSON WITH HIV/AIDS

TABLE 12.1

(continued)

Progressive multifocal leukoencephalopathy Salmonella (nontyphoid septicemia, recurrent) Toxoplasmosis of the brain with onset > 1 month of age Wasting syndrome in the absence of a concurrent illness other than HIV infection that could explain the following findings: persistent weight loss > 10% of baseline or downward crossing of at least two of the following percentile lines on the weight-for-age chart in a child > 1 year of age or > 5th percentile on weight-for-height chart on two consecutive measurements > 30 days apart plus chronic diarrhea (i.e., at least two loose stools per day for > 30 days) or documented fever (for > 30 days, intermittent or constant) "Modified from CDC. (1994). 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR, 43(No. RR-12), 1-10.

infants can be detected (Bryson, Luzuriaga, Sullivan, & Wara, 1993). The HIV PCR test can detect 93% of children infected with HIV if they are tested by 14 days of age (Dunn et al., 1995). If negative, additional HIV testing should be carried out again at 1 to 2 months, and between 3 to 6 months of age. Blood from the umbilical cord should not be used due to possible contamination by maternal blood (Bryson et al., 1993). The child older than 18 months of age can be accurately tested with the Western blot and ELISA tests used in detecting HIV antibodies in adults (Working Group on Antiretroviral Therapy and Medical Management of HlV-Infected Children, 1999). HIV culture is equally as sensitive as HIV PCR but is more complicated and expensive than HIV PCR and may take 2 to 4 weeks for test results (Mclntosh et al., 1994). Standard and immune complexdissociated p24 antigen tests have also been used to diagnose HIV infection in infants and children but have been found to be less sensitive than HIV PCR and HIV culture and to have a high frequency of false positive results (Nesheim et al., 1997). Another test used for HIV diagnosis in children is HIV RNA assays that detect the HIV in plasma. This test promises to be more sensitive for early diagnosis than the HIV DNA PCR, but reliable information regarding specificity and sensitivity is currently unavailable (Steketee et al., 1997). Many researchers have proposed that if an infant has a positive virologic test at or before 48 hours of life, then congenital infection acquired transplacentally should be suspected. Infants having negative virologic tests during the first week of life and positive virologic

HIV DISEASE IN CHILDREN

437

tests later are suspected of acquiring HIV late during the delivery process (Bryson et al., 1993). Presently, researchers postulate that 30% to 50% of vertically infected infants acquire the disease in utero, and the other 50% to 70% acquire HIV during the intrapartum or neonatal period ("Perinatal and Postnatal Transmission of HIV Infection: A Fact Sheet," 1999). Infants acquiring early infection appear to experience a more severe, rapid progression of the disease than infants infected during the birth process. Many infectious disease pediatricians therefore advocate that the infants should receive initial aggressive antiretroviral therapy (Dickover et al., 1998; Krishnan & Hanson, 1998; Mayaux et al., 1996). It has been found that the HIV RNA copy number after the first few months of life and CD4+ percent were a better indicator of rapid disease progression than the exact age that the virologic test was first positive (Mofenson et al., 1997; Shearer et al., 1997), as well as HIV RNA levels in the mother at delivery (Dickover et al., 1998). Researchers have most recently been examining the effects of a virus phenotype and genotype (Van Dyke et al., 1999; Viani, Smith, & Spector, 1998). HIV infection is ruled out with considerable certainty after two negative virologic tests, with the first conclusive test being at or after 1 month and the other test occurring at or after 4 months (CDC, 1995). Also, HIV infection can be dismissed as a diagnosis in infants with no clinical presentation of HFVif two or more HIV immunoglobulin G (IgG) tests return negative after the infant is 6 months of age (seroreversion). These tests must take place at least 1 month apart. One can be absolutely sure that the infant has not acquired HIV infection at 18 months of age when maternal antibodies are no longer present and there have been negative virologic tests up to that age and no clinical symptomatology, as well as no presence of HIV IgG antibody or hypogammaglobulinemia (Working Group on Antiretroviral Therapy and Medical Management of HFV-Infected Children, 1999). NATURAL HISTORY AND CLINICAL SYMPTOMATOLOGY OF PEDIATRIC HIV The initial immunological response to HIV is described in chapter 2. In pediatric cases, especially with perinatal vertical transmission,

438

THE PERSON WITH HIV/AIDS

the infant is a susceptible host due to a developing and immature immune system, which is composed of the cell-mediated or T cell system and the humoral or B cell system. The T cell system is mature at birth, whereas the B cell system is not (Kamani & Douglas, 1991). Failure to produce sufficient antibodies and hypergammaglobulinemia are the major consequences of the undeveloped B cell system, and this exposes the infant to infection. Opportunistic infections (OIs) occur as a result of deficits in the cell-mediated immune system, leading researchers to suggest that the occurrence of OIs in the first year of life may denote intrauterine infection and a poor prognosis. The CD4+ T lymphocyte (hereafter CD4+) count and percentage, T4/T8 ratio, and presence and degree of lymphopenia in infants and children with HIV infection show different patterns than in adults (Koup & Wilson, 1994) and may be strongly affected by the degree of HIV infection in the infant's thymus (Buseyne et al., 1998; Kirschner, Mehr, & Perelson, 1998; Kourtis et al., 1996) and warrant further study. Further discussion of the effect of the CD4+ count and percentage is found later in this chapter under immunologic effect. Due to these physiological differences, infants and children typically experience a shorter period of time from infection to presentation of clinical symptoms (Pizzo, 1990). As children live longer with this disease, researchers are identifying new manifestations of the disease (Bye, 1996). Mortality Many researchers have described a bimodal distribution of pediatric HIV mortality (Abrams etal., 1995; Blanche et al., 1997; Ciuta, Boros, Napoli, Pezzotti, & Rezza, 1998; European Collaborative Study, 1994; Frederick, Mascola, Eller, O'Neil, & Byers, 1994). Approximately 15% to 20% of infants with HIV infection experience a rapid onset of defining symptomatology, and these infants have a poorer prognosis and an earlier death. The most common and earliest symptoms associated with HIV infection are nonspecific and include failure to thrive, fever, splenomegaly and hepatomegaly, diarrhea, lymphadenopathy, and/or parotitis. Mayaux and associates (1996) found that infants with adenopathies and/or liver and/or spleen enlargement in the first year or a low CD4+ percentage (< 30%) at birth had very

HIV DISEASE IN CHILDREN

439

poor survival. Early incidence of heart disease, neurological disease (i.e., encephalopathies), and/or kidney disease were also prognostic of early death in the first 2 years. Disease progression in a child is further influenced by the severity of the disease in the mother at the time of birth, maternal HIV RNA levels at the time of delivery, and other obstetrical events such as prolonged rupture of membranes (> 4 hours), use of scalp electrodes, and prematurity (Blanche et al., 1994; Dickover et al., 1998; Kuhn et al., 1999; Nielsen, 1998; "Perinatal and Postnatal Transmission of HIV Infection: A Fact Sheet," 1999; Tardieu et al., 1995; Van Dyke et al., 1999). Recently, researchers have found that the viral load in perinatally infected infants has high peaks in the first 2 months of life before gradually decreasing. Infants with higher viral loads in those first few months had a poorer prognosis (Dickover et al., 1998; Shearer et al., 1997). The remaining 80% to 85% of infected children experience a slower progression of the disease with 60% being referred to as intermediate progressors and 20% falling into the category of slow progressors or long-term survivors ("Infants, Children, & HIV: Just the Facts," 1999). Blanche and colleagues (1997) found that 75% of 392 children prospectively studied were still alive at 6 years of age. Barnhart and associates (1996), in their study of 2,148 children, found similar results. Additionally, children in their study, on the average, spent 10 months in category N, 4 months in category A, 65 months in categoiy B, and 34 months in category C (as defined in Table 12.1). They found a 50% chance overall of having severe symptoms of AIDS by 5 years of age. For the children in category B, the researchers found a 60% chance of acquiring severe symptomatology within the next 5 years and 65% chance of surviving until 10 years of age. In the total sample, the time from birth to category C was an average of 6.6 years; the time from birth to death, 9.4 years. Grubman and associates (1995) studied 42 children with perinatal HIV infection who were alive after 9 years of age. These children were diagnosed at a mean age of 88 months, and over half were still asymptomatic at that time. Approximately 4 years from diagnosis, almost 60% had AIDS-defining symptomatology. Two thirds of the children had lost their mothers to AIDS and were living with family members. Greater than half of the children (57%) knew their diagnosis. With improvements in treatment, the long-term survival of chil-

440

THE PERSON WITH HIV/AIDS

dren with perinatally acquired HIV infection, the progression of their disease, and the quality of their lives need further study. VIROLOGIC, IMMUNOLOGIC, AND MULTISYSTEM EFFECTS OF PEDIATRIC HIV INFECTION Effect of Viral Load The effect of viral load on the acute and secondary infections associated with HIV infection is different in vertically infected infants than in adults. A full description of viral load during the acute infection in adults is found in chapter 2, Kahn and Walker (1998), and Musey and colleagues (1997). As measured by reverse transcriptase-polymerase chain reaction (RNA PCR), scientists have found that the very high initial viral load in infants falls only gradually over the first year of life rather than quickly, as in adults during the acute infection Levels do not decrease enough to achieve adult levels until the child is approximately 5 years, probably due to a developing and immature immune system (Mclntosh et al., 1996). As noted under the section on mortality in this chapter, the viral load in perinatally infected infants experiences peaks during the first 2 months before any decline is noted (Shearer et al., 1997). As researchers acquire more specific evidence on viral load patterns in the early months of life, development of an antiretroviral bolus is imperative for these youngest infants (Krishnan & Hanson, 1998). Immunologic Effects CD4+ numbers and percentages in infants and children who are not HIV infected are much higher than normal adult values and do not decrease to adult values until the child reaches the approximate age of 6 years. Therefore, age must be considered when evaluating these values (Comans-Bitter et al., 1997; European Collaborative Study, 1992). As a result of this understanding, the CDC (1994a) developed a table of immune categories based on CD4+ count and percentages for three age groups: less than 12 months, 1 to 5 years, and 6 to 12 years (see Table 12.2). After the child is 12 years of age, adult values (CD4+ counts and percentages) are used. Note that only the number

441

HIV DISEASE IN CHILDREN

TABLE 12.2 1994 Revised HIV Pediatric Classification System: Immune Categories Based on Age-Specific CD4+ T-Lymphocyte and Percentage* < 12 mos

6-12 yrs

1-5 yrs

Immune category

No./|iL

(%)

NO./U.L

(%)

No./^L

(%)

Category 1: No suppression

> 1,500

(> 25%)

> 1,000

(> 25%)

> 500

(> 25%)

(15%- 200-499 24%)

(15%24%)

Category 2: Moderate suppression Category 3: Severe suppression

7501,499 < 750

(15%- 500-999 24%) (< 15%)

< 500

(< 15%)

< 200

(< 15%)

'Source: CDC. (1994). 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR, 43 (No. RR-12), 1-10, and Working Group on Antiretroviral Therapy and Medical Management of HIV-lnfected Children. (1999). Guidelines for the use of antiretroviral agents in pediatric HIV infection. [On-Line]. Available: http://www.cdcnpin.org/

of CD4+, not the percentages that are defined for each category, change. Thus, infectious-disease professionals and researchers feel that the percentage is the better predictor of disease progression. As noted in Table 12.2, CD4+ counts decrease as the disease progresses and the child experiences greater immunosuppression. Due to the importance of the immune categories to understanding disease status, CD4+ values should be obtained as soon as a positive virologic test is received and then repeated every subsequent 3 months to document status and changes. CD8+ values are also important because rapid progression is also found when CD4+ counts are < 1,900/mm3 and CD8+ counts are > 850/mm3 during the infant's first 6 months (Kourtis et al., 1996). All of these values are best obtained when the infant or child is clinically stable. Neurological Status It has been estimated that 75% to 90% of all children who are HIV positive will experience neurodevelopmental delays (Belman et al.,

442

THE PERSON WITH HIV/AIDS

1988), of whom 10% to 20% of those children perinatally infected will be diagnosed with encephalopathy (Msellati et al., 1993). In 1997 encephalopathies and dementia were the AIDS indicator condition in 23% (n = 108) of the children identified with AIDS in that year (CDC, 1998b). Today, with the reduction of PCP incidence, there is an increased incidence of encephalopathy becoming the first AIDS-defining condition in children who received PCP prophylaxis (Maldonado et al., 1998). Bale (1990) described the neurological features found in children infected with HIV. These may include encephalopathy (developmental delays), dementia (noted by loss of intellectual skills), acquired microcephaly, spasticity, rigidity, paralysis, seizures, ataxia, cortical atrophy, slowing of the brain's electrical activity, calcifications of the basal ganglia and white matter, and occasional abnormalities of the cerebrospinal fluid. Two neurologic courses have been described in the literature (Belman, 1992; Brouwers, Belman, & Epstein, 1994; Gay et al., 1995; Msellati et al., 1993). The first course is an acute progression of the disease process characterized by rapid symptom onset (6 to 24 months) and an early death (12 to 24 months after neurological and developmental symptom onset) (Rutstein, Conlon, & Batshaw, 1997). Progressive motor dysfunction and neurological deterioration are hallmarks of this progression. A second neurological course is characterized by an initial neurodevelopmental decline with a later plateau phase, where no further developmental advances are made. Following the plateau, children will either acquire new skills or begin to decline. For children who are infected but have no signs of progressive encephalopathy, subtle signs of static encephalopathy are frequently seen (Nozyce et al., 1994). For example, controlling for maternal drug abuse and other at-risk indicators, children with HIV infection progressed more slowly developmentally during the first 6 months but had caught up by 1 year of age. Other researchers (Italian Register for HIV Infection in Children, 1994) found that after developmental testing at 1, 2, and 4 years of age, children with HIV infection performed in the low normal range. An increased incidence of attention-deficit/hyperactivity disorder, learning disabilities (Grubman et al., 1995), expressive (Brouwers et al., 1994) and receptive language delays, short-term memory problems, and percep-

HIV DISEASE IN CHILDREN

443

tual-spatial deficits (Fundaro et al., 1998; Seidel, 1992) have also been found in school-age children with HIV infection. Environmental factors that may also influence the child's neurodevelopmental progress are poverty, poor prenatal care, prenatal complications, prematurity and low birthweight, medical side effects of the treatment for HFV-related conditions, chronic hypoxemia, separation from family, and chronic illness that requires frequent or sporadic hospitalizations (Seidel, 1992). Antiretroviral treatment protocols may also affect neurodevelopmental status. Long-term effects are not widely known. Growth and development studies related to pediatric HIV infection and AIDS are just beginning to report concurrent medication therapy of the subjects. In one study, Pizzo and associates (1988) found a one standard deviation improvement in cognitive function over 6 months using AZT. Tepper and colleagues (1998) found a lessening and some reversal of neurodevelopmental and neurologic symptoms in one child after initiation of combination antiretroviral therapy consisting of ritonavir, zidovudine, and 3TC. Culnane and associates (1999) found no growth or developmental sequelae in unaffected children exposed to zidovudine as long as 5.6 years after exposure. Further prospective research and developmental testing are needed to delineate the clinical and developmental pictures of these courses of HIV, especially in light of current drug therapies which have decreased the incidence of AIDS-defining infections (e.g., PCP). Infections Children with HFV infection will acquire normal viral and bacterial infections just as any other child not infected, but often these infections will result in more severe symptomatology, last for longer periods of time, and may become recurrent, sometimes fatal. Infections that most often affect children with HIV infection can be classified into bacterial, mycobacterial, viral, fungal, and parasitic. They can also be found in the list of clinical symptoms in the 1994 CDC revised classification system (see Table 12.1). Bacterial infections. Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus are the most common bacterial organ-

444

THE PERSON WITH HIV/AIDS

isms causing infection in children with HIV infection (Andiman, Mezger, & Shapiro, 1994). The risk for infection with these organisms is increased when the child has a central venous catheter and other indwelling tubes. Myobacterial infections. Approximately 30% to 50% of children ages 6 years or more with HIV infection whose CD4+ counts fall below 50 cells/mm3 will become infected with Mycobacterium avium complex (MAC). Infants rarely get this condition in their first year of life, but rather acquire this condition after becoming severely immunocompromised. If MAC is acquired before age 2 years, CD4+ counts will be higher. This accounts for the variability of CD4+ counts and age when determining dosage for prophylaxis for MAC. See Table 12.3 for prophylaxis related to age and CD4+ count. Symptoms of MAC include low-grade fever, weight loss, diarrhea, abdominal pain, neutropenia, anemia, and night sweats (CDC draft, 1999; Lewis et al., 1992; Oleske & The Working Group on Antiretroviral Therapy and Medical Management of Infants, Children, and Adolescents with HIV Infection, 1998). M. tuberculosis infection is also found in children with increasing frequency. To help identify these infants at birth, it is recommended that the mother's TB status be ascertained before she and her baby leave the hospital (American Academy of Pediatrics, Committee on Pediatric AIDS, 1997). Viral infections. Herpes viruses are perhaps the most lethal to children with HIV infection. Cytomegalovirus (CMV) can cause localize or disseminated infections involving the eyes, mouth, liver, lungs, and gastrointestinal system (Mustafa, 1994). CMV retinitis affects fewer children than adults, but it is still important to acquire routine ophthalmologic examinations especially in children, birth to 2 years, in stage C disease (Boriskin, Sharland, Dalton, duMont, & Booth, 1999). Some researchers are suggesting that a CMV urine culture at birth or soon after could identify infants with CMV. Also children who are CMV-seronegative, HlV-infected, and immunocompromised should be tested annually beginning at 1 year for CMV antibodies. If positive, retinitis should be ruled out (CDC, 1999 draft). Chicken pox (varicella zoster virus, VZV) in children with HIV infection is often severe with high morbidity and mortality and may

445

HIV DISEASE IN CHILDREN

TABLE 12.3 Prophylaxis for First Episode of Opportunistic Disease in HIV-lnfected Infants and Children Preventive Regimens Pathogen

Indication

First Choice

Alternatives

1. Strongly recommended as standard of care HIV-infected or HlV-indeterminate infants aged 1-12 mo; HIV-infected children aged 1-5 yr with CD4+ count < 500/uL or CD4+ percentage < 15%; HIV-infected children aged 6-12 yr with CD4+ count < 200/(iL or CD4+ percentage < 15%.

Trimethoprimsulfamethoxazole (TMP-SMZ), 150/ 750 mg/m2/d in 2 divided doses po t.i.w. on consecutive days Acceptable alternative dosage schedules: Single dose po t.i.w. on consecutive days; 2 divided doses po q.d.; 2 divided doses po t.i.w. on alternative days

Dapsone (children aged > 1 mo.), 2 mg/kg (max 100 mg) po q.w.; Aerosolized pentamidine (children aged > 5 yr), 300 mg q.m. via Respirgard II™ nebulizer; Atovaquone (age 13 mo. and > 24 mos., 30 mg/kg po q.d.; age 4-24 mo. 45 mg/kg po q.d.)

Isoniazidsensitive

1ST reaction > 5 mm or prior positive 1ST result without treatment or contact with case of active tuberculosis

Isoniazid 10-15 mg/kg (max 300 mg) po q.d. x 9 mo or 20-30 mg/ kg (max 900 mg) po b.i.w. x 9 mo.

Rifampin, 10-20 mg/kg (max 600 mg) po q.d. x 4-6 mo

Isoniazidresistant

Same as above; high probability of exposure to isoniazid-resistant tuberculosis

Rifampin, 10-20 mg/kg (max 600 mg) po q.d. x 4-6 mo

Uncertain

Pneumocystis carinif

Mycobacterium tuberculosis*

(continued)

THE PERSON WITH HIV/AIDS

446

TABLE 12.3

(continued) Preventive Regimens Indication

First Choice

Alternatives

Multidrug(isoniazid and rifampin) resistant

Same as above; high probability of exposure to multidrug-resistant tuberculosis

Choice of drugs requires consultation with public health authorities

None

Mycobacterium avium complex*

For children aged > 6 yrs, CD4+ count < 50/uL; aged 2-6 yrs, CD4+ count < 751 ul; aged 1-2 yrs, CD4+ count < 500/u.L; aged < 1 yr., CD4+ count < 750/uL

Clarithromycin, 7.5 mg/kg (max 500 mg) po b.i.d., or azithromycin, 20 mg/kg (max 1 ,200 mg) po q.w.

Azithromycin , 5 mg/kg (max 250 mg) po q.d.; children aged > 6 yrs, ribabutin , 300 mg po q .d.

Varicella zoster virus®

Significant exposure to varicella with no history of chickenpox or shingles

Varicella zoster immune globulin (VZIG), 1 vial (1.25mL)/10kg (max 5 vials) im, administered < 96 hrs after exposure, ideally within 48 hrs

None

Vaccinepreventable pathogens$

HIV exposure/infection

Routine immunization (see Figure)

None

Pathogen

HIV DISEASE IN CHILDREN

TABLE 12.3

447

(continued) Preventive Regimens

Pathogen

Indication

First Choice

Alternatives

II. Generally recommended Toxoplasma gondii"

IgG antibody to Toxoplasma and severe immunosuppression

TMP-SMZ, 1507 750 mg/m2/d in 2 divided doses po q.d.

Dapsone (children aged > 1 mo), 2 mg/kg or 15 mg/m2 (max 25 mg) po q.d. plus pyrimethamine, 1 mg/kg poq.d. p/usleucovorin, 5 mg po every 3 days Atovaquone (age 1-3 mo. and > 24 mo., 3 mg/kg po q.d.; age 14-24 mo. 45 mg/kg po q.d.)

Varicella zoster virus$

HIV-infected children who are asymptomatic and not immunosuppressed

Varicella zoster vaccine (see vaccine-preventable pathogens)

None

Influenza virus$

All patients (annually, before influenza season)

Influenza vaccine (see vaccine-preventable pathogens)

Rimantadine or amantadine (during outbreaks of influenza A); age 1-9, 5 mg/kg in 2 divided doses po q.d.; age > 10, use adult doses (continued)

THE PERSON WITH HIV/AIDS

448

TABLE 12.3

(continued) Preventive Regimens

Pathogen

Indication

First Choice

Alternatives

III. Not recommended for most children; indicated for use in unusual circumstances Invasive bacterial infections" Cryptococcus neoformans

Hypogammaglobulinemia Severe immunosuppression

IVIG (40 mg/kg/ q.m.) Fluconazole, 3-6 mg/kg po q.d.

Histoplasma capsulatum

Severe immunosuppression, endemic geographic area

Itraconazole, 2-5 mg/kg po q 12-24 hr

Cytomegalovirus (CMVr

CMV antibody positivity and severe immunosuppression

Oral ganciclovir 30 mg/kg po t.i.d.

None Itraconazole, 2-5 mg/kg po q 12-24 hr None

None

NOTE: Information included in these guidelines may not represent Food and Drug Administration (FDA) approval or approved labeling for the particular products or indications in question. Specifically, the terms "safe" and "effective" may not be synonymous with the FDA-defined legal standards for product approval, b.i.w. = twice a week; CMV - cytomegalovirus; IVIG = intravenous immune globulin; q.m. = monthly; t.i.w. - three times a week; TMP-SMZ trimethoprim-sulfamethoxazole; and VZIG = varicella zoster immune globulin. The Respirgard II™ nebulizer is manufactured by Marquest, Englewood, CO. See text and corresponding table in the 1999 Guidelines for Opportunistic Diseases Prophylaxis (see below for reference) for the strength of the above recommendations. "Daily TMP-SMZ reduces the frequency of some bacterial infections. TMP-SMZ, dapsonepyrimethamine, and possibly atovaquone (with or without pyrimethamine) appear to protect against toxoplasmosis, although data have not been prospectively collected. When compared with weekly dapsone, a recent study suggested that daily dapsone is associated with lower incidence of PCP but higher hematologic toxicity and mortality (Mclntosh et al., 1999, Pediatric Infectious Disease Journal, 18,432-439). The efficacy of parenteral pentamidine (eg., 4 mg/ kg/q 2-4 wks) is controversial. Patients receiving therapy for toxoplasmosis with sulfadiazinepyrimethamine are protected against Pneumocystis carinii pneumonia (PCP) and do not need TMP-SMZ. ^Significant drug interactions may occur between rifamycins (rifampin and rifabutin) and protease inhibitors and non-nucleoside reverse transcriptase inhibitors. Consult a specialist. ®Children routinely being administered intravenous immune globulin (IVIG) should receive VZIG if the last dose of IVIG was administered > 21 days before exposure.

HIV DISEASE IN CHILDREN

TABLE 12.3

449

(continued)

$

HIV-infected and HIV-exposed children should be immunized according to the following childhood immunization schedule (see Table 12.9) which has been adapted from the JanuaryDecember 1999 schedule recommended for immunocompetent children by the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, and the American Academy of Family Physicians. This schedule differs from that for immunocompetent children in that IPV replaces OPV, and vaccination against influenza and S. pneumoniae should be offered. MMR should not be administered to severely immunocompromised children. Vaccination against varicella is indicated only for asymptomatic non-immunosuppressed children, and rotavirus vaccine is contraindicated in all HIV-infected children. Once an HIVexposed child is determined not to be HIV infected, the schedule for immunocompetent children applies. Protection against Toxoplasma is provided by the preferred anti-pneumocystis regimens and possibly by atovaquone. The latter may be used with or without pyrimethamine. Pyrimethamine alone probably provides little, if any, protection. "Respiratory syncytial virus (RSV) IVIG, not monoclonal RSV antibody, may be substituted for IVIG during the RSV season to provide broad anti-infective protection, if this product is available. ^Oral ganciclovir results in reduced CMV shedding in CMV-infected children. Acyclovir is not protective against CMV. Source: Centers for Disease Control and Prevention. (1999). 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus (Draft). [On-Line]. Available: http://www.cdcnpin.org/.

reoccur in the form of shingles or chicken pox again later in life (Srugo et al., 1993). More recent discussion has centered on the deleterious effects of the Epstein-Barr, measles, and respirator)' syncytial (RSV) viruses. The Epstein-Barr virus (EBV), whether primary or reactivated, can result in lymphadenopathy, with or without parotitis or lymphocytic interstitial pneumonitis (LIP), and occasionally, polyclonal lymphoproliferative syndrome (Katz, Berkman, & Shapiro, 1992). Children with HIV infection appear to develop primary EBV infection earlier than unaffected children (Pedneault et al., 1998). The measles virus can be lethal and can manifest atypically, for example, progressin to a giant cell pneumonia in the absence of a rash (Kaplan, Daum, Smaron, & McCarthy, 1992; Nadel, McGann, Hodinka, Rutstein, & Chatten, 1991). RSV, with or without adenovirus, can progress to a fatal respiratory compromise (King et al., 1993). Fungal infections. The most common fungal infections in children with HIV infection are oral and esophageal candidiasis. The advance-

450

THE PERSON WITH HIV/AIDS

ment of the disease is associated with fungal infections (Hickset al., 1998; Muller, Groll, & Walsh, 1999; Walsh et al., 1995). Pneumocystis carinii pneumonia (PCP), the most common and most lethal opportunistic infection (OI), was a pediatric indicator disease in 16% (n= 77) of the AIDS cases reported to CDC in 1997 (CDC, 1998b). OI continues to be the major cause of death for infants with HIV infection under 1 year of age (Cvetkovich & Frenkel, 1993) and usually develops from primary infections (Fahrner & Benson, 1996). The peak incidence of PCP occurs between 3 and 6 months of age. This finding prompted the development of guidelines for PCP prophylaxis in infants and children with HIV infection in 1995 and the revised draft this year (see Table 12.3 and section on secondary opportunistic infection prophylaxis later in this chapter). Continued prophylaxis after the first 12 months of life is determined by child's CD4+ T-lymphocyte count and percentage (CDC, 1999 draft).

Pulmonary Problems The most common pulmonary manifestation seen primarily in pediatric HIV infection is lymphocytic interstitial pneumonitis (LIP). LIP may affect as many as half of the children with HIV infection. The etiology of LIP in children with HIV infection is not fully understood, but the combined effects of concurrent HIV infection and EBV has been postulated. The clinical picture for this condition can range from the child being asymptomatic with only radiologic pathology or severely symptomatic with respiratory compromise. Symptoms may include dyspnea, cough, tachypnea, and exercise intolerance. Recent evidence has led researchers to believe that antiretroviral therapy may indirectly decrease the incidence of LIP. Researchers and clinicians have found that infants infected early on in life with LIP rather than an OI, such as PCP, have a much improved prognosis (Connor & Andiman, 1994).

Cardiovascular Manifestations HIV infection may be the foremost etiology of acquired cardiovascular disease in children. The most common cardiac manifestations

HIV DISEASE IN CHILDREN

451

noted in children with HIV infection were dilated cardiomyopathy, left ventricular dysfunction, EKG abnormalities, and arrhythmias (Lane-McAuliffe & Lipschultz, 1995; Lipschultz et al., 1998). Dilated cardiomyopathy occurs in 14% to 93% of children with HIV infection (Luginbuhl, Orav, Mclntosh, & Lipschultz, 1993). Symptoms most commonly found in cardiomyopathy include tachypnea, fatigue hepatosplenomegaly, an S3 gallop, and tachycardia and usually occur during the final stages of the disease (Holt, 1998; Lipschultz et al., 1989). Left ventricular dysfunction occurs along with encephalopathy and was found in 21% to 34% of children with HIV infection (Lane-McAuliffe & Lipschultz, 1995; Lipschultz et al., 1998). Electrocardiographic abnormalities were further identified in 30% to 65% of children with HIV infection and arrhythmias in 24% to 35% of children HIV-infected (Lane-McAuliffe & Lipschultz, 1995).

Gastrointestinal Tract Disorders Disorders throughout the gastrointestinal tract are common in children with HIV infection. Their symptomatology ranges from asymptomatic to severe, often resulting in weight loss and the inability to gain weight. Nausea and vomiting are often associated with infections, central nervous system disorders, and/or medications (Winter & Chang, 1996). Parotitis may be present unilaterally or bilaterally alone or due to LIP (Soberman et al., 1991). Mouth or esophageal ulcers as a result of Candida or herpes simplex often occur (Walsh, 1994), as well as angular cheilitis, hairy leukoplakia, and HFV periodonitis. Children with HIV infection are more prone to dental caries than unaffected children (Ferguson, Nachman, & Berentsen, 1997). These conditions often cause dysphagia and/or painful swallowing (Winter & Chang, 1996). Moreover, if a child is genetically prone to lactose intolerance, he or she will acquire the condition sooner if HIV-infected, but this condition does not seem to enhance incidence of diarrheal disease or promote growth retardation (Miller et al., 1991). Diarrhea is also common and may be the result of Cryptospondia, Microsporidia, Shigella, Salmonella, rotavirus, adenovirus, and other bacteria, fungi, parasites, and/or viruses (Oshitani et al., 1994; Winter & Chang, 1996). Furthermore, the incidence of pancreatitis is increasing in children with HIV infection most often due to

452

THE PERSON WITH HIV/AIDS

infections (e.g., MAC, CMV) or drugs (e.g., dapsone, didanosine, pentamidine, and zalcitabine) (Butler et al., 1993; Miller, Winter, Luginbuhl, Orav, & Mclntosh, 1992; Winter & Chang, 1996). Renal Disease Mesangial hyperplasia and focal glomerulosclerosis are the most common renal manifestations in children with HIV infection (Mueller & Pizzo, 1997). Hematopoietic System Manifestations Anemia occurs in 16% to 94% of children with HIV infection depending on the age of the child, regimen of antiretroviral drugs, and HIV disease status (Hilgartner, 1991). Factors II, VII, IX, and X dependent on vitamin K are also commonly deficient (Mueller & Pizzo, 1997). Endocrine Disorders The failure to thrive that is common in infants with HIV infection often is not endocrine-related (Laue, Pizzo, Butler, & Cutler, 1990; Schwartz et al., 1991). Chronic failure to thrive is also referred to as wasting syndrome and may affect up to 10% of children with AIDS. This condition is also not solely endocrine-related but is multifactorial, resulting from primary and secondary manifestations in many systems (Jenkins, 1996). Thyroid deficiencies do occur frequently in children with HIV infection and are associated with disease progression (Hirschfeld, Laue, Cutler, & Pizzo, 1996). Cancer Non-Hodgkin's lymphoma (NHL) is the most common form of malignancy in children with HIV infection. This condition can manifest as a primary central nervous system (CNS) tumor or systemically.

HIV DISEASE IN CHILDREN

453

The second leading cancer in children is leiomyosarcoma. Both of these leading cancers have high mortality rates (Granovsky, Mueller Nicholson, Rosenberg, & Rabkin, 1998). Kaposi's sarcoma is rare but is increasing in incidence among children with HIV infection. Other malignancies that occur in children with HIV infection are CNS lyrnphornas, leiomyomas (associated with EBV virus, along with leiomyosarcoma), proliferative lesions of mucosa-associated lymphoid tissue (MALT), and leukemias. Although cancers are rare in children, accounting for approximately 2% of the AIDS-defining illness, it is expected that the incidence of cancers in children and adolescents with HIV infection will grow as survival increases (McClain, Joshi, & Murphy, 1996; Mueller & Pizzo, 1997; Parmley, 1997; Ziegler & Katongole-Mbiddle, 1996). CLINICAL MANAGEMENT OF PEDIATRIC HIV INFECTION The clinical management of pediatric HIV infection is complex, challenging, dynamic, and individualized and has been described for the premature, neonate, infant, and child (American Academy of Pediatrics, Committee on Pediatric AIDS, 1997). The infant or child and his or her family are best managed by an interdisciplinary team whose members specialize in pediatric HIV disease. This includes medications, therapies, treatments, laboratory work, radiology, and psvchosocial care. Antiretroviral Therapy The consideration of appropriate antiretroviral therapy and its dosage for infants, children, and adolescents is important because the immunologic and virologic processes in infants and children, although similar in some ways to the adult form, are unique in a variety of ways for infants and children. The members of the Working Group on Antiretroviral Therapy and Medical Management of HIVInfected Children (hereafter referred to as the Working Group on Antiretroviral Therapy) (CDC, 1999) listed these unique considerations:

454

THE PERSON WITH HIV/AIDS

1. Acquisition of infection through perinatal exposure for many infected children 2. In utero exposure to zidovudine (ZDV) and other antiretroviral medications in many perinatally infected children 3. Differences in diagnostic evaluation in perinatal infection 4. Differences in immunologic markers (e.g., CD4+ T lymphocyte count) in young children 5. Changes in pharmacokinetic parameters with age caused by the continuing development and maturation of organ systems involved in drug metabolism and clearance 6. Differences in the clinical and virologic manifestations of perinatal HIV infection secondary to the occurrence of primary infection in growing, immunologically immature persons 7. Special considerations associated with adherence to treatment for children and adolescents In 1993 the Working Group on Antiretroviral Therapy recommended antiretroviral therapy for any infant or child with a diagnosis of HIV infection, HIV-associated symptoms, and/or immunodeficiency based on an age-dependent CD4+ count. Based on the success of ZDV in the 076 protocol concerning maternal-infant vertical transmission, ZDV was prescribed as the gold standard for the initiation of antiretroviral therapy. Infants and children who were HIV positive and with no symptoms or minimal symptoms with normal immune systems were not placed on antiretroviral therapy (Working Group on Antiretroviral Therapy, 1999b). Because of recent advances in protease inhibitors and clinical trials with combinations of drugs, ZDV is no longer recommended as monotherapy for initial treatment of HIV infection. In fact, in research studies comparing ZDV alone with other combinations of drugs, the ZDV group was found to be least effective and resulted in viral resistance (Wilfert & McKinney, 1998). Combination therapy with a protease inhibitor and two nucleoside analogue reverse transcriptase inhibitors (NRTIs) is the preferred antiretroviral regimen for infants and children (see Table 12.4). Antiretroviral therapy is most often initiated when HIV-infected children present with any clinical symptoms of HIV infection and/or have any evidence of immune suppression at any age regardless of viral load (see Table

HIV DISEASE IN CHILDREN

455

TABLE 12.4 Recommended Antiretroviral Regimens for Initial Therapy for Human Immunodeficiency Virus (HIV) Infection in Children Strongly Recommended Clinical trial evidence of clinical benefit and/or sustained suppression of HIV replication in adults and/or children. One highly active protease inhibitor plus two nucleoside analogue reverse transcriptase inhibitors (NRTIs) —Preferred protease inhibitor for infants and children who cannot swallow pills or capsules: nelfinaviror ritonavir. Alternative for children who can swallow pills or capsules: indinavir. —Recommended dual NRTI combinations: the most data on use in children are available for the combinations of zidovudine (ZDV) and dideoxyinosine (ddl) and for ZDV and lamivudine (3TC). More limited data are available for the combinations of stavudine (d4T) and ddl, d4T and 3TC, and ZDV and zalcitabine (ddC)* Alternative for children who can swallow capsules: Efavirenz (Sustiva)** plus 2 NRTIs (see above) or efavirenz (Sustiva) plus nelfinavir and 1 NRTI. Recommended as an Alternative Clinical trial evidence of suppression of HIV replication, but (1) durability may be less in adults and/or children than with strongly recommended regimens; or (2) the durability of suppression is not yet defined; or (3) evidence of efficacy may not outweigh potential adverse consequences (e.g., toxicity, drug interations, cost, etc.). Nevirapine and two NRTIs. Abacavir in combination with ZDV and 3TC. Offer only in Special Circumstances Clinical trial evidence of (1) limited benefit for patients; or (2) data are inconclusive, but may be reasonably offered in special circumstances. Two NRTIs Not Recommended Evidence against use because of (1) overlapping toxicity; and/or (2) because use may be virologically undesirable. (continued)

456

THE PERSON WITH HIV/AIDS

TABLE 12.4 (continued)

Any monotherapy* d4T and ZDV ddC and ddl ddC and d4T ddC and 3TC *ddC is not available in a liquid preparation commercially, although a liquid formulation is available through a compassionate use program of the manufacturer (Hoffman-LaRoche Inc., Nutley, New Jersey). ZDV and ddC is a less preferred choice for use in combination with a protease inhibitor. "Efavirenz is currently available only in capsule form, but liquid preparation is currently being evaluated. There are currently no data on appropriate dosage of efavirenz in children under age 3 years. ^Except for ZDV chemoprophylaxis administered to HIV-exposed infants during the first 6 weeks of life to prevent perinatal HIV transmission; if an infant is identified as HIV-infected while receiving ZDV prophylaxis, therapy should be changed to a combination antiretroviral drug regimen. Source: Working Group on Antiretroviral Therapy and Medical Management of HIV-lnfected Children. (1999). Guidelines for the use of antiretroviral agents in pediatric HIV infection. [On-Line]. Available: http://www.cdcnpin.org/.

12.5) (Working Group on Antiretroviral Therapy, 1999). Early treatment with antiretrovirals has slowed down the progress of the disease in infants and decreased mortality rates (Englund et al., 1997; Katzenstein et al., 1996; McKinney, 1997). It is important in choosing the initial antiretroviral regimen to consider limitations in subsequent treatment options if resistance to the initial regimen should develop (CDC, 1999). A list of available pediatric antiretroviral drugs is found in Table 12.6. The current aim of antiretroviral therapy is to suppress viral replication, preserve natural immunologic function, decrease the chance of developing drug resistance (Working Group on Antiretroviral Therapy, 1999), and prevent untoward side effects. Further clinical research is needed to understand the long-term effects of the different classes of antiretroviral drugs currently being used alone or in combination, the combined effects of antiretroviral drugs with prophylactic drugs and/or other drugs used for HIV-related and other symptomatology, the effects of antiretroviral drugs and/or other drugs used for HIV-related and other symptomatology on premature infants and neonates, and the effects of the myriad of

HIV DISEASE IN CHILDREN

457

TABLE 12.5 Indications for Initiation of an Antiretroviral Therapy in Children with Human Immunodeficiency Virus (HiV) Infection* Clinical symptoms associated with HIV infection (i.e., clinical categories A, B, or C). Evidence of immune suppression, indicated by CD4+ T-lymphocyte absolute number or percentage (i.e., immune category 2 or 3). Age < 12 months—regardless of clinical, immunologic, or virologic status. For asymptomatic children aged > 1 year with normal immune status, two options can be considered: —Preferred Approach Initiate therapy—regardless of age or symptom status. —Alternative Approach Defer treatment in situations in which the risk for clinical disease progression is low and other factors (e.g., concern for the durability of response, safety, and adherence) favor postponing treatment. In such cases, the health-care provider should regularly monitor virologic, immunologic, and clinical status. Factors to be considered in deciding to initiate therapy include the following: —High or increasing HIV RNA copy number. —Rapidly declining CD4+ T-lymphocyte number or percentage to values approaching those indicative of moderate immune suppression (i.e., immune category 2). —Development of clinical symptoms. 'indications for initiation of antiretroviral therapy in post-pubertal HIV-infected adolescents should follow the adult guidelines (Office of Public Health and Science, Department of Health and Human Services. Availability of report of NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults. Federal Register 1997; 62:33418-8). Source: Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children. (1999). Guidelines for the use of antiretroviral agents in pediatric HIV infection. [On-Line]. Available: http://www.cdcnpin.org

drugs on the child's growth, development, self-image, and neurologic disease. Many drug trials have recently been completed and their results reported (McKinney et al., 1998; Mirochnick et al, 1998; Mueller et al., 1998; Wintergerst et al., 1998). Drug trials are in progress to look at many of these areas. For example, as of August 1998, the National Institute for Child and Human Development (NICHD) was funding 38 pediatric HIV sites for pediatric AIDS clinical trial group (PACTG) protocols (http://pactg.s-3.com/ NICHDpede.htm) and 17 perinatal HIV sites for PACTG protocols

458 TABLE 12.6

Drug Group and Name

THE PERSON WITH HIV/AIDS

Available Pediatric Antiretroviral Drugs

Dosage

Most Frequent Toxicities

Nucleoside Reverse Transcriptase Inhibitors**" Abacavir (GW 1592U89) (ABC), Ziagen™

Neonatal dose: Not approved for infants less than 3 months of age. In infants between 1 and 3 months of age, a dose of 8 mg/kg of body weight twice daily is under study. Pediatric/adolescent dose: 8 mg/kg of body weight twice daily, maximum dose 300 mg twice daily.

Nausea, vomiting, headache, fever, rash, anorexia, and fatigue.

Didanosine (dideoxyinosine) (ddl), WDEX®

Neonatal dose (infants aged < 90 days): 50 mg per m2 of body surface area every 12 hours. Pediatric usual dose: In combination with other antiretrovirals: 90 mg per m2 of body surface area every 12 hours. Pediatric dosage range: 90 to 150 mg per m2 of body surface area every 12 hours. (Note: may need higher dose in patients with central nervous system disease). Adolescent/Adult dose: Body weight > 60 kg: 200 mg twice daily. Body weight < 60 kg: 125 mg twice daily.

Diarrhea, abdominal pain, nausea, and vomiting.

Lamivudine (3TC), EP/Wfl®

Neonatal dose (infants aged < 30 days): 2 mg per kg of body weight twice daily. Pediatric dose: 4 mg per kg of body weight twice daily. Adolescent/Adult dose: Body weight > 50 kg: 150 mg twice daily. Body weight < 50 kg: 2 mg per kg body weight twice daily.

Headache, fatigue, nausea, diarrhea, skin rash, and abdominal pain.

HIV DISEASE IN CHILDREN TABLE 12.6 Drug Group and Name

459

(continued) Dosage

Most Frequent Toxicities

Stavudine (d4T), ZERir

Neonatal dose: Under evaluation in Pediatric AIDS Clinical Trial Group protocol 332. Pediatric dose: 1 mg per kg of body weight every 12 hours (up to weight of 30 kg). Adolescent/Adult dose: Body weight > 60 kg: 40 mg twice daily. Body weight < 60 kg: 30 mg twice daily.

Headache, gastrointestinal disturbances, and skin rashes.

Zalcitabine (ddC), HIVICP

Neonatal dose: Unknown. Pediatric usual dose: 0.01 mg per kg of body weight every 8 hours. Pediatric dosage range: 0.005 to 0.01 mg per kg of body weight every 8 hours. Adolescent/Adult dose: 0.75 mg three times a day.

Headache, gastrointestinal disturbances, and malaise.

Zidovudine (ZDV, AZT), RETROVIR1'

Dose for premature infants: (Standard neonatal dose may be excessive in premature infants). Under study in Pediatric AIDS Clinical Trial Group protocol 331: 1.5 mg per kg of body weight every 12 hours from birth to 2 weeks of age; then increase to 2 mg per kg of body weight every 8 hours after 2 weeks of age. Neonatal dose: Oral: 2 mg per kg of body weight every 6 hours. Intravenous: 1.5 mg per kg of body weight every 6 hours. Pediatric usual dose: Oral 160 mg per m2 of body surface area every 8 hours. Intravenous

Hematologic toxicity, including granulocytopenia and anemia, and headache.

(continued)

THE PERSON WITH HIV/AIDS

460

TABLE 12.6

Drug Group and Name

(continued)

Dosage

Most Frequent Toxicities

(intermittent infusion): 120 mg per m2 of body surface area every 6 hours. Intravenous (continuous infusion): 20 mg per m2 of body surface area per hour. Pediatric dosage range: 90 mg per m2 of body surface area to 180 mg per m2 of body surface area every 6-8 hours. Adolescent/Adult dose: 200 mg three times a day or 300 mg twice daily. Non-nucleoside Reverse Transcriptase Inhibitors**" Delavirdine (DLV), RESCHIPTOH®

Neonatal dose: Unknown. Pediatric dose: Unknown. Adolescent/Adult dose: 400 mg three times a day.

Headache, fatigue, gastrointestinal complaints, and rash (may be severe).

Efavirenz (DMP-266), Sustiva™

Neonatal dose: Unknown Pediatric dose: Administered once daily. Body weight 10 to < 15 kg: 200 mg; 15 to < 20 kg: 250 mg; 20 to < 25 kg: 300 mg; 25 to < 32.5 kg: 350 mg; 32.5 to < 40 kg: 400 mg; > 40 kg: 600 mg. There are currently no data available on the appropriate dosage for children under age 3 years. Adult/adolescent dose: 600 mg once daily.

Skin rash; central nervous system (somnolence, insomnia, abnormal dreams, confusion, abnormal thinking, impaired concentration, amnesia, agitation, depersonalization, hallucinations, euphoria), primarily reported in adults; increased amniotransferase levels, teratogenic in primates (use in pregnancy should be avoided and women of childbearing potential should undergo pregnancy testing before initiating therapy).

HIV DISEASE IN CHILDREN

TABLE 12.6 Drug Group and Name Nevirapine (NVP), VIRAMUNE®

461

(continued) Dosage

Most Frequent Toxicities

Neonatal dose (through age 3 months): Under study in Pediatric AIDS Clinical Trial Group protocol 365: 5 mg per kg of body weight once daily for 14 days, followed by 120 mg per m2 of body surface area every 12 hours for 14 days, followed by 200 mg per m2 of body surface area every 12 hours. Pediatric dose: 120 to 200 mg per m2 of body surface area every 12 hours. Note: Initiate therapy with 120 mg per m2 of body surface area administered once daily for 14 days. Increase to full dose administered every 12 hours if there are no rash or other untoward effects. Adolescent/Adult dose: 200 mg every 12 hours. Note: Initiate therapy at half dose for the first 14 days. Increase to full dose if there is no rash or other untoward effects.

Skin rash (some severe and life-threatening, including Stevens-Johnson syndrome), sedative effect, headache, diarrhea, and nausea.

Protease Inhibitors**** Indinavir, CRIXIVA^

Neonatal dose: Unknown. Due to side effect of hyperbilirubinemia, should not be given to neonates until further information is available. Pediatric dose: Under study in clinical trials: 500 mg per m2 of body surface area every 8 hours. Adolescent/Adult dose: 800 mg every 8 hours.

Nausea, abdominal pain, headache, metallic taste, dizziness, and asymptomatic hyperbilirubinemia (10%).

(continued)

THE PERSON WITH HIV/AIDS

462 TABLE 12.6

Drug Group and Name

(continued)

Dosage

Most Frequent Toxicities

Nelfinavir, VIRACEPT®

Neonatal dose: Under study in Pediatric AIDS Clinical Trial Group protocol 353:10 mg per kg of body weight three times a day. (Note: no preliminary data available, investigational). Pediatric dose: 20 to 30 mg per kg of body weight three times a day. Adolescent/Adult dose: 750 mg three times a day.

Diarrhea.

Ritonavir, NORVIR®

Neonatal dose: Under study in Pediatric AIDS Clinical Trial Group protocol 354 (single dose pharmacokinetics) Pediatric usual dose: 400 mg per m2 of body surface area every 12 hours. To minimize nausea/vomiting, initiate therapy starting at 250 mg per m2 of body surface area every 12 hours and increase stepwise to full dose over 5 days as tolerated. Pediatric dosage range: 350 to 400 mg per m2 of body surface area every 12 hours. Adolescent/Adult dose: 600 mg twice daily. To minimize nausea/vomiting, initiate therapy starting at 300 mg twice daily and increase stepwise to full dose over 5 days as tolerated.

Nausea, vomiting, diarrhea, headache, abdominal pain, and anorexia.

HIV DISEASE IN CHILDREN TABLE 12.6

463

(continued)

Drug Group and Name Saquinavir INVIRASE" (hard gel capsule) and FORTOVASF" (soft gel capsule)

Dosage

Most Frequent Toxicities

Neonatal dose: Unknown. Pediatric dose: Unknown (will be studied in Pediatric AIDS Clinical Trials Group protocol 397). Adolescent/Adult dose: Hard gel capsules: 600 mg three times a day; Soft gel capsules: 1200 mg three times a day.

Diarrhea, abdominal discomfort, headache, nausea, paresthesias, and skin rash.

"information in this Table is not all inclusive. Complete and detailed prescribing and toxicity information on these drugs is available from the drug companies and should be reviewed by the health-care provider before prescribing these drugs. "Adolescents in early puberty (Tanner l-ll) should be dosed using pediatric schedules, whereas those in late puberty (Tanner Stage V) should be dosed using adult schedules. Youth who are in the midst of their growth spurt (Tanner III females and Tanner IV males) should be closely monitored for medication efficacy and toxicity when choosing adult or pediatric dosing guidelines. "Further information regarding current Pediatric AIDS Clinical Trials, see below. + Data in children are limited, and doses may change as more information is obtained about the pharmacokinetics of these drugs in children (i.e., protease inhibitors). Source: Working Group on Antiretroviral Therapy and Medical Management of HIV-lnfected Children. (1999). Guidelines for the use of antiretroviral agents in pediatric HIV infection. [On-Line]. Available: http://www.cdcnpin.org/.

(http://pactg.s-3.com/NICHDpn.htm). Funding for developmental, psychosocial, and quality of life studies has been limited. A Sample of Current Clinical Trials for Children with HIV Infection*^ NCI 93-C-0207: A pilot study to examine the treatment of nonHodgkin's lymphoma in patients with acquired and inherited immunodeficiency syndromes, including HIV. "Current trials as of June, 1999. A NOTE: The information for this list was culled from the AIDS Clinical Trials Group, AIDS Treatment Data Network, AIDS Treatment Information Service, Centers for Disease Control

464

THE PERSON WITH HIV/AIDS

NCI 95-C-0144: A two part study conducted by the National Cancer Institute is looking at the combination of all-trans-retinoic acid and alpha interferon for children under 18 years of age with or without HIV infection and a lymphoproliferative disorder. NCI 95-C-0172: A phase I study to evaluate the safety of HIV-1 Immunogen in children with HIV infection. NCI 95-C-0183: A pilot study of Recombinant IL-2 in children and adolescents with HIV infection. NCI 95-C-0184: A phase I study of Levamisole in children and adolescents with advanced HIV infection. NCI 97-C-0119: F-dda (a nucleoside analog) is being tested alone and with nelfinavir and stavudine by the National Cancer Institute for the treatment of HIV infection in children, ages 6 months to 18 years who have become toxic on other therapy(ies). NCI 98-C-0041: This pilot study is examining the effect of highly active antiretroviral therapy (HAART) on immunologic reconstitution. Examination of the effects of Ritonavir, Nevirapine, and Stavudine in combination will also be done. ACTG: 247: HIV-positive pregnant women due soon to deliver are being recruited to test an increased caloric density infant formula on growth and nutritional status in their infants at sites in New York. ACTG 254: Different drug combinations, including Bactrim, atovaquone, and azithromycin are being tested for the prevention of PCP in children and adolescents with HIV, ages 2 to 19 years, at sites in New York, Maryland, and Pennsylvania. ACTG 299: IL-2 (aldesleukin) is being tested for the treatment of HIV infection in children between the ages of 3 to 12 years at sites in New York and Pennsylvania. ACTG 321: AZT and abacavir are being tested in newborns (birth to 72 hours of age for two parts of the study and 21 to 28 days of age for a third part of the study) for the treatment of HIV infection in Bronx, NY. and Prevention National AIDS Clearinghouse, and the National Cancer Institute-HIV & AIDS Malignancy Branch.

HIV DISEASE IN CHILDREN

465

ACTG 331: Premature infants, aged 1 to 5 days and vertically exposed to HIV infection, are being treated with AZT at sites in New York. ACTG 345: Different combinations of drugs, including AZT, 3TC, and ritonavir (a protease inhibitor) are being tested in children with HIV infection, 1 month to 2 years of age, for the treatment of HIV infection at a site in New York, NY. ACTG 356: Different drug combinations, including AZT, 3TC, nevirapine, and abacavir, are being used for the treatment of HIV infection in children, ages 15 days to 2 years, at sites in New York. CNAA3006: The use of Abacavir and combivir (3TC/AZT) for the treatment of HIV infection in children ages 3 months to 12 years with a viral load of under 100,000 is being tested at sites in New York and New Jersey. The AIDS Clinical Trials Information Service (ACTIS) reports 36 ongoing clinical trials ivith infants and children (see http://cgi.actis.org/ demo/cgi-bin/SFgate.cgi). During the course of treatment, a change in antiretroviral therapy must sometimes be made because of (1) failure or resistance to the regimen resulting in progression of the disease, (2) severe side effects and/or toxicity, and/or (3) new research results indicating a better method of drug management (see Table 12.7) (CDC, 1999). A current controversy in the initial treatment using antiretroviral agents surrounds the amount of dosage. If an adult becomes infected via a needlestick, for example, he or she is immediately treated aggressively with large doses of antiretroviral agents to help prevent the onset of the disease. Many physicians and researchers are advocating for the same treatment approach when initially treating infants. Arguing that the period of time of primary infection is known in infants, basically the first day of life in those infants perinatally infected (e.g., through the birth canal), a bolus protocol could be initiated to prevent the disease by reducing viral load (Krishnan & Hanson, 1998; Luzuriaga et al., 1997). It is important to consider that little is known about the pharmokinetics of drugs in infants under 6 months, that drug therapy is likely to be needed over the lifetime, and the risk and possibility for antiretroviral resistance at some point in time (CDC, 1999). Further research is needed to

466

THE PERSON WITH HIV/AIDS

TABLE 12.7 Considerations for Changing Antiretroviral Therapy for Human Immunodeficiency Virus (HlV)-lnfected Children Virologic Considerations* Less than a minimally acceptable virologic response after 8-12 weeks of therapy. For children receiving antiretroviral therapy with two nucleoside analogue reverse transcriptase inhibitors (NRTIs) and a protease inhibitor, such a response is defined as a < 10-fold (1.0 Iog10) decrease from baseline HIV RNA levels. For children who are receiving less potent antiretroviral therapy (i.e., dual NRTI combinations), an insufficient response is defined as a less than five-fold (0.7 Iog10) decrease in HIV RNA levels from baseline. HIV RNA not suppressed to undetectable levels after 4-6 months of antiretroviral therapy/ Repeated detection of HIV RNA in children who initially responded to antiretroviral therapy with undetectable levels." A reproducible increase in HIV RNA copy number among children who have had a substantial HIV RNA response but still have low levels of detectable HIV RNA. Such an increase would warrant change in therapy if, after initiation of the therapeutic regimen, a greater than threefold (0.5 Iog10) increase in copy number for children aged > 2 years and a greater than fivefold (0.7 Iog10) increase is observed for children aged < 2 years. Immunologic Considerations* Change in immunologic classification.* For children with CD4+ T-lymphocyte percentages of <15% (i.e., those in immune category 3), a persistent decline of five percentiles or more in CD4+ cell percentage (e.g., from 15% to 10%). A rapid and substantial decrease in absolute CD4+ T-lymphocyte count (e.g., a > 30% decline in < 6 months). Clinical Considerations Progressive neurodevelopmental deterioration. Growth failure defined as persistent decline in weight-growth velocity despite adequate nutritional support and without other explanation. Disease progression defined as advancement from one pediatric clinical category to another (e.g., from clinical category A to clinical category B).**

HIV DISEASE IN CHILDREN

TABLE 12.7

467

(continued)

*At least two measurements (taken 1 week apart) should be performed before considering a change in therapy. + The initial HIV RNA level of the child at the start of therapy and the level achieved with therapy should be considered when contemplating potential drug changes. For example, an immediate change in therapy may not be warranted if there is a sustained 1.5 to 2.0 Iog10 decrease in HIV RNA copy number, even if RNA remains detectable at low levels. A

More frequent evaluation of HIV RNA levels should be considered if the HIV RNA increase is limited (e.g., if when using an HIV RNA assay with a lower limit of detection of 1,000 copies/ml, there is a < 0.7 Iog10 increase from undetectable to approximately 5,000 copies/mL in an infant aged < 2 years). "Minimal changes in CD4+ T-!ymphocyte percentile that may result in change in immunologic category (e.g., from 26% to 24%, or 16% to 14%) may not be as concerning as a rapid substantial change in CD4+ percentile within the same immunologic category (e.g., a drop from 35% to 25%). **ln patients with stable immunologic and virologic parameters, progression from one clinical category to another may not represent an indication to change therapy. Thus, in patients whose disease progression is not associated with neurologic deterioration or growth failure, virologic and immunologic considerations are important in deciding whether to change therapy. Source: Working Group on Antiretroviral Therapy and Medical Management of HIV-lnfected Children. (1999). Guidelines for the use of antiretroviral agents in pediatric HIV infection. [On-Line]. Available: http://www.cdcnpin.org/.

identify the correct dosage of antiretroviral drugs and to test for side effects that may be affected by the immature immune system and/or mutations of the virus. Treatment Against Infections Bacterial infections. Bacterial infections are treated with appropriate antibiotic regimens. Resistance to often-used antibiotics (e.g., penicillin and ceftriaxone) must be considered after incidence of recurrent infections (Kaplan et al., 1998). For serious bacterial infections and to prevent such infections in children with HIV infection and hypogammaglobulinemia, intravenous immunoglobulin (IVIG) (400 mg/kg, IV monthly) has reduced the incidence of such infections and fevers. However, it now appears that this treatment adds very little in children who are receiving trimethoprim-sulfamethoxazole (TMP-SMZ) for PCP prophylaxis, but its use is still advocated for children who have recurrent serious bacterial infections (CDC,

468

THE PERSON WITH HIV/AIDS

1999). Use of this drug has not affected survival (National Institute of Child Health and Human Development, Intravenous Immunoglobulin Study Group, 1991; Spector et al., 1994). Prophylaxis regimes have been developed for a number of opportunistic infections and viruses (see Table 12.3) as well as for recurrence of opportunistic diseases (see Table 12.8). Myobacterial infections. Treatment is usually a combination of drugs, such as ciprofloxacin, clarithromycin or azithromycin, rifampin and/or amikacin, ethambutol, and clofazimine. Clarithromycin and azithromycin are the preferred drugs of choice for MAC in children just as they are in adults. There presently is not a liquid form of rifabutin available for children. MAC is prophylaxed in children according to age and CD4+ counts: < 12 months—< 750 cells/fil; 1-2 years—< 500 cells/nj; 2-6 years—< 75 cells/ill; and > 6 years—< 50 cells/j4,l (see Table 12.3). These values reflect the viral load as related to age (CDC, 1999). Unfortunately, drug therapy can only reduce symptoms; the infection is only deterred and does progress over time (Husson et al., 1994; Masur & The Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium complex, 1993). Viral Infections. The drugs of choice for CMV retitinis are ganciclovir or foscarnet (Mueller & Pizzo, 1997) with ganciclovir the best choice for primary prophylaxis when the child is severely immunocompromised (CDC, 1999) (see Table 12.3). Acyclovir (1,500 mg/m2/day, three times a day) is immediately initiated with the onset of chicken pox (VZV) in a child with HIV infection. Foscarnet can be used if the virus reoccurs and acyclovir is not effective. For prevention purposes, intravenous immunoglobulin (FVIG) or specific hyperimmune globulin (VZIG) is given to children with HIV infection and to other members of the household within 72 hours of exposure to VZV (Peter, 1997). Moreover, oral acyclovir in an age-appropriate dose can be given for mild herpes simplex infections (e.g., stomatitis). For more severe infections, such as esophagitis, oral or intravenous acyclovir or famciclovir should be administered (CDC, 1999; Peter, 1997). Fungal infections. Oral and esophageal infections caused by the herpes simplex virus or Candida can be treated with antifungals

HIV DISEASE IN CHILDREN

469

TABLE 12.8 Prophylaxis for Recurrence of Opportunistic Disease (after Chemotherapy for Acute Disease) in HIV-lnfected Infants and Children Preventive Regimens Pathogen

Indication

First Choice

Alternatives

I. Recommended for life as standard of care Pneumocystis cannn

Prior P. carinii pneumonia

TMP-SMZ, 150/ 750 mg/m2/d divided doses po t.i.w. on consecutive days. Acceptable alternative schedules for same dosage: Single dose po t.i.w. on consecutive days; 2 divided doses po q.d.; 2 divided doses po t.i.w. on alternative days

Dapsone (children aged >1 mo), 2 mg/kg (max 100 mg) po q.d. or 4 mg/kg (max 200 mg)poq.w.; Aerosolized pentamidine (children aged > 5 yrs), 300 mg q.m. via Respirgard II™ nebulizer; Atovaquone (age 1-3 mo. and > 24 mo., 30 mg/kg po q.d.; age 4-24 mo., 45 mg/ kg po q.d.)

Toxoplasma gondii'

Prior toxoplasmic encephalitis

Sulfadiazine, 85120 mg/kg/d in 2-4 divided doses po q.d. plus pyrimethamine, 1 mg/ kg or 15 mg/m2 (max 25 mg) po q.d. plus leucovorin, 5 mg po every 3 days.

Clindamycin, 20-30 mg/kg/d in 4 divided doses po q.d. plus pyrimethamine, 1 mg/ kgpoq.d.p/usleucovorin, 5 mg po every 3 days.

(continued)

THE PERSON WITH HIV/AIDS

470

TABLE 12.8

(continued) Preventive Regimens

Pathogen

Indication

First Choice

Alternatives

Mycobacterium avium complex"

Prior disease

clarithromycin, 7.5 mg/kg (max 500 mg) po b.i.d. plus ethambutol, 15 mg/kg (max 900 mg) po q.d.; with or without rifabutin, 5 mg/kg (max 300 mg) po q.d.

Cryptococcus neoformans

Documented disease

Fluconazole, 3-6 mg/kg po mg/kg iv 1-3x/week;

Amphotericin B, 0.5-1.0 q.d. itraconazole, 2-5 mg/kg po q 12-24 hr.

Histoplasma capsulatum

Documented disease

Itraconazole, 2-5 mg/kg po q 12-48 hr.

Amphotericin B, 1.0 mg/kg iv q.w.

Coccidioides immitis

Documented disease

Fluconazole, 6 mg/kg po q.d.

Amphotericin B, 1.0 mg/kg iv q.w.; itraconazole 2-5 mg/kg po q 12-24 hr.

Cytomegalovirus

Prior end-organ disease

Ganciclovir, 5 mg/ kg iv q.d.; or foscarnet, 90-120 mg/ kg iv q.d.

(For retinitis) Ganciclovir sustained-release implant q 6-9 mo. plusganciclovirSO mg/kg po t.i.d.

Salmonella species (non-typhi)#

Bacteremia

TMP-SMZ, 150/ 750 mg/m2 in 2 divided doses po q.d. for several months.

Antibiotic chemoprophylaxis with another active agent.

471

HIV DISEASE IN CHILDREN

TABLE 12.8

(continued) Preventive Regimens

Pathogen

Indication

First Choice

Alternatives

II. Recommended only if subsequent episodes are frequent or severe Invasive bacterial infections*

> 2 infections in 1yr period

TMP-SMZ, 150/ 750 mg/m2 in divided doses po q.d.; or IVIG, 400 mg/kg q.m.

Herpes simplex virus

Frequent/severe recurrences

Acyclovir, 80 mg/

Antibiotic chemoprophylaxis with another active agent.

kg/d in 3-4 divided doses po

q.d. Candida (oropharyngeal) Candida

Frequent/severe recurrences Frequent/severe recurrences

Fluconazole, 3-6 mg/kg po q.d. Fluconazole, 3-6 mg/kg po q.d.

Itraconazole pill, 5-10 mg/kg po q24 hr; ketoconazole, 5-10 mg/kg

po q 12-24 hr. NOTE: Information included in these guidelines may not represent Food and Drug Administration (FDA) approval or approved labeling for the particular products or indications in question. Specifically, the terms "safe" and "effective" may not be synonymous with the FDA-defined legal standards for product approval. IVIG = intravenous immune globulin; q.m. = monthly; q.w. = weekly; t.i.w. = three times a week; and TMP-SMZ = trimethoprim-sulfamethoxazole. The Respirgard II™ nebulizer is manufactured by Marquest, Englewood, CO. "Only pyrimethamine plus sulfadiazine confers protection against PCP as well as toxoplasmosis. Although the clindamycin plus pyrimethamine regimen is the preferred alternative in adults, it has not been tested in children. However, these drugs are safe and are used for other infections. "Significant drug interactions may occur between rifabutin and protease inhibitors and nonnucleoside reverse transcriptase inhibitors. Consult an expert. * Drug should be determined by susceptibilities of the organism isolated. Alternatives to TMP-SMZ include ampicillin, chloramphenicol, or ciprofloxacin. However, ciprofloxacin is not approved for use in persons aged < 18 years; therefore, it should be used in children with caution and only if no alternatives exist. (continued)

472

TABLE 12.8

THE PERSON WITH HIV/AIDS

(continued)

^Antimicrobial prophylaxis should be chosen based on the microorganism and antibiotic sensitivities. TMP-SMZ, if used, should be administered daily. Providers should be cautious about using antibiotics solely for this purpose because of the potential for development of drug-resistant microorganisms. IVIG may not provide additional benefit to children receiving daily TMP-SMZ prophylaxis. Choice of antibiotic prophylaxis vs. IVIG should also involve consideration of adherence, ease of intravenous access, and cost. If IVIG is used, RSVIVIG, not monoclonal RSV antibody, may be substituted for IVIG during the RSV season to provide broad anti-infective protection, if this product is available. Source: Centers for Disease Control and Prevention. (1999). 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus (Draft). [On-Line]. Available: http://www.cdcnpin.org/.

(i.e., azoles), or if resistant, with amphotericin B (Walsh, 1994). For example, topical nystatin (Mycostatin) and oral and vaginal suppositories (100 mg) used by sucking in the mouth are usually effective in the beginning (Fahrner & Benson, 1996). For an indepth discussion of the" classification, diagnosis, and treatment of fungal infections see Muller, Groll, and Walsh (1999) and Ramos-Gomez etal. (1999). Tuberculosis A child with HIV infection needs to be evaluated for tuberculosis (TB) by having a 5-TU PPD around 9 to 12 months of age and retesting every 2 to 3 years (CDC, 1999). When an active diagnosis of TB is ruled out, prophylaxis should be given with an appropriate suppressing drug. If the bacterium cannot be identified, drug therapy is begun with isoniazid for 15 to 18 months (CDC, 1999; O'Hara & D'Orlando, 1996) (see Table 12.3). Prophylaxis Against Secondary Opportunistic Infections The CDC (1999) guidelines for PCP prophylaxis in infants and children recommend prophylaxis to begin at 4 to 6 weeks of life to all infants born to mothers with HIV infection regardless of the infant's immunologic status or CD4 count and percentage for the

HIV DISEASE IN CHILDREN

473

first full year of life. Children who are HlV-negative should have the prophylaxis discontinued. Subsequent prophylaxis after the first year of life is determined by the child's age and CD4+ count (see Table 12.3). In each of the schedules for prophylaxis (i.e., PGP and MAC), the safety for discontinuing the prophylaxis is not known when the use of antiretrovirals have improved the child's health status (CDC, 1999). TMP-SMZ orally 150 mg of TMP/mVday and SMZ 750 mg/ mVday, in two divided doses daily during three consecutive days per week is given. Alternative dosage schedules can be given (see Table 12.3). After an infant or child has had an episode of PCP, he or she should begin a regimen of prophylaxis for the remainder of their life (American Academy of Pediatrics, Committee on Pediatric AIDS, 1997; CDC, 1999). Alternative regimens include the use of oral dapsone, atovaquone, or aerosolized pentamidine (CDC, 1999; Mueller, Butler, Husson, & Pizzo, 1991; Nachman, Mueller, Mirochnik, & Pizzo, 1994). TMP-SMZ when given for PCP prophylaxis also provides prophylaxis for toxoplasmosis. If the child is on another drug for PCP prophylaxis, they should be serologically tested for toxoplasmosis as the other drugs may not be effective. If the child is found positive for toxoplasmosis, then prophylaxis for both conditions should be administered (see Table 12.3) (CDC, 1999). Cardiovascular Manifestations Children with HIV infection are at-risk for cardiac problems both as a result of their disease and the treatment they are receiving. Therefore, it is important for the child to receive regular cardiac evaluations (Lane-McAuliffe & Lipschultz, 1995). Treatment for dilated cardiomyopathy is the same for children with or without HIV infection (Mueller & Pizzo, 1997). If this condition occurs toward the end of the child's life, the interdisciplinary team must consider quality of life when making decisions about drug therapy for all of the concurrent conditions. Treatment for dilated cardiomyopathy includes decreasing the preloading of the heart chambers with diuretics such as Lasix. The accompanying congestive heart failure is treated with cligoxin and to aid in decreasing the after load, captopril and hydralazine can be used (Holt, 1998).

474

THE PERSON WITH HIV/AIDS

Gastrointestinal Problems When nausea and vomiting are present, a careful history and thorough physical examination should be completed, including a neurological examination. For chronic nausea and vomiting, in the absence of liver disorders and pancreatitis, an endoscopic evaluation is often needed for diagnosis. Mucosal biopsies may also need to be taken. In the situation that no cause is found, treatment with medications, such as prochlorperazine (Compazine) and triethylperazine (Torecan) can be administered. A number of medications can also be used to treat oral and esophageal lesions. Furthermore, a thorough workup is required to discover the cause if diarrhea and/or abdominal pain persists (Winter & Chang, 1996). Endocrine Disorders Recombinant growth hormone and insulinlike growth factor 1 have been used to test for physical growth, weight, and immunologic benefits. The final results of these clinical trials have yet to be published (Mueller & Pizzo, 1997). These drugs are also currently being tested for beneficial effects in many types of chronic illnesses and disabilities (e.g., spina bifida and Down syndrome). PRIMARY CARE OF THE INFANT AND CHILD WITH HIV INFECTION Today, much of the health care being delivered is through managed care plans. Families must choose a pediatrician or family practitioner who is listed under their health care plan. These physicians may or may not have had previous experience in caring for a child with HIV infection. It is imperative not only that age-appropriate wellchild care is delivered, but that referral and consultation with pediatricians and other health care professionals expert in the care of infants and children with HIV infection are sought in a timely manner. The overall health care of infants and children with HIV infection must be interdisciplinary and involve the following quality indicators:

HIV DISEASE IN CHILDREN

475

family-centered community based high quality coordinated comprehensive prevention oriented available early and continuously aimed at engaging parents as partners with professionals respectful of cultural, language, and socioeconomic differences noncategorical in approach an integration of health, social, and education services flexible and adaptive to changes in children's health or developmental status and in the social circumstances of their families (Brady, Grim, Caldwell, & Koranyi, 1996). UNAIDS has also issued a statement on the rights of the child with HIV infection (UNAIDS, as cited in CDC, 1997a). The Rights of the Child in the Context of HIV/AIDS* The United Nations Convention on the Rights of the Child in the context of HIV/AIDS has spelled out principles for reducing children's vulnerability to infection and for protecting children from discrimination because of their real or perceived HIV/AIDS status. This human rights framework can be used by governments to ensure that the best interests of children with regard to HIV/AIDS are promoted and addressed: Children's right to life, survival, and development should be guaranteed. Children should have access to HIV/AIDS prevention education and information both in school and out of school, irrespective of their HIV/AIDS status. No discrimination should be suffered by children in leisure, recreational, sport, and cultural activities because of their HIV/ AIDS status. "UNAIDS, June 1997, as cited in CDC, HIVAIDS Prevention, December 1997, p. 2.

476

THE PERSON WITH HIV/AIDS

States should include HIV/AIDS as a disability, if disability laws exist, to strengthen the protection of people living with HIV/ AIDS against discrimination. Children should have access to health care services and programs, and barriers to access encountered by especially vulnerable groups should be removed. All children should receive adequate treatment and care for HIV/AIDS, including those children for whom this may require additional costs because of their circumstances, such as orphans. Children should have access to social benefits, including social security and social insurance. Children should enjoy adequate standards of living. Special measures should be taken by governments to prevent and minimize the impact of HIV/AIDS caused by trafficking, forced prostitution, sexual exploitation, inability to negotiate safe sex, sexual abuse, use of [injection] drugs, and harmful traditional practices. The civil rights and freedoms of children should be respected, with emphasis on removing policies which may result in children being separated from their parents or families. Children should have access to HIV/AIDS prevention education, information and to the means of prevention. Measures should be taken to remove social, cultural, political, or religious barriers that block children's access to these. Children's right to confidentiality and privacy in regard to their HIV status should be recognized. This includes the recognition that HIV testing should be voluntary and done with the informed consent of the person involved, which should be obtained in the context of pretest counseling. If children's legal guardians are involved, they should pay due regard to the child's view, if the child is of an age to have such views. Well-Child Care Unless clinical symptomatology is present, the infant and child should receive well-child care according to guidelines (e.g., Bright Futures) (Green, 1994). Well-child care can be managed by a primary physician and/or nurse practitioner, but often after immunologic

HIV DISEASE IN CHILDREN

477

and/or clinical symptomatology appears, the interdisciplinary team at the pediatric HIV clinic takes over both well-child care and disease management. The infant or child with HIV infection should be followed by the health care team every 3 to 6 months unless he or she becomes symptomatic and needs to be seen more often (Shea, 1997). Standard precautions remain a standard in giving care to all children.

Pain Management Pain should be regularly assessed and appropriate management given. Recent research has found that pain is present in the lives of approximately 60% of children with HIV infection and tends to be either limb or gastrointestinal pain. Pain has been under-treated in children with HIV infection because (1) the medical goal has been to prolong life; (2) specialists in HIV infection have not been adequately educated in pain management; (3) younger children could not express their pain in words; and/or (4) many parents, with or without a drug history, did not want their child addicted to any drug. Another concern is that non-steroidal anti-inflammatory drugs and morphine interrupt the pharmokinetics of zidovudine and may lead to toxic levels of zidovudine. Guidelines need to be developed for appropriate and adequate pain management for children with HIV infection (Hirschfeld, Moss, Dragisic, Smith, & Pizzo, 1996; Vaster 8c Schechter, 1996). Oleske and the Working Group on Antiretroviral Therapy and Medical Management of Infants, Children, and Adolescents with HIV Infection (1998) have proposed a protocol for pain management.

Growth and Development Close monitoring of growth and development parameters are essential in the management of HIV infection in infants and children. Failure to thrive, opportunistic infections (namely, PCP), and encephalopathy are hallmarks of a poor prognosis (Blanche et al., 1990; Hirschfeld, 1996).

478

THE PERSON WITH HIV/AIDS

Effects on Growth. Several researchers have examined growth parameters in HIV-positive infants, seroreverters, and infants having never been infected with HIV (Leeds, 1992; Miller et al., 1993; Moye et al., 1996). In his study in New York, Leeds found that the HIVpositive children (n = 67) were smaller for their age, up to 85% shorter and weighing less than 76% of their same-age peers. None of these positive children were at the 20th percentile or less for head circumference measurements up to 24 months of age. Miller and colleagues (1993) in a study of 89 children (37 seroreverted and 52 HIV-positive) found no difference between the two groups in gestational age and birth weight, but the weight and weight for height percentiles were significantly different by 19 to 21 months of age (51st percentile vs. 33rd percentile and 66th percentile vs. 48th percentile, respectfully). The arm muscle circumference was also significantly lower in the HIV-positive children (64th percentile vs. 43rd percentile). Rich and associates (1993) found in a sample of 203 infants (42 HIV-positive and 161 unaffected) that by the second month, significant decreases in weight and head circumference were observed. Significant changes in the measurement of length was not noted until around 4 months of age. Decrements in these growth parameters remained through 18 months. Moye and colleagues (1996) found that the effect of HIV infection on children perinatally infected "is one of early and progressive decrements in attained linear growth and growth in mass, early and sustained decrements in head growth, and marked early decrements in body mass index" (p. 58). Laue and Cutler (1994) emphasized that other social and environmental factors such as malnutrition, drug abuse, and poverty will affect birth weight and postnatal growth patterns and stressed the importance of accurate and periodic assessments of height and weight in the HIV-positive child that is plotted on appropriate growth charts for age. Developmental Patterns. As HIV infection progresses to stage 3, or AIDS, developmental delay or loss of developmental milestones occurs (Boivin et al., 1995; Brazdziunas, Roizen, Kohrman, & Smith, 1994; Cohen, Papola, & Alvarez, 1994; Msellati et al., 1993; Nozyce et al., 1994; Papola, Alvarez, & Cohen, 1994; Wolters, Brouwers, Moss, & Pizzo, 1995). Significant developmental delays were found most often in the areas of motor (Boivin et al., 1995; Nozyce et

HIV DISEASE IN CHILDREN

479

al., 1994) and language (Cohen et al., 1994; Welters et al., 1995) development. Children with neurological diagnoses (i.e., encephalopathies), often scored in the mentally retarded range on standardized cognitive scales (Brazdziunas et al., 1994; Cohen et al., 1994; Nozyce et al., 1994; Papola et al., 1994). In Papola and colleague (1994) study, the incidence of language impairments (50%) and emotional/behavioral disorders (42%) were significant enough to warrant having each child with HIV infection evaluated periodically for expressive and receptive language ability and presence of any emotional and/or behavioral problems, as well as having the appropriate services available for the children needing them (see developmental recommendations below). The need for regular language assessment was more recently stressed by Coplan and his associates (1998). Mellins, Levenson, Zawadzki, Kairan, and Westori (1994) completed a study of three groups of infants (4 to 30 months) who were HIV-positive, seroreverters, and prenatally exposed to drugs and not HIV-positive. Seventy-seven percent of the HIV-positive and seroreverters were drug-exposed at birth. After the Bayley Scales of Infant Development were administered to the subjects, results showed that the HIV-positive and drug-exposed infants performed significantly lower in psychomotor functions over the other groups. In contrast, Levenson, Mellins, Zawadzki, Kairan, and Stein (1992) found no significant differences when ethnicity, prenatal drug exposure, and gender were controlled. It is apparent that longitudinal, interdisciplinary early developmental research on children with HIV infection is necessary for the identification of the child's developmental strengths and weaknesses and to develop recommendations for educational and developmental programming to obtain optimal developmental achievement (Armstrong, Seidel, 8c Swales, 1993; Cohen, 1994). Developmental Recommendations for Infants and Children with HIV Infection. Butler, Hittelman, and Hauger (1991) stressed that in order to identify developmental delays as soon as they occur, children who are HIV-positive need to be developmentally assessed at regular

THE PERSON WITH HIV/AIDS

480

TABLE 12.9 Immunization Schedule for HIV-lnfected Children Age

Birth

Vaccine

1 mo

2 mOS

4 mos

6 mos

12 mos

15 mos

18 mos

24 mos

4-6

yrs

11-12 years

Recommendations for these vaccines are the same as those for immunocompetent children HepB-1 Hepatitis B * HepB-2 Diphtheria, Tetanus, Pertussis ' Haemophilia Influenza type b

HepB-3

DTaP

DTaP

DTaP

Hib

Hib

HB

DtaP or DTP

DlaP or DTP

Td

Hib

Recommendations for these vaccines differ from those for immunocompetent children Polio" Measles, Mumps, Rubella"

IPV

IPV

Do not give to severely immunosuppressed (Cat. 3) Children.

Influenza11

IPV MMR

MMR

Influenza (a dose is required every year) Pnaumococcal

Streptococcus pneumonlae" Varicella™

Give only to asymptomatic non-immunosuppressed (Cat. 1) children. CONTRAINDICATED in all other HIV-infected persons.

Varicella

Rotavlrus

Note: Modified from the immunization schedule for immunocompetent children. This schedule also applies to children born to HIV-infected mothers whose HIV infection status has not been determined. Once a child is known not to be HIV-infected, the schedule for immunocompetent children applies. This schedule indicates the recommended age for routine administration of currently licensed childhood vaccines. Some combination vaccines are available and may be used whenever administration of all components of the vaccine is indicated. Providers should consult the manufacturers' package inserts for detailed recommendations. Vaccines are listed under the routinely recommended ages. [Bars indicate range of acceptable ages for vaccination. Shaded bars indicate catch-up vaccination; at 11-12 years of age, hepatitis B vaccine should be administered to children not previously vaccinated. ^Infants bom to HBsAg-negative mothers should receive 2.5 |ag of Merck vaccine (RecombiVax HB®) or 10 ng of SmithKline Beecham (SB) vaccine (Engerix-B®). The 2nd dose shoul be administered > 1 mo after the 1 st dose. Infants bom to HBsAg-positive mothers should receive 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hrs of birth and either 5 ng of Merck vaccine (Recombivax HB®) or 10 JKJ of SB vaccine (Engerix-B®) at a separate site. The 2nd dose is recommended at 1-2 mos of age and the 3rd dose at 6 mos of age. Infants bom to mothers whose HBsAg status is unknown should receive 5 ug of Merck vaccine (Recombivax HB®) or 10 \ig of SB vaccine (Engerix-B®) within 12 hrs of birth. The 2nd dose of vaccine is recommended 1 mo of age and the 3rd dose at 6 mos of age. Blood should be drawn at the time of delivery to determine the mother's HBsAg status; if it is positive, the infant should receive HBIG as soon as possible (no later than 1 wk of age). The dosage and timing of subsequent vaccine doses should be based upon the mother's HBsAg status.

14-16 years

HIV DISEASE IN CHILDREN §

481

Children and adolescents who have not been vaccinated against hepatitis B in infancy may begin the series during any childhood visit. Those who have not previously received 3 doses of hepatitis B vaccine should initiate or complete the series during the 11- to 12-year-old visit. The 2nd dose should be administered at least 1 mo after the 1st dose, and the 3rd dose should be administered at least 4 mos after the 1st dose and at least 2 mos after the 2nd dose. ^DtaP (diphtheria and tetanus toxoids and acellular pertussis vaccine) is the preferred vaccine for all doses in the vaccination series, including completion of the series in children who have received > 1 dose of whole-cell DTP vaccine. Whole-cell DTP is an acceptable alternative to DTaP. The 4th dose of DTaP may be administered as early as 12 mos of age, provided 6 mos have elapsed since the 3rd dose, and if the child is considered unlikely to return at 15-18 mos of age. Td (tetanus and diphtheria toxoids, adsorbed, for adult use) is recommended at 11-12 yrs of age if at least 5 yrs have elapsed since the last dose of DTP, DTaP, or DT. Subsequent routine Td boosters are recommended every 10 yrs. "Three H. influenza type b (Hib) conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHIB®) [Merck]) is administered at 2 and 4 mos of age, a dose at 6 mos is not required. After the primary series has been completed, any Hib conjugate vaccine may be used as a booster. ^Inactivated poliovirus vaccine (IPV) is the only polio vaccine recommended for HIV-infected persons and their household contacts. Although the third dose of IPV is generally administered at 12-18 months, the third dose of IPV has been approved to be administered as early as 6 months of age. Oral poliovirus vaccine (OPV) should NOT be administered to HIV-infected persons or their household contacts. §§ MMR should not be administered to severely immunocompromised children. HIV-infected children without severe immunosuppression should routinely receive their first dose of MMR as soon as possible upon reaching the first birthday. Consideration should be given to administering the second dose of MMR vaccine as soon as one month (i.e., minimum 28 days) after the first dose, rather than waiting until school entry. ^Influenza virus vaccine should be administered to all HIV-infected children > 6 months of age each year. Children aged 6 months-8 years who are receiving influenza vaccine for the first time should receive two doses of split virus vaccine separated by at least one month. In subsequent years, a single dose of vaccine (split virus for persons < 12 years of age, whole or split virus for persons > 12 years of age) should be administered each year. The dose of vaccine for children aged 6-35 months is 0.25 \\L; the dose for children aged > 3 years is 0.5 u.L. "'The 23-valent pneumococcal vaccine should be administered to HIV-infected children at 24 months of age. Revaccination should generally be offered to HIV-infected children vaccinated 3-5 years (children aged < 10 years) or > 5 years (children aged > 10 years) earlier, tttvarivax®—va ricella zoster virus vaccine 0.5 ml_ is given as a subcutaneous dose between 12 months to 12 years of age; a second dose should be given 3 months later. The vaccine should be given only to asymptomatic, non-immunosuppressed children. Source: Centers for Disease Control and Prevention, 1999 (April 15, 1999 draft).

482

THE PERSON WITH HIV/AIDS

intervals. They suggest assessment at the initial health visit, between 6 and 9 weeks, then at 6 months of age, and every 6 months thereafter until 24 months of age, then yearly. Appropriate assessment would include the evaluation of mental, motor, and language development, social and emotional status, and short-term memory and attential functioning. Attentional and emotional problems should be evaluated after 24 months, whereas, perceptual-motor skills should be assessed after 30 months. This schedule is similar to the Brouwers, Belman, and Epstein (1994) recommendations for developmental testing. Brouwers and associates divided their recommendations based on the child's age and clinical status. Severely symptomatic children should be assessed more frequently, but using less time due to their health status. Such careful evaluation and analysis must be undertaken in order to delineate specific developmental syndromes or developmental courses in perinatal HIV infection (Armstrong et al., 1993). The authors of the Clinical Practice Guideline for Evaluation and Management of Early HIV Infection (El-Sadr et al., 1994) recommend age-related developmental testing on all HLV-exposed and HIV-positive children every three months for the first 24 months of life and then every 6 months. For a detailed description of neurodevelopmental assessment in the infant and child with HIV infection, see Wachtel and Conlon (1996). Early intervention programs are recommended for those children who are neurodevelopmentally at risk and delayed, and early and regular Head Start programs are suggested for those children developing normally but at risk due to their environment.

Immunizations Infants and children with HIV infection follow the same guidelines for immunizations as any other child except for the following considerations listed in Table 12.9. Also, due to poor immunologic response as a result of HIV, passive immunoprophylaxis is given after exposure regardless of vaccine history as the infant or child is considered susceptible (Peter, 1997). Polio. The inactivated poliomyelitis vaccine (IPV) is recommended over the traditional oral polio vaccine (OPV). In asymptomatic chil-

HIV DISEASE IN CHILDREN

483

dren with HIV infection, IPV should still be given as the child may be immunosuppressed as a result of the HIV and would be at risk for paralytic poliomyelitis due to the vaccine. Seronegative children living in the same household as a child with HIV infection also receive IPV, as the polioviruses can be transmitted via excretions (Peter, 1997). Measles, Mumps, and Rubella. The standard schedule should be used for this vaccine unless the child is severely immunocompromised in which no MMR is given (American Academy of Pediatrics, Committee on Infectious Diseases, 1999). In order to achieve an immune response, the first MMR should be given at 12 months of age. In the case of a suspected outbreak of measles in the community, initial vaccination can begin as early as 6 to 9 months of age. Other seronegative children living with a child with HIV infection can be vaccinated with MMR, as this virus is not transmitted (Peter, 1997). In any child with HIV infection, prophylaxis against measles should include the administration of immune globulin (IG) after any exposure. The child with symptomatic HIV infection should receive IG 0.5 ml/kg (maximum 15 ml) regardless of whether he or she has been immunized or not. Asymptomatic children with HIV infection and susceptible should receive IG 0.25 ml/kg. Susceptible household contacts of the asymptomatic child with HIV infection who has been exposed to measles should also receive IG, especially infants. If the child with HFV infection is currently receiving IVIG infusions, prophylaxis with IG may not be necessary if a dose of FVIG was given 3 weeks prior to the exposure (Peter, 1997). Vitamin A should also be given for the treatment of measles in those children with HIV infection who are not already receiving it, especially in developing countries (Fawzi et al., 1999; Oleske and the Working Group on An tire troviral Therapy and Medical Management of Infants, Children, and Adolescents with HIV Infection, 1998). Pneumococcus. The 23-valent pneumococcal vaccine is given to all children with HIV infection at 2 years of age because of the increased incidence of infection with Pneumococci in patients with HIV infection. For those children older than 2 years, vaccination against Pneumococcusis given after HIV diagnosis. Revaccination is recommended after 3 to 5 years in children < 10 years or after 5 years in children >

484

THE PERSON WITH HIV/AIDS

10 years (CDC, 1999b; Peter, 1997). The use of five-valent pneumo coccal conjugate vaccine is under investigation and may enable children to be immunized for Pneumococcus at an earlier age (King et al., 1997). Influenza. A yearly influenza vaccine is given in the fall to HFVexposed and infected infants beginning at age 6 months, children and adolescents with HIV infection, and household contacts, includ ing other seronegative children (Peter, 1997). See Table 12.9 for information on specific doses. Varicella. Varicella vaccine should only be given to non-immune suppressed, asymptomatic children (CDC, 1999b). See Table 12.9 for dosage and schedule. Varicella zoster immune globulin (VZIG) is also given as passive immunoprophylaxis for exposure to varicella. VZIG is not given if the infant or child with HIV infection received FVIG or VZIG in the past 3 weeks. (See also section on clinical management of viral infections earlier in this chapter.) The infant or child with HIV infection should not be in contact with someone who has developed a rash after immunization against varicella. If contact does occur, administration of VZIG is not warranted (Peter, 1997). Tetanus. If a child with HIV infection receives a wound that might be suspect for tetanus, tetanus immune globulin (TIG) is given regardless of prior vaccination (Peter, 1997). Tuberculosis. The administration of the vaccine for tuberculosis, BCG, is not recommended for use in children with HIV infection in the United States. In developing countries where the incidence of TB is much greater, the World Health Organization recommends the administration of BCG to asymptomatic newborns regardless of the mother's HIV status (Peter, 1997). In January 1998, the American Academy of Pediatrics, Committee on Infectious Diseases determined that a recommended childhood immunization schedule would appear for the total calendar year and be published in Pediatrics each January. This immunization schedule is approved by the Advisory Committee on Immunization Practice (ACIP), the American Academy of Pediatrics (AAP), and

HIV DISEASE IN CHILDREN

485

the American Academy of Family Physicians (AAFP). For indepth information on the immunizations and their contraindications, the current Red Book should be consulted (Peter, 1997). Nutrition The importance of the impact of nutrition on the physiologic and psychosocial well-being of infants, children, and their family members is paramount. Good nutritional status affects quality of life, immune function, and the effectiveness of antiretroviral therapy and other drugs used for the management of the disease. Recurrent Candida esophagitis and diarrhea lead to problems with eating and maintaining weight. Raw or undercooked eggs, poultry, seafood, meat, and unpasteurized dairy products should be avoided as they may contain enteric pathogens. Cross contamination of food must be avoided. Hot dogs should be boiled for severely immunocompromised children to prevent listeriosis. Also, water should be boiled or bottled water used at all times for children with severe immunosuppression to decrease incidence of cryptosporidiosis and giardiasis (CDC, 1999). Dietary supplements (e.g., Pediasure, Ensure), enteral feedings, and later IV alimentation may be needed for children with HIV infection. Winter and Miller (1994) found a strong correlation between HIV infection and malabsorption, malnutrition, enteric pathogens, and immune suppression, as almost all children with HIV infection (95%) develop malnutrition.

Sleep Symptomatic children with HIV infection may experience disruptions in their sleep due to complicated drug regimens, symptoms of the disease and/or other secondary conditions, and/or age-related sleep problems (e.g., night terrors, nightmares), which may be increased due to disease-related, family, and/or environmental influences. Elimination Infants with HIV infection who are also infected with Candida may also experience diaper dermatitis. Diarrhea can also excoriate the

486

THE PERSON WITH HIV/AIDS

perineal area. Both of these conditions require diligent care. Universal precautions should always be used when caring for diarrhea or blood in the perineal area. Toilet training can also be affected if the child with HIV infection is experiencing severe symptoms, especially neurological sequelae.

LIVING WITH A CHRONIC ILLNESS Adherence In any long-term health condition requiring drug therapy and/ or treatment, adherence is important for optimal effects. This is especially true for infants and children with HIV infection. Due to their age, infants and children are dependent on a parent, caregiver, or other adult to give them their medicine, perform any treatments, take them to the doctor and/or hospital, and any other function involved in the management of their illness. Specifically, antiretroviral therapy must be closely monitored. This requires frequent bloodwork for determination of the child's CD4+ values and HIV RNA copy number. Other considerations for compliance include (1) the ease and palpitability of the oral medications, (2) complexity of the medication regime (e.g., Are medications required while the child is in school? How many pills are taken at one time? Are medications or nutritional supplements delivered by alternative routes such as central lines or nasogastric tubes?) and its impact on quality of life, (3) possible drug reactions and untoward side effects, and (4) available support systems, both medical and emotional (Working Group on An tire troviral Therapy, 1999). In response to the need for adherence, the Elizabeth Glaser Pediatric AIDS Foundation (1998) has issued a treatment adherence guide for parents of children with HIV infection.

Multigenerational Effect Qohen (1994), in her review of research on families and pediatric HIV disease, stated that we know very little about family functioning

HIV DISEASE IN CHILDREN

487

in ethnic and racial minorities of varying socioeconomic status and other environmental influences (e.g., urban living). She went on to ask: (1) How can parenting skills be identified, taught, and increased? (2) Are support groups for families having HIV-positive children effective? (3) How do we identify and describe families that are functioning well? Researchers have found that parents of HIV-positive children experience guilt, fear, secrecy, anxiety, and depression (Cohen, Nehring, Malm, & Harris, 1995; Melvin & Sherr, 1993); use informal rather than formal support systems (Weiner, Riekert, Theut, Steinberg, & Pizzo, 1995); worry about health concerns, obtaining child care, and having the time and energy needed to care for the child (Andrews et al., 1993); and have financial worries (Cohen et al., 1995; Melvin & Sherr, 1993). It is also known that parents of children with HIV infection experience increased levels of anxiety, depression, anticipatory grief, and posttraumatic stress disorder (Murphy, Koranyi, Grim, & Whited, 1999; Weiner et al., 1995) and need support (Hansell et al., 1999; Rose & Clark-Alexander, 1998). Hopkins and associates (1989) also stressed the importance of teaching parental coping skills in caring for children who are disabled and/or chronically ill. Time and attention must also be given to the sensitive discussion of respite needs and, later, the dying process and death of family members and the child (American Academy of Pediatrics, Committee on Pediatric AIDS, 1999; Armstrong-Dailey & Fair, 1994). More recently, researchers have begun to look at the effects of HIV infection in children on grandmothers (Caliandro & Hughes, 1998) and extended family members (Hansell etal., 1998). Cultural, language, psychological, and economic needs of families who have HIV-positive children must also be considered. Case management using a family-centered care approach provides comprehensive support, education, and care encompassing the above issues (Brady, Grim, Caldwell, & Karanyi, 1996; Nehring, Larson, & Boyer, 1997). Pets Children with HIV infection, as well as adults with the disease, can get illnesses from pets, but this is rare. To date, no incidence of animal-to-human transmission of HIV infection has been reported.

488

THE PERSON WITH HIV/AIDS

The general rules of owning a pet with a person in the house with HIV infection include: (1) washing your hands after handling the pet; (2) do not purchase a young animal (< 6 months of age) or an ill animal; (3) the person with HIV infection should avoid contact with the pet's feces; (4) if the person with HIV infection must clean up after the pet, they should wear gloves; (5) the cage, litter box, or aquarium should be cleaned daily; (6) avoid strays or exotic animals for pets; (7) if the animal has any episode of prolonged diarrhea or becomes ill, the care of a veterinarian should be sought as soon as possible; and (8) do not allow your pet to eat raw meats (CDC, 1999; Glaser, Angulo, & Rooney, 1994). Specifically, the risk of the person with HIV infection getting toxoplasmosis or Bartonella from a pet cat is small, but the general rules above should be followed. Also, pet cats should not be allowed to hunt; keeping them in the house is advised. Dogs transmit enteric infections to humans more often than do cats. For example, Salmonella, Campylohbacter, Cryptosporidia, and Giardia are present in dogs more so than in cats (CDC, 1999; Glaser, Angulo, & Rooney, 1994). The risk of a person with HIV infection becoming sick from a pet bird is very low. In fact, wild birds pose the greater risk, especially for Cryptococcusand Campylobacter. Therefore, persons with HIV infection should avoid parks and areas where pigeon droppings are prevalent (CDC, 1999; Glaser, Angulo, & Rooney, 1994). Other animals may also pose risks. Farm animals may have enteric infections caused by Cryptosporidium for example. Reptiles also often have Salmonella and their ownership should be avoided. Fish make good pets and the only precaution would be to wear gloves when cleaning the aquarium. On the other hand, hamsters and gerbils can carry many of the above mentioned bacterium and persons with HIV infection should be advised to follow the general rules listed earlier (CDC, 1999; Glaser, Angulo, & Rooney, 1994). Overall, because of the good that having an animal around can do for any person, the benefits of having a pet still outweigh the risks.

Disclosure A question that all families who have a child with HIV infection must ask is when should they inform the child that he or she is HIV-

HIV DISEASE IN CHILDREN

489

positive. Parents, whether natural or foster, fear that their child will not understand the disease, will be stigmatized or ostracized, and/ or the child may tell other children and adults whom parents would not choose to tell. They also fear that the child will be angry at them and become depressed, withdrawn, or will experience a decreasing health status. Parents who are often unsure how to describe the disease and how to explain the reason for the transmission delay telling their child, especially if they are the birth parents and are themselves HIV-positive. A past and/or current history of drug use and illicit sexual relationships add to this difficulty. Parents must also answer questions regarding their own (if applicable) and their child's mortality and determine who should know. On the other hand, benefits may include elimination of secrecy, improvement in coping with the illness, improved parent-child relationships, increased compliance with treatment regimes, increased support, and future prevention of further transmission (Lashley 8c Nehring, 1997; Lipson, 1996; Murphy, Koranyi, Grim, & Whited, 1999; National Pediatric and Family HIV Resource Center, 1995). It is important that parents do not carry the burden of disclosing alone. The interdisciplinary team that cares for the child, alone or together with the family's personal network of family, friends, religious leaders, etc., can help in planning for and telling the child. Information should be given in private and be age-appropriate. Disclosure is a process and should take place across a number of years. Time should be given for the child to absorb the information, confront his or her feelings regarding this information, and ask questions later and receive honest age-appropriate answers. The disclosure of information should not occur once but should be repeated as necessary when the affected child asks. Support should be given individually to the parent(s) and child (Lee 8c Johann-Liang, 1999; Lipson, 1996; National Pediatric and Family HIV Resource Center, 1995; Weiner, Battles, & Heilman, 1998). Cohen and DeMaria (1997) found that by age 10 years, only half of the children with HIV infection knew their diagnosis. Severity of illness did not predict disclosure. Children were most often told by their family members (59%), a physician and a family member (24%), or a physician alone with permission by the parent(s) (17%). These findings concur with other research (Funck-Brentano, 1997; Grubman et al, 1995; Weiner et al, 1998).

490

THE PERSON WITH HIV/AIDS

Siblings are not to be forgotten in this process. Deciding when the siblings are to be told is equally important. Whether the siblings should be told soon after the affected child is told, before if the siblings are older, or later after the affected child is told or much later if the siblings are younger is an important consideration (National Pediatric and Family HIV Resource Center, 1995). Additional decisions need to be made regarding disclosure to other family members, friends, the school, and other important support systems as needed by the parents. Again, the interdisciplinary health care team should be available to assist in this process. Numerous books and videotapes are available to assist parents in this process. These may be found at the public library, bookstores under the "children with special needs section," or from local, state, and national organizations. The national organizations listed at the end of this chapter have books and videotapes available for families. These are listed on their Web pages.

Day Care and School Issues Statutes in Illinois and South Carolina still require health department personnel to give notice to principals of the schools in which a child with HIV infection is enrolled. In South Carolina this relates only to public schools. These are antiquated laws that are not supported by the other states and by other educational, public health, and medical organizations, such as the American Public Health Association and the American Academy of Pediatrics (1992). Disclosure to the schools remains an issue of privacy, confidentiality, and infection control. Especially with the increased complexity of drug regimes and the need for continuous infusion of some medications, however, privacy will be harder to maintain. Many parents presently schedule their children's medications around the school hours to maintain their privacy (Cohen & DeMaria, 1997). Although the initiation of the Ryan White Act of 1990 and the Americans with Disabilities Act of 1992 has allowed children with HIV infection to attend public schools, there are additional educational efforts that must be undertaken, especially for the purpose of prevention. The American Academy of Pediatrics, Committee on Pediatric AIDS (1998a) has advocated for information on HIV infection and

HIV DISEASE IN CHILDREN

491

AIDS to be constantly updated in the K-12 health education curriculum. Members of the committee have also stressed that health care professionals expert in pediatric and adolescent HIV infection and AIDS need to consult and speak to outside groups, including students, student teachers, schoolteachers, and administrators, on proper prevention and the current facts related to the disease. Additionally, a school health advisory committee should be formed in ever)' community composed of students, parents, a community physician, a medical adviser for the school, a school nurse, a health educator, the school administrator, a faculty member, a mental health professional, and other community representatives as appropriate. Such information should always be developmentally appropriate for age and culturally sensitive. Another concern for schools is the transmission of HIV infection in the athletic setting. The American Academy of Pediatrics, Committee on Sports Medicine and Fitness (1991) recommends that until an episode of transmission occurs between athletes, there should be no restrictions in participation. Sports, often associated with bloody cuts, should be avoided if possible. In all athletic situations, universal precautions should be followed. Foster Care and Alternative Living Arrangements Many infants and children are living in foster care arrangements, either traditional or kinship. These children and their caregivers have special needs for disease management, personal support, and comprehensive agency support. Guidelines are available regarding children with HIV infection in foster care (American Academy of Pediatrics, Committee on Infectious Diseases, 1987; American Academy of Pediatrics, Task Force on Pediatric AIDS, 1989; American Academy of Pediatrics, Task Force on Pediatric AIDS, 1992; CDC, 1985). Typically, foster parents are older in age than natural parents of infants and children with HIV infection. They often choose to foster a child with special health care needs after their own natural children were grown. Themes that have arisen from interviews with foster mothers of infants and children with HIV infection included the decision to become a foster parent of an HIV-positive child, health

492

THE PERSON WITH HIV/AIDS

and social characteristics of the HIV-positive foster child, the fear of transmission, concerns about the child's development, the effects of caring for a HIV-positive child on the other members of the family, and preparation for the eventual death of the child (Cohen et al., 1995). Providing consistent and frequent support to families who foster a child with HIV infection was found to be significantly beneficial (Hansell et al., 1998). Cohen and Nehring (1994) conducted the only national survey of state foster care administrators to determine the current number of HIV-positive children in foster care in 1991, cumulative numbers to that date, recruitment measures and policies, foster parent licensure, foster parent training, supplemental services, adoption possibilities, payments, and the expressed fears and doubts of the foster parents. In 1991 there were 1,149 infants and children across the country who were HIV-positive and in foster care. The current number is unknown but suspected to be much higher. Fifty percent of the states in 1991 placed the HIV-positive children in general foster care as opposed to the categories of medical, special needs, HIV children's, or specialized foster care. Fears and doubts of the foster parents included the fear of transmission or infection, the child's dying while in care and being blamed for the death, stigma, discrimi nation, day care and school issues, grief, universal precautions, HIV testing availability and results, and availability of support services. A recent study (Parsons & Merrick-Roddy, 1996) conducted in Louisiana predicted that by 2000, the number of orphans from parents dying of AIDS will range from 1,242 to 2,627 (all will not be HFV-infected). The authors speculate that if only 50% of this number uses the foster care system, the costs to the state could be greater than $500,000/year. A current accounting of children with HIV infection in foster care nationwide would be valuable to plan appropriate care and provide appropriate education to the staffs of these state and private foster care agencies. Prenatal and Perinatal Drug Exposure and Sexual Abuse Mothers who are HIV infected and used drugs and/or alcohol during pregnancy often produce premature and small for gestational age babies with very immature immunological systems. Learning and

HIV DISEASE IN CHILDREN

493

developmental delays, attention disorders, and/or motor deficits often result. These insults are in addition to the effects of HIV infection (Mueller & Pizzo, 1997). Infants, children, and adolescents can acquire HIV infection through sexual abuse, although presently rare. This trauma may also create additional emotional distress. Adolescence Adolescence is normally a time of risk taking. Adolescent boys and girls feel that no harm can come to them and therefore often increase their intake of alcohol and drugs and/or engage in unprotected sexual activities. Even with increased education in the schools and community groups about HIV disease, adolescents test well on the knowledge but continue to engage in high-risk behaviors (American Academy of Pediatrics, Committee on Pediatric AIDS, 1998a). Although the largest single age group for people with AIDS is 24 to 44 years, with a mean length of time before clinical symptoms in adults of 10 years, a significant percentage of these adults were infected in their adolescent years (Wiznia, Lambert, & Pavlakis, 1996). Another group of adolescents to be aware of are those who were infected perinatally or as a result of breastfeeding as infants or in childhood due to contaminated blood products who are living now into their adolescent years. These young men and women not only want to be like their peers, but have the additional threat of passing on their disease. They need education and counseling to assist them in making appropriate decisions regarding risk-taking behaviors. During adolescence, the body goes through many physiological changes, both normal and HFV-related. For example, puberty is delayed in adolescents with HIV infection, especially males, due to malnutrition and growth deficits (Hirschfeld, 1996). These overall changes may also affect the efficacy of the medications. Adolescence is also a time when pediatric dosages are changed to adult dosages based on the adolescent's Tanner stage, not age (El-Sadar et al., 1994). Adolescents can manage much of their care with variable amounts of assistance from parents or another adult. Because this is such an

494

THE PERSON WITH HIV/AIDS

important time to be with friends and be like them, adolescents often choose not to follow medication schedules; this can affect their clinical picture. It may also be a time that parent or other adult family members die from HIV infection if they had been infected. This results in a chaotic time in an adolescent's life already affected from normal developmental processes. Careful and sensitive assessment, intervention, and follow-up by the interdisciplinary team is essential.

Economic Issues In a retrospective study of 29 children with HIV infection as a result of perinatal transmission in Wisconsin (Havens, Cuene, & Holtgrave, 1997), the costs of lifetime care were estimated using a median survival time of 10 years. The estimated total lifetime charges for hospital-based care was $408,307 (with a range of $172,217 to $498,539). The authors assumed that hospital care represented 83% of the total care costs. If this is held true, then the estimated total lifetime care costs for a child with HIV infection is $491,936 (with a range of $207,490 to $600,649). The authors further propose that if women at risk for HIV infection follow the recommendations for HIV counseling and appropriate pregnancy HIV testing, then follow through with appropriate treatment if infected, the savings to the federal government could be $426,753,768. (See also projected costs of foster care for children with HIV infection in one state described in the foster care section of this chapter.)

REFERENCES Abrams, E. J., Matheson, P. B., Thomas, P. A., Thea, D. M., Krasinski, K., & Lambert, G. (1995). Neonatal predictors of infection status and early death among 332 infants at risk of HFV-1 infection monitored prospectively from birth. Pediatrics, 96, 451-458. American Academy of Pediatrics, Committee on Infectious Diseases. (1987). Health guidelines for the attendance in day care and foster care settings of children infected with human immunodeficiency virus. Pediatrics, 79, 466-471. . (1998). Recommended childhood immunization schedule—United States, January-December 1998. Pediatrics, 101, 154-157.

HIV DISEASE IN CHILDREN

495

. (1999). Measles immunization in HlV-infected children. Pediatrics, 103, 1057-1060. American Academy of Pediatrics, Committee on Pediatric AIDS. (1997). Evaluation and medical treatment of the HIV-exposed infant. Pediatrics, 99, 909-917. . (1998a). Human immunodeficiency virus/acquired immunodeficiency syndrome education in schools. Pediatrics, 101, 933-935. . (1998b). Surveillance of pediatric HIV infection. Pediatrics, 101, 315-319. . (1999). Planning for children whose parents are dying of HIV/AIDS. Pediatrics, 103, 509-511. American Academy of Pediatrics, Committee on Sports Medicine and Fitness. (1991). Human immunodeficiency virus [acquired immunodeficiency syndrome] (AIDS) virus in the athletic setting. Pediatrics, 88, 640-641. American Public Health Association, & the American Academy of Pediatrics. (1992). Coring for our children: National health and safety standards: Guidelines for out-ofhome child care programs. Washington, DC: American Academy of Pediatrics. Ammann, A. J., Cowan, M. J., Wara, D. W., Weintrub, P., Dritz, S., & Goldman, H. (1983). Acquired immunodeficiency in an infant: Possible transmission by means of blood products. The Lancet, 1, 956-958. Andiman, W. A., Mezger, }., & Shapiro, E. (1994). Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1. Journal of Pediatrics, 124, 846-852. Andrews, S., Williams. A. B., & Neil, K. (1993). The mother-child relationship in the HIV-1 positive family. Image, 25, 193-198. Armstrong, F. I).. Seidel, J. F., & Swales, T. P. (1993). Pediatric HIV infection: A neuropsychological and educational challenge. Journal of Learning Disabilities, 26, 92-103. Armstrong-Dailey, A., & Fair, C. (1994). Respite and terminal care for children with HIV infection and their families. In P. A. Pizzo & C. M. Wilfert (Eds.), Pediatric AIDS: The challenge of HIV infection in infants, children, and adolescents (2nd ed., pp. 829-838). Baltimore: Williams and Wilkins. Bale, J. F., Jr. (1990). The neurologic complications of AIDS in infants and young children. Infants and Young Children, 3(2), 15-23. Barnhart, H. X., Caldwell, M. B., Thomas, P., Mascola, L., Ortiz, J., & Hsu, H. W. (1996). Natural history of human immunodeficiency virus disease in perinatally infected children: An analysis from the pediatric spectrum of disease project. Pediatrics, 97, 710-716. Belman, A. L. (1992). Acquired immunodeficiency syndrome and the child's central nervous system. Pediatric Clinics of North America, 39, 691-714. Belman, A. L., Diamond, G., Dickson, D., Horoupian, D., Llena, J., & Lantos, G. (1988). Pediatric acquired immunodeficiency syndrome: Neurological syndromes. American Journal of Diseases of Children, 142, 29-35. Black, M. M., Nair, P., Knight, C., Wachtel, R., Roby, P., & Schuler, M. (1994). Parenting and early development among children of drug-abusing women: Effects of home intervention. Pediatrics, 94, 440-448. Blanche, S., Mayaux, M.-J., Rouzioux, C., Teglas, J.-P., Firtion, G., & Monpoux, F. (1994). Relation of the course of HIV infection in children to the severity

496

THE PERSON WITH HIV/AIDS

of the disease in their mothers at delivery. New England Journal of Medicine, 330, 308-312. Blanche, S., Newell, M.-L., Mayaux, M.-J., Dunn, D. T., Teglas, J. P., & Rouzioux, C. (1997). Morbidity and mortality in European children vertically infected by HIV-1: The French Pediatric HIV Infection Study Group and European Collaborative Study. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 14, 442-450. Blanche, S., Tardieu, M., Duliege, A.-M., Rouzioux, C., LeDeist, F., & Fukunaga, K. (1990). Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. American Journal of Diseases in Children, 144, 1210-1215. Bobat, R., Moodley, D., Coutsoudis, A., & Coovadia, H. (1997). Breastfeeding by HFV-l-infected women and outcome in their infants: A cohort study from Durban, South Africa. AIDS, 11, 1627-1633. Boivin, M. J., Davies, A. G., Mokil, J. K. L., Green, S. D. R., Giordani, B., & Cutting, W. A. M. (1995). A preliminary evaluation of the cognitive and motor effects of pediatric HIV infection in Zairian children. Health Psychology, 14, 13-21. Boriskin, Y. S., Sharland, M., Dalton, R., duMont, G., & Booth, J. C. (1999). Viral loads in dual infection with HIV-1 and cytomegalovirus. Archives of Diseases in Children, 80, 132-136. Brady, M. T., Grim, L., Caldwell, L., & Koranyi, K. (1996). Family-centered care: A paradigm for care of the HIV-affected family. Pediatric AIDS and HIV Infection: Fetus to Adolescent, 7, 168-175. Brazdziunas, D. M., Roizen, N. J. M., Kohrman, A. F., & Smith, D. K. (1994). Children of HIV-positive parents: Implications for intervention. Psychosocial Rehabilitation Journal, 17, 145-149. Brouwers, P., Belman, A. L., & Epstein, L. (1994). Central nervous system involvement: Manifestations, evaluation, and pathogenesis. In P. A. Pizzo & C. M. Wilfert (Eds.), Pediatric AIDS: The challenge of HIV infection in infants, children, and adolescents (2nd ed., pp. 433-455). Baltimore: Williams and Wilkins. Bryson, Y.J., Luzuriaga, K, Sullivan, J. L., & Wara, D. W. (1993). Proposed definitions for in utero versus intrapartum transmission of HIV-1 disease. New England Journal of Medicine, 327, 1246-1247. Buseyne, F., Burgard, M., Teglas, J. P., Bui, E., Rouzioux, C., & Mayaux, M.-J. (1998). Early HIV-specific cytotoxic T lymphocytes and disease progression in children born to HFV-infected mothers. AIDS Research and Human Retroviruses, 14, 14351444. Butler, C., Hittelman, J., & Hauger, S. B. (1991). Approach to neurodevelopmental and neurologic complications in pediatric HIV infection. Journal of Pediatrics, 119, S41-S46. Butler, K. M., Venzon, D., Henry, N., Husson, R. N., Mueller, B. U., & Balis, F. M. (1993). Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine. Pediatrics, 91, 747-751. Bye, M. R. (1996). HIV in children. Clinics in Chest Medicine, 17, 787-796. Caliandro, G., & Hughes, C. (1998). The experience of being a grandmother who is the primary caregiver for her HIV-positive grandchild. Nursing Research, 47, 107-113.

HIV DISEASE IN CHILDREN

497

Centers for Disease Control and Prevention. (1985). Education and foster care of children infected with human T-lymphotropic virus type IH/lymphadenopathyassociated virus. Mortality and Morbidity Weekly Report, 34, 517—521. . (1994a). 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morbidity and Mortality Weekly Report, 43, 1-10. . (1994b). Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. Morbidity and Mortality Weekly Report, 43(No. RR-11), 1-20. . (1995). U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. Morbidity and Mortality Weekly Report,, 44(No. RR-7), 1-15. . (1997a, December). The rights of the child in the context of HIV/AIDS. HIV/AIDS Prevention, 2. . (1997b). World AIDS day—December 1, 1997. Morbidity and Mortality Weekly Report, 46, 1085. . (1998a). Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Morbidity and Mortality Weekly Report, 47(No. RR-2), 1-30. . (1998b). Year end 1997 edition surveillance report, 9(2), 1-44. . (1998c). Year-end 1998 Edition Surveillance Report, 70(2), 1-43. . (1999), 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus (Draft). [On-Line]. Available: http://www.cdcnpin.org/ Cervia, J. (1999). HIV/AIDS rounds: HIV in children. AIDS Patient Care and STDs, 13, 165-173. Chu, S. Y., Buehler, J. W., Oxtoby, M.J., & Kilbourne, B. W. (1991). Impact of the human immunodeficiency virus epidemic on mortality in children. United States. Pediatrics, 87, 806-810. Ciuta, S. T., Boros, S.. Napoli, P. A., Pezzotti, P., & Rezza, G. (1998). Predictors of survival in children with acquired immunodeficiency syndrome in Italy, 1983 to 1995. AIDS Patient Care and STDs, 12, 629-637. Civitello, L. A. (1991). Neurologic complications of HIV infection in children. Pediatric Neurosurgery, 17, 104-112. Cohen, F. L. (1994). Research on families and pediatric HFV disease: A review and needed directions. Developmental and Behavioral Pediatrics, 15, S43-S51. Cohen, F. L., & Nehring, W. M. (1994). Foster care of HIV-positive children in the United States. Public Health Reports, 109, 60-67. Cohen, F. L., Nehring, W. M., Malm, K. C., & Harris, D. (1995). Family experiences when a child is HIV-positive: Reports of natural and foster parents. Pediatric Nursing, 21, 248-254. Cohen, H. )., Papola, P., & Alvarez, M. (1994). Neurodevelopmental abnormalities in school-age children with HIV infection. Journal of School Health, 64, 11-15. Cohen,J., ScDeMaria, A. (1997). School-related issues among HIV-infected children. Pediatrics, 100, 126-130.

498

THE PERSON WITH HIV/AIDS

Colling, J. (1999). Guidelines for children's participation in HIV/AIDS programs. [OnLine]. Available: http://www.pedhivaids.org/education/children_living.html Comans-Bitter, W. M., de Groot, R., van den Beemd, R., Neijens, H. J., Hop, W. C., & Groeneveld, K. (1997). Immunophenotyping of blood lymphocytes in childhood: Reference values for lymphocyte subpopulations./owrna/ of Pediatrics, 130, 388-393. Connor, E. M., & Andiman, W. A. (1994). Lymphoid interstitial pneumonitis. In P. A. Pizzo & C. M. Wilfert (Eds.), Pediatric AIDS: The challenge of HIV infection in infants, children and adolescents (2nd ed., pp. 467-481). Baltimore: Williams and Wilkins. Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., & O'Sullivan, M. J. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New England Journal of Medicine, 331,11731180. Coplan, J., Contello, K. A., Cunningham, C. K., Weiner, L. B., Dye, T. D., & Roberge, L. (1998). Early language development in children exposed to or infected with human immunodeficiency virus. Pediatrics, 102, 132. Culnane, M., Fowler, M., Lee, S. S., McSherry, G., Brady, M., & O'Donnell, K. (1999). Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HFV-infected women. Journal of the American Medical Association, 281, 151-157. Cvetkovich, T. A., & Frenkel, L. M. (1993). Current management of HIV infection in children. Pediatric Annals, 22, 428-434. Cynn, C. (1999). Whose virus is it anyway? Mandatory testing of newborns. Body Positive, 12. [On-Line]. Available: http://www.thebody.com/bp/jan99/ virus.html Dickover, R. E. (1994). Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants. Journal of Infectious Diseases, 170, 1279-1284. Dickover, R. E., Dillon, M., Leung, K-M, Krogstad, P., Plaeger, S., & Kwok, S. (1998) Early prognostic indicators in primary perinatal human immunodeficiency virus type 1 infection: Importance of viral RNA and the timing of transmission on long-term outcome. Journal of Infectious Diseases, 178, 375-387. Dunn, D. T., Brandt, C. D., Krivine, A., Cassol, S. A., Roques, P., & Borkowsky, W. (1995). The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS, 9, F7-F11. Early HIV Infection Guideline Panel. (1994). Evaluation and management of early HIV infection (Clinical Practice Guideline No. 7). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Elizabeth Glaser Pediatric AIDS Foundation. (1998). Taking medications to treat HIV/ AIDS: A treatment adherence guide for parents of children with HIV infection [Online]. [http://www.pedaids.org/TakingMeds.html] El-Sadar, W., Oleske, J. M., Agins, B. D., Bauman, K. A., Brosgart, C. L., & Brown, G. M. (1994). Evaluation and management of early HIV infection (AHCPR Pub. No.

HIV DISEASE IN CHILDREN

499

94-0572). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Englund, J. A., Baker, C. J., Raskino, C., McKinney, R. E., Petrie, B., & Fowler, M. G. (1997). Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. New England Journal of Medicine, 336, 1704-1712. European Collaborative Study. (1992). Age-related standards for T lymphocyte subsets based on uninfected children born to human immunodeficiency virus 1-infected women. Pediatric Infectious Disease Journal, 11, 1018-1026. . (1994). Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics, 94, 815-819. Fahrner, R., & Benson, M. (1996). HIV infection and AIDS. In P. L.Jackson & J. A. Vessey (Eds.), Primary care of the child with a chronic condition (2nd ed., pp. 463-484). St. Louis: Mosby. Fawzi, W. W., Mbise, R, L., Hertzmark, E., Fataki, M. R., Herrera, M. G., & Ndossi, G. (1999). A randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus-infected and uninfected children in Tanzania. Pediatric Infectious Disease Journal, 18, 127-133. Faye, A., Burgard, M., Crosnier, H., Retbi, J.-M., & Blanche, S. (1997). Human immunodeficiency virus type 2 infection in children. Journal of Pediatrics, 130, 994-997. Ferguson, F. S., Nachman, S., & Berentsen, B. (1997). Implications and management of oral diseases in children and adolescents with HIV infection. New York State Dental Journal, 33, 46-50. Frederick, T., Mascola, L., Eller, A., O'Neil, L., & Byers, B. (1994). Progression of human immunodeficiency virus disease among infants and children infected perinatally with human immunodeficiency virus or through neonatal blood transfusion. Pediatric Infectious Disease Journal, 13, 1091-1097. Funck-Brentano, I. (1997). Patterns of disclosure and perceptions of the human immunodeficiency virus in infected elementary school-age children. Archives of Pediatrics and Adolescent Medicine, 151, 978-985. Fundaro, C., Miccinesi, N., Baldieri, N. F., Genovese, O., Rendeli, C., & Segni, G. (1998). Cognitive impairment in school-age children with asymptomatic HTV infection. AIDS Patient Care and STDs, 12, 135-140. Gay, C. L., Armstrong, F. D., Cohen, D., Lai, S., Hardy, M. D., & Swales, T. P. (1995). The effects of HIV on cognitive and motor development in children born to HIV-seropositive women with no reported drug use: Birth to 24 months. Pediatrics, 96, 1078-1082. Glaser, C. A., Angulo, F. J., & Rooney,J. A. (1994). Animal-associated opportunistic infections among persons infected with the human immunodeficiency virus. Clinical Infectious Diseases, 18, 14-24. Granovsky, M. ()., Mueller, B. U., Nicholson, H. S., Rosenberg, P. S., & Rabkin, C. S. (1998). Cancer in human immunodeficiency virus-infected children: A case series from the Children's Cancer Group and the National Cancer Institute. Journal of Clinical Oncology, 16, 1729-1735. Green, M. (Ed.). (1994). Bright futures: Guidelines for health supervision of infants, children, and adolescents. Arlington, VA: National Center for Education in Maternal and Child Health.

500

THE PERSON WITH HIV/AIDS

Grubman, S., Gross, E., Lerner-Weiss, X., Hernandez, M., McSherry, G. D., & Hoyt, L. G. (1995). Older children and adolescents living with perinatally acquired human immunodeficiency virus infection. Pediatrics, 95, 657-663. Hansell, P. S., Hughes, C. B., Caliandro, G., Russo, P., Budin, W. C., & Hartman, B. (1998). The effect of a social support boosting intervention on stress, coping, and social support in caregivers of children with HIV/AIDS. Nursing Research, 47, 79-86. Hansell, P. S., Hughes, C. B., Caliandro, G., Russo, P., Budin, W. C., & Hartman, B. (1999). Boosting social support in caregivers of children with HIV/AIDS. AIDS Patient Care and STDs, 13, 297-302. Havens, P. L., Cuene, B. E., & Holtgrave, D. R. (1997). Lifetime costs of care for children with human immunodeficiency virus infection. Pediatric Infectious Disease Journal, 16, 607-610. Hicks, M. J., Carter, A. B., Rossmann, S. N., Demmler, G. J., Simon, C. L., & Cron, S. G. (1998). Detection of fungal organisms in saliva from HIV-infected children: A preliminary cytologic analysis. Pediatric Dentistry, 20, 162-168. Hilgartner, M. (1991). Hematologic manifestations in HFV-infected children. Journal of Pediatrics, 119, S47-S49. Hirschfeld, S. (1996). Dysregulation of growth and development in HIV-infected children. Journal of Nutrition, 126, 2641S-2650S. Hirschfeld, S., Laue, L., Cutler, G. B.Jr., & Pizzo, P. A. (1996). Thyroid abnormalities in children infected with human immunodeficiency virus. Journal of Pediatrics, 128, 70-74. Hirschfeld, S., Moss, H., Dragisic, K., Smith, W., & Pizzo, P. A. (1996). Pain in pediatric human immunodeficiency virus infection: Incidence and characteristics in a single-institution pilot study. Pediatrics, 98, 449-452. Holt, C. F. (1998). Health challenges: Alteration in cardiovascular status. In V. R. Bowden, S. B. Dickey, & C. S. Greenberg (Eds.), Children and their families: The continuum of care (pp. 781-862). Philadelphia: Saunders. Husson, R. N., Ross, L. A., Sandelli, S., Inderlied, C. B., Venzon, D., & Lewis, L. L. (1994). Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immunodeficiency syndrome. Journal of Pediatrics, 124, 807-814. Infants, children & HIV: Just the facts. (1999). [On-Line]. Available: http:// www.pedhivaids.org/fact/child_usl_txt.html Italian Register for HIV Infection in Children. (1994). Features of children perinatally infected with HIV-1 surviving longer than 5 years. The Lancet, 343, 191-195. Italian Register for HIV Infection in Children. (1999). Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. ACTA Paediatrica, 88(2), 228-232. Italian Register for HIV Infection in Children. (1999). Rapid disease progression in HrV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. AIDS, 13, 927-933. Jenkins, M. (1996). Human immunodeficiency virus type 1 infection in infants and children. In A. M. Rudolph, J. I. E. Hoffman, & C. D. Rudolph (Eds.), Rudolph's pediatrics (20th ed., pp. 655-661). Stamford, CT: Appleton & Lange.

HIV DISEASE IN CHILDREN

501

Kahn, J. O., & Walker, B. D. (1998). Acute human immunodeficiency virus type 1 infection. New England Journal of Medicine, 339, 33-39. Kamani, N. R., & Douglas, S. D. (1991). Structure and development of the immune system. In D. P. Sites & A. F. Terr (Eds.), Basic and clinical immunology (7th ed., pp. 9-33). Norfolk, CT: Appleton and Lange. Kaplan, L. J., Daum, R. S., Smaron, M., & McCarthy, C. A. (1992). Severe measles in imrnunocompromised patients. Journal of the American Medical Association, 267, 1237-1241. Kaplan, S. L., Mason, E. O., Jr., Barson, W. J., Wald, E. R., Arditi, M., & Tan, T. Q. (1998). Three-year rnulticenter surveillance of systemic pneumococcal infections in children. Pediatrics, 102, 538-545. Katz, B. Z., Berkman, A. B., Be Shapiro, E. D. (1992). Serological evidence of active Epstein-Ban virus infection in Epstein-Barr virus-associated lymphoproliferative disorders of children with acquired immunodeficiency syndrome. Journal of Pediatrics, 120, 228-236. Katzenstein, D. A., Hammer, S. M., Hughes, M. D., Gundeker, H., Brooks Jackson, J., & Fiscus, S. (1996). The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. New England Journal of Medicine, 335, 1091-1098. King, J. C., Burke, A. R., Clemens, J. D., Nair, P., Farley, J. J., & Vink, P. E. (1993). Respirator)' synctial virus illnesses in human immunodeficiency virus-and noninfected children. Pediatric Infectious Disease Journal, 12, 733-735. King, J. C., Vink, P. E., Farley, J. J., Similie, M., Parks, M., & Lichenstein, R. (1997). Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics, 99, 575-580. Kirschner, D. F.., Mehr, R., & Perelson, A. S. (1998). Role of the thymus in pediatric HIV-1 infection. Journal of Acquired Deficiency Syndromes and Human Retrovirology, 18, 95-109. Koup, R. A., & Wilson, C. B. (1994). Clinical immunology of HIV-infected children. In P. A. Pizzo, & C. M. Wilfert (Eds.), Pediatric AIDS: The challenge of HIV infection in infants, children and adolescents (2nd ed., pp. 405-418). Baltimore: Williams and Wilkins. Kourtis, A. P., Ibegbu, C., Nahimias, A. J., Lee, F. K., Clark, W. S., & Sawyer, M. K. (1996), Early progression of disease in HIV-infected infants with thymus dysfunction. New England Journal of Medicine, 335, 1431-1436. Krishnan, V., & Flanson, I. C. (1998). Reviewer's comments. Pediatrics, 9S(Suppl.), 475. Kuhn, L., Steketee, R. W., Weedon, J., Abrams, E. J., Lambert, G., & Bamji, M. (1999). Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. The Journal of Infectious Diseases, 779,52-58. Lackritz, E. M. (1998). Prevention of HIV transmission by blood transfusion in the developing world: Achievements and continuing challenges. AIDS, 12(Suppl. A), S81-S86,

502

THE PERSON WITH HIV/AIDS

Lane-McAuliffe, E. M., & Lipshultz, S. E. (1995). Cardiovascular manifestations of pediatric HIV infection. Nursing Clinics of North America, 30, 291-315. Lashley, F. R., & Nehring, W. M. (1997). How did we find out? Parental experiences in disclosure of the diagnosis of HFV-infected children. Proceedings of the Seventh Annual Sigma Theta Tau Epsilon Eta Chapter and Southern Illinois University Edwardsville School of Nursing Research Day, 10. [Unpublished.] Laue, L., & Cutler, G. B., Jr. (1994). Abnormalities in growth and development. In P. A. Pizzo, & C. M. Wilfert (Eds.), Pediatric AIDS: The challenge of HIV infection in infants, children, and adolescents (2nd ed., pp. 575-590). Baltimore: Williams and Wilkins. Laue, L., Pizzo, P. A., Butler, K., & Cutler, G. B. (1990). Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome. Journal of Pediatrics, 117, 541-545. Lee, C., & Johann-Liang, R. (1999). Disclosure of the diagnosis of HIV/AIDS to children born of HIV-infected mothers. AIDS Patient Care and STDs, 13, 41-45. Leeds, S. (1992). Medical and developmental profiles of 148 children born HIV-positive and placed in foster families (New York City, 1985-1991). New York: Leakes and Watts Services. Lepage, P., Spira, R., Kalibala, S., Pillay, K., Giaquinto, C., & Castetbon, K. (1998). Care of human immunodeficiency virus-infected children in developing countries. Pediatric Infectious Disease Journal, 17, 581-586. Leroy, V., Newell, M.-L., Dabis, F., Peckham, C., dePerre, P. V., & Butterys, M. (1998). International multicentre pooled analysis of the late postnatal motherto-child transmission of HIV-1 infection. The Lancet, 352, 597-600. Lesar, S., & Maldonado, Y. A. (1997). The impact of children with HIV infection on the family system. Families in Society: The Journal of Contemporary Human Services, 78, 272-279. Levenson, R. L., Mellins, C. A., Zawadzki, R., Kairam, R., & Stein, Z. (1992). Cognitive assessment of human immunodeficiency virus-exposed children. Americanjournal of Disease in Childhood, 146, 1479-1483. Lewis, L. L., Butler, K. M., Husson, R. N., Mueller, B. U., Fowler, C. L., & Steinberg, S. M. (1992). Defining the population of human immunodeficiency virus-infected children at risk for Mycobacterium avium-intracellulare infection. Journal of Pediatrics, 121, 677-683. Lindegren, M. L., Hanson, C., Miller, K., Byers, R. H., Jr., & Onorato, I. (1994). Epidemiology of human immunodeficiency virus infection in adolescents: United States. Pediatric Infectious Disease Journal, 13, 525-535. Lipshultz, S. E., Chanock, S., Sanders, S. P., Golan, S. D., Perez-Atayde, A., & Mclntoshy, K. (1989). Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. AmericanJournal of Cardiology, 63,14891497. Lipshultz, S. E., Easley, K. A., Orav, J., Kaplan, S., Stare, T. J., & Bricker, T. (1998). Left ventricular structure and function in children infected with human immunodeficiency virus: The prospective P2C2 HIV multicenter study. Circulation, 97, 1246-1256.

HIV DISEASE IN CHILDREN

503

Lipson, M. (1996, February). Disclosing HIV status to HFV-infected children. [Online]. Alive & Kicking!, 52. [http://www.critpath.org/newsletters/wtp/0296/ disclosu.htm] Love, J. T., Jr., & Shearer, W. T. (1996). Prevention, diagnosis, and treatment of pediatric HIV infection. Comprehensive Therapy, 22, 719-726. Luginbuhl, L. M., Orav, E. J., Mclntosh, K., & Lipshultz, S. E. (1993). Cardiac morbidity and related mortality in children with HIV infection. Journal of the American Medical Association, 269, 2869-2875. Luzuriaga, K., Bryson, Y., Krogstad, P., Robinson, }., Stechenberg, B., & Lamson, M. (1997). Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. New England Journal of Medicine, 336, 1343-1349. Maldonado, Y. A., Araneta, R. G., Hersh, A. L., and the Northern California Pediatric HIV Consortium. (1998). Pneumocystis carinii pneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection. Pediatric Infectious Disease Journal, 17, 398-402. Mann, J. M. (1992). AlDS-the second decade: A global perspective. Journal of Infectious Diseases, 165, 245-250. Masur, H., & The Public Health Service Task Force on Prophylaxis and Therapy for Myc.obacteri.um avium Complex. (1993). Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Neiv England Journal of Medicine, 329, 898-904. Mayaux, M.-J., Burgard, M., Teglas, J.-P., Cottalorda, J., Krivine, A., & Simon, F. (1996). Neonatal characteristics in rapidly progressive perinatally acquired HIV1 disease. Journal of the American Medical Association, 275, 606-610. McClain, K. L.. Joshi, V. V., & Murphy, S. B. (1996). Cancers in children with HIV infection. Hematology/Oncology Clinics of North Am.enica, 10, 1189-1201. Mclntosh, K., Pitt, J., Brambilla, D., Carroll, S., Diaz, C., & Handelsman, E. (1994). Blood culture in the first 6 months of life for the diagnosis of vertically transmitted human immunodeficiency virus infection: The Women and Infants Transmission Study Group. Journal of Infectious Diseases, 170, 996-1000. Mclntosh, K., Shevitz, A., Zaknun, D., Kornegay.J., Chads, P., & Karthas, N. (1996). Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatric Infectious Disease Journal, 15, 1087-1091. McKinney, R. E., for the PACTG Protocol 300 Team. (1997). Pediatric ACTG Trial 300: Clinical efficacy of ZDV/3TC vs. ddl vs. ZDV/ddl in symptomatic, HIVinfected children. Program and abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America (Abstract 768). McKinney, R. E. Jr., Johnson, G. M., Stanley, K., Yong, F. H., Keller, A., & O'Donnell, K. J. (1998). A randomized study of combined zidovudine-lamivudine versus didanosine montherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. Journal ofPediatncs, 133, 500-508.

504

THE PERSON WITH HIV/AIDS

Mellins, C. A., Levenson, R. L. Jr., Zawadzki, R., Kairam, R., & Weston, M. (1994). Effects of pediatric HIV infection and prenatal drug exposure on mental and psychomotor development. Journal of Pediatric Psychology, 19, 617-628. Melvin, D., & Sherr, L. (1993). The child in the family—Responding to AIDS and HIV. AIDS Care, 5, 35-42. Meyers, A. (1994). Natural history of congenital HIV infection. Journal of School Health, 64, 9-10. Meyers, A., & Weitzman, M. (1991). Pediatric HIV disease: The newest chronic illness of childhood. Pediatric Clinics of North America, 38(\), 169-194. Miller, T. L., Evans, S. J., Orav, E. J., Morris, V., Mclntosh, K., & Winter, H. S. (1993). Growth and body composition in children infected with the human immunodeficiency virus-1. American Journal of Clinical Nutrition, 57, 588-592. Miller, T. L., Orav, E. J., Martin, S. R., Cooper, E. R., Mclntosh, K., & Winter, H. S. (1991). Malnutrition and carbohydrate malabsorption in children with vertically transmitted human immunodeficiency virus 1 infection. Gastroenterology, 100(5, Pt. 1), 1296-1302. Miller, T. L., Winter, H. S., Luginbuhl, L. M., Orav, E. J., & Mclntosh, K. (1992). Pancreatitis in pediatric human immunodeficiency virus infection. Journal of Pediatrics, 120, 223-227. Mintz, M., & Epstein, L. G. (1992). Neurologic manifestations of pediatric acquired immunodefiency syndrome: Clinical features and therapeutic approaches. Seminars in Neurology, 12, 51-56. Mirochnick, M., Fenton, T., Gagnier, P., Pav, J., Gwynne, M., & Siminski, S. (1998). Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. The Journal of Infectious Diseases, 178, 368-374. Mofenson, L. M., Korelitz, J., Meyer, W. A., Bethel, J., Rich, K, & Pahwa, S. (1997). The relationship between serum human immunodeficiency virus type 1 (HFV1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1 infected children. Journal of Infectious Disease, 175, 1029-1038. Moye, J., Rich, K. C., Kalish, L. A., Sheon, A. R., Diaz, C., & Cooper, E. R. (1996). Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. Journal of Pediatrics, 128, 58-69. Msellati, P., Lepage, P., Hitimana, D.-G., Van Goethem, C., Van de Perre, P., & Dabis, F. (1993). Neurodevelopmental testing of children born to human immunodeficiency virus type 1 seropositive and seronegative mothers: A prospective cohort study in Kigali, Rwanda. Pediatrics, 92, 843-848. Mueller, B. U., Butler, K. M., Husson, R. N., & Pizzo, P. A. (1991). Pneumocystis carinii pneumonia despite prophylaxis in children with human immunodeficiency virus infection. Journal of Pediatrics, 119, 992-996. Mueller, B. U., Nelson, R. P. Jr., Sleasman, J., Zuckerman, J., Heath-Chiozzi, M., & Steinberg, S. M. (1998). A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics, 101, 335-343. Mueller, B. U., & Pizzo, P. A. (1997). Pediatric human immunodeficiency virus infections. In V. T. DeVita, Jr., S. Hellman, & S. A. Rosenberg (Eds.), AIDS:

HIV DISEASE IN CHILDREN

505

Biology, diagnosis, treatment and prevention (4th ed., pp. 443-464). Philadelphia: Lippincott-Raven. Muller, F.-M. C., Groll, A. H., & Walsh, T.J. (1999). Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus. European Journal of Pediatrics, 158, 187-199. Murphy, L. M. B., Koranyi, K., Grim, L., & Whited, S. (1999). Disclosure, stress, and psychological adjustment among mothers affected by HIV. AIDS Patient Care and STDs, 13, 111-118. Musey, L., Hughes,]., Schacker, T., Shea, T., Corey, L., & McElrath, M. J. (1997). Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. New England Journal of Medicine, 337, 1267-1274. Mustafa, M. M. (1994). Cytomegalovirus infection and disease in the immunocompromised host. Pediatric Infectious Disease Journal, 13, 249-257. Nachrnan, S. A., Mueller, B. U., Mirochnik, M., & Pizzo, P. A. (1994). High failure rate of dapsone and pentamidine as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal, 13, 1004-1006. Nadel, S., McGann, K., Hodinka, R. L., Rutstein, R., & Chatten, J. (1991). Measles giant cell pneumonia in a child with human immunodeficiency virus infection. Pediatric Infectious Disease Journal, 10, 542-544. National Institute of Child Health and Human Development, Intravenous Immunoglobulin Study Group. (1991). Intravenous immune globulin for the prevention of bacterial infectious in children with symptomatic human immunodeficiency virus infection. New England Journal of Medicine, 325, 73-80. National Pediatric & Family HPV Resource Center. (1995). HW and AIDS in children, Newark, NJ: Author and the Maternal and Child Health Bureau, Health Resources and Services Administration, Public Health Service, U.S. Department of Health and Human Sendees. Nehring, W. M., Larson, B., & Boyer, S. G. (1997). Caring for the child with HIV infection or AIDS: Key points for community care. ADVANCE for Nurse Practitioners, 7(2), 37-38, 41-42. Nesheim, S., Lee, F., Kalish, M. L., Ou, C. Y, Sawyer, M., & Clark, S. (1997). Diagnosis of perinatal human immunodeficiency virus infection by polymerase chain reaction and p24 antigen detection after immune complex dissociation in an urban community \\osp\tal.JoumalofhifectiousDisease, 175, 1333-1336. Nielsen, K. (1998). Pediatric HIV infection. [On-Line]. Available: http://hiv. medscape.(om/medscape/hiv/clinicalmgmt/cm.vl2/public/indexcm.vl2.html Nozyce, M., Hittelman, J., Muenz, L., Durako, S. J., Fischer, M. L., & Willoughby, A. (1994). Effect of perinatally acquired human immunodeficiency virus infection on neurodevelopment in children during the first two years of life. Pediatrics, 94, 883-891. O'Hara, M. [.. & D'Orlando, D. (1996). Ambulatory care of the HIV-infected child. Nursing Climes of North America, 37(1), 179-205.

506

THE PERSON WITH HIV/AIDS

Oleske, J., & Minnefor, A. (1983). Acquired immune deficiency syndrome in children. Pediatric Infectious Disease, 2, 85-86. Oleske, J., and the Working Group on Antiretroviral Therapy and Medical Management of Infants, Children and Adolescents with HIV Infection. (1998). Antiretroviral therapy and medical management of pediatric HIV infection and 1997 USPHS/IDSA report on the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Pediatrics, 102(Suppl.), 1004-1062. Oshitani, H., Kasolo, F. C., Mpabalwani, M., Luo, N. P., Matsubayashi, N., & Bhat, G. H. (1994). Association of rotavirus and human immunodeficiency virus infection in children hospitalized with acute diarrhea, Lusaka, Zambia. Journal of Infectious Disease, 169, 897-900. Palumbo, P. E., Raskino, C., Fiscus, S., Pahwa, S., Fowler, M. G., & Specter, S. A. (1998). Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HFV-infected infants and children. Journal of the American Medical Association, 279, 756-761. Palumbo, P. E., Raskino, C., Fiscus, S., Pahwa, S., Schutzbank, T., & Spector, S. A. (1999). Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children. The Journal of Infectious Diseases, 179, 576-583. Papola, P., Alvarez, M., & Cohen, H. J. (1994). Developmental and service needs of school-age children with human immunodeficiency virus infection: A descriptive study. Pediatrics, 94, 914-918. Parsons, S., & Merrick-Roddy, P. (1996). AIDS orphans in Louisiana in the year 2000: The potential economic impact on the foster care system. Journal of the Louisiana State Medical Society, 148, 391-398. Parmley, R. T. (1997). Evolution of AIDS and AIDS related malignancies in pediatric patients in the United States. Journal of Nihon University School of Dentistry, 39, 8-11. Pedneault, L., Lapointe, N., Alfieri, C., Ghadirian, P., Carpentier, L., & Samson, J. (1998). Natural history of Epstein-Barr virus infection in a prospective pediatric cohort born to human immunodeficiency virus-infected mothers. Journal of Infectious Disease, 177, 1087-1090. Perinatal and postnatal transmission of HIV infection: A fact sheet. (1999). [OnLine]. Available: http://www.pedhivaids.org/fact/perinatal_fact_us_txt.html. Peter, G. (Ed.). (1997). 1997redbook. Report of the committee on infectious diseases (24th ed.). Elk Grove Village, IL: American Academy of Pediatrics. Pizzo, P. A. (1990). Pediatric AIDS: Problems within problems. Journal of Infectious Disease, 161, 316-325. Pizzo, P. A., Eddy, J., Fallon, J., Balis, F. M., Murphy, R. F., & Moss, H. (1988). Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. New England Journal of Medicine, 319, 889-896. Ramos-Gomez, F. J., Flaitz, C., Catapano, P., Murray, P., milnes, A. R., & Dorenbaum, A. (1999). Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HrV-infected pediatric patients. The Journal of Clinical Pediatric Dentistry, 23, 85-96. Rich, K., Sheon, A., Diaz, C., Cooper, E., Pitt, J., & Handelsman, E. (1993, December) . Natural history of somatic growth in pediatric HIV infection: Preliminary data of

HIV DISEASE IN CHILDREN

507

the women and infants transmission study (WITS). Paper presented at the First National Conference on Human Retroviruses and Related Infections. Washington, DC. Rose, M. A., & Clark-Alexander, B. (1998). Caregivers of children with HIV/AIDS: Quality of life and coping styles. Journal of the Association of Nurses in AIDS Care, 9, 58-65. Rutstein, R. M., Conlon, C. J., & Batshaw, M. L. (1997). HIV and AIDS: From mother to child. In M. L. Batshaw (Ed.), Children with disabilities (4th ed., pp. 163-181). Baltimore: Brookes. Schwartz, L. J., St. Louis, Y., Wu, R., Wiznia, A., Rubinstein, A., & Saenger, P. (1991 Endocrine function in children with human immunodeficiency virus infection. American Journal of Diseases in Children, 145, 330-333. Schooley, R. T. (1995). Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. AIDS, 9(Suppl. 2), S15-S19. Seidel, J. F. (1992). Children with HIV-related developmental difficulties. Phi Delta Kappan, 38-41. Shea, K. A. (1997). HIV/AIDS. InJ. A. Fox (Ed.), Primary health care of children (pp. 878-891). St. Louis: Mosby. Shearer, W. T., Quinn, T. C., LaRussa, P., Lew, J. F., Mofenson, L., & Almy, S. (1997). Viral load and disease progression in infants infected with human immunodeficiency virus type 1. New England Journal of Medicine, 336, 1337-1342. Soberman, N., Leonidas, J. C., Berdon, W. E., Bonagura, V., Haller, J. O., & Posner, M. (1991). Parotid enlargement in children seropositive for human immunodeficiency virus imaging findings. American Journal of Radiology, 157, 553-556. Spector, S. A., Gelber, R. D., McGrath, N., Wara, D., Barzilai, A., & Abrams, E. (1994). A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. New England Journal of Medicine, 331, 1181-1187. Sperling, R. S., Shapiro, D. E., McSherry, G. D., Britto, P., Cunningham, B. E., & Culnane, M. (1998). Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 study. AIDS, 12, 1805-1813. Srugo, L, Israele, V., Wittek, A. E., Courville, T., Vimal, V. M., & Brunnell, P.. A. (1993). Clinical manifestations of varicella-zoster virus infections in human immunodeficiency virus-infected children. American Journal of Diseases in Children, 147, 742-745. Steketee, R. W., Abrams, E. J., Thea, D. M., Brown, T. M., Lambert, G., & Orloff, S. (1997). Early detection of perinatal human immunodeficiency virus (HrV) type 1 infection using HIV RNA amplification and detection. Journal of Infectious Diseases, 175, 707-711. Stiehm, E. R., Lambert, J. S., Mofenson, L. M., Bethel, J., Whitehouse.J., & Nugent, R. (1999). Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HFV-infected women with advanced disease: Results of Pediatric AIDS Clinical Trials Group Protocol 185. The Journal of Infectious Diseases, 179, 567-575.

508

THE PERSON WITH HIV/AIDS

Tardieu, M., Mayaux, M.-J., Siebel, N., Funck-Bretano, I., Teglas, J.-P., & Blanche, S. (1995). Cognitive assessment of school-age children infected with maternally transmitted human immunodeficiency virus type 1. Pediatrics, 126, 375-438. Task Force on Pediatric AIDS. (1991). Education of children with human immunodeficiency virus infection. Pediatrics, 88, 645-647. . (1992). Guidelines for human immunodeficiency virus (HIV)-infected children and their foster families. Pediatrics, 89, 681-683. Task Force on Pediatric AIDS. (1989). Infants and children with acquired immunodeficiency syndrome: Placement in adoption and foster care. Pediatrics, 83, 609612. Tepper, V. J., Farley, J. J., Rothman, M. I., Houck, D. L., Davis, K. F., & CollinsJones, T. L. (1998). Neurodevelopmental/neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using HIV-specific protease inhibitor ritonavir. Pediatrics, 101, 462-463. Van Dyke, R. B., Korber, B. T., Popek, E., Macken, C., Widmayer, S. M., & Bardeguez, A. (1999). The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. The Journal of Infectious Diseases, 179, 319-328. Viani, R. M., Smith, I. L., & Spector, S. A. (1998). Human immunodeficiency virus type 1 phenotypes in children with advanced disease treated with long-term zalcitabine. The Journal of Infectious Diseases, 777,565-570. Wachtel, R. C., & Conlon, C. J. (1996). Pediatric neuro-AIDS. In A. J. Capute, & P. J. Accardo (Eds.), Developmental disabilities in infancy and childhood (2nd ed., Vol. 1, pp. 195-213). Baltimore: Brookes. Wachtel, R. C., Tepper, V. J., Houch, D. L., Nair, P., Thompson, C., & Johnson, J. P. (1993). Neurodevelopment in pediatric HFV-1 infection: A prospective study. Pediatric AIDS and HIV Infection, 4, 198-203. Wade, N. A., Birkhead, G. S., Warren, B. L., Charbonneau, T. T., French, P. T., & Wang, L. (1998). Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. New England Journal of Medicine, 339, 1409-1414. Walsh, T. J. (1994). Fungal infections complicating pediatric HIV infection. In P. A. Pizzo, & C. M. Wilfert (Eds.), Pediatric AIDS: The challenge of HIV infection in infants, children, and adolescents (2nd ed., pp. 321-347). Baltimore: Williams and Wilkins. Walsh, T. J., Gonzoles, C., Roilides, E., Mueller, B. U., Ali, N., & Lewis, L. L. (1995). Fungemia in children infected with the human immunodeficiency virus: New epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clinical Infectious Disease, 20, 900-906. Weiner, L. S., Battles, H. B., & Heilman, N. E. (1998). Factors associated with parents' decision to disclose their HIV diagnosis to their children. Child Welfare, 77, 115-121. Weiner, L., Riekert, K. A., Theut, S., Steinberg, S. M., & Pizzo, P. A. (1995). Parental psychological adaptation and children with HIV: A follow-up study. AIDS Patient Care, 9, 233-239.

HIV DISEASE IN CHILDREN

509

Wilfert, C. M., £ McKinney, R. E., Jr. (1998). When children harbor HIV. Scientific American. 279(1), 94-95. Winter, H., & Chang, T.-L. (1996). Gastrointestinal and nutritional problems in children with immunodeficiency and AIDS. Pediatric Clinics of North America, 43, 573-590. Winter, H. S., & Miller, T. L. (1994). Gastrointestinal and nutritional problems in HIV disease. In P. A. Pizzo, & C. M. Wilfert (Eds.), Pediatric AIDS: The challenge of HFV infection in infants, children and adolescents (2nd ed., pp. 513-533). Baltimore: Williams and Wilkins. Wintergerst, U., Hoffmann, F., Solder, B., Notheis, G., Petropoulou, T., & Eberle, J. (1998). Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus. Pediatric Infectious Disease journal, 17, 495-499. Wiznia, A. A., Lambert, G., & Pavlakis, S. (1996). Pediatric HIV infection. Medical Clinics of North America, 80, 1309-1336. Wolters, P. L., Brouwers, P., Moss, H. A., & Pizzo, P. A. (1995). Differential receptive and expressive language functioning of children with symptomatic HIV disease and relation to CT scan brain abnormalities. Pediatrics, 95, 112-119. Working Group on Antiretroviral Therapy and Medical Management of HlV-Infected Children. (1999, April 15). Guidelines for the use of antiretroviral agents in pediatric HIV infection [Online]. Available: http://www.cdenpin.org/ Working Group on Antiretroviral Therapy and Medical Management of HlV-Infected Children. (1999). Guidelines for the use of antiretroviral agents in pediatric HIV infection. [On-Line]. Available: http://www.cdcnpin.org/ World Health Organization. (1998). Report on the global HIV/AIDS epidemic June 1998. Global HIV/AIDS & STD Surveillance [Online], [http://www.who.int/ emc-hiv/global_report/rep_html/report6.html] Vaster, M., & Schechter, N. (1996). Pain and human immunodeficiency virus infection in children. Pediatrics, 100, 455-456. Ziegler, J. L., £ Katongole-Mbiddle, E. (1996). Kaposi's sarcoma in childhood: An analysis of 100 cases from Uganda and relationship to HIV infection. International Journal of Cancer, 65, 200-203.

This page intentionally left blank

13

Minorities Living with HIV Infection/AIDS:

Stories and Practical Strategies Barbara Aranda-Naranjo

s we enter the 21st century, it is clear that AIDS has become a disease of the poor and the vulnerable in America. Vulnerable ^populations are at risk for poor physical, psychological, and social health (Aday, 1993). The two major minority groups that fall into this vulnerability status are African-Americans and HispanicAmericans. For the purpose of this chapter, other minorities, such as American Indians, Haitians, Asians, and Pacific Islanders, will not be covered separately, but rather the commonalties these groups share as vulnerable populations will be addressed. The two largest minorities, African-Americans and Hispanic Americans, have emerged as the new faces of HIV infection in the second decade of the AIDS epidemic in the United States (Fullilove & Fullilove, 1998; Van Oss Marin, & Gomez, 1998). Fifty-five percent of the cases of AIDS in the United States reported as of December 1998 are among Blacks and Hispanics (Centers for Disease Control and Prevention, 1998). Among men with AIDS, Blacks and Hispanics accountfor 32.4% and 17.7%, respectively; amongwomen with AIDS,

A

511

512

THE PERSON WITH HIV/AIDS

56.6% are Black and 20.1% are Hispanic. The major mode of transmission is injecting drug use, which adds to the complexity of HIV infection among these two groups. Many persons from these two minority groups not only are living with HIV infection but are also devastated by living with other medical and social problems. They live with multiple medical diagnoses such as drug addiction, mental health diagnoses, and an array of social issues such as inadequate housing needs, permanent unemployment, and food and transportation problems. The poverty rate among these Americans is disproportionate to their number in this country. This one factor alone places them at risk for a number of infectious diseases and other medical/ social problems. They become the "vulnerable" in America. The needs of vulnerable minorities living with HIV infection can be categorized as medical, psychological, social, and spiritual. The primary needs of a person or family in this group are not related to HIV infection but rather to basic social needs, specifically food and shelter. If providers cannot understand or meet either by direct services or community linkages, they will lose the client. This action should not be considered noncompliance on the part of the client but rather negligence on the part of the provider. In serving the vulnerable, every provider and program need to include an array of health and human services for the person/family. Because many children are usually brought to clinic appointments by women, services need to be co-located and or linked in such a way as to decrease travel and time for the family. In addition, patient education should occur at each visit and be reinforced by the entire team, especially the case managers. Learning takes time and repetition. Many providers make the mistake of teaching by overload and are surprised when they have to repeat themselves. Client teaching should take place over many sessions in a comfortable, nonthreatening environment. The teacher and learner should develop a mutual plan that includes some discussion on behavior modification to assist in addressing the multiple diagnoses such as drug addiction. All family members need to be included in a teaching plan. The definition of family should be left up to the individual client. However, the provider can, over time, assess a pattern by which clients define their families within a particular community. In one clinic in the South, a young African-American woman had sisters and

MINORITIES LIVING WITH HIV INFECTION/AIDS

513

brothers that she adopted, though not legally, who were her family. In Hispanic communities there may be a godmother or godfather who is not a blood relative but is considered part of the nuclear family structure. Again, it is important for providers to observe community patterns, then seek validation from community members. The health and human service needs for minority families are best coordinated by case managers. Case managers should be knowledgeable about not only HIV disease but the array of health and human services that multiple infected families are going to require. One example of a case management model used in San Antonio, Texas, by the South Texas AIDS Center for women, children and families (STAC; Title IV-funded program under the Ryan White Care Act) depicts the process that occurs when a client/family is referred (see Figure 13.1). The major emphasis is on coordinating care for the entire family and linking to resources needed by each individual of the family. According to Eliseo Smith, coordinator of case management for STAC, the program's major focus is on primary care. Community-based organizations throughout San Antonio are contacted for other services needed by individuals and families. The team attempts to link clients/families to agencies closer to home when possible. The complexity of the care for many minorities lies in the multiplicity of medical and social problems, such as drug addiction, mental health diagnoses. HIV infection, TB infection, homelessness, family violence, unemployment, and inadequate transportation and housing, to name a few (Doran, 1993; Nyamathi & Flaskerud, 1992). In addition, these families often have multiple members living with HIV disease, which complicates the delivery of health services. Provi ers need to prepare to change their unit of analyses/assessment from one to two or four, even six, at a time. Let me give an example: On a home visit a nurse was giving intravenous gammaglobulin to a child who had been diagnosed with AIDS. As she was about to insert the butterfly needle, the mother, who was helping to hold down the child, let the child go. The needle flew up in the air, and the nurse attempted to catch the needle so that no one would get stuck. She was able to catch the needle and keep the child from falling off the bed. As she turned to look at the mother, who was crying uncontrollably, she held the mother's hand and said nothing for a moment. Then the mother said quietly, "I have something to

514

THE PERSON WITH HIV/AIDS

FIGURE 13.1 STAC care coordination/case management model.

MINORITIES LIVING WITH HIV INFECTION/AIDS

515

tell you; I hope you won't think I'm a bad mother." The mother went on to say, "I know you might think that I am crying for my son, but I'm not; I am crying for myself. I wonder when it will be me that you come to stick." This is a teachable moment for that nurse and for all of us as providers. Families can no longer be served in isolation of the effect that HIV infection has on each individual member and the multiplying effect for the primary caregiver. In minority families the primary caregiver is usually a woman, a mother or grandmother. The rapidly shifting sociodemographics of the HIV epidemic include a surge in new infections among minority women. Women now represent 15.7% of the total AIDS cases reported to the Centers for Disease Control and Prevention (1998). As the number of women with HIV and AIDS increases, it is important to understand the particular psychosocial profiles and needs of the population in order to tailor appropriate prevention and treatment strategies. For example, many minority women who are homeless are at increased risk of acquiring and transmitting HIV because of the need to exchange sex for money, protection, or drugs (Fisher, Howell, Hofstetter, & Hough, 1995; Singer, 1994). In practice I have also seen many courageous men caring for their children amidst their own HIV infection. Providers need to develop models that address the family as a unit and provide outcome indicators that record the complexity of providing for the needs of multiple family members. THE VITAL SIGNS OF COMMUNITY Minority communities are essential players in both prevention and direct intervention services for people living with HFV disease. Because many minorities who are at risk for HIV infection live in lowincome neighborhoods/barrios/colonias/housing projects, they are isolated from mainstream society. This isolation can be a protective defense mechanism and can lead to making the population more vulnerable to unforeseen diseases such as AIDS. In a study of 200 women sampled from mass transit waiting areas in an urban center, anonymous surveys of AIDS-related risk behavior, perceptions of susceptibility, and knowledge revealed that many women were found

516

THE PERSON WITH HIV/AIDS

to be at continued risk (Kalichman, Hunter, & Kelly, 1992). Perceptions of susceptibility were associated with an interaction between ethnicity and level of risk; nonminority women at high risk reported greater concern about AIDS than did minority women at high risk, who did not differ from women at low risk. Therefore, every provider should be aware of the "community vital signs" and the ways of knowing for the people of a particular community. Community vital signs include, but are not limited to, The prevailing cultural beliefs Pressing issues for the community Employment rate Level of poverty Definition of health Access to health care Community leaders The followers Support structures Level of trust among providers/researchers The last providers to assess the community The community vital signs can be linked to a community's ecological system (Meyer, 1988). The ecological system urges the practitioner and/or researcher to view the people of the community in the context of their environment. The interrelatedness of community people to their environment leads one to view people not as subjects, but rather as integral parts of a whole community. One simplistic application of the vital signs is to understand the cultural beliefs. Many minority groups believe in the spiritual dimension of health, for example, yet so few clinics offer the services of a chaplain or other clergy. Providing health and human services for HIV-infected people reminds the world that environment is an essential part of any effective assessment. When providers fail to recognize this essential truth, clients are forced to lie and enact noncompliance in an effort to be heard. Understanding the ways of knowing helps the provider or team choose the methods to explain or link a client/family to services. One example is knowing the definition of health for people in a community. In one community in Texas, for example, the

MINORITIES LIVING WITH HIV INFECTION/AIDS

517

definition of health is: "Vas con el doctor cuando ya estas cerca de la muerte" (You go to the doctor when you are close to death). In this particular community many of the people are uninsured and are day laborers. To miss work means losing a day's wages and paying a day's wages for the visit. People have to make choices, and many minority people choose basic needs as their priority over health care. This one scenario has great implications for AIDS prevention. In this particular community, when could a provider expect to see an HlV-infected minority person? When the person is symptomatic from HIV infection or close to death. How do we reach these communities? We must first understand their ways of knowing and living. Without knowing the community vital signs, health professionals can do and have done more harm than good, and can destroy the public's trust. The important outcome in health care is not asking, Did the patient get better? but rather, Did the provider inspire the patient with enough confidence and trust in those who seek to heal him or her, and does the patient have an expectation that good things will happen? (Cousins, 1979). LIVING IN SECRECY Many minority communities are still living in secrecy (Aranda-Naranjo, 1997; Mason, Marks, Simoni, Ruiz, & Richardson, 1995; Simoni, et al., 1995). The reasons for nondisclosure vary among the ethnic groups, and research in this area needs to be conducted. In one qualitative study of 17 HIV-positive Mexican-American women conducted by this author in 1997, one woman revealed the following: There is too much stigma still in our communities and among family members to tell anyone. I chose only to tell rny family that I have problems with my blood like anemia. I don't want my two girls who are negative to be ridiculed or stigmatized. There will always be someone in the family who is a blabbermouth, you know what I mean. For 5 years I did not even think about HIV; now I look back after 8 years and think I was in big-time denial, but it helped me get through rny pregnancy.

According to a survey of 65 ethnically diverse women at two outpatient HIV clinics in Los Angeles during 1991-1992, Spanish-speaking Hispanics were less likely to disclose their sero status or to discuss

518

THE PERSON WITH HIV/AIDS

HIV-related worries with others than were English-speaking Hispanics, African-Americans, and Anglo-Americans. The researchers speculated that the influence of cultural factors and the secrecy of the diagnosis, once disclosed, would spread quickly in small, tight-knit communities, which may have inhibited disclosure among Spanishspeaking Hispanics (Simoni et al., 1995). The importance of identifying cultural patterns and beliefs about seeking help are important when working with diverse minority groups.

PREVENTION: WHAT WORKS IN MINORITY COMMUNITIES? Given the complexity of the lives of vulnerable populations, prevention programs cannot focus solely on HIV prevention. They need to cover an array of medical and social problems, such as drug addiction, mental health problems, and homelessness (Sabo & Carivein, 1994; Weeks, Schensul, Williams, Singer, & Grier, 1995). It appears logical to view HIV disease, in context, but there are still many programs that fail to integrate the whole picture for the client/family. Also important are the individual provider's attitudes about working with poor minorities. In a study to assess the perceptions of family practice residents regarding health care and poor patients (TV = 130), Price and associates (1988) discovered the following findings: The majority of residents believed that poor patients are more likely than others to miss appointments without canceling (73%), more likely to be late for appointments (51%), and less knowledgeable about their illnesses (80%). One in four residents believed that poor patients tend not to appreciate the work of physicians and nurses, and 43% claimed that the poor are more difficult patients. Finally, 41% believed that poor patients usually care less than others about their own health status. Minority populations in general are distrustful of "the system" and anyone working in it. For African-Americans, it is the constant reminder of the Tuskegee research; for other minority groups, it is an array of injustices they may have experienced as they were growing up. Any effort to establish effective AIDS prevention programs will

MINORITIES LIVING WITH HIV INFECTION/AIDS

519

have to incorporate the experiences and beliefs of the people in the community. One example of an attempt by a Hispanic organization to provide education in the community to primarily Mexican-Americans became a teachable moment. Two outreach workers were invited to the home of the leader of the community, 76-year-old Mr. Sanchez. Mr. Sanchez invites all his nine children and their wives and husbands after work to his home for the educational session on HIV/AIDS. As the two outreach workers approach, he greets them and asks the women to stay in the house and all the men to go outside in the backyard. One outreach worker (a woman) stays inside to give the class to the women; the other outreach worker (a man) goes outside with Mr. Sanchez to give the class to the men. At the end of the session, Mr. Sanchez invites the outreach workers inside his house and asks them to sit down. He brings all of his family together and asks his wife to get a pitcher of water and a soaked sponge. The two outreach workers look at each other and wonder if they had insulted the family or are going to be blessed. Neither of these two scenarios occur. Rather, Mr. Sanchez begins to talk and says, "You health people come to our barrios and tell us we are at risk for heart disease because we are too fat and eat too many tamales; we are at risk for diabetes; we don't exercise enough; we are at risk for cancer because we work in the fields; we are at risk for TB and. . . . As Mr. Sanchez is speaking, he is pouring the water on the saturated sponge on the coffee table that is now dripping. No one in the room moves, everyone's attention is fixed on Mr. Sanchez. Then he stops and turns to the outreach workers and says, "what about esperanza (hope) ? Don't take away all our dreams and hope for living; it gives us something to live for. You overwhelm my family tonight; why try, when so much is against us?" With that he hugs the outreach workers and thanks them for the information—yet another teachable moment by community to providers. If we are to curve the wave of the AIDS epidemic and save all our communities from HIV infection, we must partner with people of the community. Partnering with members of a community involves listening and incorporating diverse strategies into a comprehensive program.

520

THE PERSON WITH HIV/AIDS

REFERENCES Aday, L. A. (1993). At risk in America: The health and health care needs of vulnerable populations in the United States, San Francisco: Jossey-Bass. Aranda-Naranjo, B. (1997). The health-seeking experiences of Mexican-American women with HIV/AIDS. Unpublished doctoral dissertation. University of Texas School of Nursing, Austin, Texas. Centers for Disease Control and Prevention. (1997). Update: Acquired immunodeficiency syndrome. United States. Morbidity and Mortality Weekly Report, 35, 17-21. . (1998). Update: Acquired immunodeficiency syndrome: United States. HIV/ AIDS Surveillance Report, 10(2), 29. Cousins, N. (1979). Anatomy of an illness. New York: Bantam. Doran, T. (1993). HIV/AIDS in women and children in South Texas: Experience at a family AIDS clinic. Texas Medicine, 3(3), 5-16. Fisher, B., Howell, M, Hofstetter, C. R., & Hough, R. (1995). Risks associated with long-term homelessness among women: Battery, rape and HIV infection. International Journal of Health Services, 25(2), 351-309. Fullilove, R., & Fullilove, M. (1998). HIV prevention and intervention in the African American community: A public health perspective. In P. T. Cohen, M. A. Sande, P. A. Volberding (Eds.), A textbook on HIV disease from the University of California, San Francisco and San Francisco General Hospital, 3rd Ed. (HIV InSite Version). http://hivinsite.ucsf.edu/akb/1997/09aapre/. Kalichman, S. C., Hunter, T. L., & Kelly, J. A. (1992). Perception of AIDS susceptibility among minority and nonminority women at risk for HIV infection. Journal of Consulting and Clinical Psychology, 60(5), 725-732. Kaplan, M. S., Marks, G., & Martens, S. B. (1997). Distress and coping among women with HIV infections: Preliminary findings from a multiethnic sample. American Journal of Orthopsychiatry, 67(1), 80-91. Mason, H. R. C., Marks, G., Simoni, J. M., Ruiz, M. S., & Richardson,]. L. (1995). Culturally sanctioned secrets? Latino men's nondisclosure of HIV infection to family, friends and lovers. Health Psychology, 14(1), 6-12. Meyer, C. H. (1988). "The eco-system perspective." In R. A. Dorfman (Ed.), Paradigms of clinical social work (pp. 275-294). New York: Brunner Mazel. Nyamathi, A. M., & Flaskerud, J. (1992). A community-based inventory of current concerns of impoverished homeless and drug-addicted minority women. Researching Nursing and Health, 15, 121-129. Price, J. H., Desmond, S. M., Snyder, F. F., & Kimmel, S. R. (1988). Perceptions of family practice residents regarding health care and poor patients. Journal of Family Practice, 27(6), 615-621. Sabo, C. E., & Carwein, V. (1994). Women and HIV/AIDS. Journal of the Association of Nurses in AIDS Care, 5(3), 15-21. Simoni, J., Mason, H. R. C., Marks, G., Ruiz, M. S., Reed, D., & Richardson, J. (1995). Women's self-disclosure of HIV infection: Rates, reasons and reactions. Journal of Consulting and Clinical Psychology, 63(3), 474-478. Singer, M. (1994). AIDS and the health crisis of the U.S. urban poor: The perspective of critical medical anthropology. Social Science Medicine, 39(7), 931-948.

MINORITIES LIVING WITH HIV INFECTION/AIDS

521

Van Oss Marin, B., & Gomez, C. (1998). Latinos and HIV: Cultural issues and AIDS prevention. In P. T. Cohen, M. A. Sande, & P. A. Volberding (Eds.), A textbook on HI\r disease from the University of California, San Francisco and San Francisco General Hospital, 3rd Ed. (HIV InSite Version), http://hivinsite.ucsf.edu/akb/ 1997/09hispre/. Weeks, M. R., Schensul, J. J., Williams, S. S., Singer, M., & Grier, M. (1995). AIDS prevention for African-American and Latina women: Building culturally and gender-appropriate intervention. AIDS Education and Prevention, 7(3), 251-263.

This page intentionally left blank

14

Ethical and Legal Dimensions Jerry D. Durham

ince the first cases of AIDS were reported to the Centers for Disease Control and Prevention (CDC) almost two decades ago, the epidemic has created ethical dilemmas for infected persons, caregivers, and society as a whole. These dilemmas have been described in the following manner:

S

For the individual, measures to control the spread of AIDS may invade privacy, constrain sexual conduct and procreation, and limit liberty. For the public, AIDS retrovirus infection continues to spread, especially among high-risk groups, and is often fatal. . . . We therefore believe that AIDS poses the most profound issues of constitutional law and public health since the Supreme Court approved compulsory immunization in 1905. (Mills, Wofsy, & Mills, 1986, p. 931)

A central question with which America has grappled since the onset of the epidemic has been, "Can we protect the individual rights of those in various stages of HIV infection while at the same time attending to the rights of those not infected?" In their book exploring ethics and public policy generated by AIDS, Pierce and Van DeVeer (1988) posed the question, "When is it all right, if ever, to interfere with the capacity of competent people to direct their own lives?" In other words, when is it ethically permissi ble to employ coercion in influencing behavior? When is it permissi523

524

THE PERSON WITH HIV/AIDS

ble to infringe upon the liberties of others in order to protect them, presumably from themselves, and to protect society from them or their actions? Proposals or practices such as mandatory HIV screening of newborns and pregnant women, mandatory name reporting, prohibition of HIV seropositive individuals from certain jobs and occupations, and isolation of HIV seropositive persons interfere with the choices or acts of others and are thus ethically problematic (Carusi, Learman, & Posner, 1998; Gostin, Ward, & Baker, 1997; Institute of Medicine, 1998). During the first decade of the HIV/AIDS epidemic Gay leaders and civil libertarians worked to shape policies and measures that were noncoercive and differed from approaches that had been historically used to confront infectious disease epidemics. These policies and approaches (e.g., mass education and voluntary testing) have been termed "exceptionalism" (Bayer, 1991). But the advances of medicine in treating HIV/AIDS have altered the status of HIV/AIDS as "exceptional." According to Bayer (1999): In the United States and other economically advanced nations, the threat of contracting the human immunodeficiency virus (HIV) has abated. The incidence of infection has declined, and the prevalence of infection has stabilized and, in some instances, begun to fall. The pattern of HIV spread, where it has continued, has been dramatically circumscribed to marginalized populations. The panic of the mid-1980s has passed, and in many nations, AIDS has lost its salience as a public issue. A sense of therapeutic impotence no longer prevails, and a new mood of triumphalism has taken hold. (p. 1042)

According to Hanssens (1998), however, those who believe that HIV/ AIDS exceptionalism threatens public health are ignoring unique features of the present epidemic. She argues, for example, that AIDS has been criminalized (unlike many other infectious diseases of the past) and that insurance companies limit treatment benefits for those needing care. She also raises concerns about the adequacy of safeguards to prevent discrimination against those identified as HIVinfected and to guarantee access to care. Because HIV transmission arises mainly as a result of behaviors, beliefs about what constitutes permissible constraints on such behaviors inevitably influences decisions about permissible strategies and public policies to address HIV-related questions (Pierce & VanDeVeer, 1988). These decisions raise additional questions about benefi-

ETHICAL AND LEGAL DIMENSIONS

525

cence, respect for persons, autonomy, intimacy, and privacy, to list only the most obvious ethical concerns. But the understanding and rational use of principles to determine when it is ethically defensible to restrict the liberties of others has proven an insufficient tool in the current HIV epidemic. As Rowland (1986, p. 44) has noted, "[the] power of prejudice can be chillingly greater than the power of logic." As the twentieth century closes, there appears to be a shift in thinking of HIV/AIDS as an "exceptional" condition, the result being that those responsible for formulating public health policies are increasingly inclined to view HIV infection as just one of an array of transmissible diseases. BALANCING INDIVIDUAL RIGHTS WITH THE PUBLIC GOOD: LAW AND PUBLIC POLICY Balancing individual rights with public good has received considerable attention in America's legal system. For over 100 years jurists have sought to balance society's interest in controlling communicable disease against society's claim of liberty. Until the passage of the Fourteenth Amendment to the Constitution, however, Americans had little protection against the abuses of individual civil liberties (Merritt, 1986). However, since 1940 the courts have recognized that individuals have certain fixed rights-even when these endanger others (Merritt, 1986). Moreover, the courts have grown increasingly wary of medical experts' claim that certain persons are dangerous (e.g., the mentally ill) or that certain procedures are essential to the promotion of public health (e.g., certain vaccinations). Thus Merritt (1986) believes that the courts will continue to play a key role in upholding constitutionally based rights of individuals and balancing these rights with the public good in this democratic society. This key role of the courts was demonstrated in 1998 when the United States Supreme Court held in Bragdon vs. Abbott that HIV is an impairment that substantially limits a major life function (reproduction). The court essentially concluded in this important ruling that HlV-infected persons are covered by the Americans with Disabilities Act, which prohibits discrimination against persons with actual or perceived disabilities. In another important earlier decision, that of the School Board of Nassau County, Florida vArline, the Supreme

526

THE PERSON WITH HIV/AIDS

Court held that discrimination against a handicapped person, in this case a teacher with tuberculosis, on the basis of fears deriving from the handicap's contagious nature, violated the Federal Rehabilitation Act of 1973 (Banta, 1987). According tojayasuriya (1988), AIDS-related laws can be placed in three broad categories: product-related laws, behavior- and attitudeoriented laws, and institution-oriented laws. In the first category, product-related laws seek to protect supplies of products (e.g., semen, tissue, blood, and condoms). In the second category, behaviorand attitude-oriented laws are aimed at reducing high-risk behavior, making it an offense to engage in sex while infected; requiring compulsory screening, quarantine, and contact tracing; and providing for deportation and for the refusal of visas. Laws in this category generate the greatest controversy and are most likely to be challenged to court by individuals. In the third category, institution-oriented laws seek to promote research, education, counseling, and care of people with AIDS. Laws that prevent discrimination against people with HIV/AIDS may also be included in this category. A more recent review by the AIDS Litigation Project of 600 cases involving persons with HIV/AIDS in federal and state courts found that subsets of litigation involved HIV/AIDS in the public health and health care systems (Gostin & Webber, 1998a, b). Litigation included cases related to testing and reporting; privacy and control of information about a person's HIV status, including the duty to warn and the right to know; physician standards of care in prevention and treatment; discrimination and access to health care; exclusion and isolation of HIV seropositive persons; discrimination in employment, housing, public accommodations, commercial establishments and the military; and efforts by infected individuals to obtain needed public benefits. The authors of this review concluded: Considerable progress has been made—serially and legally—during the first 2 decades of the HIV/AIDS epidemic. Reductions in stigma and new statutes to protect privacy and proscribe discrimination have emerged. The serious consequences of the epidemic, however, are not over. While instances of gross abuse are less frequent, intolerance and animus stubbornly persist. .. . The health care and public health systems need . . . new strategies to reduce the deep personal and social burdens of HIV disease in the united States. (Gostin & Webber, 1998b, p. 1111)

ETHICAL AND LEGAL DIMENSIONS

527

. . . Many challenges still face America in its social and legal response to AIDS: (i) disability law may not, after all, protect persons with asymptomatic infection; (ii) the 'significant risk' standard has been bent to permit discrimination in cases where the probabilities of transmission are exceedingly low; (iii) the public's right to know has rationalized breeches of privacy; (iv) the business interests of insurers have often taken precedence over the health care needs of persons with HIV/AIDS; and (v) the administrative efficiency of the corrections system has justified infringements on the privacy and autonomy of inmates. (Gostin & Weber, 1998a, p. 17)

The courts will be busy in future years settling increasing numbers of cases that emerge from the HIV/AIDS epidemic. The courts will evaluate state and federal laws in terms of medical, scientific, and technological readiness and validity; constitutional, ethical, cultural, and social acceptability; political expediency; and economic feasibility (Jayasuriya, 1988). Stigmatization Until more recently, the public reaction to HIV/AIDS has outweighed the dangers imposed by the epidemic. Because AIDS first appeared in this country among a group of persons whom sociologists label as "pariahs," many came to believe that AIDS mirrored the moral defilement of its "victims." Those having contact with individuals known to have AIDS often consciously or unconsciously engage in distancing behaviors, both verbal and nonverbal, further reinforcing the stigmatized status and isolation of persons with AIDS. While few caregivers now refuse to provide care for persons with AIDS, some continue, perhaps unconsciously, to isolate them as a result of homophobia, unrealistic fears of contagion, death anxiety, and racial prejudice (Barrick, 1988; Baylor & McDaniel, 1996; Beating the odds, 1996; Bennett, 1995; Cole, 1996; McCann, 1997; Pomerance & Shields, 1989). For the welfare of their patients and for their own mental well-being, health care workers should, when appropriate, participate in programs to reduce their AIDS social anxiety and stigma (Bean et al, 1989). Fear of contagion neither explains nor justifies Stigmatization of and discrimination against people with HIV/AIDS (Sherman & Quellette, 1999). Since most Americans are quite knowledgeable

528

THE PERSON WITH HIV/AIDS

about AIDS (Dawson, Cynamon, & Fitti, 1988), what explains the hateful behaviors of some toward people with AIDS? Do they simply not trust the reassurances of scientists, government officials, and physicians about their own risk of becoming infected through casual contact? It is more likely that these fears actually represent hate and loathing of people with HIV/AIDS and what their condition symbolizes (Pryor, 1988). Unfortunately, this hatred and loathing may impede conventional educational efforts to quell fear of AIDS. To the extent that these negative reactions are a function of symbolic factors, they are likely to persist even in the absence of fears about contagion. Another factor influencing ethical decision making is the JudeoChristian heritage of most Americans, a tradition brimming with lessons of sin and punishment. In this tradition, blame may be heaped upon those who, because they did bad things, became ill, and sometimes even upon those having a special relationship with the ill (Sabatier, 1988). In this view, God punishes as a warning to others about the wages of sin. Those not accepting responsibility for or not in control of their behaviors are held accountable for the consequences. AIDS and Justice The HIV epidemic raised compelling questions about health care justice, questions of a fundamental nature that center upon the right to health care, fair opportunity, and distribution of resources. At a time when efforts to provide a minimal level of health care for all Americans have failed, justice within the health care system is much more than a set of erudite arguments among ethicists. The ways in which health care justice is achieved, or not achieved, can mean the difference between living and dying in America. If nothing else, the HIV epidemic has caused America's policymakers to reflect upon and begin to deal more constructively with issues of health care justice. The AIDS epidemic vividly illustrates the limits of this nation's health resources; it reminds us that we may not have an infinite capacity to provide needed care for every sick American; it reminds us that we may have to make uncomfortable decisions about the distribution of our heath care resources; it reminds us that we live

ETHICAL AND LEGAL DIMENSIONS

529

in a sometimes unjust society, which struggles to made good on its promises of justice for all; and it reminds us that not everything is possible in America. Daniels (1985) has raised difficult questions related to health care justice: 1. 2. 3. 4. 5.

Is health care a right to which everyone is entitled? What kinds of health care services will/should exist in a society? Who will get these services and on what basis? Who should deliver these services? How will the burdens of financing these services be distributed?

If one claims that all people, including those with HIV/AIDS, have a right to health care, hard questions must still be answered. For example: 1. What share of America's total health resources should be allocated to AIDS? 2. To which areas should this allocation of resources be made— prevention, direct care, research? Which one is a priority, given that health care resources are not infinite? 3. Who should be entitled to make decisions about resource allocation—the federal government, states, local government? Should the federal government set aside a special fund for AIDS care and distribute these funds to states according to the number of needy persons in those states? 4. What constitutes a fair share of the health budget for HIV/ AIDS? Is it fair to divert resources from other health areas to AIDS? 5. What level of care, if any, is the government morally obligated to provide for people with AIDS? If health care is special and if some level of care should be guaranteed for all, how does one ensure that health care providers will embrace concepts of justice? As increasing numbers of people with AIDS come from the ranks of injection drug users, the unemployed, poor women, and racial minorities, it is not difficult to see that concerns for health care justice will become paramount in any discussions of the epidemic.

530

THE PERSON WITH HIV/AIDS

The tension generated in efforts to balance provider autonomy, power, and special interests with efforts to establish health care justice is not easily resolved. If people with AIDS are to have access to adequate health care, it would seem that several concerns related to human resources also need to be addressed (Daniels, 1985): 1. What are the ethical duties of providers to deliver care to people with AIDS? 2. In what ways does a duty (or perhaps even a legal requirement) to provide care infringe upon the liberties of providers? 3. Do the requirements of health care justice improperly infringe upon the economic interests of certain providers? 4. Do some types of health care providers have a greater obligation than others in helping to achieve health care justice? Do all equally have a special contract to provide care? 5. Do providers have an obligation to treat people with AIDS regardless of their ability to pay? Or do only some providers have this obligation? 6. Do practitioners have a moral or legal obligation to work in a specialty of need because there is an inadequate number of specialists in that area?

The daily travails of people with AIDS underscore the difficulties millions face in achieving health care justice in this nation's uncoordinated and increasingly costly health care system. Nowhere in America is the contrast between the haves and have nots more starkly drawn than in the health care system. Those with insurance can obtain the resources they need for adequate health care, while an estimated 40 million Americans lacking insurance must settle for no health care or less than adequate health care. Justice rings hollow for millions of Americans denied access to adequate health care because they lack insurance, because they are unemployed or unemployable, because their employer does not offer insurance coverage, or because they cannot afford to co-pay the insurance premium of their employer's insurance. The fact that tens of millions of American are uninsured or underinsured would seem to argue that, while most Americans believe that all of this nation's citizens should have adequate health care, in reality, health care in America is a barterable commodity.

Privacy and Confidentiality Stemming from the conflict between individual rights and public good are concerns related to privacy and confidentiality. Privacy and

ETHICAL AND LEGAL DIMENSIONS

531

confidentiality have been core concerns of persons who are HIV seropositive and of their advocates since the onset of the epidemic. Privacy may be thought of as the freedom of the individual to pick and choose for himself the time and circumstances under which, and the extent to which, his attitudes, beliefs, behaviors, and opinions are shared or withheld form others (Kelman, 1977). Some ethicists maintain that privacy is a conditional right, while others believe that privacy is a basic human need and as such is on par with rights rooted in other basic human needs. In law, privacy is conceptually linked to "being let alone." Ordinarily intrusions into privacy, in either research or clinical care, require informed consent. Although most social injuries result from breaches in confidentiality, invasions of privacy also carry considerable risk. This risk includes the following concerns of subjects: that public exposure of their views and actions may have damaging consequences for them; that the procedures used to elicit information may deprive them of control over their self-preservation; and that research may probe into areas that constitute their private space, overstepping the boundary between self and environment. (Kelman, 1977, p. 169)

Researchers and caregivers often inquire into the most private and intimate aspects of their subjects' /patients' lives. Rawnsley (1980) has noted that the hospital provides a laboratory of sorts in which the invasion of privacy may be endemic. Early in their education health providers learn that they do not ordinarily intrude into an individual's privacy without obtaining informed consent. But outside of the hospital in daily life, persons are often asked to provide information about their lives that may eventually lead to the denial of health of life insurance on the basis of suspect AIDS infection. Ought insurance companies, for example, have the right to obtain this personal information, the right to test blood samples with or without the individuals knowledge, the right to examine the medical and social histories in search of factors that tip them off to the true nature of an AIDSrelated illness? The answers to such questions may rest partially upon society's willingness to sanction intrusions into privacy. These questions are increasingly urgent in view of rapidly developing information networks containing private data, which can be shared or accessed without an individual's knowledge or permission.

532

THE PERSON WITH HIV/AIDS

Confidentiality, although sometimes used interchangeably with privacy, may be thought of as the mode of management of private information about the persons with AIDS being shared inappropriately or inadvertently with others. It follows that the greater the number of persons who have knowledge of private information, the greater the risk that confidentiality will be breached. It is for this reason that the rigorous maintenance of confidentiality is considered critical to the success of the public health endeavor to prevent the transmission and spread of HIV infection. . . . An effective guarantee of confidentiality is the major bulwark against that fear [of discrimination]. A federal statute that carefully balances the need for confidentiality of HIV information against the protection of public health is a necessary and appropriate response to confidentiality concerns (Presidential Commission on the Human Immunodeficiency Virus Epidemic, 1988, p. 126). Many states (1) require that HIV-positive test results be reported to the top state health official, including names-based reporting in some states; (2) have strengthened confidentiality standards to protect HIV-infected persons from discrimination; (3) have created additional means for anonymous HFV testing; (4) include AIDS under laws protecting the handicapped; and (5) limit health officials' power to quarantine and isolate those with communicable disease while strengthening due process for those who are infected (Eubanks, 1988). In 1999 the Centers for Disease Control and Prevention proposed national guidelines urging all fifty states to adopt names-based HIV reporting systems. This proposal would seem to support the argument by some that the era of HIV/AIDS exceptionalism is coming to an end; however, critics of this proposal have raised several concerns, including the following: Some people will be dissuaded from seeking testing if they know their names will be reported. While this concern has been addressed by Nakashima and associates (1998) who reported that names-based reporting had minimal effect on the decision to seek testing in publicly funded testing programs, their conclusions have been questioned by other researchers. Those persons at highest risk—racial minorities, injection drug uses, men who have sex with men—have a historical distrust of

ETHICAL AND LEGAL DIMENSIONS

533

the government and will not be persuaded to undergo testing by reassurances about confidentiality; There are no known means to absolutely ensure that lists of names of HIV seropositive persons can be maintained confidentially by government agencies; Unless federal regulations are in place to prohibit the misuse of testing information, names-based reporting systems create risks for those who undergo testing. With the advent of routinely computerized health records, breaches of privacy and confidentiality are an increasing risk for those with HIV disease (Gostin, 1997b). Several principles have been proposed for the development of standards and policies to guarantee the confidentiality of personal health information while promoting access to high quality care and the viability of medical research. The principles address: The right to privacy established by law; Limitations on identifiable information; The right to access and supplement personal health information; The right to be notified when individually identifiable health information is shared with third parties; The prohibition of the use of disclosure or use of individually identifiable health information without informed consent; Protections that do not impede important public health efforts of research; A requirement for the development of security safeguards in the use, disclosure, and storage of personal health information; Strong and enforceable remedies for violations of privacy protections and for whistle blowers who disclose such violations; A national law providing a floor for the protection of individual privacy rights but not a ceiling. (Badzek & Gross, 1999) Because the multiple interests of individual health care consumers, health care providers, and other third parties must be considered in crafting policies and laws governing the confidentiality of private health information, consensus among all interested parties is extraordinarily challenging.

534

THE PERSON WITH HIV/AIDS

Testing/Screeningfor HIV. Testing and screening for HIV infection raise concerns about intrusions into privacy and about how to maintain confidentiality of results. (See also chapter 9.) Early arguments against mandatory HIV testing focused on problems of false-negative and false-positive test results as a reason for not requiring widespread testing. Researchers also discovered that at least some persons who are HlV-infected may not be detected by screening methods now in wide use. Early in the epidemic, those ethicists arguing against mandatory screening usually alluded to technical difficulties in the testing process. Diagnostic procedures now widely available have reduced concerns about test sensitivity and specificity. Thus the controversy over who should be tested and under what circumstances now rest on ethical, rather than biotechnological, grounds. Testing of persons for a communicable disease generally rests on the belief that infected individuals need to be identified so that these individuals can be counseled to reduce the health risk to themselves and others. With the advent of an tire tro viral medications and early treatment, testing of individuals believed to be at risk has been widely advocated. Testing is also often encouraged so that carriers can be identified and educated to change behaviors that might pose a risk to themselves and others. But knowledge of another person's HIV status is not a prerequisite to the provision of education that potentially leads to changing behaviors that may place one at risk of infection. Nor is knowing one's own HIV status a prerequisite to the adoption of behaviors that reduce or eliminate the risk of acquiring an HIV infection. Many Gay men, for example, have made lifestyle changes on the basis of their understanding about the transmission of HIV. One can argue, however, that information about HIV and AIDS, and particularly information on the prevention of infection, should be widely available for all persons, particularly for populations identified at highest risk, regardless of an individual member's HIV status. Having information about one's own or another's HIV status generates hard questions: 1. Who has or should have access to this information? 2. Who should be informed when an individual is found to be HIV seropositive? An employer, a sexual partner, parents, insurance companies? Should health care workers, policemen and firemen, morticians, or teachers be informed so that they can take precautions in the event they are exposed

ETHICAL AND LEGAL DIMENSIONS

535

to body fluids? Or put another way, are HIV test results private information, or do certain others have the right to this information? 3. Should one be required to identify individuals who have been placed at risk of infection through sexual contact, intravenous drug sharing, or other exposure? (Health care providers, particularly physicians and public health workers, are concerned about a duty to warn sexual partners of infected persons and often cite the 1976 legal decision in Tarasoff v. the University of California, which imposed a duty upon psychotherapists to warn third parties form the potentially dangerous acts of their clients. (Perry, 1989; Zonana, 1989)

On one hand, infected individuals may risk negative reaction by others and the loss of social status, insurance, or employment if their infected status becomes known. On the other hand, not knowing that one is infected can potentially mean that lifesaving or lifeprolonging therapy is not implemented until late in the course of infection. Under such circumstances an individual may have missed the opportunity to prolong his life or that of another at risk of infection because early treatment was not begun. While only a small portion of HlV-infected Americans are believed to have been tested, the question of whether one should be tested for HIV rests at this time principally upon individual psychological factors and upon individual evaluation of risk for infection. Even when the risk for infection is high, some persons decide not to be tested because of greater concerns about losses that might occur were this information to be shared with others. Contact tracing of persons identified by individuals who have HIV seropositive remains controversial. Most states provide no clear statutory authority for public health authorities to trace contact of HlV-infected persons. Gostin and Curran (1987) argue that there are strong reasons against statutory contact tracing as a public health measure against AIDS. They maintain that the direct public health benefits would be marginal and the introduction of intrusive measures would seriously undermine other public health measures to contain the disease. Contact tracing of potentially infected individuals is difficult because some infected persons have had numerous anonymous contacts. Moreover, because of the long incubation associated with AIDS, it is sometimes difficult for persons to remember all of their contacts within the past five years and for public health officials to locate these contacts. It has also been argued that the

536

THE PERSON WITH HIV/AIDS

cost of contact tracing would be too burdensome for society. Still others have argued that contact tracing cannot be implemented because there simply are not adequate numbers of trained personnel to carry out such tracing programs. Experts who have argued in favor of contact tracing note that unprotected sex is still common in some populations and that many HIV-infected persons, including those not using condoms, do not tell their sexual partners that they carry the virus. Advocates for contact tracing believe, therefore, that failure to carry out contact tracing potentially harms those unknowingly exposed to the virus and is thus ethically wrong. As better treatments become available for HIV/AIDS, those in favor of contact tracing may well justify such a program on both ethical and economic grounds. Discrimination Against Persons with HIV/AIDS Fear of discrimination is a major constraint to the acceptance of many effective public health measures (Institute of Medicine, 1988). In 1988 James Watson, chairman of the Presidential Commission on the HIV Epidemic, called for a federal law barring discrimination against persons with HIV/AIDS. According to Admiral Watson, "If the nation does not address this issue squarely, it will be difficult to solve most other HIV-related problems. People will simply not come forward to be tested, nor supply names of sexual contacts . . . if they feel they will lose their jobs and homes" (Blendon & Donelan, 1988, p. 1022). The Institute of Medicine-National Academy of Sciences Committee for the Oversight of AIDS activities had made a similar recommendation earlier (Institute of Medicine, 1988). Such federal legislation has not been passed. Only a few studies and reports have discussed the scope of HIV/ AIDS-related discrimination and related legal protection (Curran, Gostin, & Clark, 1986; Pabst, 1987). The extent of this discrimination was reported in a study by Blendon and Donelan (1988), which found that many Americans would refuse to work alongside someone who had AIDS and would support the rights of employers to fire such workers; that many parents would take their child out of school to avoid a classmate with AIDS; and that a substantial minority believe that those with AIDS should not be allowed to live in their neighbor-

ETHICAL AND LEGAL DIMENSIONS

537

hood or community, and they favor landlords' having the right to evict those with the disease. The study also found that 76% of the American public favored more extensive voluntary testing as a means of controlling the epidemic. While they noted that antidiscrimination laws do not necessarily eliminate fears and hostility, the authors noted that the possibility of legal prosecutions can alter discriminatory behavior. Many federal, state and local laws prohibit discrimination on the basis of disability or health status. The best known of these is the federal Americans with Disabilities Act of 1990 (Gostin, Feldblum, & Webber, 1999). In addition, a number of states and municipalities have passed antidiscrimination laws aimed at protecting the rights of those who are infected. Some of these laws, however, have been preempted by state law or repealed by ballot initiative. The AIDS epidemic raises numerous ethical and legal questions for employers, including employers of infected health care workers (Rundle, 1989). Many of these questions are related to discrimination in employment and employee benefit. In spite of federal and state antidiscrimination laws, some persons with HIV/AIDS are fired once their status or illness becomes known to their employer, who may fear them or believe their presence will have a negative impact upon other workers or the business itself. Others become too ill to work and are forced to leave their position. Discharged employees are often too ill to contest their employer's actions or die before obtaining legal redress. HIV/AIDS continue to have a major impact upon this nation's workforce and present economic problems for employers. Only a few businesses have yet developed policies to deal with HIV/AIDS in the workplace and many businesses and organizations still have no plans for their response in the event an employee is diagnosed with AIDS. With the advent of better treatments for HIV, there is now a pressing need for state and federal policies that will facilitate the reentry of those with HIV disease into the work place without a loss of the disability safety net (e.g., the proposed Work Incentive Improvement Act of 1999). The Citizens Commission on AIDS, a private, independent, foundation-supported group of prominent citizens, has developed "Workplace Principles," intended to help employers, unions, and employee representatives examine existing AIDS policies to determine appropriate responses (Levine, 1989). These principles are as follows:

538

THE PERSON WITH HIV/AIDS

1. People with AIDS or HIV (Human Immunodeficiency Virus) infection are entitled to the same rights and opportunities as people with other serious or life-threatening illnesses. 2. Employment policies must, at a minimum, comply with federal, state, and local laws and regulations. 3. Employment policies should be based on the scientific and epidemiological evidence that people with AIDS and HIV infection do not pose a risk of transmission of the virus to coworkers through ordinary workplace contact. 4. The highest levels of management and union leadership should unequivocally endorse nondiscriminatory employment policies and education programs about AIDS. 5. Employers and unions should communicate their support of these policies to workers in simple, clear, and unambiguous terms. 6. Employers should provide employees with sensitive, accurate, and up-todate education about risk reduction in their personal lives. 7. Employers have a duty to protect the confidentiality of employee's medical records. 8. To prevent work disruption and rejection by coworkers of an employee with AIDS or HIV infection, employers and unions should undertake education for all employees before such an incident occurs and as needed thereafter. 9. Employers should not require HIV screening as part of pre-employment or general workplace physical examinations. 10. In those special occupational settings where there may be a potential risk of exposure to HIV (for example, in health care, where employees may be exposed to blood or blood products), employers should provide specific ongoing education and training, as well as the necessary equipment, to reinforce appropriate infection control procedures and ensure that they are implemented, (pp. 80-81)

The passage of hundreds of laws at the local, state, and federal levels that affect the lives of persons with HIV/AIDS has led to the need to be informed about organizations that assist persons experiencing discrimination and other legal problems because of their status. A partial list of these organizations and their addresses is shown in Table 14.1.

THE DUTY TO CARE An important ethical issue related to the care and treatment of people with HIV/AIDS is concerned with whether health care workers have the right to refuse to provide services to people living with

ETHICAL AND LEGAL DIMENSIONS

539

TABLE 14.1 List of Selected Resources on the World Wide Web: Ethics, Law, Research, and Public Policy AEGIS Law Library http://www.aegis.com/ AIDS Discrimination Unit (Los Angeles) http://www.cityofla.org/ATTY/aidsdisc.htm AIDS/HIV Law and Policy Resource http://www.critpath.org/aidslaw/ AIDS Legal Referral Panel (San Francisco) http://www.alrp.org/ AIDS Litigation Project http://HIVInSite.ucsf.edu/social/kaiserJamilyJound/2098.2a96.html Americans with Disabilities Act http://www.usdoj.gov/crt/ada/adahom1.htm American Civil Liberties Union http://www.aclu.org/ Choice in Dying http://www.choices.org/ Guide to Disability Rights Law (United States Justice Department) http://www.pueblo.gsa.gov/cicjext/misc/disability/disrits.htm HIV InfoWeb http://www.infoweb.org/ HIV/AIDS Policy and Law Newsletter (Canada) http://www.aidslaw.ca/elements/bulletinE.html HIV/AIDS Policy Compendium Database http://www.tfgi.com/areas/hivaids.htm HIVdent Public Policy and News Update http://www.hivdent.org/publicp/pubpolicy.htm International Gay and Lesbian Human Rights commission http://www.iglhrc.org/ JAMA HIV/AIDS Information Center http://www.ama-assn.org/special/hiv/ LAMBDA Legal Defense and Education Fund http://www.lambdalegal.org/ (continued)

THE PERSON WITH HIV/AIDS

540

TABLE 14.1

(continued)

Medical College of Wisconsin Institutional Review Board Discussion Forum http://www.mcwirb.org/ National Bioethics Advisory Commission http://bioethics.gov/cgi-bin/bioeth_counter.pl National Health Law Program http://www.healthlaw.org/ New York State Division of Human Rights http://www.nysdhr.com/ Office for Civil Rights (U.S. Department of Education) http://www.ed. gov/off ices/OC R/ Office for Protection from Research Risks (NIH) http://www.nih.gov/grants/oprr/oprr.htm Stateserv Health Policy Tracking Service http://www.stateserv.hpts.org/public/pubhome.nsf

HIV/AIDS (Sherman & Quellette, 1999; Smolkin, 1997). Reports circulated in the early 1980s that some nurses who refused to provide care to AIDS patients were discharged; still others were reported to have resigned rather than render such care. These nurses apparently were reportedly concerned for their safety and possibly that of their families. Such concerns have now decreased considerably in the face of more accurate knowledge about AIDS and its transmissibility, established infection control guidelines, and the extremely low risk to health care persons providing care for AIDS patients. According to Sherman and Ouellette (1999): Health care professionals are moving beyond the negativity of AIDS care and realizing their ethical responsibilities in caring for patients with AIDS. Slowly, researchers and practitioners are extending their focus beyond the knowledge, attitudes, and perceptions of health care providers to an examination of the AIDS patients', and perceptions of health care providers to an examination of the AIDS patients' perceptions of nursing and medical care, an understanding of their health care needs, and a concern for their quality of life. . .. Fear of AIDS is slowly being transcended, (p. 44)

Nurses' ethical duty to care for persons with HIV/AIDS is further supported by the American Nurses Association's (ANA) Code for

ETHICAL AND LEGAL DIMENSIONS

541

Nurses (1985a) and the International Council of Nurses' Code of Nurses (1987). These codes underscore nurses' historical service to all persons, regardless of nationality, creed, race, color, age, sex, social/economic status, and illness. The ANA Committee on Ethics (1986) prepared a "Statement Regarding Risk Versus Responsibility in Providing Nursing Care," which states in part that "accepting personal risk which exceeds the limits of duty is not morally obligatory; it is a moral option." This statement notes that the differentiation between benefiting another as a moral duty and benefiting another as a moral option is found in four fundamental criteria: 1. The patient is at significant risk of harm, loss, or damage if the nurse does not assist. 2. The nurse's intervention or care is directly relevant to preventing harm. 3. The nurse's care will probably prevent harm, loss or damage to the patient. 4. The benefit the patient will gain outweighs any harm the nurse might incur and does not present more than minimal risk to the health care provider. This statement seems to suggest that a nurse must determine whether patient benefit outweighs harm to the nurse. On the basis of present scientific data, the risk of harm to the nurse caring for a person with HIV/AIDS is negligible (although not zero) if well-established infection control measures are followed. Freedman (1988) points out that the Committee's statement does not define minimal risk; thus the level or quantity of risk a nurse is obligated to accept remains vague. The Code for Nurses is undergoing revision and clarification of nurses' moral duty to themselves, which is left out of the 1985 Code, is being considered for inclusion in the revised Code (Daly, 1999). Life-sustaining versus Supportive Care While persons with HIV disease are living longer and better lives, thousands still die each year. In the recent past, end-of-life concerns have captured the attention of the public, the courts, and caregivers. Physician-assisted suicide has been of particular interest to ethicists

542

THE PERSON WITH HIV/AIDS

and researchers (Breitbart, Rosenfeld, & Passik, 1996; Cook, Gourlay, Collette, Boccellari, Chesney, & Folkman, 1998; Gostin, 1997a; Patrick, Pearlman, Starks, Cain, Cole, & Uhlman, 1997; Quill, Meier, Block, & Billings, 1998; Schneiderman, Kaplan, Rosenberg, & Teetzel, 1997; Slome, Mitchell, Charlebois, Benevedes, & Abrams). An important ethical dilemma for caregivers of persons with AIDS is related to issues of live-sustaining treatment versus supportive care. Dilemmas in this area are noteworthy because (1) caregiver and patient may not always agree on the treatment course to follow, (2) persons with AIDS may become mentally incapable of making decisions, and (3) decision-making guidelines are difficult to follow in view of the high stress related to the care of persons with AIDS (Steinbrook et al., 1986). Ideally, medical treatment with AIDS should be jointly determined by patient and physician because preferences for care cannot be accurately predicted without discussion; however, many people with AIDS are ambivalent about discussing life-sustaining treatment (Steinbrook et al., 1986). While almost three-fourth of AIDS patients in one study wanted to discuss lifesustaining measures, only one-third had done so (Steinbrook et al., 1986). The plight of persons with AIDS underscores already widely debated questions about individuals' rights to refuse life-sustaining treatment; physicians' rights to provide, withhold, or withdraw lifesustaining treatment for terminally ill patients (although it should be emphasized that many persons with AIDS are not "terminally" ill); and the rights of individuals to arrange an assisted death. Some persons with AIDS have drawn up living wills to ensure that their desires are carried out, although the nature of these instruments and these wills raise additional ethical concerns (Ney, 1989). Lifesustaining issues serve as the focus for statements and reports issued by various professional organizations and think tanks, as well as opinions issued by state and federal courts. In some cases staff and/or significant others must make treatment choices that affect the outcome of the patient's life. When decisions are made by other persons without the patient's wishes being known, value judgments may inappropriately affect decision-making. Patients with AIDS should consider appointing a trusted person as their durable power of attorney so that if they are unable to make decisions about their health care and other matters, this appointee can carry out their wishes. Many persons with AIDS prefer to appoint

ETHICAL AND LEGAL DIMENSIONS

543

their friends or partners, rather than relatives, as substitute decisionmakers (Steinbrook et al., 1986). Studies over the past decade suggest that professional and lay caregivers have assisted terminally ill persons with AIDS to die. Such caregivers need to understand the psychological and social distress that may underlie these requests.

Ethical Concerns in HIV/AIDS Research Numerous ethical concerns have been raised regarding research and experimental treatment of individuals with AIDS (Bayer, Levine, & Murray, 1984; Bhagwanjee, Muckart, Jeena, & Moodley, 1997; Gray Lyons, & Melton, 'l995; Joseph, 1998; Kass, Taylor, & King, 1996; Marwick, 1998; Schuklenk & Hogan, 1996; Weijer, 1996). These concerns, while not unique to HIV/AIDS research, have been greatly shaped by the political and social landscape surrounding AIDS research. The HIV/AIDS research literature has focused on several important topics of ethical/legal concern to researchers: Collecting, storing, and protecting confidential data Minimizing iritrusiveness of research Obtaining informed consent Knowing when a need may exist to warn third parties Reporting illegal behavior observed in the course of research, e.g., drug use, prostitution, sodomy, etc. Considering how to promote access to clinical trials Designing research that both adheres to accepted ethical principles and is scientifically rigorous Conducting research in other nations (transnational research), especially in developing countries where ethical principles of research may differ from those in the United States Conducting research involving special populations, e.g., pregnant women, children and adolescents, prisoners, injection drug users, sex workers, the mentally ill In the conduct of research involving human subjects, the researcher is always concerned about respect for persons, beneficence, and justice, among other principles (Macklin & Fiedland, 1986).

544

THE PERSON WITH HIV/AIDS

Beneficence may be thought of as treating people in an ethical manner not only by respecting their decisions and protecting them from harm, but also by making efforts to secure their well-being (Nati6nal Commission for the Protection of Human Subjects, 1979). Beneficence is expressed by efforts to do no harm, to maximize possible benefits, and to minimize possible harms. In achieving these goals, researchers often do a risk-benefit analysis. However, learning what will benefit may require exposing individuals to risk (AIDS Trails Ethics Questioned, 1997; Lallemant, Mclntosh, Jourdain, et al., 1998). In clinical trials of drugs to treat HIV, the subject may be exposed to considerable risk of harm. Is it acceptable to weigh these risks against the gains others may acquire as a result of such research? In the case of pregnant HFV-infected women, clinical trials of potent drugs hold the potential to harm not only the mother but also the fetus. How can one justify the use of randomized, controlled drug trials when those receiving a placebo (or suboptimal drug or drugs) may not benefit, while those receiving the experimental treatment have at least some chance of gain? The question that arises is: Are there any diseases with such grave prognoses that placebo controls should never be considered? Macklin and Friedland (1986), in providing a somewhat unsatisfactory response to this dilemma, hold that the obligations imposed on research physicians by the principle of beneficence are not entirely patient-centered. They point out that divided loyalties constitute a potential hazard of all clinical research. Allowing patients to take second place, they believe, can be ethically justified by the respect-for-persons principle. Other critics believe that there are no ethical grounds for conducting randomized, controlled trials with persons with AIDS in the effort to find efficacious drug therapies. According to Angell (1997), "Only when there is no known effective treatment is it ethical to compare a potential new treatment with a placebo. When effective treatment exists, a placebo may not be used" (p. 847). The ethical principle of justice asks, among other research-related questions, "Who ought to receive the benefits of research and bear its burdens?" Fair selection of subjects for study is one issue related to this principle. Taking steps to ensure that both risks and benefits are equally distributed among the at-risk population is another issue. In a related matter, some potentially effective drugs have not received

ETHICAL AND LEGAL DIMENSIONS

545

approval from the Food and Drug Administration (FDA) because of concerns about their proven safety and efficacy. Given the possibility that experimental drug therapy might prolong or save lives and the probability that most people with AIDS will die without a drug breakthrough, the FDA has adopted regulations and procedures that allow the introduction of unproven but promising drugs more quickly in specific circumstances. More rapid drug approval, however, may increase the risk of harm to individuals taking such drugs. CONCLUSION Over a period of almost two decades the HIV/AIDS epidemic has created ethical dilemmas and raised legal issues that profoundly affect the lives of all Americans and greatly influence the social fabric of this nation. A major concern of ethicists in the present epidemic is the balance between rights and duties of infected individuals and those of the greater society. The tension generated by efforts to balance these rights have led to policies influencing many aspects of American life. Because of their historical roles as patient advocate and direct care provider, nurses, and particularly those in leadership positions, must join their colleagues in medicine, government, philosophy, and law in debating AJDS-related ethical and legal issues that affect their lives, the lives of people with HIV/AIDS, and ultimatelv the lives of all Americans and citizens of the world. REFERENCES AIDS ethics questioned. (1997, April 25). Science, 276, 520-523. American Nurses Association. (1985a). Code for nurses with interpretative statements. Kansas City: Author. Angell, M. (1997). The ethics of clinical research in the third world. New England Journal oj Medicine, 337, 847-849. Badzek, L., £ Gross, L. (1999). Confidentiality and privacy: At the forefront for nurses. American Journal of Nursing, 99(6), 52-54. Banta, W. (1987). AR)S in the workplace. Lexington, MA: Lexington Books. Barrick, B. (1988). The willingness of nursing personnel to care for persons with AIDS syndrome. Journal of Professional Nursing, 4(5), 366-371. Bayer, R. (1999). Clinical progress and the future of HIV exceptionalism. Archives of Internal Medicine, 159, 1042-1048.

546

THE PERSON WITH HIV/AIDS

Bayer, R. (1991). Public health policy and the AIDS epidemic: An end to HIV exceptionalism? New England Journal of Medicine, 324, 1500-1504. Bayer, R., Levine, C., & Murray, T. (1984). Guidelines for confidentiality in research in AIDS. IRB, 6, 1-7. Baylor, R., & McDaniel, A. (1996). Nurses' attitudes toward caring for patients with acquired immune deficiency syndrome. Journal of Professional Nursing, 12,99-105. Bean, J., Keller, L., Newberg, C., & Brown, M. (1989). Methods for the reduction of AIDS social anxiety and social stigma. AIDS Education and Prevention, jf(3), 194221. Beating the odds. (1996, February 12). U.S. News and World Report, 60-68. Bennett, J. (1995). Nurses' attitudes about acquired immunodeficiency syndrome care: What research tells us. Journal of Professional Nursing, 11, 339-350. Bhagwanjee, S., Muckart, D., Jeena, P., & Moodley, P. (1997). Commentary: Why we "did not seek informed Consent before testing patients for HIV. British Medical Journal, 314, 1082-1083. Blendon, R., & Donelan, K. (1988). Discrimination against people with AIDS. New England Journal of Medicine, 319(15), 1033-1036. Breitbart, W., Rosenfeld, B., & Passik, S. (1996). Interest in physician-assisted suicide among ambulatory HIV-infected patients. American Journal of Psychiatry, 153, 238242. Carusi, D., Learman, L., & Posner, S. (1998). Human immunodeficiency virus test refusal in pregnancy: A challenge to voluntary testing. Obstetrics and Gynecology, 91, 540-545. Cole, F. (1996). Factors associated with student nurses' intent to provide physical and psychosocial care to persons with acquired immune deficiency syndrome. Journal of Professional Nursing, 12, 217-224. Cook, M., Gourlay, L., Collette, L., Boccellari, A., Chesney, M., & Folkman, S. (1998). Informal caregivers and the intention to hasten AIDS-related death. Archives of Internal Medicine, 158, 69-75. Daly, B. (1999). Why a new code. American Journal of Nursing, 99(6), 64-66. Daniels, N. (1985). Just health care. Cambridge: Cambridge University Press. Dawson, D., Cynamon, M., & Fitti, J. (1988, March 9). AIDS knowledge and attitudes for November, 1987. NCHS Advanced Data, 150, 1-2. Eubanks, P. (1988, October 20). States have one goal, many paths, to fight AIDS. Hospitals, 62, 68. Freedman, B. (1988, April/May). Health professions, codes, and the right to refuse to treat HIV-infectious patients. Hastings Center Report, 18(2), 20-25. Gostin, L. (1997a). Deciding life and death in the courtroom: From Quinlan to Cruzan, Glucksberg, and Vacco—A brief history and analysis of constitutional protection to the "right to die." Journal of the American Medical Association, 278, 1523-1528. Gostin, L. (199b). Health care information and protection of personal privacy: Ethical and legal considerations. Annals of Internal Medicine, 727(8S), 683-690. Gostin, L., & Curran, W. (1986). The limits of compulsion in reporting AIDS. Hastings Center Report, 16(6), 24-29 (Suppl.).

ETHICAL AND LEGAL DIMENSIONS

547

Gostin, L., & Curran, W. (1987). Legal control measures for AIDS: Reports requirements, surveillance, quantitative, and regulation of public meeting places. American Journal of Public Health, 77(2), 214-218. Gostin, L., Feldblum, C., & Webber, D. (1999). Disability discrimination in America: HIV/AIDS and other health conditions. Journal of the American Medical Association, 281, 745-752. Gostin, L., Ward,J., & Baker, A. (1997). National HIV case reporting for the United States: A defining moment in the history of the epidemic. New England Journal of Medicine, 337, 1162-1167. Gostin, L., & Webber, D. (1998a). The AIDS litigation project, part II. AIDS and Public Policy Journal, 13(1), 3-19. Gostin, L., & Webber, D. (1998b). HIV infection and AIDS in the public health and health care systems: The role of law and litigation. Journal of the American Medical Association, 279,1108-1113. Gray, J., Lyons, P., & Melton, G. (1995). Ethical and legal issues in AIDS research. Baltimore: Johns Hopkins University Press. Hanssens, G. (1998). Inventing "AIDS exceptionalism." (1998, February 28). Lambda Legal Defense and Education Fund, Neivs and Views. http://www.lambdalegal. org/cgi-bin/pages/documents/record?record=207. Institute of Medicine. (1988). Confronting AIDS. Washington, DC: National Academy Press. Institute of Medicine. (1998). Reducing the odds: Preventing perinatal transmission of HIV in the United States. Washington, DC: National Academy Press. International Council of Nurses. (1987). Code for Nurses. In C. Quinn & M. Smith (Eds.), The professional commitment: Issues and ethics in nursing (pp. 179-180). Philadelphia: Saunders. Jayasuriya, D. (1988). AIDS-related health legislation. In A. Fleming, M. Carballo, D. Fitzsimons, M. Bailey, &J. Mann (Ed.), The global impact of AIDS (pp. 313-316). New York: Alan R. Liss. Joseph, K. (1998). Ethics in clinical research: Searching for absolutes. Canadian Medical Association Journal, 158, 1303-1305. Kass, N., Taylor, H., &• King, P. (1996). Harms of excluding pregnant women from clinical research: The case of HIV-infected pregnant women. Journal of Law, Medicine, & Ethics, 24, 36-46. Kelman, H. (1977). Privacy and research with human beings. Journal of Social Issues, 33(3), 169-195. Prescott, N., & Essex, M. (1998). Ethics of placebo-controlled zidovudine to prevent perinatal transmission of HIV in the third world. New England Journal of Medicine, 338, 836-841. Levine, C. (1989). Charleston declaration on AIDS education, counseling and prevention. AIDS Education and Prevention, 1 ( 1 ) , 89—93. Macklin, R., & Friedland, G. (1986). AIDS research: The ethics of clinical trials. Law, Medicine and Health Care, 14(5-6), 273-280. Marwick, C. (1998). Bioethics group considers transnational research. Journal of the American Medical Association, 279, 1425.

548

THE PERSON WITH HIV/AIDS

McCann, T. (1997). Willingness to provide care and treatment for patients with HIV/AIDS. Journal of Advanced Nursing, 25, 1033-1039. Merritt, D. (1986, December). The constitutional balance between health and liberty. Hastings Center Report, 16(6), 2-10(Suppl.). Mills, M., Wofsy, C., & Mills, J. (1986). The acquired immunodeficiency syndrome: Infection control and public health law. New England Journal of Medicine, 314(14), 931-936. Nakashima, A., Horsley, R., Frey, R., Sweeney, P., Weber, J., & Fleming, P. (1998). Effect of HIV reporting by name on use of HIV testing in publicly funded counseling and testing program. Journal of the American Medical Association, 280, 1421-1426. National Commission for the Protection of Human Subjects. (1979). Belmont report. Washington, DC: Department of Health and Human Services. Ney, C. (1989). Living wills: The ethical dilemmas. Critical Care Nurse, 9(8), 20-41. Pabst, T. (1987). Protection of AIDS victims from employment discrimination under the Rehabilitation Act. University of Illinois Law Review, 1987, 355-378. Patrick, D., Pearlman, R., Starks, H., Cain, K., Cole, W., & Uhlmann, R. (1997). Validation of preferences for life-sustaining treatment: Implications for advance care planning. Annals of Internal Medicine, 127, 509-517. Perry, S. (1989). Warning third parties at risk of AIDS: APA's policy is a barrier to treatment. Hospital and Community Psychiatry, 40(2), 158-161. Pierce, C., & VanDeVeer, D. (1988). AIDS: Ethics and public policy. Belmont, CA: Wadsworth. Pomerance, L., & Shields, J. (1989). Factors associated with hospital workers' reactions to the treatment of persons with AIDS. AIDS Education and Prevention, 1(3), 184-193. Presidential Commission on the Human Immunodeficiency Virus Epidemic. (1988). Report of the Presidential Commission on the human immunodeficiency virus epidemic. Washington, DC: Author. Pryor, J. (1988, October). Attitudes toward persons with AIDS: A mixture of fear and loathing. Paper presented at the Midwest Conference on the Social Implications of AIDS, Normal, IL. Quill, T., Meier, D., Block, S., & Billings, A. (1998). The debate over physicianassisted suicide: Empirical data and convergent views. Annals of Internal Medicine, 128, 552-558. Rawnsley, M. (1980). The concept of privacy. Advances in Nursing Science, 2(2), 25-31. Rowland, C. (1986, April 1). The call for quarantine. The Advocate, 443, 42-46. Rundle, R. (1989, January 4). Medical industry faces the tough issue of dealing with its workers with AIDS. Wall Street Journal, p. Bl. Sabatier, R. (1988). Blaming others. London: Panos Institute. Schuklenk, U., & Hogan, C. (1996). Patient access to experimental drugs and AIDS clinical trials designs: Ethical issues. Cambridge Quarterly of Healthcare Ethics, 5, 400-409. Schneiderman, L., Kaplan, R., Rosenberg, E., & Teetzel, H. (1997). Do physicians' own preferences for life-sustaining treatment influence their perceptions of

ETHICAL AND LEGAL DIMENSIONS

549

patients' preferences? A second look. Cambridge Quarterly of Healthcare Ethics, 6, 131-137. Sherman, I)., & Quellette, S. (1999). Moving beyond fear. Nursing Clinics of North America, 3 4 ( 1 ) , 1-48. Slome, L., Mitchell, T., Charlebois, E., Benevedes, }., & Abrams, D. (1997). New England Journal of Medicine, 336, 417-421. Smolkin, D. (1997). HIV infection, risk-taking, and the duty to treat. The Journal of Medicine and Philosophy, 22, 55-74. Steinbrook, R., Lo, B., Moulton, J., Saika, G., Hollander, H., & Volberding, P. (1986). Preferences of homosexual men with AIDS for life-sustaining treatment. New England Journal of Medicine, 314(1), 457-460. Weijer, C. (1996). Evolving ethical issues in selection of subjects for clinical research. Cambridge. Quarterly of Healthcare Ethics, 5, 334-345. Zonana, H. (1989). Warning third parties at risk of AIDS: APA's policy is a reasonable approach. Hospital and Community Psychiatry, 40(2), 162-164.

This page intentionally left blank

Appendix I Considerations in Caring for Persons after Potential

Nonoccupational Exposure to HIV Wh`en Data

Are Inadequate

EVALUATION FOR STDS AND SUBSTANCE ABUSE Sexual activities associated with a risk for HIV transmission also are associated with risk for unintended pregnancy and STDs (e.g., syphilis, gonorrhea, chlamydia, or hepatitis B virus). Treatment for STDs should follow the CDC's 1998 Guidelines for Treatment of Sexually Transmitted Diseases, and victims of sexual assault should receive additional evaluation and counseling. Women at risk for unintended pregnancy should be offered emergency contraception. Persons with possible HIV exposure through percutaneous routes from sharing syringes or needles should be assessed for hepatitis B and hepatitis C virus infections and considered for hepatitis B virus vaccination. They also should be assessed and referred for appropriate substance abuse treatment.

HIV EVALUATION AND MANAGEMENT Persons who report possible nonoccupational HIV exposure should be evaluated for sexual and injecting-drug-use behavior that might 551

APPENDIX I

552

lead to recurrent exposure. In all situations, health-care providers should offer confidential risk-reduction counseling during initial and follow-up visits. Persons who have been sexually assaulted also can be referred for anonymous or confidential voluntary counseling and testing within 72 hours of exposure to establish their HIV status at the time of the assault. Some patients (e.g., those who have inconsistently or incorrectly used condoms or relapsed into injecting-drug use) will need to be referred for intensive risk-reduction interventions. Health-care providers evaluating persons for nonoccupational HIV exposure should know where such services are available and help patients obtain them promptly. Persons with nonoccupational HIV exposures should receive medical evaluations, including HIV-antibody tests at baseline and periodically for at least 6 months after exposure (e.g., at 4-6 weeks, 12 weeks, and 6 months). All persons evaluated for possible nonoccupational HIV exposure should be counseled to initiate or resume protective behaviors to prevent additional exposure and to prevent possible secondary transmission if they become infected while receiving antire troviral therapy. CONSIDERATIONS IN INITIATING ANTIRETROVIRAL THERAPY Physicians considering the initiation of an tire troviral therapy in an attempt to reduce the risk for HIV infection in an exposed person should take the following steps in consultation with an expert in the use of an tire troviral agents: Evaluate the HIV status and risk-behavior history of the reported source of HIV exposure. Provide medical care, supportive counseling, and prevention services to persons who are determined to be HIV-infected when they seek care for a potential HIV exposure. Evaluate the risk for HIV transmission (if there is convincing evidence of HIV infection in the reported source patient). Physicians should determine the specifics of the risk event (e.g., no condom, torn condom, whether receptive or insertive partner, injection before or after others, number of persons sharing

APPENDIX I

553

injection equipment) and the presence or absence of factors that would modify risk (e.g., vaginal or anal tears or bleeding, visible genital ulcers or other evidence of an active STD, or bleach treatment of injection equipment). Determine the time elapsed between exposure and presentation for medical care. Although animal studies indicate that an tire troviral agents are most effective within 1-2 hours of exposure and probably not effective when started later than 24-36 hours after exposure, the interval during which therapy can be beneficial for humans is unknown. Evaluate the frequency of HIV exposure. Uninfected persons who request antiretroviral agents should be evaluated for sexual, injecting-drug-use, and other behaviors that might lead to recurrent HIV exposures. Antiretroviral therapy is not a replacement for adherence to behaviors that reduce the risk of HIV exposure. Provide counseling and obtain informed consent. Because postexposure prophylaxis is an experimental therapy of unproven efficacy, informed consent should be obtained and recorded in the medical charts of all persons prescribed antiretroviral agents following nonoccupational exposure. Such consent should document the patient's understanding of a) the need to initiate or resume relevant HIV risk-reduction behaviors (e.g., condom use and/or drug treatment); b) the limited knowledge about the effectiveness and toxicity of antiretroviral treatment for nonoccupational exposure; c) the known side effects of the medications being prescribed; d) the name and phone number of a source for follow-up medical care; e) the frequency and timing of recommended follow-up HIV testing; f) the signs and symptoms associated with acute HIV seroconversion; and g) the need for adherence to prescribed medications to maximize efficacy and reduce the risk for infection with a drug-resistant variant. The patient should be told that physicians have diverse opinions about the use of antiretroviral medications to treat possible nonoccupational HIV exposure and that the PHS [Public Health Service] cannot make definitive recommendations because of limited knowledge. Persons younger than age 16 years at the time of exposure should be evaluated (before therapy is initiated) by pediatricians, family physicians, or other clinicians expert in the specific medical

554

APPENDIX I

needs, consent issues, and other factors involved in their treatment, including the use of antiretroviral medicines for children and adolescents. These factors can include the investigation of possible child sexual abuse, state-specific legal reporting requirements for situations that endanger the welfare of minors, and local definitions of emancipation or other consent requirements that define the circumstances under which children and adolescents can give legal consent for their own medical care. HlV-exposed women who are pregnant (or could become so as a consequence of the exposure event) should be evaluated before antiretroviral therapy is initiated in consultation with obstetricians or other physicians expert in the care of HIV infection during pregnancy to define which antiretroviral agent(s) would be appropriate to the health of the woman and the fetus. Women should be counseled on a) the limited data available about the short-term safety for the fetus and the long-term safety of in utero antiretroviral exposure for the infant; b) the theoretical risks of suggested antiretroviral agents to the fetus during specific gestational periods; and c) CDC's recommendations regarding antiretroviral therapy for HFV-infected pregnant women. No studies have been conducted on the safety and effectiveness of antiretroviral agents in preventing HIV infection in uninfected women during attempts to conceive with HIV-infected partners, and this therapy is not recommended for such use. If antiretroviral therapy is used, drug-toxicity monitoring should include a complete blood count and renal and hepatic chemical function tests when therapy is initiated and again 2 weeks after the patient begins to take the medications. If subjective or objective toxicity is noted, physicians should consult with their experts on the need for further diagnostic studies and dose reduction or drug substitution. It is possible that antiretroviral therapy during early HIV infection could benefit the patient by reducing the initial level of viral replication (i.e., the set point) and decreasing the extent of lymph node infiltration. Thus, for patients with the highest-risk exposures, health-care providers may consider continuing therapy until HIV test results are received from a specimen drawn after 28 days of treatment. Patients should be monitored for signs and symptoms of acute HIV infection during therapy. If such conditions develop, the patient should

APPENDIX I

555

be tested for HIV (p24 antigen, HIV viral load assays) during their 4-week course of therapy with confirmation by standard HIV antibody tests. Persons who become infected while taking antiretroviral therapy should be advised to continue taking the medication pending transfer to a health-care provider who specializes in long-term HIV care. Source: Centers for Disease Control and Prevention. (1998). Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HFV, including considerations related to antiretroviral therapy. Morbidity and Mortality Weekly Report, 47(No. RR-17), 8-10.

This page intentionally left blank

Appendix II Prophylaxis for First Episode of Opportunistic Disease in HIVInfected Adults and Adolescents

Preventive regimens Pathogen

Indication

First choice

Alternatives

I. Strongly recommended as standard of care Pneumocystis cannu

CD4+ count < 200/(lL ororopharyngeal candidiasis or unexplained fever > 2 weeks

Trimethoprimsulfamethoxazole (TMP-SMZ), 1 DS po q.d.; TMP-SMZ, 1 SS po q.d.

Dapsone, 50 mg po bid. or 100 mg po q.d.; dapsone, 50 mg po q.d. plus Pyrimethamine, 50 mg po q.w. plus leucovorin, 25 mg po q.w.; dapsone, 200 mg po plus pyrimethamine, 75 mg po plus leucovorin, 25 mg po q.w.; aerosolized pentamidine, 300 mg q.m. via Respirgard II™ nebulizer; atovaquone 1500 mg po qd; TMP-SMZ, IDS po tiw (continued)

557

APPENDIX II

558 APPENDIX II (continued)

Preventive regimens Pathogen

Indication

First choice

Alternatives

Mycobacterium tuberculosis Isoniazidsensitive^

TST reaction > 5 mm or prior positive TST result without treatment or contact with case of active tuberculosis

Isoniazid, 300 mg po plus pyridoxine, 50 mg po q.d. x 9 mo or isoniazid, 900 mg po plus pyridoxine, 100 mg po b.i.w. x 9 mo Rifampin 600 mg plus pyrazinamide 20 mg/kg po q.d. x 2 mo

Rifabutin, 300 mg po q.d. plus pyrazinamide 20 mg/kg qd x 2 mo. Rifampin, 300 mg po q.d. x 4 mo

Isoniazidresistant

Same; high probability of exposure to isoniazid-resistant tuberculosis

Rifampin, 600 mg plus pyrazinamide 20 mg/kg po q.d. x 2 mo.

Rifampin, 300 mg po q.d. x 12 mo

Multidrug(isoniazid and rifampin) resistant

Same; high probability of exposure to multidrug-resistant tuberculosis

Choice of drugs requires consultation with public health authorities

None

Toxoplasma gondifi

IgG antibody to Toxoplasma and CD4+ count > 100/jiL

TMP-SMZ, 1 DS po q.d.

TMP-SMZ, 1 SS po q.d.: dapsone, 50 mg po p.d. plus pyrimethamine, 50 mg po q.w. plus leucovorin, 25 mg po q.w.; atavaquone 1500 mg po q.d.

Mycobacterium avium complex'

CD4+ count < 50^iL

azithromycin or clarithromycin, 500 mg po b.i.d. or 1,200 mg po q.w.

Rifabutin, 300 mg po q.d.; azithromycin, 1,200 mg po q.w. plus rifabutin, 300 mg po q.d.

559

APPENDIX II

APPENDIX II (continued)

Preventive regimens Pathogen

Indication

First choice

Alternatives

Varicella zoster virus (VZV)

Significant exposure to chickenpox or shingles for patients who have no history of either condition or, if available, negative antibody to VZV

Varicella zoster immune globulin (VZIG),5 vials (1.25 mL each) im, administered < 96 h after exposure, ideally within 48 h

Acyclovir, 800 mg po 5 times/d for 3 weeks

II. Generally recommended Streptococcus pneumonia/'

All patients

Pneumococcal vaccine, 0.5 m/L im x (CD4+ > 200/ML; CD4+ < 200uL —may reimmunize if initial immunization was given when CD4+ < 250/|aL and if CD4+ increases to > 200/flL on HAART

None

Hepatitis B virust1

All susceptible (anti-HBc and anti-HBsnegative) patients

Hepatitis vaccine: 3 doses

None

Influenza virus1"1"

All patients (annually, before influenza season)

Whole or split virus, 0.5 mL im/yr

Rimantadine, 100 mg po b.i.d. or amantadine, 100 mg po b.i.d.

Hepatitis A virus1*

All susceptible (anti-HAVnegative) patients with chronic hepatitis C

Hepatitis A vaccine: two doses

None

(continued)

560

APPENDIX II

APPENDIX II (continued) Preventive regimens Pathogen

Indication

First choice

Alternatives

III. Not routinely indicated

Bacteria

Neutropenia

Cryptococcus neoforman^

CD4+ count < 50 uL

Histoplasma capulatun$&

CD4+ count < 100 (iL, endemic geographic area CD4+ count < 50/uL and CMV antibody positivity

Cytomegalovirus (CMV)«

Granulocyte-colonystimulating factor (G-CSF), 5-10 rig/kg sc q.d. x 2-4w or granulocyte-macrophage colony-stimulating factor (GMCSF), 250 ug/m2 iv over 2 h q.d. x 2-4w Fluconazole, 100200 mg po q.d. Itraconazole, 200 mg po q.d. Oral ganciclovir, 1 g po t.i.d.

Itraconazole, 200 mg po p.d. None

None

Note: Information included in these guidelines may not represent Food and Drug Administration (FDA) approval or approved labeling for the particular products or indications in question. Specifically, the terms "safe" and "effective" may not be synonymous with the FDA-defined legal standards for product approval. Anti-HBc = antibody to hepatitis B core antigen; b.i.w. = twice a week; CMV = cytomegalovirus; DS = double-strength tablet; q.m. = monthly; q.w. = weekly; SS = single-strength tablet; t.i.w. = three time a week; TMP-SMZ = trimethoprim-sulfamethoxazole; and TST = tuberculin skin test. The Respirgard II® nebulizer is manufactured by Marquest, Englewood, CO. *Prophylaxis should also be considered for persons with a CD4+ percentage < 14%, for persons with a history of an AIDS-defining illness, and possibly for those with CD4+ count > 200 but < 250 cells/|xL. TMP-SMZ also reduces the frequency of toxoplasmosis and some bacterial infections. Patients receiving dapsone should be tested for glucose-6 phosphate dehydrogenase deficiency. A dosage of 50 mg q.d. is probably less effective than that of 100 mg q.d. The efficacy of parenteral pentamidine (e.g., 4 mg/kg/month) is uncertain. Fansidar (sulfadoxine-pyrimethamine) is rarely used because of severe hypersensitivity reactions. Patients who are being administered therapy for toxoplasmosis with sulfadiazine-pyrimethamine are protected against Pneumocystis carinii pneumonia and do not need additional prophylaxis against PCP.

APPENDIX II

561

APPENDIX II (continued) ^Directly observed therapy recommended for isoniazid (INH), 900 mg b.i.w.; INH regimens should include pyridoxine to prevent peripheral neuropathy. Rifampin should not be administered concurrently with protease inhibitors or non-nucleoside reverse transcriptase inhibitors. Rifabutin should not be given with hard-get saquinavir, ritonavir, or delavirdine; caution is also advised when the drug is co-administered with soft-gel saquinavir. Rifabutin may be administered at a reduced dose (150 mg qd) with indinavir, nelfmavir, or amprenavir, or at an increased dose (450 mg qd) with efavirenz; information is lacking regarding co-administration of rifabutin with nevaripine. Exposure to multidrug-resistant tuberculosis may require prophylaxis with two drugs; consult public health authorities. Possible regimens include pyrazinamide plus either ethambutol or a fluoroquinolone. ^Protection against Toxoplasma is provided by TMP-SMZ, dapsone plus pyrimethamine, and possibly by atovaquone. The latter may be used with or without pyrimethamine. Pyrimethamine alone probably provides little, if any, protection. ^See footnote above (f) regarding use of rifabutin with protease inhibitors or non-nucleoside reverse transcriptase inhibitors. ' "Vaccination should be offered to persons who have a CD4+ T-lymphocyte count < 200 cells/ u,L, although the efficacy may be diminished. Revaccination > 5 years after the first dose or sooner if the initial immunization was given when the CD4+ count was < 200 cells/nJL and if the CD4+ count has increased to > 200 cells/fiL on HAART is considered optional. Some authorities are concerned that immunizations may stimulate the replication of HIV. However, one study showed no adverse effect of pneumococcal vaccination on patient survival. ^These immunizations or chemoprophylactic regimens do not target pathogens traditionally classified as opportunistic but should be considered for use in HIV-infected patients as indicated. ^There may be a few unusual occupational or other circumstances under which to consider prophylaxis; consult a specialist. "Acyclovir is not protective against CMV. Valaciclovir is not recommended because of an unexplained trend toward increased mortality observed in persons who have AIDS who were being administered this drug for prevention of CMV disease. Source: L'SPH/IDSA Prevention of Opportunistic Infection Working Group (1999).

This page intentionally left blank

Appendix III Prophylaxis for Recurrence of Opportunistic Disease (after Chemotherapy for Acute Disease) in HIV-Infected Adults and Adolescents

Preventive regimens Pathogen

Indication

First Choice

Alternatives

I. Recommended for life as standard of care Pneumocystis canmi

Prior P. carinii pneumonia

Trimethoprimsnlfamethoxazole (TMP-SMZ), 1 DS po q.d. (TMP-SMZ) 1 SS po q.d.

Dapsone, 50 mg po q.d. b.i.d. or 100 mg po q.d.; dapsone, 50 mg po q.d. plus pyrimethamine, 50 mg po q.w. plus leucovorin, 25 mg po q.w.; dapsone, 200 mg po plus pyrimethamine, 75 mg po plus leucovorin, 25 mg po q.w.; aerosol'continued)

563

APPENDIX III

564

APPENDIX III (continued) Preventive regimens Pathogen

Indication

First Choice

Alternatives ized penta-midine, 300 mg q.m. via Respirgard II™ nebulizer. Atovaquone 1500 mg po q.d. TMPSMZ, IDS po t.i.w.

Toxoplasma gondif

Prior toxoplasmic encephalitis

Sulfadiazine 5001000 mg po q.i.d. plus pyrimethamine 25-75 mg po q.d. plus leucovorin 10 mg po q.d.

Clindamycin, 300-450 mg po q 6-8 h plus pyrimethamine, 25-75 mg po q.d. leucovorin, 10-25 mg po q.d.-q.i.d.

Mycobacterium avium complex^

Documented disseminated disease

Clarithromycin, 500 mg po b.i.d. plus ethambutol, 15 mg/kg po q.d.; with or without rifabutin, 300 mg po q.d.

Azithromycin, 500 mg po q.d. plus ethambutol, 15 mg/kg po q.d.; with or without rifabutin, 300 mg po q.d.

Cytomegalovirus

Prior end-organ disease

Gancyclovir, 5-6 mg/kg iv 5-7 days/wk or 1,000 mg po t.i.d.; or foscarnet, 90120 mg/kg iv q.d.; (for retinitis) ganciclovir sustained-release implant q 6-9 months plus gancyclovir 1.0-1.5 g po t.i.d.

APPENDIX III

565

APPENDIX III (continued) Preventive regimens Pathogen

Indication

First Choice

Alternatives

Cryptococcus neoformans

Documented disease

Fluconazole, 200 mg po q.d.

Amphotericin B, 0.6-1.0 mg/kg iv q.w.-t.i.w.; itraconazole, 200 mg po q.d.

Histoplasma capsulatum

Documented disease

Itraconazole, 200 mg po b.i.d.

Amphotericin B, 1.0 mg/kg iv q.w.

Coccidioides immitis

Documented disease

Fluconazole, 400 mg po q.d.

Amphotericin B, 1.0 mg/kg iv q.w.: itraconazole 200 mg po b.i.d.

Salmonella species (non-typhi)

Bacteremia

Ciprofloxacin, 500 mg po b.i.d. for several months

None

II. Recommended only if subsequent episodes are frequent or severe Frequent/severe recurrences

Acyclovir, 200 mg po t.i.d. or 400 mg po b.i.d.; famciclovir 500 mg po b.i.d.

None

Candida (oropharyngeal or vaginal)

Frequent/severe recurrences

Fluconazole, 100200 mg po q.d.

Itraconazole solution, 200 mg po q.d.; ketoconazole, 200 mg po q.d.

Candida (esophageal)

Frequent/severe

Fluconazole 100200 mg po q.d.

Itraconazole solution, 200 mg po q.d.; ketoconazole, 200 mg po q.d.

Herpes simplex VIRUS

DS—double-strength tablet; q.m.—monthly; q.w.—weekly; SS—single-strength tablet; t.i.w.— three time a week; and TMP-SMZ—trimethoprirn-sulfamethoxazole. The Respirgard II nebulizer is manufactured by Marquest, Englewood, CO. Source: USPH/IDSA Prevention of Opportunistic Infection Working Group (1999).

This page intentionally left blank

Appendix IV Advising Patients Concerning Prevention of Exposure to

Opportunistic Pathogens

Sexual Exposures (1) Patients should use a latex condom during every act of sexual intercourse to reduce the risk of acquisition of cytomegalovirus, herpes simplex virus, and human papilloma virus, as well as other sexually transmitted pathogens. Condom use also will, theoretically, reduce the risk of acquisition of human herpesvirus 8, as well as superinfection with an HIV strain that has become resistant to antiretroviral drugs and will prevent transmission of HIV and other sexually transmitted pathogens to others. Data regarding the use and efficacy of "female condoms" are incomplete, but these devices should be considered as a risk-reduction strategy. (2) Patients should avoid sexual practices that may result in oral exposure to feces (e.g., oral-anal contact) to reduce the risk of intestinal infections (e.g., cryptosporidiosis, shigellosis, campylobacteriosis, amebiasis, giardiasis, and hepatitis A and B). Injection Drug Use Exposures (1) Injection drug use is a complex behavior that puts HlV-infected persons at risk for hepatitis C virus infection, additional, 567

568

APPENDIX IV

possibly drug-resistant strains of HIV, and other blood-borne pathogens. Assessments of an individual's readiness to change this practice and efforts to provide education and support directed at recovery should be encouraged. Patients should be counseled to stop using injection drugs, to enter and complete substance-abuse treatment, including relapse prevention programs. (2) If continuing to inject, patients should be counseled: a) To never reuse or "share" syringes, needles, water, or drug preparation equipment; if, nonetheless, injection equipment that has been used by other persons is shared, to first clean the equipment with bleach and water; b) To use only sterile syringes obtained from a reliable source (e.g., pharmacies or syringe exchange programs); c) To use sterile (e.g., boiled) water to prepare drugs; if not possible to use clean water from a reliable source (such as fresh tap water); d) To use a new or disinfected container ("cooker") and a new filter ("cotton") to prepare drugs; e) To clean the injection site before injection with a new alcohol swab; and f) To safely dispose of syringes after one use. Environmental and Occupational Exposures (1) Certain activities or types of employment may increase the risk of exposure to tuberculosis. These include volunteer work or employment in health-care facilities, correctional institutions, and shelters for the homeless, as well as other settings identified as high risk by local health authorities. Decisions about whether to continue with such activities should be made in conjunction with the health-care provider and should be based on such factors as the patient's specific duties in the workplace, the prevalence of tuberculosis in the community, and the degree to which precautions designed to prevent the transmission of tuberculosis are taken in the workplace. These decisions will affect the frequency with which the patient should be screened for tuberculosis.

APPENDIX IV

569

(2) Child care providers and parents of children in child care are at increased risk of acquiring CMV infection, cryptosporidiosis, and other infections (e.g., during diaper changing and after contact with urine or saliva). All children in child care facilities also are at increased risk of acquiring these same infections; parents and other caretakers of HIV-infected children should be advised of this risk. (3) Occupations involving contact with animals (e.g., veterinary work and employment in pet stores, farms, or slaughterhouses) may pose a risk of cryptosporidiosis, toxoplasmosis, salmonellosis, campylobacteriosis, or Bartonella infection. However, the available data are insufficient to justify a recommendation against work in such settings. (4) Contact with young farm animals, especially animals with diarrhea, should be avoided to reduce the risk of cryptosporidiosis. (5) Hand washing after gardening or other contact with soil may reduce the risk of cryptosporidiosis and toxoplasmosis. (6) In areas endemic for histoplasmosis, patients should avoid activities known to be associated with increased risk (e.g., creating dust when working with surface soil, cleaning chicken coops that are heavily contaminated with compost droppings, disturbing soil beneath bird-roosting sites, cleaning, remodeling or demolishing old buildings, and cave exploring). (7) In areas endemic for coccidioidomycosis, when possible, patients should avoid activities associated with increased risk, including those involving extensive exposure to disturbed native soil (e.g., at building excavation sites or during dust storms).

Pet-Related Exposures Health-care providers should advise HIV-infected persons of the potential risk posed by pet ownership. However, they should be sensitive to the possible psychological benefits of pet ownership and should not routinely advise HIV-infected persons to part with their pets. Specifically, providers should advise HIV-infected patients of the following.

570

APPENDIX IV

General (1) Veterinary care should be sought when a pet develops diarrheal illness. If possible, HIV-infected persons should avoid contact with animals that have diarrhea. A fecal sample should be obtained from animals with diarrhea and examined for Cryptosporidium, Salmonella, and Campylobacter. (2) When obtaining a new pet, HIV-infected patients should avoid animals aged < 6 months (or < 1 year for cats), especially those with diarrhea. Because the hygienic and sanitary conditions in pet-breeding facilities, pet stores, and animal shelters are highly variable, the patient should be cautious when obtaining a pet from these sources. Stray animals should be avoided. Animals aged < 6 months, especially those with diarrhea, should be examined by a veterinarian for Cryptosporidium, Salmonella, and Campylobacter. (3) Patients should wash their hands after handling pets (especially before eating) and avoid contact with pets' feces to reduce the risk of cryptosporidiosis, salmonellosis, and campylobacteriosis. Hand washing for HIV-infected children should be supervised. Cats (4) Patients should consider the potential risks of cat ownership because of cat ownership because of the risks of toxoplasmosis and Bartonella infection, as well as enteric infections. Those who elect to obtain a cat should adopt or purchase and animal that is aged > 1 year and in good health to reduce the risk of cryptosporidiosis, Bartonella infection, salmonellosis, and campylobacteriosis. (5) Litter boxes should be cleaned daily, preferably by an HIVnegative, nonpregnant person; if the HIV-infected patient performs this task, he or she should wash hands thoroughly afterward to reduce the risk of toxoplasmosis. (6) To reduce the risk of toxoplasmosis, cats should be kept indoors, should not be allowed to hunt, and should not be fed raw or undercooked meat.

APPENDIX IV

571

(7) Although declawing is not generally advised, patients should avoid activities that may result in cat scratches or bites to reduce the risk of Bartonella infection. Patients should also wash sites of cat scratches or bites promptly and should not allow cats to lick open cuts or wounds. (8) Care of cats should include flea control to feduce the risk of Bartonella infection. (9) Testing cats for toxoplasmosis or Bartonella infection is not recommended. Birds (10) Screening healthy birds for Cryptococcus neoformans, Mycobacterium avium, or Histoplasma capsulatum is not recommended. Other (11) Contact with reptiles (e.g., snakes, lizards, iguanas, and turtles) should be avoided to reduce the risk of salmonellosis. (12) Gloves should be used during the cleaning of aquariums to reduce the risk of infection with Mycobacterium marinum. (13) Contact with exotic pets (e.g., nonhuman primates) should be avoided. Food- and Water-Related Exposures (1) Raw or undercooked eggs (including foods that may contain raw eggs [e.g., some preparations of hollandaise sauce, Caesar and certain other salad dressings, and mayonnaise]); raw or undercooked poultry, meat, seafood; and unpasteurized dairy products may contain enteric pathogens. Poultry and meat should be cooked until no longer pink in the middle (internal temperature, > 165 F [73.8 C]). Produce should be washed thoroughly before being eaten. (2) Cross-contamination of foods should be avoided. Uncooked meats should not be allowed to come in contact with other

572

APPENDIX IV

foods; hands, cutting boards, counters, and knives and other utensils should be washed thoroughly after contact with uncooked foods. (3) Although the incidence of listeriosis is low, it is a serious disease that occurs unusually frequently among HIV-infected persons who are severely immunosuppressed. Some soft cheeses and some ready-to-eat foods (e.g., hot dogs and cold cuts from delicatessen counters) have been know to cause listeriosis. An HIV-infected person who is severely immunosuppressed and who wishes to reduce the risk of food borne disease can prevent listeriosis by reheating these foods until they are steaming before eating them. (4) Patients should not drink water directly from lakes or rivers because of the risk of cryptosporidiosis and giardiasis. Waterborne infection may also result from swallowing water during recreational activities. Patients should avoid swimming in water that is likely to be contaminated with human or animal waste and should avoid swallowing water during swimming. (5) During outbreaks or in other situations in which a community "boil water advisory" is issued, boiling water for 1 minute will eliminate the risk of acquiring cryptosporidiosis. Using submicron, personal-use water filters (home/office types) and/or drinking bottled water* may reduce the risk. Current data are inadequate to support a recommendation j that all HIV-infected persons boil or otherwise avoid drinking tap water in nonoutbreak settings. However, persons/who wish to take independent action to reduce their risk c»f waterborne cryptosporidiosis may choose to take precautions similar to those recommended during outbreaks. Such decisions are best made in conjunction with a health-care provider. Persons who opt for a personal-use filter or bottled water should be aware of the complexities involved in selecting the appropriate products, the lack of enforceable standards for destruction or removal of oocysts, the cost of the products, and the difficulty of using these products consistently. Patients taking precautions to avoid acquiring cryptosporidiosis from drinking water See section on cryptosporidiosis in disease-specific recommendations for information on personal-use filters and bottled water.

APPENDIX IV

573

should be advised that ice made from contaminated tap water also can be a source of infection. Such persons should be aware that fountain beverages served in restaurants, bars, theaters, and other public places may also pose a risk, because these beverages, as well as the ice they may contain, are made from tap water. Nationally distributed brands of bottled or canned carbonated soft drinks are safe to drink. Commercially packaged noncarbonated soft drinks and fruit juices that do not require refrigeration until after they are opened (e.g., those that can be stored unrefrigerated on grocery shelves) also are safe. Nationally distributed brands of frozen fruit juice concentrate are safe if they are reconstituted by the user with water from a safe source. Fruit juices that must be kept refrigerated from the time they are processed to the time of consumption may be either fresh (unpasteurized) or heat treated (pasteurized); only juices labeled as pasteurized should be considered free of risk from Cryptosporidium. Other pasteurized beverages and beers are also considered safe to drink. No data are available concerning survival of Cryptosporidium oocysts in wine. Travel-Related Exposures (1) Travel, particularly to developing countries, may carry significant risks for the exposure of HIV-infected persons to opportunistic pathogens, especially for patients who are severely imrnunosuppressed. Consultation with health-care providers and/or with experts in travel medicine will help patients plan itineraries. (2) During travel to developing countries, HIV-infected persons are at even higher risk for food borne and waterborne infections than they are in the United States. Foods and beverages—in particular, raw fruits and vegetables, raw or undercooked seafood or meat, tap water, ice made with tap water, unpasteurized milk and dairy products, and items purchased from street vendors—maybe contaminated. Items that are generally safe include steaming-hot foods, fruits that are peeled by the traveler, bottled (especially carbonated) bever-

574

APPENDIX IV

ages, hot coffee or tea, beer, wine, and water brought to a rolling boil for 1 minute. Treating water with iodine or chlorine may not be as effective as boiling but can be used, perhaps in conjunction with filtration, when boiling is not practical. (3) Waterborne infections may result from swallowing water during recreational activities. To reduce the risk of cryptosporidiosis and giardiasis, patients should avoid swallowing water during swimming and should not swim in water that may be contaminated (e.g., with sewage or animal waste). (4) Antimicrobial prophylaxis for traveler's diarrhea is not recommended routinely for HIV-infected persons traveling to developing countries. Such preventive therapy can have adverse effects and can promote the emergence of drug-resistant organisms. Nonetheless, several studies (none involving an HIVinfected population) have shown that prophylaxis can reduce the risk of diarrhea among travelers. Under selected circumstances (e.g., those in which the risk of infection is very high and the period of travel brief), the provider and patient may weigh the potential risks and benefits and decide that antibiotic prophylaxis is warranted. For those persons to whom prophylaxis is offered, fluoroquinolones (e.g., ciprofloxacin [500 mg q.d.]) can be considered, although fluroquinolones should not be given to children or pregnant women. Trimethoprim-sulfamethoxazole (TMP-SMZ) (one double-strength tablet daily) also has been shown to be effective, but resistance to this drug is now common in tropical areas. Persons already taking TMP-SMZ for prophylaxis against Pneumocystis carinii pneumonia (PCP) may gain some protection against traveler's diarrhea. For HIV-infected persons who are not already taking TMP-SMZ, health-care providers should be cautious in prescribing this agent for prophylaxis of diarrhea because of the high rates of adverse reactions and the possible need for the agent for other purposes (e.g., PCP prophylaxis) in the future. (5) All HIV-infected travelers to developing countries should carry a sufficient supply of an antimicrobial agent to be taken empirically should diarrhea develop. One appropriate regimen is 500 mg of ciprofloxacin b.i.d. for 3-7 days. Alternative antibiotics (e.g., TMP-SMZ) should be considered as empirical therapy for use by children and pregnant women. Travelers should

APPENDIX IV

575

consult a physician if their diarrhea is severe and does not respond to empirical therapy, if their stools contain blood, if fever is accompanied by shaking chills, or if dehydration develops. Antiperistaltic agents (e.g., diphenoxylate and loperamide) are used for the treatment of diarrhea; however, they should not be used by patients with high fever or with blood in the stool, and their use should be discontinued if symptoms persist beyond 48 hours. These drugs are not recommended for children. (6) Travelers should be advised about other preventive measures appropriate for anticipated exposures (e.g., chemoprophylaxis for malaria, protection against arthropod vectors, treatment with immune globulin, and vaccination). They should avoid direct contact of the skin with soil or sand (e.g., by wearing shoes and protective clothing and using towels on beaches) in areas where fecal contamination of soil is likely. (7) In general, live-virus vaccines should be avoided. One exception is measles vaccine, which is recommended for nonimmune persons. However, measles vaccine is not recommended for those who are severely immunosuppressed; immune globulin should be considered for measles-susceptible, severely immunosuppressed persons who are anticipating travel to measles-endemic countries. Another exception is varicella vaccine, which may be given to asymptomatic non-immunosuppressed children. Inactivated (killed) poliovirus vaccine should be used instead of oral (live) poliovirus vaccine, which is contraindicated for HIV-infected persons. Persons at risk for exposure to typhoid fever should be administered an inactivated parenteral typhoid vaccine instead of the live attenuated oral preparation. Yellow fever vaccine is a live-virus vaccine with uncertain safety and efficacy in HIV-infected persons. Travelers with asymptomatic HIV infection who cannot avoid potential exposure to yellow fever should be offered the choice of vaccination. If travel to a zone with yellow fever is necessary and vaccination is not administered, patients should be advised of the risk, instructed in methods for avoiding the bites of vector mosquitoes, and provided with a vaccination waiver letter.

576

APPENDIX IV

(8) In general, killed vaccines (e.g., diphtheria-tetanus, rabies, hepatitis A, Japanese encephalitis vaccines) should be used for HIV-infected persons just as they would be used for nonHIV-infected persons anticipating travel. Preparation for travel should include a review and updating of routine vaccinations, including diphtheria-tetanus for adults and all routine immunizations for children. The currently available cholera vaccine is not recommended for persons following a usual tourist itinerary, even if travel includes countries reporting cases of cholera. (9) Travelers should be informed about other area-specific risks and instructed in ways to reduce those risks. Geographically focal infections that pose a high risk to HIV-infected persons include visceral leishmaniasis (a protozoan infection transmitted by the sandfly) and several fungal infections (e.g., Penidllium marneffei infection, coccidioidomycosis, and histoplasmosis). Many tropical and developing areas have high rates of tuberculosis. Source: USPH/IDSA Prevention of Opportunistic Infection Working Group (1999).

Appendix V Selected Sources of

Information on the World Wide Web

The following World Wide Web sites provide information of possible interest to health care professionals and persons living with HIV/ AIDS. Many listed sites have links to other sources of HIV/AIDS information. The following information is not endorsed by the editors. It is the responsibility of the user to evaluate this information based on individual needs and community standards prior to use. AIDS Caregivers Support Network http://www. wolfenet. com/~acsn/ AIDS Clinical Trials Information Service http://www. actis. org/actis. asp ?URL=index&VIEW=general AIDS Drug Assistance Program (ADAP) Monitoring Project http://www. aidsinfonyc. org/adap/index, html AIDS Drug (ADAP) Working Group http://www. aidsinfonyc. org/awg/index. html AIDS Education Global Information Center (Aegis) http://www. aegis, com/ AIDS Healthcare Foundation http: //www. aidshealth. org/ AIDS Knowledge Base: A Textbook http://hivinsite. ucsf. edu/akb/1997/index, html 577

578

APPENDIX V

AIDS News http://www. aidsnews. net/ AIDS in Prison Project http://www. aidsinfonyc. org/aip/about, html AIDS Research Information Center http://www. critpath. org/aric/ AIDS Survival Project http://www. mindspring. com/-asp/index, htm AIDS Treatment Data Network http://204.179.124.69/network/index.html AIDS Treatment Project (United Kingdom) http: //www. atp. org. uk/ AIDS Virtual Library http://planetq. com/aidsvl/index. html AIDS/HIV Resources on the Net http:/'/www. geodties. com/Athens/5003'/science, html AMFAR AIDS/HIV Treatment Directory http://www. amfar. org/id/cover, html American Foundation for AIDS Research http://www. amfar. org/ American Red Cross HIV/AIDS Education http://www. redcross. org/hss/HIVAIDS/index. html Americans with Disabilities Act Home Page (U.S. Department of Justice) http://www. usdoj.gov/crt/ada/adahoml.htm Association of Nurses in AIDS Care http://www. anacnet. org/ The Body: An AIDS and HIV Information Resource http://www. thebody. com/index, shtml Bulletin of Experimental Treatments for AIDS http: //www. sfaf. org/beta/

APPENDIX V

579

Center for AIDS Prevention Studies (University of California, San Francisco) http://www. caps. ucsf. edu/

CenterWatch Clinical Trials Listing Service http:/'/www. centerwatch. com/

Centers for Disease Control and Prevention Home Page http://www. cdc.gov/

Centers for Disease Control and Prevention MMWR Reports on HIV/AIDS http: //www. cdc.gov/nchstp/hiv_aids/pubs/mmwr. html

Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report http: //www. cdc.gov/epo/mmwr/mmwr. html

Centers for Disease Control and Prevention National Center for HIV, STD, and TB Prevention http: //www. cdc. gov/nchstp/hiv_aids/dhap. htm

Centers for Disease Control and Prevention National Prevention Information Network http: //www. cdcnpin. org/

Clinical Directors Network http: //www. aidsinfonyc. org/cdn/index. html

Community AIDS Treatment Information Exchange http: //www. catie. ca/network, html

Community Programs for Clinical Research on AIDS http:/'/www. cpcra. org/

Community Research Initiative on AIDS http: //www. aidsinfonyc. org/cria/index. html

Correctional HIV Consortium (CHC). http: //www. silcom. com/~chc/

Critical Path AIDS Project http: //www. critpath. org/

580

APPENDIX V

Elizabeth Glaser Pediatric AIDS Foundation http://www.pedaids. org/homefrm. html European Association of Nurses in AIDS Care http://www. uwcm. ac. uk/uwcm/ns/EANA C/ Food and Drug Administration Home Page http://www.fda.gov/ Forum for Collaborative HIV Research (George Washington University) http: //www. gwumc. edu/chpr/hivforum. htm Gay Men's Health Crisis http://www.gmhc. org/ God's Love We Deliver http://www.glwd. org/indexSt. html Harvard AIDS Institute http: //www. hsph. harvard, edu/hai/home. html Hemophilia Home Page http://www. web-depot, com/hemophilia/ Hepatitis Information Network http://www. hepnet. com/ HIV/AIDS Bureau (Health Resources and Services AdministrationDHHS) http: //www. hrsa. dhhs.gov/hab/ HIV/AIDS Glossary http://www2. me. duke, edu/aids/educate/glossary, html HIV/AIDS Information http: //www. mcphu. edu/~ALDSinfo/default, HIV/AIDS Information Index http://www. arens. com/hiv/ HIV/AIDS Peer Educators http://www.fau.edu/student/safersex/

htm

APPENDIX V

581

HIV Home Test Information http: //www. koool. com/hivtest. html HIV positive.com http: //www. hivpositive. com/ International Association of Physicians in AIDS Care http: //www. iapac. org/ International Council of AIDS Service Organizations http: //www. web. net/~icaso/icaso. html Jewish AIDS Network http: //www. shalom. com/jane, htm HIV InSite (University of California San Francisco) http://hivinsite. ucsf. edu/ HIV Newsline and AIDS Care http: //www. thebody. com/hivnews/newsix. html HIV Plus http://www. aidsinfonyc. org/hivplus/index, html International Center for HIV/AIDS Research and Clinical Training in Nursing http://nurseiueb. ucsf. edu/www/ctrhiv. htm Johns Hopkins AIDS Service http: //www. hopkins-aids. edu/ Journal of the American Medical Association HIV/AIDS Information Center http: //www. ama-assn. org/'special'/hiv/ Magazines, Periodicals, and Libraries (HIV/AIDS) http: //gopher, hivnet. org: 70/1/magazines Medscape Multispecialty: AIDS Page http://www.medscape.com/Home/Topics/multispecialty/multisp ecialty.html Momentum AIDS Project (Food and Family for People Living with HIV) http: //www. aidsinfonyc. org/momentum/

582

APPENDIX V

Mount Sinai Medical Center's Adolescent Health Center's Adolescent AIDS Prevention and Treatment Program http: //www. mssm. edu/peds/aids. html NAMES Project Foundation: AIDS Memorial Quilt http: //www. aidsquilt. org/ National AIDS Fund Workplace Resources http: //www. aidsfund. org/workplac. htm National AIDS Treatment Advocacy Project http: //www. natap. org/ National Association of People with AIDS http: //www. napwa. org/ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Division of Acquired Immunodeficiency Syndrome http: //www. niaid. nih.gov/research/daids. htm National Library of Medicine (for AIDSLINE Search) http://igm. nlm. nih.gov/ National Library of Medicine HIV/AIDS Information http://sis. nlm. nih.gov/aidswww. htm National Minority AIDS Council http://www. nmac. org National Pediatric and Family HIV Resource Center http://www.pedhivaids. org/ Needle Exchange Report http: //www. caps. ucsf. edu/'publications/needlereport. html New York City HIV/AIDS Resources http: //www. aidsnyc. org North American Needle Exchange Network http://www. nasen. org/NASEN_II/index, html Office of AIDS Research (National Institutes of Health) http://sis. nlm. nih.gov/aids/oar. html

APPENDIX V

The Orphan Project http: //www. aidsinfonyc. org/orphan/index, html Pets Are Wonderful Support (PAWS) http:/'/www. pawssf. org/ People with AIDS Health Group http:/'/www. aidsinfonyc. org/pwahg/index. html People with HIV/MBS Action Coalition http: //www. beingalivela. org/index2. html Positively Kids http: //www. aidsinfonyc. org/posikids/index, html POZ Magazine http: //www. thebody. com/poz/pozix. html Project Inform http:/'/www. projinf. org/ Rural Center for AIDS/STD Prevention http: //www. indiana. edu/~aids/ Safe Works AIDS Project http: //www. safeworks. org/ San Francisco AIDS Foundation http: //www. sfaf. org/ Shanti (San Francisco) http:/'/www. shanti. org/ Stop AIDS Project http: //www. stopaids. org/ TeenAIDS Site http: //www. teenaids. org/ UNAIDS (The Joint United Nations Programme on HIV/AIDS) http://www. unaids. org/index. html The Vaccine Page http: //www. vaccines, com/

583

584

APPENDIX V

VIH y SIDA (Spanish) http://www. ctv. es/USERS/fpardo/home, html World Health Association Office of HIV/AIDS and Sexually Transmitted Diseases http://www. who. int/asd/

Index

in children, 441-453 cultural aspects, 16-17, 42-43, 110111, 114-116, 127, 475,487, 512-513, 515-519 definitions, 2-7 etiology, 4, 6-12 epidemiology, 7, 9-10, 33-43, 401403, 429-432 ethical/legal aspects, 376-377, 417, 420-421, 433, 518, 523-549 exposure categories, 43-59 geographic distribution, 34—35, 38-42 health promotion, 139-165, 384-385 historical background, 1-3, 8-11, 45-46, 54-56, 387-388 immune system in, 2-4, 81-91, 144145, 168-176, 206, 222, 227, 231, 235, 246, 251, 292, SISSIS, 317, 345, 348, 403, 409410, 412, 437-441, 457, 473, 557-561 indicator conditions adults, 5-6 children, 234-236 malignancies, 1, 2, 6, 33, 46, 48, 53, 168, 170, 219, 225-226, 229, 233, 238-239, 241-243, 248, 251, 277, 298, 435 opportunistic infections, 5-6, 167170, 177-219, 238, 443-450, 568-576

Abacavir, 312, 323, 324, 464, 465, 458 Abstinence, 103, 380 Access to care, 420-421, 476, 528-530 Acquired immunodeficiency syndrome, see AIDS ACTG 096, 121-122, 413-415, 432; see also Perinatal transmission Acupuncture, 19 Acute retroviral syndrome, 5, 26, 82, 172-174, 346; see also Primary infection Adherence to treatment, 276, 312, 315, 317-322, 345-346, 486, 553 Adolescents, 33-34, 36-37, 48, 99, 109-110, 463 Adrenal manifestations, 183, 194, 225, 251 African-American populations, see Minorities; Racial/ethnic aspects of HIV infection Africa, HIV/AIDS and, 11-12, 38-39, 41-43, 49 Age and HIV infection/AIDS, 32-33, 35-37, 402 AIDS, see also HIV infection and specific topics Africa, 11-12, 38-39, 41-43 age, 32-33, 35-37, 402 classification, 3-7, 171-172 pediatric. 434-436 clinical manifestations, 167-269 585

586 AIDS (continued) origin of, 11-12 pediatric, 429-510 post-exposure prophylaxis, 25-28, 124, 173, 241-242, 346-347, 355, 551-555 prevention, 20, 36, 48, 50-51, 97138, 288-290, 355-363, 378381, 383, 396, 413-417, 518-519, 567-576 racial/ethnic aspects, 37-38, 48-49, 402,486-487,511-521 sex distribution, 35-36, 401-402 statistics, 33-43, 429-430 symptom management, 271-309 treatment, 170-171, 178, 180-219, 226-228, 233-234, 241-242, 246-247, 249, 274-275, 328, 331-333, 413-417, 453-474 312-318, 552-555 in women, 30, 43, 115, 145-146, 200-203, 207-209, 227, 250251, 347, 401-428, 515, 553554, 570, 574 AIDS dementia complex, 228-232; see also Nervous system manifestations Alcohol use, 30, 51, 102, 111, 119, 146-147, 154, 301, 380; see also Behavioral factors Alternate living arrangements, 491-492 Americas, HIV/AIDS in, 38-40, 49 Amprenavir, 312, 335-337, 342-343; see also Treatment; Protease inhibitors Anal sex, 15-16, 18, 42, 47, 54-55, 98, 100, 237 Anemia, 207, 277-280, 324, 327-328, •330, 434 Anonymous HIV testing, 374-376, 382; see also HIV counseling/testing Anorectal manifestations, 219, 239, 241 Antiretroviral therapy, 33, 124, 241, 249, 312-318, 320, 322-348

INDEX

in children, 453-468 as post-exposure prophylaxis, 25-28, 124, 173, 241-242, 346-347, 355, 551-555 in pregnancy, 19-20, 413-415 Anxiety, 302, 487 Aphthous ulcers, 243; see also Oral manifestations Apoptosis, 89-90 Arthritis, 246, 249-250 Artificial insemination, 16 Asia, HIV/AIDS and, 38-40, 49 Aspergillosis, 196-197, 249, 251; see also Fungal infections Assessment, 271-272, 275-276, 279, 284-286, 291-292, 296, 298, 300, 302-303, 314, 321, 370, 378-380, 390-391, 417, 421, 433, 477-479, 551-552, 568 Asymptomatic phase, 3, 5, 26, 316-317 Athletics and HIV transmission, see Sports Autoimmune thrombocytopenic purpura, 5, 242, 251, 252-253 Bacillary angiomatosis, 5; see also Cat scratch disease; Bartonella Bacterial infections, see also specific infections, 3, 5, 145, 169, 209-219, 233, 239-241, 244, 247, 277, 292, 294, 405, 434, 444-446, 488, 560, 569-571 in children, 435-436, 443-444, 448, 467-468, 471 Bacterial pneumonia, 3, 145, 219, 247, 405; see also Bacterial infections Barriers to care, 404, 420-422, 515 Bartonella infections, 5, 241, 245, 488, 569-571; see also Bacterial infections Behavioral factors, 2, 13, 30, 33, 47-48, 98-100, 107-129; see also Alcohol use; Substance use; Risk factors; Cofactors Biliary effects, 178, 180, 200, 241 Bisexuality, 13, 55, 107-108, 112, 402

587

INDEX

Bleach use, 117-118, 553 Bloodborne transmission, 18-19, 45,

46, 55-57, 113, 120-121, 380, 430 Blood transfusion receipt, 19, 45-46, 55-57, 120-121, 430 Body piercing, 113 Brain, effect of HIV on, see Nervous system Branched chain DNA, 314, 317; see also HIV counseling/testing Breast milk, see Breastfeeding Breastfeeding, 19-22, 380, 412-413, 430-431 Buffalo hump, 251, 284; see also Lipodystrophy

Campylobacter, 239, 240, 294, 488, 569, 570 Cancers, see Neoplasms Candida infections, 5-6, 53, 189-192, 238-239, 241, 244-245, 249, 251, 295-297, 405, 434-435, 468, 485, 557, 565 in children, 434-435, 449-450, 471 Candidiasis, see Candida infections Cardiovascular manifestations, 217218, 225, 249, 434 in children, 450-451, 473 Cardiomyopathy, 249, 434, 451 Caregivers, 420, 486-487, 491-492, 515 Case control study, 7 Case finding, 390 Case management, 387-399, 513-515 Cat scratch disease, 215; see also Bartonella; Bacillary angiomatosis

CCR5, 31-32, 79, 87 CD4 + lymphocytes, 2-4, 81-91, 144145, 168-174, 176, 206, 227, 231, 235, 246, 251, 292, SISSIS, 317, 345, 348, 412, 437439, 457, 473, 557-561 in AIDS classification systems, 2-4 selected conditions and, 170 Centers for Disease Control and Prevention (CDC)

classification systems, 3-7, 171-172, 433-436, 441 definitions, 2-4, 171 exposure categories, 43-49, 429-430 HlV-infected health careworkers, 23-28, 354-356 non-occupational exposure guidelines, 551-555 perinatal transmission reduction guidelines, 414-418 post-exposure prophylaxis, 25-28 prevention of exposure to opportunistic pathogens, 567-576 prophylaxis for opportunistic diseases, 445-449, 469-478, 557-565 Central Nervous System, see Nervous system Cervical abnormalities, 226-227, 250251, 405-407 Cervical cancer, 208, 226-227, 250251, 316, 405-407 Cervical dysplasia, see Cervical abnormalities Cervical intraepithelial neoplasia, see Cervical abnormalities; Cervical cancer Cesarean delivery, 20, 411 Chemical dependency, see Substance use; Injecting drug use Chemokine receptors, see also Specific receptors, 31-32, 79, 87 Chickenpox in HFV infected children, 444, 447, 449; see also Varicella Children, see Pediatric HIV infection/ AIDS Children, rights of, 475-476 Chlamydia trachomatis, 250, 551; see also Sexually transmitted diseases Cholecystitis, see Biliary manifestations Chronic illness, HIV as, 141-143, 429, 486-494; see also Case management Classification systems, 3-7, 171-172 in children, 433-436, 441

588 Clinical manifestations of HIV infection, 167-269, 405-409; see also Symptom management; Specific condition in children, 441-453 Clinical trials, 457, 463-465, 544 Clostridium difficile, 218-219, 292, 294 Cocaine, 33, 48, 301, 402; see also Substance use; Injecting drug use Coccidioidomycosis, 195-196, 229, 233, 241, 248, 277, 300, 470, 565, 569, 576 Cofactors, 16-17, 29-33, 141-149 Cohort, 7 Community assessment, 515-517 case management, 392-393 prevention and, 125-127, 394-396 Community based care/services, 475, 515-517 Condoms, 104-107, 109-113, 120, 149, 419-420, 567 female condom, 104, 106-107, 420, 567 Condylomas, 208; see also Sexually transmitted diseases Confidential HIV testing, 374-376, 532-533 Confidentiality, 476, 530-536 Contraception, 104, 107, 419-420, 551 Coreceptors, 8, 31-32, 78-79 Crack, 13, 33, 119, 402; see also Substance use; Injecting drug use Cryptococcus neoformans, 6, 53, 192-194, 229, 239, 241, 242, 247, 251, 435, 448, 470, 488, 560, 565, 571; see also fungal diseases Cryptosporidiosis, 6, 179-181, 239, 240, 248, 249, 277, 282, 300, 435, 470, 488, 567, 569-570, 572-573, 574 Cultural factors/issues, 16-17, 38, 4243, 110-111, 114-116, 127, 475, 487, 512-513, 515-519 Cushing's disease, 251

INDEX

Cutaneous manifestations, see Dermatologic manifestations Cydospora cayetanesis, 185 Cytomegalovirus (CMV), 198-200, 229, 235, 236, 238-240, 242, 247, 249, 251, 282, 294, 444, 449, 468, 470, 560-561, 564, 568-569 in children, 435, 444, 448, 470 Day care, 490-491 Definitions, 2-7 Delaviridine, 312, 325-326, 333, 343, 460; see also Treatment; Non-nucleoside reverse transcriptase inhibitors Dental dam, see also Prevention, 104 Dental problems, 242-243; see also Oral manifestations Depression, 155, 487 Dermatologic manifestations, 176, 185, 194, 201-204, 207-208, 215, 217-221, 244-245, 247, 326, 332-333, 485-486 Developing countries, 3-4, 12, 20-22, 38-43, 178, 431, 573-576 Development, in children, 442-443, 477-479, 482, 493 Diagnosis, 173-174, 314-315, 370-371, 382-384, 433, 437, 554-555 Diarrhea, 180-181, 184, 246, 282, 290295, 329, 451, 485-486, 570, 574-575; see also Gastrointestinal manifestations Didanosine, 312, 323-324, 330, 343344, 455-456, 458; see also Treatment; Nucleoside reverse transcriptase inhibitors Directly observed therapy, 561 Disclosure, 107-108, 148-149, 488490, 517-518, 536-538 Discrimination, 536-538; see also Stigmatization Drug-food interactions, see Food-drug interactions Drug interactions, 322-343

INDEX

Drug resistance, 317-322, 334-346 Drug therapy for HIV infection, see Treatment; Individual drugs Drug therapy for opportunistic conditions, 167-268; see also Treatment Durable power of attorney, 542-543 Duty to care, 538, 540-541 Ear manifestations, 251 Economic issues, 15, 395-396, 494 Education programs, see Prevention Efavirenz, 312, 325-326, 333-334, 343, 460; see also Treatment; Non nucleoside reverse transcriptase inhibitors Elderly, and HIV, 33, 36 ELISA, 7, 56, 180, 371, 379; see also HIV counseling/testing Encephalopathy, 6, 435, 442-443, 477; see also Nervous system manifestions Encephalitis, 182-183, 564; see also Nervous system manifestations Encephalitozoon intestinalis, 183-184 End of life decisions, 541-543 Endocrine manifestations, 194, 251, 275, 282-283, 452, 474 Entamoeba histolytica, 294 Enterocytozoon bieneusi, 183-184 Epidemiology of HIV infection and AIDS! 7, 9-10, 33-43, 401-403 in children, 429-432 Epstein-Barr virus, 204-206, 225, 449, 453; see also Viral infections; Hairy leukoplakia Esophagus, see Candidiasis; Gastrointestinal manifestations Ethical issues, 376-377, 417, 420-421, 433, 518, 523-545 Etiology of AIDS, 4, 6-12 Europe, 39-41, 49 Exercise, 147-148 Exposure to HIV, 551-555, 568-569; see also Transmission Exposure categories for AIDS, 43-59

589

Eye manifestations, 183-184, 199-200, 204, 247-248; see also Cytomegalovirus Enzyme linked immunosorbent assay, see ELISA Failure to thrive in children, 452 Family, 486-492, 512-513 Fat redistribution, 284-285; see also Lipodystrophy; specific conditions Fatigue, 273-277, 324 Female to female transmission, 15-16, 35-36, 380 Female condom, 104, 106-107, 420, 567 Fever, 5, 252, 274, 299-300, 557 Food-drug interactions, 322-344 Foster care, 491-492 Fungal infections, 5-6, 186-197, 229, 233, 238-239, 241-242, 244245, 247-249, 251, 277, 295, 297, 300, 405, 435, 448, 468470, 485, 488, 557, 565, 569, 576, 434-435, 449-450, 468469, 470; see also Individual infections in children Gall bladder, see Biliary effects Gastrointestinal manifestations, 178181, 184-185, 189-191, 200, 202, 210, 212, 216-218, 224226, 237-242, 246, 280-282, 290-298, 328-330, 338, 567, 570, 572, 574-575 in children, 451-452, 474 Gay community, see Homosexual Genetic aspects, 30-33, 86-87, 188189, 403 Genital herpes infection, 200-203; see also Herpes simplex; Gynecological manifestations Genital ulcers, 30, 200-203, 405-406, 553; see also Gynecological manifestions

590 Genital warts, 145-146, 207-209, 409; see also Gynecological manifestions Geographic distribution, 13, 34-35, 38-42 Giardia lamblia, 186, 240, 282, 294, 488, 567, 572, 574 Glucose-6-phosphate dehydrogenase deficiency, 188-189, 560 Gonorrhea, see Sexually transmitted diseases Growth and development, 477-479, 482 Guidelines HIV counseling/testing, 191-192, 377-385 Gynecological manifestations of HIV infection, 30, 145-146, 200203, 207-209, 227, 250-251, 405-409, 553 HAART, see Highly active antiretroviral therapy Haemophilus influenzas, 216-217, 219, 444 Hair effects of HIV infection, 246-247 Hairy leukoplakia, 5, 145, 205-206, 243 Haitians, 44-45 Hardiness, 150 Harm reduction, 116, 383, 388 Head and neck manifestations, 251 Health care workers, 23-26, 353-356 duty to care, 538, 540-541 HIV-infected, 24, 353-354 occupational risks, 23-26, 122-123, 353-356, 380, 568-569 postexposure procedures, 25-28, 124, 173, 346-347, 355 transmission and, 23-26 Health promotion, 139-165, 384-385 Hearing loss, 251 Heart, see Cardiovascular manifestations Hemophilia/coagulation disorders, 18, 51-53, 58, 120, 430

INDEX

Hematological manifestations, 207, 252, 277-280, 324, 327-328, 330, 434, 452 Hepatitis, 23, 30, 49, 184, 200, 208209, 241, 272, 274, 282, 326, 330, 355, 551, 559, 567 Herpes virus, 197 Herpes simplex virus, 6, 200-203, 229, 238-239, 243-244, 247, 249, 251, 294, 298, 406, 565, 568 in children, 471 in women, 409 Herpes zoster, 5, 353 Heterosexual contact, 15-16, 53-55; see also Sexual transmission HHV-8, see Human herpes virus 8 Highly active antiretroviral therapy, 180, 313, 347, 414, 559, 561; see also Treatment; Antiretroviral therapy Hispanic population, see Minorities Histoplasmosis, 6, 194-195, 239, 241, 248, 251, 277, 300, 435, 448, 470, 560, 565, 569, 576; see also Fungal infections Historical perspective, 1-3, 8-11, 4345, 54-56, 387-388 HIV in body cells, fluids and tissues, 13-15 classification, 8, 75-76, 78-79 genes of, 76-78 life cycle, 78-82 mechanism of infection, 30-33, 78-87 origin, 11-12 replication, 313-319 structure, 76-77, 370-371 subtypes, 6-8 transmission, 10, 13, 16, 23-26, 4546, 55-57, 97-98, 113, 120121, 312-318, 322-348, 351-360, 379-380, 412, 430431, 551-555, 568-569 HIV-associated dementia, 228-232

INDEX

HIV counseling and testing, 369-386, 404, 415-418, 534-536, 551-552 HIV infection; see also AIDS acute infection, 5, 26, 82, 172-174, 346-347 age and, 32-33, 35-37, 402 case management in, 387-399, 573-575 classification system, 3-7, 171-172, 433, 436 clinical spectrum of, 167-269, 441-453 co-receptors, 8, 31-32, 78-79 in developing countries, 3-4, 11-12, 20-22, 38-39, 41-43, 178 immune aspects, see also CD4+ cells, 2-4, 81-91, 144-145, 168-176, 206, 222, 227, 231, 235, 246, 251, 292, 313-315, 317, 345, 348, 403, 409-410, 412, 437441, 457, 473, 557-561 malignancies, 1-2, 6, 33, 46, 48, 53, 168, 170-171, 219, 225-227, 229, 233, 238-239, 241-243, 247-248, 251, 277, 298, 405407, 435 minorities and, 37-38, 112, 302, 487 511-521 natural history, 26-29, 84-87, 140, 174-177, 404-405, 437-440 opportunistic conditions, 167-269, 443-453 pathogenesis, 75-95 phases, 29 prevalence, 7, 10, 12-13, 40-42, 395, 431 prevention, 50-51, 97-138, 288-290, 355-363, 378-381, 383, 396, 413-417, 518-519, 567-576 primary infection, 5, 26, 82, 172174, 346 progression, 26, 29-33, 85-87, 140, 176-177, 313-316, 347, 438-441 symptom management, 271-309

591 transmission of, 10, 13-25, 43-59, 97-102 treatment of, 170-171, 178, 180219, 226-228, 233-234, 241242, 246-247, 249, 274-275, 328, 331-333, 413-417, 453474, 312-318, 552-555 HFV-2, 9-11, 370, 431 HIV seroprevalence, 12-13, 40-42, 395, 431 HIV wasting syndrome, 236-237, 280-290 HIA 30-31, 250 Hodgkin's disease, 219, 226, 243; see also Malignancies Homosexual men, 1-2, 14-15, 39, 40, 42, 45-48; see also Bisexual; Men who have sex with men Home HIV testing, 372-373 HPV, see Human papilloma virus HTLV, 8-9 Human herpes virus (HHV), 8, 220, 567; see also Kaposi's sarcoma Human immunodeficiency virus, see HFV Human papillomaviruses (HPVs), 145146, 207-208, 227, 250, 407, 409, 567 Hydroxyurea, 329-330 Hypogonadism, 251, 287-288 Immune system and HIV, 2-4, 81-91, 144-145, 168-176, 206, 222, 227, 231, 235, 246, 251, 292, 313-315, 317, 345, 348, 403, 409-410, 412, 437-441, 457, 473, 557-561; see also CD4+ lymphocytes Immunizations, 272, 559, 575-576; see also Prophylaxis in children, 446-448, 480-485 Incidence rate, 7 Indinavir, 312, 333, 335-340, 342-343, 461; see also Treatment; Protease inhibitors

592

Indeterminate HIV test result, 173, 379; see also HIV counseling/ testing Infection control, 351-367 Infections, see Opportunistic infections specific conditions Influenza, 145, 447, 559 Informed consent, 376, 553 Injecting drug use, 14, 18, 36-37, 41, 45,48-51,58, 102, 113-120, 168, 392, 402, 551, 567-568 Invirase, 338 Isolation, social, 282-283, 517-518 Isosporu belli, 239, 240, 282, 294, 176, 185, 194, 201-204, 207-208, 215, 217-221, 244-245, 435 Isosporiasis, see Isospora belli J. C. virus, 197, 206-207 Raposi's sarcoma, 1-2, 6, 33, 46, 48, 53, 168, 170, 238-239, 241245, 247-249, 251, 277, 298, 405, 435 Latin America, 38-39, 40 Latinos, see Minorities; Racial/ethnic aspects of HIV/AIDS Lazarus syndrome, 301, 394 Legal issues, 523-545 Leiomyosarcoma, 453 Leishmaniasis, 576 Lesbians, 402; see also Female-to-female transmission Lamivudine, 312, 323-324, 327, 331332, 455-456, 459, 464-465; see also Treatment; Nucleoside reverse transcriptase inhibitors Libido, 287 LIP, see Lymphoid interstitial pneumonia's Lipodystrophy, 251, 253, 284 Listeriosis, 5, 572 Liver dysfunction, 147, 208-209, 215216, 239, 241, 327; see also specific conditions

INDEX Lung cancer, 219 Lung manifestations, see Respiratory manifestations; Specific conditions Lymphadenopathy, see Progressive generalized lymphadenopathy Lymphadenopathy associated virus, 9 Lymphoid interstitial pneumonitis (LIP), 434-435, 449-450 Lymphomas, 2, 6, 219, 225-226, 229, 233, 238-239, 241-243, 248, 251, 277, 298, 435; see also Neoplasms Malabsorption, 237, 282 Malignancies, 1-2, 6, 33, 46, 48, 53, 168, 170, 219, 225-226, 229, 233, 238-239, 241-243, 248, 251, 277, 298, 435 Mandatory HIV testing, 376-377, 433, 524 Maternal-fetal transmission, see Perinatal transmission Medical treatment, 311-350, 445-474; see also specific conditions; Prophylaxis; Treatment Medication management, 276 Men who have sex with men (MSM), 15-18, 45-48; see also Homosexuality; Bisexual; Exposure categories Meningitis, 37, 45-48, 168, 434; see also Nervous system manifestations Menopause, 16 Menstrual irregularities, 250-251, 406-407 Menstruation and HIV transmission, 16 Microsporidiosis, 183-184, 282, 294 Minorities, 13, 35, 37-38, 112, 487, 511-521 Molluscum contagiosum, 207, 244-245, 247 Mononeuropathy multiplex, 235; see also Neuromuscular disease Morbidity rate, 7

INDEX

Mortality, 33-34; see also Epidemiology; Natural history; Progression Mortality rate, 7 Multidisciplinary teams, 391-393, 474-475 Multigenerational effects, 401, 486-487 Multiple myeloma, 219 Musculoskeletal manifestations, 249-250 Mycobacteria, atypical, see also Mycobacterium avium complex, 6, 209211, 571 Mycobacterium avium complex (MAC), 6, 209-211, 239, 241, 244, 247,249, 251, 277, 282-283, 294, 300, 558, 564 in children, 435-436, 444, 446, 470 Mycobacterium tuberculosis, 6, 169, 211214, 233, 244, 277, 444-446; see also Tuberculosis Myopathy, 234-236 Nail manifestations, 246-247 Native Americans, see Minorities; Racial/ethnic aspects of HIV/ AIDS Natural history of HFV infection, 2629, 84-87, 140, 174-177 in children, 437-440 in women, 404-405 Nausea, 282, 329-330, 336, 338 Nelfmavir, 312, 335-337, 339, 341-343, 462 Neoplasms, see Malignancies; Specific conditions Neurologic manifestations, see Nervous system Neuromuscular manifestations, 234-236 Nervous system manifestations, 173, 182-183, 192-194, 196-197, 199-201, 203-204, 206-207, 212, 225, 227-236; see also Specific conditions in children. 440-443

593 Nevirapine, 312, 325-326, 332, 341, 343, 455, 460, 464-465 Nocardiosis, 214-215, 219, 248-249, 434 Nondisclosure, see Disclosure Non-Hodgkins lymphoma, 225-226, 243, 452; see also Malignancies NRTI, see Nucleoside reverse transcriptase inhibitors NNRTI, see Non-nucleoside reverse transcriptase inhibitors Non-nucleoside reverse transcriptase inhibitors, 312, 322, 332-334, 453-467; see also Antiretroviral therapy Nucleoside reverse transcriptase inhibitors, 312, 322-332, 453-467; see also Antiretroviral therapy Nursing interventions, 156-157, 271309, 321, 378-385, 421-422 Nutrition, 143-144, 147, 274, 284-285 in children, 485 Nutritional assessment, 143-144, 286, 485 Obstetrical issues, see Perinatal; Pregnancy Ocular manifestations, 183-184, 204, 199-200, 247-248; see also specific conditions Occupational exposure to HIV, 23-26, 122-123, 353-356, 380, 568-569 Opportunistic infections, 5-6, 167170, 177-219, 238, 568-576; see also specific infections in children, 443-450 Oral contraceptives, 326, 339 Oral hairy leukoplakia, 5, 145, 205206, 243; see also Epstein-Barr virus Oral HIV testing, 372 Oral manifestations, 145, 189-191, 203, 205-206, 242-243, 451 Oral sex, 15-16, 98, 100, 402

594

Other/undetermined exposure category, 44-46, 57-58 Otitis media, in children, 251 Outercourse, 103 p24 antigen, 57, 371, 412, 555; see also HIV counseling/testing Pain, 297-299, 477 Pancreatic manifestations, 147, 189, 241-242, 298, 324, 327-330, 451-453, 474 Pancreatitis, see Pancreatic manifestations Papanicolaou (Pap) test, 272, 406-407 Parasitic infections, 179-186, 239-240, 248-249, 277, 282, 300, 435, 470, 488, 567, 569-570, 572573, 574; see also specific infections Partner history, 107-108, 378 Partner notification, 103, 112-113, 119, 378 Parvovirus, 207, 252, 277 Patient education, 105-106, 108-109, 116-127, 271-304, 316-317, 378-381, 412, 567-578; see also HIV counseling/testing; Nursing interventions PCR, see Polymerase chain reaction Pediatric HIV infection/AIDS, 12, 46, 58-59, 429-509; see also Perinatally-acquired HIV infection Pelvic inflammatory disease, 5, 250 Penicillium marneffei, 196, 576 Perinatal HIV, 19-22, 43, 121-122, 238, 405, 410-417; see also Pediatric HIV infection/AIDS Peripheral neuropathy, 5, 298, 324, 329-331 Persistent generalized lymphadenopathy (PGL), 3-5, 175-176 Pets, 487-488, 569-571 Pityrosporium orbiculare, 245 Pituitary manifestations, 251; see also Endocrine

INDEX

Pneumocystis carinii, 186, 247, 445, 450, 469, 563 extrapulmonary, 188, 247 pneumonia, 2, 6, 46, 51, 53-54, 56, 145, 186-189, 300, 432, 435, 445, 450, 469, 473, 563, 574 Policies, 524-527 Polymerase chain reaction, 313, 317, 321, 433; see also HIV testing Polyneuropathies, 236 Post-exposure prophylaxis, 25-28, 124, 173, 346-347, 355, 551-555 Postnatal transmission of HIV, 19-22; see also Breastfeeding Poverty, 282-283, 512 Precautions against transmission, 355363; see also Standard precautions; Prevention Pregnancy, HIV and, 146, 347, 409410, 413-418, 570, 554, 574 Prenatal diagnosis, 413 Prevention, 48, 50-51, 55, 97-138, 288-290, 378-381, 383, 394396, 413-417, 518-519, 567-576 in health care settings, 355-363 in minority communities, 36, 518-519 perinatal, 20, 119-122, 411-418, 432-433 Prevalence of HIV/AIDS, 10, 12-13, 40-42, 395, 431 Prevalence rate, 7 Primary care, 271-272, 474-486 Primary HIV infection, 5, 26, 82, 172174, 346-347 Privacy, 430-436 Progression of HIV disease, 26, 29-33, 53, 85-87, 140, 176-177, 313316, 347, 405 in children, 438-441 Progressive generalized lymphadenopathy, 3-5, 175-176 Progressive multifocal leukoencephalopathy, 197, 206-207, 229, 436 Prophylaxis

INDEX

in children, 432, 445-449, 469-472 against infection, 169, 178, 288-290, 320, 567-576 post-exposure prophylaxis, 25-28, 124, 173, 346-347, 355, 551-555 Protease inhibitors, 312, 322, 334-343, 461-463; see also Treatment Protease pouch, 251; see also Lipodystrophy Pseudomonas aeroginosa, 217, 219, 248, 251 Psoriasis, 246 Psychological responses, 300-304, 383384, 487 Psychosocial issues, 155, 237, 300-304, 378-385, 404-406, 420, 476, 486-487, 517-518, 527-528 Pulmonary manifestations, see Respiratory manifestations Quality of life, 142, 150, 251, 278, 292 315 Racial/ethnic aspects of HIV/AIDS, 37-38, 48-49, 402, 486-487, 511-521 Rape, 16, 124 Rapid HIV antibody testing, 373-374; see also HIV counseling and testing Reiter's syndrome, 246, 250 Relative risk. 7 Renal manifestations/effects, 248-249, 452 Reproductive concerns/decision-making, 409-420 Research, ethics and, 543-545 Resistance to therapy, 31-32, 87-88, 318-322, 345 Resources, 108, 289, 356, 539-540, 577-584 Respiratory manifestations, 182-189, 192-197, 200, 210-214, 216217, 219, 224, 247, 248, 363; see also specific conditions

595

in children, 449-450 Respiratory syncytial virus, 449 Respite, 487 Retinitis, 199-200, 564; see also Ocular manifestations; Cytomegalovirus Reverse transcriptase inhibitors, 322-334 Rhodococcus equi, 216, 219 Risk, 7 Risk behaviors, 47-48, 97-104, 107125, 375-384, 403 Risk factors, 29-33, 47, 412-413, 552-554 Risk reduction, 380, 421, 552, 568; see also Prevention; Prophylaxis Rights of individuals, 524-527 Ritonovir, 312, 335-340, 343-344, 462, 464-465; see also Treatment; Protease inhibitors RT-PCR, 313, 317, 436 Ryan White Act, 388, 490 Safer sex guidelines, 108, 383; see also Prevention Salmonella infections, 6, 218, 239-240, 293, 436, 470, 488, 565, 569571; see also Gastrointestinal manifestations; Bacterial infections; Diarrhea Saquinavir, 312, 333-335, 338-340, 343-344, 463; see also Treatment; Protease inhibitors Scabies, 245 School-based prevention, 126 Schools, 126, 490-491 Seborrheic dermatitis, 245-246 Self-care, 141-142, 149, 152-156 Self-efficacy, 119, 322 Seminoma, 219 Set point, 82, 175-177 Sexual abuse, 16, 476, 493, 534 Sexual activity, see Men who have sex with other men; Lesbians; Heterosexual contact Sexual assault, 16, 551-552

596

Sexual behavior, 16-17, 43, 98-100, 146-147 Sexual dysfunction, 251 Sexually transmitted diseases (STDs), 51, 100-102, 250, 551-553, Sexual transmission of HIV, 14-19, 551, 553, 567-568; see also Transmission; Exposure categories Shigella infections, 293, 353; see also Gastrointestinal manifestations Siblings, impact on, 490 Sinusitis, 251 Skin manifestations, 176, 185, 194, 201-204, 207-208, 215, 217221, 244-247, 326, 332-333, 485-486; see also specific conditions Sleep, 275, 277, 485 Slim disease, 178; see also Wasting Smoking, 144-146 Socioeconomic issues, see Poverty Spirituality, 150, 393 Sports related risks, 18, 124-125, 491 Standard precautions, 357-358 Staphylococcus aureus, 217, 244, 246247, 249, 251, 444 Statistics/patterns of HIV/AIDS 10, 12-13, 33-43, 395, 431 Stavudine, 312, 323-324, 331, 455-456, 464 Stigmatization, 155, 300-301, 420, 517-518, 527-528 Streptococcus pneumoniae, 219, 444, 559 Stress, 300-301 Strongyloides stercoralis, 184-185, 239-240 Substance use, 30, 111, 113-120, 378379, 381; see also Injecting drug use; Individual substances Suicide, 302, 384 Super antigens, 90 Survival with HIV Symptom management, 271-309 Syncytia, 18, 78, 89

INDEX Syphilis, 13, 233, 236, 247, 406, 551; see also Sexually transmitted diseases Syringe exchange programs, 50-51, 118, 150-151, 568 Tattooing, 18, 113 Testicular cancer, 219 Testing, see HIV counseling/testing Thrush, see Candidiasis Thyroid manifestations, 251; see also Endocrine T-lymphocytes, see CD4+ lymphocytes Thrombocytopenia, 252-253 Toilet training in children, 486 Toxoplasma gondii, see Toxoplasmosis Toxoplasmosis, 6, 181-183, 229, 239, 242, 247, 558, 560-561, 564, 569-571, 654 in children, 434, 436, 447, 469, 473, 488 Transfusion recipients, see Blood transfusion Transmission of HIV, 10, 13-26, 4546, 55-57, 97-98, 113, 120121, 322-328, 351-360, .379-380, 412-413, 430-431, 551-554 Travel precautions, 291, 573-576 Treatment of HIV infection, 170-171, 178, 180-219, 226-228, 233234, 241-242, 246-247, 249, 274-275, 312-318, 552-555; see also Prophylaxis in children, 328, 331-332, 453-474, 553-554 in pregnancy, 328, 413-417, 554 Trichomonas vaginalis infection, 405-408 Tuberculosis, 3, 6, 30, 211-214, 251, 274, 277, 353, 358, 363, 375, 435, 444-445, 472, 484-485, 513, 576, 558, 560-561, 568 Tuskegee syphilis study, 518 Twins, 20, 411

597

INDEX

United States statistics/patterns, 33-38, 43-59 Urine, HIV testing of, 372 Vaccines against HIV, 128-129 Vaccinations, see Immunizations Vacuolar myopathy, 232-233 Vaginal candidiasis, 191-192, 250 Vaginal infections, 191-192, 407-409 Varicella zoster virus, 145, 203-204, 229, 243, 245, 247, 248, 353, 358, 434, 444-447, 484, 559 Vertical transmission, 121-122; see also Perinatally-acquired HIV infection Viral infections, 5-6, 8, 197-209, 229, 235-236, 238-240, 242-244, 247, 249, 251, 282, 294, 298, 406, 444, 449, 468, 470, 560561, 564-565, 568-569 in children, 435, 444, 448-449, 468 Viral culture, 433 Viral load, 292, 313-318, 344-345, 347, 348, 403, 417, 440, 466-467, 555 Virology of HIV, 75-83 Vitamin A, 20, 412; see also Perinatal transmission Vomiting, 282, 329-330, 336, 338 Vulnerable populations, 511-521; see also Minorities; Racial/ethnic aspects of HIV/AIDS; Poverty

Wasting, 6, 143, 178, 236-237, 280290, 436, 452 Welmess, promotion of, 139-165 Western blot, 371, 379; see also HIV counseling/testing White, Ryan, see Ryan White Act Window period, 29, 378-379 Women, 43, 115, 401-428, 515; see also Perinatal HIV epidemiology of HIV infection/ AIDS, 35-38, 43, 55, 401-403 natural history in, 404-405 pregnancy and, 146, 347, 409-410, 413-418, 570, 554, 574 prevention, 403-404 racial/ethnic distribution, 35-38 Women who have sex with women, 15-16, 35-36, 302, 380; see also Lesbians; Female to female transmission Worldwide statistics and patterns, 21, 38-43 Xerostomia, 252 Zalcitabine (ddc, HIVID), 312, 323324, 330, 343-344, 455-456, 458 Zidovudine (AZT), 10-11, 19-20, 2526, 312, 323-324, 327-328, 344, 347, 411,413-415, 453, 455-456

Springer Publishing Company Patient and Family Education in

Managed Care and Beyond Seizing the Teachable Moment William B. Bateman, Elizabeth J. Kramer and Kimberly S. Classman, Editors This practical guide provides crucial strategies and concepts for patient education and self-care in today's evolving health care system. The book includes sample curricula for asthma, HIV/AIDS, hemophilia, and more. A multidisciplinary group of authors has written the book for nurses, physicians, health educators, and other health professionals involved in direct patient care. "The common sense practical approach the authors have taken makes this book a particularly effective guide for all clinicians." -Eileen M. Freitag, President and CEO Jewish Association on Aging, Pittsburgh, PA "This book is a must read for health care professionals who are struggling with how to provide auality patient and family education in a managed care environment.' -Marylin J. Dodd, PhD, MSN, RN, FAAN Professor and Associate Dean for Academic Personnel School of Nursing University of California, San Francisco "As a former nurse who is now a physician, I find this an outstanding reference for front-line providers ofnealth care. The book is very well organized. Each chapter is a reference within itself." -Catharine M. Mintzer, MD, Private Practice Cambridge Massachusetts Clinical Instructor, Medicine, Harvard Medical School 1999 272pp. 0-8261-1295-1 hard

www.springerpub.com

36 Broadway, New York, NY 10012-3955 • (212) 431-4370 • Fax (212) 941-784